

This Page Is Inserted by IFW Operations  
and is not a part of the Official Record

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning documents *will not* correct images,  
please do not report the images to the  
Image Problem Mailbox.**

**THIS PAGE BLANK (USPTO)**

GenCore version 4.5  
Copyright (c) 1993 - 2000 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: June 14, 2001, 08:04:29 ; Search time 31.39 Seconds  
(without alignments)  
2016.320 Million cell updates/sec

Title: US-09-445-223-1  
Perfect score: 2829  
Sequence: 1 MNGEAFCSALPTIPYHKLAD.....PEILVYVRSPLNLLQKSM 540

Scoring table: BLOSUM62  
Gapop 10.0 , Gapext 0.5

Searched: 374700 seqs, 117207915 residues 374700  
Total number of hits satisfying chosen parameters:

Minimum DB seq length: 0  
Maximum DB seq length: 2000000000  
Post-processing: Minimum Match 0%  
Maximum Match 100%  
Listing first 45 summaries

- Database : SPREMBL\_15.\*
- 1: sp\_archaea.\*
  - 2: sp\_bacteria.\*
  - 3: sp\_fungi.\*
  - 4: sp\_human.\*
  - 5: sp\_invertebrate.\*
  - 6: sp\_mammal.\*
  - 7: sp\_mhc.\*
  - 8: sp\_organelle.\*
  - 9: sp\_phage.\*
  - 10: sp\_plant.\*
  - 11: sp\_rodent.\*
  - 12: sp\_unclassified.\*
  - 13: sp\_vertebrate.\*
  - 14: sp\_virus.\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	2823	99.8	540	043353	O43353 homo sapien
2	401	14.2	486	11 Q9QZL0	Q9qz10 mus musculus
3	389.5	13.8	806	10 Q9ZSD8	Q9zsd8 lycopersico
4	389.5	13.8	829	10 Q9ZSD9	Q9zsd9 lycopersico
5	385.5	13.6	829	10 Q24027	Q24027 lycopersico
6	375	13.3	518	4 Q9Y572	Q9y572 homo sapien
7	359.5	12.7	963	10 Q9SPU7	Q9stt7 arabidopsis
8	353	12.5	773	10 Q9M8C1	Q9m8c1 arabidopsis
9	348.5	12.3	370	10 Q9S7D5	Q9s7d5 arabidopsis
10	348.5	12.3	763	10 Q9M8C3	Q9m8c3 arabidopsis
11	340	12.0	981	10 Q65833	Q65833 lycopersico
12	337.5	11.9	1030	10 Q9SFP9	Q9sfp9 arabidopsis
13	335.5	11.9	736	10 Q82754	Q82754 arabidopsis
14	334.5	11.8	835	4 Q9Y2V6	Q9y2v6 homo sapien
15	332.5	11.8	405	10 Q9LW09	Q9lwg9 arabidopsis
16	329	11.6	671	10 Q9M8C2	Q9m8c2 arabidopsis
17	327.5	11.6	406	10 Q23719	Q23719 arabidopsis
18	327	11.6	678	5 Q9V3Q6	Q9v3q6 drosophila
19	317.5	11.2	462	10 Q39886	Q39886 glycine max

20	316.5	11.2	776	10 O80963	O80963 arabidopsis
21	313.5	11.1	888	11 Q63796	Q63796 rattus norv
22	313.5	11.1	1200	10 Q9MAE9	Q9mae9 arabidopsis
23	312	11.0	579	4 Q43317	Q43317 homo sapien
24	311	11.0	579	11 Q62073	Q62073 mus musculus
25	310	11.0	546	10 Q22558	Q22558 arabidopsis
26	309	10.9	438	10 Q9XI87	Q9xi87 arabidopsis
27	309	10.9	445	10 Q9LMF8	Q9lmf8 arabidopsis
28	308	10.9	491	4 Q9NZ70	Q9nzt0 homo sapien
29	308	10.9	539	4 Q9NTR1	Q9ntr1 homo sapien
30	307	10.9	553	10 Q81808	Q81808 arabidopsis
31	306.5	10.8	475	10 Q9STG5	Q9stgs arabidopsis
32	306.5	10.8	888	11 Q60700	Q60700 mus musculus
33	306.5	10.8	988	10 Q9LM32	Q9lm32 arabidopsis
34	304.5	10.8	616	13 Q73613	Q73613 xenopus lae
35	304.5	10.8	888	11 P70286	P70286 mus musculus
36	304	10.7	451	4 Q9NTR3	Q9ntr3 homo sapien
37	301.5	10.7	886	10 Q9LX18	Q9lyx18 arabidopsis
38	300.5	10.6	606	4 Q43318	Q43318 homo sapien
39	300	10.6	443	10 Q65239	Q65239 arabidopsis
40	299.5	10.6	1055	13 Q42440	Q42440 oryzias lat
41	299	10.6	567	10 Q9ZQ05	Q9zq05 arabidopsis
42	298	10.5	518	4 Q43319	Q43319 homo sapien
43	297.5	10.5	545	10 Q9SZM7	Q9szm7 arabidopsis
44	297	10.5	1055	13 Q9PVW4	Q9pvw4 oryzias lat
45	296.5	10.5	566	4 Q9NTR2	Q9ntr2 homo sapien

ALIGNMENTS

RESULT 1  
O43353 PRELIMINARY; PRT; 540 AA.  
AC O43353;  
DT 01-JUN-1998 (TREMBlrel. 06, Created)  
DT 01-NOV-1998 (TREMBlrel. 08, Last sequence update)  
DT 01-OCT-2000 (TREMBlrel. 15, Last annotation update)  
DE SERINE/THREONINE KINASE RICK.  
GN RICK OR RIP2.  
OS Homo sapiens (Human).  
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
OX NCBI\_TaxID=9606;  
RN [1]  
RP SEQUENCE FROM N.A.  
RX MEDLINE=98241596; PubMed=9575181;  
RA Inohara N., del Peso L., Koseki T., Chen S., Nunez G.;  
RT "RICK, a novel protein kinase containing a caspase recruitment domain,  
interacts with CLARP and regulates CD95-mediated apoptosis.";  
J. Biol. Chem. 273:12296-12300(1998).  
RN [2]  
RP SEQUENCE FROM N.A.  
RA Ozersky P., Holmes A., Broly M.;  
RL Submitted (JAN-1998) to the EMBL/GenBank/DBJ databases.  
RN [3]  
RP SEQUENCE FROM N.A.  
RX MEDLINE=98307936; PubMed=9642260;  
RA McCarthy J.V., Ni J., Dixit V.M.;  
RT "RIP2 is a novel NF-kappaB-activating and cell death-inducing  
kinase.";  
J. Biol. Chem. 273:16968-16975(1998).  
RN [4]  
RP SEQUENCE FROM N.A.  
RA Thome M., Hofmann K., Burns K., Martinon F., Bodmer J.-L.,  
Mattmann C., Tschopp J.;  
RT "Identification of CARDIAC, a RIP-like kinase that associates with  
caspase-1.";  
Curr. Biol. 8:0-0(1998).  
RN [5]  
RP SEQUENCE FROM N.A.  
RA Platzer M., Varon R.;  
RL Submitted (DEC-1998) to the EMBL/GenBank/DBJ databases.

RA EMBL; AF027706; AAC34970.1; -  
 RT EMBL; AC004003; AAC24561.1; -  
 RL EMBL; AF078530; AAC27722.1; -  
 DR EMBL; AF064824; AAC25566.1; -  
 DR EMBL; AF117829; AAD04634.1; -  
 DR HSSP; P00523; 2PTK.  
 DR INTERPRO; IPR000719; -  
 DR INTERPRO; IPR001315; -  
 DR INTERPRO; IPR002290; -  
 DR PFAM; PF00069; pkinase; 1.  
 DR PFAM; PF00619; CARD; 1.  
 DR PROSITE; PS00108; PROTEIN\_KINASE\_ST; 1.  
 DR PROSITE; PS50011; PROTEIN\_KINASE\_DOM; 1.  
 KW Kinase.  
 SQ SEQUENCE 540 AA; 61194 MW; 575A692239505792 CRC64;

Query Match 99.8%; Score 2823; DB 4; Length 540;  
 Best Local Similarity 99.8%; Pred. No. 1.9e-220;  
 Matches 539; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1 MNGEATCSALPTIPYKHLADRLYLSRGASGTYSARRHADRWYQVAVKHLHIHTPLLDSE 60  
 Db 1 MNGEATCSALPTIPYKHLADRLYLSRGASGTYSARRHADRWYQVAVKHLHIHTPLLDSE 60  
 Qy 61 KDVLREAEILHKARFSYIPIIGICNEPEFLGIVTEYMPNGSLNELLHRKTEYPDVAVPL 120  
 Db 61 KDVLREAEILHKARFSYIPIIGICNEPEFLGIVTEYMPNGSLNELLHRKTEYPDVAVPL 120  
 Qy 121 RFRILHEIALGVNLYLHNMTPLLDLHDKTQNILLDNEFHVKADFGLSKWRMMSLSQSR 180  
 Db 121 RFRILHEIALGVNLYLHNMTPLLDLHDKTQNILLDNEFHVKADFGLSKWRMMSLSQSR 180  
 Qy 181 SKSAPGGTIYPPENYEPGQSRASIKHDIYSYAVITWEVLSRKQPEDVTPNQIMY 240  
 Db 181 SKSAPGGTIYPPENYEPGQSRASIKHDIYSYAVITWEVLSRKQPEDVTPNQIMY 240  
 Qy 241 SVSGHRPVIINESLPIPHARMISLIESGWAQNDPERSFLKCLIELEPVLRFTFEI 300  
 Db 241 SVSGHRPVIINESLPIPHARMISLIESGWAQNDPERSFLKCLIELEPVLRFTFEI 300  
 Qy 301 TFEAVTQKTKLOSVAIHCDDKMKELSLNIPVNHGQESGSSOLHNSGSPET 360  
 Db 301 TFEAVTQKTKLOSVAIHCDDKMKELSLNIPVNHGQESGSSOLHNSGSPET 360  
 Qy 361 SRSLPAPQDNDFLSRKAQDCYFMKHHCPGNHSDSTISGQRAAFCDHKTTPCSSAIIN 420  
 Db 361 SRSLPAPQDNDFLSRKAQDCYFMKHHCPGNHSDSTISGQRAAFCDHKTTPCSSAIIN 420  
 Qy 421 PLSTAGNSERLQPGIAQQWTSKREDIVNQTEACLNSLDLALLSRDLIMKEDYELVSTK 480  
 Db 421 PLSTAGNSERLQPGIAQQWTSKREDIVNQTEACLNSLDLALLSRDLIMKEDYELVSTK 480  
 Qy 481 PRTSKVROLDDTDIOGEEFAKVIQKLDKNGKMGLOPYPELLVYSRPSLNLQNKSM 540  
 Db 481 PRTSKVROLDDTDIOGEEFAKVIQKLDKNGKMGLOPYPELLVYSRPSLNLQNKSM 540

RESULT 2  
 Q9QZL0 PRELIMINARY; PRT; 486 AA.  
 AC Q9QZL0;  
 DT 01-MAY-2000 (TrEMBLrel. 13, Created)  
 DT 01-MAY-2000 (TrEMBLrel. 13, Last sequence update)  
 DT 01-JUN-2000 (TrEMBLrel. 14, Last annotation update)  
 DE RECEPTOR INTERACTING PROTEIN 3.  
 GN RIP3.  
 OS Mus musculus (Mouse).  
 OC Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;  
 OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Mus.  
 OX NCBI\_TaxID=10090;  
 RN [1]  
 RP SEQUENCE FROM N. A.

RA Pazdernik N.J., Donner D.B., Goebel M.G., Harrington M.A.;  
 RT "Mouse Interacting Protein 3 Does Not Contain a Caspase-Recruiting or  
 a Death Domain but Induces Apoptosis and Activates NF-kappab.";  
 RL Mol. Cell. Biol. 19:0-0(1999).  
 DR EMBL; AF178953; AAF03133.1; -  
 DR INTERPRO; IPR000719; -  
 DR INTERPRO; IPR001245; -  
 DR INTERPRO; IPR002290; -  
 DR PFAM; PF00069; pkinase; 1.  
 DR PFAM; PF00109; TYRKINASE.  
 DR PROSITE; PS00107; PROTEIN\_KINASE\_ATP; 1.  
 DR PROSITE; PS00108; PROTEIN\_KINASE\_ST; 1.  
 DR PROSITE; PS50011; PROTEIN\_KINASE\_DOM; 1.  
 KW Receptor.  
 SQ SEQUENCE 486 AA; 53336 MW; DD264E69187D3436 CRC64;

Query Match 14.2%; Score 401; DB 11; Length 486;  
 Best Local Similarity 28.0%; Pred. No. 2.6e-24;  
 Matches 140; Conservative 70; Mismatches 192; Indels 98; Gaps 18;

Qy 8 SALPTIPYKHLADRLYLSRGASGTYSARRHADRWYQVAVKHLHIHTPLLDSEKQDVLREA 67  
 Db 12 SAVPLVSRREELKLEFVGGGEGVFRHRRTRWHDVAVKIVN-----SKLISREW 62  
 Qy 68 EILHKARFSYIPIIGICNEPEF-----LGIVTEYMPNGSLNELLHRKTEYPDVAVPLRF 122  
 Db 63 KAMVNLRENVLVLLGLVTEDLQWDFVSGOALVTREMGSLAGLLQPECPRP---WPLLC 119  
 Qy 123 RILHEIALGVNLYLHNMTPLLDLHDKTQNILLDNEFHVKADFGLSKWRMMSLSQSR-S 181  
 Db 120 RLLEQEVVGMVYLSLDDPPLHDKTQNILLDPELHAKLADFGLSFGGSGSGSGS 179  
 Qy 182 KSAPEGGTIYMPPE-----NYEPGQSRASIKHDIYSYAVITWEVLS-RKQPFEDVTP 235  
 Db 180 GSRDSGGTLAYLDPELLFKVNL-----KASKADSVYSGILVWVLAGREAEALVDKTS 233  
 Qy 236 LQIMYSVSGHRPVIINESLPIPHARMISLIESGWAQNDPERSFLKCLIELEPVLR 295  
 Db 234 IRETVDROSRPPLTELPPGSPETPGLEKLMELHMCWQSGENRPFQDC---EP-K 287  
 Qy 296 TFEETITFLF-----AVIQLKTKLOSVAIHL-----CDKK---KMELSL 333  
 Db 288 TNEVYLVKDKYDAAVSEVKYLSHQHSSGRNLSAREPSORGTMDCPRETMVSKMLDRL 347  
 Qy 334 NIPVNHGQESGSSOLHNSGSPETSRLPAPQDNDFLSRKAQDCYFMKHLH----- 386  
 Db 348 HLEEPSGVPKCPERQAQDTSVGPAT-----PARTSSDPVAGTTPQIPHTLPRGTTGPV 403  
 Qy 387 --HCPGNHSDSTISGQRAAFCDHKTTP-----CS-----SALINPL 422  
 Db 404 FTETPGHPORN--QDGRHGTWPYPTPPNPMGTGPPALVFNCSVQIGNVSLVAPPR 461  
 Qy 423 STAGNS---ERLQPGIAQOOW 439  
 Db 462 TTASSAKYDQAGFRGRGW 481

RESULT 3  
 Q9ZSD8 PRELIMINARY; PRT; 806 AA.  
 AC Q9ZSD8;  
 DT 01-MAY-1999 (TrEMBLrel. 10, Created)  
 DT 01-MAY-1999 (TrEMBLrel. 10, Last sequence update)  
 DT 01-OCT-2000 (TrEMBLrel. 15, Last annotation update)  
 DE ETHYLENE-INDUCIBLE CTR1-LIKE PROTEIN KINASE.  
 OS Lycopersicon esculentum (Tomato).  
 OC Eukaryota; Viridiplantae; Embryophyta; Tracheophyta; Spermatoxyta;  
 OC Magnoliophyta; eudicotyledons; core eudicots; Asteridae; euasterids I;  
 OC Solanales; Solanaceae; Solanum.  
 OX NCBI\_TaxID=4081;  
 RN [1]  
 RP SEQUENCE FROM N. A.



KW Hypothetical protein; Kinase.  
 SQ SEQUENCE 829 AA; 91912 MW; 08FCF7468993537D CRC64;

Query Match 13.6%; Score 385.5; DB 10; Length 829;  
 Best Local Similarity 33.2%; Pred. No. 9.8e-23;  
 Matches 104; Conservative 56; Mismatches 108; Indels 45; Gaps 12;

QY 3 GEATCSALPT-----TPYKHLADRLYLSRGASGTVSSARHADWR-VQYAVKHL- 49  
 Db 529 GGHVSAIPESELDLDFEFPWDLILMEKIGAGSFGTV---HRGDWHGSDVAVKILM 585

QY 50 --HIHTPLDSEKVDLRAEILHKARFSYIFPILGICNEPEFLGIVTVMGNSLLELL 107  
 Db 586 EQDFHAERL---KEFLREVAIMKRLRHPNIVLEFGAVIQPNLSVTEYLSRGSILYRL 641

QY 108 HRKTEYPDVAMPRLRILHEIALGVNLYLHMTPPLLHDKTONILLDNFHVKADPGL 167  
 Db 642 HKFGAREVLDERRRLCMAYDVANGMNYLHRNPPIVHRDLKSPNLVADKKYTKICDFGL 701

QY 168 SKWRMMSLSQSRSSKSAPEGGTTIYMPPD--NVPEGOKSRASIKHDIYSYAVITWEVLSR 225  
 Db 702 SRFKANFVLSKTAAGTPE-----WNAPEVIRDEPSE-----KSDVYSGVILLWELATL 751

QY 226 KQPFEDVTPNQIMYSVSGHRPVINEESLPYDIPH--RARMISLIESGWAQNDPDRPSF 283  
 Db 752 QQPWNKL-NPPQVIAAVG-----FNRKRL--DIPSDLNPQVAIITEACWANEPWKRPSF 802

QY 284 LKCLIELEPVLRT 296  
 Db 803 STIMDLRPLHKS 815

RESULT 6  
 QY572 ID QY572 PRELIMINARY; PRT; 518 AA.

AC QY572;  
 DT 01-NOV-1999 (TrEMBLrel. 12, Created)  
 DT 01-NOV-1999 (TrEMBLrel. 12, Last sequence update)  
 DT 01-OCT-2000 (TrEMBLrel. 15, Last annotation update)  
 DE RIP-LIKE KINASE.  
 GN RIP3.  
 OS Homo sapiens (Human).  
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
 OX NCBI\_TaxID=9606;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RX MEDLINE=99272740; PubMed=10339433;  
 RA Payan D.G., Luo Y.;  
 RA Yu P.W., Huang B.C., Shen M., Quast J., Chan E., Xu X., Nolan G.P.,  
 RT Identification of RIP3, a RIP-like kinase that activates apoptosis  
 and NFkappaB.  
 RL Curr. Biol 9:539-542(1999).  
 DR EMBL; AF156884; AAD39005.1; -  
 DR HSSP; P08631; IADS.  
 DR INTERPRO; IPR000719; -  
 DR INTERPRO; IPR001245; -  
 DR PFAM; PF00069; pkinase.1.  
 DR PRINTS; PR00109; TYRKINASE.  
 DR PROSITE; PS50011; PROTEIN\_KINASE\_DOM; 1.  
 KW Kinase.  
 SQ SEQUENCE 518 AA; 56901 MW; 38A3ECFEBBD4151 CRC64;

Query Match 13.3%; Score 375; DB 4; Length 518;  
 Best Local Similarity 31.3%; Pred. No. 3.6e-22;  
 Matches 100; Conservative 62; Mismatches 127; Indels 30; Gaps 11;

QY 11 PTPYHKLADRLYLSRGASGTVSSARHADWRVQYAVKHLHIHTPLDSEKVDLRAEIL 70  
 Db 14 PLYSIELELNQELVGRDGFVTRAQHRKRWGYDVAKIYN-----SKAISREVKAM 64

QY 71 HKARESYIFPILGICNEPEF-----LGIVTEYMPGNSLLELHHRKTEYPDVAVMLRFRIL 125  
 Db 65 ASLDNEFFVLRLEGVLEKYVNDODPKPALVYTKFMENSGLSGLLQSOCPRP---WPLLCRLL 121

QY 126 HEIAGVNYLHMTPPLLHDKTONILLDNFHVKADPGLSKWRMMSLSQSRSSKSAKAP 185  
 Db 122 KEVVLGMFYLLHQDQVLLHRLDKPSNVLDPPELHVKLADPGLSLTFQ--GGSOQSGTSGSEP 179

QY 186 EGGTTIYMPPENYEPGOKSRASIKHDIYSYAVITWEVLSRKOPPFEDVTPNQIMYSV-SO 244  
 Db 180 -GGTGLYLAPELF-VVNRKASTASDVYSGVILMVAVLAGE-VELPTEPSLYVEAVCNR 236

QY 245 GHRPVINEESLPY---DIPHRARMISLIESGWAQNDPDRPSFKLCLELEPVLRFTEIT 301  
 Db 237 QNRPSLAE-LPQAGPETPGLGELKMLQKWSSEPKDRPSFQECLEPKTDFVOMVE--N 292

QY 302 FLEAVIQLKKYKLSQVSSA 320  
 Db 293 NMNAAVSTVKDFLSQLKSS 311

RESULT 7  
 Q9STU7 ID Q9STU7 PRELIMINARY; PRT; 963 AA.

AC Q9STU7;  
 DT 01-MAY-2000 (TrEMBLrel. 13, Created)  
 DT 01-MAY-2000 (TrEMBLrel. 13, Last sequence update)  
 DT 01-OCT-2000 (TrEMBLrel. 15, Last annotation update)  
 DE HYPOTHETICAL 108.0 KDA PROTEIN.  
 GN T22A6\_310 OR AT4G24480.  
 OS Arabidopsis thaliana (Mouse-ear cress).  
 OC Eukaryota; Viridiplantae; Embryophyta; tracheophyta; Spermatophyta;  
 OC Magnoliophyta; eudicotyledons; core eudicots; Rosidae; eurosids II;  
 OC Brassicales; Brassicaceae; Arabidopsids.  
 OX NCBI\_TaxID=3702;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RA Bevan M., Zimmermann W., Gruenisen A., Wambutt R., Bancroft I.,  
 RA Mewes H.W., Mayer K.F.X., Lemcke K., Schueller C.;  
 RL Submitted (JUN-1999) to the EMBL/GenBank/DBJ databases.  
 RN [2]  
 RP SEQUENCE FROM N.A.  
 RA EU Arabidopsis sequencing project.  
 RL Submitted (JUN-1999) to the EMBL/GenBank/DBJ databases.  
 RN [3]  
 RP SEQUENCE FROM N.A.  
 RA Zimmermann W., Gruenisen A., Wambutt R., Kalicki J., Wohlmann P.,  
 RA Smith A., Mewes H.W., Lemcke K., Mayer K.F.X.;  
 RL Submitted (MAR-2000) to the EMBL/GenBank/DBJ databases.  
 RN [4]  
 RP SEQUENCE FROM N.A.  
 RA EU Arabidopsis sequencing project;  
 RL Submitted (MAR-2000) to the EMBL/GenBank/DBJ databases.  
 DR EMBL; AL1078637; CAB45083.1; -  
 DR EMBL; AL161561; CAB79358.1; -  
 DR HSSP; P06239; 3LCK.  
 DR INTERPRO; IPR000719; -  
 DR INTERPRO; IPR001245; -  
 DR INTERPRO; IPR002290; -  
 DR PFAM; PF00069; pkinase.1.  
 DR PRINTS; PR00109; TYRKINASE.  
 DR PROSITE; PS00107; PROTEIN\_KINASE\_ATP; 1.  
 DR PROSITE; PS00108; PROTEIN\_KINASE\_ST; 1.  
 DR PROSITE; PS50011; PROTEIN\_KINASE\_DOM; 1.  
 KW Hypothetical protein.  
 SQ SEQUENCE 963 AA; 107993 MW; 10DD8910F44C140E CRC64;

Query Match 12.7%; Score 359.5; DB 10; Length 963;  
 Best Local Similarity 31.7%; Pred. No. 1.5e-20;  
 Matches 93; Conservative 60; Mismatches 105; Indels 35; Gaps 11;

QY 20 DLRYLSRGASGTVSSARHADWR-VQYAVKHLHIHTPLDSEKVDLRE-----AELHKA 73

Db 668 ELHIKERVGAGSGFTVHRAEHWGSDVAVKLSIQ-DFHDDQFREFLREYCKQAVAIKRV 726  
 Qy 74 RESYFPIIGICNEPEFLGIVTEYMPNGSLNELLHRKT--EYDVAVWPLRFRI----LH 126  
 Db 727 RHPNVVLFMGAVTERPRLSIITTEYLPGRSLFRILHRRPAGSELDDQRRRLRMALDVVCAIP 786  
 Qy 127 EIALGVNYLHNMTPPLLLHDLKTONILLDNEFHVKIADFLGSKWRMMSLSQSRSSKSAPE 186  
 Db 787 HYAKGLNYLHCLNPPVHWDLKSNLLVDKNTVKVCDGLSRFKANTFIPSKSVAGTPE 846  
 Qy 187 GGTIYMPPE--NYEPQKRSASIKHDIYSYAVITWEVLSRKQPFEDVTPNLOIMYSV- 243  
 Db 847 -----WMAPEFLRGEPTNE-----KSDVYSFGVYVWELITLQOPWNGL-SPAQVVGAVAF 895  
 Qy 244 OGHRVPIINEESLPYDIPHRARMSLIESGWAQNPDRPSPFLKCLILEPVLRT 296  
 Db 896 QNRLLIIPNTSPV-----LVSLEACWADEPSPQAPFAGSIVDTFLKLLKS 941

RESULT 8  
 Q9M8C1 PRELIMINARY; PRT; 773 AA.  
 AC Q9M8C1  
 AC Q9M8C1  
 DT 01-OCT-2000 (TREMBlrel. 15, Created)  
 DT 01-OCT-2000 (TREMBlrel. 15, Last sequence update)  
 DE PROTEIN KINASE, PUTATIVE.  
 GN F566 5.  
 OS Arabidopsis thaliana (Mouse-ear cress).  
 OC Eukaryota; Viridiplantae; Embryophyta; Tracheophyta; Spermatophyta;  
 OC Magnoliophyta; eudicotyledons; core eudicots; Rosidae; eurosids II;  
 OC Brassicales; Brassicaceae; Arabidopsids.  
 OX NCBI\_TaxID=3702;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RC STRAIN=CV. COLOMBIA;  
 RA Lin X., Kaul S., Town C.D., Benito M., Creasy T.H., Haas B., Wu D.,  
 RA Maiti R., Ronning C.M., Koo H., Fujii C.Y., Utterback T.R.,  
 RA Barnstead M.E., Bowman C.L., White O., Nierman W.C., Fraser C.M.;  
 RT "Arabidopsis thaliana chromosome III BAC F566 genomic sequence."  
 RL Submitted (APR-2000) to the EMBL/GenBank/DBSJ databases.  
 DR EMBL; AC020580; AAF63631.1; --  
 KW Kinase.  
 SQ SEQUENCE 773 AA; 86054 MW; C1B70D3E6848A340 CRC64;

Query Match 12.5%; Score 353; DB 10; Length 773;  
 Best Local Similarity 32.0%; Pred. No. 3.8e-20;  
 Matches 94; Conservative 62; Mismatches 102; Indels 36; Gaps 11;  
 Qy 24 LSRGAGTYSSARHADW-RVQVAVK---HLHIHTPLLDSEKDKVLRAREILHKARESYIF 79  
 Db 500 VQGGCGTV--YHGLWFGSDVAVKVFQKQEVLSAEVIESFKQEVL----LKRRLRPVNL 552  
 Qy 80 PILGICNEPEFLGIVTEYMPNGSLNELLHRKTEYDVAWPLRFRIHLHEIALGVNYLHNM 139  
 Db 553 LFMGAVTSQRLCIYSEFLPRGSLFRLLQKSTKLD--WRRRTHMALDIARGMNYLHCS 610  
 Qy 140 PELLHDLKTONILLDNEFHVKIADFLGSKWRMMSLSQSRSSKSAPEGGTIYMPENYE 199  
 Db 611 PPIIHRDLKSNLLVDKNTVKVADPGLSRIRKIHETILTSGKGTPO----WMAPEVL- 664  
 Qy 200 PQKRSASIKHDIYSYAVITWEVLSRKQPFEDVTPNLOIMYSVSGHRVPIINEESLPYDI 259  
 Db 665 --RNESADKSDIYSFGVYVWELATEKIPWETL-NSMQVIGAVGFMQDRL----EIPKDI 717  
 Qy 260 PHRARMISLIESGWAQNPDRPSPFLKCLILEPVLRTFEEITFLEAVIQLKTK 313  
 Db 718 D--PRWISLMSCHWSDTKLRTFFQELMDKLRDLQRKY-----MIQFQATR 761  
 RESULT 9

Q9S7D5 PRELIMINARY; PRT; 370 AA.  
 AC Q9S7D5  
 DT 01-MAY-2000 (TREMBlrel. 13, Created)  
 DT 01-OCT-2000 (TREMBlrel. 13, Last sequence update)  
 DE PROTEIN KINASE ATNI-LIKE PROTEIN.  
 GN T3A5.110 OR F18B3.10.  
 OS Arabidopsis thaliana (Mouse-ear cress).  
 OC Eukaryota; Viridiplantae; Embryophyta; Tracheophyta; Spermatophyta;  
 OC Magnoliophyta; eudicotyledons; core eudicots; Rosidae; eurosids II;  
 OC Brassicales; Brassicaceae; Arabidopsids.  
 OX NCBI\_TaxID=3702;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RA Bloeker H., Mewes H.W., Lemcke K., Mayer K.F.X., Quetier F.,  
 RA Salanoubat M.;  
 RL Submitted (NOV-1999) to the EMBL/GenBank/DBSJ databases.  
 RN [2]  
 RP SEQUENCE FROM N.A.  
 RA EU Arabidopsis sequencing project;  
 RL Submitted (DEC-1999) to the EMBL/GenBank/DBSJ databases.  
 RN [3]  
 RP SEQUENCE FROM N.A.  
 RA Rieger M., Gabel C., Mueller-Auer S., Schaefer M., Zipp M.,  
 RA Mewes H.W., Mayer K.F.X., Lemcke K., Schueller C., Quetier F.,  
 RA Salanoubat M.;  
 RL Submitted (MAY-1999) to the EMBL/GenBank/DBSJ databases.  
 RN [4]  
 RP SEQUENCE FROM N.A.  
 RA EU Arabidopsis sequencing project;  
 RL Submitted (JUN-1999) to the EMBL/GenBank/DBSJ databases.  
 DR EMBL; AL132979; CAB62442.1; --  
 DR EMBL; AL049862; CAB42902.1; --  
 DR HSSP; P08631; IADS.  
 DR INTERPRO; IPR000719; --  
 DR INTERPRO; IPR001245; --  
 DR PFAM; PF00069; pkinase; 1.  
 DR PRINTS; P00109; TYRKINASE.  
 DR PROSITE; PS00107; PROTEIN\_KINASE\_ATP; 1.  
 DR PROSITE; PS50011; PROTEIN\_KINASE\_DOM; 1.  
 KW Kinase.  
 SQ SEQUENCE 370 AA; 42328 MW; A508F716B432804B CRC64;

Query Match 12.3%; Score 348.5; DB 10; Length 370;  
 Best Local Similarity 29.2%; Pred. No. 3.2e-20;  
 Matches 94; Conservative 63; Mismatches 106; Indels 59; Gaps 13;  
 Qy 44 VAVKHLHIHT--PLDSEKDKVLRAREILHKARFSYIFPILGICNEPEFLGIVTEYMPNG 101  
 Db 61 VAVKIMDPSTTSVAVTKAHHKTKFQKVEVLLSKMKHNDIVFVGACIEPQLI-IVTELVEGG 119  
 Qy 102 SNLHLLHRKTEYDVAWPLRFRIHLHEIALGVNYLHNMTPPLHDLKTONILLDNEF-HV 160  
 Db 120 TLOREHMSRPGPLDKMSLSFAL--DISRAMEFVH--SNGIHRDLNRPRLVTDGLKHV 175  
 Qy 161 KTADFLGSKWRMMSLSQSRSSKSAPEGGTIYMPENYE-----CQKRSASIKHDIYSY 215  
 Db 176 KLADFGIAR-----ETRGGMTC-EAGTSKMAPEVYSPEPLRVGKREYDVKADIYSF 228  
 Qy 216 AVITWEVLSRKQPFEDVTPNLOIMYSVSGHRVPIINEESLPYDIPHRARMISLIESGWAQ 275  
 Db 229 AIVLWGLVINEPEFPDPVNSLFPVLYVSGRRPILKTP---DV-----FVPIVESCWQAQ 280  
 Qy 276 NFERPSPFLKCLILEPVLRTFEEITFLEAVIQLKTKLQSVSSAHLCKKMKMELSLNI 335  
 Db 281 DPDARPEFKSIVMLTNLLR-----RMSDSS-----IGTTL 312  
 Qy 336 P---VNHQPQESCGSSQLHEN 354  
 Db 313 PDGEAYEGEMESENSPQLQEH 334

RESULT 10  
 Q9M8C3 PRELIMINARY; PRT; 763 AA.  
 ID Q9M8C3  
 AC Q9M8C3  
 DT 01-OCT-2000 (TREMBLrel. 15, Created)  
 DT 01-OCT-2000 (TREMBLrel. 15, Last sequence update)  
 DT 01-OCT-2000 (TREMBLrel. 15, Last annotation update)  
 DE PROTEIN KINASE, PUTATIVE.  
 GN F5E6.3.  
 OS Arabidopsis thaliana (Mouse-ear cress).  
 OC Eukaryota; Viridiplantae; Embryophyta; Tracheophyta; Spermatophyta;  
 OC Magnoliophyta; eudicotyledons; core eudicots; Rosidae; euasterids II;  
 OC Brassicales; Brassicaceae; Arabidopsis.  
 OC NCBI\_TaxID=3702;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RC STRAIN=CV. COLUMBIA;  
 RA Lin X., Kaul S., Town C.D., Benito M., Creasy T.H., Haas B., Wu D.,  
 RA Maiti R., Ronning C.M., Koo H., Fujii C.Y., Utterback T.R.,  
 RA Barnstead M.E., Bowman C.L., White O., Nierman W.C., Fraser C.M.;  
 RA "Arabidopsis thaliana chromosome III BAC F5E6 genomic sequence.";  
 RL Submitted (APR-2000) to the EMBL/GenBank/DBJ databases.  
 DR EMBL; AC020580; AAF63629.1; -  
 KW Kinase.  
 SQ SEQUENCE 763 AA; 85593 MW; F6787110603C597C CRC64;  
  
 Query Match 12.3%; Score 348.5; DB 10; Length 763;  
 Best Local Similarity 31.9%; Pred. No. 8.7e-20;  
 Matches 99; Conservative 57; Mismatches 109; Indels 45; Gaps 13;  
  
 QY 24 LSRGASGVSSARHADW-RVQAVKHL--HIHPTLDDSKVDLREAEILHKARFSVIF 79  
 Db 452 IQQSCGTV---YGLWFGSDVAVKLISKQYSEVQSFQEV---SLMQRLRHPNVL 504  
 QY 80 PILGICNEPEFLGIVTEYMPNGSLNELLHRKTEYDVAMPFRILHEIALGVNVLHNM 139  
 Db 505 LFMGAVTLPQGLICVSEFLPRGSLFRLIQRNMSKLD--WRRRINNALDIARGMNYLHRCS 562  
 QY 140 PLLHDKTKTONILLDNEFHVKIADFGLSKWRMMSLSQSSKSAPEGGTIYMPNENYE 199  
 Db 563 PPIHTRDLKSNLLVDKNTLVKADFGLSRKRKHHYLFYSKSGKMPQ----WMAPEVL- 616  
 QY 200 PQKSRASIKHDIYSYAVITWEVLSRKOPFEDVTPNLPQIMYSVQGRPVINEE-SLPYD 258  
 Db 617 --RNESADEKSDIYSFGVVLRELATEKIPWENL-NSMQVICAVG----FMNQRLEIPKD 668  
 QY 259 IPHRMTSLIESGWAQNPDERPFLKCLIELEPVLTFTFEITFEAVIQLKTKLQSVS 318  
 Db 669 ID--PDWISLIESCWHRDAKLRPTFQELMERLRLQPKY-----TIQFOATRAA--- 715  
 QY 319 SAIHLCDKXK 328  
 Db 716 ----LSDKNK 721  
  
 RESULT 11  
 O65833 PRELIMINARY; PRT; 981 AA.  
 ID O65833  
 AC O65833  
 DT 01-AUG-1998 (TREMBLrel. 07, Created)  
 DT 01-AUG-1998 (TREMBLrel. 07, Last sequence update)  
 DT 01-OCT-2000 (TREMBLrel. 15, Last annotation update)  
 DE TCYR2 PROTEIN.  
 GN TCYR2  
 OS Lycopersicon esculentum (Tomato).  
 OC Eukaryota; Viridiplantae; Embryophyta; Tracheophyta; Spermatophyta;  
 OC Magnoliophyta; eudicotyledons; core eudicots; Asteridae; euasterids I;  
 OC Solanales; Solanaceae; Solanum.  
 OC NCBI\_TaxID=4081;  
 RN [1]  
 RP SEQUENCE FROM N.A.

RC STRAIN=CV. AILSA CRAIG;  
 RA Lin Z., Hackett R.M., Payton S., Grierson D.;  
 RL Submitted (MAR-1998) to the EMBL/GenBank/DBJ databases.  
 DR EMBL; AJ005077; CAA06334.1; -  
 DR HSSP; P12931; 1FMK.  
 DR MENDEL; 29910; Lyces; 2342; 29910.  
 DR INTERPRO; IPR000568; -  
 DR INTERPRO; IPR000719; -  
 DR INTERPRO; IPR002290; -  
 DR PFAM; PF00069; pkinase; 1.  
 DR PROSITE; PS00107; PROTEIN\_KINASE\_ATP; 1.  
 DR PROSITE; PS00108; PROTEIN\_KINASE\_ST; 1.  
 DR PROSITE; PS00449; ATPASE\_A; UNKNOWN\_1.  
 DR PROSITE; PS50011; PROTEIN\_KINASE\_DOM; 1.  
 KW Kinase.  
 SQ SEQUENCE 981 AA; 107175 MW; 04522B40F3425068 CRC64;  
  
 Query Match 12.0%; Score 340; DB 10; Length 981;  
 Best Local Similarity 30.8%; Pred. No. 6e-19;  
 Matches 90; Conservative 56; Mismatches 108; Indels 38; Gaps 11;  
  
 QY 13 IPYHKLADRLYLSRGASGVSSARHADWR-VQAVKHLHHTPLLDSE----RKDVLRE 66  
 Db 695 IPWEDLVIGERIGLGSYGEV---YHADWNGTEVAVK-----KFLDQDFSGAALAEFKRE 745  
 QY 67 AEILHKARFSYIPIILGICNEPEFLGIVTEYMPNGSLNELLHRKTEYDVAMPFRILH 126  
 Db 746 VRIMRRLRHPNVLHNMPPPLHDKTKTONILLDNEFHVKIADFGLSKWRMMSLSQSSKSAPE 803  
 QY 127 EIALGVNVLHNMPPPLHDKTKTONILLDNEFHVKIADFGLSKWRMMSLSQSSKSAPE 186  
 Db 804 DVAKGMDCLHTSNTPIVHRDLKSPNLLVDWVYKVCDFGLSRLKHTLFLSSKSTAGTPE 863  
 QY 187 GGTIYMPPE-NVEPGKSRASIKHDIYSYAVITWEVLSRKOPFEDVTPNLPQIMYSVS- 243  
 Db 864 ----WMAPEVLRNEPNE-----KCDIYSEGVLLWELATLRLPWSGM-NPMQVVGAVGF 912  
 QY 244 QGHRPVINEESLPYDIPHRMTSLIESGWAQNPDERPFLKCLIELEPVLR 295  
 Db 913 QNKRLEIPKELDPT-----VARIWECWQTDPNLRPSPAQLTVALTLPQR 957  
  
 RESULT 12  
 O9SFN9 PRELIMINARY; PRT; 1030 AA.  
 ID O9SFN9  
 AC O9SFN9  
 DT 01-MAY-2000 (TREMBLrel. 13, Created)  
 DT 01-MAY-2000 (TREMBLrel. 13, Last sequence update)  
 DT 01-OCT-2000 (TREMBLrel. 15, Last annotation update)  
 DE HYPOTHETICAL 112.2 KDA PROTEIN.  
 GN F25P22.8.  
 OS Arabidopsis thaliana (Mouse-ear cress).  
 OC Eukaryota; Viridiplantae; Embryophyta; Tracheophyta; Spermatophyta;  
 OC Magnoliophyta; eudicotyledons; core eudicots; Rosidae; euasterids II;  
 OC Brassicales; Brassicaceae; Arabidopsis.  
 OC NCBI\_TaxID=3702;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RC STRAIN=CV. COLUMBIA;  
 RA Lin X., Kaul S., Town C.D., Benito M., Creasy T.H., Haas B., Wu D.,  
 RA Ronning C.M., Koo H., Fujii C.Y., Utterback T.R., Barnstead M.E.,  
 RA Bowman C.L., White O., Nierman W.C., Fraser C.M.;  
 RL "Arabidopsis thaliana chromosome I BAC F25P22 genomic sequence.";  
 RL Submitted (JAN-2000) to the EMBL/GenBank/DBJ databases.  
 DR EMBL; AC012679; AAF24836.1; -  
 DR HSSP; P00523; 2PTK.  
 DR INTERPRO; IPR000104; -  
 DR INTERPRO; IPR000719; -  
 DR INTERPRO; IPR001245; -  
 DR INTERPRO; IPR002290; -  
 DR PFAM; PF00069; pkinase; 1.  
 DR PRINTS; PRO0109; TYRKINASE.





Search completed: June 14, 2001, 08:06:41  
Job time: 132 sec

Db 624 --OPGNLRWMAPEVFT--OCTRYTIKADVFSYALCLWELILTGEIFFAHL-KPAAAAADMA 678  
 QY 244 OGH-RPVINEESLVDIPHRARMTSLTESGWAQNPDRSPFLKCLIELEPLVTFEITTF 302  
 Db 679 YHHLRPPIG----YSP--KPISSLIRGNWACPEGRPEFSEVMKLECLCNIE---L 728  
 QY 303 LEAVIQLKTKLQVSSAIIHLCDDK-----KMSLSLNIPVNHGPOEESCG- 347  
 Db 729 MSPASSNSGSLSPSSSDDLNRGGPGRSHVAALRSRFELEYALNAR-SYAALSQSAGQ 787  
 QY 348 -SSQLHENSQSPETSRLP-APQDN-DFLSRKAQDCYFMKLHHCPCGNHSDST 397  
 Db 788 YSSO---GLSLEMKRSLQYTPDKGYVSDPMSMHF---HSCRNSSEEDS 834

RESULT 15  
 Q9LVQ9  
 ID Q9LVQ9 PRELIMINARY; PRT; 405 AA.  
 AC Q9LVQ9;  
 DT 01-OCT-2000 (Tremblrel. 15, Created)  
 DT 01-OCT-2000 (Tremblrel. 15, Last sequence update)  
 DT 01-OCT-2000 (Tremblrel. 15, Last annotation update)  
 DE PROTEIN KINASE ATNI-LIKE PROTEIN.  
 OS Arabidopsis thaliana (Mouse-ear cress).  
 OC Eukaryota; Viridiplantae; Embryophyta; Tracheophyta; Spermatophyta;  
 OC Magnoliophyta; eudicotyledons; core eudicots; Rosidae; eurosids II;  
 OC Brassicales; Brassicaceae; Arabidopsids.  
 OX NCBI\_TaxID=3702;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RC STRAIN=COLUMBIA;  
 RA Sato S., Nakamura Y., Kaneko T., Katoh T., Asamizu E., Kotani H.,  
 RA Tabata S.;  
 RT "Structural analysis of Arabidopsis thaliana chromosome 5. X. Sequence  
 RT features of the regions of 3,076,755 bp covered by sixty pl and TAC  
 RL DNA Res. 7:31-63(2000).  
 DR EMBL; AB018119; BAR97277.1; .  
 KW Kinase.  
 SQ SEQUENCE 405 AA; 46012 MW; C7C4CF29E8DA3111 CRC64;

Query Match 11.8%; Score 332.5; DB 10; Length 405;  
 Best Local Similarity 30.1%; Pred. No. 7.1e-19;  
 Matches 112; Conservative 64; Mismatches 135; Indels 61; Gaps 18;  
 QY 12 TIPYKLIADRLYLSRG---ASGTVSSARHADWR--VQVAVKHLHIHTP-----LLDSERK 61  
 Db 59 TINTELLVDVKDISIGDFIGEGSSSVYRGLFRVYVSVK---IFQPKFTSALSIEQRK 115  
 QY 62 DVLREABILHKARFSYIFPILGICNEPEFLGIVTEYMPNGSLNELLHRKTEYP-DVAVPL 120  
 Db 116 KFOREVLLLSKFRHENIVRFIGACIEPKLM-IITELMEGNTLQKFMLSVVRPKPLDLKLSI 174  
 QY 121 RERLHEIAGVAVYLNMTPLHLDLTKONILL-DNEFHVKIADFGLSKWRMMSLSQSR 179  
 Db 175 SFAL--DIARGMEFLN--ANGIIHRDLKPSNMLLTGDKHVKLADFGLAR-----EET 223  
 QY 180 SSKSAPEGGTIIMYPENY-----EPQKSRASIKKHDIYSYAVITWEVLSRKQPFEDVTN 234  
 Db 224 KGFMTREAGYRWMAPPELFSYDLEIGEKHYDKYDVSFAIVFWELLLTKTPFKGKNN 283  
 QY 235 PLOIMYVSOCHRPVINEESLPYDIPHRARMTSLTESGWAQNPDRSPFLKCLIELEPLV 294  
 Db 284 -IFVAASAQNRPV--ENLPEGV-----VSIQSCWAENPDARPEFKEITYSLTLL 334  
 QY 295 RTFEETLFAVIQLKTKL---QSVSSATH---LGD-----KKMELSINIP 336  
 Db 335 RLSUSD--DATSSNKANATETDSTSSLVQERVCCPLKMSKTKLKKTKNKLMMNI 392  
 QY 337 VNHGPOEESCGS 348  
 Db 393 VPFLKIFKSCMS 404



**THIS PAGE BLANK (USPTO)**

Gencore version 4.5  
Copyright (c) 1993 - 2000 Compugen Ltd.

OM protein - protein search, using sw model

Run on: June 14, 2001, 08:04:28 ; Search time 51.9 seconds  
(without alignments)  
594.762 Million cell updates/sec

Title: US-09-445-223-1

Perfect score: 2829

Sequence: 1 MNGRAICSAITPIYHKLAD.....PEILVRSRPSLNLLQNKSM 540

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 390729 seqs, 57163235 residues

Total number of hits satisfying chosen parameters: 390729

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%  
Maximum Match 100%  
Listing first 45 summaries

- Database : A\_Geneseq\_0401.\*
- 1: /SIDS6/gcgdata/geneseq/geneseqp/AA1980.DAT.\*
  - 2: /SIDS6/gcgdata/geneseq/geneseqp/AA1981.DAT.\*
  - 3: /SIDS6/gcgdata/geneseq/geneseqp/AA1982.DAT.\*
  - 4: /SIDS6/gcgdata/geneseq/geneseqp/AA1983.DAT.\*
  - 5: /SIDS6/gcgdata/geneseq/geneseqp/AA1984.DAT.\*
  - 6: /SIDS6/gcgdata/geneseq/geneseqp/AA1985.DAT.\*
  - 7: /SIDS6/gcgdata/geneseq/geneseqp/AA1986.DAT.\*
  - 8: /SIDS6/gcgdata/geneseq/geneseqp/AA1987.DAT.\*
  - 9: /SIDS6/gcgdata/geneseq/geneseqp/AA1988.DAT.\*
  - 10: /SIDS6/gcgdata/geneseq/geneseqp/AA1989.DAT.\*
  - 11: /SIDS6/gcgdata/geneseq/geneseqp/AA1990.DAT.\*
  - 12: /SIDS6/gcgdata/geneseq/geneseqp/AA1991.DAT.\*
  - 13: /SIDS6/gcgdata/geneseq/geneseqp/AA1992.DAT.\*
  - 14: /SIDS6/gcgdata/geneseq/geneseqp/AA1993.DAT.\*
  - 15: /SIDS6/gcgdata/geneseq/geneseqp/AA1994.DAT.\*
  - 16: /SIDS6/gcgdata/geneseq/geneseqp/AA1995.DAT.\*
  - 17: /SIDS6/gcgdata/geneseq/geneseqp/AA1996.DAT.\*
  - 18: /SIDS6/gcgdata/geneseq/geneseqp/AA1997.DAT.\*
  - 19: /SIDS6/gcgdata/geneseq/geneseqp/AA1998.DAT.\*
  - 20: /SIDS6/gcgdata/geneseq/geneseqp/AA1999.DAT.\*
  - 21: /SIDS6/gcgdata/geneseq/geneseqp/AA2000.DAT.\*
  - 22: /SIDS6/gcgdata/geneseq/geneseqp/AA2001.DAT.\*

Pred: No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Query	Score	Match	Length	DB	ID	Description
1	2829	100.0	540	20	W92795		Human B1 protein.
2	2823	99.8	540	21	Y68774		Amino acid sequenc
3	2823	99.8	540	21	B43570		Human cancer assoc
4	2817	99.6	540	20	Y31140		Human CARD-3 prote
5	2774	98.1	531	21	Y59404		Human RICK protein
6	2497	98.3	478	21	Y59405		Human RICK protein
7	1475	52.1	284	21	Y59407		Human RICK protein
8	867	30.6	167	21	Y59407		Human RICK protein
9	797	28.2	153	21	B58938		Breast and ovarian
10	577	20.4	786	21	Y69163		Amino acid sequenc
11	576	20.4	787	21	Y76079		Murine protein kin

12	576	20.4	787	22	B56018	Skin cell protein,
13	574	20.3	590	21	Y76123	Murine RIP protein
14	574	20.3	590	22	B56062	Skin cell protein,
15	574	20.3	763	21	Y79154	Mouse protein kina
16	536	18.9	536	21	Y76007	Murine RIP protein
17	536	18.9	536	22	B55946	Skin cell protein,
18	394	13.9	656	18	W04627	Mouse receptor int
19	389	13.8	518	21	B01530	Kinase of death (K
20	388	13.7	518	21	B01524	Kinase of death (K
21	388	13.7	656	20	W80994	Human receptor int
22	386.5	13.7	420	21	B01529	Kinase of death (K
23	385	13.6	518	21	B01526	Kinase of death (K
24	380	13.4	518	21	B01525	Kinase of death (K
25	376	13.3	821	16	R80574	Arabidopsis CTRL p
26	376	13.3	821	18	W17938	Constitutive tripl
27	376	13.3	821	22	B50438	Arabidopsis thalia
28	375	13.3	436	21	Y45043	Human Apop3 (1-436
29	375	13.3	519	21	Y45042	Human Apop3 protei
30	372	13.1	261	21	B01527	Kinase of death (K
31	372	13.1	821	15	R46723	Arabidopsis thalia
32	371.5	13.1	671	18	W04628	Human receptor int
33	370	13.1	671	18	W15461	Human receptor int
34	369	13.0	519	21	Y45046	Human Apop3 (K50D)
35	369	13.0	671	21	Y78502	Human RIP-1 amino
36	359	12.7	933	22	B50437	Arabidopsis thalia
37	347	12.3	485	21	B18658	A human regulator
38	341.5	12.1	970	22	B50443	Barley EDR1. Hord
39	340	12.0	982	22	B50439	Tomato TCFR2. Lyc
40	334.5	11.8	835	21	B01470	Human CARK (Cardia
41	334.5	11.8	835	22	B65674	Novel protein kina
42	331	11.7	437	21	Y45047	Human Apop3 (82-51
43	330.5	11.7	903	22	B50440	Rice EDR1. Oryza
44	322.5	11.4	251	21	Y45044	Human Apop3 (1-251
45	316	11.2	984	21	B25544	Eucalyptus grandis

ALIGNMENTS

RESULT 1  
W92795  
ID W92795 standard; Protein; 540 AA.

AC W92795;

DT 07-MAY-1999 (first entry)

DE Human B1 protein.

KW B1 protein; intracellular mediator; modulator; inflammation; cell death;  
cell survival pathway; intracellular signalling; AIDS; cancer; human.

OS Homo sapiens.

PN W09855507-A2.

PD 10-DEC-1998.

PF 01-JUN-1998; 98WO-IL00255.

PR 11-SEP-1997; 97IL-0121746.

PR 05-JUN-1997; 97IL-0121011.

PR 30-JUN-1997; 97IL-0121199.

(YEDA ) YEDA RES & DEV CO LTD.

Boldin M, Malinin N, Wallach D;

WPI: 1999-070258/06.

N-PSDB; X02558.

New B1 protein regulates cell death and cell survival pathways -  
derivatives, DNA and antibodies, also regulate intracellular

FT inflammation; for treating AIDS, cancer  
PS Claim 4; Fig 3A; 90pp; English.  
XX

CC This invention describes the isolation of a novel human B1 protein which  
CC can interact with, intracellular mediators or modulators of inflammation,  
CC cell death and/or cell survival pathways, directly or indirectly. Cells  
CC can be modulated or mediated in inflammation, cell death or cell survival  
CC pathways or another intracellular signalling activity using B1.  
CC Conditions such as AIDS and cancer can be treated using B1. Antibodies,  
CC oligonucleotides and ribozymes can also be used to regulate the above  
CC pathways.  
XX  
SQ Sequence 540 AA;

Query Match 100.0%; Score 2829; DB 20; Length 540;  
Best Local Similarity 100.0%; Pred. No. 5.2e-257;  
Matches 540; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MNGEAICSALEPTIPYKHLADLRVLSRGASCTVSSARHADWRVQVAVKHLHHTPLDLSER 60  
Db 1 mngEAICSALEPTIPYkhlADLRVlsrgASctvSSARhadwrvQvAVkHLhhtPLdLser 60  
Qy 61 KDVLRREABILHARFSTYFPLIGICNPEFELGIVTEYMPNGSLNELLHRKTEYPDVAVPL 120  
Db 61 kdVLRreAbILhARfSTyFPLIGicNpeFELgIVteYmPngSLnELLhRkTEyPDvAVpl 120  
Qy 121 RFRILHETALGVNVLHNMTPPLLHDLKTONILLDNEFHVKIADFGLSKWRMMSLSQSR 180  
Db 121 rfrILhEtAlgvNvLhNmTppLLhDlKtOnIlLdNefHvkiAdfGLskWRmMSlSqsr 180  
Qy 181 SKSAPEGGTIYMPENYEPQKSRASIKHDIYSYAVITWVLSRKQPFEDVTNPLQIMY 240  
Db 181 sksApegGTiYmPeNyEPqKsRAsIkHdIySyaVITwVlSRkQPFEDvTNpLQImy 240  
Qy 241 SVSGHRPVINEESLIPYDIPHRMISLIESGWAQNDDERPSFLKCLIELEPVLRTEEEI 300  
Db 241 svsgHrpVineesLipYdIPhrMISlIEsGwaQnDDerPSfLkClIElePvLrTEeeI 300  
Qy 301 TFLAVIQKTKLQSVSSAHLCDKMKMELSLNIPVNHGPOEESCGSSQLHENSQSPET 360  
Db 301 tflAVIQkTKlQsvSSaHLcdKmkMELslNIPvNHgPOeESCGSSqlHensqSPet 360  
Qy 361 SRSLPAPQDNFLSRKAQDCYFMKLHHCPCGNHSDSTISSGORAFCDDHKTTPCSSLAIN 420  
Db 361 srslpApQdnfLsrKaqDcyfMklhHcpcGNhSDstISSgORaFCDDhktTPcSSlAIN 420  
Qy 421 PLSTAGNSERLQPGTAQMIQSKREDIYNQWTEACLNQSLDALLSRDLIMKEDYELVSTK 480  
Db 421 plstAgnsERlqPgTaqMIqSKredIYNqWteAClnQsLDallSRdlImkEdYelVstK 480  
Qy 481 PRTSKVRQLLDTTIOGEEFAKVIQKLDKQKQMLQYQYPIIVVSRPSLNLLQNKSM 540  
Db 481 prtSkvRqLLdTTIOgEEfAKvIQkLDkQkQmLqYqYpIIVvSRpsLNllQnkSm 540

RESULT 2  
Y68774.  
ID Y68774 standard; Protein; 540 AA.  
AC Y68774;  
XX  
DT 16-MAY-2000 (first entry)  
XX  
DE Amino acid sequence of a human phosphorylation effector PHSP-6.  
XX  
KW Human; phosphorylation effector; PHSP; proliferative disorder;  
KW immune disorder; neuronal disorder.  
XX  
OS Homo sapiens.  
XX  
FH Key Location/Qualifiers

Region 18..287  
FT /note= "protein kinase family signature sequence"  
FT Modified-site 23  
FT /note= "potential phosphorylation site"  
FT Modified-site 34  
FT /note= "potential phosphorylation site"  
FT Modified-site 58  
FT /note= "potential phosphorylation site"  
FT Modified-site 100  
FT /note= "potential phosphorylation site"  
FT Modified-site 102  
FT /note= "potential phosphorylation site"  
FT Modified-site 180  
FT /note= "potential phosphorylation site"  
FT Modified-site 183  
FT /note= "potential phosphorylation site"  
FT Modified-site 207  
FT /note= "potential phosphorylation site"  
FT Modified-site 224  
FT /note= "potential phosphorylation site"  
FT Modified-site 267  
FT /note= "potential phosphorylation site"  
FT Modified-site 296  
FT /note= "potential phosphorylation site"  
FT Modified-site 301  
FT /note= "potential phosphorylation site"  
FT Modified-site 360  
FT /note= "potential phosphorylation site"  
FT Modified-site 374  
FT /note= "potential phosphorylation site"  
FT Modified-site 391  
FT /note= "potential glycosylation site"  
FT Modified-site 401  
FT /note= "potential phosphorylation site"  
FT Modified-site 428  
FT /note= "potential phosphorylation site"  
FT Modified-site 442  
FT /note= "potential phosphorylation site"  
FT Modified-site 457  
FT /note= "potential glycosylation site"  
FT Modified-site 478  
FT /note= "potential phosphorylation site"  
FT Modified-site 478  
FT /note= "potential phosphorylation site"  
FT Modified-site 484  
FT /note= "potential phosphorylation site"  
FT Modified-site 537  
FT /note= "potential glycosylation site"  
XX WC200006728-A2.  
XX 10-FEB-2000.  
XX 28-JUL-1999; 99WO-US17132.  
XX 28-JUL-1998; 98US-0123494.  
XX 14-SEP-1998; 98US-0152814.  
XX 14-OCT-1998; 98US-0173482.  
XX 03-NOV-1998; 98US-0106889.  
XX 19-NOV-1998; 98US-0109093.  
XX 22-DEC-1998; 98US-0113796.  
XX 12-JAN-1999; 99US-0173482.  
XX 12-JAN-1999; 99US-0229005.  
XX (INCY-) INCYTE PHARM INC.  
XX Hillman JL, Lal P, Tang YT, Corley NC, Guegler KJ, Baughn MR.  
XX Patterson C, Bandman O, Au-Young J, Gorgone GA, Yue H, Azimzai Y,  
XX Reddy R, Lu DAM, Shih LL;  
XX WPI; 2000-103125/16.  
XX DR N-PSDB; 246143.  
XX



PT New human phosphorylation effectors useful for the diagnosis, immune and neuronal disorders  
 XX and prevention of proliferative, immune and neuronal disorders  
 PS Claim 1; Page 84-85; 142pp; English.  
 XX  
 CC Y68769-95 and Y68797-99 represent human phosphorylation effectors (PHSP),  
 CC designated PHSP1-PHSP31 (The protein sequence for PHSP28 is not given  
 CC in the specification). The sequences were isolated from cDNA libraries  
 CC prepared from various human tissues. The PHSP proteins are useful for  
 CC the diagnosis, treatment and prevention of proliferative disorders,  
 CC immune disorders and neuronal disorders. The PHSP proteins form  
 CC pharmaceutical compositions which useful for treating or preventing  
 CC disorders associated with decreased PHSP expression/activity. PHSP  
 CC antagonists are useful for treating or preventing disorders associated  
 CC with increased PHSP expression/activity.  
 XX  
 SQ Sequence 540 AA;

Query Match 99.8%; Score 2823; DB 21; Length 540;  
 Best Local Similarity 99.8%; Pred. No. 1.9e-256;  
 Matches 539; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1 MNGEAIKALPTIPYHKLADRYLSRGASGVSSARHADRWVQVAVKHLHHTPLDSE 60  
 Db 1 mngeaiclsalptipyhkladrylsrgasgtvssarhadrwvqavkhlhhtplldser 60  
 Qy 61 KDVLEAEILHKARFSYFPILGICNEPEFLGIVTEYMPNGSLNELLHRKTEYDVAWPL 120  
 Db 61 kdvlreaeilhkarfsyfpilgicnepeflgivteympngslnellhrkteydvawpl 120  
 Qy 121 RFRILHEIALGVNLYLHNMTPPLLHDLKTONILLDNEFHVKIADFGLSKWRMMSLSQSR 180  
 Db 121 rfrilheialgvnlylhnmtppllhdldktonilldnefhnvkiadfglskwrmslsqsr 180  
 Qy 181 SKSAPGEGTIIYMPPEYEPGOKSRASIKHDIYSYAVITWVLSRKQPFEDVTPNLIQIMY 240  
 Db 181 sksapeggtiymppenyepgoksraskhdiysyavitwvlsrkqpfedvtpnlqimy 240  
 Qy 241 SVSGHRPVIINESLYDIPHRARMISLIESGWAQNDPERSFLKCLIELEPVLRTFEEI 300  
 Db 241 svsghrpviineeslydiphrarmisliesgwaqndpersflkclielepvlrtfee 300  
 Qy 301 TFLAVIQLKTKLQSVSSAHLCDKMKMELSLNIPVNHGQFEGSCGSSQLHENSQSPET 360  
 Db 301 tflaviqkktkqsvssahlcdkkmkmslnipvnhgqfegscgssqlhensqspet 360  
 Qy 361 SRSLPAPQDNDFLSRKAQDCYFMKHLHCPGNHSDWSTISGSRQAFCDHKTTPCSSALIN 420  
 Db 361 srslpapqdnndfslrkaqdcyfmkhlhcpgnhswdstisgsraqafcdhkttpcssalin 420  
 Qy 421 PLSTAGNERLQPGFAQOQWIOSKREDIVNMTQEAACLNQSLDALLSRDLIMKEDYELVSTK 480  
 Db 421 plstagnserlqpgfaqoqwioskredivnmtqeaaclnqslldallsrdlmkedyelvst 480  
 Qy 481 PRTSKVRLDITDIOGEEFAKIVQKLDKQKMGLOQYPEILVYVSRSPSLNLLQKSM 540  
 Db 481 prtskvrllditdigeeefakivqkldkqkmgloqypelivyvrspslnllqkms 540

RESULT 3  
 B43570 ID B43570 standard; Protein; 544 AA.  
 XX AC B43570;  
 XX AC B43570;  
 DT 08-FEB-2001 (first entry)  
 XX Human cancer associated protein sequence SEQ ID NO:1015.  
 DE Human; cancer associated gene: cancer antigen; detection; cancer;  
 KW diagnosis; cytosolic; proliferative; vulnerable; immunomodulator;  
 KW antidiabetic; antiasthmatic; antirheumatic; antiarthritic; antiviral;

KW antiinflammatory; antithyroid; antiallergic; antibacterial; cardiant;  
 KW dermatological; neuroprotective; thrombolytic; coagulant; nootropic;  
 KW vasotopic; antipsoriatic; antiangiogenic; gene therapy; inflammation;  
 KW immune disorder; haematopoietic cell disorder; autoimmune disorder;  
 KW allergic reaction; graft versus host disease; organ rejection;  
 KW haemostatic; thrombolytic; cardiovascular disorder; infection;  
 KW neurological disease; drug screening.  
 OS Homo sapiens.  
 PN WO200055350-A1.  
 XX 21-SEP-2000.  
 XX 08-MAR-2000; 2000WO-US05882.  
 XX 12-MAR-1999; 99US-0124270.  
 XX (HUMA-) HUMAN GENOME SCI INC.  
 XX Rosen CA, Ruben SM;  
 XX WPI: 2000-587533/55.  
 XX N-PSDB: C77779.  
 PT Novel isolated nucleic acids comprising sequences encoding peptides  
 XX useful for treating or diagnosing e.g. cancer  
 XX Claim 11; Page 1595-1597; 2352pp; English.  
 CC C77607 to C78448 encode the human cancer associated proteins given in  
 CC B43398 to B44239. The proteins can have activities based on the tissues  
 CC and cells the genes are expressed in. Example of activities include:  
 CC cytosolic; proliferative; vulnerable; immunomodulator; antidiabetic;  
 CC antiasthmatic; antirheumatic; antiarthritic; antiinflammatory;  
 CC antithyroid; antiallergic; antibacterial; antiviral; dermatological;  
 CC neuroprotective; cardiant; thrombolytic; coagulant; nootropic;  
 CC vasotopic; antipsoriatic and antiangiogenic. The polynucleotides and  
 CC polypeptides can be used for preventing, treating or ameliorating medical  
 CC conditions and diagnosing pathological conditions. Polynucleotides,  
 CC polypeptides, antibodies, agonists and antagonists from the present  
 CC invention may be used to treat immune disorders by activating or  
 CC inhibiting the proliferation, differentiation or mobilisation of immune  
 CC cells, to treat disorders of haematopoietic cells, autoimmune disorders,  
 CC allergic reactions, graft versus host disease and organ rejection,  
 CC modulate haemostatic or thrombolytic activity, modulate inflammation,  
 CC cancers, cardiovascular disorders, neurological disease and bacterial or  
 CC viral infections. The peptides, nucleotides, antibodies, agonists and  
 CC antagonists may be also be used in drug screens. C78449 to C78457 and  
 CC B44240 represent sequences used in the exemplification of the present  
 CC invention.  
 XX  
 SQ Sequence 544 AA;

Query Match 99.8%; Score 2823; DB 21; Length 544;  
 Best Local Similarity 99.8%; Pred. No. 1.9e-256;  
 Matches 539; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1 MNGEAIKALPTIPYHKLADRYLSRGASGVSSARHADRWVQVAVKHLHHTPLDSE 60  
 Db 5 mngeaiclsalptipyhkladrylsrgasgtvssarhadrwvqavkhlhhtplldser 64  
 Qy 61 KDVLEAEILHKARFSYFPILGICNEPEFLGIVTEYMPNGSLNELLHRKTEYDVAWPL 120  
 Db 65 kdvlreaeilhkarfsyfpilgicnepeflgivteympngslnellhrkteydvawpl 124  
 Qy 121 RFRILHEIALGVNLYLHNMTPPLLHDLKTONILLDNEFHVKIADFGLSKWRMMSLSQSR 180  
 Db 125 rfrilheialgvnlylhnmtppllhdldktonilldnefhnvkiadfglskwrmslsqsr 184  
 Qy 181 SKSAPGEGTIIYMPPEYEPGOKSRASIKHDIYSYAVITWVLSRKQPFEDVTPNLIQIMY 240  
 Db 181 sksapeggtiymppenyepgoksraskhdiysyavitwvlsrkqpfedvtpnlqimy 240

Db 185 sksapeggtiymppenyepgqksrasikhdiysyavitwevlsrkqpfedvtnplqimy 244  
 QY 241 SVSQGHRPVINEESLPYDIPHRARMISLIESGWAQNPDRPSPFLKCLIELEPLVLRFFEEI 300  
 Dd 245 svsgghrpvinesepdydipharmisliesgwaqnpdrpderpsflkclieleplvtrfteei 304  
 QY 301 TFLAVIQLKTKYKQVSSAIHLCDKMKMELSLNIPVNHGPOEESGSQLHENSQSPPT 360  
 Dd 305 tflavaiqlkktklqsvsaihldckkkmelslnipvnhgpgqeescgssqlhensgspt 364  
 QY 361 SRSLPAPQNDFLSRKAOQCYFPMKLLHPCGNSHSDSTISGQRAAFCDHKHTTPCSSAIIN 420  
 Dd 365 srslpapqndfslrkaqcymkllhpcgnswhdstisgsraafcdhktkpcssaain 424  
 QY 421 PLSTAGNSERLQPIAQQWIOSKREDIVNQWTEACLNSQSLDALLSRDLIMKEDYELVSTK 480  
 Dd 425 plstagnserlqpiaggwioskredivngmteacnsgldallsrdlimkedyelvstck 484  
 QY 481 PRTTSKVRQLDPTDIOGEEFAKVIYQKLDKQKMGLOPYPELLVYRSFSLNLLQNKSM 540  
 Dd 485 prttskvrqltdtdioggeefakvivqkldkqkmglopyPELLVYRSFSLNllqpkam 544

RESULT 4  
 Y31140  
 ID Y31140 standard; Protein; 540 AA.  
 XX Y31140;

DT 25-OCT-1999 (first entry)  
 DE Human CARD-3 protein.

XX CARD-3; caspase recruitment domain; CARD-4; regulation; detection;  
 KW caspase activation; detection; screening; therapy; diagnosis; disease;  
 KW apoptotic cell death; Fas/APO-1 receptor complex; TNF receptor complex;  
 KW cancer; follicular lymphoma; carcinoma; p53 mutation; viral infection;  
 KW hormone-dependent tumour; autoimmune disorder; Alzheimer's disease;  
 KW systemic lupus erythematosus; immune-mediated glomerulonephritis; stroke;  
 KW Parkinson's disease; amyotrophic lateral sclerosis; retinitis pigmentosa;  
 KW spinal muscular dystrophy; cerebellar degeneration; anaemia; drug;  
 KW myelodysplastic syndrome; myocardial infarction; cell proliferation;  
 KW cell differentiation; cell survival; CARD-4L; CARD-4S; CARD-4Y;  
 KW CARD-4Z; human.  
 XX Homo sapiens.

XX Location/Qualifiers  
 FH Domain 1..300  
 FT /note= "predicted kinase domain"  
 FT Domain 301..431  
 FT /note= "predicted linker domain"  
 FT Domain 432..540  
 FT /note= "predicted CARD domain"

PN W09940102-A1.  
 XX 12-AUG-1999.  
 XX 05-FEB-1999; 99WO-US02544.  
 XX 08-DEC-1998; 98US-0207359.  
 PR 06-FEB-1998; 98US-0019942.  
 PR 17-JUN-1998; 98US-0099041.  
 XX (MILL-) MILLENNIUM PHARM INC.  
 XX Bertin J;  
 XX WPI; 1999-494269/41.  
 DR N-PSDB; 209246.

XX Novel CARD-3 and CARD-4 genes and polypeptides used or treating

PT regulation of cellular proliferation and differentiation and cell  
 FT survival

XX Example 2; Fig 2; 181pp; English.

CC This invention describes the isolation of novel human caspase  
 CC recruitment domain, CARD-3 and CARD-4 polynucleotides and proteins and a  
 CC partial murine CARD-4L protein and genes. The genes and proteins of  
 CC the invention are involved in the regulation of caspase activation.  
 CC The caspase recruitment domain (CARD) polynucleotides, polypeptides,  
 CC homologues and antibodies can be used in screening assays, detection  
 CC assays, predictive medicine and therapeutic and prophylactic methods of  
 CC treatment. The methods may be used to diagnose and treat patients which  
 CC are suffering from a disorder associated with abnormal level or rate of  
 CC apoptotic cell death, abnormal activity of the Fas/APO-1 receptor  
 CC complex, abnormal activity of the TNF receptor complex, or abnormal  
 CC activity of a caspase. Diseases that may be treated include with mutations  
 CC (particularly follicular lymphoma, carcinomas associated with mutations  
 CC in p53 and hormone-dependent tumours), autoimmune disorders (e.g.  
 CC systemic lupus erythematosus, immune-mediated glomerulonephritis), viral  
 CC infections, Alzheimer's disease, parkinson's disease, amyotrophic lateral  
 CC sclerosis, retinitis pigmentosa, spinal muscular dystrophy, cerebellar  
 CC degeneration, anaemia, myelodysplastic syndrome, myocardial infarction,  
 CC and stroke. CARD-3 protein interacts with other cellular proteins, and so  
 CC can be used for regulation of cellular proliferation and differentiation  
 CC and cell survival. The CARD proteins may also be used to screen drugs  
 CC or compounds which modulate their activity. The CARD-4 gene can express a  
 CC long transcript that encodes CARD-4L, a short transcript that encodes  
 CC CARD-4S or two CARD-4 splice variants, CARD-4Y and CARD-4Z. This sequence  
 CC represents the human CARD-3 protein described in the method of the  
 CC invention.

XX Sequence 540 AA;

QY Query Match 99.6%; Score 2817; DB 20; Length 540;  
 Dd Best Local Similarity 99.6%; Pred. No. 6.9e-256;  
 QY Matches 538; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1 MNGEATCSALPTIPYHKADLRYLSRGASGTVSSARHADRWVAVKHLIHTPLDLSR 60  
 Dd 1 mngaeatcsalptipyhkadiadlyrsgasgtsvssarhadrwvavkhlhhtplldsr 60  
 QY 61 KDVLREAEILHKARFSYIFPILGICNEPEFLGIVTEYMPNGSLNELLHRRKTEYPDVAVPL 120  
 Dd 61 kdvlreaeilhkarsyifpiligicnepeflgivteympngslnellhrkteydvavpl 120  
 QY 121 RFRILHEIALGVNYLHNMTPPLLHDLKTONILLDNEFHVKIADFGLSKWRMMSLSQRS 180  
 Dd 121 rfrilheialgvnylhnmtppllhdldktonilldnefhwkiadfglskrwmmslsqrs 180  
 QY 181 SKSAPEGGTIYMPPENYEPGQKSRAIKHDIYSYAVITWEVLSRKQPFEDVTPNPLQIMY 240  
 Dd 181 sksapeggtiymppenyepgqksrasikhdiysyavitwevlsrkqpfedvtnplqimy 240  
 QY 241 SVSQGHRPVINEESLPYDIPHRARMISLIESGWAQNPDRPSPFLKCLIELEPLVLRFFEEI 300  
 Dd 241 svsgghrpvinesepdydipharmisliesgwaqnpdrpderpsflkclieleplvtrfteei 300  
 QY 301 TFLAVIQLKTKYKQVSSAIHLCDKMKMELSLNIPVNHGPOEESGSQLHENSQSPPT 360  
 Dd 301 tflavaiqlkktklqsvsaihldckkkmelslnipvnhgpgqeescgssqlhensgspt 360  
 QY 361 SRSLPAPQNDFLSRKAOQCYFPMKLLHPCGNSHSDSTISGQRAAFCDHKHTTPCSSAIIN 420  
 Dd 361 srslpapqndfslrkaqcymkllhpcgnswhdstisgsraafcdhktkpcssaain 420  
 QY 421 PLSTAGNSERLQPIAQQWIOSKREDIVNQWTEACLNSQSLDALLSRDLIMKEDYELVSTK 480  
 Dd 421 plstagnserlqpiaggwioskredivngmteacnsgldallsrdlimkedyelvstck 480  
 QY 481 PRTTSKVRQLDPTDIOGEEFAKVIYQKLDKQKMGLOPYPELLVYRSFSLNLLQNKSM 540  
 Dd 481 prttskvrqltdtdioggeefakvivqkldkqkmglopyPELLVYRSFSLNllqnksm 540



Db 481 prtstkrvrlldtdtdiggeefakvivqklkdnkqmgllqpypeillvvsrspslnllqkmsk 540

RESULT 5  
Y59404

ID Y59404 standard; Protein; 531 AA.  
AC Y59404;  
XX  
XX 21-MAR-2000 (first entry)  
DE Human RICK protein sequence.  
XX  
XX RICK; human; RIP-like interacting CLARP kinase; apoptosis regulator; ARC;  
KW caspase-8; caspase-10; CD95 signalling; apoptosis signalling pathway;  
KW CIDE-A; CIDE-B; DREP-1; diagnosis; cell growth; apoptosis dysregulation;  
KW gene therapy; cardiac disorder; cancer; neurodegenerative disorder; AIDS;  
KW aplastic anaemia; ischaemic injury; toxin-induced liver disease.  
XX  
OS Homo sapiens.  
XX  
XX W09955134-A2.  
XX  
XX 04-NOV-1999.  
XX  
XX 27-APR-1999; 99WO-US09183.  
XX  
XX 27-APR-1998; 98US-0069023.  
XX  
XX (UNMI ) UNIV MICHIGAN.  
XX  
XX Nunez G, Inohara N, Koseki T;  
XX  
XX WPI: 2000-072163/06.  
XX  
XX Compositions for identifying apoptosis signalling pathway inhibitors  
XX useful for treating diseases  
XX  
XX Claim 1; Fig 7a; 93pp; English.  
XX  
XX This sequence is the human RICK (RIP-like interacting CLARP kinase)  
XX protein of the invention. The RICK protein acts as a positive regulator  
XX of apoptosis, potentiating apoptosis induced by caspase-8 and caspase-10  
XX during CD95 signalling. The invention provides methods for identifying  
XX apoptosis signalling pathway inhibitors and activators, and methods and  
XX compositions for screening compounds which will modulate the interactions  
XX of the various compositions identified: ARC, RICK, and the CIDE family of  
XX activators (CIDE-A, CIDE-B and DREP-1). RICK is useful in screening  
XX assays for agents, useful in the diagnosis, prognosis or treatment of  
XX disease associated with excess cell growth and dysregulation of  
XX apoptosis. Complexes containing RICK and CLARP can be used in drug  
XX screening assays to identify inhibitor molecules blocking CD95-mediated  
XX apoptosis. Overexpression of ARC in an in vitro cell system can be used  
XX to identify inhibitors of the enzymatic activity of caspase-8.  
XX Identification of ARC-like inhibitory compounds may be useful for gene  
XX therapy treatment of disease with increased cell death in muscle tissue  
XX and cardiac disorders. Therapeutic compositions of CIDEs can be used to  
XX treat e.g. cancer, AIDS, neurodegenerative disorders, aplastic anaemia,  
XX ischaemic injury, and toxin-induced liver disease. Antirick antibodies  
XX can be used as reagents for the preparation of affinity chromatography  
XX media, and for diagnostically measuring RICK levels. A specific inhibitor  
XX of an essential step in the biochemistry of apoptosis is needed. RICK  
XX interaction with intracellular factors such as CLARP and FADD appears to  
XX be essential for apoptosis. Inhibitors of RICK binding to intracellular  
XX apoptosis factors are potential drug candidates.  
XX  
XX 50 Sequence 531 AA;

Query Match 98.1%; Score 2774; DB 21; Length 531;  
Best Local Similarity 99.6%; Pred. No. 7.4e-252;  
Matches 529; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

Qy 10 LPTIPYHKLADLYLSRGASGTVSSARHADWRVQVAVKHLHHTPLDLSERKDVLRREAEI 69  
:|||||  
Db 1 mptlpyhkladlrylrgasgtvssarhadwrqvavkhlhhtpldlsrkdvireaei 60  
Qy 70 LHKARFSYIFFILGICNEPEFLGIVTEYMPNGSLNELLHRKTEYDPVAVPLFRLLHEIFA 129  
:|||||  
Db 61 lhkarfsyiffilgicnepeflgivteympngslnellhrkteydpvavplfrilheifa 120  
Qy 130 LCVNYLHNWTPPLHLHLKTONILLDNFHVKIDAFGLSKWRMMSLSOSRSSKSAPEGGT 189  
:|||||  
Db 121 lgvnylhnwtpplhlhldktonilldnfshvkiaafglskwrmmsslsqrsrsksaapeggt 180  
Qy 190 IYPPENYEPQKSRASIKHDIYSYAVITWEVLSRKQPFEDVTNPLQIMYSVSGHRPV 249  
:|||||  
Db 181 iyppenyepqkkrasikhdhysyavitwevlsrkqpfedvtntplqimysvsghrpv 240  
Qy 250 INEESLPYDIPHRARMSLIESGWAQNDPDRPFLKCLIELEPVLTFFEEITFLEAVIQL 309  
:|||||  
Db 241 ineeslpydipharmisliesgwaqndpdrpflkclielepvltffeeitfleavql 300  
Qy 310 KKTKLQSVSSATHLCKKKMELSLNIPYVNHGQPEESQSSQLHNSGSPETSRLPAPQD 369  
:|||||  
Db 301 kktklqsvssathlckkkmelslnipvnhgqpeescssqlhnsdspetsrslpabqd 360  
Qy 370 NDFLSRKAQDCVFMKLRHCPGNHSDSTISGSORAAFCDHKTPCSSAIINPLSTAGNSE 429  
:|||||  
Db 361 ndflsrkaqdcvfmklrhcpgnhsdstisgsoraaafdchktppcssaiinplstagnse 420  
Qy 430 RLQPGIAQQWIQSKREDIVNQMTACLMSLDALSRLLMKEDYELVSTKPTRTSKVRQ 489  
:|||||  
Db 421 rlqpgiaqqwinqskredivnqmtaclmsldalsrllmkedyelvstkprrtskvrq 480  
Qy 490 LLDFTDIOGEEFAKVIYVOKLNDKQKQMLQPEIILVWSRSPSLNLLQNKSM 540  
:|||||  
Db 481 lldftdigeefakvivqklkdnkqmgllqpypeillvvsrspslnllqkmsk 531

RESULT 6  
Y59405  
ID Y59405 standard; Protein; 478 AA.  
XX  
AC Y59405;  
XX  
DT 21-MAR-2000 (first entry)  
XX  
DE Human RICK protein sequence residues 54-531.  
XX  
KW RICK; human; RIP-like interacting CLARP kinase; apoptosis regulator; ARC;  
KW caspase-8; caspase-10; CD95 signalling; apoptosis signalling pathway;  
KW CIDE-A; CIDE-B; DREP-1; diagnosis; cell growth; apoptosis dysregulation;  
KW gene therapy; cardiac disorder; cancer; neurodegenerative disorder; AIDS;  
KW aplastic anaemia; ischaemic injury; toxin-induced liver disease.  
XX  
OS Homo sapiens.  
XX  
XX W09955134-A2.  
XX  
XX 04-NOV-1999.  
XX  
XX 27-APR-1999; 99WO-US09183.  
XX  
XX 27-APR-1998; 98US-0069023.  
XX  
XX (UNMI ) UNIV MICHIGAN.  
XX  
XX Nunez G, Inohara N, Koseki T;  
XX  
XX WPI: 2000-072163/06.  
XX  
XX Compositions for identifying apoptosis signalling pathway inhibitors  
XX useful for treating diseases  
XX

PS Claim 6; Page -: 93pp; English.

XX This sequence is a fragment of the human RICK (RIP-like interacting CLARP kinase) protein of the invention. RICK acts as a positive regulator of apoptosis, potentiating apoptosis induced by caspase-8 and caspase-10 during CD95 signalling. The invention provides methods for identifying apoptosis signalling pathway inhibitors and activators, and methods and compositions for screening compounds which will modulate the interactions of the various compositions identified: ARC, RICK, and the CIDE family of activators (CIDE-A, CIDE-B and DREP-1). RICK is useful in screening assays for agents, useful in the diagnosis, prognosis or treatment of disease associated with excess cell growth and dysregulation of apoptosis. Complexes containing RICK and CLARP can be used in drug screening assays to identify inhibitor molecules blocking CD95-mediated apoptosis. Overexpression of ARC in an in vitro cell system can be used to identify inhibitors of the enzymatic activity of caspase-8. Identification of ARC-like inhibitory compounds may be useful for gene therapy treatment of disease with increased cell death in muscle tissue and cardiac disorders. Therapeutic compositions of CIDEs can be used to treat e.g. cancer, AIDS, neurodegenerative disorders, aplastic anaemia, ischaemic injury, and toxin-induced liver disease. AntiRICK antibodies can be used as reagents for the preparation or affinity chromatography media, and for diagnostically measuring RICK levels. A specific inhibitor of an essential step in the biochemistry of apoptosis is needed. RICK interaction with intracellular factors such as CLARP and FADD appears to be essential for apoptosis, inhibitors of RICK binding to intracellular factors are potential drug candidates. Note: This sequence was created using information given in the specification.

XX Sequence 478 AA;

Query Match 88.3%; Score 2497; DB 21; Length 478; Best Local Similarity 99.8%; Pred. No. 6.7e-226; Matches 477; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 63 VLREAELHKARFSYFPIILGICNEPEFLGIVTEYMPNGSLNELLHRKTEYFDVAVPLRF 122
Db 1 vlreaelhkarsfyfpiilgicnepelfgivteympngslnellhrkteyfdvavplrf 60
QY 123 RILHEALGVNYLHNTWPLLDKTONILLDNEFHVKIADPGLSKRMSISQSRSSK 182
Db 61 rilhelalgvnylhmtptllhdktqnlilldnefhvkiadpfglskrwmmslsgrssk 120
QY 183 SAPEGGTIIYMPPEYFGQKSRASIKHDIYSYAVITWEVLSRKQPFEDVTNPLQIMYSV 242
Db 121 sapeggtiymppeneyfgqksrasikhdiysyavitwevlsrkqpfedvtnplqimysv 180
QY 243 SQGHRPVINEESLPYDIPHRMISLIESGWAQNPDERPSFKLLELPVLTFFEEITF 302
Db 181 sqghrpvineeslpydiphrmisliesgwaqnpderpsfkllelepvlrtffeeitf 240
QY 303 LEAVIOLKTKLOSVAIHLCDKKEWLSLNTPVNHGQEECSGSQLHENSQSPETS 362
Db 241 leavigliktklgsvasahcdkkmwlslntpvnhgqeesqsgsqlhensqspetsr 300
QY 363 SLPAPONDLSRKAQDCYPMKLRHCPGNHSDSTISGQRAAFCDHKTPCSSALINPL 422
Db 301 slpapqndflsrkaqdcyfmklrhpcpghnhsdstisgqraafcdhktppcssalinpl 360
QY 423 STAGNSERLQPIAQOIQSKREDIVNQMTFACLNQSLDALSRDLIMKEDYELVSTKPT 482
Db 361 stagnserlqpiagqiwqskredivnqmtfaclnqslgdallsrdlimkedyelvstkpt 420
QY 483 RTSKVRQLLDTIQEFAKVIYOKLKDKNQKGLQPYPELILVVSRSPLNLLQNKSM 540
Db 421 rtskvrqlldtdiqeefakviyoklkdknqkmgllqpypeililvvsrspsnlllqnksm 478

RESULT 7
Y59406
ID Y59406 standard; Protein; 284 AA.

XX AC

XX DT 21-MAR-2000 (first entry)

XX DE Human RICK protein sequence residues 248-531.

XX KW RICK: human; RIP-like interacting CLARP kinase; apoptosis regulator; ARC; caspase-8; caspase-10; CD95 signalling; apoptosis signalling pathway; CIDE-A; CIDE-B; DREP-1; diagnosis; cell growth; apoptosis dysregulation; gene therapy; cardiac disorder; cancer; neurodegenerative disorder; AIDS; aplastic anaemia; ischaemic injury; toxin-induced liver disease.

XX OS Homo sapiens.

XX PN W09955134-A2.

XX PD 04-NOV-1999.

XX PF 27-APR-1999; 99WO-US09183.

XX PR 27-APR-1998; 98US-0069023.

XX PA (UNMI ) UNIV MICHIGAN.

XX PI Nunez G, Inohara N, Koseki T;

XX DR WPI; 2000-072163/06.

XX PT Compositions for identifying apoptosis signalling pathway inhibitors useful for treating diseases -

XX PS Claim 6; Page -: 93pp; English.

XX This sequence is a fragment of the human RICK (RIP-like interacting CLARP kinase) protein of the invention. RICK acts as a positive regulator of apoptosis, potentiating apoptosis induced by caspase-8 and caspase-10 during CD95 signalling. The invention provides methods for identifying apoptosis signalling pathway inhibitors and activators, and methods and compositions for screening compounds which will modulate the interactions of the various compositions identified: ARC, RICK, and the CIDE family of activators (CIDE-A, CIDE-B and DREP-1). RICK is useful in screening assays for agents, useful in the diagnosis, prognosis or treatment of disease associated with excess cell growth and dysregulation of apoptosis. Complexes containing RICK and CLARP can be used in drug screening assays to identify inhibitor molecules blocking CD95-mediated apoptosis. Overexpression of ARC in an in vitro cell system can be used to identify inhibitors of the enzymatic activity of caspase-8. Identification of ARC-like inhibitory compounds may be useful for gene therapy treatment of disease with increased cell death in muscle tissue and cardiac disorders. Therapeutic compositions of CIDEs can be used to treat e.g. cancer, AIDS, neurodegenerative disorders, aplastic anaemia, ischaemic injury, and toxin-induced liver disease. AntiRICK antibodies can be used as reagents for the preparation or affinity chromatography media, and for diagnostically measuring RICK levels. A specific inhibitor of an essential step in the biochemistry of apoptosis is needed. RICK interaction with intracellular factors such as CLARP and FADD appears to be essential for apoptosis, inhibitors of RICK binding to intracellular factors are potential drug candidates. Note: This sequence was created using information given in the specification.

XX SQ Sequence 284 AA;

Query Match 52.1%; Score 1475; DB 21; Length 284; Best Local Similarity 100.0%; Pred. No. 3.1e-130; Matches 284; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 257 YDIPHRMISLIESGWAQNPDERPSFKLLELPVLTFFEEITFLEAVIOLKTKLOS 316
Db 1 ydiphrmisliesgwaqnpderpsfkllelepvlrtffeeitfleavliqkktkls 60

Qy 317 VSSAIHLCDKKMELSLNIPVNHGPEESQSSQLHENSQSPETSRLPAPQNDLFRK 376  
 |||  
 Db 61 vssahlcdkkmelslnipvnhgpeesqssqlhensgpetrsr.papqndflsrk 120  
 Qy 377 AQDCYFMKHLHPCGNHSDSTISGSRAAFCDHKHTPPCSSAIINPLSTAGNSERLQPIA 436  
 |||  
 Db 121 agdcyfmklhpcgnhswdstisgsraafcdhkttpcssainplstagnserlqpi 180  
 Qy 437 QOWIQSKREDIVNOMTEACLNSLDLALLSRDLIMKEDYELVSTKPTRTSKVROLDDT 496  
 |||  
 Db 181 qowiqskredivnqmtceacingsldallsrdlmkedyelvstkprrtskvrqllddt 240  
 Qy 497 QGEFEAKVIVOKLKNQKMGLOPYPEILVSRSPSLNLLQNKSM 540  
 |||  
 Db 241 qgeefakvivoklknqkmglyppeilvsvsrpslnllqnksm 284  
 Y59407 standard; Protein: 167 AA.  
 Y59407;  
 21-MAR-2000 (first entry)  
 Human RICK protein sequence residues 365-531.  
 RICK; human; RIP-like interacting CLARP kinase; apoptosis regulator; ARC;  
 caspase-8; caspase-10; CD95 signalling; apoptosis signalling pathway;  
 CIDE-A; CIDE-B; DREP-1; diagnosis; cell growth; apoptosis dysregulation;  
 gene therapy; cardiac disorder; cancer; neurodegenerative disorder; AIDS;  
 aplastic anaemia; ischaemic injury; toxin-induced liver disease.  
 Homo sapiens.  
 W09955134-A2.  
 04-NOV-1999.  
 27-APR-1999; 99WO-US09183.  
 27-APR-1998; 98US-0069023.  
 (UNMI ) UNIV MICHIGAN.  
 Nunez G, Inohara N, Koseki T;  
 WPI: 2000-072163/06.  
 Compositions for identifying apoptosis signalling pathway inhibitors  
 useful for treating diseases -  
 Claim 6; Page -: 93pp; English.  
 This sequence is a fragment of the human RICK (RIP-like interacting CLARP  
 kinase) protein of the invention. RICK acts as a positive regulator  
 of apoptosis, potentiating apoptosis induced by caspase-8 and caspase-10  
 during CD95 signalling. The invention provides methods for identifying  
 apoptosis signalling pathway inhibitors and activators, and methods and  
 compositions for screening compounds which will modulate the interactions  
 of the various compositions identified: ARC, RICK, and the CIDE family of  
 activators (CIDE-A, CIDE-B and DREP-1). RICK is useful in screening of  
 disease associated with excess cell growth and dysregulation of  
 apoptosis. Complexes containing RICK and CLARP can be used in drug  
 screening assays to identify inhibitor molecules blocking CD95-mediated  
 apoptosis. Overexpression of ARC in an in vitro cell system can be used  
 to identify inhibitors of the enzymatic activity of caspase-8.  
 Identification of ARC-like inhibitory compounds may be useful for gene  
 therapy treatment of disease with increased cell death in muscle tissue  
 and cardiac disorders. Therapeutic compositions of CIDEs can be used to  
 treat e.g. cancer, AIDS, neurodegenerative disorders, aplastic anaemia,  
 ischaemic injury, and toxin-induced liver disease. AntiRICK antibodies

CC can be used as reagents for the preparation or affinity chromatography  
 CC media, and for diagnostically measuring RICK levels. A specific inhibitor  
 CC of an essential step in the biochemistry of apoptosis is needed. RICK  
 CC interaction with intracellular factors such as CLARP and FADD appears to  
 CC be essential for apoptosis, inhibitors of RICK binding to intracellular  
 CC apoptosis factors are potential drug candidates.  
 CC Note: This sequence was created using information given in the  
 CC specification.  
 XX Sequence 167 AA;  
 SQ  
 Query Match 30.6%; Score 867; DB 21; Length 167;  
 Best Local Similarity 100.0%; Pred No. 1.8e-73;  
 Matches 167; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 374 SRKAQDCYFMKHLHPCGNHSDSTISGSRAAFCDHKHTPPCSSAIINPLSTAGNSERLQ 433  
 |||  
 Db 1 srkaqdcyfmklhpcgnhswdstisgsraafcdhkttpcssainplstagnserlq 60  
 QY 434 GTAQOWIQSKREDIVNOMTEACLNSLDLALLSRDLIMKEDYELVSTKPTRTSKVROLDDT 493  
 |||  
 Db 61 gtaqowiqskredivnqmtceacingsldallsrdlmkedyelvstkprrtskvrqll 120  
 QY 494 TDIQGEFEAKVIVOKLKNQKMGLOPYPEILVSRSPSLNLLQNKSM 540  
 |||  
 Db 121 tdiqgeefakvivoklknqkmglyppeilvsvsrpslnllqnksm 167  
 RESULT 9  
 B58938  
 ID B58938 standard; Protein: 153 AA.  
 AC B58938;  
 XX  
 XX 27-MAR-2001 (first entry)  
 XX  
 DE Breast and ovarian cancer associated antigen protein sequence SEQ ID 646.  
 DE  
 KW Human; breast cancer; ovarian cancer; cytostatic; immunosuppressive;  
 KW nootropic; neuroprotective; antiviral; anti-allergic; hepatotropic;  
 KW antidiabetic; anti-inflammatory; anti-ulcer; vulnerary; anticonvulsant;  
 KW antibacterial; antifungal; antiparasitic; cardiatic; immune disorder;  
 KW Addison's disease; allergy; autoimmune haemolytic anaemia;  
 KW autoimmune thyroiditis; diabetes mellitus; Crohn's disease;  
 KW multiple sclerosis; rheumatoid arthritis; ulcerative colitis;  
 KW cardiovascular disorder; wound healing; neurological disease.  
 XX  
 OS Homo sapiens.  
 XX  
 XX W0200055173-A1.  
 XX  
 XX 21-SEP-2000.  
 XX  
 XX 08-MAR-2000; 2000WO-US05881.  
 XX  
 XX 12-MAR-1999; 99US-0124270.  
 XX  
 XX (HUMA-) HUMAN GENOME SCI INC.  
 XX  
 XX Rosen CA, Ruben SM;  
 XX  
 XX WPI: 2000-611515/58.  
 XX  
 XX N-PSDB; F21841.  
 XX  
 XX New human breast and ovarian cancer associated gene sequences and the  
 XX polypeptides encoded by these genes, useful in the prevention,  
 XX treatment and diagnosis of cancer, immune disorders, cardiovascular  
 XX disorders and neurological diseases -  
 XX  
 XX Claim 11; Page 1086; 1299pp; English.  
 XX  
 XX Sequences F21614 - F22031 represent DNA sequences encoding human proteins  
 CC

CC B58711 - B59128. The DNA and protein sequences are associated with  
 CC breast and ovarian cancer. Included in the invention are sequences  
 CC E22032 - F22040 and B59129 which are used in the isolation and  
 CC characterisation of the DNA and protein sequences of the invention. The  
 CC breast and ovarian cancer associated DNA, protein, agonist or antagonist  
 CC sequences exhibit cytostatic; immunosuppressive; nootropic;  
 CC neuroprotective; antiviral; anti-allergic; hepatotoxic; antidiabetic;  
 CC anti-inflammatory; anticancer; vulnary; anticonvulsant; antibacterial;  
 CC antifungal; antiparasitic and cardiant activity. The polynucleotide and  
 CC protein sequences are used in the diagnosis of cancer, particularly  
 CC breast and ovarian cancer. The nucleic acid sequences, proteins, agonists  
 CC and agonists may also be used in the diagnosis, prevention and treatment  
 CC of immune disorders e.g. Addison's disease, allergies, autoimmune  
 CC haemolytic anaemia, autoimmune thyroiditis, diabetes mellitus, Crohn's  
 CC disease, multiple sclerosis, rheumatoid arthritis and ulcerative colitis;  
 CC cardiovascular disorders such as myocardial ischaemias; wound healing;  
 CC neurological diseases such as cerebral anoxia and epilepsy; and  
 CC infectious diseases.  
 XX  
 SQ Sequence 153 AA;

Query Match 28.2%; Score 797; DB 21; Length 153;  
 Best Local Similarity 99.3%; Pred. No. 5.9e-67;  
 Matches 149; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 97 YMPNGSLNELLHRKTEYPDVAVWPLRFRILHEIALGVNLYLHNMTPPLLHDLKTONILLDN 156  
 Db 1 ympngslnellhrkteypdvavwplrfirilheialgvnylhnmtppllhdldktonilldn 60

QY 157 EFHVKADFGLSKRWMSLSQSRSSKSAPEGGTTIYMPNENYEPGQKRSASIKHDIYSYA 216  
 Db 61 efhvkiadfglskwrmslsqsrssksapeggttiymppeneyepgqkrsasikhdiysya 120

QY 217 VITWEVLSRKQKPEFYTNPLQIMYSVSOQH 246  
 Db 121 vitwevskrkqkpefytnplqimysvsqgh 150

RESULT 10  
 Y69163  
 ID Y69163 standard; Protein; 786 AA.  
 AC Y69163;  
 XX  
 XX 30-MAY-2000 (first entry)  
 XX  
 XX  
 XX Amino acid sequence of a death associated kinase with ankyrin repeats.  
 XX  
 KW Death associated kinase protein containing ankyrin repeats; DAKAR;  
 KW kinase; quality assurance agent; shelf life; marker.  
 XX  
 OS Mus sp.  
 XX  
 FH Key Location/Qualifiers  
 FT Misc-difference 1 /note= "Met encoded by GTG"  
 FT 17..297  
 FT Domain /note= "N-terminal kinase domain"  
 FT 471..768  
 FT Region /note= "this region contains a series of nine tandem ankyrin repeats"  
 FT  
 FT  
 XX WO200008177-A2.  
 XX  
 XX 17-FEB-2000.  
 XX  
 XX 04-AUG-1999; 99WO-US17576.  
 XX  
 XX 04-AUG-1998; 98US-0095269.  
 XX 11-SEP-1998; 98US-0099973.  
 XX 09-FEB-1999; 99US-0119353.  
 XX

PA (IMMV ) IMMUNEX CORP.  
 XX  
 PI Bird TA, Virca GD;  
 XX  
 XX WPI: 2000-195582/17.  
 DR N-PSDB; Z61161.  
 XX  
 PT Novel death associated kinase containing ankyrin repeats (DAKAR) used  
 PT as molecular weight marker and as controls for peptide fragmentation  
 XX  
 XX Claim 13; Page 10; 7lpp; English.  
 PS  
 XX The present sequence represents a murine death associated kinase protein,  
 CC containing ankyrin repeats, designated DAKAR. The DAKAR polynucleotides  
 CC can be used to express the polypeptides, and as probes to identify  
 CC nucleic acids encoding proteins having kinase activity. DAKAR  
 CC polypeptides and fragmented polypeptides are used for purifying  
 CC proteins, e.g. to measure protein activity; as quality assurance agents  
 CC to monitor shelf life and stability of binding partner proteins; as  
 CC research agents, e.g. in assays to determine protein kinase activity,  
 CC to identify novel molecules involved in signal transduction pathways,  
 CC and to identify therapeutic compounds which may interfere with  
 CC apoptosis; as molecular weight and isoelectric focusing markers; as  
 CC controls for peptide fragmentation; identification of unknown proteins,  
 CC e.g. by comparison with proteins in databases; and for preparation of  
 CC antibodies. The antibodies can be used in assays to detect the presence  
 CC of the protein, and to purify the protein by immunoaffinity  
 CC chromatography. The antibodies can also be used to block binding of  
 CC the DAKAR polypeptides to their binding partners. Compounds that inhibit  
 CC or enhance the kinase activity of DAKAR can be used to treat diseases  
 CC characterized by overproduction or upregulated production of or  
 CC underproduction or downregulated production of DAKAR.  
 XX  
 SQ Sequence 786 AA;

Query Match 20.4%; Score 577; DB 21; Length 786;  
 Best Local Similarity 33.3%; Pred. No. 3.7e-45;  
 Matches 172; Conservative 64; Mismatches 150; Indels 120; Gaps 21;

QY 1 MNGEA---ICSAALPTIPYHKLADLRYLSRGASGTVSSARHADRWVQAVK---HLHIHT 53  
 Db 1 megegrwalglrlrtfdagefagewkvgsgfgykvrvhvwktwlaikespslhvd- 59

QY 54 PLLDSERKDVLRPAEILHKARFSYFPPIIGICNEPPEFLGIVTEYMPNGSLNELLHRKTEY 113  
 Db 60 ---drermelleeakmemakfrilpvyvicqep--vglmeymetgalekilase--- 111

QY 114 PDYAWPLRFRILHEIALGVNLYLHNMTPPLLHDLKTONILLDNFHFVKIADFGLSKRWMM 173  
 Db 112 -pdpwldrfrihvethavgmnlhcmppllhldkpanllldahyhwklsdfgakcngm 170

QY 174 SLSQSRSSKSAPEG--GTIYMPNENYEPGQKRSR--SIKHDIYSYAVITWEVLSRKQKPE 230  
 Db 171 shshdlsm---dglftgiaylpperir--eksrldtkhdvysfaivgwvltqkpkfa 224

QY 231 DVTNPLQIMYSVSOQHRPINEESLPYDIPHR---ARMISLIESGWAQNPDRPSEFKCL 287  
 Db 225 deknllhimmkvkghrp---elppicrpracasliglmqrcwhadpqrp----- 274

QY 288 IELEPVLRFEEITFLEAVQLKTKLQSVSSAIHLCDKMKMELSLNIPVNHGPOEESCG 347  
 Db 275 -----tfqelt-----setedicekpdeevk---dlahepggekssl 307

QY 348 SSQLEHNSGSPETSRSLPAPQDNDF-----LSRKAQDCYFMKL 395  
 Db 308 esksearpessrlikrasappfdndcslsellsqldsgisqtllegpeelrssec---kl 364

QY 386 -----HFCPGNHSWSTIS--GSQRAAF-----CDHKHTPCSSAIINPLSTAG 426  
 Db 365 psssgskrlsgvssvdsatsrsgslsfsereastgldptdtkkklvdall-----sg 419

QY 427 NSERLQPIAQOQWIOSKREDIVNQMTAEACLNQSIDA 462

Db 420 dtsrl-----mkilpqdvdlvldssasllhlavea 450

RESULT 11

Y76079 standard; Protein; 787 AA.

AC Y76079;
DT 27-MAR-2000 (first entry)
XX Murine protein kinase/ankyrin homologue, SEQ ID NO:334.

KW Skin; dermal papilla; keratinocyte; neonatal foreskin fibroblast;
KW embryonic skin cell; keratinocyte stem cell; transit amplifying cell;
KW secreted; transmembrane; inflammation; cancer; neurological disease;
KW angiogenesis; tumour vascularisation; growth disorder;
KW developmental disorder; skin wound; hair follicle disorder;
KW anti-inflammatory; cytostatic; neuroprotective; vulnery.

OS Mus sp.

XX WO9955865-A1.

PN 04-NOV-1999.

XX 29-APR-1999; 99WO-NZ00051.

XX 29-APR-1998; 98US-0069726.

PR 09-NOV-1998; 98US-0188930.

XX (GENE-) GENESIS RES & DEV CORP LTD.

XX Strachan L, Sleeman M, Watson JD, Onrust R, Kumble A, Murison JG;
XX WPI; 2000-072177/06.
XX N-PSDB; Z61784.

XX Novel polynucleotides useful for the treatment of various conditions
XX including wounds and cancer -
XX Claim 4; Page 195-196; 235pp; English.

CC The invention relates to novel nucleic acid sequences derived from rat
CC dermal papilla, human keratinocytes and neonatal foreskin fibroblasts,
CC and mouse embryonic skin, keratinocyte stem cells and transit amplifying
CC cells. Polypeptides of the invention may be used to treat inflammation,
CC cancer and neurological diseases. The proteins may be used to stimulate
CC the growth and motility of keratinocytes, to inhibit the growth of
CC cancer cells, to modulate angiogenesis and tumour vascularisation, to
CC modulate skin inflammation, to modulate epithelial cell growth and to
CC inhibit binding of HIV-1 to leukocytes. The invention may also be used to
CC treat growth and developmental defects, skin wounds and hair follicle
CC disorders. Sequences Y75942-Y76123 represent polypeptides encoded
CC by cDNA sequences derived from several mouse, rat or human skin cell
CC types. Sequences Y75942-Y75947, Y76020-Y76024, Y76094-Y76104 and
CC Y76119 are proteins with an N-terminal signal sequence, indicating that
CC they are secreted. Sequences Y75986-Y75989, Y76061-Y76071, Y76106-Y76109
CC and Y76121-Y76122 are proteins with one or more putative transmembrane
CC domains.

XX Sequence 787 AA;

Query Match 20.4%; Score 576; DB 21; Length 787;
Best Local Similarity 33.8%; Pred. No. 4.6e-45;
Matches 169; Conservative 64; Mismatches 154; Indels 116; Gaps 20;

OY 10 LPRIPIVHKLADLRYLSRGASGTYSSARHADRVQVAVK---HLHIHTPLDSDSRKDYVRE 66
Db 15 lrtfdgefagwekvsgggfgykvrvhvwkwaikcspshvd---dremeliee 70

OY 67 AEILHKARFSYIEPILGICNEPEFLGIVTEYMPNGSLNELLHHRKTEYDVPVAVPLFRFILH 126
Db 71 akkmemakfryilpvgyicqep--vglvmeymetsglsleklase---plpwwdlrfrivh 124
OY 127 EIALGVNYLHNMPPLHLHDLKTONILLDNDFHVKYADPGLSKWRMMMSLSOSRSKSAPE 186
Db 125 etavgmmlhcmppllhldkpanilldahyhvkiadfglakcngmshhdism----d 180
OY 187 G--CTIYMPENYEGKQKRA-SIKHDIYSYAVITWELVSRKOPPFEDVTPLOIYSVS 243
Db 181 glfgtiaylpperir--eksrldtkhdvysfaivgwitqkkpfdaknllhimmkvv 238
OY 244 QGHRPVINEESLPYDIPHR---ARMSLIESGWAQNDPERPSFLKCLIELEPVLRTFEEI 300
Db 239 kghrp-----elppicrpracasligmqrcwhadpqrp-----tfgei 280
OY 301 TFLNAVQLKTKLQSVSSAIHCDKKMELSLNIPVNHGQPQESCGSSQJLHNSGGSPET 360
Db 281 t-----setedicekpddevk---dlahepgeksslesksearpessrl 321
OY 361 SRSLPAPQDNDF-----LSRKAQDCYFMKL-----HHCFGNH 392
Db 322 krasappfndcslsellsqldsgisqtleppeelsrssec---klpssssgrkrlsgvs 378
OY 393 SWDSTIS--GSQRAAF-----CDHKTTPCSSAIINPLSTAGNSERLQFGIAQOW 439
Db 379 svdsafsrgrslsifeeastgldptdtkkklvdail-----sgdterl-----mki 428
OY 440 IQSKREDIVNQTAEACLNQSLDA 462
Db 429 lqpqdvdlvldssasllhlavea 451

RESULT 12

ID B56018 standard; Protein; 787 AA.

XX B56018;

XX 08-MAR-2001 (first entry)
XX Skin cell protein, SEQ ID NO: 334.

KW Mouse; skin cell; cytostatic; antiinflammatory; anti-HIV;
KW neurotropic; neuroprotective; vulnery; immunomodulatory; vaccine;
KW keratinocyte growth stimulation; cancer; angiogenesis inhibition;
KW inflammation; neurological disease.

OS Mus sp.

XX WO2000069884-A2.

XX 23-NOV-2000.

XX 15-MAY-2000; 2000WO-NZ000075.

XX 14-MAY-1999; 99US-0312283.

XX (GENE-) GENESIS RES & DEV CORP LTD.
XX Watson JD, Strachan L, Onrust R, Sleeman M, Kumble KD, Murison JG;

XX WPI; 2001-007495/01.
XX N-PSDB; C99717.

XX New isolated polynucleotide used in the identification of genetic
XX disorders and encoding polypeptides used for treating inflammatory
XX disease, cancer and neurological diseases -

XX Claim 4; Page 262-263; 352pp; English.

XX The present sequence is a polypeptide which is expressed in
XX mammalian skin cells. The polypeptide is useful for stimulating



Qy 393 SWDSTIS--GSORAAF-----CDHKTTPCSSAIINPLSTAGNSERLQPGIAQOW 439  
 Db 379 svdsafsrqslslsfereastgdllpctdiqkklvdaai-----sgdtsrl-----mki 428  
 Qy 440 IQSKREDIVNQTEACLNSLDA 462  
 Db 429 lqpgdvdlvldssasllhlaeva 451

RESULT 14  
 ID B56062 standard; Protein; 590 AA.  
 XX B56062;  
 DT 08-MAR-2001 (first entry)  
 DE Skin cell protein, SEQ ID NO: 409.

XX Mouse; skin cell; cytostatic; antiinflammatory; anti-HIV;  
 KW neutropic; neuroprotective; vulnerary; immunomodulatory; vaccine;  
 KW keratinocyte growth stimulation; cancer; angiogenesis inhibition;  
 KW inflammation; neurological disease.

OS Mus sp.  
 XX WO200069884-A2.  
 XX 23-NOV-2000.  
 PF 15-MAY-2000; 2000WO-NZ000075.  
 PR 14-MAY-1999; 99US-0312283.  
 PA (GENE-) GENESIS RES & DEV CORP LTD.

PI Watson JD, Strachan L, Onrust R, Sleeman M, Kumble KD, Murison JG;  
 DR WPI; 2001-007495/01.  
 DR N-PSDB; C99763.

PT New isolated polynucleotide used in the identification of genetic  
 PT disorders and encoding polypeptides used for treating inflammatory  
 PT disease, cancer and neurological diseases -  
 XX Claim 4; Page 309-310; 352pp; English.

XX The present sequence is a polypeptide which is expressed in  
 CC mammalian skin cells. The polypeptide is useful for stimulating  
 CC keratinocyte growth and motility, inhibiting the growth of cancer cells,  
 CC modulating angiogenesis, inhibiting angiogenesis and vascularisation of  
 CC tumours, modulating skin inflammation, stimulating the growth of  
 CC epithelial cells, inhibiting the binding of human immunodeficiency virus  
 CC (HIV)-1 to leukocytes, and treating inflammatory disease, cancer and  
 CC neurological diseases. The polynucleotide can be used as a marker, in  
 CC the identification of genetic disorders, and for the design of  
 CC oligonucleotides for examining expression patterns.

XX Sequence 590 AA;  
 Query Match 20.3%; Score 574; DB 22; Length 590;  
 Best Local Similarity 33.4%; Pred. No. 4.5e-45;  
 Matches 168; Conservative 65; Mismatches 154; Indels 116; Gaps 20;

Qy 10 LPTTYPYHKLADLRYSRGSAGTSSARHADRWQVAVK---HLHHTPLLDSEKDKVLR 66  
 Db 15 lrtfdagefagwkvqgvgfgykvrhvhwkwlakcspshvd-----drermellee 70  
 Qy 67 AEILHKARFSEIPLGICNPEEFLGIYTYMPSGSLNELLHRKTEYFDVAVPLFRILH 126  
 Db 71 akmemakfryllpvygicqep--vglvmeymetgslsleklase----plpwwlrfriavh 124

Qy 127 ETALGVNIHNHTPPLLHHLKNTONILLDNEFHVIADFGLSKWRMMSLSRSRKSAP 186  
 Db 125 etavgmfnlhcmsppllhldlkpanllidahyhvkisdfgiakcngmshhdslm-----d 180  
 Qy 187 G--GTIITPPENYEPPGKSR--SIKHDIYSYAVITWEVLSRKPQFEDVTNPLOIMYSVS 243  
 Db 181 glfgtiaylptferir--eksrldtkhdvysfaiwgvltgqkpfafadeknilhimmkvv 238  
 Qy 244 OGHREVINEESLPHYDIPHR---ARMISLIESGWAONPDERPSFLACLLELEPVLTFFEEI 300  
 Db 239 kggrp---elpicrpracasligimgrcwhadpvrp-----tfgei 280

Qy 301 TFLEAVIOLKTKLOSVAIHLCDKMKMELSLNTPVNHGPOECSGSQHLHENSGPSPT 360  
 Db 281 t-----setedlcekpdeevk---dlahpegeksslesksearpessrl 321  
 Qy 361 SRSLPAPODNDF-----LSRKADQCYFMKL-----HHCPCGNH 392  
 Db 322 krasappfdndcsellsqidsgisqtlegpeeisrssec---klpsssgkrlsgvs 378

Qy 393 SWDSTIS--GSORAAF-----CDHKTTPCSSAIINPLSTAGNSERLQPGIAQOW 439  
 Db 379 svdsafsrqslslsfereastgdllpctdiqkklvdaai-----sgdtsrl-----mki 428  
 Qy 440 IQSKREDIVNQTEACLNSLDA 462  
 Db 429 lqpgdvdlvldssasllhlaeva 451

RESULT 15  
 ID Y79154 standard; Protein; 763 AA.  
 XX Y79154;  
 DT 05-JUN-2000 (first entry)  
 DE Mouse protein kinase Fel.  
 KW Fel; protein kinase; mouse; signal transduction.

OS Mus musculus.  
 XX WO2000008178-A2.  
 XX 17-FEB-2000.  
 PF 04-AUG-1999; 99WO-US17577.  
 PR 04-AUG-1998; 98US-0095269.  
 PR 11-SEP-1998; 98US-0099973.  
 PA (IMMV ) IMMUNEX CORP.

PI Virca GD, Bird TA, Anderson DM, Marken JS;  
 DR WPI; 2000-205722/18.  
 DR N-PSDB; Z58584.

PT Novel murine polynucleotides encoding kinase polypeptides, used as  
 PT probes to identify nucleic acids encoding proteins having kinase  
 PT activity -  
 PS Claim 2; Fig 7; 93pp; English.

XX The present sequence is that of murine Fel, a novel protein kinase.  
 CC The sequence represents translation (reading frame 3) of Genes  
 CC clone 971025TRAM004820HT (see Z58584). The invention relates to  
 CC purified murine polypeptides having kinase function (see Y79152-56)  
 CC and isolated nucleic acids encoding them (see Z58582-86). Claimed  
 CC vectors comprising the novel nucleic acids, and claimed host cells  
 CC (bacterial, yeast, plant, insect or animal) transfected or  
 CC transduced with the vectors, are used to produce the polypeptides.

CC

CC The kinase polypeptides and their fragments are used as mol.wt. and  
 CC isoelectric focusing markers, and as controls for peptide  
 CC fragmentation. They also have a number of therapeutic uses, as  
 CC kinases play a central role in cellular signal transduction. As  
 CC such, alterations in kinase expression and/or activation can have a  
 CC profound effect on a plethora of cellular processes, e.g.  
 CC proliferation and programmed cell death (apoptosis). The kinase  
 CC polypeptides could also be used to identify binding partner  
 CC proteins, or as reagents to identify proteins that regulate or  
 CC interact with them. They may also be used for preparation of  
 CC antibodies useful for detection, purification, and for blocking  
 CC binding of kinase polypeptides to their binding partners.

XX Sequence 763 AA;

Query Match 20.3%; Score 574; DB 21; Length 763;  
 Best Local Similarity 34.2%; Pred. No. 6.8e-45;  
 Matches 166; Conservative 62; Mismatches 142; Indels 116; Gaps 20;

QY 27 GASGTSSARHADRWVQAVK---HLHIHTPLDSEKDVLRRAELHKARFSYIPLIG 83  
 Db 8 gfggyvkvrvhwktwlaikcspshvd----dremelleeakkmemakfryilpvyg 63

QY 84 ICNEPEFLGIVTYMPNGSLNELLHRKTEYDVAWPLRFRILHEIALGVNLYLHNMTPLL 143  
 Db 64 icqep--vglvmeymetgslekllase---plpwlfrfrivhetavgmfnlhcmsppll 117

QY 144 HDLKTQNILLDNEFHVKIADFLGSKWRMMSLSQSRSSKSAPEG--GTIYMPPEYEPG 201  
 Db 118 hldlkanillldahyvkksdfglakcngmshhdism----dglfgtiayipperir-- 171

QY 202 QKSRASIKHDIYSYAVITWEVLSRKPDPEDVNPLOIMVSVSOGRHPVINEESLPYDIP 260  
 Db 172 eksrlftkhdvysfaivlgvltqkpkfadeknlhmmkvkghrp---elppicrp 227

QY 261 HR---ARMISLIESGNAQNPDERPSEFLKLIIELEPVLFTEETFEAVIQLAKTKLQSV 317  
 Db 228 rpracaslglmqrcwhadpqvrp-----tfgeit----- 257

QY 318 SSATHLCDKKKMLSLNIPVNHGQPEESGSQLHENSQSPETSRSLLPAPQDNDF----- 372  
 Db 258 setedlcekpdeevk---dlahepgekkslesksearpesrkrasappfndcslsel 314

QY 373 -----LSRKAQDCYFMKL-----HRCFNGHSDSTIS--GSQRAAF- 406  
 Db 315 lsqldsglsqtlegpeelsrssec---klpssssgkrlsgvsvdgsafssrgslslsfe 371

QY 407 -----CDHKTFPCSSAIIINPLSTAGNSERLQPGIAQOWIQSKREDIVNQMTENCL 456  
 Db 372 reastgldgptdqkklvdail-----sgdtsrl-----mkilpqdvdivdssasl 421

QY 457 NQSLDA 462  
 Db 422 hlavea 427

Search completed: June 14, 2001, 08:07:36  
 Job time: 188 sec



GenCore version 4.5
Copyright (c) 1993 - 2000 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: June 13, 2001, 15:39:37 ; Search time 84.7 Seconds
(without alignments)
4324.869 Million cell updates/sec

Title: US-09-445-223-2
Perfect score: 2098
Sequence: 1 ggcattatggatggatggg.....aaaaaaaaaaaaaaaaaaaa 2098

Scoring table: IDENTITY\_NUC
Gapop 10.0 , Gapext 1.0

Searched: 302621 segs, 87301344 residues

Total number of hits satisfying chosen parameters: 605242

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

- Database : Issued\_patents\_NA.\*
1: /cgnl\_7/ptodata/1/ina/5A\_COMB.seq.\*
2: /cgnl\_7/ptodata/1/ina/5B\_COMB.seq.\*
3: /cgnl\_7/ptodata/1/ina/6A\_COMB.seq.\*
4: /cgnl\_7/ptodata/1/ina/6B\_COMB.seq.\*
5: /cgnl\_7/ptodata/1/ina/PTUS\_COMB.seq.\*
6: /cgnl\_7/ptodata/1/ina/backfiles1.seq.\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Table with columns: Result No., Score, Query Match, Length, DB ID, Description. Contains 27 rows of search results.

Table with columns: 28, 49.6, 2.4, 991, 3, US-08-924-747-25, Sequence 25, Appl. Contains 45 rows of alignment data.

ALIGNMENTS

RESULT 1
US-09-019-942-2
Sequence 2, Application US/09019942
Patent No. 6033855
GENERAL INFORMATION:
APPLICANT: Berlin, John
TITLE OF INVENTION: GENES ENCODING CASPASE RECRUITMENT
TITLE OF INVENTION: DOMAIN POLYPEPTIDES
NUMBER OF SEQUENCES: 4
CORRESPONDENCE ADDRESS:
ADDRESSEE: Fish & Richardson P.C.
STREET: 225 Franklin Street
CITY: Boston
STATE: MA
COUNTRY: USA
ZIP: 02110-2804
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette
COMPUTER: IBM Compatible
OPERATING SYSTEM: Windows 95
SOFTWARE: FASTSEQ for Windows Version 2.0b
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/019,942
FILING DATE: 06-FEB-1998
PRIOR APPLICATION DATA:
APPLICATION NUMBER:
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: Meiklejohn, Ph.D., Anita L.
REGISTRATION NUMBER: 35,283
REFERENCE/DOCKET NUMBER: 07334/068001
TELECOMMUNICATION INFORMATION:
TELEPHONE: 617/542-5070
TELEFAX: 617/542-8906
TELEX: 200154
INFORMATION FOR SEQ ID NO: 2:
SEQUENCE CHARACTERISTICS:
LENGTH: 1931 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: CDNA
US-09-019-942-2

Query Match 88.9%; Score 1865.6; DB 3; Length 1931;
Best Local Similarity 99.8%; Pred. No. 0;
Matches 1868; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

Qy 58 gtcagctctgttctggagaagcagcggctgctggccatcccggaatggggccctc 117

```

Db 1092 TTTGAGAACATTTGAAGAGATAACTTTTCCTTGAAGACTGTTATTCAGCTAAAGAAACAA 1151
Qy 1198 gttcacagagtggttcaagtccattccattcactatgtgacaagaagaataatggaattatctct 1257
Db 1152 GTTACAGAGTGTTCAGTGCCTTCACCTTGATGACAAAGAAAGAAAGAAATGGAATTAATCTCT 1211
Qy 1258 gaacatacctgtaaatcatggtccacacagaagaaatcaatgtggatctctcagccagtcacatg 1317
Db 1212 GAACATACCTGTAAATCATGTGCCAACAGAGAAATCATGTGGATCCTCTCAGCTCAGTCAATGA 1271
Qy 1318 aaaaatggttcctgaaactcaagttccctccagctccctcaagcagaactgattcttt 1377
Db 1272 AAATAGTGGTTCCTCGAAACTTCAAGGTCCCTCCAGGCTCCTCAAGAAATGATGATTTTTT 1331
Qy 1378 atctgaaaagctcaagactgatttattatgaagctgcatcactgtcctcgtgaaaaccagac 1437
Db 1332 ATCTAGAAAAGCTCAAGACTGTTATTTATGAAGCTGCATCACATGCTGGAAATCACAG 1391
Qy 1438 ttgggataagcacaattctgtgatacctaagaaggtcgaattctgtgatacacaagcaactcc 1497
Db 1392 TTGGGATAGCACCATTCTGGATCTCAAGGCTGCATTTCTGTGATCACAAAGACCAATCC 1451
Qy 1498 atgctctcagcaataaatacactcctcaactgcagaaaactcagaactctgtgcagcc 1557
Db 1452 ATGCTTCACGAAATTAATTCCTCCTCACTCAAGAACTCAGAAAGCTCGCACG 1511
Qy 1558 tggatagocccagcagtgatccagagcaaaaagggaagacattgtgaacccaaatgacagaa 1617
Db 1512 TGGTATAGCCAGCAGCTGGATCCAGAGCAAAAAGGAAAGACATTTGTGAACMAATGACAGA 1571
Qy 1618 agcctgccttaacagtcgtagatgcccctcctcctgccagagctcagcagagctgcaagaagaa 1677
Db 1572 AGCCCTGCCTTAACCAGTCGTAGTGTGCCTTCGACGGGACTTGTATCTGAAAGAGA 1631
Qy 1678 ctatgaactgttagtaccagcctcaagagccctcaaaaagctcaaaagctcagcaaatctagacac 1737
Db 1632 CRTAGAACCTTTAGTACCAAGCCTCAAGGACCTCAAAAGCTCAGCAAAATTTACTAGACAC 1691
Qy 1738 tactgatcccaagagagaattgcccagaagttgcaaaagttatagtaaaaaatgaaagataaa 1797
Db 1692 TACTGACATCCAAAGGAAAGAAATTTGCCAAAGTTATAGTACAAAAAATTTGAAAGATACAA 1751
Qy 1798 acaaatgggtcttcagccctaccagcaacacactgtggtttcttagatcacaactcttataa 1857
Db 1752 ACAAATGGGTCTCAGCCTTACCCTCCGGAATACTTGTGGTTCCTAGATCACCAATCAATAA 1811
Qy 1858 ttactcaaaaataaaagcatgtaagtagactgttttcaagaagaagaatgcttttataaa 1917
Db 1812 TTTACTCAAAAATAAAAAGCATGTAAGTACTGTTTTCAAGAAAGAAATGTTTTTCATAAA 1871
Qy 1918 aggatatttata 1929
Db 1872 AGGATATTTATA 1883

```

```

RESULT 2
US-08-700-575-31
; Sequence 31, Application US/08700575
; Patent No. 5817479
; GENERAL INFORMATION:
; APPLICANT: Au-Young, Janice
; APPLICANT: Bandman, Olga
; APPLICANT: Hawkins, Phillip R.
; APPLICANT: Walde, Craig G.
; TITLE OF INVENTION: NOVEL HUMAN KINASE HOMOLOGS
; NUMBER OF SEQUENCES: 45
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: INCYTE PHARMACEUTICALS, INC.
; STREET: 3174 PORTER DRIVE
; CITY: PALO ALTO
; STATE: CA
; COUNTRY: USA
; ZIP: 94304

```

```

Db 12 GTACGCTGTGTTGAGGAAAGACGGGGCTGGCGTGGCCCATCCGGGAATGGCGCCCTC 71
Qy 118 gtgacctagtgttcgaggggcaaaaagggtcttgcgggctctgctcagggggggatc 177
Db 72 GTGACCTACTGTGGGGCAAAAAGGGTCTTTGCCGGCCCTGCCTGTCAGGGGGGCTATP 131
Qy 178 tggggccttgagcggcgtgagccttgaggcgtgcgagccgcagggggcaaccccga 237
Db 132 TGGGGCCCTTAGGGGCGGCTGGGAGCCCTTGGGAGCCCGCGCAGAGGGGGCACCCCGA 191
Qy 238 acgggctgagcggccgggacacatgaacggggggcctctgagcggccttcccaccat 297
Db 192 ACCGGCTGAGCCGGGACCATGAACGGGAGGCCATCTCAGCGCCCTGCCACCAT 251
Qy 298 tccctacaacaactgcgcagcactgctcactgagcggcggccctctggaactgctc 357
Db 252 TCCCTACCACAACTCGCCAGCTGGGCTACCTGAGCGCGGGCGCTCTGACCCTGTGHC 311
Qy 358 gtccgcccgcagcagactggtggcgtccaggtggcggcagcaactgcacatccacac 417
Db 312 GTCCGGCCGGCAGGACTGGGGCTGCCAGGTGGCGGTGAAGCACCCTGCACATCCACAC 371
Qy 418 tccgctctccagctgaagaagaagatgctttaagagaagctgaaattttacaacaagc 477
Db 372 TCCGCTGCTCGACAGTGAAGAAGAGATGCTTAAAGAGAAAGCTGAATTTTACACAAGC 431
Qy 478 tagatttagtcaatttcccaatttggaaatttgcacatgagcctgaaatttgggaaat 537
Db 432 TAGATTTAGTTACTGCTTCCAAATTTGGGAATTTGCAATGAGCCTGAAATTTTGGGAA 491
Qy 538 agttactgaatacatgccaaatggtatcaatgaaactcctacatagaaaactgaaata 597
Db 492 AGTTACTGAATACATGCCAAATGGATCAATAAATAACTCTACATAGAAAACATGAATA 551
Qy 598 tccctgatttgggtgccatgtgagattccgcatcctcgtgaatgcaatggccctgggtaaa 657
Db 552 TCCTGATGTTGGTGGCCATGAGATTTGGCATFCCATGCCATGAATTTGCCCTGGGTAAA 611
Qy 658 taccctgcaaatgactcctccttactctatcatctgactgaaagctcagaatactct 717
Db 612 TTACTGCAAAATGACTCCTCTCCTTTACTTTCTATCAATGACTGGAAGCTCAGAAATATCT 671
Qy 718 attggcaaatgaaatttcaatttgatagatggatgtttgtttatcaaaagtgccgatgat 777
Db 672 ATGAGCAATGAATTCATGTTAAGATTGCAGATTTGGTTTATCAAAAGTGGCGCATGAT 731
Qy 778 gtcctctcagctcagcaagtgcgcaaatctgcacagagaaggggacaatattatata 837
Db 732 GTCCTCTCACAGTCAGAAAGTAGCAAAATCTGCACCAAGAGGAGGACAAATTAATCATAT 791
Qy 838 gccaacctgaaactatgaaactgacaaatacaaaactcaaggccagctcaagcagatata 897
Db 792 GCCACCTGAANAATGAACTGCAACATTCGAACAAATTCAGGGCCAGTATCAAGCAGCATATA 851
Qy 898 tagctatgcagttatcacatggaagtggttatccagaaaaacagcctttgagagatc 957
Db 852 TAGTATGCAAGTATACATGGAAGTGTATCCAGAAAACAGCCCTTTGAAAGATGTCAC 911
Qy 958 caactctcagaataatgtagtgcacagcaactgcgacatgcgactgttataatgaaag 1017
Db 912 CAATFCCCTTTCAGATAATGATGATGTTGTCACAAAGACATCGACCCCTGTTATTAATGA 971
Qy 1018 aagtttgccatgataaccctcaccagcagcagcagcagctctcctcctcaataagaagtgatg 1077
Db 972 AAGTTTCCCATATGATATACCTCACCGAGCAGCTATGATCTCTAATAGAAAAGTGATG 1031
Qy 1078 ggaacaaaactccagagaaagaccatctctcaaatgttttaataagaactgaaacagt 1137
Db 1032 GGCACAAAATCCAGATGAAGACCATCTTTTAAAAATGTTTAAATAAGAACTTGAACCCGT 1091
Qy 1138 ttgagaaacttgagagagataaactttcctgtgaagctgttattcagcctaaagaacaaa 1197

```

```

; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/700,575
; FILING DATE:
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: BILLINGS, LUCY J
; REGISTRATION NUMBER: 36749
; REFERENCE/DOCKET NUMBER: SP-100 US
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 415-855-0555
; TELEFAX: 415-845-4166
; INFORMATION FOR SEQ ID NO: 31:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 210 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: cDNA
; IMMEDIATE SOURCE:
; LIBRARY: THP-1 Phorbol LPS
; CLONE: 156108
; US-08-700-575-31

```

Query Match 10.0%; Score 210; DB 1; Length 210;  
 Best Local Similarity 100.0%; Pred. No. 4.4e-39;  
 Matches 210; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

QY 844 tgaacctgacactgggacaataaacaagggcaggatcaagcagcatatataagctc 903
Db 1 TCGAACATGTAACCTGGACAAATCAAGGCCAGTATCAAGCAGCAGATATATAGCTA 60
QY 904 tgcagttaccatgggaagtggttccagaaacagcccttttggaagtccaccaatcc 963
Db 61 TCCAGTATACATGGGAAAGTATATCCAGAAACAGCCCTTTTGAAGATGTCACCAATCC 120
QY 964 ttgcagataatgtagtggtcacaagacatcgacctgatttaataagaagaagt 1023
Db 121 TTTGCAATAGTATAGTGTCACAGGACATCGACCTGTTATATGAAAGAGTTT 180

```

QY 1024 gccatgatataacctcaccggcagctat 1053  
 Db 181 GCCATGATATACCTCACCAGCAGCTAT 210

RESULT 3  
 US-09-188-930-257  
 ; Sequence 257, Application US/09188930A  
 ; Patent No. 6150502  
 ; GENERAL INFORMATION:  
 ; APPLICANT: Watson, James D.  
 ; APPLICANT: Strachan, Lorna  
 ; APPLICANT: Sleeman, Matthew  
 ; APPLICANT: Onrust, Rene  
 ; APPLICANT: Mursion, James Greg  
 ; TITLE OF INVENTION: Compositions Isolated From Skin Cells  
 ; FILE OF INVENTION: and Methods For Their Use  
 ; FILE REFERENCE: 11000.1011c1  
 ; CURRENT APPLICATION NUMBER: US/09/188,930A  
 ; CURRENT FILING DATE: 1998-11-09  
 ; NUMBER OF SEQ ID NOS: 348  
 ; SOFTWARE: FASTSEQ for Windows Version 3.0  
 ; SEQ ID NO 257  
 ; LENGTH: 3516  
 ; TYPE: DNA  
 ; ORGANISM: Mouse  
 ; US-09-188-930-257

Query Match 4.9%; Score 102.4; DB 4; Length 3516;  
 Best Local Similarity 51.8%; Pred. No. 3.4e-14;  
 Matches 372; Conservative 0; Mismatches 316; Indels 30; Gaps 5;

```

QY 287 ctgccaccattccctaccacaaaacccgcagcttcacctcctcctgagcgcgcgcctct 346
Db 43 ctgcgacctcagcgcgcgacattcgagctggagagagttgctcggcgcgcttctc 102
QY 347 ggcactgtgctcccgccgcccagcagcgctcgcgcctcgcgcctcgcgcctcgcgcctg 406
Db 103 gggcagggtgcaaaagtgcctatgctcagcagcgggagcggcctcagctcaagtctcg 162
QY 407 cacatccacactccctcgcgcagctgcaagaagagagttttaaagagaagcctaaaatt 466
Db 163 cccagct---tgcaagtcgacgacagcaggaacgaaggagctcctcgaggagaaagaa 219
QY 467 ttacacaaagctagatttagttacctttttccaattttgggaatttgggaatttgcactgaa 526
Db 220 atggagatggcaagtccgatattacctgtgcagcgcacataatgccaaggaaacctg-- 277
QY 527 ttttgggaatagttactgaatcacaacccaatggaattcaattaaatgaactcctacaagg 586
Db 278 ----tcggcttggtcatgagtcacatggagcagccctccctggagaagtctggcctca 333
QY 587 aaaactgaaatactctgctgcttggccatggatgattcgcctcctcctcctgataaaaaattgc 646
Db 334 gagccat-----tgccttggaactgcgctttcgcactcgtgcacgacagacc 381
QY 647 ctggtgtaatactcgcacaatagctcctcctcctcctcctcctcctcctcctcctcctcctc 706
Db 382 gtgggcatgaactcctcgtcactgactgctcgcctcgcctcgcctcgcctcgcctcgcctcgc 441
QY 707 cagaatctctttagacaataaatttcatttaagttaagattgcagattttggtttatacaaag 766
Db 442 ggcacactcctggtggatgccactaccatgcaagatttctgacttttggtggcctcag 501
QY 767 tggcgcagatgctccctccacagtcacagtagcaaatctgcaccagaagaggagaca 826
Db 502 tgcaatggatgtcccactcctcagctcagctcagctcagctcagctcagctcagctcagctc 555
QY 827 attatttatacccactgaaactgaaactgaaactgaaactgaaactgaaactgaaactgaaact 886
Db 556 acgctaccctcctccagagcgaatt---cgtgagaagagccgctttgttgacacccaa 612
QY 887 cagcatatagctatgcagttatcacatgggaagttatccagaacacagctttt 946
Db 613 catgattacagctcctcctcctcctcctcctcctcctcctcctcctcctcctcctcctcct 672
QY 947 gaagatgccaactcctcttgcagataatgtagtggtagtggtagtggtagtggtagtggtagtgg 1004
Db 673 gcagatgaaagaacacatcctacacatcatgatgaaagtggtaaaagggccaccgcccag 730

```

RESULT 4  
 US-07-928-464-1  
 ; Sequence 1, Application US/07928464  
 ; Patent No. 5367065  
 ; GENERAL INFORMATION:  
 ; APPLICANT: Ecker, Joseph R.  
 ; APPLICANT: Kieber, Joseph J.  
 ; TITLE OF INVENTION: Constitutive Triple Response Gene and  
 ; NUMBER OF SEQUENCES: Mutations  
 ; CORRESPONDENCE ADDRESS:  
 ; ADDRESS: Woodcock, Washburn, Kurtz, Mackiewicz and  
 ; ADDRESS: No. 5367065r1s  
 ; STREET: One Liberty Place - 46th Floor  
 ; CITY: Philadelphia  
 ; STATE: PA  
 ; COUNTRY: U.S.A.  
 ; ZIP: 19103  
 ; COMPUTER READABLE FORM:

```

MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent In Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/07/928,464
FILING DATE: 19920810
CLASSIFICATION: 800
ATTORNEY/AGENT INFORMATION:
NAME: Miller, Suzanne E.
REGISTRATION NUMBER: 32,279
REFERENCE/DOCKET NUMBER: UPN-1086
TELEPHONE: 215-568-3100
INFORMATION FOR SEQ ID NO: 1:
SEQUENCE CHARACTERISTICS:
LENGTH: 2890 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: cDNA
FEATURE:
NAME/KEY: CDS
LOCATION: 118..2583

```

```

MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent In Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/07/928,464
FILING DATE: 19920810
CLASSIFICATION: 800
ATTORNEY/AGENT INFORMATION:
NAME: Miller, Suzanne E.
REGISTRATION NUMBER: 32,279
REFERENCE/DOCKET NUMBER: UPN-1086
TELEPHONE: 215-568-3100
INFORMATION FOR SEQ ID NO: 1:
SEQUENCE CHARACTERISTICS:
LENGTH: 2890 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: cDNA
FEATURE:
NAME/KEY: CDS
LOCATION: 118..2583

```

```

Query Match 3.9%; Score 81.4; DB 1; Length 2890;
Best Local Similarity 50.1%; Pred. No. 1.8e-09;
Matches 202; Conservative 0; Mismatches 201; Indels 0; Gaps 0;

QY 360 cgcgccccacgagcagctgcccaggctggcggcgtgagcagcctgcacatcccacactc 419
Db 1808 CTGTCACCCTGCTGAGTGGCATGGCTGGATGTTCTGTGAAAAATTCATGGAGCAAG 1867

QY 420 cgtctgctgcagtgaaagaagatgttttaagaagaagctgaaatgttttacaagaagcta 479
Db 1868 ACTTCCATGCTGACCGTGTAAATGAGTCTTAAAGAGAGGTTGGGATAAATGAAACGCCTTC 1927

QY 480 gatttagttacatgtttcccattttgggaatttgcgatgagcctgaaatggggaatag 539
Db 1928 GCCACCTAACATGTTCTTTCATGGGTGGTCTCACTCAACCTCCAAATTTGTCRAATAG 1987

QY 540 ttactgaatacatgccaaatggaatcattaaatgaactccctacatagaaactggaatc 599
Db 1988 TGACAGAATAATTTGCAAGAGGTAGTTTATACAGACTTTTTCATAAAGTGGAGCAAGGG 2047

QY 600 ctgatgttgcctgcaatgatttgcctgcctgcctgcctgcctgcctgcctgcctgcct 659
Db 2048 AGCAANTAGATGAGAGACGTGCCTGAGTATGGCTTATGATGCTTAAAGGGAATGAATT 2107

QY 660 acctgcacaatagacctctctctctctctctctctctctctctctctctctctctctct 719
Db 2108 ATCTTCACAATCCCAATCCCAATTTGTCATAGAGATCTAAATCTCCAAACTTATTGG 2167

QY 720 tggacaataattcattgtaagattgcaatggcctgtgcaatggcctgtgcaatggcctgt 762
Db 2168 TTGACAAAAAATATACAGTCAAGGTTGTGATTTGGTCTCTC 2210

```

```

Query Match 3.9%; Score 81.4; DB 1; Length 2890;
Best Local Similarity 50.1%; Pred. No. 1.8e-09;
Matches 202; Conservative 0; Mismatches 201; Indels 0; Gaps 0;

QY 360 cgcgccccacgagcagctgcccaggctggcggcgtgagcagcctgcacatcccacactc 419
Db 1808 CTGTCACCCTGCTGAGTGGCATGGCTGGATGTTCTGTGAAAAATTCATGGAGCAAG 1867

QY 420 cgtctgctgcagtgaaagaagatgttttaagaagaagctgaaatgttttacaagaagcta 479
Db 1868 ACTTCCATGCTGACCGTGTAAATGAGTCTTAAAGAGAGGTTGGGATAAATGAAACGCCTTC 1927

QY 480 gatttagttacatgtttcccattttgggaatttgcgatgagcctgaaatggggaatag 539
Db 1928 GCCACCTAACATGTTCTTTCATGGGTGGTCTCACTCAACCTCCAAATTTGTCRAATAG 1987

QY 540 ttactgaatacatgccaaatggaatcattaaatgaactccctacatagaaactggaatc 599
Db 1988 TGACAGAATAATTTGCAAGAGGTAGTTTATACAGACTTTTTCATAAAGTGGAGCAAGGG 2047

QY 600 ctgatgttgcctgcaatgatttgcctgcctgcctgcctgcctgcctgcctgcctgcct 659
Db 2048 AGCAANTAGATGAGAGACGTGCCTGAGTATGGCTTATGATGCTTAAAGGGAATGAATT 2107

QY 660 acctgcacaatagacctctctctctctctctctctctctctctctctctctctctctct 719
Db 2108 ATCTTCACAATCCCAATCCCAATTTGTCATAGAGATCTAAATCTCCAAACTTATTGG 2167

QY 720 tggacaataattcattgtaagattgcaatggcctgtgcaatggcctgtgcaatggcctgt 762
Db 2168 TTGACAAAAAATATACAGTCAAGGTTGTGATTTGGTCTCTC 2210

```

```

; CITY: Philadelphia
; STATE: PA
; COUNTRY: U.S.A.
; ZIP: 19103
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: PCT/US93/07347
; FILING DATE: 19930805
; CLASSIFICATION:
; ATTORNEY/AGENT INFORMATION:
; NAME: Miller, Suzanne E.
; REGISTRATION NUMBER: 32,279
; REFERENCE/DOCKET NUMBER: UPN-1086
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 215-568-3100
; INFORMATION FOR SEQ ID NO: 1:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 2890 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: cDNA
; FEATURE:
; NAME/KEY: CDS
; LOCATION: 118..2583
; PCT-US93-07347-1

```

```

; CITY: Philadelphia
; STATE: PA
; COUNTRY: U.S.A.
; ZIP: 19103
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: PCT/US93/07347
; FILING DATE: 19930805
; CLASSIFICATION:
; ATTORNEY/AGENT INFORMATION:
; NAME: Miller, Suzanne E.
; REGISTRATION NUMBER: 32,279
; REFERENCE/DOCKET NUMBER: UPN-1086
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 215-568-3100
; INFORMATION FOR SEQ ID NO: 1:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 2890 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: cDNA
; FEATURE:
; NAME/KEY: CDS
; LOCATION: 118..2583
; PCT-US93-07347-1

```

```

; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/07/928,464
; FILING DATE: 19920810
; CLASSIFICATION: 800
; ATTORNEY/AGENT INFORMATION:
; NAME: Miller, Suzanne E.
; REGISTRATION NUMBER: 32,279
; REFERENCE/DOCKET NUMBER: UPN-1086
; TELEPHONE: 215-568-3100
; INFORMATION FOR SEQ ID NO: 1:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 2890 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: cDNA
; FEATURE:
; NAME/KEY: CDS
; LOCATION: 118..2583

```

```

; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/07/928,464
; FILING DATE: 19920810
; CLASSIFICATION: 800
; ATTORNEY/AGENT INFORMATION:
; NAME: Miller, Suzanne E.
; REGISTRATION NUMBER: 32,279
; REFERENCE/DOCKET NUMBER: UPN-1086
; TELEPHONE: 215-568-3100
; INFORMATION FOR SEQ ID NO: 1:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 2890 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: cDNA
; FEATURE:
; NAME/KEY: CDS
; LOCATION: 118..2583

```

```

; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/07/928,464
; FILING DATE: 19920810
; CLASSIFICATION: 800
; ATTORNEY/AGENT INFORMATION:
; NAME: Miller, Suzanne E.
; REGISTRATION NUMBER: 32,279
; REFERENCE/DOCKET NUMBER: UPN-1086
; TELEPHONE: 215-568-3100
; INFORMATION FOR SEQ ID NO: 1:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 2890 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: cDNA
; FEATURE:
; NAME/KEY: CDS
; LOCATION: 118..2583

```

```

; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/07/928,464
; FILING DATE: 19920810
; CLASSIFICATION: 800
; ATTORNEY/AGENT INFORMATION:
; NAME: Miller, Suzanne E.
; REGISTRATION NUMBER: 32,279
; REFERENCE/DOCKET NUMBER: UPN-1086
; TELEPHONE: 215-568-3100
; INFORMATION FOR SEQ ID NO: 1:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 2890 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: cDNA
; FEATURE:
; NAME/KEY: CDS
; LOCATION: 118..2583

```

```

; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/07/928,464
; FILING DATE: 19920810
; CLASSIFICATION: 800
; ATTORNEY/AGENT INFORMATION:
; NAME: Miller, Suzanne E.
; REGISTRATION NUMBER: 32,279
; REFERENCE/DOCKET NUMBER: UPN-1086
; TELEPHONE: 215-568-3100
; INFORMATION FOR SEQ ID NO: 1:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 2890 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: cDNA
; FEATURE:
; NAME/KEY: CDS
; LOCATION: 118..2583

```

```

; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/07/928,464
; FILING DATE: 19920810
; CLASSIFICATION: 800
; ATTORNEY/AGENT INFORMATION:
; NAME: Miller, Suzanne E.
; REGISTRATION NUMBER: 32,279
; REFERENCE/DOCKET NUMBER: UPN-1086
; TELEPHONE: 215-568-3100
; INFORMATION FOR SEQ ID NO: 1:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 2890 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: cDNA
; FEATURE:
; NAME/KEY: CDS
; LOCATION: 118..2583

```

```

; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/07/928,464
; FILING DATE: 19920810
; CLASSIFICATION: 800
; ATTORNEY/AGENT INFORMATION:
; NAME: Miller, Suzanne E.
; REGISTRATION NUMBER: 32,279
; REFERENCE/DOCKET NUMBER: UPN-1086
; TELEPHONE: 215-568-3100
; INFORMATION FOR SEQ ID NO: 1:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 2890 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: cDNA
; FEATURE:
; NAME/KEY: CDS
; LOCATION: 118..2583

```

```

; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/07/928,464
; FILING DATE: 19920810
; CLASSIFICATION: 800
; ATTORNEY/AGENT INFORMATION:
; NAME: Miller, Suzanne E.
; REGISTRATION NUMBER: 32,279
; REFERENCE/DOCKET NUMBER: UPN-1086
; TELEPHONE: 215-568-3100
; INFORMATION FOR SEQ ID NO: 1:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 2890 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: cDNA
; FEATURE:
; NAME/KEY: CDS
; LOCATION: 118..2583

```

; TITLE OF INVENTION: and Mutations  
 ; NUMBER OF SEQUENCES: 13  
 ; CORRESPONDENCE ADDRESS:  
 ; ADDRESSEE: Woodcock Washburn Kurtz Mackiewicz and  
 ; ADDRESS: No 5444166xis  
 ; STREET: One Liberty Place - 46th Floor  
 ; CITY: Philadelphia  
 ; STATE: PA  
 ; COUNTRY: U.S.A.  
 ; ZIP: 19103  
 ; COMPUTER READABLE FORM:  
 ; MEDIUM TYPE: Floppy disk  
 ; COMPUTER: IBM PC compatible  
 ; OPERATING SYSTEM: PC-DOS/MS-DOS  
 ; SOFTWARE: WordPerfect 5.1  
 ; CURRENT APPLICATION DATA:  
 ; APPLICATION NUMBER: US/08/003.311B  
 ; FILING DATE: January 12, 1993  
 ; CLASSIFICATION: 800  
 ; PRIOR APPLICATION DATA:  
 ; APPLICATION NUMBER: 07/928.464  
 ; FILING DATE: August 10, 1992  
 ; ATTORNEY/AGENT INFORMATION:  
 ; NAME: Lori Y. Beardell  
 ; REGISTRATION NUMBER: 34,293  
 ; REFERENCE/DOCKET NUMBER: UPN-1108  
 ; TELECOMMUNICATION INFORMATION:  
 ; TELEPHONE: 215-568-3100  
 ; TELEFAX: 215-568-3439  
 ; INFORMATION FOR SEQ ID NO: 1:  
 ; SEQUENCE CHARACTERISTICS:  
 ; LENGTH: 3033 base pairs  
 ; TYPE: nucleic acid  
 ; STRANDEDNESS: single  
 ; TOPOLOGY: linear  
 ; MOLECULE TYPE: cDNA  
 ; FEATURE:  
 ; NAME/KEY: CDS  
 ; LOCATION: 118..2583  
 ; US-08-003-311B-1

Query Match 3.9%; Score 81.4; DB 1; Length 3033;  
 Best Local Similarity 50.1%; Pred. No. 1.9e-09;  
 Matches 202; Conservative 0; Mismatches 201; Indels 0; Gaps 0;

Qy 360 cgcgcccgcagcagactggcgctccaggtggccggtgagcagcctgcacatccacactc 419  
 Db 1808 CTGTCCACCCGTGCTGAGTGGCATGGCTCGGATGTGCTGTGAAAATTTCTCAATGAGCAAG 1867  
 Qy 420 cgcgtcgcagctgaaagaaggatgttttaagagaagctgaaattttacacaaagcta 479  
 Db 1868 ACTTCCATGCTGAGCGTGTAAATGAGTCTTAAGAGAGGTTGCGGATAATGAAACGCCCTTC 1927  
 Qy 480 gatttagttacattttcccaattttgggaatttgcgaatggcctggaatttttgggaatag 539  
 Db 1928 GCCACCCCTAACATATTTCTTCTTCATGGGTGGGTCACCTCAACCTCCAAATTTGTCAATAG 1987  
 Qy 540 ttactgatacatcctcaaatgatcatttaaatgaactcctcataggaactgaatc 599  
 Db 1988 TGACAGAAATATTTGTCAAGAGGTAGTTTATACAGACTTTTGCATAAAAGTGGAGCAAGGG 2047  
 Qy 600 ctgatgttgcctggccattgagatttcgcatcctcgcagctgaaattggccttgggtaaat 659  
 Db 2048 AGCAATFAGATGAGAGAGTCCCTGAGTATGGCTTATGATGTGGCTAAGGGAATGAATT 2107  
 Qy 660 acctgcaaatatgactcctccttactcatcatgatgacttgaagactcagaaatccttat 719  
 Db 2108 ATCTTCAAAATCGCAATCTCCAAATTTGTGCATAGAGATCAAAATCTCCAAACTTATTGG 2167  
 Qy 720 tggcaaatgatttcctgtaagattcagatttttggttatc 762  
 Db 2168 TTGACAAAAAATATACAGTCAAGGTTTGTGATTTGGTCTCTC 2210

RESULT 7

US-08-261-432-1  
 ; Sequence 1, Application US/08261432  
 ; Patent No. 5602322  
 ; GENERAL INFORMATION:  
 ; APPLICANT: Ecker, Joseph R.  
 ; APPLICANT: Kieber, Joseph J.  
 ; TITLE OF INVENTION: Constitutive Triple Response Gene  
 ; TITLE OF INVENTION: and Mutations  
 ; NUMBER OF SEQUENCES: 13  
 ; CORRESPONDENCE ADDRESS:  
 ; ADDRESSEE: Woodcock Washburn Kurtz Mackiewicz and  
 ; ADDRESS: No. 5602322rls  
 ; STREET: One Liberty Place - 46th Floor  
 ; CITY: Philadelphia  
 ; STATE: PA  
 ; COUNTRY: U.S.A.  
 ; ZIP: 19103  
 ; COMPUTER READABLE FORM:  
 ; MEDIUM TYPE: Floppy disk  
 ; COMPUTER: IBM PC compatible  
 ; OPERATING SYSTEM: PC-DOS/MS-DOS  
 ; SOFTWARE: WordPerfect 5.1  
 ; CURRENT APPLICATION DATA:  
 ; APPLICATION NUMBER: US/08/261.432  
 ; FILING DATE: June 17, 1994  
 ; CLASSIFICATION: 800  
 ; PRIOR APPLICATION DATA:  
 ; APPLICATION NUMBER: 08/003.311  
 ; FILING DATE: January 12, 1993  
 ; ATTORNEY/AGENT INFORMATION:  
 ; NAME: Lori Y. Beardell  
 ; REGISTRATION NUMBER: 34,293  
 ; REFERENCE/DOCKET NUMBER: UPN-1864  
 ; TELECOMMUNICATION INFORMATION:  
 ; TELEPHONE: 215-568-3100  
 ; TELEFAX: 215-568-3439  
 ; INFORMATION FOR SEQ ID NO: 1:  
 ; SEQUENCE CHARACTERISTICS:  
 ; LENGTH: 3033 base pairs  
 ; TYPE: nucleic acid  
 ; STRANDEDNESS: single  
 ; TOPOLOGY: linear  
 ; MOLECULE TYPE: cDNA  
 ; FEATURE:  
 ; NAME/KEY: CDS  
 ; LOCATION: 118..2583  
 ; US-08-261-432-1

Query Match 3.9%; Score 81.4; DB 1; Length 3033;  
 Best Local Similarity 50.1%; Pred. No. 1.9e-09;  
 Matches 202; Conservative 0; Mismatches 201; Indels 0; Gaps 0;

Qy 360 cgcgcccgcagcagactggcgctccaggtggccggtgagcagcctgcacatccacactc 419  
 Db 1808 CTGTCCACCCGTGCTGAGTGGCATGGCTCGGATGTGCTGTGAAAATTTCTCAATGAGCAAG 1867  
 Qy 420 cgcgtcgcagctgaaagaaggatgttttaagagaagctgaaattttacacaaagcta 479  
 Db 1868 ACTTCCATGCTGAGCGTGTAAATGAGTCTTAAGAGAGGTTGCGGATAATGAAACGCCCTTC 1927  
 Qy 480 gatttagttacattttcccaattttgggaatttgcgaatggcctggaatttttgggaatag 539  
 Db 1928 GCCACCCCTAACATATTTCTTCTTCATGGGTGGGTCACCTCAACCTCCAAATTTGTCAATAG 1987  
 Qy 540 ttactgatacatcctcaaatgatcatttaaatgaactcctcataggaactgaatc 599  
 Db 1988 TGACAGAAATATTTGTCAAGAGGTAGTTTATACAGACTTTTGCATAAAAGTGGAGCAAGGG 2047  
 Qy 600 ctgatgttgcctggccattgagatttcgcatcctcgcagctgaaattggccttgggtaaat 659

Db 2048 AGCAATTAGATGAGACGCTGCCCTGAGTATGGCTATATGATGCTAAGGAATGAAAT 2107  
 QY 660 acctgcacaatgactcctcttacttccatcatgacttgaaagactcagaatattcttat 719  
 Db 2108 ATCTTCAACATCGCAATCCTCAATTTGCTATGAGATCTAAATCTCCAAACTTATTGG 2167  
 QY 720 tggacaatgaattcaatgaaagattgcaagatttgggtttacc 762  
 Db 2168 TTGCACAAAAAATATACAGTCAAGGTTTGTGATTTGGTCTCTC 2210

RESULT 8  
 US-09-188-930-66  
 ; Sequence 66, Application US/09188930A  
 ; Patent No. 6150502  
 ; GENERAL INFORMATION:  
 ; APPLICANT: Watson, James D.  
 ; APPLICANT: Strachan, Lorna  
 ; APPLICANT: Sleeman, Matthew  
 ; APPLICANT: Orust, Rene  
 ; APPLICANT: Murison, James Greg  
 ; TITLE OF INVENTION: Compositions Isolated From Skin Cells  
 ; TITLE OF INVENTION: and Methods For Their Use  
 ; FILE REFERENCE: 11000.1011c1  
 ; CURRENT APPLICATION NUMBER: US/09/188,930A  
 ; CURRENT FILING DATE: 1998-11-09  
 ; NUMBER OF SEQ ID NOS: 348  
 ; SOFTWARE: FASTSEQ for Windows Version 3.0  
 ; SEQ ID NO 66  
 ; LENGTH: 1888  
 ; TYPE: DNA  
 ; ORGANISM: mouse  
 ; FEATURE:  
 ; NAME/KEY: unsure  
 ; LOCATION: (1690)...(1690)  
 ; NAME/KEY: unsure  
 ; LOCATION: (1755)...(1755)  
 ; NAME/KEY: unsure  
 ; LOCATION: (1864)...(1864)  
 ; US-09-188-930-66

Query Match 3.7%; Score 78.2; DB 4; Length 1888;  
 Best Local Similarity 50.6%; Pred. No. 8.1e-09;  
 Matches 365; Conservative 0; Mismatches 323; Indels 33; Gaps 6;  
 QY 287 ctgcccacattccctaccacaactccgcgacctgcgtacctgagccggcgccctct 346  
 Db 43 ctgcccaccttcgacccgagcgaattccgagctgggagaggtggcctcggggccttc 102  
 QY 347 ggcactgtctccgcccgcagactggcgcgtccagtgccggtgcccgtgagcacctg 406  
 Db 103 gggcaggtgtacaagtgcccaatgctgactggaagacgtggcctcgcgatcaagtctcg 162  
 QY 407 cacatccactccctgctcgcagtgaaagaagatgttttaagagaagctgaaatt 466  
 Db 163 cccaagtc---tgcagctgcagcagcagcgaatggagctcctcggaggaagctaaaga 219  
 QY 467 ttacacaagctagatttagttacattttccaaattttggaaatttgcaatgagcctgaa 526  
 Db 220 atggagatggccaagttcccgatattctacattctcctggttacggcatabtgcaggaaacctg-- 277  
 QY 527 tttttgggaatgactgtaatacagtcacaaatggatcattaaatgaaacctccctacatag 586  
 Db 278 ----tcggcttggctcagtgagtagacagcagcctccctggagagcctgctggcctca 333  
 QY 587 aaactgaatctcgtgattgtgttgccattgagatttgcgcatcctgcaatgaaattgcc 646  
 Db 334 gagccat-----tgccttggaccctgccttttcgcatcgtgcagcagacagcc 381  
 QY 647 ctgggtgaaattacctgcacaataatgacctccctcttacctatcatgacttgaagacc 706

Db 382 gtgggcatgaaacttctctgattgcatgtctccgcccactgctgcacactagacctgaaagcca 441  
 QY 707 cagaatattcttattggacaatgaatttctatgt---taagattgcaagatttgggtttatca 763  
 Db 442 gcaaatcttctgctgagctgcccactcacaatgtcaagatttctgacttggctggctggcc 501  
 QY 764 aagtggcgcagatgctcctctccatcagcagcagcagcagcagcagcagcagcagcagcagc 823  
 Db 502 aagtgcacaatgctgcccactcctcatgacctcagcat----ggatggcctgtttggt 555  
 QY 824 acaattatttatgcccctccctgaaactatgaaactgaaactgaaactgaaactgaaactgaaact 883  
 Db 556 .acaatcgctcctcctccagagcgaatt---cgtgagaagagcgcctgtgtttgacacc 612  
 QY 884 aagcagcagatataagctatgctgactgactgactgactgactgactgactgactgactgact 943  
 Db 613 aaacatgatgatacagcttccctcattgtgactgctgctgctgctgctgctgctgctgctg 672  
 QY 944 ttgaaagatgccaactcctcttgcagataatgataatgataatgataatgataatgataatgata 1003  
 Db 673 ttgcatgataagagaacatcctacacatcatgatgaaagtggtgtaagggccaccgccc 732  
 QY 1004 g 1004  
 Db 733 g 733

RESULT 9  
 US-08-587-680A-24  
 ; Sequence 24, Application US/08587680A  
 ; Patent No. 5977434  
 ; GENERAL INFORMATION:  
 ; APPLICANT: Ronald, Pamela C.  
 ; APPLICANT: Wang, Guo-Liang  
 ; APPLICANT: Song, Wen-Yuang  
 ; APPLICANT: Szabo, Veronique  
 ; TITLE OF INVENTION: Procedures and Materials for Conferring  
 ; TITLE OF INVENTION: Disease Resistance in Plants  
 ; NUMBER OF SEQUENCES: 27  
 ; CORRESPONDENCE ADDRESS:  
 ; ADDRESSEE: Townsend and Townsend and Crew LLP  
 ; STREET: Two Embarcadero Center, Eighth Floor  
 ; CITY: San Francisco  
 ; STATE: California  
 ; COUNTRY: USA  
 ; ZIP: 94111-3834  
 ; COMPUTER READABLE FORM:  
 ; MEDIUM TYPE: Floppy disk  
 ; COMPUTER: IBM PC compatible  
 ; OPERATING SYSTEM: PC-DOS/MS-DOS  
 ; SOFTWARE: PatentIn Release #1.0, Version #1.30  
 ; CURRENT APPLICATION DATA:  
 ; APPLICATION NUMBER: US/08/587,680A  
 ; FILING DATE: 17-JAN-1996  
 ; CLASSIFICATION: 800  
 ; PRIORITY APPLICATION DATA:  
 ; APPLICATION NUMBER: US 08/373,375  
 ; FILING DATE: 17-JAN-1995  
 ; PRIORITY APPLICATION DATA:  
 ; APPLICATION NUMBER: US 08/475,891  
 ; FILING DATE: 07-JUN-1995  
 ; PRIORITY APPLICATION DATA:  
 ; APPLICATION NUMBER: US 60/004,645  
 ; FILING DATE: 29-SEP-1995  
 ; PRIORITY APPLICATION DATA:  
 ; APPLICATION NUMBER: US 08/567,375  
 ; FILING DATE: 04-DEC-1995  
 ; ATTORNEY/AGENT INFORMATION:  
 ; NAME: Bastian, Kevin L.  
 ; REGISTRATION NUMBER: 34,774  
 ; REFERENCE/DOCKET NUMBER: 023070-0589400S  
 ; TELECOMMUNICATION INFORMATION:  
 ; TELEPHONE: (415) 576-0200



Db 338 ctggccgctcccttgcgcctgctgaagaagtgtgcttggaatgttcttaacctgcacg 397  
Qy 669 atatgactcctcttactatcatatgactgaaagactcagaatactttattggacaatg 728  
Db 398 accaagaacctgctcctgcaccgctcaagcctcaagcctcaagcctcaagcctgacccag 457  
Qy 729 aattcatgttaagattgcaatggttttggctttatcaagtggtggcctcctccac 788  
Db 458 agctgcacgccaagctggcagatggtttgctgtccaccattccaggaggtccacagtcag 517  
Qy 789 agtccagc 795  
Db 518 ggacagg 524

RESULT 12  
US-09-329-418-1  
; Sequence 1, Application US/09329418  
; Patent No. 6096539  
; GENERAL INFORMATION:  
; APPLICANT: ZENECA Limited  
; TITLE OF INVENTION: PROTEIN ACTIVATOR OF APOPTOSIS  
; FILE REFERENCE: PHM 70536  
; CURRENT APPLICATION NUMBER: US/09/329,418  
; CURRENT FILING DATE: 1999-06-11  
; NUMBER OF SEQ ID NOS: 39  
; SOFTWARE: FastSEQ for Windows Version 3.0  
; SEQ ID NO 1  
; LENGTH: 1873  
; TYPE: DNA  
; ORGANISM: Homo Sapiens  
US-09-329-418-1

Query Match 2.6%; Score 54.2; DB 3; Length 1873;  
Best Local Similarity 55.6%; Pred. No. 0.0022;  
Matches 104; Conservative 0; Mismatches 83; Indels 0; Gaps 0;  
Qy 609 ctgaggccattgattcgcctcctgcctgcaataatgacctgttgtaaatctccgtcaca 668  
Db 505 ctgaggccctcttgccgctcctgcaagaatggtgctggatggttttaacctgcacg 564  
Qy 669 atagactcctcttactcattcatctgactgaaagactcagaatactttattggacaatg 728  
Db 565 accaagaacctgctcctgcaccggtgacccctcaagcctcaagcctcaagcctcctgctgacccag 624  
Qy 729 aattcatgttaagattgcaatggttttggctttatcaagtggtggcctcctccac 788  
Db 625 agctgcacgccaagctggcagatggtttgctgtccaccattccaggaggtccacagtcag 684  
Qy 789 agtccagc 795  
Db 685 ggacagg 691

RESULT 13  
US-08-545-196B-10  
; Sequence 10, Application US/08545196B  
; Patent No. 6080577  
; GENERAL INFORMATION:  
; APPLICANT: MELKI, JUDITH  
; APPLICANT: MUNNICH, ARNOLD  
; TITLE OF INVENTION: SURVIVAL MOTOR NEURON (SMN) GENE: A GENE  
; TITLE OF INVENTION: FOR SPINAL MUSCULAR ATROPHY  
; NUMBER OF SEQUENCES: 65  
; CORRESPONDENCE ADDRESS:  
; ADDRESS: BIRCH, STEWART, KOLASCH AND BIRCH, LLP  
; STREET: PO BOX 747  
; CITY: FALLS CHURCH  
; STATE: VA  
; COUNTRY: USA  
; ZIP: 22040-0747

COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: Patent In Release #1.0, Version #1.30  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/545,196B  
FILING DATE: 19-OCT-1995  
CLASSIFICATION: 435  
ATTORNEY/AGENT INFORMATION:  
NAME: FARACI, C. J.  
REGISTRATION NUMBER: 32,350  
REFERENCE/DOCKET NUMBER: 2121-110P  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (703) 205-8000  
TELEFAX: (703) 205-8050  
INFORMATION FOR SEQ. ID NOS: 10:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 1582 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: double  
TOPOLOGY: linear  
MOLECULE TYPE: CDNA  
US-08-545-196B-10

Query Match 2.6%; Score 53.6; DB 3; Length 1582;  
Best Local Similarity 49.2%; Pred. No. 0.0029;  
Matches 122; Conservative 6; Mismatches 120; Indels 0; Gaps 0;  
Qy 1850 tctttaaatttactcacaataaaagcagtgctgacgtttttcaagaagaaaatggtg 1909  
Db 1335 TCCTAAAATGTTCAAATGTTAAACAATAATGTATGTAGGGCTATGTGCACAAAATGTTA 1394  
Qy 1910 ticataaagaagatattatctctctgttcttttttttttttttttttttttttttttt 1969  
Db 1395 CAGAAATCACTAATCTGAGGGCTGTCTGTCTGTCTGTCTGTCTGTCTGTCTGTCTGT 1454  
Qy 1970 attaaagcttwrwaargktcttttktaaatattagttcctccatgacacactgcagt 2029  
Db 1455 TTAATAAGTATAATAAATAAATAATTTAATTTTTTTAATAAATAAATAAATAAATAA 1514  
Qy 2030 atttttttttaattacacagtaaaagtgtaattggaagaaaaaagaaagaaagaaa 2089  
Db 1515 AAAAAAAAATAAATAAATAAATAAATAAATAAATAAATAAATAAATAAATAAATAA 1574  
Qy 2090 aaaaaaaa 2097  
Db 1575 AAAAAAAA 1582

RESULT 14  
US-08-545-196B-12  
; Sequence 12, Application US/08545196B  
; Patent No. 6080577  
; GENERAL INFORMATION:  
; APPLICANT: MELKI, JUDITH  
; APPLICANT: MUNNICH, ARNOLD  
; TITLE OF INVENTION: SURVIVAL MOTOR NEURON (SMN) GENE: A GENE  
; TITLE OF INVENTION: FOR SPINAL MUSCULAR ATROPHY  
; NUMBER OF SEQUENCES: 65  
; CORRESPONDENCE ADDRESS:  
; ADDRESS: BIRCH, STEWART, KOLASCH AND BIRCH, LLP  
; STREET: PO BOX 747  
; CITY: FALLS CHURCH  
; STATE: VA  
; COUNTRY: USA  
; ZIP: 22040-0747  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: Patent In Release #1.0, Version #1.30



```

CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/545,196B
FILING DATE: 19-OCT-1995
CLASSIFICATION: 435
ATTORNEY/AGENT INFORMATION:
NAME: FARACI, C. J.
REGISTRATION NUMBER: 32,350
REFERENCE/DOCKET NUMBER: 2121-110P
TELECOMMUNICATION INFORMATION:
TELEPHONE: (703) 205-8000
TELEFAX: (703) 205-8050
INFORMATION FOR SEQ ID NO: 12:
SEQUENCE CHARACTERISTICS:
LENGTH: 1582 base pairs
TYPE: nucleic acid
STRANDEDNESS: double
TOPOLOGY: linear
MOLECULE TYPE: cdna
US-08-545-196B-12.

```

```

Query Match 2.68; Score 53.6; DB 3; Length 1582;
Best Local Similarity 49.28; Pred. No. 0.0029;
Matches 122; Conservative 6; Mismatches 120; Indels 0; Gaps 0;

```

```

Qy 1850 tctttaatttcaaaataaaagcagctgtaagtgactgtttttccaagaagaatgtg 1909
||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 1335 TCTTAAATGTTCAATGGTTAAACAAATGATGTGAGCGGTATGGCCAAATGTTA 1394
Qy 1910 tctataaagagatttatctctgtgcttggactttttttatataaaacccgtgsgt 1969
||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 1395 CAGAACTAAGTGGACATGCTGTTCAATGTACTGTTTTTTTCTATCTATATGT 1454
Qy 1970 attaaagcttwwraargkctttsrktaaatattagctccctccatgacactgcagt 2029
||||| :||| :||| :||| :||| :||| :||| :||| :||| :|||
Db 1455 TTAAGTATATAATAATAATAATAATAATAATAATAATAATAATAATAATAATA 1514
Qy 2030 atttttttaataacacaagtaaaagttgaaatttgaaatttgaaatttgaaatttgaa 2089
||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 1515 AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 1574
Qy 2090 aaaaaaaa 2097
|||||
Db 1575 AAAAAAAAAA 1582

```

```

RESULT 15
US-07-867-106-2/c
Sequence 2, Application US/07867106
Patent No. 5389526
GENERAL INFORMATION:
APPLICANT: Slade, Martin B
APPLICANT: Chang, Andy C M
APPLICANT: Williams, Keith L
TITLE OF INVENTION: Improved Plasmid Vectors for Cellular
TITLE OF INVENTION: Slime Moulds of the Genus Dictyostelium
NUMBER OF SEQUENCES: 19
CORRESPONDENCE ADDRESS:
ADDRESS: Woodcock Washburn Kurtz Mackiewicz & No. 5389526/ris
STREET: One Liberty Place 46th Floor
CITY: Philadelphia
STATE: PA
COUNTRY: USA
ZIP: 19103
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/07/867,106
FILING DATE: 19920625
PRIOR APPLICATION DATA:

```

```

APPLICATION NUMBER: AU PJ 7187
APPLICATION NUMBER: PCT/AU90/00530
FILING DATE: 02-NOV-1989
ATTORNEY/AGENT INFORMATION:
NAME: Feeney, Joanne Longo
REGISTRATION NUMBER: 35,134
REFERENCE/DOCKET NUMBER: RICE-0002
TELECOMMUNICATION INFORMATION:
TELEPHONE: 215-568-3100
TELEFAX: 215-568-3439
INFORMATION FOR SEQ ID NO: 2:
SEQUENCE CHARACTERISTICS:
LENGTH: 5852 base pairs
TYPE: NUCLEIC ACID
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
ANTI-SENSE: NO
FEATURE:
NAME/KEY: CDS
LOCATION: 2378..5038
FEATURE:
NAME/KEY: CDS
LOCATION: 2378..5038
US-07-867-106-2

```

```

Query Match 2.58; Score 53.2; DB 1; Length 5852;
Best Local Similarity 49.68; Pred. No. 0.006;
Matches 121; Conservative 5; Mismatches 118; Indels 0; Gaps 0;
Qy 1855 aaatttacttcaaaataaaagcagctgtaagtgactgtttttccaagaagaatgtg 1914
||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 5837 AAAGTAACTAAGTACTAATAAAGATCTTTAAATTTATTATATACATTTTAAATGCTT 5778
Qy 1915 aaaaggatatttatctctgttggcttggactttttttatataaaacccgtgagattaa 1974
||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 5777 ATTTAAATTTAATTAATTTAATTTAATTTAATTTAATTTAATTTAATTTAATTTAAT 5718
Qy 1975 agcttwwraargkctttsrktaaatattagctccctccatgacactgcagattttt 2034
||||| :||| :||| :||| :||| :||| :||| :||| :||| :|||
Db 5717 TTTTACTTATATTTCTATTTTATTTAATAATAATAATAATAATAATAATAATAATA 5658
Qy 2035 ttttaattcaacagtaaaagttgaaatttgaaatttgaaatttgaaatttgaaatttgaa 2094
||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 5657 AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 5598
Qy 2095 aaaa 2098
|||||
Db 5597 AAAA 5594

```

```

Search completed: June 13, 2001, 17:33:58
Job time: 6861 sec

```



GenCore version 4.5  
Copyright (c) 1993 - 2000 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: June 13, 2001, 11:10:10 ; Search time 1923.15 Seconds  
(without alignments)  
9530.371 Million cell updates/sec

Title: US-09-445-223-2  
Perfect score: 2098  
Sequence: 1 ggccattatgatgatggg.....aaaaaaaaaaaaaaaaaaaa 2098

Scoring table: IDENTITY\_NUC  
Gapop 10.0 , Gapext 1.0

Searched: 9623517 seqs, 4368049070 residues  
Total number of hits satisfying chosen parameters: 19247034

Minimum DB seq length: 0  
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%  
Maximum Match 100%  
Listing first 45 summaries

Database : EST:  
1: gb\_est1:\*  
2: gb\_est2:\*  
3: gb\_est3:\*  
4: gb\_est4:\*  
5: gb\_est5:\*  
6: gb\_est6:\*  
7: gb\_est7:\*  
8: gb\_est8:\*  
9: gb\_est9:\*  
10: gb\_est10:\*  
11: gb\_est11:\*  
12: gb\_est12:\*  
13: gb\_est13:\*  
14: gb\_est14:\*  
15: gb\_est15:\*  
16: gb\_est16:\*  
17: gb\_est17:\*  
18: gb\_est18:\*  
19: gb\_est19:\*  
20: gb\_est20:\*  
21: gb\_est21:\*  
22: gb\_est22:\*  
23: gb\_est23:\*  
24: gb\_est24:\*  
25: gb\_est25:\*  
26: gb\_est26:\*  
27: gb\_est27:\*  
28: gb\_est28:\*  
29: gb\_est29:\*  
30: gb\_est30:\*  
31: gb\_est31:\*  
32: gb\_est32:\*  
33: gb\_est33:\*  
34: gb\_est34:\*  
35: gb\_est35:\*  
36: gb\_est36:\*  
37: gb\_est37:\*  
38: gb\_est38:\*  
39: gb\_est39:\*  
40: gb\_est40:\*  
41: gb\_est41:\*  
42: gb\_est42:\*  
43: gb\_est43:\*  
44: gb\_est44:\*  
45: gb\_est45:\*  
46: gb\_est46:\*  
47: gb\_est47:\*

em\_esthum10:\*  
em\_esthum11:\*  
em\_esthum12:\*  
em\_esthum13:\*  
em\_esthum14:\*  
em\_esthum15:\*  
em\_esthum16:\*  
em\_esthum17:\*  
em\_esthum18:\*  
em\_esthum19:\*  
em\_esthum20:\*  
em\_esthum21:\*  
em\_esthum22:\*  
em\_esthum23:\*  
em\_esthum24:\*  
em\_esthum25:\*  
em\_esthum26:\*  
em\_esthum27:\*  
em\_esthum28:\*  
em\_estin1:\*  
em\_estin2:\*  
em\_estin3:\*  
em\_estin4:\*  
em\_estin5:\*  
em\_estom1:\*  
em\_estom2:\*  
em\_estov2:\*  
em\_estpl1:\*  
em\_estpl2:\*  
em\_estpl3:\*  
em\_estpl4:\*  
em\_estpl5:\*  
em\_estpl6:\*  
em\_estpl7:\*  
em\_estpl8:\*  
em\_estpl9:\*  
em\_estpl10:\*  
em\_estro1:\*  
em\_estro2:\*  
em\_estro3:\*  
em\_estro4:\*  
em\_estro5:\*  
em\_estro6:\*  
em\_estro7:\*  
em\_estro8:\*  
em\_estro9:\*  
em\_estro10:\*  
em\_estro11:\*  
em\_estro12:\*  
em\_estro13:\*  
em\_estro14:\*  
em\_estro15:\*  
em\_estro16:\*  
em\_estro17:\*  
em\_estro18:\*  
em\_estro19:\*  
em\_estro20:\*  
gb\_est25:\*  
gb\_est26:\*  
gb\_est27:\*  
gb\_est28:\*  
gb\_est29:\*  
gb\_est30:\*  
gb\_est31:\*  
gb\_est32:\*  
gb\_est41:\*  
gb\_est42:\*  
gb\_est43:\*  
gb\_est44:\*  
gb\_est45:\*  
gb\_est46:\*  
gb\_est47:\*

```

117: gb_est48:*
118: gb_est49:*
119: gb_est50:*
120: gb_est51:*
121: gb_est52:*
122: gb_est53:*
123: gb_est54:*
124: gb_est55:*
125: gb_est56:*
126: gb_est57:*
127: gb_est58:*
128: gb_est59:*
129: gb_est60:*
130: gb_est61:*
131: gb_est62:*
132: gb_est63:*
133: gb_est64:*
134: gb_est65:*
135: gb_est66:*
136: gb_est67:*
137: gb_est68:*
138: gb_est69:*
139: gb_est70:*
140: gb_est71:*
141: gb_est72:*
142: gb_est73:*
143: gb_est74:*
144: gb_est75:*
145: gb_est76:*
146: gb_est77:*
147: gb_est78:*
148: gb_est79:*
149: gb_est80:*
150: gb_est81:*
151: gb_est82:*
152: gb_est83:*
153: gb_est84:*
154: gb_est85:*
155: gb_est86:*
156: gb_est87:*
157: gb_est88:*
158: gb_est89:*
159: gb_est90:*
160: gb_est91:*
161: gb_est92:*
162: gb_est93:*
163: gb_est94:*
164: gb_est95:*
165: gb_est96:*
166: gb_est97:*
167: gb_est98:*
168: em_gss_fun:*
169: em_gss_hum1:*
170: em_gss_hum2:*
171: em_gss_hum3:*
172: em_gss_hum4:*
173: em_gss_hum5:*
174: em_gss_hum6:*
175: em_gss_hum7:*
176: em_gss_hum8:*
177: em_gss_hum9:*
178: em_gss_inv1:*
179: em_gss_inv2:*
180: em_gss_inv3:*
181: em_gss_other:*

```

```

190: em_gss_pln1:*
191: em_gss_pln2:*
192: em_gss_pro:*
193: em_gss_rod1:*
194: em_gss_rod2:*
195: em_gss_rod3:*
196: em_gss_rod4:*
197: em_gss_rod5:*
198: em_gss_vrtl:*
199: em_gss_vrt2:*
200: em_gss_vrt3:*
201: gb_gss1:*
202: gb_gss2:*
203: gb_gss3:*
204: gb_gss4:*
205: gb_gss5:*
206: gb_gss6:*
207: gb_gss7:*
208: gb_gss8:*
209: gb_gss9:*
210: gb_gss10:*
211: gb_gss11:*
212: gb_gss12:*
213: gb_gss13:*
214: gb_gss14:*
215: gb_gss15:*
216: gb_gss16:*
217: gb_gss17:*
218: gb_gss18:*
219: gb_gss19:*
220: gb_gss20:*
221: gb_gss21:*
222: gb_gss22:*
223: gb_gss23:*
224: gb_gss24:*
225: gb_gss25:*
226: gb_gss26:*
227: gb_gss27:*
228: gb_gss28:*
229: gb_gss29:*
230: gb_gss30:*
231: gb_gss31:*
232: gb_gss32:*
233: gb_gss33:*
234: gb_gss34:*

```

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match %	Length	DB	ID	Description
1	745.8	35.5	811	174	BG170405	BG170405 602322736
2	686	32.7	870	140	BE877822	BE877822 601486392
3	655.8	31.3	828	140	BE875947	BE875947 601486423
C 4	621.8	29.6	636	136	BE551615	BE551615 7a42906.x
C 5	609.4	29.0	641	111	AW150819	AW150819 xg99f08.x
C 6	592	28.2	592	24	A1745575	A1745575 wc34f12.x
C 7	590.6	28.2	606	110	AW085560	AW085560 wy67c04.x
C 8	588.8	28.1	647	122	AW960501	AW960501 EST372572
C 9	587	28.0	654	136	BE536247	BE536247 601062632
C 10	561	26.7	615	102	AI801150	AI801150 LO85H04.x
C 11	558.6	26.6	645	3	AA160647	AA160647 zq49611.r
C 12	554	26.4	839	144	BF125028	BF125028 601762610
C 13	550.4	26.2	1112	144	BF125423	BF125423 601763549
C 14	546.8	26.1	616	18	AI307810	AI307810 eb28g07.x
C 15	542	25.8	762	103	AI904799	AI904799 IL-BT087-
C 16	532.6	25.4	568	3	AA161113	AA161113 z058g05.s
C 17	513.4	24.5	917	165	BE274455	BE274455 601120495
C 18	506	24.1	518	117	AW593657	AW593657 xl94d07.x

c 19 478.2 22.8 483 19 AI343247  
 20 466.8 22.2 484 5 AA315575  
 c 21 464 22.1 476 13 AA913804  
 c 22 452.2 21.6 487 114 AW393452  
 c 23 450.6 21.5 496 114 AW393431  
 c 24 449 21.4 455 19 AI343850  
 c 25 441.4 21.0 445 120 AW820715  
 c 26 439.8 21.0 445 120 AW820730  
 c 27 438.2 20.9 940 169 BF796292  
 c 28 430.4 20.5 446 117 AW610171  
 c 29 428.4 20.4 448 21 AI499817  
 c 30 425.6 20.3 439 19 AI380994  
 c 31 423 20.2 423 9 AA574167  
 c 32 422.8 20.2 446 161 BE002713  
 c 33 422 20.1 443 16 AI123747  
 c 34 418 19.9 432 11 AA723533  
 c 35 416.6 19.9 472 168 BF706215  
 c 36 410.2 19.6 503 10 AA655189  
 c 37 402.4 19.2 426 114 AW385842  
 c 38 394 18.8 400 12 AA826052  
 c 39 388.6 18.5 423 143 BF062840  
 c 40 382.8 18.2 432 3 AA158827  
 c 41 382.8 18.2 462 114 AW361643  
 c 42 381.4 18.2 401 11 AA740822  
 c 43 371.2 17.7 493 175 C05866  
 c 44 366.2 17.5 510 114 AW389863  
 c 45 364 17.3 447 114 AW361603

ALIGNMENTS

RESULT 1  
 BGI70405 BGI70405 811 bp mRNA EST 06-FEB-2001  
 LOCUS 602322736F1 NIH\_MGC\_89 Homo sapiens cDNA clone IMAGE:4426016 5',  
 mRNA sequence.  
 DEFINITION BGI70405.1 GI:12677108  
 ACCESSION BGI70405  
 VERSION BGI70405.1  
 KEYWORDS EST.  
 SOURCE human.  
 ORGANISM Homo sapiens  
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
 REFERENCE 1 (bases 1 to 811)  
 NIH-MGC http://mgi.nci.nih.gov/  
 AUTHORS National Institutes of Health, Mammalian Gene Collection (MGC)  
 JOURNAL Unpublished (1999)  
 COMMENT Contact: Robert Strausberg, Ph.D.  
 Tel: (301) 496-1550  
 Email: Robert\_Strausberg@nih.gov  
 Tissue Procurement: ATCC  
 CDNA Library Preparation: Life Technologies, Inc.  
 CDNA Library Arrayed by: The I.M.A.G.E. Consortium (LLNL)  
 DNA Sequencing by: Incyte Genomics, Inc.  
 Clone Distribution: MGC clone distribution information can be  
 found through the I.M.A.G.E. Consortium/LLNL at:  
 http://image.llnl.gov  
 Plate: LLAM10172 Row: g Column: 09  
 High quality sequence stop: 721.  
 Location/Qualifiers  
 1..811  
 /organism="Homo sapiens"  
 /db\_xref="taxon:9606"  
 /clone="IMAGE:4426016"  
 /clone\_lib="NIH\_MGC\_89"  
 /tissue\_types="hybernephroma, cell line"  
 /lab\_host="DH10B (phage-resistant)"  
 /note="Organ: kidney; Vector: pCMV-SPORT6; Site\_1: NotI;  
 Site\_2: SalI; Cloned unidirectionally; oligo-dT primed.  
 Average insert size 1.3 kb. Library enriched for  
 full-length clones, and constructed by Life Technologies.  
 Note: this is a NIH\_MGC Library."

BASE COUNT 272 a 177 c 156 g 206 t  
 ORIGIN  
 Query Match 35.5%; Score 745.8; DB 174; Length 811;  
 Best Local Similarity 96.9%; Pred. No. 2e-153;  
 Matches 782; Conservative 0; Mismatches 22; Indels 3; Gaps 2;  
 OY 1032 atatactaccgagcagcagtgatctctcaataagaagtgagggcacaacaaatccag 1091  
 Db 1 ATATACCTCACCGGACGATGATCTCTCTAATAAGAAAGTGGATGGCCAAAATCCAG 60  
 OY 1092 atgaagaccattcttcttaaaatttaataagaactgaaccagttttgagaacattg 1151  
 Db 61 ATGAAAGACCATTCTTAAATCTTAAATAGAACTTGAACCACTTTGAGAACATTG 120  
 OY 1152 aagagataaacattttttgaagctgtattcagcctaagaagaaagttacagagtgtt 1211  
 Db 121 AAGAGATAAATCTTCTTGAAGCTGTTATTCAGCTAAAGAAAACAAGTTACAGAGTGT 180  
 OY 1212 caagtgcattccacctatgtgacaagaagaataatggaattatctctgaacatccctgtaa 1271  
 Db 181 CAAGTGCCTATCCCTATGTGACAAAGAAATGGAATATCTCTGAACATACCTGTAA 240  
 OY 1272 atcattgtccacaagaggaaatcattgtgatccctcagctccatgaaatagtgtctc 1331  
 Db 241 ATCATGTTCCACAAGAGGAATCATGTGGATCCTCTCAGCTCCATGAAAATAGTGTCTC 300  
 OY 1332 ctgaaattcaggctccctgccagctcctcaagacaagatttttttatcagaaaagctc 1391  
 Db 301 CTGAAACTTCAAGSTCCCTGCCAGCTCCTCAAGACAATGATTTTATCTAGAAAAGCTC 360  
 OY 1392 aagactgtatttttaagctgcacactgtcctcctgggaaatcacagttggatgacacca 1451  
 Db 361 AAGACTGTATTTATGAAAGCTGCACTACTGTCCTGGAAATCACAGTTGGGTAGCACA 420  
 OY 1452 tttctggatcctaaagggctgattctgtgatcacaagaccactcctcctcctcagcaaa 1511  
 Db 421 TTTCTGGATCTCAAAGGGTGCATTTCTGTGATCACAAAGACCCTCCATCTCTTCAGCAA 480  
 OY 1512 taataaacctcctcaactgcagaaactcaagcgtcctcagccttgatagccagc 1571  
 Db 481 TAATAAATCCACTCTCAACTGCAGGAAACTCAGAAAGCTGCGAGCTGGTATAGCCACG 540  
 OY 1572 agtggatccagcagaagaagacattgtgaacaaatgacagaagcctccttaacc 1631  
 Db 541 AGTGGATCCAGACAAAGGGAAAGACATTTGAAACAAATGACAAAGCCCTTAAAC 600  
 OY 1632 agtcgtagatgcccttctgtccagggactgtatcatgaaagaggactatgaactgtta 1691  
 Db 601 AGTCGTAGATGCCCTTCTGTCCAGGACTTGCATGATGAAAGGACTATGAACTTGTTA 660  
 OY 1692 gtaccaagcctacaaggacctcaaaagtcaga-caattactagacactagacatccaa 1750  
 Db 661 GTACCAAGCCCTACAAGGACCTCAAAGTCAAGACCAATTAAGACACTACTGACATCCA 720  
 OY 1751 ggagagaatttgcacaaagtattatagtaacaaattgaaagatacaacaaatgggtctt 1810  
 Db 721 GGAGAAAGATTTGCCAAAGTTATACCTACAAAATAAATTTGACGATTTACCAG -CAATGGGTCTT 778  
 OY 1811 cagccttaccggaaatactgtggtt 1837  
 Db 779 AAGCCTTACCAGAAATACTGTGGGTT 805  
 RESULT 2  
 BE877822 BE877822 870 bp mRNA EST 20-OCT-2000  
 LOCUS 601486392F1 NIH\_MGC\_69 Homo sapiens cDNA clone IMAGE:3888815 5',  
 mRNA sequence.  
 DEFINITION BE877822  
 ACCESSION BE877822  
 VERSION BE877822.1 GI:10326598  
 KEYWORDS EST.

SOURCE ORGANISM human.  
 Homo sapiens  
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 Mammalia; Eutheria; Primates; Catarrhini; Hominoidea; Homo.  
 REFERENCE NIH-MGC http://mgc.nci.nih.gov/  
 AUTHORS National Institutes of Health, Mammalian Gene Collection (MGC)  
 TITLE Unpublished (1999)  
 JOURNAL  
 COMMENT Contact: Robert Strausberg, Ph.D.  
 Tel: (301) 496-1550  
 Email: Robert\_Strausberg@nih.gov  
 Tissue Procurement: DCTD/DTP/Gazdar  
 cDNA Library Preparation: Life Technologies, Inc.  
 cDNA Library Arrayed by: The I.M.A.G.E. Consortium (LLNL)  
 DNA Sequencing by: Incyte Genomics, Inc.  
 Clone distribution: MGC clone distribution information can be  
 found through the I.M.A.G.E. Consortium/LLNL at:  
 http://image.llnl.gov  
 Plate: LLAM9669 row: 9 column: 24  
 High quality sequence stop: 739.  
 Location/Qualifiers  
 1..870  
 /organism="Homo sapiens"  
 /db\_xref="taxon:9606"  
 /clone\_image="388815"  
 /clone\_lib="NIH\_MGC\_69"  
 /tissue\_type="large cell carcinoma, undifferentiated"  
 /lab\_host="DH10B (phage-resistant)"  
 /note="Organ: lung; Vector: pCMV-SPORT6; Site\_1: NotI;  
 Site\_2: SalI; Cloned unidirectionally. Primer: Oligo dt.  
 Average insert size 1.1 Kb. Library constructed by Life  
 Technologies."

BASE COUNT 288 a 200 c 170 g 212 t  
 ORIGIN  
 Query Match 32.7%; Score 686; DB 140; Length 870;  
 Best Local Similarity 97.2%; Pred. No. 2.7e-140;  
 Matches 762; Conservative 0; Mismatches 15; Indels 7; Gaps 6;  
 QY 1153 agagataactttctgaagcttattcagctaaagaacaagaagttcagagttttc  
 Db 1 AGAGTANCTTTCTTGAAGCTGTTATTCAGCTAAGAAACAAAGAAAGTTTACAGAGTGTTC 60  
 QY 1213 aagtgccattccactgtgacaagaagaatggaaattatctctgaacataacctgaa 1272  
 Db 61 AAGTGCCATTCCACTATGTGACAAAGAAATGGAATATCTCTGAACATACCTGTAAA 120  
 QY 1273 tcatygtcccaagaggaatcattgtggatcctcctcagctccatgaaaatagtggtctcc 1332  
 Db 121 TCATGGTCCACAAAGAGGAATCATGTGGATCCTCTCAGCTCCATGAAATAGTGGTCTCC 180  
 QY 1333 tgaacttcaggctccctcagctcctcagcaatgattttttctagaaaagctca 1392  
 Db 181 TGAATTCARAGTCCCTGCGCAGCTCTCAGACAAATGATTTTTTATCTAGAAAAGCTCA 240  
 QY 1393 agactgtattttatgaagctgatcactgtcctggaaatcacagttgggatagcaccat 1452  
 Db 241 AGACTGTTATTTATGAAGCTGCATCACTCTCCTGGAAATCACAGTTGGGATAGCACCAT 300  
 QY 1453 tcttgatctcaaaagggctcattctgtatcacaagacaacacctcctcctcagcaat 1512  
 Db 301 TTCTGGATCTCAAAAGGGCTGCATTTCTGTATCACAAAGACACCTCCATGCTCTTCAGCAAT 360  
 QY 1513 aataatcccactccaactcagaaactcagacgctcagcctcagcctggtatagcccagca 1572  
 Db 361 AATPAAATCCACTCTCACTGCAGGAACTCAGACGCTCTCGACCTGGTATAGCCAGCA 420  
 QY 1573 gtggatccagagcaaaagggagacattgtgaaccataatgacagagaagcctcctcctaacca 1632  
 Db 421 GTGGATCCAGGCAAAAGGGAAGACATTTGTGAACCAATGACAGAGCCCTGCCTTAACCA 480  
 QY 1633 gtgcgtagatgcccttctgtcccaggagactgatcatgaaagaagagactatgaactgtgtag 1692

Db 481 GTCGCTAGATGCCCTTCTGTCCA-GGACTTGATCATGAAAGAGGACTATGAACCTTTGTTAG 539  
 QY 1693 taccagcctcaagagcctcaaaaagtcagacaattactagacactactagacatccaa-g 1751  
 Db 540 TACCAAGCCTACAAAGGACTCAAAAAGTCAGACAATTTACTAGACACTACTGACATCCAAAG 599  
 QY 1752 gagaagaatttcccaagattatagtcacaaaattgaaagaatacaaaaagcttctt- 1810  
 Db 600 GAGAAGAATTTGCCRAAGTTATAGTACAAAATTTGAAGATTAACAACAATAATGGGCTTT 659  
 QY 1811 -cagcctaccgggaaataacttgggtttcttagatcaaacatttcaaa-ttctactcaaa 1868  
 Db 660 CAGGCTTACCCGGAATACTTGTGTTTCTAGATCACCATCTTTAAATTTTACTTTCAGA 719  
 QY 1869 ataaaagcattgaagctgttttcaagaagaagattgttttcaaaaagagatattat 1928  
 Db 720 ATAAAAGCTGTTAAGTGACTGTCTTC-AGCAGACATGTG-TTCCTTACCAGATATTTAT 777  
 QY 1929 atct 1932  
 Db 778 CTCT 781

RESULT 3  
 BE875947 828 bp mRNA EST 20-OCT-2000  
 LOCUS 601486423Fl NIH\_MGC\_69 Homo sapiens cDNA clone IMAGE:3888965 5',  
 DEFINITION mRNA sequence.  
 ACCESSION BE875947  
 VERSION BE875947.1 GI:10324723  
 KEYWORDS EST.  
 SOURCE human.  
 ORGANISM Homo sapiens  
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 Mammalia; Eutheria; Primates; Catarrhini; Hominoidea; Homo.  
 REFERENCE 1 (bases 1 to 828)  
 AUTHORS NIH-MGC http://mgc.nci.nih.gov/  
 TITLE National Institutes of Health, Mammalian Gene Collection (MGC)  
 JOURNAL Unpublished (1999)  
 COMMENT Contact: Robert Strausberg, Ph.D.  
 Tel: (301) 496-1550  
 Email: Robert\_Strausberg@nih.gov  
 Tissue Procurement: DCTD/DTP/Gazdar  
 cDNA Library Preparation: Life Technologies, Inc.  
 cDNA Library Arrayed by: The I.M.A.G.E. Consortium (LLNL)  
 DNA Sequencing by: Incyte Genomics, Inc.  
 Clone distribution: MGC clone distribution information can be  
 found through the I.M.A.G.E. Consortium/LLNL at:  
 http://image.llnl.gov  
 Plate: LLAM9669 row: n column: 06  
 High quality sequence stop: 795.  
 Location/Qualifiers  
 1..828  
 /organism="Homo sapiens"  
 /db\_xref="taxon:9606"  
 /clone\_image="3888965"  
 /clone\_lib="NIH\_MGC\_69"  
 /tissue\_type="large cell carcinoma, undifferentiated"  
 /lab\_host="DH10B (phage-resistant)"  
 /note="Organ: lung; Vector: pCMV-SPORT6; Site\_1: NotI;  
 Site\_2: SalI; Cloned unidirectionally. Primer: Oligo dt.  
 Average insert size 1.1 Kb. Library constructed by Life  
 Technologies."  
 BASE COUNT 287 a 163 c 165 g 213 t  
 ORIGIN  
 Query Match 31.3%; Score 655.8; DB 140; Length 828;  
 Best Local Similarity 98.4%; Pred. No. 1.2e-133;  
 Matches 694; Conservative 0; Mismatches 7; Indels 4; Gaps 3;  
 QY 1267 tgtaaatcatggtcccaagaggaatcatggtggtatcctcagctccatgaaatagtg 1326

Db 4 TGTAAATCATGTCCACAAAGGAATCATGTGGATCTCTCAGCTCCATGAAATAGTGG 63  
 QY 1327 ttctctgaacctcaaggtccctccagctcctcaagacaatgtttttttatctagaaa 1386  
 Db 64 TTTCTCTGNAACCTTCAGGGTCCCTCCAGCTCCTCAAGCAATGATTTTTTATCFAGAAA 123  
 QY 1387 agctcaagactgtttttatgaagctgcactgcctgcctgcaaatcacagttggtatg 1446  
 Db 124 AGCTCAAGACTGTATTTATGAAGCTGCATCAGTCTCCTGGAAATCACAGTTGGATAG 183  
 QY 1447 caeatttcttgatctcaaaaggtcgcattctgtgatcaacaagaccctccatgctctc 1506  
 Db 184 CACCATTCTGGATCTCAAAAGGCTGCAFTCTGTGATCAACAAGACCCTCCATGCTTTC 243  
 QY 1507 agcaataataactcactcctcaactgcaggaactcaagaactcgcagcctggtatagc 1566  
 Db 244 ACCATATATAATCCACTCTCACTGCAGAAACTCAGAACCTCTGCAGCCTGGTATAGC 303  
 QY 1567 ccagcagtggaaccagagcaaaaggaagacattgtgaaccacaatgacagaagcctgct 1626  
 Db 304 CCAGCAGTGGATCCAGAGCAAAAGGAAGACATTTGTAACCAAAATGACAGAAGCCTGCCT 363  
 QY 1627 taaccagctgtagtgccttctcagggacttgatcatgaagaggaactatgaact 1686  
 Db 364 TAACCAGTGGCTAGATGCGCTTCTGCCA-GGACTGTGATGAAAGAGGACTATGAAT 422  
 QY 1687 ttttagtaccagcctcaagagcctcaaaagctcaaaagctcagacaattactagacactgacat 1746  
 Db 423 TGTAGTACCAAGCTTACAGAGCCTCAAAAGCTCAAAAGCTCAGACAAATCTAGACACTCTGACAT 482  
 QY 1747 ccaaggaagaattgtccaaagttatagtaaaaaattgaaagatacaaaaatggg 1806  
 Db 483 CCAAGGAGAAGAAATTTGCCAAAGTTATAGTACAAAAATTTGAAAGATACAAAAAATGGG 542  
 QY 1807 tcttcagccttaccggaaactt-gtggttcttagatcaccatctttaaattactct 1865  
 Db 543 TCTTACGCTTACCAGGAAATCTTGGTGTCTTCTAGATCACCATCTTTAAATTTACTTTC 602  
 QY 1866 aaaaataaagcattgaagtgactgttttcaagaagaatgttttataaagaagatt 1925  
 Db 603 AAAATPAAAAGCATGTAGTGACTGTTTTTCAAGAAGAAATGTTTTTCAAAAAGGATATT 662  
 QY 1926 tatatctgttctgactttttatataaaaaatccgctgagta 1970  
 Db 663 TATACTCTGGTG--TTGACTTTTTTTTATATAAATCCGGAGTATA 705

RESULT 4  
 BE551615/c  
 LOCUS 7a42g06.x1 NCI\_CGAP.GC6 Homo sapiens cDNA clone IMAGE:3221434 3'  
 DEFINITION similar to TR:O43353 O43353 SERINE/THREONINE KINASE RICK. ;, mRNA  
 BE551615  
 BE551615.1 GI:9793227  
 human.  
 ORGANISM Homo sapiens  
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 Mammalia; Eutheria; Primates; Catarrhini; Hominiidae; Homo.  
 REFERENCE 1 (bases 1 to 636)  
 AUTHORS NCI-CGAP http://www.ncbi.nlm.nih.gov/ncicgap.  
 TITLE National Cancer Institute, Cancer Genome Anatomy Project (CGAP),  
 Tumor Gene Index  
 JOURNAL Unpublished (1997)  
 COMMENT Contact: Robert Strausberg, Ph.D.  
 Tel: (301) 496-1550  
 Email: Robert\_Strausberg@nih.gov  
 Tissue Procurement: Christopher A. Moskaluk, M.D., Ph.D., Michael  
 R. Emmert-Buck, M.D., Ph.D.  
 cDNA Library Preparation: M. Bento Soares, Ph.D., M. Fatima  
 BonaGo, Ph.D.

cdna Library Arrayed by: Greg Lennon, Ph.D.  
 DNA Sequencing by: Washington University Genome Sequencing Center  
 Clone distribution: NCI-CGAP clone distribution information can be  
 found through the I.M.A.G.E.B. Consortium/LLNL, send email to:  
 info@image.llnl.gov  
 seq primer: -400P from Gibco  
 High quality sequence stop: 455.  
 Location/Qualifiers  
 1. 636  
 /organism="Homo sapiens"  
 /db\_xref="taxon:9606"  
 /clone\_image="IMAGE:3221434"  
 /clone\_lib="NCI\_CGAP\_GC6"  
 /tissue\_type="pooled germ cell tumors"  
 /lab\_host="DH10B"  
 /note="Vector: pMT73p-Pac (Pharmacia) with a modified  
 polylinker; Plasmid DNA from the normalized library  
 NCI\_CGAP\_GC4 was prepared, and ss circles were made in  
 vitro. Following HAP purification, this DNA was used as  
 tracer in a subtractive hybridization reaction. The driver  
 was PCR-amplified cDNAs from a pool of 5,000 clones made  
 from the same library (cloneIDs 1257096-1258631,  
 1469064-1470983, and 1475592-1476743). Subtraction by  
 Bento Soares and M. Fatima BonaGo."  
 BASE COUNT 175 a 118 c 135 g 208 t  
 ORIGIN  
 Query Match 29.6%; Score 621.8; DB 136; Length 636;  
 Best Local Similarity 99.5%; Pred. No. 3.2e-126;  
 Matches 634; Conservative 0; Mismatches 2; Indels 1; Gaps 1;  
 QY 1337 acttcaaggtccctccagctcctcaagacaatgtttttttatctagaaaagctcaagac 1396  
 Db 636 ACTTCAGGGTCCCTCCAGCTCCTCAAGCAATG-TTTTTTATCFAGAAAAGCTCAAGAC 578  
 QY 1397 tgttattttatgaagctgcactgcctgcaaatcacagttggatagcaccattct 1456  
 Db 577 TGTATTTTATGAAGCTGCATCCCTGCTCGAAATCACAGTTGGATAGCACCATTCT 518  
 QY 1457 ggatctcaaaaggtcattctgtgatcaacaagaccctccatctcttcagcaataata 1516  
 Db 517 GGATCTAAAAGGGCTGCAFTCTGTGATCAACAAGACCCTCCATGCTTTCAGCAATAA 458  
 QY 1517 aatccactcactcaactgcaggaactcagaaactcgcagcctggtatagccagcagtg 1576  
 Db 457 AATCCACTCAACTCAAGCAAGCAAGCAAGCAAGCAAGCAAGCAAGCAAGCAAGCA 398  
 QY 1577 atccagagcaaaaggaagacattgtgaaccacaatgacagaagcctgccttaaccagctg 1636  
 Db 397 ATCCAGAGCAAAAGGGAAGACATTTGTAACCAAAATCACAGAAGCCTGCCTTAACCCAGTCC 338  
 QY 1637 ctagatgcccctctgtccagggacttgatcatgaagaggaactatgaacttttagtaacc 1696  
 Db 337 CTAGATGCCCTTCTCTCCAGGACTGTGATGAAAGAGGACTATCAACTTTTGTAGTACC 278  
 QY 1697 aagcctcaagagcctcaaaagctcagacaattactagacactactgacactcaagaagaga 1756  
 Db 277 AAGCCTCAAGGACCTCAAAAAGCTCAGACAAATTTACTAGACACTACTGACATCCCAAGAGANA 218  
 QY 1757 gaattgccaaaagttatagtaaaaaattgaaagatacaaaaatgggtctcagcct 1816  
 Db 217 GAAATTTGCCAAAAGTTATAGTACAAAAATTTGAAAGATACAAAAAATGGGTCTTCCAGCCT 158  
 QY 1817 taccggaaaaactgtgttcttagatcaccatcttaaatcttcaaaaataaagaa 1876  
 Db 157 TACCCGGAAAATACTTGTGTCTTAGATCACCATCTTTAAATTTTACTCAAAAATAAAGAC 98  
 QY 1877 atgtaagtgactgttttcaagaagaatgttttataaagaagatttatctctgt 1936  
 Db 97 ATGTAAAGTACTGTTTTTCAAGAAGAAATGTTTTTCAAAAAGGATATTTTATATCTCTGT 38  
 QY 1937 tgccttgactttttttataaaaaatccgctgagtatta 1973

```

|||||TGCTTTGACATTTTATATAAATCCGTCAGTATTA 1
Db 37
RESULT 5
AW150819/c 641 bp mRNA EST 03-NOV-1999
LOCUS x939f08.x1 NCI_CGAP_ut1 Homo sapiens cDNA clone IMAGE:2629959 3'
DEFINITION similar to TR:043353 043353 SERINE/THREONINE KINASE RICK. ; mRNA
sequence.
ACCESSION AW150819
VERSION AW150819.1 GI:6198717
KEYWORDS EST.
SOURCE human.
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1 (bases 1 to 641)
AUTHORS NCI-CGAP http://www.ncbi.nlm.nih.gov/ncicgap.
TITLE National Cancer Institute, Cancer Genome Anatomy Project (CGAP),
Tumor Gene Index
JOURNAL Unpublished (1997)
COMMENT Contact: Robert Strausberg, Ph.D.
Tel: (301) 496-1550
Email: Robert_Strausberg@nih.gov
Tissue Procurement: Christopher Moskaluk, M.D., Ph.D., Michael R.
Emmert-Buck, M.D., Ph.D.
cDNA Library Preparation: Life Technologies, Inc.
CDNA Library Arrayed by: Greg Lennon, Ph.D.
DNA Sequencing by: Washington University Genome Sequencing Center
Clone distribution: NCI-CGAP clone distribution information can be
found through the I.M.A.G.E. Consortium/LLNL at:
www-bio.llnl.gov/bbrp/image/html
Seq primer: -40UP from Gibco
High quality sequence stop: 402.
Location/Qualifiers
1. .641
/organism="Homo sapiens"
/db_xref="taxon:9606"
/clone="IMAGE:2629959"
/clone_lib="NCI_CGAP_ut1"
/tissue_type="well-differentiated endometrial
adenocarcinoma, 7 pooled tumors"
/lab_host="DH10B"
/notes="Organ: uterus; Vector: pCMV-SPORT6; Site:1: Sali;
Site:2: NotI; Cloned unidirectionally. Primer: Oligo dt.
Average insert size 1.75 kb. Life Technologies catalog #:
11538-014"
BASE COUNT 185 a 116 c 123 g 215 t 2 others
ORIGIN
Query Match 29.0%; Score 609.4; DB 111; Length 641;
Best Local Similarity 95.9%; Pred No 1.7e-123;
Matches 613; Conservative 9; Mismatches 17; Indels 0; Gaps 0;
Qy 1427 ggaatcacagtggtagaccattctggatctcctcaaaagggctgattctgtgacac 1486
||||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 641 GCAATCAAGTGGAAATAGCACCATTTNTGGATGTCACAGGGGTGCTTCTGTAATCAC 582
Qy 1487 aagaccactcctctcttcgaataaataaacctcctcaactcgaggaaactcagaa 1546
||||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 581 AAGCCCATCCACGCTTTCAGCAANTAAATAATCCACTCTCAACTGCAGNAACTCAGAA 522
Qy 1547 cgtctgcagctgtatagccacagctgacccagagcaaaagggagacattgtgaac 1606
||||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 521 CGCTGACGCTTGGTATAGCCACAGTGGATCCAGAGCAAAAGGGAAGACATTTGTGAAC 462
Qy 1607 caaatgacagagcctgcttaaacagctgcgtagatgccctctctgcccaggacttgatc 1666
||||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 461 CAATGACAGAAAGCCCTGCTTAAACAGCTGCTAGATGCCCTTCTGTCCAGGACTTGATC 402
Qy 1667 atgaaagaggactatgaactttagtaccaaagcctcaagggactcaaaagttagagcaa 1726
|||||
Db 401 ATGAAAGAGGACTATGAACTTGTAGTACCAAGCCCTACAAGGACCTCAAAAAGTCAGACAA 342
Qy 1727 ttactagacactactgacatccaaagaggaagtccaaagttagtacaaaaaattg 1786
|||||
Db 341 TTACTAGACACTACTGACATCCCAAGGAGAAGAAATTTGCCAAAAGTTATAGTACAAAATTTG 282
Qy 1787 aaagatacaaaaacaatgggtctccagccttaccgggaaatacttggttcttagatca 1846
|||||
Db 281 AAAGATACAAACAATGGGTCTTACGCCCTTACCCGGAATACTGTGGTTTCTAGATCA 222
Qy 1847 ccactcttaaatctcctcaaaataaaagcctgaagtgaactgttttccaagaagaaatg 1906
|||||
Db 221 CCATCTTTAAATTTACTTCAAAATAAAGCATGTAAGTCACTGTTTTTCAAGAAGAAATG 162
Qy 1907 tgttccataaaaggatatttatctctctctgttctgttgaacttttttatataaaaccggtg 1966
Db 161 TGTTCATAAAAGGATATTTATATCTCTGTTGCTTTGACTTTTTTTATATAAAAATCCGGTG 102
Qy 1967 agtattaaagcttwwraargktctttrktaaaatattagctccctccatgacactgc 2026
Db 101 AGTATTAAGCTTATTTGAAGGTTCTTTGGTAAATATTAGTCTCCCTCCATGACACTGC 42
Qy 2027 agtatttttttaattaatacaagaataaaagtgaattt 2065
Db 41 AGTATTTTAAATTAATAACAAAGTAAAGTTTGAAT 3
RESULT 6
AW1745575/c
LOCUS AI745575 592 bp mRNA EST 17-DEC-1999
DEFINITION wc34f12.x1 NCI_CGAP_Pr28 Homo sapiens cDNA clone IMAGE:2317103 3'
similar to TR:043353 043353 SERINE/THREONINE KINASE RICK. ; mRNA
sequence.
ACCESSION AI745575
VERSION AI745575.1 GI:5113863
KEYWORDS EST.
SOURCE human.
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1 (bases 1 to 592)
AUTHORS NCI-CGAP http://www.ncbi.nlm.nih.gov/ncicgap.
TITLE National Cancer Institute, Cancer Genome Anatomy Project (CGAP),
Tumor Gene Index
JOURNAL Unpublished (1997)
COMMENT Contact: Robert Strausberg, Ph.D.
Tel: (301) 496-1550
Email: Robert_Strausberg@nih.gov
Tissue Procurement: Michael J. Brownstein, M.D., Ph.D., Michael R.
Emmert-Buck, M.D., Ph.D.
cDNA Library Preparation: M. Bento Soares, Ph.D.
CDNA Library Arrayed by: Greg Lennon, Ph.D.
DNA Sequencing by: Washington University Genome Sequencing Center
Clone distribution: NCI-CGAP clone distribution information can be
found through the I.M.A.G.E. Consortium/LLNL at:
www-bio.llnl.gov/bbrp/image/image.html
Insert Length: 673 .Std Error: 0.00
Seq primer: -40UP from Gibco
High quality sequence stop: 459.
Location/Qualifiers
1. .592
/organism="Homo sapiens"
/db_xref="taxon:9606"
/clone="IMAGE:2317103"
/clone_lib="NCI_CGAP_Pr28"
/sex="male"
/dev_stage="adult"
/lab_host="DH10B"
/notes="Organ: prostate; Vector: pT7T3D-pac (Pharmacia)
with a modified polylinker; Plasmid DNA from the
normalized library NCI_CGAP_Pr22 was prepared, and ss
circles were made in vitro. Following HAP purification,

```



this DNA was used as a tracer in a subtractive hybridization reaction. The driver was PCR-amplified cDNAs from a pool of 5,000 clones made from the same library (clones IDs 985608-986759, 1101192-1101959, and 1217928-1220615). Subtraction by Bento Soares and M. Fatima Bonaldo.

BASE COUNT 153 a 111 c 128 g 200 t  
ORIGIN

```

Query Match      28.2%; Score 592; DB 24; Length 592;
Best Local Similarity 100.0%; Pred. No. 1.1e-119;
Matches 592; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1337 acttcaaggctccctccagctcctcaagaacaatgattttttatctagaaaagctcaagc 1396
|||||
Db 592 ACTTCAAGTCCCTCCAGCTCCTCAAGACAATGATTTTTTATCTAGAAAAGCTCAAGAC 533
|||||

QY 1397 tttattttatgaagctgcatcactgtccctgaaatcacagctggtagaccatttct 1456
|||||
Db 532 TGTATTTTATGAAGCTGCATCTGCTGGAAATCACAGTTGGGATAGCACCATTCT 473
|||||

QY 1457 ggatctcaaggctgattctgtaatacaagaccctccatgctcttcacaataata 1516
|||||
Db 472 GATCTCAANGGGCTGCAATCTGATATCAAGACCACCTCCATGCTCTTCAGCAATAA 413
|||||

QY 1517 aatccactctcaactgcaggaactcagaacgtctgagcctgggtatagccagcagtg 1576
|||||
Db 412 AATCCACTCTCAACTGCAGGAACCTCAGAACCTCTGCAGCCTGTATAGCCAGCAGTGG 353
|||||

QY 1577 atccgagcaaaagggagacattgtgaaaccaaaatgacaagaagcctgcttaaccagctg 1636
|||||
Db 352 ATCCAGAGCAAAAAGGGAGACATTTGTAAACCAAAATGACAGAAGCCCTTAACCCAGTGG 293
|||||

QY 1637 ctagatgcccctctgctcaggaactgcatgcatgaaagagactatgaacttttagtaac 1696
|||||
Db 292 CTAGATGCCCCTCTGTCCAGGACTTGATCATGAAGAGGACTATGAACCTTTAGTACC 233
|||||

QY 1697 aagctcaagagactcctcaaaagctcagacaattactagacactactgacatccaaaggagaa 1756
|||||
Db 232 AAGCCTACAAAGGACCTCAAAAGTCAGACAATTTACTTAGACACTACTGACATCCAAAGGAGAA 173
|||||

QY 1757 gaatttccaagattatagtaaaaaattgaagatacaaaaaaataaaggttccagcct 1816
|||||
Db 172 GAATTTGCCAAAGTATAGTACAAAATTTGAAGATTAACAAAATAATGGGTCTTCAGCCT 113
|||||

QY 1817 taccggaaactctgtgtttctagatcacatctttaaatttacttcaaaataaaagc 1876
|||||
Db 112 TACCCGGAATACTGTGGTTCTAGATCACCATCTTTTAAATTTACTTCAAAATRAAAGC 53
|||||

QY 1877 atgtaagtactgttttcaagaagaataatgttttcaataaaaggatattat 1928
|||||
Db 52 ATGTAAGTACTGTTTTCAAGAAGAAATGTGTTTCATATAAAGGATATTTAT 1
|||||

```

```

RESULT 7
AW085560/c
LOCUS      AW085560      606 bp      mRNA      EST      09-MAR-2000
DEFINITION      wy67c04.x1 Soares NSF_F8_9W_OT_PA_P_S1 Homo sapiens cDNA clone
IMAGE:2553606.3, similar to TR:043353 043353 SERINE/THREONINE
KINASE RICK. ;, mRNA sequence.
ACCESSION      AW085560
VERSION        AW085560.1 GI:6040712
KEYWORDS
SOURCE        human.
ORGANISM      Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE      1 (bases 1 to 606)
AUTHORS      NCI-CGAP http://www.ncbi.nlm.nih.gov/ncicgap.
TITLE        National Cancer Institute, Cancer Genome Anatomy Project (CGAP),
Tumor Gene Index
JOURNAL
Unpublished (1997)
Contact: Robert Strausberg, Ph.D.

```

Tel: (301) 496-1550  
Email: Robert Strausberg@nih.gov  
This clone is available royalty-free through LNL; contact the IMAGE Consortium (info@image.lnl.gov) for further information.  
Insert Length: 885 Std Error: 0.00  
Seq primer: -400P from Gibco  
High quality sequence stop: 470.  
Location/Qualifiers

```

FEATURES
Source
1..606
/organism="Homo sapiens"
/db_xref="taxon:9606"
/clone="IMAGE:2553606"
/cname="lib=Soares_NSF_F8_9W_OT_PA_P_S1"
/lab_host="DHI0B"
/notes="Organ: pooled; Vector: pT7M3D-Pac (Pharmacia) with a modified polylinker; Site_1: Not I; Site_2: Eco RI; Equal amounts of plasmid DNA from five normalized libraries were mixed, and ss circles were made in vitro. Following HAP purification, this DNA was used as tracer in a subtractive hybridization reaction. The driver was PCR-amplified cDNAs from pools of 5,000 clones made from the same 5 libraries. The pools consisted of the following libraries and clones: Soares NbHSF pool 1: 309384-310919, 323208-325895 Soares Nb2HP pool 1: 145032-147335, 147720-148103, 148872-149255, 15002 - 150407, 151176-152327 Soares Nb2HF8-9W pool 1: 758280-760583, 772104-774407 Soares NbHPA pool 1: 304776-306311, 320136-322823, 326280-326663 Soares NbHOT pool 1: 723720-726407, 739080-740999 Subtraction by Bento Soares and M. Fatima Bonaldo."
BASE COUNT 166 a 114 c 122 g 203 t
ORIGIN

```

```

Query Match      28.2%; Score 590.6; DB 110; Length 606;
Best Local Similarity 98.7%; Pred. No. 2.3e-119;
Matches 598; Conservative 6; Mismatches 1; Indels 1; Gaps 1;

QY 1385 aaagctcaagactgtttttatgaagctgcatcactgctccctggaaatcacagttgggat 1444
|||||
Db 606 AAAGCTCAAGACTGTTATTTATGAAGCTGCATCTACTGTCTGGAAATCAGAGTTGGGAT 547
|||||

QY 1445 agcacatttctgtagtctcaaaagggctgattctgtgatacaagaaccactccatgctct 1504
|||||
Db 546 AGCACCATTTCTGGATCTCAAAGGGCTGCATCTGTGTGATCACAAGACCCTCATGCTCT 487
|||||

QY 1505 tcagcaataataaaaccactcactcagcaaaactcagaactcagcctgagctggtata 1564
|||||
Db 486 TCAGCAATAATAAAATCCACTCTCAACTGCAGGAAATCAGAAGCTGTGAGGCTGTGATA 427
|||||

QY 1565 gccagcagtgatccagagcaaaagggagacatttgaaccaaatgacagaagcctgc 1624
|||||
Db 426 GCCCAGCAGTGGATCCAGAGCAAAAGGGAGACATTTGTGAACCAATGACAGAGCCTGC 367
|||||

QY 1625 ctttaaccagctgtagatgcccttctgtccaggac-ttgatcatgaaagagactatga 1683
|||||
Db 366 CTTAACCAGCTGCTAGATGCCCTTCTGTCCAGGACTTTGATCATGAAAAGAGACTATGA 307
|||||

QY 1684 acttgttagtaccagcctcaagaacctcaaaagctcagaactactagacactactga 1743
|||||
Db 306 ACTTGTAGTACCAAGCCTTACAAAGCCTCAAAAGCTCAAGCAATTTACTAGACTACTGA 247
|||||

QY 1744 catcaagagagaagaatttgcacaaagtatagtaaaaaattgaaagaatacaacaacaat 1803
|||||
Db 246 CATCAAGGAGAAAGATTTGCCCAAAAGTTATAGTACAAAATTTGAAGATATACAAACAAT 187
|||||

QY 1804 gggcttccagccttaccggaaatactgtgtgtttctagatccacctcttataattact 1863
|||||
Db 186 GGGCTTCCAGCTTACC CGAAAATACTTGTGTCTTAGATCACCATCTTTAAATTTACT 127
|||||

QY 1864 tcaaaataaaacatgtaagtactgttttcaagaagaataatgttttataaaaggata 1923
|||||
Db 126 TCAAAATAAAGCATGTAAGTACTGTTTTTCAGAAGAAATGTGTTCATATAAAGGATA 67
|||||

```



```

QY 1248 aattatctgaacatacctgtaaatcatggtcccacagagaaatcagtgtgacctctc 1307
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Db 61 AATTATCTCTGAACAFACCTGTAATCATGGTCCACACAGAGAAATCATGTGGATCCTC 120
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
QY 1308 a-gctccatgaaaa tagtgggttcttctctgaaactcacaagcctccagcctcacaagac 1366
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Db 121 ANGCTCCATGAATAATAGTGGTCTCCTGAAACTTCAAGTCCCTCCAGCTCTCAAGAC 180
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
QY 1367 aatgattttttatcagaagaactcaagcgtttattttatgaaactgcaatcactgctc 1426
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Db 181 AATGATTTTTTATCTAGAAAAGCTCAAGACTGTTATTTTTATGAAGCTGCATCACATGCTCT 240
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
QY 1427 ggaatacactggtgtagcaccatttctgtagtctcacaagcgttcgcatcttggtatcac 1486
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Db 241 GGAATACACAGTGGGATAGCACCATTTCTGGATCTCAAGGGCTGCATCTGTGATCAC 300
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
QY 1487 agaccactccaatgcttctcagcaataataatccactctcaactcgcagggaaactcagaa 1546
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Db 301 AAGACCCTCCATGCTCTTCCAGCAATAATAATCCACTTCAACTGCAGAAACTCAGAA 360
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
QY 1547 cgtctgcagcctggtatagccacagcagtgatccagagcaaaaagggaaagacatttgaac 1606
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Db 361 CGTCTGAGCCCTGGTATAGCCACAGTGATCCAGAGCAAAAGGGAAGACATTTGTGAC 420
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
QY 1607 caaatgcagaagcctgcttaaccagctcgttagatgccccctctcctcaggaccttgatc 1666
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Db 421 CAATGACAGAAGCCTG-CCTTAACAGTGGCTTCCATGAGGCTTCTTCCAGGGACTTGATC 479
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
QY 1667 atgaaagggaactgaactgcttaccagaagcctcaagcactcacaagcctcaaaagccagaaa 1726
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Db 480 ATGAAAGAGGACTGAACTGTTGTATGTAACCAAGCCTACAAAGCCTCAAAAGTCAAGCAA 539
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
QY 1727 ttactagacactactgacatcaaagg-agaagaatttcgaagttatagtaaaaatt 1785
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Db 540 TTGCTTAGACTCTGTGATCTCCAGGACGAGAAATTGGCANAGTATAGTACAAAAT 599
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
QY 1786 --gaagatacaaaaataatgggttccagccttcccggaaataacttgggtg 1837
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Db 600 TGCAAGATAACCAACAAATAAGTGGCTTCCAGCCCTTACCCTGCGGAACTTGCTGGCT 653
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |

RESULT 10
AI801150/c
LOCUS
DEFINITION
similar to TR:O43353 O43353 SERINE/THREONINE KINASE RICK. ; mRNA
sequence.
AI801150
VERSION AI801150.1 GI:5366622
KEYWORDS EST.
SOURCE human.
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominiidae; Homo.
1 (bases 1 to 615)
NCI-CGAP http://www.ncbi.nlm.nih.gov/ncicgap.
National Cancer Institute, Cancer Genome Anatomy Project (CGAP),
Tumor Gene Index
Unpublished (1997)
Contact: Robert Strausberg, Ph.D.
Tel: (301) 496-1550
Email: Robert_Strausberg@nih.gov
Tissue Procurement: Christopher Moskalkuk, M.D., Ph.D., Michael R.
Emmert-Buck, M.D., Ph.D.
CDNA Library Preparation: Life Technologies, Inc.
CDNA Library Arrayed by: Greg Lennon, Ph.D.
DNA Sequencing by: Washington University Genome Sequencing Center
Clone distribution: NCI-CGAP clone distribution information can be
found through the I.M.A.G.E. Consortium/LLNL at:
www-bio.llnl.gov/bbrp/image/image.html
Insert Length: 3507 Std Error: 0.00
Seg primer: -400p from Gibco

```

```

High quality sequence stop: 421.
Location/Qualifiers
1..615
/organism="Homo sapiens"
/db_xref="taxon:9606"
/clone="IMAGE:2185111"
/tissue_type="NCI_CGAP_Gas4"
/lab_host="DH10B"
/feature="poorly differentiated adenocarcinoma with signet ring cell features"
/lab_host="DH10B"
/organism="Homo sapiens"
/db_xref="taxon:9606"
/clone="IMAGE:2185111"
/tissue_type="NCI_CGAP_Gas4"
/lab_host="DH10B"
/feature="poorly differentiated adenocarcinoma with signet ring cell features"
Average insert size 1.69 kb. Life Technologies catalog #: 11549-011#

BASE COUNT 179 a 110 c 120 g 206 t
ORIGIN

Query Match 26.7%; Score 561; DB 102; Length 615;
Best Local Similarity 97.4%; Pred. No. 7.2e-113;
Matches 591; Conservative 9; Mismatches 4; Indels 3; Gaps 3;

QY 1460 tctcaaaagggtcatttctgtgtacacaaagacacctcccaatgctctccagcaataataa 1519
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Db 615 TCTCAAAGGGCTGCATCTGTGTAT-ACAGGACCCACTCCATGCTTCCAGCAATAAT-AA 558
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
QY 1520 ccactcacaactgcagaaactcagaacgctcgcag-cttgtagcaccagcaatgtag 1578
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Db 557 CCACCTCAACTGACAGAAACATCAGAACTGTGCAGCCCTCGGTATAGCCACAGTGGAT 498
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
QY 1579 ccagagaaaaggaaagcatttggtaaccaaaatgacagaagcctcccttaaccagctgc 1638
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Db 497 CCAGAGAAAAGGGAGACATTGTAACCAAAATGACAGAAAGCTGCCTTAACCAGTCGGT 438
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
QY 1639 agatgcccccttctgcccaggaacttgatcatgaaagaggaactatgactttgttagt 1698
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Db 437 AGATGCCCTTCTGTCCAGGGACTTGATCATGAAGAGGGACTATGAACCTGTGGTAGTAC 378
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
QY 1699 gcctcaagggactcacaagtcagcaaatctacagacactcactcacatccaagagaga 1758
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Db 377 GCCTACAGGACTCAAAAGTCTCAGCAATTTAGACACTACTGACATCCAGAGGAGA 318
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
QY 1759 atttccaaaagttagtcacaaaattgaaagatacaaaaataatgggtcttcagocctta 1818
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Db 317 ATTTCGAAAAGTTATAGTACAAAATTTAAGATAAACAACAATAAATGGGCTTTCAGCC 258
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
QY 1819 ccggaataacttggtttcttagatcaccatcttataatttcaataaaaagaagat 1878
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Db 257 CCCGAAATACATTGGTGGTTTCTAGATACCATCTTTAAATTTTACTTCAAAAAT 198
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
QY 1879 gtaagtactgttttcagaagaaaatgttttcataaaagaattatatactctctg 1938
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Db 197 GTAAGTAGTGTGTTTCAGAGAAAATCTGTTTCATAAAGGATATTTATATCTCTG 138
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
QY 1939 ctttgacttttttatataaaatccgctgagtgatgaaagcttwawraargkctcttsrkt 1998
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Db 137 CTTTCAGCTTTTTTATATAAAAATCCGTCAGTATAAAGCTTTATGAAGGTCTTTGG 78
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
QY 1999 aaatattagctccctccatgacactgacttttttttaatttaatacaagaataaag 2058
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Db 77 AAATATGCTCTCCTCCATGACTGCAGTATTTTTTTTTTAAATAATAAACAAGTA 18
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |

QY 2059 tgaattt 2065
| | | | |
Db 17 TTAAT 11
| | | | |

RESULT 11
AA160647
LOCUS
DEFINITION Zq49c11.r1 Stratagene hNT neuron (#937233) Homo sapiens CDNA clone
IMAGE:633044 5', mRNA sequence.
ACCESSION AA160647
AA160647 645 bp mRNA EST 16-DEC-1996
Zq49c11.r1 Stratagene hNT neuron (#937233) Homo sapiens CDNA clone
IMAGE:633044 5', mRNA sequence.
ACCESSION AA160647

```

AA160647.1 GI:1736024  
EST. |||||  
SOURCE |||||  
ORGANISM Homo sapiens

REFERENCE Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
1 (bases 1 to 645) Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.

AUTHORS Hillier, L., Lennon, G., Becker, M., Bonaldo, M.F., Chiapelli, B.,  
Chissoe, S., Dietrich, N., Dubuque, T., Favello, A., Gish, W., Hawkins  
, M., Hultman, M., Kucaba, T., Lacy, M., Le, M., Le, N., Mardis, E., Moore  
, B., Morris, M., Parsons, J., Prange, C., Rifkin, L., Rohlfing, T.,  
Schellenberg, K., Soares, M.B., Tan, F., Thierry-Mieg, J., Trevas, E.,  
Underwood, K., Wohlmann, P., Waterston, R., Willson, R. and Warr, M.  
Generation and analysis of 280,000 human expressed sequence tags  
Genome Res. 6 (9), 807-828 (1996)  
97044478

TITLE Contact: Wilson RK  
JOURNAL Washington University School of Medicine  
MEDLINE 4444 Forest Park Parkway, Box 8501, St. Louis, MO 63108  
COMMENT Tel: 314 286 1800  
Fax: 314 286 1810  
Email: est@watson.wustl.edu  
This clone is available royalty-free through LML; contact the  
IMAGE Consortium (info@image.llnl.gov) for further information.  
Seq primer: -28M13 rev2 from Amersham  
High quality sequence stop: 373.

FEATURES  
source Location/Qualifiers  
1..645 /organism="Homo sapiens"  
/db\_xref="GDB:5183128"  
/db\_xref="taxon:9606"  
/clone="IMAGE:63304"  
/dev\_stage="hNT neurons"  
/lab\_host="SOLR (kanamycin resistant)"  
/note="vector: pBluescript SK-; Site\_1: EcoRI; Site\_2:  
XhoI; Cloned unidirectionally. Primer: Oligo dt.  
Differentiated, post mitotic hNT neurons. Average insert  
size: 1.5 kb; Uni-ZAP XR Vector; -5' adaptor sequence: 5'  
GAATTCGGCCAGCAG 3' -3' adaptor sequence: 5'  
CTCGAGTTTTTTTTTTTTTTT 3'"  
BASE COUNT 205 a 138 c 123 g 178 t 1 others  
ORIGIN

Query Match 26.6%; Score 558.6; DB 3; Length 645;  
Best Local Similarity 99.1%; Pred. No. 2.4e-112;  
Matches 572; Conservative 0; Mismatches 4; Indels 1; Gaps 1;

Qy 952 tgtcaccatactcttcagataatgtatgtgtcacaaggacatcgacctgtattaa 1011  
|||||  
Db 1 TGTCAACCAATCCTTTGCAGATAATGTATAGTGTGTCAAGGACATCGACCTGTTATTA 60

Qy 1012 tgaagaagtgtgcatatagatatacatctaccggagcagctatgatctcttaataagaag 1071  
|||||  
Db 61 TGAAGAAGTTGGCAATATACCTCAACCGGACAGGATGATCTCTAATPAGAAG 120

Qy 1072 tggatggcacaacaatccagatgaagaccatctttcttaaaatgtttaagaactga 1131  
|||||  
Db 121 TGGATGGCCACAAATCCAGATGAAGACCATCTTTCTTAAATGTTTAAATAGACTTGA 180

Qy 1132 accagttttgagaacaatttgaagagataaacttttcttgaagctgtttatcagctaaagaa 1191  
|||||  
Db 181 ACCAGTTTGAACAATTTGAAGAGATAAATTTCTTGAAGCTGTTTATTCAGCTAAAGAA 240

Qy 1192 acaaaagtacagagtgtttcaactgcaactcaactatgtaacaagagaagaaatgcaatt 1251  
|||||  
Db 241 AACAAAGTTACAGAGTGTTCAGTGGCCATTCACCTATGTGACAAAGAAGAAATGGAAAT 300

Qy 1252 atctctgaacataacctgtaaatctggtccacaagaggaatcatgtggtatctctcagct 1311  
|||||  
Db 301 ATCTCTGAACATACCTGTAAATCATGTGTCACAAAGAGAAATCATGTGATCTCAGCT 360

Qy 1312 ccataaaaaatagttgtctcctgaaactcaagggtccctccagctccctcaagaacaatga 1371  
|||||  
Db 361 CCATGAAAATAGTGGTTCCTCTGAAACTTCAAGGTCAAGGTCCCTCCCAAGACAATGA 420

Qy 1372 tttttattatagaagaagtcaagactgtttattttatgaagctgcatcactgtccctggaaa 1431  
|||||  
Db 421 TTTTTTATCTAGAAAAGCTCAAGACTGTTATTTTATGAAGCTGCATCACTGCTCTGGAAA 480

Qy 1432 tcacagtgtgtagatagaccattcttgatctcaaaaggctgctattctgtgatacaagaagc 1491  
|||||  
Db 481 TCACAGTGGGATAGACCATTCTTGGATCTCAAGGGCTGCAATCTGTGATTCACAGAC 540

Qy 1492 cactccatctctcagcaataataaatacactctca 1528  
|||||  
Db 541 CACTCCATCTCTTCAGC-ATAATAATCCACTCTCA 576

RESULT 12  
LOCUS BF125028 839 bp mRNA EST 24-OCT-2000  
DEFINITION 601762610F1 NIH\_MGC\_20 Homo sapiens cDNA clone IMAGE:4025427 5',  
mRNA sequence.  
ACCESSION BF125028  
VERSION BF125028.1 GI:10964068  
KEYWORDS EST.  
SOURCE human.  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.  
REFERENCE NIH-MGC http://mgc.nci.nih.gov/  
AUTHORS National Institutes of Health, Mammalian Gene Collection (MGC)  
TITLE Unpublished (1999)  
JOURNAL  
COMMENT Contact: Robert Strausberg, Ph.D.  
Tel: (301) 496-1550  
Email: Robert\_Strausberg@nih.gov  
Tissue Procurement: ATCC/DCTD/DTF  
cDNA Library Preparation: Ling Hong/Rubin Laboratory  
cDNA Library Arrayed by: The I.M.A.G.E. Consortium (LLNL)  
DNA Sequencing by: Incyte Genomics, Inc.  
Clone distribution: MGC clone distribution information can be  
found through the I.M.A.G.E. Consortium/LLNL at: image.llnl.gov  
Plate: L1CM854 row: d column: 04  
High quality sequence stop: 636.

FEATURES  
source Location/Qualifiers  
1..839 /organism="Homo sapiens"  
/db\_xref="taxon:9606"  
/clone="IMAGE:4025427"  
/tissue\_type="melanotic melanoma"  
/lab\_host="DH10B (phage-resistant)"  
/note="Organ: skin; Vector: pORF7; Site\_1: XhoI; Site\_2:  
EcoRI; cDNA made by oligo-dT priming. Directionally  
cloned into EcoRI/XhoI sites using the following 5'  
adaptor: GGCACGAG(G). Size-selected >500bp for average  
insert size 1.8kb. Library constructed by Ling Hong in  
the laboratory of Gerald M. Rubin (University of  
California, Berkeley) using ZAP-cDNA synthesis kit  
(Stratagene) and Superscript II RT (Life Technologies)."  
BASE COUNT 213 a 195 c 246 g 185 t  
ORIGIN

Query Match 26.4%; Score 554; DB 144; Length 839;  
Best Local Similarity 94.8%; Pred. No. 2.6e-111;  
Matches 660; Conservative 0; Mismatches 25; Indels 11; Gaps 8;

Qy 77 agcagcggctgtggcgtggccatccgggggaatggcgccctctgacctagctgtgcgggg 136  
|||||  
Db 1 AGCAGCGGCTGGCGTGGCCATCCGGGGAATGGCGCCCTCGTAGCTAGCTGTGGCGGG 60

Qy 137 caaaaaaggctctgcccggcctctcgtgcaagggggtatctctgggcccctgagcggggc 196



RESULT 14  
 AI307810/c  
 LOCUS 616 bp mRNA EST 08-APR-1999  
 DEFINITION tb28d07.x1 NCI\_CGAP\_kid12 Homo sapiens cdna clone IMAGE:2055661 3',  
 mRNA sequence.  
 ACCESSION AI307810  
 VERSION AI307810.1 GI:4002414  
 KEYWORDS EST.  
 SOURCE human.  
 ORGANISM Homo sapiens  
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
 REFERENCE 1 (bases 1 to 616)  
 AUTHORS NCI-CGAP <http://www.ncbi.nlm.nih.gov/ncicgap>.  
 TITLE National Cancer Institute, Cancer Genome Anatomy Project (CGAP),  
 Tumor Gene Index  
 JOURNAL Unpublished (1997)  
 COMMENT Contact: Robert Strausberg, Ph.D.  
 Tel: (301) 496-1550  
 Email: Robert.Strausberg@nih.gov  
 Tissue Procurement: Christopher Moskaluk, M.D., Ph.D., Michael R.  
 Emmert-Buck, M.D., Ph.D.  
 CDNA Library Preparation: M. Bento Soares, Ph.D.  
 CDNA Library Arrayed by: Greg Lennon, Ph.D.  
 DNA Sequencing by: Washington University Genome Sequencing Center  
 Clone distribution: NCI-CGAP clone distribution information can be  
 found through the I.M.A.G.E. Consortium/LLNL at:  
[www-bio.llnl.gov/bbrp/image/image.html](http://www-bio.llnl.gov/bbrp/image/image.html)  
 Insert Length: 680 Std Error: 0.00  
 Seq primer: -40UP from Gibco  
 High quality sequence stop: 444.  
 Location/Qualifiers  
 1..616  
 /organism="Homo sapiens"  
 /db\_xref="taxon:9606"  
 /clone\_lib="IMAGE:2055661"  
 /clone\_lib="NCI\_CGAP\_Kid12"  
 /tissue\_type="2 pooled tumors (clear cell type)"  
 /lab\_host="DH10B"  
 /note="Organ: kidney; Vector: p7T3D-Pac (Pharmacia) with  
 a modified polylinker; Site\_1: Not 1; Site\_2: Eco RI;  
 Plasmid DNA from the normalized library NCI\_CGAP\_Kid5 was  
 prepared, and ss circles were made in vitro. Following HAP  
 purification, this DNA was used as tracer in a subtractive  
 hybridization reaction. The driver was PCR-amplified cDNAs  
 from a pool of 5 000 clones made from the same library  
 (cloneIDs 1323912-1325831, 1471568-1472903 and  
 1492104-1493255). Subtraction by Bento Soares and M.  
 Fatima Bonaïdo."  
 BASE COUNT 178 a 109 c 112 g 217 t  
 ORIGIN  
 Query Match 26.1%; Score 546.8; DB 18; Length 616;  
 Best Local Similarity 96.4%; Pred. No. 9.4e-110;  
 Matches 559; Conservative 11; Mismatches 11; Indels 1; Gaps 1;  
 QY 1502 tcttcgaacaataatccaactccaactgcaggaactcagaactctgcagcctggt 1561  
 Db 579 TATTAGCAATAATAACCTCACCTCAACTGCAGGAACCTCAGAACCTGTGCAGCCTGGT 520  
 QY 1562 atagcccagctggatcccagagcaaaagggaagacattgtgaaccaaaatgacagaagcc 1621  
 Db 519 ATAGCCAGACGTGGATCCAGACCAAAAAGGAAGACATGTGACCAATACAGAAAGCC 460  
 QY 1622 tgcttaaccagctcgctagatgccctctctgcaggagactgatcagaagagactat 1681  
 Db 459 TGCTTAACCAAGTCGGTATGCCTTCCTCAGAGACTGTGATCATGAAGAAGGACTAT 400  
 QY 1682 gaacttgtagtaccagcctacaagagaccctcaaaagtcagacaattactagacactat 1741  
 Db 399 GAACTTGTAGTACCAAGCCCTACAAGACCTCAAAAAGTCAACAATTAAGTACTACTACTACT 340  
 QY 1742 gatattcaaggggagaagaattgccaagaattatagtaacaataaggaatacaacaaca 1801  
 Db 339 GACATCCAAGGAGAGAATAATTGCCAAGTGA-AGTACAAAATAATTGAAAGATAACAACA 281  
 QY 1802 atgggtcttcagcctaccgggaacttgcgtgtcttagatccaccatcttcaaat 1861  
 Db 280 ATGGGTCTTCAGCCTACCAGGAAATACATTCGTGTTCAGATCAACCATCTTAAATTA 221  
 QY 1862 cttcaaaataaaagcatgaagtgactgttcttcaagaagaataatggttccataaaagga 1921  
 Db 220 CTTCAAAAATAAAGCATGTAAAGTCACTGTCTTTCAAGAGAAATGTCTTCATAAAAGGA 161  
 QY 1922 tattatattctgctgttgacttctttatataaaaaatcccggatagtaagcttwa 1981  
 Db 160 TATTATATCTGCTGTGTGACTTTTTATATAAAATCCGCTGAGTATTAAAGCTTTA 101  
 QY 1982 wtraaragkctttsrkrtaaatattagctccctccctccatgacacgcagtagtattttt 2041  
 Db 100 TTGAAGGTTCTTTGGTAAATAATTAGTCTCCCTCCATGCACATGACAGTAATTTTTTAA 41  
 QY 2042 taatacaagtaaaagttgaattgaaaaaanaaaaaa 2081  
 Db 40 TAATACAAGTAAAAAGTTTTGAATTTTGTCTACATAAAAAA 1  
 RESULT 15  
 AI904799 762 bp mRNA EST 30-MAR-2000  
 LOCUS IL-BT067-190199-023 BT067 Homo sapiens cdna, mRNA sequence.  
 DEFINITION AI904799  
 ACCESSION AI904799  
 VERSION AI904799.1 GI:6495186  
 KEYWORDS EST.  
 SOURCE human.  
 ORGANISM Homo sapiens  
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
 REFERENCE 1 (bases 1 to 762)  
 AUTHORS Dias Neto, E., Garcia Correa, R., Verjovsky-Almeida, S., Briones, M.R.,  
 Nagai, M.A., da Silva, W. Jr., Zago, M.A., Bordin, S., Costa, F.F.,  
 Goldman, G.H., Carvalho, A.F., Matsukuma, A., Baia, G.S., Simpson, D.H.,  
 Brunstein, A., de Oliveira, P.S., Bucher, P., Jongeneel, C.V., O'Hare,  
 M.J., Soares, F., Brentani, R.R., Reis, L.F., de Souza, S.J. and  
 Simpson, A.J.  
 TITLE Shotgun sequencing of the human transcriptome with ORF expressed  
 sequence tags  
 JOURNAL Proc. Natl. Acad. Sci. U.S.A. 97 (7), 3491-3496 (2000)  
 MEDLINE 20202663  
 COMMENT Contact: Simpson A.J.G.  
 Laboratory of Cancer Genetics  
 Ludwig Institute for Cancer Research  
 Rua Prof. Antonio Prudente 109, 4 andar, 01509-010, Sao Paulo-SP,  
 Brazil  
 Tel: +55-11-2704922  
 Fax: +55-11-2707001  
 Email: asimpson@ludwig.org.br  
 This sequence was derived from the FAPESP/LICR Human Cancer Genome  
 project. This entry can be seen in the following URL  
 (<http://www.ludwig.org.br/seq/gethtml.pl?tl=IL&t2=IL-BT067-023.html>)  
 Seq primer: puc 18 forward.  
 Location/Qualifiers  
 1..762  
 /organism="Homo sapiens"  
 /db\_xref="taxon:9606"  
 /clone\_lib="BT067"  
 /sex="female"  
 /dev\_stage="Adult"  
 /note="Organ: breast; Vector: puc18; Site\_1: SmaI; Site\_2:  
 SmaI; A mini-library was made by cloning products derived  
 from ORESTES PCR (U.S. Letters Patent application No. 196  
 /716 - Ludwig Institute for Cancer Research) profiles

into the pUC 18 vector. Reverse-transcription of tissue mRNA and cDNA amplification were performed under low stringency conditions.

BASE COUNT 232 a 157 c 137 g 208 t 28 others  
ORIGIN  
Query Match 25.8%; Score 542; DB 103; Length 762;  
Best Local Similarity 90.3%; Pred. No. 1.le-108;  
Matches 621; Conservative 0; Mismatches 62; Indels 5; Gaps 5;

Table with columns for accession number (e.g., Qy 931, Db 1, Qy 991, Db 61, Qy 1051, Db 121, Qy 1111, Db 181, Qy 1171, Db 241, Qy 1231, Db 301, Qy 1291, Db 361, Qy 1351, Db 421, Qy 1410, Db 480, Qy 1470, Db 538, Qy 1530, Db 597, Qy 1590, Db 657) and corresponding nucleotide sequences.

Search completed: June 13, 2001, 16:33:08  
Job time: 19378 sec





GenCore version 4.5
Copyright (c) 1993 - 2000 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: June 13, 2001, 15:58:26 ; Search time 169.91 Seconds
(without alignments)
7208.364 Million cell updates/sec

Title: US-09-445-223-2
Perfect score: 2098
Sequence: 1 ggcattatgatgatggg.....aaaaaaaaaaaaaaaaaaaaa 2098

Scoring table: IDENTITY NUC
Gapop 10.0 , Gapext 1.0

Searched: 678276 seqs, 291890651 residues

Total number of hits satisfying chosen parameters: 1356552

Minimum DB seq length: 0
Maximum DB seq length: 2000000000
Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

- Database : N\_Geneseq\_0401.\*
1: /cgnl\_8/gcgdata/geneseq/geneseq/NA1980.DAT.\*
2: /cgnl\_8/gcgdata/geneseq/geneseq/NA1981.DAT.\*
3: /cgnl\_8/gcgdata/geneseq/geneseq/NA1982.DAT.\*
4: /cgnl\_8/gcgdata/geneseq/geneseq/NA1983.DAT.\*
5: /cgnl\_8/gcgdata/geneseq/geneseq/NA1984.DAT.\*
6: /cgnl\_8/gcgdata/geneseq/geneseq/NA1985.DAT.\*
7: /cgnl\_8/gcgdata/geneseq/geneseq/NA1986.DAT.\*
8: /cgnl\_8/gcgdata/geneseq/geneseq/NA1987.DAT.\*
9: /cgnl\_8/gcgdata/geneseq/geneseq/NA1988.DAT.\*
10: /cgnl\_8/gcgdata/geneseq/geneseq/NA1989.DAT.\*
11: /cgnl\_8/gcgdata/geneseq/geneseq/NA1990.DAT.\*
12: /cgnl\_8/gcgdata/geneseq/geneseq/NA1991.DAT.\*
13: /cgnl\_8/gcgdata/geneseq/geneseq/NA1992.DAT.\*
14: /cgnl\_8/gcgdata/geneseq/geneseq/NA1993.DAT.\*
15: /cgnl\_8/gcgdata/geneseq/geneseq/NA1994.DAT.\*
16: /cgnl\_8/gcgdata/geneseq/geneseq/NA1995.DAT.\*
17: /cgnl\_8/gcgdata/geneseq/geneseq/NA1996.DAT.\*
18: /cgnl\_8/gcgdata/geneseq/geneseq/NA1997.DAT.\*
19: /cgnl\_8/gcgdata/geneseq/geneseq/NA1998.DAT.\*
20: /cgnl\_8/gcgdata/geneseq/geneseq/NA1999.DAT.\*
21: /cgnl\_8/gcgdata/geneseq/geneseq/NA2000.DAT.\*
22: /cgnl\_8/gcgdata/geneseq/geneseq/NA2001.DAT.\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Table with columns: Result No., Score, Match, Length, DB ID, Description. Contains 11 rows of search results.

Table with columns: ID, Score, Match, Length, DB ID, Description. Contains 45 rows of search results.

ALIGNMENTS

Table with columns: RESULT, ID, Description. Contains alignment details for various sequences.

New BI protein regulates cell death and cell survival pathways - derivatives, DNA and antibodies, also regulate intracellular

PT Inflammation; for treating AIDS, cancer  
 PS Claim 4; Fig 3B; 9Opp; English.  
 XX This invention describes the isolation of a novel human B1 protein which  
 CC can interact with, intracellular mediators or modulators of inflammation,  
 CC cell death and/or cell survival pathways, directly or indirectly. Cells  
 CC can be modulated or mediated in inflammation, cell death or cell survival  
 CC pathways or another intracellular signalling activity using B1.  
 CC Conditions such as AIDS and cancer can be treated using B1. Antibodies,  
 CC oligonucleotides and ribozymes can also be used to regulate the above  
 CC pathways.  
 XX  
 SQ Sequence 2098 BP; 649 A; 452 C; 449 G; 539 T; 9 other;

Query Match 99.98; Score 2094.4; DB 20; Length 2098;  
 Best Local Similarity 100.0%; Pred. No. 0;  
 Matches 2098; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 ggcattatggtggatggcggcgtacggcgttggccaccagctctagaagaagtc 60  
 Dd 1 ggcattatggtggatggcggcgtacggcgttggccaccagctctagaagaagtc 60  
 Qy 61 agctctgttcgggagagcagcggcgtggcgtggccatccgggaaatggggccctcgtg 120  
 Dd 61 agctctgttcgggagagcagcggcgtggcgtggccatccgggaaatggggccctcgtg 120  
 Qy 121 acctagttgtcgggagagcagcggcgtggcgtggccatccgggaaatggggccctcgtg 180  
 Dd 121 acctagttgtcgggagagcagcggcgtggcgtggccatccgggaaatggggccctcgtg 180  
 Qy 181 ggcctgagcggcgtgggagcgttggcgtggccatccgggaaatggggccctcgtg 240  
 Dd 181 ggcctgagcggcgtgggagcgttggcgtggccatccgggaaatggggccctcgtg 240  
 Qy 241 ggcctgagcggcgtgggagcgttggcgtggccatccgggaaatggggccctcgtg 300  
 Dd 241 ggcctgagcggcgtgggagcgttggcgtggccatccgggaaatggggccctcgtg 300  
 Qy 301 ctaccacaaactcgcgcactcctcctcctcctcctcctcctcctcctcctcctcctcct 360  
 Dd 301 ctaccacaaactcgcgcactcctcctcctcctcctcctcctcctcctcctcctcctcct 360  
 Qy 361 gcgcgcacacagcagcgttggcgtggccatccgggaaatggggccctcgtg 420  
 Dd 361 gcgcgcacacagcagcgttggcgtggccatccgggaaatggggccctcgtg 420  
 Qy 421 gctgctgacagtgaaagaagatgttttaagaagaagcctgaaatttacacaagctag 480  
 Dd 421 gctgctgacagtgaaagaagatgttttaagaagaagcctgaaatttacacaagctag 480  
 Qy 481 attagttacattttccaaatttggaaattgcaatgagcctgaaatttggaaatgt 540  
 Dd 481 attagttacattttccaaatttggaaattgcaatgagcctgaaatttggaaatgt 540  
 Qy 541 tactgaa tacatgccaaatgatatcaaaatgaaactcctacataggaactgaaactgaaatcc 600  
 Dd 541 tactgaa tacatgccaaatgatatcaaaatgaaactcctacataggaactgaaactgaaatcc 600  
 Qy 601 tgaattgtcgtggcattgagatttcgcatcctcctcctcctcctcctcctcctcctcctcct 660  
 Dd 601 tgaattgtcgtggcattgagatttcgcatcctcctcctcctcctcctcctcctcctcctcct 660  
 Qy 661 cctgacaaatgactcctccttactcctcctcctcctcctcctcctcctcctcctcctccttatt 720  
 Dd 661 cctgacaaatgactcctccttactcctcctcctcctcctcctcctcctcctcctcctccttatt 720  
 Qy 721 ggacaatgaatttccatgttaagattgcagatttggtttatacaagtggcgatgatgctc 780  
 Dd 721 ggacaatgaatttccatgttaagattgcagatttggtttatacaagtggcgatgatgctc 780  
 Qy 781 cctctcagctcagcagatgacaaatctgcaccagagggggcaaatattttatattatgccc 840

Db 781 cctctcagctcagcagatgacaaatctgcaccagaggggacaaattattttatattgccc 840  
 Qy 841 acctgaaaactatgaaacctggacaaaaaaacaaagggcagctatacaagcagcagataatag 900  
 Dd 841 acctgaaaactatgaaacctggacaaaaaaacaaagggcagctatacaagcagcagataatag 900  
 Qy 901 ctatgagttatcacatgggaaagtgtatccagaaaaacagccttttgaagatgacccaa 960  
 Dd 901 ctatgagttatcacatgggaaagtgtatccagaaaaacagccttttgaagatgacccaa 960  
 Qy 961 tcccttgcagataaatgtatagttgtccaaaggacatcagctgtttatttaagagaagag 1020  
 Dd 961 tcccttgcagataaatgtatagttgtccaaaggacatcagctgtttatttaagagaagag 1020  
 Qy 1021 ttgtccatatgatatacctcacccagcagctatgctcctcttaataagaaagtggcgccc 1080  
 Dd 1021 ttgtccatatgatatacctcacccagcagcagctatgctcctcttaataagaaagtggc 1080  
 Qy 1081 acaaaatccagatgaaagaccattctttcttaaaatgttttaataagaaactgaaaccagttt 1140  
 Dd 1081 acaaaatccagatgaaagaccattctttcttaaaatgttttaataagaaactgaaaccagttt 1140  
 Qy 1141 gagaacatttgaagagataaacttttctgaagctgtttttcagcttaagaaagaaagagtt 1200  
 Dd 1141 gagaacatttgaagagataaacttttctgaagctgtttttcagcttaagaaagaaagagtt 1200  
 Qy 1201 acagagtttcaagtgcattccattatgacaaagaaataatgaaatctctctctgaa 1260  
 Dd 1201 acagagtttcaagtgcattccattatgacaaagaaataatgaaatctctctctgaa 1260  
 Qy 1261 cctacctgttaaa tcaatgggttcccaagagaaatcatgctggatctctcagctccatgaaa 1320  
 Dd 1261 cctacctgttaaa tcaatgggttcccaagagaaatcatgctggatctctcagctccatgaaa 1320  
 Qy 1321 tagtggttcctgaaactcctcaaggtccctcagcctcctcaagaaatgatgtttttatc 1380  
 Dd 1321 tagtggttcctgaaactcctcaaggtccctcagcctcctcaagaaatgatgtttttatc 1380  
 Qy 1381 tagaaaactcagactgtttatttttaagaagcgtcactcctcctggaactcagacttg 1440  
 Dd 1381 tagaaaactcagactgtttatttttaagaagcgtcactcctcctggaactcagacttg 1440  
 Qy 1441 gtagtagcactctctggtatctcaaaaggtctgctctgatacaagaagcctccatg 1500  
 Dd 1441 gtagtagcactctctggtatctcaaaaggtctgctctgatacaagaagcctccatg 1500  
 Qy 1501 ctcttcaagcaataaataaactcactcctcaactcagaaactcagaaactcagcagctcg 1560  
 Dd 1501 ctcttcaagcaataaataaactcactcctcaactcagaaactcagaaactcagcagctcg 1560  
 Qy 1561 tatagcccagctggatccagagcaaaagggaagcatttgtaaccacaaatgacagaagc 1620  
 Dd 1561 tatagcccagctggatccagagcaaaagggaagcatttgtaaccacaaatgacagaagc 1620  
 Qy 1621 ctgcttbaaccagctgctagatgcccctctctcagggagcctgataatgaaaggagacta 1680  
 Dd 1621 ctgcttbaaccagctgctagatgcccctctctcagggagcctgataatgaaaggagacta 1680  
 Qy 1681 tgaactgttagtaccagcctcagaaagcctcaaaagcctcaaaagcctcaaaagcctcaaa 1740  
 Dd 1681 tgaactgttagtaccagcctcagaaagcctcaaaagcctcaaaagcctcaaaagcctcaaa 1740  
 Qy 1741 tgacatccaaggagaagaaattgocaaagttatagtaaaaaatgaaagatacaaaaa 1800  
 Dd 1741 tgacatccaaggagaagaaattgocaaagttatagtaaaaaatgaaagatacaaaaa 1800  
 Qy 1801 aatgggtctcagccttaccgggaaaacttggtttctagatcaccactctttaaattt 1860  
 Dd 1801 aatgggtctcagccttaccgggaaaacttggtttctagatcaccactctttaaattt 1860  
 Qy 1861 acttcaaaataaaagcactgaagcactgttttcaagaagaaatgtgtttcaaaaag 1920  
 Dd 1861 acttcaaaataaaagcactgaagcactgttttcaagaagaaatgtgtttcaaaaag 1920

Db 1861 acttcaaaataaagcatgtaagtactgtttttccaagaagaataagtgtttccataaaagg 1920  
 Qy 1921 atattatctctgtctgttggacttttttatataaaatccgtgagtattaaagcttw 1980  
 Db 1921 atattatctctgtctgttggacttttttatataaaatccgtgagtattaaagcttw 1980  
 Qy 1981 awraargktctttrktaaatattagtctccctccatgacactgcagttatttttttaa 2040  
 Db 1981 awraargktctttrktaaatattagtctccctccatgacactgcagttatttttttaa 2040  
 Qy 2041 ttaatacaagtaaaaagttgattgaaaataaataaataaataaataaataaataa 2098  
 Db 2041 ttaatacaagtaaaaagttgattgaaaataaataaataaataaataaataaataa 2098

RESULT 2  
 C77779  
 ID C77779 standard; cDNA; 2709 BP.  
 AC C77779;  
 XX  
 DT 08-FEB-2001 (first entry)  
 XX  
 DE Human cancer associated gene sequence SEQ ID NO:173.  
 XX  
 KW Human; cancer associated gene; cancer antigen; detection; cancer;  
 diagnosis; cytostatic; proliferative; vulnarary; immunomodulator;  
 antidiabetic; antiarthmatic; antirheumatic; antiarthritic; antiviral;  
 antiinflammatory; antithyroid; antiallergic; antibacterial; cardiac;  
 dermatological; neuroprotective; thrombolytic; coagulant; nootropic;  
 vasotropic; antipsoriatic; antiangiogenic; gene therapy; inflammation;  
 immune disorder; haematopoietic cell disorder; autoimmune disorder;  
 allergic reaction; graft versus host disease; organ rejection;  
 haemostatic; thrombolytic; cardiovascular disorder; infection;  
 neurological disease; drug screening; ss.  
 XX  
 OS Homo sapiens.  
 XX  
 PN WO200053350-A1.  
 XX  
 PD 21-SEP-2000.  
 XX  
 PF 08-MAR-2000; 2000WO-US05882.  
 XX  
 PR 12-MAR-1999; 99US-0124270.  
 XX  
 PA (HUMA-) HUMAN GENOME SCI INC.  
 XX  
 PI Rosen CA, Ruben SM;  
 XX  
 DR WPI; 2000-587533/55.  
 DR P-PSDB; B43570.  
 XX  
 PT Novel isolated nucleic acids comprising sequences encoding peptides  
 PT useful for treating or diagnosing e.g. cancer -  
 XX  
 PS Claim 1; Page 751-752; 2352pp; English.  
 XX  
 CC C77607 to C78448 encode the human cancer associated proteins given in  
 CC B43398 to B44239. The proteins can have activities based on the tissues  
 CC and cells the genes are expressed in. Example of activities include:  
 CC cytostatic; proliferative; vulnarary; immunomodulator; antidiabetic;  
 CC antiarthmatic; antirheumatic; antiarthritic; antiinflammatory;  
 CC antithyroid; antiallergic; antibacterial; antiviral; dermatological;  
 CC neuroprotective; cardiac; thrombolytic; coagulant; nootropic;  
 CC vasotropic; antipsoriatic and antiangiogenic. The polynucleotides and  
 CC polypeptides can be used for preventing, treating or ameliorating medical  
 CC conditions and diagnosing pathological conditions. Polynucleotides,  
 CC polypeptides, antibodies, agonists and antagonists from the present  
 CC invention may be used to treat immune disorders by activating or  
 CC inhibiting the proliferation, differentiation or mobilisation of immune  
 CC cells, to treat disorders of haematopoietic cells, autoimmune disorders,  
 CC allergic reactions, graft versus host disease and organ rejection.

CC modulate haemostatic or thrombolytic activity, modulate inflammation,  
 CC cancers, cardiovascular disorders, neurological disease and bacterial  
 CC viral infections. The peptides, nucleotides, antibodies, agonists and  
 CC antagonists may be also used in drug screens. C78449 to C78457 and  
 CC B44240 represent sequences used in the exemplification of the present  
 CC invention.  
 XX  
 SQ Sequence 2709 BP; 810 A; 580 C; 540 G; 769 T; 10 other;

Query Match 96.8%; Score 2031.6; DB 21; Length 2709;  
 Best Local Similarity 99.1%; Pred. No. 0;  
 Matches 2028; Conservative 12; Mismatches 6; Indels 0; Gaps 0;

Qy 20 gcgagcctacggcttggccacagctctagaaaagaagtgcctgcttccggagaacg 79  
 Db 27 gcgagcctacggcttggccacagctctagaaaagaagtgcctgcttccggagaacg 86  
 Qy 80 agcggctggcggcattccgggaatggcgccctctgtgaccctagtttgcggggcaa 139  
 Db 87 agcggctggcggcattccgggaatggcgccctctgtgaccctagtttgcggggcaa 146  
 Qy 140 aaaggtttccggcctctgtgcaagggcgctatctgggcccctgagcggcgctgg 199  
 Db 147 aaaggtttccggcctctgtgcaagggcgctatctgggcccctgagcggcgctgg 206  
 Qy 200 gacgttgggacccggcagcagggggcaacccggaaaccggccctgagcggcgacc 259  
 Db 207 gacgttgggacccggcagcagggggcaacccggaaaccggccctgagcggcgacc 266  
 Qy 260 atgaacggggagccatctgcagcgccctgccaccattccctaccacaactcgccgac 319  
 Db 267 atgaacggggagccatctgcagcgccctgccaccattccctaccacaactcgccgac 326  
 Qy 320 ctgctactgagcggcgccctctgctgtgcaatgctgcggccggcggccagcagactgg 379  
 Db 327 ctgctactgagcggcgccctctgctgtgcaatgctgcggccggcggccagcagactgg 386  
 Qy 380 cggctccagggtggcgctgagcactgcacatccacatcccgctctgctgacagtagaa 439  
 Db 387 cggctccagggtggcgctgagcactgcacatccacatcccgctctgctgacagtagaa 446  
 Qy 440 aaggatgttttaagagaagctgaaattttcacaaagctagatttagttacatatttcca 499  
 Db 447 aaggatgttttaagagaagctgaaattttcacaaagctagatttagttacatatttcca 506  
 Qy 500 atttgggaatttgcaatgagcctgaaattttgggaaatagttactgaaatgcaaat 559  
 Db 507 atttgggaatttgcaatgagcctgaaattttgggaaatagttactgaaatgcaaat 566  
 Qy 560 ggatcattaaatgaaactcctacataggaactgaatatacctgagttgttggccattg 619  
 Db 567 ggatcattaaatgaaactcctacataggaactgaatatacctgagttgttggccattg 626  
 Qy 620 agatttcgactcctgatgaaattgcccctttgtgtaaatatacctgcacaaatgactct 679  
 Db 627 agatttcgactcctgatgaaattgcccctttgtgtaaatatacctgcacaaatgactct 686  
 Qy 680 ccttacttccatcactgacttgagactcagaatatacttttggacaactgaaatgactgt 739  
 Db 687 ccttacttccatcactgacttgagactcagaatatacttttggacaactgaaatgactgt 746  
 Qy 740 aagattgcagatttggttttcaaatggcagatgctcctcctcagcagtcagaact 799  
 Db 747 aagattgcagatttggttttcaaatggcagatgctcctcctcagcagtcagaact 806  
 Qy 800 agcaaatcgcaccagaagggcaactatttatatgccaccctgaaactatgaact 859  
 Db 807 agcaaatcgcaccagaagggcaactatttatatgccaccctgaaactatgaact 866  
 Qy 860 gacaaaaatcaagggccagtcacagcagatataatagctatgactgtacatg 919  
 Db 867 gacaaaaatcaagggccagtcacagcagatataatagctatgactgtacatg 926

Qy 920 gaagtgttaccagaacaacagccttttgaagatgtcaccacacccctcttgcagataaattgtat 979  
 Db 927 gaagtgttaccagaacaacagccttttgaagatgtcaccacacccctcttgcagataaattgtat 986  
 Qy 980 agtgtgtcacaagagacatgcacctgttattaaagaagaagtttgccatgatataacct 1039  
 Db 987 agtgtgtcacaagagacatgcacctgttattaaagaagaagtttgccatgatataacct 1046  
 Qy 1040 caccgagcagatgatctctcttaataagtagaagtggtgagcacaacaaccagatgaaaga 1099  
 Db 1047 caccgagcagatgatctctcttaataagtagaagtggtgagcacaacaaccagatgaaaga 1106  
 Qy 1100 ccattcttttaaaatttaataagaaacttgaaaccagttttgagaacatttgaagagata 1159  
 Db 1107 ccattcttttaaaatttaataagaaacttgaaaccagttttgagaacatttgaagagata 1166  
 Qy 1160 accttttgaagctgtattcagctaaagaacaacaagaattacagagtggtttccaagtgc 1219  
 Db 1167 accttttgaagctgtattcagctaaagaacaacaagaattacagagtggtttccaagtgc 1226  
 Qy 1220 attcaactctgacagaagaagaattggaattatctctgaaactacactgtaaatcatggt 1279  
 Db 1227 attcaactctgacagaagaagaattggaattatctctgaaactacactgtaaatcatggt 1286  
 Qy 1280 ccacaagagaatcatgtgactctcagctccatgaaataatggtttctctcctgaaact 1339  
 Db 1287 ccacaagagaatcatgtgactctcagctccatgaaataatggtttctctcctgaaact 1346  
 Qy 1340 tcaaggtccctgcagctcctcaagacaatgatttttattctagaaaagctcaagactgt 1399  
 Db 1347 tcaaggtccctgcagctcctcaagacaatgatttttattctagaaaagctcaagactgt 1406  
 Qy 1400 tatttttgaagctgcaactcctctggaatacaagttgggatagcaacatttcttggga 1459  
 Db 1407 tatttttgaagctgcaactcctctggaatacaagttgggatagcaacatttcttggga 1466  
 Qy 1460 tctcaaaagggctgattctgtgacacaagaccactcctctctcagcaataaataa 1519  
 Db 1467 tctcaaaagggctgattctgtgacacaagaccactcctctcagcaataaataa 1526  
 Qy 1520 ccaactcaactgagaaactcagaactctcagcctggtatagcccagcagtggtgac 1579  
 Db 1527 ccaactcaactgagaaactcagaactctcagcctggtatagcccagcagtggtgac 1586  
 Qy 1580 cagagcaaaagggagacatttgaaaccaaatagcagaagcctgcttaaccagtcgcta 1639  
 Db 1587 cagagcaaaagggagacatttgaaaccaaatagcagaagcctgcttaaccagtcgcta 1646  
 Qy 1640 gatgccctctctccaggacttgatcatgaaagaggactatgaacttggtagtaccacaag 1699  
 Db 1647 gatgccctctctccaggacttgatcatgaaagaggactatgaacttggtagtaccacaag 1706  
 Qy 1700 cctcaagggactcacaagtcagaactactgacactactgacatccaagggagaaga 1759  
 Db 1707 cctcaagggactcacaagtcagaactactgacactactgacatccaagggagaaga 1766  
 Qy 1760 ttgccaagacttagtacaacaaattgaaagatacaacaacaattgggtcttccagccttac 1819  
 Db 1767 ttgccaagacttagtacaacaaattgaaagatacaacaacaattgggtcttccagccttac 1826  
 Qy 1820 ccggaataacttgggtttcttagatcaccatctttaaattacttcaaaaataaaagcag 1879  
 Db 1827 ccggaataacttgggtttcttagatcaccatctttaaattacttcaaaaataaaagcag 1886  
 Qy 1880 taagtactgttttcaagaagaattgtttctcaaaagatttatctctctgttc 1939  
 Db 1887 taagtactgttttcaagaagaattgtttctcaaaagatttatctctctgttc 1946  
 Qy 1940 ttgacttttttataaaaatccgtgatttaaagctttwwraargkctttsrktta 1999  
 Db 1947 ttgacttttttataaaaatccgtgatttaaagctttattaaagcttttattgaaggtttcttgggta 2006

Qy 2000 aaattattagctccctccatgcactgacactgagctatttttttaataatacaagtaaaagtt 2059  
 Db 2007 aaattattagctccctccatgcactgacactgagctatttttttaataatacaagtaaaagtt 2066  
 Qy 2060 gaattt 2065  
 Db 2067 tgaatt 2072

RESULT 3  
 Z48762  
 ID Z48762 standard; cDNA; 2502 BP.  
 XX  
 AC Z48762;  
 XX  
 DT 21-MAR-2000 (first entry)  
 XX  
 DE Human RICK coding sequence.  
 XX  
 KW RICK; human; RIP-like interacting CLARP kinase; apoptosis regulator; ARC;  
 KW caspase-8; caspase-10; CD95 signalling; apoptosis signalling pathway;  
 KW CIDE-A; CIDE-B; DREP-1; diagnosis; cell growth; apoptosis dysregulation;  
 KW gene therapy; cardiac disorder; cancer; neurodegenerative disorder; AIDS;  
 KW aplastic anaemia; ischaemic injury; toxin-induced liver disease; ss.  
 XX  
 OS Homo sapiens.  
 XX  
 PN W09955134-A2.  
 XX  
 PD 04-NOV-1999.  
 XX  
 PF 27-APR-1999; 99WO-US09183.  
 XX  
 PR 27-APR-1998; 98US-0069023.  
 XX  
 PA (UNMI) UNIV MICHIGAN.  
 XX  
 PI Nunez G, Inohara N, Koseki T;  
 XX  
 DR WPI: 2000-072163/06.  
 DR P-PSDB; Y59404.  
 XX  
 PT Compositions for identifying apoptosis signalling pathway inhibitors  
 XX  
 PS Claim 8; Fig 7b; 93pp; English.  
 CC  
 CC This sequence encodes the human RICK (RIP-like interacting CLARP kinase)  
 CC protein of the invention. The RICK protein acts as a positive regulator  
 CC of apoptosis, potentiating apoptosis induced by caspase-8 and caspase-10  
 CC during CD95 signalling. The invention provides methods for identifying  
 CC apoptosis signalling pathway inhibitors and activators, and methods and  
 CC compositions for screening compounds which will modulate the interactions  
 CC of the various compositions identified: ARC, RICK, and the CIDE family of  
 CC activators (CIDE-A, CIDE-B and DREP-1). RICK is useful in screening of  
 CC assays for agents, useful in the diagnosis, prognosis or treatment of  
 CC disease associated with excess cell growth and dysregulation of  
 CC apoptosis. Complexes containing RICK and CLARP can be used in drug  
 CC screening assays to identify inhibitor molecules blocking CD95-mediated  
 CC apoptosis. Overexpression of ARC in an in vitro cell system can be used  
 CC to identify inhibitors of the enzymatic activity of caspase-8.  
 CC Identification of ARC-like inhibitory compounds may be useful for gene  
 CC therapy treatment of disease with increased cell death in muscle tissue  
 CC and cardiac disorders. Therapeutic compositions of CIDES can be used to  
 CC treat e.g. cancer, AIDS, neurodegenerative disorders, aplastic anaemia,  
 CC ischaemic injury, and toxin-induced liver disease. Antirick antibodies  
 CC can be used as reagents for the preparation or affinity chromatography  
 CC media, and for diagnostically measuring RICK levels. A specific inhibitor  
 CC of an essential step in the biochemistry of apoptosis is needed. RICK  
 CC interaction with intracellular factors such as CLARP and FADD appears to  
 CC be essential for apoptosis, inhibitors of RICK binding to intracellular  
 CC apoptosis factors are potential drug candidates.  
 XX

SQ Sequence 2502 BP; 769 A; 535 C; 499 G; 699 T; 0 other;

Query\_Match 95.7%; Score 2006.8; DB 21; Length 2502;  
 Best\_Local\_Similarity 99.2%; Pred. No. 0;  
 Matches 2016; Conservative 9; Mismatches 6; Indels 1; Gaps 1;

Qy 36 ggcaccagctctatagaaagaagtcagctctgttcgagaaagcagcggctggcggc 95  
 Db 1 ggcaccagctctatagaaagaagtcagctctgttcgagaaagcagcggctggcggc 60

Qy 96 catcggggaaatggcgcctctgtgacctagttgtcgcggggcaaaaaggtctccggc 155  
 Db 61 catcggggaaatggcgcctctgtgacctagttgtcgcggggcaaaaaggtctccggc 120

Qy 156 ctgcctcgtcgaaggcgtactcctggcctcgtgagcgcggcggctgggagccgc 215  
 Db 121 ctgcctcgtcgaaggcgtactcctggcctcgtgagcgcggcggctgggagccgc 180

Qy 216 cgcagcgggggacacccggaaacggcctgagcgcggcggaccatgaacggggagccca 275  
 Db 181 cgcagcgggggacacccggaaacggcctgagcgcggcggaccatgaacggggagccca 240

Qy 276 tctgagggccc-tgcaccacatccctaccacaactcgcgcacctgcgctaccctgagc 334  
 Db 241 tctgagggcccattcccaaccatccctaccacaactcgcgcacctgcgctaccctgagc 300

Qy 335 cgcggcgcctcctggcactgtcgtccggcccgccagcagcctggcggctccagctggcc 394  
 Db 301 cgcggcgcctcctggcactgtcgtccggcccgccagcagcctggcggctccagctggcc 360

Qy 395 gtgaagcactcgcacatccacactccgctcgcagtgaaagaaagatgttttaaga 454  
 Db 361 gtgaagcactcgcacatccacactccgctcgcagtgaaagaaagatgttttaaga 420

Qy 455 gaagctgaaattttacaaaagctagatttagttacattttcccaattttgggaaattgc 514  
 Db 421 gaagctgaaattttacaaaagctagatttagttacattttcccaattttgggaaattgc 480

Qy 515 aatgagcctgaaattttgggaatagttactgaaatcacaagcgaatggatcattaaatgaa 574  
 Db 481 aatgagcctgaaattttgggaaatagttactgaaatcacaagcgaatggatcattaaatgaa 540

Qy 575 ctctcatagaaactgaaatctcctgatgttctgttgccattgagatttcgcactctg 634  
 Db 541 ctctcatagaaactgaaatctcctgatgttctgttgccattgagatttcgcactctg 600

Qy 635 catgaaattgcctcgtggtgaaattaccctgcacaataagcctcctcttacttaccat 694  
 Db 601 catgaaattgcctcgtggtgaaattaccctgcacaataagcctcctcttacttaccat 660

Qy 695 gacttgaagactcagaatctcttattgacaatgaattttcattgttaagattgcagatttt 754  
 Db 661 gacttgaagactcagaatctcttattgacaatgaattttcattgttaagattgcagatttt 720

Qy 755 gttttatcaagctggcgcgatgatgtccctctcacagtcacgaagtagcaaatctgcacca 814  
 Db 721 gttttatcaagctggcgcgatgatgtccctctcacagtcacgaagtagcaaatctgcacca 780

Qy 815 gaaggaggacaattatttatgaccactgaaactgaaactatgaacctggacaaaaatcaagg 874  
 Db 781 gaaggaggacaattatttatgaccactgaaactgaaactatgaacctggacaaaaatcaagg 840

Qy 875 gccagatcaagcagcagatataatagctatgcagttatcacatgggaagtgattaccaga 934  
 Db 841 gccagatcaagcagcagatataatagctatgcagttatcacatgggaagtgattaccaga 900

Qy 935 aaacagccttttgaagatgctcaccactcctttgcagataatgtagtgcacaaagga 994  
 Db 901 aaacagccttttgaagatgctcaccactcctttgcagataatgtagtgcacaaagga 960

Qy 995 catcgacctgttattaaatgaagaaagttggccatataatcctcaccggcagcagctatg 1054  
 Db 961 catcgacctgttattaaatgaagaaagttggccatataatcctcaccggcagcagctatg 1020

Db 961 catcgacctgttattaaatgaagaaagttggccatataatcctcaccggcagcagctatg 1020

Qy 1055 atctctcaatagaagaatggtatgggcacaaaaatccagatgaagaccatctttcttaaaa 1114  
 Db 1021 atctctcaatagaagaatggtatgggcacaaaaatccagatgaagaccatctttcttaaaa 1080

Qy 1115 tgtttaaatagaactgaaaccagttttgagaacattttgaagagataaactttcttgaagct 1174  
 Db 1081 tgtttaaatagaactgaaaccagttttgagaacattttgaagagataaactttcttgaagct 1140

Qy 1175 gttatcagctaaagaaacaaagtacagagttgtttcaagtccatccacatactgac 1234  
 Db 1141 gttatcagctaaagaaacaaagtacagagttgtttcaagtccatccacatactgac 1200

Qy 1235 aagaagaaatgaaattatctcctgaacacacctcgttaaacatcattggtccacaagaggaatca 1294  
 Db 1201 aagaagaaatgaaattatctcctgaacacacctcgttaaacatcattggtccacaagaggaatca 1260

Qy 1295 tgtgatcctctcagctccatgaaatagttgttctcctgaaactcaaggtccctgcca 1354  
 Db 1261 tgtgatcctctcagctccatgaaatagttgttctcctgaaactcaaggtccctgcca 1320

Qy 1355 gctctcaagaaacaaatgattttttatctagaaagctcaagactgttattttatgaagctg 1414  
 Db 1321 gctctcaagaaacaaatgattttttatctagaaagctcaagactgttattttatgaagctg 1380

Qy 1415 catcactgctcctggaaatcacagttgggagtagcacattctcggatcctcaagggctgca 1474  
 Db 1381 catcactgctcctggaaatcacagttgggagtagcacattctcggatcctcaagggctgca 1440

Qy 1475 tttctggtacacaagaacccactcctcctcagcaataataatccactctcaactgca 1534  
 Db 1441 tttctggtacacaagaacccactcctcctcagcaataataatccactctcaactgca 1500

Qy 1535 ggaactcaagaacgtctgcagcctggatagcccagcagctggatccagagcaaaaagggaa 1594  
 Db 1501 ggaactcaagaacgtctgcagcctggatagcccagcagctggatccagagcaaaaagggaa 1560

Qy 1595 gacattgtgaacaaatgacagaagcctccttaaccagctcagctagatccctctcgtcc 1654  
 Db 1561 gacattgtgaacaaatgacagaagcctccttaaccagctcagctagatccctctcgtcc 1620

Qy 1655 agggactgactcatgaaagagcactatgaactgttttagtaccagcctacaagcactca 1714  
 Db 1621 agggactgactcatgaaagagcactatgaactgttttagtaccagcctacaagcactca 1680

Qy 1715 aaagtcaagaacttactagactactgacatcccaaggaagaatttgccaaagtata 1774  
 Db 1681 aaagtcaagaacttactagactactgacatcccaaggaagaatttgccaaagtata 1740

Qy 1775 gtacaaaaattgaaagataacaaacaaatgggtctcctcagcctaccgggaaataactgtg 1834  
 Db 1741 gtacaaaaattgaaagataacaaacaaatgggtctcctcagcctaccgggaaataactgtg 1800

Qy 1835 gttctagatcaccatctttaaattacttcaaaaataaaagcattgaagtactgttttt 1894  
 Db 1801 gttctagatcaccatctttaaattacttcaaaaataaaagcattgaagtactgttttt 1860

Qy 1895 caagaagaaatggtttcataaaaagataattatctcgtgtgtttgactttttttat 1954  
 Db 1861 caagaagaaatggtttcataaaaagataattatctcgtgtgtttgactttttttat 1920

Qy 1955 ataaaaatcogtgaattaaagcttwwraargktctttrktaaaatattagctcctcc 2014  
 Db 1921 ataaaaatcogtgaattaaagcttwwraargktctttrktaaaatattagctcctcc 1980

Qy 2015 ccatgacactgcagttatttttttaataatacaagtaaaaaagttgaaattg 2066  
 Db 1981 ccatgacactgcagttatttttttaataatacaagtaaaaaagttgaaattg 2032

ID 246143 standard; cDNA; 2024 BP.  
 AC 246143;  
 XX DT 16-MAY-2000 (first entry)  
 DE cDNA sequence encoding a human phosphorylation effector PHSP-6.  
 KW Human; phosphorylation effector; PHSP; proliferative disorder;  
 KW Immune disorder; neuronal disorder; ss.  
 XX OS Homo sapiens.  
 XX FH Key Location/Qualifiers  
 FT 203..1825  
 FT /\*tag- a  
 FT /product= "phosphorylation effector"  
 XX W0200006728-A2.  
 XX 10-FEB-2000.  
 XX 28-JUL-1999; 99WO-US17132.  
 XX 28-JUL-1998; 98US-0123494.  
 PR 14-SEP-1998; 98US-0152814.  
 PR 14-OCT-1998; 98US-0173482.  
 PR 03-NOV-1998; 98US-0106889.  
 PR 19-NOV-1998; 98US-0109093.  
 PR 22-DEC-1998; 98US-0113796.  
 PR 12-JAN-1999; 99US-0173482.  
 PR 12-JAN-1999; 99US-0229005.  
 XX (INCY-) INCYTE PHARM INC.  
 XX Hillman JL, Lal P, Tang YT, Corley NC, Guegler KJ, Baughn MR;  
 PI Patterson C, Bandman O, Au-Young J, Gorgone GA, Yue H, Azimzai Y;  
 PI Reddy R, Lu DAM, Shih LL;  
 XX WPI; 2000-183125/16.  
 DR P-PSDB; Y68774.  
 XX PT New human phosphorylation effectors useful for the diagnosis, treatment  
 and prevention of proliferative, immune and neuronal disorders  
 XX Claim 9; Page 121-122; 142pp; English.  
 XX 246138-246168 encode human phosphorylation effectors (PHSP),  
 CC designated PHSP1-PHSP31 (the protein sequence for PHSP28 is not given  
 CC in the specification). The sequences were isolated from cDNA libraries  
 CC prepared from various human tissues. The PHSP proteins are useful for  
 CC the diagnosis, treatment and prevention of proliferative disorders,  
 CC immune disorders and neuronal disorders. The PHSP proteins form  
 CC pharmaceutical compositions which useful for treating or preventing  
 CC disorders associated with decreased PHSP expression/activity. PHSP  
 CC antagonists are useful for treating or preventing disorders associated  
 CC with increased PHSP expression/activity.  
 XX Sequence 2024 BP; 612 A; 445 C; 434 G; 533 T; 0 other;  
 XX Query Match 95.3%; Score 1999.6; DB 21; Length 2024;  
 XX Best Local Similarity 98.9%; Pred. No. 0;  
 XX Matches 2002; Conservative 9; Mismatches 13; Indels 0; Gaps 0;  
 QY 58 gtcaactctgttcggagagaacgcaggctggctggccatccggggaatggcgccctc 117  
 Db 1 gtcaactctgttcggagagaacgcaggctggctggccatccggggaatggcgccctc 60  
 QY 118 gtcaactctgttcggggaacgaaggtcttgcggccctcgctcggaggcgctatc 177  
 Db 61 gtcaactctgttcggggaacgaaggtcttgcggccctcgctcggaggcgctatc 120

```

Db 1201 gaaacactctgaaatcattggtccacaagagaatcatggtgatctctcagctccatga 1260
Oy 1318 aaatagtggtctctcctgaaactcgaagctcctccagctcctcgaagacaatgattttt 1377
Db 1261 aaatagtggtctctcctgaaactcgaagctcctccagctcctcgaagacaatgattttt 1320
Oy 1378 atcagaaaagctcaagactgtattttatgaagctgcatcactgtcctgaaatcacag 1437
Db 1321 atcagaaaagctcaagactgtattttatgaagctgcatcactgtcctgaaatcacag 1380
Oy 1438 ttggatagaccatttctgactcacaaggctcctcctgcttctgctacacaagaccactcc 1497
Db 1381 ttggatagaccatttctgactcacaaggctcctcctgcttctgctacacaagaccactcc 1440
Oy 1498 atgctcttcagcaataaataaacactcctcaactcagcaagaaactcagaaactcagccc 1557
Db 1441 atgctcttcagcaataaataaacactcctcaactcagcaagaaactcagaaactcagccc 1500
Oy 1558 tggatagccagcagtgatccagagcaaaagggaagacattggaaccaaatacagaca 1617
Db 1501 tggatagccagcagtgatccagagcaaaagggaagacattggaaccaaatacagaca 1560
Oy 1618 agctgccttaaccagctcagtagatgcccctctgtccagggacttgatcattgaaagagga 1677
Db 1561 agctgccttaaccagctcagtagatgcccctctgtccagggacttgatcattgaaagagga 1620
Oy 1678 ctatgaactttgatcccaagctcacaagaccctcaaaagtcagaactcagcaatcagacac 1737
Db 1621 ctatgaactttgatcccaagctcacaagaccctcaaaagtcagaactcagcaatcagacac 1680
Oy 1738 tactgacatccaagagagaattggccaagttatagatcacaataatgaaagatacaaa 1797
Db 1681 tactgacatccaagagagaattggccaagttatagatcacaataatgaaagatacaaa 1740
Oy 1798 acaaatgggtcttcgctcaccggaataacttggtggtttctagatcaccatctttaaa 1857
Db 1741 acaaatgggtcttcgctcaccggaataacttggtggtttctagatcaccatctttaaa 1800
Oy 1858 tttactcacaataaaagcatgtaagctactgttttccaagaaagtgtttccataaa 1917
Db 1801 tttactcacaataaaagcatgtaagctactgttttccaagaaagtgtttccataaa 1860
Oy 1918 aggatatttatactctgtgcttggacttttttatataaaatccgtgagattcaaacg 1977
Db 1861 aggatatttatactctgtgcttggacttttttatataaaatccgtgagattcaaacg 1920
Oy 1978 ttwaawraargkttttsrktaaatattagttctcctccatgacactgcagttattttt 2037
Db 1921 ttattggaaggtctcttgggtaaaatattagttctcctccatgacactgcagttattttt 1980
Oy 2038 taattaatacagaagtaaaaagttgaaattgaaataaaataaaataaaataaa 2081
Db 1981 taattaatacagaagtaaaaagttgaaattgaaattgaaataaaataaaataaa 2024

```

```

RESULT 5
Z09246
ID Z09246 standard; cDNA; 1931 BP.
AC Z09246;
XX
DT 25-OCT-1999 (first entry)
DE Human CARD-3 cDNA.
XX
KW CARD-3; caspase recruitment domain; CARD-4; regulation; detection;
KW caspase activation; detection; screening; therapy; diagnosis; disease;
KW apoptotic cell death; Fas/APO-1 receptor complex; TNF receptor complex;
KW cancer; follicular lymphoma; carcinoma; p53 mutation; viral infection;
KW hormone-dependent tumour; autoimmune disorder; Alzheimer's disease;
KW Parkinson's disease; amyotrophic lateral sclerosis; retinitis pigmentosa;

```

```

KW spinal muscular dystrophy; cerebellar degeneration; anaemia; drug;
KW myelodysplastic syndrome; myocardial infarction; cell proliferation;
KW cell differentiation; cell survival; CARD-4L; CARD-4S; CARD-4Y;
KW CARD-4Z; human; ds.
XX Homo sapiens.
XX
Key Location/Qualifiers
CDS 214..1836
/*tag= a
/product= "CARD-3"
WO9940102-A1.
XX
PD 12-AUG-1999.
XX
PF 05-FEB-1999; 99WO-US02544.
PR 08-DEC-1998; 98US-0207359.
PR 06-FEB-1998; 98US-0019942.
PR 17-JUN-1998; 98US-0099041.
XX
PA (MILL-) MILLENNIUM PHARM INC.
XX
Bertin J;
WPI; 1999-494269/41.
P-PSDB; Y31140.
DR
DR Novel CARD-3 and CARD-4 genes and polypeptides used or treating
PT regulation of cellular proliferation and differentiation and cell
PT survival
XX
XX Example 2; Fig 1; 181pp; English.
XX
CC This invention describes the isolation of novel human caspase
CC recruitment domain, CARD-3 and CARD-4 polynucleotides and proteins and a
CC partial murine CARD-4L protein and genes. The genes and proteins of
CC the invention are involved in the regulation of caspase activation.
CC The caspase recruitment domain (CARD) polynucleotides, polypeptides,
CC homologues and antibodies can be used in screening assays, detection
CC assays, predictive medicine and therapeutic and prophylactic methods of
CC treatment. The methods may be used to diagnose and treat patients which
CC are suffering from a disorder associated with abnormal level or rate of
CC apoptotic cell death, abnormal activity of the Fas/APO-1 receptor
CC complex, abnormal activity of the TNF receptor complex, or abnormal
CC activity of a caspase. Diseases that may be treated include cancer
CC (particularly follicular lymphoma, carcinomas associated with mutations
CC in p53 and hormone-dependent tumours), autoimmune disorders (e.g.
CC systemic lupus erythematosus, immune-mediated glomerulonephritis), viral
CC infections, Alzheimer's disease, parkinson's disease, amyotrophic lateral
CC sclerosis, retinitis pigmentosa, spinal muscular dystrophy, cerebellar
CC degeneration, anaemia, myelodysplastic syndrome, myocardial infarction,
CC and stroke. CARD-3 protein interacts with other cellular proteins, and so
CC can be used for regulation of cellular proliferation and differentiation
CC and cell survival. The CARD proteins may also be used to screen drugs
CC or compounds which modulate their activity. The CARD-4 gene can express a
CC long transcript that encodes CARD-4L, a short transcript that encodes
CC CARD-4S or two CARD-4 splice variants, CARD-4Y and CARD-4Z. This sequence
CC encodes the human CARD-3 protein described in the method of the
XX invention.
SQ Sequence 1931 BP; 613 A; 429 C; 416 G; 473 T; 0 other;

```

```

Query Match 88.8%; Score 1864; DB 20; Length 1931;
Best Local Similarity 99.7%; Pred. No. 0;
Matches 1867; Conservative 0; Mismatches 5; Indels 0; Gaps 0;
Oy 58 gtcagctctggttcgagaagcagcagcggctggtggccatccggggaatggcctcc 117
Db 12 gtcagctctggttcgagaagcagcagcggctggtggccatccggggaatggcctcc 71

```

QY 118 gtacactagttgctgggcaaaaaggctctccggcctcctcgtcgtgcaaggcgtatc 177  
 Db 72 gtacactagttgctgggcaaaaaggctctcggcctcctcgtcgtgcaaggcgtatc 131  
 QY 178 tgggcccctgagcgcggcgtgagcctctgggagcccgccgagcagcagcccccga 237  
 Db 132 tgggcccctgagcgcggcgtgagcctctgggagcccgccgagcagcagcccccga 191  
 QY 238 accgcccctgagcgcggcgtgagcctctgggagcccgccgagcagcagcccccga 297  
 Db 192 accgcccctgagcgcggcgtgagcctctgggagcccgccgagcagcagcccccga 251  
 QY 298 tccctaccacaactcgcgacctcgtctacctgagccgcccctcctgagcactgtgc 357  
 Db 252 tccctaccacaactcgcgacctcgtctacctgagccgcccctcctgagcactgtgc 311  
 QY 358 gtccgcccacagagactggcgcgtccaggtccaggtggcgcgtgagcactgcacatccacac 417  
 Db 312 gtccgcccacagagactggcgcgtccaggtggcgcgtgagcactgcacatccacac 371  
 QY 418 tccgctgctgcagcgtgaaagaagatgttttaagagagctgaaattttacacaaagc 477  
 Db 372 tccgctgctgcagcgtgaaagaagatgttttaagagagctgaaattttacacaaagc 431  
 QY 478 tagatttagttaactttcccaattttggaaatttgcgaatggcctgaaattttgggaat 537  
 Db 432 tagatttagttaactttcccaattttggaaatttgcgaatggcctgaaattttgggaat 491  
 QY 538 agttactgaatacatgccaaatggatcattaaatgaactcctacatagaaactgaata 597  
 Db 492 agttactgaatacatgccaaatggatcattaaatgaactcctacatagaaactgaata 551  
 QY 598 tccctgattgctggccattgagatttgcattcctgcattgaaatggccttgggtgtaa 657  
 Db 552 tccctgattgctggccattgagatttgcattcctgcattgaaatggccttgggtgtaa 611  
 QY 658 ttaactgcaaatatgactcctccttactcattcattcattcattcattcattcattcatt 717  
 Db 612 ttaactgcaaatatgactcctccttactcattcattcattcattcattcattcattcatt 671  
 QY 718 attggcaaatgaaattcattgaaattgcaatttggatttcaaaatggccttgggtgtaa 777  
 Db 672 attggcaaatgaaattcattgaaattgcaatttggatttcaaaatggccttgggtgtaa 731  
 QY 778 gtccctcctcacagctcgaagtagcaaaaactgcccagagaggggacaaattattatat 837  
 Db 732 gtccctcctcacagctcgaagtagcaaaaactgcccagagaggggacaaattattatat 791  
 QY 838 gccacctgaaactatgaaactgggacaaaactcgaagccagatcgaagcagatata 897  
 Db 792 gccacctgaaactatgaaactgggacaaaactcgaagccagatcgaagcagatata 851  
 QY 898 tagctagcagttatcacatgggaagttatccagaaaacagccttttgaagatgtcac 957  
 Db 852 tagctagcagttatcacatgggaagttatccagaaaacagccttttgaagatgtcac 911  
 QY 958 caatccttgcagataatgtagtgcacaaagagacacagccttatttaataagaaga 1017  
 Db 912 caatccttgcagataatgtagtgcacaaagagacacagccttatttaataagaaga 971  
 QY 1018 aggtttgcatatgatatacctcaccgagcagctatgctcctccttaataagaagggatg 1077  
 Db 972 aggtttgcatatgatatacctcaccgagcagctatgctcctccttaataagaagggatg 1031  
 QY 1078 ggcacaaaatccagatgaaagaccatttcttaaaatttttaataagaactgaaacagct 1137  
 Db 1032 ggcacaaaatccagatgaaagaccatttcttaaaatttttaataagaactgaaacagct 1091  
 QY 1138 ttggaacattgaaagataacttttctgaaagcttattcagctaaagaaacaaa 1197  
 Db 1092 ttggaacattgaaagataacttttctgaaagcttattcagctaaagaaacaaa 1151  
 QY 1198 gttacagagtttcaagtgccattcaccctatgtgcaagaagaataatggaattatctct 1257

Db 1152 gttacagagtttcaagtgccattcaccctatgtgcaagaagaataatggaattatctct 1211  
 QY 1258 gaacatcactgtaaaatcattggtcccaagaagaaatcattggtggtcctcctcagctccatga 1317  
 Db 1212 gaacatcactgtaaaatcattggtcccaagaagaaatcattggtggtcctcctcagctccatga 1271  
 QY 1318 aaatagtggttccctgaaacttcaagggtccctcagctccctcagagaaatgatitttt 1377  
 Db 1272 aaatagtggttccctgaaacttcaagggtccctcagctccctcagagaaatgatitttt 1331  
 QY 1378 atctagaagaactcgaagctgtttattttatgaagctcactcactcctcctcctcctcagcaag 1437  
 Db 1332 atctagaagaactcgaagctgtttattttatgaagctcactcactcctcctcctcctcagcaag 1391  
 QY 1438 ttgggtagcaccatttctggatctcctcaagggtcctcattctgtagcaagaagaccctcc 1497  
 Db 1392 ttgggtagcaccatttctggatctcctcaagggtcctcattctgtagcaagaagaccctcc 1451  
 QY 1498 atgctctcagcaataataaatacctcactcactcactcaggaactcagagctcctcagcc 1557  
 Db 1452 atgctctcagcaataataaatacctcactcactcactcaggaactcagagctcctcagcc 1511  
 QY 1558 tggtagccccagcagtgtagccagagcaaaagggaagacattgtgaaacaaatgcaga 1617  
 Db 1512 tggtagccccagcagtgtagccagagcaaaagggaagacattgtgaaacaaatgcaga 1571  
 QY 1618 agcctgcttaaacctcagctcagctcctcctcctcctcctcctcctcctcctcctcctcctcct 1677  
 Db 1572 agcctgcttaaacctcagctcagctcctcctcctcctcctcctcctcctcctcctcctcctcct 1631  
 QY 1678 ctatgaactgtagtaccagcctcagagcctcagagcctcagagcctcagagcctcagagcctcagagcct 1737  
 Db 1632 ctatgaactgtagtaccagcctcagagcctcagagcctcagagcctcagagcctcagagcctcagagcct 1691  
 QY 1738 tactgacatcccaaggaagaattgcccagaagttatagcaaaaaatgaaagataacaa 1797  
 Db 1692 tactgacatcccaaggaagaattgcccagaagttatagcaaaaaatgaaagataacaa 1751  
 QY 1798 acaaatggctcctcagcctcctcagcctcctcagcctcctcagcctcctcagcctcctcagcctcctcagcct 1857  
 Db 1752 acaaatggctcctcagcctcctcagcctcctcagcctcctcagcctcctcagcctcctcagcctcctcagcct 1811  
 QY 1858 ttacttcaaaaataaaagcagctgtagtactgttttcaagaagaataatggtttcctataa 1917  
 Db 1812 ttacttcaaaaataaaagcagctgtagtactgttttcaagaagaataatggtttcctataa 1871  
 QY 1918 aggatattata 1929  
 Db 1872 aggatattata 1883

RESULT 6  
 F21841  
 ID F21841 standard; DNA; 463 BP.  
 XX  
 AC F21841;  
 XX  
 DT 27-MAR-2001 (first entry)  
 XX  
 DE Human breast and ovarian cancer associated antigen gene SEQ ID 228.  
 XX  
 KW Human; breast cancer; ovarian cancer; cytostatic; immunosuppressive;  
 KW nootropic; neuroprotective; antiviral; anti-allergic; hepatotropic;  
 KW anti-diabetic; anti-inflammatory; anti-ulcer; vulnerary; anticonvulsant;  
 KW antibacterial; antifungal; antiparasitic; cardiant; immune disorder;  
 KW Addison's disease; allergy; autoimmune haemolytic anaemia;  
 KW auto-immune thyroiditis; diabetes mellitus; Crohn's disease;  
 KW multiple sclerosis; rheumatoid arthritis; ulcerative colitis;  
 KW cardiovascular disorder; wound healing; neurological disease; ds.  
 OS Homo sapiens.  
 XX



WO200055173-A1.  
 21-SEP-2000.  
 08-MAR-2000; 2000WO-US05881.  
 12-MAR-1999; 99US-0124270.  
 (HUMA-) HUMAN GENOME SCI INC.  
 Rosen CA, Ruben SM;  
 WPI; 2000-611515/58.  
 P-PSDB; B58938.  
 New human breast and ovarian cancer associated gene sequences and the polypeptides encoded by these genes, useful in the prevention, treatment and diagnosis of cancer, immune disorders, cardiovascular disorders and neurological diseases  
 Claim 1; Page 653; 1299pp; English.  
 Sequences F21614 - F22031 represent DNA sequences encoding human proteins B5711 - B59128. The DNA and protein sequences are associated with breast and ovarian cancer. Included in the invention are sequences F22032 - F22040 and B59129 which are used in the isolation and characterisation of the DNA and protein sequences of the invention. The breast and ovarian cancer associated DNA, protein, agonist or antagonist sequences exhibit cytostatic; immunosuppressive; neurotropic; neuroprotective; antiviral; anti-allergic; hepatotropic; antidiabetic; anti-inflammatory; antiulcer; vulnerary; anticonvulsant; antibacterial; antifungal; antiparasitic and cardiant activity. The polynucleotide and protein sequences are used in the diagnosis of cancer, particularly breast and ovarian cancer. The nucleic acid sequences, proteins, agonists and antagonists may also be used in the diagnosis, prevention and treatment of immune disorders e.g. Addison's disease, allergies, autoimmune haemolytic anaemia, autoimmune thyroiditis, diabetes mellitus, Crohn's disease, multiple sclerosis, rheumatoid arthritis and ulcerative colitis; cardiovascular disorders such as myocardial ischaemias; wound healing; neurological diseases such as cerebral anoxia and epilepsy; and infectious diseases.  
 Sequence 463 BP; 150 A; 92 C; 89 G; 131 T; 1 other;

Query Match 21.7%; Score 454.6; DB 21; Length 463;  
 Best Local Similarity 98.7%; Pred. No. 1.6e-80;  
 Matches 457; Conservative 1; Mismatches 5; Indels 0; Gaps 0;

546 aatacatgccaaaatggatcattaaatgaactcctcatagaggaaactgaatcctgatg 605  
 1 aatacatgccaaaatggatcattaaatgaactcctcatagaggaaactgaatcctgatg 60  
 606 ttgcttgccattgagattgcctcctgcagtaaatgccccttggtgtaaatcctgc 665  
 61 ttgcttgccattgagattgcctcctgcagtaaatgccccttggtgtaaatcctgc 120  
 666 acaatgactcctcttactcctcatgactgaactgaactcagaatctttattggaca 725  
 121 acaatgactcctcttactcctcatgactgaactgaactcagaatctttattggaca 180  
 726 atgaattcattgtaagattgcagattttggtttatcaaatgcccagatgctcctct 785  
 181 atgaattcattgtaagattgcagattttggtttatcaaatgcccagatgctcctct 240  
 786 cacagtcacgaagtgcaaaatctgcacagaaggagggaacaatttttatgcccactg 845  
 241 cacagtcacgaagtgcaaaatctgcacagaaggagggaacaatttttatgcccactg 300  
 846 aaaactgaacctggacaaaatcaaggccagatcaagcacgatatattagctatg 905  
 301 aaaactgaacctggacaaaatcaaggccagatcaagcacgatatattagctatg 360

QY 906 cagttatcacatgggaagtgtttatccagaaaaacagccttttgaagatgtccacaatcctt 965  
 PD |||||||  
 DB 361 cagttatcacatgggaagtgtttatccagaaaaacagccttttgaagatgtccacaatcctt 420  
 QY 966 tgcagataatgtagtgggtgtcacagggacatcgacctgttat 1008  
 DB 421 tgcagataatgtagtgggtgtcacagggacatcgacctgttat 1463

RESULT 7  
 V33547  
 ID V33547 standard; cDNA; 210 BP.  
 AC V33547;  
 XX V33547;  
 XX V33547;  
 DT 29-DEC-1998 (first entry)  
 DE Clone 156108 cDNA fragment encoding a human protein kinase homolog.  
 DE Protein kinase; cell signalling; inflammation; carcinoma; diabetes;  
 KW human X-linked agammaglobulinemia; nonspherocytic haemolytic anaemia;  
 KW artherosclerosis; glioma; restenosis; cholera-based septic shock;  
 KW U01064 Dictyostelium Y kinase; ss.  
 OS Homo sapiens.  
 OS US5817479-A.  
 PN US5817479-A.  
 XX US5817479-A.  
 PD 06-OCT-1998.  
 XX 06-OCT-1998.  
 PD 07-AUG-1996; 96US-0700575.  
 XX 07-AUG-1996; 96US-0700575.  
 PR 07-AUG-1996; 96US-0700575.  
 XX 07-AUG-1996; 96US-0700575.  
 PA (INCY-) INCYTE PHARM INC.  
 XX Au-Young J, Bandman O, Hawkins PR, Wilde CG;  
 PI WPI; 1998-556387/47.  
 DR Human kinase polynucleotide(s) and recombinant products - useful  
 XX for identification of modulators of the enzyme, and treatment of  
 PT diseases associated with abnormal kinase expression  
 PS Claim 1; Columns 45-48; 30pp; English.  
 CC The invention provides polynucleotides which encode novel protein  
 CC kinase homologs expressed in various human cells and tissues. The  
 CC present sequence represents the clone 156108 cDNA fragment derived from  
 CC a human cDNA library designated THP-1 phorbol LPS. The cDNA encodes  
 CC a protein kinase which shows homology to the U01064 Dictyostelium Y  
 CC kinase. Vectors and host cells can be used for recombinant production  
 CC of the protein kinase homolog. The recombinant proteins may be used to  
 CC raise antibodies for use as anti-kinase therapeutics. Oligonucleotides  
 CC based on the polynucleotide sequences, i.e. probes and antisense  
 CC constructs, the peptides and antibodies are claimed to be useful as  
 CC tools for studying signalling cascades in cells and proteins, and for  
 CC identifying inhibitors (drugs) to treat diseases and inflammatory  
 CC conditions associated with abnormal kinase expression. Diseases that  
 CC are claimed to be treatable include human X-linked agammaglobulinemia,  
 CC nonspherocytic haemolytic anaemia, artherosclerosis, carcinomas,  
 CC diabetes, gliomas, restenosis, cholera-based septic shock, etc.  
 XX Sequence 210 BP; 74 A; 40 C; 41 G; 55 T; 0 other;

Query Match 10.0%; Score 210; DB 19; Length 210;  
 Best Local Similarity 100.0%; Pred. No. 1.3e-32;  
 Matches 210; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 844 tgaaaactgaaactggacaaaatcaaggccagatcaagcacgatatattagctatg 903  
 DB 1 tgaaaactgaaactggacaaaatcaaggccagatcaagcacgatatattagctatg 60



```

PD 23-NOV-2000.
PF 15-MAY-2000; 2000WO-NZ00075.
PR 14-MAY-1999; 99US-0312283.
PA (GENE-) GENESIS RES & DEV CORP LTD.
PI Watson JD, Strachan L, Orrust R, Sleeman M, Kumble KD, Murison JG;
DR WPI; 2001-007495/01.
DR P-PSDB; B56062.
PT New isolated polynucleotide used in the identification of genetic
PT disorders and encoding polypeptides used for treating inflammatory
PT disease, cancer and neurological diseases .
XX
XX Claim 1; Page 305-306; 352pp; English.
XX
XX The present polynucleotide encodes a polypeptide which is expressed in
XX mammalian skin cells. The polypeptide is useful for stimulating
XX keratinocyte growth and motility, inhibiting the growth of cancer cells,
XX modulating angiogenesis, inhibiting angiogenesis and vascularisation of
XX tumours, modulating skin inflammation, stimulating the growth of
XX epithelial cells, inhibiting the binding of human immunodeficiency virus
XX (HIV)-1 to leukocytes, and treating inflammatory disease, cancer and
XX neurological diseases. The polynucleotide can be used as a marker, in
XX the identification of genetic disorders, and for the design of
XX oligonucleotides for examining expression patterns.
XX
XX Sequence 1774 BP; 406 A; 490 C; 526 G; 352 T; 0 other;
XX
Query Match 4.9%; Score 102.4; DB 22; Length 1774;
Best Local Similarity 51.8%; Pred. NO. 2.7e-11;
Matches 372; Conservative 0; Mismatches 316; Indels 30; Gaps 5;
QY 287 ctgcccaccattccctaccacaacacccgacctgcctgctgacctgagccgcccctct 346
DB 1111111111111111111111111111111111111111111111111111111
QY 45 ctgcgacccttcgcgagccgcgaatccgcagctgggagaagtgctcgccgcggcttc 104
DB 1111111111111111111111111111111111111111111111111111111
QY 347 ggcactgtgctccgcgcgcgacgacgctgctccacgctccagctgctggagcactg 406
DB 1111111111111111111111111111111111111111111111111111111
QY 407 cacatccacacctcgctgctgcacagtgaagaaagagatgctttaaagagaactgaatt 466
DB 1111111111111111111111111111111111111111111111111111111
QY 165 cccagtc---tgcagctgacgacgggaacgaaatgtagctcctggaggaaagctaaaga 221
DB 1111111111111111111111111111111111111111111111111111111
QY 467 ttacacaaagctagattagttaccatttccaattttgggaattttgcaatgagcctgaa 526
DB 1111111111111111111111111111111111111111111111111111111
QY 222 atggagatggccaaagtccgatccatctacctgtgtaaggatgtaaggaaactgtg-- 279
DB 1111111111111111111111111111111111111111111111111111111
QY 527 tttttgggaatgtaactgaatatacaccacaaatggaatgacattaaatgaactctacatagg 586
DB 1111111111111111111111111111111111111111111111111111111
QY 280 ----tcggcttggctgatgtagacacgagacagagcagctccctggagaagctgacctca 335
DB 1111111111111111111111111111111111111111111111111111111
QY 587 aaactgaatcctgatgctgtgcttgccatgagatttcgcatctcgcatgataaattgccc 646
DB 1111111111111111111111111111111111111111111111111111111
QY 336 gagccat-----tgccttgggacctgctgcttctgcatctgctgacgagacagcc 383
DB 1111111111111111111111111111111111111111111111111111111
QY 647 ctgttgtaaatctgcacaataatgatctcctctctcttacttcatcagcttgaagact 706
DB 1111111111111111111111111111111111111111111111111111111
QY 384 gtggcagtaactcctgattgctgctgctccgccacgctgctcactgacctgagccga 443
DB 1111111111111111111111111111111111111111111111111111111
QY 707 cagaatatcttattggacaatgatttcagttaagattgacagatgtttggtttaccaag 766
DB 1111111111111111111111111111111111111111111111111111111
QY 444 gcgaacatcctgctggtatgcccactacacatgatcagagattttcactttggtgtgccaa 503
DB 1111111111111111111111111111111111111111111111111111111
QY 767 tggcgctgatgctcctctcaccagctcagcaagtagcaaatctgcaccagaagagggaca 826
DB 1111111111111111111111111111111111111111111111111111111
QY 504 tgcfaatgctgtcccactctcctcagctcagctcagctggtggtcctgttt-----ggtaca 557
DB 1111111111111111111111111111111111111111111111111111111

```

```

QY 827 attatttatgccaccctgaaacactatgaacctgacacaaatcaaggccagtatcaag 886
DB 1111111111111111111111111111111111111111111111111111111
QY 558 atcgcttaccctccagagcaatt---cgtgagaagagcccttgtttgacaccaaa 614
DB 1111111111111111111111111111111111111111111111111111111
QY 887 cactatatactagctatgacagttacacatggagtgatccagaaaaaacagcctttt 946
DB 1111111111111111111111111111111111111111111111111111111
QY 615 catgatatatacagcttgccttgctgctgctgctgctgctgctgctgctgctgctgct 674
DB 1111111111111111111111111111111111111111111111111111111
QY 947 gaagatgctcaccacacccttgcagataatgtatgctgctacagaagacatgacactg 1004
DB 1111111111111111111111111111111111111111111111111111111
QY 675 gcagatgaaagaacacactacacatcatgatgaaagtgtgtaaggccaccgcccag 732
DB 1111111111111111111111111111111111111111111111111111111

```

```

RESULT 10
ID Z61161 standard; DNA; 2370 BP.
AC Z61161;
XX
XX 30-MAY-2000 (first entry)
XX
XX DNA encoding a death associated kinase with ankyrin repeats.
XX
XX Death associated kinase protein containing ankyrin repeats; DAKAR;
XX kinase; quality assurance agent; shelf life; marker; ss.
XX
XX Mus sp.
XX
XX Location/Qualifiers
XX Key 10..2370
XX CDS /*tag= a
XX /transl_except= (pos:10..12, aa: Met)
XX
XX WO200008177-A2.
XX
XX 17-FEB-2000.
XX
XX 04-AUG-1999; 99WO-US17576.
XX
XX 04-AUG-1998; 98US-0095269.
XX
XX 11-SEP-1998; 98US-0099973.
XX
XX 09-FEB-1999; 99US-0119353.
XX
XX (IMMV ) IMMUNEX CORP.
XX
XX Bird TA, Virca GD;
XX
XX WPI; 2000-195582/17.
XX
XX P-PSDB; Y69163.
XX
XX Novel death associated kinase containing ankyrin repeats (DAKAR) used
XX as molecular weight marker and as controls for peptide fragmentation .
XX
XX Claim 1; Page 9-10; 71pp; English.
XX
XX The present sequence encodes a murine death associated kinase protein,
XX containing ankyrin repeats, designated DAKAR. The DAKAR polynucleotides
XX can be used to express the polypeptides, and as probes to identify
XX nucleic acids encoding proteins having kinase activity. DAKAR
XX polypeptides and fragmented polypeptides are used for purifying
XX proteins, e.g. to measure protein activity; as quality assurance agents
XX to monitor shelf life and stability of binding partner proteins; as
XX research agents, e.g. in assays to determine protein kinase activity,
XX to identify novel molecules involved in signal transduction pathways,
XX and to identify therapeutic compounds which may interfere with
XX apoptosis; as molecular weight and isoelectric focusing markers; as
XX controls for peptide fragmentation; identification of unknown proteins,
XX e.g. by comparison with proteins in databases; and for preparation of
XX antibodies. The antibodies can be used in assays to detect the presence
XX of the protein, and to purify the protein by immunoaffinity
XX chromatography. The antibodies can also be used to block binding of
XX the DAKAR polypeptides to their binding partners. Compounds that inhibit
XX or enhance the kinase activity of DAKAR can be used to treat diseases
XX

```



QY 647 cttggttaattactgcacaaatgactccctttacttcatcatgacttgaagact 706  
 II III III III III III III III III III III III III III III III III III  
 Db 382 gtgggatgaacttctgcatgctgcctccgactgctgcacactagacacactgaagcca 441  
 QY 707 cagaatactttatggacaagtgaatttcaatgttaagattgcaagatttggttatacaag 766  
 III III III III III III III III III III III III III III III III III III  
 Db 442 ggcgaactcctgtagcggccaccaccatgcaagatttctgactttggtggctggccaag 501  
 QY 767 tggcgcgatgtccctctccagtcacagaaagtagcaaatctgcaccagaagaggagaca 826  
 III III III III III III III III III III III III III III III III III III  
 Db 502 tgcgaatgcatgtcccactctcatgacctcagcagcatggatggctgttt-----ggtaca 555  
 QY 827 atatttatgccactgaaacatcatgaacctggagcaaaaaatcaaggccagtagtacaag 886  
 II III III III III III III III III III III III III III III III III III  
 Db 556 atcgcttacctcctccagagsgaatt---cgtgagaagagcgcctgtttgacaccaca 612  
 QY 887 cacgatatatagctatgacagttatcacatgggaagtgtttaccagaaaacagcctttt 946  
 III III III III III III III III III III III III III III III III III III  
 Db 613 catgatgtacagctctgcccattgtagctgggtgcttacacagaaagagcattt 672  
 QY 947 gaagatgcacaactcctttgagataatgtagtgcacaaagacatgacctg 1004  
 III III III III III III III III III III III III III III III III III III  
 Db 673 gcagatgaaaagaacatcctacacatcatgatgaaagtgtaaaaggccaccgcccaag 730

RESULT 12  
 C99717  
 ID C99717 standard; cDNA; 3516 BP.  
 AC C99717;  
 XX  
 DT 08-MAR-2001 (first entry)  
 XX  
 DE Skin cell cDNA, SEQ ID NO: 257.  
 XX  
 KW Mouse; skin cell; cytostatic; antiinflammatory; anti-HIV;  
 KW neotropic; neuroprotective; vulnery; immunomodulatory; vaccine;  
 KW keratinocyte growth stimulation; cancer; angiogenesis inhibition;  
 KW inflammation; neurological disease; ss.  
 XX  
 OS Mus sp.  
 XX  
 PN WO200069884-A2.  
 XX  
 PD 23-NOV-2000.  
 XX  
 PF 15-MAY-2000; 2000WO-NZ00075.  
 XX  
 PR 14-MAY-1999; 99US-0312283.  
 XX  
 PA (GENE-) GENESIS RES & DEV CORP LTD.  
 XX  
 PI Watson JD, Strachan L, Onrust R, Sleeman M, Kumble KD, Murison JG;  
 XX  
 DR WPI: 2001-007495/01.  
 XX  
 DR P-PSDB; B59958.  
 XX

New isolated polynucleotide used in the identification of genetic disorders and encoding polypeptides used for treating inflammatory disease, cancer and neurological diseases -  
 Claim 1; Page 216-218; 352pp; English.  
 The present polynucleotide encodes a polypeptide which is expressed in mammalian skin cells. The polypeptide is useful for stimulating keratinocyte growth and motility, inhibiting the growth of cancer cells, modulating angiogenesis, inhibiting angiogenesis and vascularisation of tumours, modulating skin inflammation, stimulating the growth of epithelial cells, inhibiting the binding of human immunodeficiency virus (HIV)-1 to leukocytes, and treating inflammatory disease, cancer and neurological diseases. The polynucleotide can be used as a marker, in the identification of genetic disorders, and for the design of

CC oligonucleotides for examining expression patterns.  
 XX  
 SQ Sequence 3516 BP; 810 A; 886 C; 988 G; 832 T; 0 Other;  
 Query Match 4.9%; Score 102.4; DB 22; Length 3516;  
 Best Local Similarity 51.8%; Pred. No. 3.2e-11;  
 Matches 372; Conservative 0; Mismatches 316; Indels 30; Gaps 5;  
 QY 287 ctgccaccattccctaccacaaactcgcgcactgctgaacctgaagcgcgcccctct 346  
 III III III III III III III III III III III III III III III III III III  
 Db 43 ctgvcacacttcgaccgcccgaattcgcagctggagaaagtgctcggggcgcttc 102  
 QY 347 ggcactgtctgcccgcaccagcagactggcgcgcaggtccagggtgcccgtgaaagccctg 406  
 III III III III III III III III III III III III III III III III III III  
 Db 103 gggcaggtgtacaaggtgcgcaatgctgcactggaagcagctggctcgcgataagctcg 162  
 QY 407 cacatccacactcgcgctgcagctgaaagaaagagtggttttaagagaagctgaaatt 466  
 III III III III III III III III III III III III III III III III III III  
 Db 163 cccagtc---tgcactgcacacagaggaacgaatggactcctcctggaggaagtaagaag 219  
 QY 467 ttacacaagactagatttagttacattttccaattttgggaatttggcaatggcctgaa 526  
 III III III III III III III III III III III III III III III III III III  
 Db 220 atggagatggccaaagttccgatacattcactgtgtacggcatttcgaggaactctg-- 277  
 QY 527 ttttgggaatagttactgaataacatgccaaatgggacatcattaaatgaactcctacatag 586  
 III III III III III III III III III III III III III III III III III III  
 Db 278 ---tcggcttgctcatggatagacagggcagagcctcctcctggaggaagctgctggcctca 333  
 QY 587 aaaaactgaatactgctgattgcttggccactggagatttcgcactcctgcataaattgccc 646  
 III III III III III III III III III III III III III III III III III III  
 Db 334 gagcaat-----tgccttgggacctgcgctttcgcacatgctgcacgagacgccc 381  
 QY 647 cttggtgtaaaattaccctgcacaaatgactcctcctttacttcactcatgacttgaagact 706  
 III III III III III III III III III III III III III III III III III III  
 Db 382 gtgggatgaactcctcctgcatgctgcctcgcctcctgcactgctgcactagaactgaagcca 441  
 QY 707 cagaatactttatggacaagtgaatttcaatgttaagattgcaagatttggttatacaag 766  
 III III III III III III III III III III III III III III III III III III  
 Db 442 ggcgaactcctgtagcggccaccaccatgtagctgggtgcttacacagaaagagcattt 501  
 QY 767 tggcgcgatgtccctctccagtcacagaaagtagcaaatctgcaccagaagaggagaca 826  
 III III III III III III III III III III III III III III III III III III  
 Db 502 tgcgaatgcatgtcccactctcatgacctcagcagcatggatggctgttt-----ggtaca 555  
 QY 827 attatttatgccactgaaacatcatgaacctggagcaaaaaatcaaggccagtagtacaag 886  
 III III III III III III III III III III III III III III III III III III  
 Db 556 atcgcttacctcctccagagsgaatt---cgtgagaagagcgcctgtttgacaccaca 612  
 QY 887 cagcagataatagctatgacagttatcacatgggaagtgtttaccagaaaacagcctttt 946  
 III III III III III III III III III III III III III III III III III III  
 Db 613 catgatgtacagctctgcccattgtagctgggtgcttacacagaaagagcattt 672  
 QY 947 gaagatgcacaactcctttgagataatgtagtgcacaaagacatgacctg 1004  
 III III III III III III III III III III III III III III III III III III  
 Db 673 gcagatgaaaagaacatcctacacatcatgatgaaagtgtaaaaggccaccgcccaag 730

RESULT 13  
 T19776  
 ID T19776 standard; cDNA to mRNA; 108 BP.  
 XX  
 AC T19776;  
 XX  
 DT 12-JUL-1996 (first entry)  
 XX  
 DX Human gene signature HUMGS00852.  
 DE  
 DE Gene signature; messenger RNA; mRNA; relative abundance; frequency;  
 KW human; cloning; mapping; non-biased library; diagnosis; detection;  
 KW cell typing; abnormal cell function; ss.  
 XX  
 OS Homo sapiens.

```

XX  WO9514772-A1.
PN  01-JUN-1995.
XX  11-NOV-1994; 94WO-JP01916.
XX  12-NOV-1993; 93JP-0355504.
XX  (MATS/) MATSUBARA K.
XX  (OKUB/) OKUBO K.
PA  Matsubara K, Okubo K;
PI  WPI; 1995-206931/27.
XX  Identifying gene signatures in 3'-directed human cDNA library - e.g.
PT  for diagnosis of abnormal cell function, by preparing cDNA that
PT  reflects relative abundance of corresp. mRNA in specific human
PT  tissues
XX  Claim 1; Page 469; 2245pp; Japanese.
XX  A single-stranded DNA (or its complementary strand or the corresp.
XX  double-stranded DNA) which comprises one of the 7837 "GS" sequences
XX  given in T19001-T26837 and which is able to hybridise to part of
XX  human genomic DNA, cDNA or mRNA is claimed. The GS (Gene Signature)
XX  sequences were obtained from 3'-directed cDNA libraries prepared
XX  from various human tissues; synthesis of cDNA was initiated from the
XX  3'-end of mRNA by using poly(T) as the sole primer. Since the 3'-
XX  untranslated sequence is unique to a particular mRNA species, almost
XX  all the 3'-oriented cDNAs hybridise with specific mRNAs. Each library
XX  is constructed so as to reflect accurately the relative abundance of
XX  different mRNAs in the particular tissue from which it was derived.
XX  The appearance frequency of a given GS in a cDNA library can be
XX  determined (esp. using primers and probes derived from the GS
XX  sequences) as a means of diagnosing abnormal cell function or for
XX  recognising different cell types.
XX  Sequence 108 BP; 36 A; 14 C; 13 G; 39 T; 6 other;
SQ

Query Match 4.9%; Score 102; DB 16; Length 108;
Best Local Similarity 97.1%; Pred. No. 1.7e-11;
Matches 102; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1842 gatcacatcttaaaattacttcaaaaataaaagcatgtaagtgaactgttttcaagaag 1901
Db 1 gatcacatcttaaaattacttcaaaaataaaagcatgtaagtgaactgttttcaagaag 60

QY 1902 aaatgttttcaaaaaggatatttatctctgttctgttact 1946
Db 61 aaatgttttcaaaaaggatatttatctctctnngcttact 105

RESULT 14
Z58584
ID Z58584 standard; cDNA; 2294 BP.
XX Z59584;
AC Z59584;
XX 05-JUN-2000 (first entry)
DT Mouse protein kinase Fel cDNA.
XX Fel; protein kinase; mouse; signal transduction; ss.
XX Mus musculus.
XX Location/Qualifiers
FH 3..2294
FT CDS /*tag= a
XX

```

```

PN WO200008178-A2.
XX 17-FEB-2000.
XX 04-AUG-1999; 99WO-US17577.
XX 04-AUG-1998; 98US-0095269.
XX 11-SEP-1998; 98US-0099973.
XX (IMMV) IMMUNEX CORP.
XX Virca GD, Bird TA, Anderson DM, Marken JS;
XX WPI; 2000-205722/18.
XX P-PSDB; Y79154.
XX Novel murine polynucleotides encoding kinase polypeptides, used as
PT probes to identify nucleic acids encoding proteins having kinase
PT activity -
XX Claim 1; Fig 3; 93pp; English.
XX The present sequence is that of Genesis clone 971025TRAM004820HT
XX (Fel) DNA. The translation of the clone (frame 3) is provided in
XX Y79154. The polypeptide has kinase activity. The invention
XX relates to purified murine polypeptides (see Y79152-56) that
XX have kinase function and isolated nucleic acids encoding them (see
XX Z58582-86). The nucleic acids can be used to express the
XX polypeptides, as probes to identify nucleic acids encoding proteins
XX having kinase activity, and in assays to identify chromosomes, map
XX murine genes, and study tumours. Vectors comprising the novel
XX nucleic acids and host cells (bacterial, yeast, plant, insect or
XX animal) transfected or transduced with the vectors are claimed.
XX The kinase polypeptides and their fragments are used as mol.wt. and
XX isoelectric focusing markers, and as controls for peptide
XX fragmentation. They also have a number of therapeutic uses, as
XX kinases play a central role in cellular signal transduction.
XX Sequence 2294 BP; 526 A; 639 C; 666 G; 463 T; 0 other;
SQ

Query Match 4.4%; Score 93; DB 21; Length 2294;
Best Local Similarity 51.9%; Pred. No. 2e-09;
Matches 350; Conservative 0; Mismatches 295; Indels 30; Gaps 5;

QY 330 tgagccgcggcctctggcactgtgtctccgccgcagactggcgctccag 389
Db 16 tgggctcggggcgttcgggcagggtgtacaagggtgcgcaatgtgcactggaaagcgtggc 75

QY 390 tggccgtgaagaccctgcacatcccaactccgcgtgtctgcacagtgaaagaaagatgtt 449
Db 76 tcgcatcaagtgctgcgccagtc---tgcacgtcacgacagcaggaaatggagctcc 132

QY 450 taagagaagctgaaattttacacaaagatgattttacattttcccaattttggaa 509
Db 133 tggaggaagctaaagaagatggagatggcgaagtccgatattctaccctgtgtaagcca 192

QY 510 ttgcgatgagcctgaaatttttgggaatagttactgaatcacatgcacaaatggatctaa 569
Db 193 tatgcccaagaaacctg-----tcggcttggttcatcggagtagatggagacaggtcccttg 246

QY 570 atgaactcctacataggaataatcctctgatgttctgttggccattgagatttcgca 629
Db 247 agaagctgtgacctcaagacc-----attgccttgggacctgccttctcgca 294

QY 630 tcctgcatgaaattgccccttgggtgaaattaccctgcacaatagctccctcccttacttc 689
Db 295 tcgtgcacagacagccgttgggcagactccctgcattgcattgtctcccaccactgctgc 354

QY 690 atcatgacttgaagactcagaataatcttatggacaataatcttcaatgattgattgag 749
Db 355 acctagacctgaagccagcgaacatcctctgtgtgagctccaccatcctgcaagattctg 414

```

QY 750 attttgtttatacaaaagtgccatgatgtccctctcacagtcacgaagtagcaaaatctg 809  
 | |||| | | | | | | | | | | | | | | | | | | | | | | | | | | | |  
 Db 415 accttgggtgcccagtgcaatggcagtgctccactctcatgacctcagcatggatggccc 474  
 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |  
 QY 810 caccagaaggaggcaattatttattatattatccacctgaaaactatgaacctggacaaaaat 869  
 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |  
 Db 475 tgttt-----ggtacaatcgttaccctccctccacagcgaatt---cgtgagaagagcc 525  
 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |  
 QY 870 caagggccagatcaagcagatataatagctatgctatgcttccacttccactcagctcagcatgtgttt 929  
 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |  
 Db 526 gcttgtttgacaccaaacaatgatatacagcttccctccactgctgctgggtgtgctta 585  
 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |  
 QY 930 ccagaaaacagcctttgaaagtgcaccaaaccctttgacagataatgtagtggtc 989  
 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |  
 Db 586 cacagaagaagccatttgcagtgaaaagaacatcctcacaacatcatgatgaaagtgttaa 645  
 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |  
 QY 990 aaggacatcgacctg 1004  
 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |  
 Db 646 agggccaccgcccag 660  
 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |

RESULT 15

Q98816

ID Q98816 standard; cDNA; 3033 BP.

XX Q98816;

AC Q98816;

DT DT (first entry)

XX 19-JAN-1996

DE Arabidopsis CTR1 cDNA.

XX

KW CTR1; constitutive triple response; transgenic plant; ethylene;

XX stress tolerance; crop improvement; ss.

KW Arabidopsis thaliana ecotype Columbia.

OS

FH Key

FT Location/Qualifiers

FT 118..2583

FT /\*tag= a

PN US5444166-A.

XX

PD 22-AUG-1995.

XX

PF 10-AUG-1992; 92US-0928464.

XX

PR 12-JAN-1993; 93US-0003311.

PR 10-AUG-1992; 92US-0928464.

XX

PA (UYPE-) UNIV PENNSYLVANIA.

XX

PI Ecker JR, Kieber JJ;

XX

DR WPI: 1995-302162/39.

DR P-PSDB; R80574.

XX

PT New constitutive triple response genes and mutants - isolated from

PT Arabidopsis thaliana, used to produce transgenic plants with

PT improved properties

XX

PS Claim 1; Column 21-28; 41pp; English.

XX

CC The CTR1 gene was mapped to an interval between 2 RFLPs in

CC chromosome 5 of A. thaliana and a chromosome walk in this area was

CC initiated using a YAC library. 2 Clones were isolated and used to

CC probe a cDNA library derived from polyA RNA from 3-day-old dark-

CC grown, ethylene-treated A. thaliana seedlings. The cDNA for the

CC CTR1 gene is given in Q98816. Expression of the CTR1 gene in

CC transgenic plants results in a dominant ethylene-insensitive

CC phenotype.

XX

SQ Sequence 3033 BP; 797 A; 605 C; 751 G; 860 T; 0 other;

Query Match 3.9%; Score 81.4; DB 16; Length 3033;  
 Best Local Similarity 50.1%; Pred No. 4.1e-07;  
 Matches 202; Conservative 0; Mismatches 201; Indels 0; Gaps 0;

QY 360 ccgcccgcacgcagacgtggcgctcccaggtggccggtgaagcaacctgcacatccacactc 419  
 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |  
 Db 1808 ctgtccaccgctgctgagtgccatggctcgatgtgtctgtgaaaattctcatggagcaag 1867  
 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |  
 QY 420 cgtcgtgcacagtgaagaagaagaaggatgttttaagagaagcgtgaaaattttacacaaagcta 479  
 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |  
 Db 1868 acttccatgctgagcgtgttaataagttttaaagagaggttgcgataatgaaacgcttc 1927  
 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |  
 QY 480 gattttagttacatgttttcccatttgggaatttggcaattggcaatgagcctgaaatttttggggaatag 539  
 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |  
 Db 1928 gccaccctaacaattgttcttcttcattgggtcggtcactcaacctccaaaattttgccaatag 1987  
 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |  
 QY 540 ttactgaatcacatgccaaaatggtatcattaaaatgaaacctcacaataaggaaaactgaaatc 599  
 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |  
 Db 1988 tgacagaattttgtccaagggttagttttatcacagacttttgcataaaaggaggcaaggg 2047  
 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |  
 QY 600 ctgatgttctggcaccatgagatcttgcactcctgcactgaaattcccttggtgtaaat 659  
 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |  
 Db 2048 agcaattgatgagagacgctgcctctgctgagtagtggcttatgctgagtggttaagggaatgaaat 2107  
 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |  
 QY 660 acctgcacaatatgactcctcttcttctcttctcttctcttctctctcagactcagaatattcttat 719  
 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |  
 Db 2108 atcttccaatgcaatcctcccaattgcatagagatcaaaaatctccaacttattgg 2167  
 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |  
 QY 720 tggacaatgaattcatgtaagaattgcaagattttgtttatc 762  
 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |  
 Db 2168 ttgacaaaaataacagtcaaggttttgatgtttttggtctctc 2210  
 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |

Search completed: June 13, 2001, 17:37:08  
 Job time: 5922 sec

**THIS PAGE BLANK (USPTO)**

---



GenCore version 4.5  
Copyright (c) 1993 - 2000 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: June 13, 2001, 15:03:41 ; Search time 3516.74 Seconds  
(without alignments)  
8798.208 Million cell updates/sec

Title: US-09-445-223-2  
Perfect score: 2098  
Sequence: 1 ggccattatggtgatggtgg.....aaaaaaaaaaaaaaaaaaaaa 2098

Scoring table: IDENTITY NUC  
Gapop 10.0 , Gapext 1.0  
Searched: 1283235 seqs, 7373929652 residues  
Total number of hits satisfying chosen parameters: 2566470

Minimum DB seq length: 0  
Maximum DB seq length: 2000000000  
Post-processing: Minimum Match 0%  
Maximum Match 100%  
Listing first 45 summaries

Database : GenEmbl:\*\*

- 1: gb\_ba1:\*\*
- 2: gb\_ba2:\*\*
- 3: gb\_ba3:\*\*
- 4: gb\_in1:\*\*
- 5: gb\_in2:\*\*
- 6: gb\_in3:\*\*
- 7: gb\_om:\*\*
- 8: gb\_ov:\*\*
- 9: gb\_pat1:\*\*
- 10: gb\_pat2:\*\*
- 11: gb\_ph:\*\*
- 12: gb\_pl1:\*\*
- 13: gb\_pl2:\*\*
- 14: gb\_pl3:\*\*
- 15: gb\_pl4:\*\*
- 16: em\_ba1:\*\*
- 17: em\_ba2:\*\*
- 18: em\_fun:\*\*
- 19: em\_htgo\_hum:\*\*
- 20: em\_htgo\_inv:\*\*
- 21: em\_htgo\_rod:\*\*
- 22: em\_htg\_hum1:\*\*
- 23: em\_htg\_hum2:\*\*
- 24: em\_htg\_hum3:\*\*
- 25: em\_htg\_hum4:\*\*
- 26: em\_htg\_hum5:\*\*
- 27: em\_htg\_hum6:\*\*
- 28: em\_htg\_hum7:\*\*
- 29: em\_htg\_hum8:\*\*
- 30: em\_htg\_inv1:\*\*
- 31: em\_htg\_inv2:\*\*
- 32: em\_htg\_Other:\*\*
- 33: em\_htg\_rod:\*\*
- 34: em\_hum1:\*\*
- 35: em\_hum2:\*\*
- 36: em\_hum3:\*\*
- 37: em\_hum4:\*\*
- 38: em\_hum5:\*\*
- 39: em\_hum6:\*\*
- 40: em\_hum7:\*\*
- 41: em\_in:\*\*
- 42: em\_om:\*\*
- 43: em\_or:\*\*

- 44: em\_ov:\*\*
- 45: em\_pat:\*\*
- 46: em\_ph:\*\*
- 47: em\_pl:\*\*
- 48: em\_ro:\*\*
- 49: em\_sts:\*\*
- 50: em\_sy:\*\*
- 51: em\_un:\*\*
- 52: em\_vi:\*\*
- 53: gb\_sts1:\*\*
- 54: gb\_sts2:\*\*
- 55: gb\_sts3:\*\*
- 56: gb\_sy:\*\*
- 57: gb\_un:\*\*
- 58: gb\_vil1:\*\*
- 59: gb\_vil2:\*\*
- 60: gb\_htg1:\*\*
- 61: gb\_htg2:\*\*
- 62: gb\_htg3:\*\*
- 63: gb\_htg4:\*\*
- 64: gb\_htg5:\*\*
- 65: gb\_htg6:\*\*
- 66: gb\_htg7:\*\*
- 67: gb\_htg8:\*\*
- 68: gb\_htg9:\*\*
- 69: gb\_htg10:\*\*
- 70: gb\_htg11:\*\*
- 71: gb\_htg12:\*\*
- 72: gb\_htg13:\*\*
- 73: gb\_htg14:\*\*
- 74: gb\_htg15:\*\*
- 75: gb\_htg16:\*\*
- 76: gb\_htg17:\*\*
- 77: gb\_htg18:\*\*
- 78: gb\_htg19:\*\*
- 79: gb\_htg20:\*\*
- 80: gb\_htg21:\*\*
- 81: gb\_htg22:\*\*
- 82: gb\_htg23:\*\*
- 83: gb\_htg24:\*\*
- 84: gb\_htg25:\*\*
- 85: gb\_pr1:\*\*
- 86: gb\_pr2:\*\*
- 87: gb\_pr3:\*\*
- 88: gb\_pr4:\*\*
- 89: gb\_pr5:\*\*
- 90: gb\_pr6:\*\*
- 91: gb\_pr7:\*\*
- 92: gb\_pr8:\*\*
- 93: gb\_pr9:\*\*
- 94: gb\_ro1:\*\*
- 95: gb\_ro2:\*\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Match	Query Length	DB ID	Description
1	2094.4	99.8	2098	9	AB2777 Sequence 2
2	2017.8	96.2	2501	88	AF027706 Homo sapi
3	1815.2	86.5	1902	88	AF064824 Homo sapi
4	1616.6	77.1	1623	88	AF078530 Homo sapi
5	516.6	24.6	116650	85	AC004003 Homo sapi
6	516.6	24.6	320250	88	AF117829 Homo sapi
7	210	10.0	210	9	AR044139 Sequence
8	102.4	4.9	3559	94	AF302127 Mus muscu
9	97.6	4.7	3879	92	AJ278016 Homo sapi
10	81.4	3.9	3033	10	I14046 Sequence 1
11	81.4	3.9	3033	10	I35764 Sequence 1

```

12 81.4 3.9 3033 13 ATHCRLA
13 78.2 3.7 2767 12 AF110519
14 78.2 3.7 2829 12 AF096250
15 78.2 3.7 2836 12 AF110518
16 78.2 3.7 2917 14 LETYARKINA
17 68.2 3.3 310779 60 AC005140
18 68.2 3.3 321003 84 PFMAL4P3
19 66.6 3.2 256172 60 AC005139
20 66.2 3.2 527 13 AF230506
21 65.8 3.1 759 53 CNS060XV
22 65.6 3.1 192929 60 AC005505
23 65.2 3.1 80442 15 T24D18
24 64.6 3.1 80402 12 AB025636
25 64.6 3.1 113567 12 AF058826
26 64.4 3.1 88037 84 PFMAL13P8
27 64 3.1 131473 12 AC005171
28 63.6 3.0 163443 60 AC006280
29 63.2 3.0 1833 94 AF178953
30 62.6 3.0 156060 60 AC004153
31 62.4 3.0 321003 84 PFMAL4P3
32 61.8 2.9 1554 9 AR084102
33 61.8 2.9 6372 6 DDICNEP
34 61.4 2.9 5762 6 PFARSP86A
35 61.4 2.9 47573 5 AF030694
36 61.2 2.9 214094 78 AC087188
37 61 2.9 895 53 CNS06FSV
38 60.2 2.9 1439 5 AF038050
39 60.2 2.9 2358 7 AF254119
40 60 2.9 2508 9 AX056437
41 60 2.9 3001 88 AF116826
42 60 2.9 90149 12 AC010793
43 60 2.9 175406 78 AC087128
44 59.8 2.9 196490 60 AC005507
45 59.6 2.8 2982 6 DDISSSPA
  
```

ALIGNMENTS

```

RESULT 1
AB2777 2098 bp DNA PAT 21-JAN-2000
LOCUS Sequence 2 from Patent WO9855507.
DEFINITION AB2777
ACCESSION AB2777
VERSION AB2777.1 GI:6732464
KEYWORDS unclassified.
SOURCE unclassified.
ORGANISM unclassified.
REFERENCE 1 (bases 1 to 2098)
AUTHORS Boldin, M. and Wallach, D.
TITLE MODULATORS OF INTRACELLULAR INFLAMMATION, CELL DEATH AND CELL SURVIVAL PATHWAYS
JOURNAL Patent: WO 9855507-A 2 10-DEC-1998;
BOLDIN MARK (IL); WALLACH DAVID (IL)
FEATURES Location/Qualifiers
  source
    1..2098
    /organism="unclassified"
    /db_xref="taxon:32644"
BASE COUNT 649 a 452 c 449 g 539 t 9 others
ORIGIN
  
```

```

Query Match 99.8%; Score 2094.4; DB 9; Length 2098;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 2098; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 ggccattatgatggattgaggcgctggacacggcggctggcaccagtctctagaagaagctc 60
Db 1 GCCATTATGATGGATTGGGGGGCGCTACGGCGTTGGCACCAGTCTCTAGAAAAGAAGTC 60

Qy 61 agctctgttggagaagcagcgctggcctggccttggccatccgggaatggcgccctcgtg 120
  
```

```

Db 61 AGCTCTGGTTGGAGAACGACGCGGTGGCGTGGCCATCCGCGGGAATCGGCGCCCTCCTG 120
Qy 121 acctgtttgagggaaggggcttttgcgggctcgtcggctcgttgcaggggggtatctg 180
Db 121 ACCTAGTGTGGGGGCAAAAAGGCTTGGCGGCTCGCTCGTAGGGGGTATCTGG 180
Qy 181 ggcctgagcgcgcgcttggagcctttggagccgagcgagcagcggggggcacccccgaacc 240
Db 181 GGCCTGAGCGCGGCTGGGAGCCCTGGGAGCCCGCGGACGACGAGGGGACACCCCAGAAC 240
Qy 241 ggcctgagcgcgcgcggggaccatgaaagggggggccatctgagcgcgcctgcaccacatcc 300
Db 241 GGCCTGAGCGCGCGGACCATGAACGGGGAGGCCATCTGCAGCGCCCTGCCACCATCC 300
Qy 301 ctaccacaactcgcgcacctgacctgcctgcgcgagcgcgcctcctggcactgctgctc 360
Db 301 CTACCACAACCTCGCGGACTCGGCTACCTGAGCGCGGGGCGCTCTGGGACACTGCTCGT 360
Qy 361 cgccgcgcgcgcgagactgscgctcctcagcttgggaaattgcaatgagcgcctgcaatccac 420
Db 361 CGCCGCCACGACGACTGGCGGCTCCAGGTGGCCGCTGAAGACACCTGCACATCCACACTCC 420
Qy 421 gctgctcgaactgaaagaagtgcttttaagagaactgaaattttacacaagaactag 480
Db 421 GCTGCTCGACACTGAAGAAGGATGTTTTAAGAGAAAGTGTTTTTAAGAGAAAGCTGAAAT 480
Qy 481 attagtacattttcccaatttggaaatttggcaattgcaatgagcgcctgaaattttgg 540
Db 481 ATTTAGTTACATTTTTTCCAATTTTGGGAATTTGCAATGAGCCTGAAATTTTGGGAAT 540
Qy 541 tactgaatcaccgcaaacctgagctctcctcctcctcctcctcctcctcctcctcctcct 600
Db 541 TACTGAATACATGCCAAAATGGATTCATTAAATGAACCTCCACATAGAAAACCTGAAT 600
Qy 601 tgaattgcttggccttggattgctgacctcctcctcctcctcctcctcctcctcctcct 660
Db 601 TGATGTTGCTGGCCATTTGAGATTTGCGCATTTCCGATGAAATGGCCCTGGTGTAAATTA 660
Qy 661 cctgcacaatactgactcctcctcctcctcctcctcctcctcctcctcctcctcctcct 720
Db 661 CCTGCACAATATGACTCCTCCTTCTTACTTACTCATCATGACTTGAAGACTCAGATATCTATT 720
Qy 721 ggacaatgatttctgtaagatttcagatttcgattttggttttatacaaaaggctgagtgc 780
Db 721 GGACAATGAAATTTTCAATTTAAAGATTCAGATTTGTTTTTATCAAAAGTGGCGCATGAT 780
Qy 781 cctctcacagcagcagatgcaaatcctgcaccagagaggggacacatttttatatgac 840
Db 781 CCTCTCACAGTCAGGAAATGAGAAATCTGCACCAGAAAGGGGACAAATTTATTTATGTC 840
Qy 841 acctgaaactatgaaacctggacaaaataaaggccagctatcaagcagatataatag 900
Db 841 ACCTGAAAACATGAACCTGGACAAAATAAAGGGCAGTATCAAGCAGATATATATAG 900
Qy 901 ctatgagttatacatggagagtgtaattcccaaaaacagccttttgaagatccacca 960
Db 901 CTATGCAATTTATCACCATGGGAAGTGTATCCAGAAAACAGCCCTTTTGAAGATGTCACCA 960
Qy 961 tccttgcagataatgataagtggttgcacaagcactcgcacctgatttataagagaag 1020
Db 961 TCCTTGCAGATAATGATAAGTGTGTCACAAGGACACTCGACCTGTTTAAATTAAGAAAG 1020
Qy 1021 ttggccatgataatacctcaccgagcagcagcagcagcagcagcagcagcagcagcagc 1080
Db 1021 TTGGCCATATGATAATACCTCACCAGCAGCAGTATGATCTCTTAAATAGAAAAGTGGATG 1080
Qy 1081 acaaaactcagatgaaagaccatcttttaaaagtgttaagatactgaaactgaaacagctt 1140
Db 1081 ACAAAATCCAGATGAAAGACCATCTTTCTTTAAAATGTTTTTAAATAGAACTTGAACCA 1140
Qy 1141 gagaacatttgaagagataaactttcttgaagctgttattcagcctaaagaaacaaagt 1200
Db 1141 GAGAACAATTTGAAGAGATAACTTTTCTTGAAGCTGTTTATTTCAGCTAAAAGAAAACAAGTT 1200
  
```

1201 acagagtggtttcaagtgcattccattccatgtgacaagaagaaatgaattatctctgaa 1260  
 1201 ACAGAGGTTTCAAGTGCCATTCACCTATGTGACAAGAAGAATGGAAATATCTCTGAA 1260  
 1261 catacctgtaaatcatggtccacaagaggaatcatggtgattcctcagctcccatgaaa 1320  
 1261 CATACCTGTAATCATGGTCCACAAGAGGAATCATGTGATCCTCAGCTCCATGAAA 1320  
 1321 tagtggttctctgaaacttcaaggtccctcagctccctcaagaacaatgatttttattc 1380  
 1321 TAGTGGTTCCTGAAACTTCAAGGTCCCTGCCAGCTCCTCAAGACAATGATTTTTATC 1380  
 1381 tagaaaagctcaagactgatttttataagctgcacactcactgctgctgaaatcacagt 1440  
 1381 TAGAAAAGCTCAAGACTGATTTATGAACTGCATCAGTCTCTGGAAATCAGAGTTG 1440  
 1441 ggatagacaattcttgatcctcaaaagggctgcatcttctgatacaagaaccattccatg 1500  
 1441 GGATAGCACCATTTCTGGATTCAAAGGGCTGCATTTCTGTGATCACAAGACCATTCCATG 1500  
 1501 ctcttcagcaataataatccactcactcaactcagctcaggaactcaagaactgcagctgg 1560  
 1501 CTCITCAGCAATAATAATCCACTCCTCAACTGCAGGAACCTCAGAACCTCTGCAGCTGG 1560  
 1561 tatagccagcagtggtatccagagcaaaaggaagacattgtgacccaaaatgacagaagc 1620  
 1561 TATAGCCAGCAGTGGATCCAGACAAAAGGAGACATTTGTAACCAAAATGACAGAAC 1620  
 1621 ctgcttaaccagtcgctagatgcccctctctgcccagggacttgatcaatgaagaggacta 1680  
 1621 CTGCTTAAACAGTCTGATAGTCCCTCTCTCCAGGGACTGTATCATGAAAGAGGACTA 1680  
 1681 tgaactgtagtaccagcctcaagacactcaaaactcaaaactcaaaactcaaaactcaaa 1740  
 1681 TGAACTGTTAGTACCAGCCTCAGAGCCTCAGAGCCTCAAAAGTCAAGCAATTTACTAGACACTAC 1740  
 1741 tgacatcaagagaagaatttgcacaaagttatagatacaaaatgaagatacaacaaca 1800  
 1741 TGACATCAAGGAGAAGAAATTTGCCAAAGTTATAGTACAAAATTTGAAAGATAACAACA 1800  
 1801 aatgggtcttcagcctaccggaaataactctgctgctgctgctgctgctgctgctgctg 1860  
 1801 AATGGGTCTTCAGCCTTACCCTGAAATACTTGTGTGTTCTAGATCACCATCTTTAAAATTT 1860  
 1861 actcaaaaataaagcagctgtaagctgttttcaagaagaatgctttcataaaagg 1920  
 1861 ACTCAAAAATAAAGCATGTAAGTACTGTGTTTCAAGAAAGAAATGTTTCATAAAAGG 1920  
 1921 atattatctctgttctgttctgttctgttctgttctgttctgttctgttctgttctgtt 1980  
 1921 ATATTTATATCTCTGTGCTTTGACTTTTTTTTATATAAAATCCGTGAGTATTAAGCTTT 1980  
 1981 awraaagktcttsrxtaaatattagctcctcctccatgacactgacagattttttttaa 2040  
 1981 AWRAAAGKCTTTSRXTAAATATTAGTCTCCCTCCATGACACTGCAGTATTTTTTTAA 2040  
 2041 ttaatacaagtaaaaagttgatttgaaaaaaataaaaaaataaaaaaataaaaaa 2098  
 2041 TTAATACAGTAAAAGTTGATTTGAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAA 2098

RESULT 2  
 AF027706 2501 bp mRNA PRI 10-SEP-1998  
 LOCUS Homo sapiens serine/threonine kinase RICK (RICK) mRNA, complete cds.  
 DEFINITION  
 AF027706  
 AF027706.1 GI:3123886  
 ACCESSION  
 AF027706  
 VERSION  
 AF027706.1  
 KEYWORDS  
 human.  
 SOURCE  
 ORGANISM  
 Homo sapiens  
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;

Mammalia; Eutheria; Primates; Catarrhini; Hominiidae; Homo.  
 1 (bases 1 to 2501)  
 Inohara, N., del Peso, L., Koseki, T., Chen, S. and Nunez, G.  
 RICK, a novel protein kinase containing a caspase recruitment domain, interacts with CLARP and regulates CD95-mediated apoptosis  
 J. Biol. Chem. 273 (20), 12296-12300 (1998)  
 98241596  
 2 (bases 1 to 2501)  
 Inohara, N., Koseki, T., Chen, S., del Peso, L. and Nunez, G.  
 Direct Submission  
 Submitted (01-OCT-1997) Dept. Pathology, Comprehensive Cancer & Geriatrics Center, 4-131 CCGC 1500 E. Medical Center Dr, Ann Arbor, MI 48109, USA

FEATURES  
 source  
 1..2501  
 /organism="Homo sapiens"  
 /db\_xref="taxon:9606"  
 /chromosome="8"  
 /map="8q21"  
 1..2501  
 /gene="RICK"  
 225..1847  
 /gene="RICK"  
 /function="regulates apoptosis"  
 /note="CARD domain protein; phosphorylated protein"  
 /codon\_start=1  
 /product="serine/threonine kinase RICK"  
 /protein\_id="AAC34970.1"  
 /db\_xref="GI:3123887"  
 /translation="MNGEAICSLPTIPYHKLADRLYLRSAGSTVSARRADWRVQV  
 AVHLHHTPLLSERKDLREAEILHKARFSYILPILGICNEPEFLGIVTEYMPNGS  
 LNELHRTPEVDVAVPURLERILHAIALGVNLYHMTPLLLHDKLKTONTLLDNFHFV  
 KIADFGLSKWRMNSLSOSRSKSAPEGSTIYMPPEYEPGOKSRASIKKHDIYSYAVI  
 TWFLSRKQPEDVTNQLQIMYSVSGHRVYNEELPYDIPHRARMLILESWAON  
 PDRPFLKCLIELEPVRITFEIIFLEAVIQLKKIKLQVSSYAIHLCKRKLKMLSLN  
 IPVNHGPEESGSSQLHNSGSPETSRPAPQDNDFLRSKAQDCYFMKLIHPCPNH  
 SWDTISGQRAAFCDHKHTPCSSAIINPLSTAGNSERLQFIAQOORIKKREDIVNQ  
 MTEACLNSLDALLSRLIMKEDYELVSTKPTRTSKVRQLLDDTDIOGEBFAKVIQK  
 LKDNKQGLQPYPEILVVSRSPLNLLQNKSM"  
 1833..1838  
 /gene="RICK"  
 1869  
 /gene="RICK"  
 2479..2484  
 /gene="RICK"  
 2501  
 /gene="RICK"  
 /gene="RICK"

polyA\_signal 768 a 535 c 499 g 699 t  
 polyA\_site  
 polyA\_signal  
 polyA\_site  
 polyA\_signal  
 polyA\_site

BASE COUNT 768 a 535 c 499 g 699 t  
 ORIGIN

Query Match 96.2%; Score 2017.8; DB 88; Length 2501;  
 Best Local Similarity 99.3%; Pred. No. 0;  
 Matches 2016; Conservative 9; Mismatches 6; Indels 0; Gaps 0;

Qy 36 ggcaccagctctagaagaagaagctcagctctggttcggagaagcagcgctggcgtggc 95  
 Db 1 GGCACCAGCTCTAGAAAAGAAAGTCAGCTGTGTTCCGAGAAGCAGCGCTGGCCTGGC 60  
 Qy 96 catccggggaatggcgccctcgtgacctagttgctggcggggcaaaaaaggttctgcccgc 155  
 Db 61 CATCCGGGGAATGGCGCCCTCGTGACCTAGTGTTCGGGGCAAAAAGGGTCTTCCCGCC 120  
 Qy 156 ctgcctcgtcagggggcgatctggggccctgagcggcggtgggagccttgggagcgc 215  
 Db 121 CTCGCTCGTCAGGGGGCGTATCTGGGGCCCTCAGCGCCAGTGGGAGCCTTTGGAGCCGC 180  
 Qy 216 cgcagcagggggcacaccggaaacggcctgagcggccggaccatgaacgggagccca 275  
 Db 181 CGCAGCAGGGGGCACACCCTGAGCCGCTGAGCCCGCCCGGACCATGAAACCGGGAGGCCA 240  
 Qy 276 tctcagcgcctgcccaccattccctaccacaactcccgaccctgacctgacctgagcc 335

Db 241 TCTGAGCCCTGCCCACCAATCCCTACCACAATACTGCCGACCTGCGCTACCTGAGCC 300  
 Qy 336 ggggccccctggcaactgtgctcgcccccgcacagactggcggctccaggtagccg 395  
 Db 301 GGGGCCCCCTGGCACTGTGTGGTCCGCCCCGACAGACTGGCCGCTCCAGGGTGGCCG 360  
 Qy 396 tgaagcacctgcacatcccacactccgctgctgcagctgaaagaaaggaggttttaag 455  
 Db 361 TGAAGCACCTGCCACATCCACACTCCGCTCTCGACAGTGAAGAAAGGATGCTTAAG 420  
 Qy 456 aagctgaaattttacacaaagctagatttagtaacttttcccaatttttggaaatttga 515  
 Db 421 AAGCTGAAATTTTACACAAGCTAGATTTAGTTACATTTCTCCAATTTTGGAAATTTGA 480  
 Qy 516 atgagcctgaattttgggaattttactgaatacactgcaaatggatcaattaaatgaac 575  
 Db 481 ATGAGCCTGAAATTTTGGGAATAGTTACTGAAATFACATGCAATGCAATGGATCAATTAATGAAC 540  
 Qy 576 tccatcagggaaaactgaatacctgattgttggctggccattggatttgcactctgc 635  
 Db 541 TCCTACATAGGAATACTGAATATCCCTGATGTTGCTTGGCCATGAGATTCGCATCTGC 600  
 Qy 636 atgaaattgcccctgggttaaatcctgcacaaatgactcctccttbaactcactatg 695  
 Db 601 ATGAAATGGCCCTGGTAAATACCTGCACAATATGACTCTCCTCTTACTTTCATCATG 660  
 Qy 696 acttgaagcctcaagaatactttatggacaatgaatttcaatgatttaagattgcagatttg 755  
 Db 661 ACTTGAAGACTCAGAATATCTTATGGACAATGAATTTGATGTTAAGATTGGAGATTTTG 720  
 Qy 756 gtttacaagtgccgcaatgctccctccacagtcacagtcacagtagcaaatctgcaccg 815  
 Db 721 GTTTATCAAGTGGCCGATGATGTCCTCTCACAGTCACAGTACAGTAAATGTCACCCAG 780  
 Qy 816 aaggaggacaattttataatgcccctgaaactatgaacctgcaaaaatacaagg 875  
 Db 781 AAGGGGGCAATTTACTATATGCCACTGAAACATGAACTGGACAAAATCAAGGG 840  
 Qy 876 ccagatcaagcagcagatataatagctatgctcagcttccatcagctggaggtttatccagaa 935  
 Db 841 CCAGTATCAAGCAGATATATAGCTATGCTATGCTATGCTATGCTATGCTATGCTATGCT 900  
 Qy 936 aacagccttttgaagatgtccacaaatcctttgagataatgtatagctgtgtcaaggagc 995  
 Db 901 AACAGCCTTTTGAAGATGTCCCAATCTTGGCAGATAATGATAGTGTGTCAAGAGGAC 960  
 Qy 996 atcagacctttataatgaagaatttggcctatgatacctcaccgagcagctatga 1055  
 Db 961 ATCGACCTGTTTAAATGAAGAAGTTTGGCCATATGATATACCTCACCGACAGTATGA 1020  
 Qy 1056 tctcctaaatagaagtggtggcacaataccagatgaaagaccatctttcttaaaat 1115  
 Db 1021 TCCTCTAATAGAAAGTGGATGGCCACAAAATCCAGATGAAAGACCATCTTTCTTAAAT 1080  
 Qy 1116 gtttaa tagaacttgaaccgttttgagaacatttgaagagataacttttcttgaagctg 1175  
 Db 1081 GTTTAATFAGAATTTGACCACTTTTGAACAATTTGAAGAGATAACTTTCTTTGAAGCTG 1140  
 Qy 1176 ttattcagctlaaagaacaagaattacagagtggttcaagtgccattcaactatgtgaca 1235  
 Db 1141 TTATTACAGTAAAGAAACAAGTTTACAGAGTGTTCAGTGCCATTCACCTATGTGACA 1200  
 Qy 1236 agagaataatggaatctctgaacatacctgtaaatcactgtcaaatcactgtcccaagagaaatcat 1295  
 Db 1201 AGAAGAAATGGAATTTCTGTAACATACCTGTAATATGTTTCCACAGAGAGAAATCAT 1260  
 Qy 1296 gtggatcctcagctcctcaaaaatggttctcctgaaacttcaagctcctccag 1355  
 Db 1261 GTGGATCCTCTCAGCTCCATGAAATAGTGGTCTCTCGAATTTCAAGGTCCCTGGCCAG 1320  
 Qy 1356 ctccctcagcaaatgattttttatctagaaagctcaagactgtttttatgaaagctc 1415  
 Db 1321 CTCTCAGACCAATGATTTTATCTAGAAAAGCTCAAGACTGTATTTTATGAAGCTGC 1380

Qy 1416 atcactgtcctggaaatcacagttgggtagacacacatttctggatctcaaaagggctgc 1475  
 Db 1381 ATCACTGTCTGGAAATCACAGTTGGGATAGCACCATTTCTGGTCTCAAAAGGGCTGCAT 1440  
 Qy 1476 tctgtgatacaagaaccctccactctctctcagcaataataaataccactctcaactgcag 1535  
 Db 1441 TCTGTGATCACAAAGACCCTCCATCTCTTCCAGCAATATAAATCCACTCTCAACTGCAG 1500  
 Qy 1536 gaaactcagaagctgcagctgctatagcccagcagtgatccagagcaaaagggag 1595  
 Db 1501 GAACTCAGAAGCTGTGCAGCCTGTATAGCCACAGTGGATCCAGAGCAAAAGGGAAAG 1560  
 Qy 1596 acattgtgaaccaaatacagaagcctgcttcaaacagctcgcctagatgcccctctctgcca 1655  
 Db 1561 ACATTTGTGAACCAATGACAGAAGCTGCCTTAACCAAGCTGTAGATGCCCTCTGTCTCA 1620  
 Qy 1656 gggacttgatcatgaaagagagactgactgactttagtaccagaagcctcaagagcctcaa 1715  
 Db 1621 GGGACTTGTATCATGAAGAGGACTATGAATTTGTTAGTACCAAGCTCAAGGACCTCAA 1680  
 Qy 1716 aagtgcagaacttactagacactgactgactcagagagagaaatttgcacaaagttatag 1775  
 Db 1681 AAGTCAGACAAATTTACTAGACACTACTGACTCCAGTCCAAAGGAAAGAAATTTGCCAAAGTTATAG 1740  
 Qy 1776 tacaataatgaaagatacaacaacaaatgggtcttcagccttaccgggaaaactctgttg 1835  
 Db 1741 TACAAAATTTGAAGATTAACAACAATAATGGGTCTTCAGCCTTACCCGGAAAATCTGTGG 1800  
 Qy 1836 tttctagatcacaacttttaataattacttcaaaaaataaagaatgtaagtgactgtttttc 1895  
 Db 1801 TTTCTAGATCACCACTTTTAAATTTACTTCAAAAATAAAGCATGTAAGTGACTGTTTTTC 1860  
 Qy 1896 aagaagaattggtttcacaagaagatattatctctgttctgttctgttctgtttttata 1955  
 Db 1861 AAGAAGAAATGTTTCATAAAAGGATATTATATCTCTGTTGCTTGGACTTTTTTATA 1920  
 Qy 1956 taaaatccctgagttataaagcttwraargkcttttsrktaaaataattagctccctc 2015  
 Db 1921 TAAAATCCCTGAGTATAAAGCTTTTATTGAAGTCTTTTGGGTAATAATATTAGTCTCCCTC 1980  
 Qy 2016 catgacactgcagtttttttttaatacaacaagtaaaagttgaaatttg 2065  
 Db 1981 CATGACACTGCAGTATTTTTTTTTTAAATTAATATACAAAGTAAAAGTTGAAATTTG 2031

RESULT 3  
 AF064824 1902 bp mRNA PRI 07-JUL-1998  
 LOCUS Homo sapiens CARD-containing ICE associated kinase mRNA, complete  
 DEFINITION cds.  
 ACCESSION AF064824  
 VERSION AF064824.1 GI:3290171  
 KEYWORDS human.  
 SOURCE Homo sapiens  
 ORGANISM Homo sapiens  
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 Mammalia; Eutheria; Primates; Catarrhini; Hominiidae; Homo.  
 REFERENCE 1 (bases 1 to 1902)  
 AUTHORS Thome, M., Hofmann, K., Burns, K., Martinon, F., Bodmer, J.-L.,  
 Mattmann, C. and Tschopp, J.  
 TITLE Identification of CARDIAK, a RIP-like kinase that associates with  
 caspase-1  
 JOURNAL Curr. Biol. 8 (1998) In press  
 REFERENCE 2 (bases 1 to 1902)  
 AUTHORS Thome, M., Hofmann, K., Burns, K., Martinon, F., Bodmer, J.-L.,  
 Mattmann, C. and Tschopp, J.  
 TITLE Direct Submission  
 JOURNAL Submitted (12-MAY-1998) Institute of Biochemistry, University of  
 Lausanne, Chemin des Boveresses, 155, Epalinges, CH 1066,  
 Switzerland  
 FEATURES Location/Qualifiers  
 source 1..1902





Qy 1340 tcaaggctccctgccagctcccaagacaatgattttttatcagaaagctcaagactgt 1399  
 Db 1081 TCAAGGCTCCCTGCCAGCTCCCAAGACAATGATTTTTATCTAGAAAAGCTCAAGACTGT 1140  
 Qy 1400 tatttatgaagactgcacatctctctggaatacaacagttggatagaccatttctgga 1459  
 Db 1141 TATTTTTAAGAAGCTGCACACTCTCTCTGGAATAACAGTTGGGACAGCACCATTCTCGGA 1200  
 Qy 1460 tctcaagggtcattctgtgatacaagaccctccatctctcagcaataataaat 1519  
 Db 1201 TCTCAAGGGCTGCATTCTGTGATCACAAAGACCCTCCATCTCTTCAGCAATAAATAAT 1260  
 Qy 1520 ccaactcaactcaggaactcagcaactcagcaactcagcaactcagcaactcagcaactc 1579  
 Db 1261 CCACTCTCAACTGCGAGAAACTCAGAACCTCTGAGCCTGTGATAGCCAGCAGCTGGATC 1320  
 Qy 1580 cagagcaaaaggaagacatctgacaaatgacagagcctccttaaccagctcgcta 1639  
 Db 1321 CAGACAAAGGGAAAGACATTTGTAAACCAATGACAGAAAGCCTGCCTTAAACCAGTCGCTA 1380  
 Qy 1640 gatgcccttctgtccagggacttgcatacaagaggactatgaaactgtttagttaccacaag 1699  
 Db 1381 GATGCCCTTCTGTCCAGGGACTTGATCATGAAAGAGGACTATGAACTTTAGTACCAAG 1440  
 Qy 1700 cctcaaggacctcaaaagtccagcaactcagcaactcagcaactcagcaactcagcaactc 1759  
 Db 1441 CCTCAAGGACTCAAAAAGTCCAGAAATTTACTAGACACTACTGACATCCAAAGGAGAAGA 1500  
 Qy 1760 ttgcaccaagttatagtaaaaaattgaaaagatacaaaaataaaagtgcttcagccttac 1819  
 Db 1501 TTTGCCAAAGTTATAGTACAAAATTTGAAAGATAACAACAATAAAATGGGTCTTCAGCCTTAC 1560  
 Qy 1820 ccggaataactgttggtttctagatccaccctcttaaaatttactcctcaaaataaaaagcatg 1879  
 Db 1561 CCGGAATACTTGTGTTTCTAGATCACCACCTTTAAATTTACTTCAAAATAAAGCATG 1620  
 Qy 1880 taa 1882  
 Db 1621 TAA 1623

RESULT 5  
 AC004003 116650 bp DNA PRI 21-DEC-1999  
 LOCUS AC004003 Homo sapiens BAC clone CTA-437L15 from 8q21, complete sequence.  
 DEFINITION AC004003 Homo sapiens BAC clone CTA-437L15 from 8q21, complete sequence.  
 ACCESSION AC004003  
 VERSION AC004003.1 GI:2772557  
 KEYWORDS HG.  
 SOURCE human.  
 ORGANISM Homo sapiens  
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.  
 REFERENCE 1 (bases 1 to 116650)  
 AUTHORS Ozersky,P., Holmes,A. and Broly,M.  
 TITLE The sequence of Homo sapiens BAC clone CTA-437L15  
 JOURNAL Unpublished  
 REFERENCE 2 (bases 1 to 116650)  
 AUTHORS Waterston,R.  
 TITLE Direct Submission  
 JOURNAL Submitted (15-JAN-1998) Department of Genetics, Washington University, 4444 Forest Park Avenue, St. Louis, Missouri 63108, USA  
 REFERENCE 3 (bases 1 to 116650)  
 AUTHORS Waterston,R.  
 TITLE Direct Submission  
 JOURNAL Submitted (27-JUN-1998) Department of Genetics, Washington University, 4444 Forest Park Avenue, St. Louis, Missouri 63108, USA  
 REFERENCE 4 (bases 1 to 116650)  
 AUTHORS Waterston,R.  
 TITLE Direct Submission  
 JOURNAL Submitted (21-DEC-1999) Department of Genetics, Washington University, 4444 Forest Park Avenue, St. Louis, Missouri 63108, USA  
 COMMENT ----- Genome Center  
 Center: Washington University Genome Sequencing Center

Center code: WUGSC  
 Web site: http://genome.wustl.edu/gsc  
 Contact: sapiens@watson.wustl.edu  
 Summary Statistics  
 -----  
 Center project name: H\_RG437L15  
 -----

NOTICE: This sequence may not represent the entire insert of this clone. It may be shorter because we only sequence overlapping clone sections once, or longer because we provide a small overlap between neighboring data submissions.

This sequence was finished as follows unless otherwise noted: all regions were double stranded or sequenced with an alternate chemistry; an attempt was made to resolve all sequencing problems, such as compressions and repeats; all regions were covered by sequence from more than one subclone; and the assembly was confirmed by restriction digest.

MAPPING INFORMATION:  
 This chromosome 8 clone was provided by Dr. Patrick Concannon (patcon@mmc.org) at the Virginia Mason Research Institute.

SOURCE INFORMATION:  
 Clone CTA-437L15 is from a release of the human BAC library C17B-HS-A. The library contains cloned DNA from human sperm. See: Shizuya et al., Proc. Natl. Acad. Sci. USA 89:8794-7 (1992); U-J. Kim et al., Genomics 34:213-8 (1996). The clone is available from RESEARCH Genetics, Inc. (http://www.resgen.com).  
 VECTOR: pBeloBAC11  
 Selection: chloramphenicol

NEIGHBORING SEQUENCE INFORMATION:  
 The clone sequenced to the left is CTA-237G1. The actual start of this clone is at base position 1 of CTA-437L15; actual end is at 116650 of CTA-437L15.

This clone contains STS HS275YF1 (NID:gi051703).

FEATURES  
 source 1..116650  
 /organism="Homo sapiens"  
 /db\_xref="taxon:9606"  
 /chromosome="8"  
 /map="8q21"  
 /clone="CTA-437L15"  
 /clone\_lib="C17B-HS-A"  
 repeat\_region 150..530  
 /rpt\_family="L1"  
 repeat\_region 498..649  
 /rpt\_family="L1"  
 repeat\_region 673..1096  
 /rpt\_family="MaLR"  
 repeat\_region 3188..3348  
 /rpt\_family="L1"  
 repeat\_region 3605..3726  
 /rpt\_family="(TA)n"  
 repeat\_region 3845..4563  
 /rpt\_family="L1"  
 repeat\_region 5641..6075  
 /rpt\_family="Retroviral"  
 repeat\_region 6133..6433  
 /rpt\_family="Alu"  
 misc\_feature 7110..8040  
 /note="CpG\_island (8GC=69.1, O/e=0.80, #CpGs=93)"  
 gene 7872..40218  
 /gene="WUGSC:H\_RG437L15.1"  
 CDS join(7872..8044,12642..12795,15154..15309,19584..19741,21552..21601,22478..22639,29890..29975,33855..33944,36395..36488,39123..39284,39881..40218)  
 /gene="WUGSC:H\_RG437L15.1"  
 /note="serine/threonine kinase RICK; match to protein AF027706 (PID:g3123887) and mRNA AF027706 (NID:g3123886); H\_RG437L15.1"

```

/codon_start=1
/evidence=not_experimental
/protein_id="AAC24561.1"
/db_xref="GI:3264574"
/translation="MNGEAIICSALEPTIPYHKLADLYLSRGASGVSSARHADWRVQV
AVKHLIHTPLLDREKDVLEAEILHKARESYILPILGICNEPEFLGIIVTEYMPNGS
LNEALLHRTKEVDVAVLPRFRILHEIALGVNVLHMPPPLLHDLKTONILLDDNFHVI
KADPGLSKWRMMSLQSRSSKSAPEGCTIILYMPPEAVEGQKSRASIKKHDHLYSYAVI
TWEVLSRKQPFEDVNTNPLQIMKYSQGRHPVINEESLPYDIPHRARMLSLIESWAON
IDPERSFKLIELEPLVLRTEFEITFLVAVIQLKTKLQSVSSAIHICDCKKMSLSGNH
IPVNHGQECSSQLHENSPEPTSRSLPAPQDNDPFLSRKAQDCYFMKLIHPCPGNH
WDSITSGSRAACDHKHTTPCSSAIINPLSTAGNSERLQFIAQOWIQKREDIVNO
MTEACLNGSLDALLSRDLIMKEDVELVSTKPTRTSKVROLLDITDIOGEEPAKVIYOK
LKDKNQGLQYPELIVSRSPSLNLLQKSM"

```

```

repeat_region /rpt_family="MER1_type"
34525..34939
repeat_region /rpt_family="MaLR"
34991..35256
repeat_region /rpt_family="Alu"
35388..35477
repeat_region /rpt_family="MER2_type"
35994..36286
repeat_region /rpt_family="Alu"
36886..36985
repeat_region /rpt_family="Alu"
37488..37673
repeat_region /rpt_family="L2"
37862..38161
repeat_region /rpt_family="Alu"
38297..38599
repeat_region /rpt_family="Alu"
41954..42006
repeat_region /rpt_family="L2"
42596..42777
repeat_region /rpt_family="MER1_type"
43357..43658
repeat_region /rpt_family="Alu"
44088..44386

```

```

Query Match           24.6%; Score 516.6; DB 85; Length 116650;
Best Local Similarity 97.7%; Pred. No. 3.7e-82;
Matches 513; Conservative 9; Mismatches 3; Indels 0; Gaps 0;
QY 1541 tcagaagctctgcaagcgggtatagccagcagtgatcccaagagcaacccagagcattc 1600
Db 39877 TCAGAACGCTTCAGACCCGGGTATAGCCAGCAGCAGTGGATCCAGAGGCAAAAGGAAACATT 39936
QY 1601 gtaaaccaaatgacagaaagcctgacctaacaccagtcgctagatgcctctctgcccaggac 1660
Db 39937 GTGAACCAAAATGACAGAACGCTGCCTTAACACAGTCGCATAGATGCCCTTCTGTCACGGAC 39996
QY 1661 ttgatcctgaaagagagactatgaaacttggtagtaaccagctcaagcctcaaggcccaaaagtc 1720
Db 39997 TTGATCATGAAAGAGGACTATGAACCTTGTGTAGTACCAGCCCTACAAGGACCTCAAAAGTC 40056
QY 1721 agacaatactagacacactactgacatcccaagagagaagaattgccaagaattatagatacaa 1780
Db 40057 AGACAATACTAGACACTACTGACATCCAAAGGAGAAAGATTTGCCAAAAGTTATAGTACAA 40116
QY 1781 aaattgaaagatacaaaaacaaatggtctcagccttaaccagcaataccttggttct 1840
Db 40117 AAATTGAAAGATAACAAAACAAATGGGTCTTACGCCCTTACCCCGGAAATACTTGTGGTCTT 40176
QY 1841 agatcaccatctttaaatttactcaaaataaaagcagcagcagcagcagcagcagcagcagcagc 1900
Db 40177 AGATCACCATCTTAAATTTACTTCAAAAATAAAAGCAGTGAAGTGACTGTTTTCAGAA 40236
QY 1901 gaaatggtttcataaaagcatttatctctgtgttggcttggacttttttttatatacaaa 1960
Db 40237 GAAATGTGTTTCAATAAAGGATATTTATCTCTGTGTGCTTGTGACCTTTTATATATAAAA 40296
QY 1961 tccgtgagattaaagcctwwraargktcttsktaaaataatagctccctccatga 2020
Db 40297 TCCGTGAGTATTAAGCTTTTATTAAGAGGTTCTTTGGGTAATATTAATAGTCTCCCTCCATGA 40356
QY 2021 cactgcagatttttttttaataatacaagtaaaagtgaattt 2065
Db 40357 CACTGCAGTATTTTTTTTTTAATTAATTAACAGTAAAAAAGTTGAATT 40401

```

```

RESULT 6
AF117829 320250 bp DNA 13-JAN-1999
LOCUS Homo sapiens 8q21.3: RICK gene, complete sequence.
DEFINITION AF117829
ACCESSION AF117829
VERSION AF117829.1 GI:4151947
KEYWORDS HTG.

```



```

SOURCE          human.
ORGANISM        Homo sapiens
REFERENCE       Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
AUTHORS        Mammalia; Eutheria; Primates; Catarrhini; Hominoidea; Homo.
TITLE          1 (bases 1 to 320250)
JOURNAL        Platzer, M. and Varon, R.
COMMENT        Direct Submission
               Submitted (30-DEC-1998) Genome Analysis, Institute of Molecular
               Biotechnology, Beutenbergstrasse 11, Jena 07745, Germany
               This sequence is part of a larger genomic contig. The start of this
               sequence is directed towards the centromere. The end of this
               sequence (320001..320250) overlaps with the start of the
               neighbouring Acc_number AF049895 (1..250).
FEATURES        Location/Qualifiers
               source          1..320250
               db_xref="taxon:9606"
               chromosome="8"
               map="8q21.3"
               1..137184
               organism="Homo sapiens"
               db_xref="taxon:9606"
               clone="P64M4"
               complement(572..704)
               /rpt_family="MIR"
               705..870
               /rpt_family="MIR"
               complement(930..985)
               /rpt_family="MIR"
               2222..2456
               /rpt_family="L2"
               2538..2661
               /rpt_family="L2"
               complement(2695..2845)
               /rpt_family="FAM"
               2913..3485
               /rpt_family="L2"
               3559..3679
               /rpt_family="L2"
               3776..3930
               /rpt_family="MIR"
               complement(4035..4247)
               /rpt_family="MIR"
               complement(5211..5655)
               /rpt_family="L2"
               5997..6100
               /rpt_family="L2"
               6800..6850
               /rpt_family="(TAGA)n"
               8389..8709
               /rpt_family="L2"
               complement(9413..9761)
               /rpt_family="MLT1A1"
               10399..10473
               /rpt_family="L2"
               11341..11507
               /rpt_family="MIR"
               complement(11525..11570)
               /rpt_family="(TAA)n"
               11931..11985
               /rpt_family="(CATG)n"
               complement(12051..12149)
               /rpt_family="MERS3"
               complement(12351..12760)
               /rpt_family="NSTA"
               14544..14734
               /rpt_family="MIR"
               complement(15740..15847)
               /rpt_family="MIR"
               16491..16558
               /rpt_family="MIR"
               18103..18162
               /rpt_family="MIR"
               18343..18639
               /rpt_family="AluSx"
               19005..19075
               /rpt_family="MERS7-internal"
               complement(19478..19560)
               /rpt_family="MIR"
               complement(23416..23710)
               /rpt_family="AluSg"
               complement(24833..25025)
               /rpt_family="MIR"
               complement(25333..25392)
               /rpt_family="MERS1"
               25969..26053
               /rpt_family="L1MB8"
               26167..26302
               /rpt_family="L1M4"
               complement(26512..26684)
               /rpt_family="AluJo"
               26685..26712
               /rpt_family="(TA)n"
               complement(26713..26841)
               /rpt_family="AluJo"
               complement(27456..27620)
               /rpt_family="MERSA"
               complement(27724..28020)
               /rpt_family="AluY"
               28147..28283
               /rpt_family="AluY"
               28284..28311
               /rpt_family="(TA)n"
               28312..28476
               /rpt_family="AluY"
               29222..29518
               /rpt_family="L1M2"
               29454..32583
               /rpt_family="L1MAG"
               32636..33403
               /rpt_family="L1MAG"
               33404..33705
               /rpt_family="AluSc"
               33706..33960
               /rpt_family="L1MAG"
               complement(34346..34614)
               /rpt_family="MER8"
               34786..34873
               /rpt_family="MIR"
               34839..35057
               /rpt_family="L2"
               complement(35173..35382)
               /rpt_family="AluYa5"
               35577..35746
               /rpt_family="MLT1D"
               complement(35747..36046)
               /rpt_family="AluY"
               36047..36323
               /rpt_family="MLT1D"
               complement(36593..36761)
               /rpt_family="MIR"
               complement(37858..37899)
               /rpt_family="L2"
               38652..38895
               /rpt_family="L1M2"
               38959..39811
               /rpt_family="L1M3e"
               39885..39989
               /rpt_family="L1M2"
               40242..43133
               /rpt_family="L1M2"
               43134..43499
               /rpt_family="MLT1A1"
               43500..44075
               /rpt_family="L1M2"
               44076..44391

```

repeat\_region /rpt\_family="ALUJ0" 44392 .45758  
 repeat\_region /rpt\_family="L1MA4A" complement(45759 .46216)  
 repeat\_region /rpt\_family="L1PA7" 46217 .47676  
 repeat\_region /rpt\_family="L1MA4A" 47693 .47955  
 repeat\_region /rpt\_family="L1MASA" 48227 .48421  
 repeat\_region /rpt\_family="L2" complement(49170 .49277)  
 repeat\_region /rpt\_family="MIR" complement(49409 .50232)  
 repeat\_region /rpt\_family="L1PA2" 50233 .50476  
 repeat\_region /rpt\_family="L1PA4" complement(50588 .50644)  
 repeat\_region /rpt\_family="MIR" complement(51729 .52082)  
 repeat\_region /rpt\_family="THE1C" complement(52083 .53629)  
 repeat\_region /rpt\_family="THE1C-internal" complement(53632 .53992)  
 repeat\_region /rpt\_family="THE1C" 54101 .54351  
 repeat\_region /rpt\_family="L2" 54433 .54822  
 repeat\_region /rpt\_family="L2" 54823 .55177  
 repeat\_region /rpt\_family="MLF1A2" 55178 .55291  
 repeat\_region /rpt\_family="L2" complement(55316 .55371)  
 repeat\_region /rpt\_family="L2" 55545 .55878  
 repeat\_region /rpt\_family="L2" 57436 .57481  
 repeat\_region /rpt\_family="(TTAAA)n" 60524 .60721  
 repeat\_region /rpt\_family="L1ME" complement(61481 .61865)  
 repeat\_region /rpt\_family="MSTA" 62004 .62295  
 repeat\_region /rpt\_family="MLT1E" 62427 .67614  
 repeat\_region /rpt\_family="L1PA2" 62833 .145579  
 source /organism="Homo sapiens"

Query Match 24.6%; Score 516.6; DB 88; Length 320250;  
 Best Local Similarity 97.7%; Pred. No. 3.6e-82;  
 Matches 513; Conservative 9; Mismatches 3; Indels 0; Gaps 0;

Qy 1541 tcagaacgtctgcagcctgtgtatagcccagcttgatccagagcaaaagggagacatt 1600  
 Db 179446 TCAGAAGCTGTCAGCCTGTGTATAGCCAGCTGGATCCAGAGCAAAAGGAAGACATT 179505

Qy 1601 gtagaacaataagacagagctgtcttaaccagctcagctgtagatccctctctccagggac 1660  
 Db 179506 GTGAACCAATGACAGAGGCTGCCTTACCAAGCTGGTGTAGATCCCTTGTCCAGGGAC 179565

Qy 1661 ttgatcatgaaagaggactatgaactgtttagaccagcctcaagacactcaaaagtc 1720  
 Db 179566 TTGATCATGAAAGAGGACTATGACTTTGTAGTACCAGCCTCAAGGACCTCAAAAAGTC 179625

Qy 1721 agacaatactagacactactgacatccaaagggagaaatttgccaaaagttatagtaaa 1780  
 Db 179626 AGACAATTAAGACTACTGACTGACTCAAGGAGAAATTTGCCAAAAGTTATAGTACAA 179685

Qy 1781 aaattgaagatacaaaataagtgcttcagccttaccggaaataactctlggtttct 1840  
 Db 179686 AAATTTGAAGATACAAAACAAATGGGCTTCAGCCTTACCCTTACCCTGGAAATCTTGTGGTTCT 179745

Qy 1841 agatcacatcttaaaattacttcaaaataaagaactgaagctgtttttcaagaa 1900  
 Db 179746 AGATCACCATCTTTAAATTTACTTCAAAAATAAAGCACTGAAGTACTGCTTTTCAAGAA 179805

Qy 1901 gaaatgctttcataaaaggataatttatctctctgtctgtgactttttttatataaaa 1960  
 Db 179806 GAAATGCTTTTCAAAAAGGATAATTTATATCTCTGCTGTGACTTTTATATAAAA 179865

Qy 1961 tccgtagattaaagcttwwraargktctttarktaaatattagctcctccatga 2020  
 Db 179866 FCCCGTAGTAAATTAAGCTTTATTGAAGGTTCTTGGTAAATATTAGTCTCCTCCATGA 179925

Qy 2021 cactcagatcttttttaaaatacaagaataaagaattgaatt 2065  
 Db 179926 CACTCAGTATTTTTTAAATTAATCAAGTAAAAAGTTGAATT 179970

RESULT 7  
 AR044139 AR044139 210 bp DNA PAT 29-SEP-1999  
 LOCUS Sequence 31 from patent US 5817479.  
 ACCESSION AR044139  
 VERSION AR044139.1 GI:5965604  
 KEYWORDS Unknown.  
 SOURCE Unknown.  
 ORGANISM Unclassified.  
 REFERENCE 1 (bases 1 to 210)  
 AUTHORS Au-Young, J., Bandman, O., Hawkins, P. R. and Wilde, C. G.  
 TITLE Human Kinase homologs  
 JOURNAL Patent: US 5817479-A 31 06-OCT-1998;  
 FEATURES Location/Qualifiers  
 1..210  
 source /organism="unknown"  
 BASE COUNT 74 a 40 c 41 g 55 t  
 ORIGIN

Query Match 10.0%; Score 210; DB 9; Length 210;  
 Best Local Similarity 100.0%; Pred. No. 1.1e-27;  
 Matches 210; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 844 tgaataactatgaacctggaacaaatacaagggccagatacaagcagatataatagctca 903  
 Db 1 TGAATACTATGAACCTGGACAAAAATCAAGGGCCAGTATCAAGCAGCATATATATAGCTA 60

Qy 904 tgcagttacatggaagtggtttatcccaaaaacagccttttgaagatgtcccaatcc 963  
 Db 61 TGCAGTTATCACATGGGAAGTGTTATCCAGAAAACAGCCTTTTGAAGATGTCCACCATCC 120

Qy 964 ttgtcagataatgtagtgggtcacaagcagcagcctgtttatcaatgaagaaagttt 1023  
 Db 121 TTTGCAGATAATGTTATGTTGTCACAGGACATCCACCTGTTTAAATGAAGAAAGTTT 180

Qy 1024 gccatgatataacctcaagcagcagat 1053  
 Db 181 GCCATATGATATACCTCACCGAGCAGGTAT 210

RESULT 8  
 AF302127 AF302127 3559 bp mRNA ROD 08-NOV-2000  
 LOCUS Mus musculus PKC-regulated kinase PKK mRNA, complete cds.  
 ACCESSION AF302127  
 VERSION AF302127.1 GI:11120430  
 KEYWORDS house mouse.  
 SOURCE Mus musculus  
 ORGANISM Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.  
 REFERENCE 1 (bases 1 to 3559)  
 AUTHORS Chen, L., Haider, K., Carlappa, A., Rowitch, D. and Pillai, S.

PKK, a novel ankyrin repeat-containing protein kinase regulated by protein kinase C-beta

Unpublished  
 2 (bases 1 to 3559)  
 Chen.L., Halder.K., Ciriappa.A. and Pillai.S.  
 Direct Submission  
 Submitted (01-SEP-2000) Cancer Center, Massachusetts General Hospital, 149 13th Street, Charlestown, MA 02129-2060, USA

FEATURES  
 source 1..3559  
 /organism="Mus musculus"  
 /strain="BALB/c"  
 /db\_xref="taxon:10090"  
 50..2410  
 /codon\_start=1  
 /product="PKC-regulated kinase PKK"  
 /protein\_id="AAG30871.1"  
 /db\_xref="GI:11120431"  
 /translation="MEGRRGRWALGLRITFDGEFAGWEKVKGGGQVYKRVHWH KTWLAIKPSLHVDDREMLEEAKMEMAKFRYILPVYRICEQEPVGLVMEYMETG SLEKLAEPDLRFRIVHETAAGMFLMCMSPPLHLLDLKPANILLDAHVIKITS DFGLKCNHSDLSMDGLFGTIAYLPPERIREKSLRFDTKHDVYSAFTIWIWVLT QKKPFADKNLHTMMKVVKGHRPELPPICPPRACASLIGLWQRCHADPOVPTP QEITSVDECIKEDVYKDLAHEPGEKSSLESSEARPESSRLKRAAPFFDNDCSL SELLSQDGSIGSQLEGGPEELSRSSSEKLPSSSSKRLSGVSVDSAFSSRGSLSL FERASTGLDGLPTDIQKKLVDAIISDGTSLKMLIQPDVDLSDSSALLHLDAVEA GQEEVKSLLNPNMNRKGSTPLHMAVRKRGITVELLARKTSVAKDDDQWT ALHFAAQNGEASPRALLEKNASVNEVDFQEPHMAVOCQGOENIVRLLRRVGVG LOGDKMALPLHYAAWQHLPVILKAKOPGVSNVAOPLDGTPLHAAORGHVARI LIDLCSQVNSICLQAOPTPLVAETGHTSTARLLHRGAKKALTSYGYTALHAAQON LHLATVKLIEERADYMARGLNQTALHAAAGHSEVVEVLEADLIDLSDEQGLSA HLAAQRHRSQTVETLRLHGAHNLQSLKFTGGGSSAATLLRRSKT"

BASE COUNT 826 a 901 c 1000 g 832 t  
 ORIGIN

Query Match 4.9%; Score 102.4; DB 94; Length 3559;  
 Best Local Similarity 51.8%; Pred. No. 1.4e-08;  
 Matches 372; Conservative 0; Mismatches 316; Indels 30; Gaps 5;

Qy 287 ctgccaccattccctaccacaaaactccgacacctgcgtaactgagccgcccctct 346  
 Db 89 CTGCCACCTTCGRAGCCCGCGCAATTCCGACGGCTGGAGAGGTCGGCTCGGCGGCTTC 148  
 Qy 347 ggcactgtgtccgcccaccgacagcagctggcgcctccaggtgccccggtgaaacacctg 406  
 Db 149 GGGCAGGTTGTAAGGTCGGCATTGTGCACATGGAACAGCGTGCCTGCAGTAAGTCTCG 208  
 Qy 407 cacatccactccgctgctgacagtgacaagaagaagattgttttaagaagaagtgaatt 466  
 Db 209 CCCAGTC---TGCAGTGCACAGGAGAACGAAATGGAGCTCCTGGAGGAAGTAAGAAG 265  
 Qy 467 ttacacaagctagattagttacatttttcccaatttggaaatttcgaatgagcctgaa 526  
 Db 266 ATGGAGATGCCAAGTTCGGATACATATGAGACAGGCTCCTCGAAAGAGCTGTCGCCCTCA 379  
 Qy 527 tttttggaaatagttactgaatcccaaatgacatcaataataatgaaactctcactatagg 586  
 Db 324 ---TCGGCTTGGTATGAGTACATATGAGACAGGCTCCTCGAAAGAGCTGTCGCCCTCA 379  
 Qy 587 aaaactgaatcctgattgtgttggcattgagatttgcacatcctcctcgtcgtcgaattgccc 646  
 Db 380 GAGCCAT-----TGCCTTGGACCTCGCCTTTTTCGCATCTGTCGACGAGACAGC 427  
 Qy 647 ctgtgtgaaatcctgcacaataatgactcctcctcctcctcctcctcctcctcctcctgaaact 706  
 Db 428 GTGGCATCAACTCTCTGATGCTGCTCGCCACCTGTCACCTGTGACCTGAGCCGAGCACA 487  
 Qy 707 cagaatacttattggacaatgaattcctgatttaagattgagatttggatttggatttatacaag 766  
 Db 488 CGGAACATCCCTGCTGGATGCCACTACCATGTCAAGATTTCTGACTTTGGCTGCCCAAG 547  
 Qy 767 tggcgatgatgtccctcctccagtcacgaagtgcacaaatctgcaccgaagaggagaca 826

Db 548 TCCAATGGCATGTCCCACTCTCAGGACCTCAGCATGGATGGCTGTTT-----GGTACA 601  
 Qy 827 attatttatggaccacctgaaacactatgaacctgacaaaataaagaagccatgatcaag 886  
 Db 602 ATCGCTTACCCTCCAGAGCGGAATT---CGTGAAGAGAGCGCGCTTTGTTGACACCACAA 658  
 Qy 887 cagcatatatagctatgctgtatcagatgataatgctgagtgatttccagaaaacagcctttt 946  
 Db 659 CATGATGTATACAGCTTCGCCATTGCTGATCTGGGGTGCTTACACAGAGAGGCAACTT 718  
 Qy 947 gaagatgtcccaaatccctttgcagataatgctgagctggttcacaaaggacatcgacctg 1004  
 Db 719 GCAGATGAAAGAACATCCTACACATCATGATGAAAGTGGTAAAGGCGCCACGCGCCAG 776

RESULT 9  
 HSA278016  
 LOCUS HSA278016 3879 bp mRNA PRI 19-NOV-2000  
 DEFINITION Homo sapiens mRNA for protein kinase (dik gene).  
 ACCESSION AJ278016  
 VERSION AJ278016.1 GI:9886710  
 KEYWORDS dik gene; protein kinase.  
 SOURCE human.  
 ORGANISM Homo sapiens  
 Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;  
 Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.  
 REFERENCE 1 (bases 1 to 3879)  
 AUTHORS Bahr,C., Rohwer,A., Stampka,L., Rincke,G., Marks,F. and Gschwendt,M.  
 TITLE Dik, a Novel Protein Kinase That Interacts with Protein Kinase Cdelta. CLONING, CHARACTERIZATION, AND GENE ANALYSIS  
 J. Biol. Chem. 275 (46), 36350-36357 (2000)  
 REFERENCE 2 (bases 1 to 3879)  
 Gschwendt,M.  
 DIRECT SUBMISSION  
 TITLE Dik, a Novel Protein Kinase That Interacts with Protein Kinase Cdelta.  
 JOURNAL Submitted (18-MAY-2000) Gschwendt M., Biochemistry of Tissue-specific Regulation, German Cancer Research Center, Im Neuenheimer Feld 280, D-69151 Heidelberg, GERMANY  
 FEATURES  
 source 1..3879  
 /organism="Homo sapiens"  
 /db\_xref="taxon:9606"  
 /clone\_lib="HaCat"  
 49..3843  
 /gene="dik"  
 49..2403  
 /gene="dik"  
 /function="protein phosphorylation"  
 /codon\_start=1  
 /evidence="experimental"  
 /product="protein kinase"  
 /protein\_id="CAC04247.1"  
 /db\_xref="GI:9886711"  
 /translation="MEGDGGTWPALALLRITFDAGEFTGWKVKGGGQVYKRVHWH KTWLAIKPSLHVDDREMLEEAKMEMAKFRYILPVYRICEQEPVGLVMEYMETG SLEKLAEPDLRFRIHETAAGMFLMCMAPPLHLLDLKPANILLDAHVIKITS DFGLKCNHSDLSMDGLFGTIAYLPPERIREKSLRFDTKHDVYSAFTIWIWVLT QKKPFADKNLHTMMKVVKGHRPELPPICPPRACASLIGLWQRCHADPOVPTP QEITSVDECIKEDVYKDLAHEPGEKSSLESSEARPESSRLKRAAPFFDNDCSL SELLSQDGSIGSQLEGGPEELSRSSSEKLPSSSSKRLSGVSVDSAFSSRGSLSL FERASTGLDGLPTDIQKKLVDAIISDGTSLKMLIQPDVDLSDSSALLHLDAVEA GQEEVKSLLNPNMNRKGSTPLHMAVRKRGITVELLARKTSVAKDDDQWT ALHFAAQNGEASPRALLEKNASVNEVDFQEPHMAVOCQGOENIVRLLRRVGVG LOGDKMALPLHYAAWQHLPVILKAKOPGVSNVAOPLDGTPLHAAORGHVARI LIDLCSQVNSICLQAOPTPLVAETGHTSTARLLHRGAKKALTSYGYTALHAAQON LHLATVKLIEERADYMARGLNQTALHAAAGHSEVVEVLEADLIDLSDEQGLSA HLAAQRHRSQTVETLRLHGAHNLQSLKFTGGGSSAATLLRRSKT"

polya\_signal 807 a 1074 c 1178 g 820 t  
 BASE COUNT  
 ORIGIN



Matches 202; Conservative 0; Mismatches 201; Indels 0; Gaps 0;

QY 360 ccgcccgcacagactggcgcgctcccaagtgccgctgaagcaccctgacatccacacac 419  
 Db 1808 TGACAGAATATTTTCAAGAGCTAGTTTATACAGACTTTTGCATGAAAGTGGAGCAAGG 2047  
 QY 600 ctgagtgtgctggcaccatgattcgcactcctcgcacatgcaaaatggtgtgtaatt 659  
 Db 2048 AGCAAAATAGATGAGAGACGCTCCCTGAGTATGCTGATGGCTTATGATGCTGGCTAAGGAATGAAT 2107  
 QY 660 acctgcaacaatgatcctcttactctcatcgaactggaagcctcaagatactctat 719  
 Db 2108 ATCTTCACAAATGCGCAATCTCCAAATGTCATGAGAGACTAAATCTCCAAATCTTATGG 2167  
 QY 720 tggacaatgattcatgtaagattcgcactcctcgcacatgcaaaatggtgtgtaatt 762  
 Db 2168 TTGACAAAAATATACAGTCAAGTTTGATTTGGTCTCTC 2210

RESULT 13  
 AF110519  
 LOCUS AF110519 2767 bp mRNA PLN 28-JAN-1999  
 DEFINITION Lycopersicon esculentum ethylene-inducible CTR1-like protein kinase mRNA, complete cds.  
 ACCESSION AF110519  
 VERSION AF110519.1 GI:4193949  
 KEYWORDS tomato.  
 SOURCE Lycopersicon esculentum  
 ORGANISM Lycopersicon esculentum  
 Eukaryota; Viridiplantae; Embryophyta; Tracheophyta; Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots; Asteridae; euasterids I; Solanales; Solanaceae; Solanum; Lycopersicon.  
 REFERENCE 1 (bases 1 to 2767)  
 AUTHORS Kannan,P. and Giovannoni,J.J.  
 TITLE Ethylene-inducible tomato CTR1-like protein kinase  
 JOURNAL Unpublished  
 REFERENCE 2 (bases 1 to 2767)  
 AUTHORS Kannan,P. and Giovannoni,J.J.  
 TITLE Direct Submission  
 JOURNAL Submitted (02-DEC-1998) Horticultural Sciences, Texas A&M University, Mail Stop 2133, College Station, TX 77843-2133, USA  
 FEATURES  
 source  
 1..2767  
 /organism="Lycopersicon esculentum"  
 /cultivar="Ailsa Craig"  
 /db\_xref="taxon:4081"  
 /chromosome="2"  
 /map="between TG33 and CTR106A"  
 67..2487  
 /note="protein kinase homolog; ethylene and fruit ripening inducible CTR1-like protein kinase; TCTR1v"  
 /codon\_start=1  
 /product="ethylene-inducible CTR1-like protein kinase"  
 /protein\_id="AAI0057.1"  
 /db\_xref="GI:4193950"  
 /translation="MSGRSSVYLLNQPNDNFOPAPKFSAGAGVLPYESSAAEK  
 NRKVFDDLMDRMQQSRVPSIGSQKQSGSFRGSLSEAVYVGTSG  
 HNKECCSVARNWAQQTEESYQQLALAIRLSSEATCDFNFDVYLRSDS  
 STASAVTMSHRLWINGCWSYEDKPDGYWYVWYVWALCVVQDLAKLVCDHMGGA  
 AVDFSKAPSVELIVRCNLSKELQNRHISFCSTTKKAEVDQAKLVCDHMGGA  
 APAGBEELVSMKSGCSNDLKRFRFTIVLPVIGSLVSLVGLCHRALLFKVLADIIDLPRI

QY 540 ttactgaatacagccaaatggatcattaaatgaactcctcctacatagaaactgaatc 599  
 Db 1988 TGACAGAATATTTTCAAGAGCTAGTTTATACAGACTTTTGCATGAAAGTGGAGCAAGG 2047  
 QY 600 ctgagtgtgctggcaccatgattcgcactcctcgcacatgcaaaatggtgtgtaatt 659  
 Db 2048 AGCAAAATAGATGAGAGACGCTCCCTGAGTATGCTGATGGCTTATGATGCTGGCTAAGGAATGAAT 2107  
 QY 660 acctgcaacaatgatcctcttactctcatcgaactggaagcctcaagatactctat 719  
 Db 2108 ATCTTCACAAATGCGCAATCTCCAAATGTCATGAGAGACTAAATCTCCAAATCTTATGG 2167  
 QY 720 tggacaatgattcatgtaagattcgcactcctcgcacatgcaaaatggtgtgtaatt 762  
 Db 2168 TTGACAAAAATATACAGTCAAGTTTGATTTGGTCTCTC 2210

RESULT 12  
 ATHCTRIA  
 LOCUS ATHCTRIA 3033 bp mRNA PLN 27-APR-1993  
 DEFINITION Arabidopsis thaliana negative regulator of the ethylene response pathway (CTR1) mRNA, complete cds.  
 ACCESSION L08789  
 VERSION L08789.1 GI:166679  
 KEYWORDS ethylene response pathway; negative regulator; protein kinase.  
 SOURCE Arabidopsis thaliana (strain Columbia) dark grown seedling (3 days old) hypocotyl and cotyledon cDNA to mRNA.  
 ORGANISM Arabidopsis thaliana  
 Eukaryota; Viridiplantae; Embryophyta; Tracheophyta; Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots; Rosidae; eurosids II; Brassicales; Brassicaceae; Arabidopsis.  
 REFERENCE 1 (bases 1 to 3033)  
 AUTHORS Kieber,J.J., Rothenberg M., Roman,G., Feldmann,K.A. and Ecker,J.R.  
 TITLE CTR1, a negative regulator of the ethylene response pathway in Arabidopsis, encodes a member of the Raf family of protein kinases  
 JOURNAL Cell 72, 427-441 (1993)  
 MEDLINE 93161417  
 FEATURES  
 Location/Qualifiers  
 1..3033  
 /organism="Arabidopsis thaliana"  
 /strain="Columbia"  
 /db\_xref="taxon:3702"  
 /dev\_stage="dark grown seedling (3 days old)"  
 /tissue\_type="hypocotyl and cotyledon"  
 118..2583  
 /gene="CTR1"  
 118..2583  
 /gene="CTR1"  
 /codon\_start=1  
 /product="protein kinase"  
 /protein\_id="AAA32779.1"  
 /db\_xref="GI:166680"  
 /translation="MEMPGRSNVTLLSOFSDDOVSVVGTGAPPHPHDSLSNRSNH  
 NSGNTGKAKERGFQDPDPSGGGGDLNPNRQVGNMYASSLGLQRQSGSFG  
 SLSGDIYMPYLSRAANLESYVGFQDDGRFLRGGGDLRIQMAADSGSSSGKS  
 WAQTEESYQLALAIRLSSEATCDPFLPVPDESALRTSPSAEYVSHRFPWN  
 GCLSYDKPDPVNGMLDPIWTLCIDLHESGRIPSIESLRVDSGDVLELAIIY  
 DRRDPAPKELNRVHDIKSCYITKEVVDOLAKLINCRMGGPVMGDELVPPWKEC  
 IDGLKELFKVVPVIGSLVGLCHRALLFKVLADIIDLPRIAKGCKYCNRDDAASCL  
 VRFGLREYLDLVCKPGHLEPDSLLNCPSSISLSPREPREKPVPEVDFRLLAK  
 QYFSDSSQNLVFPASDDMGFSMFHQYDNPNGDALAENGGSLPPSAMMPQNN  
 MRAENQIEAAPNAPPISQVPRNANRELDGDDMIPWCDLNIKERKIGAGSEGTVH  
 RAHWGSDVAVKILMEQDFHAERNEFLRVAIMKRLRPNVIFPMGAVTOPPLNSIV  
 TEYLSRGLYRLLHKSGAREQLDERRRLSMAYDVAKGMNVLHNRNPPVIVHRDLKSPNL  
 LVDKKYVFKVDFGLSRKASTFLSSKSAAGTPWMAPEVLRDEPSNEKSDVYSEFYI  
 LWELATLQPPNGNLNPAQVAAGVFKKRLRLEIPRLNPOVAAILLEGTCWNEPWRKPSF  
 ATIMDLRLPLKSAVPPNRSDL"

BASE COUNT 797 a 605 c 751 g 880 t  
 ORIGIN  
 Query Match 3.9%; Score 81.4; DB 13; Length 3033;  
 Best Local Similarity 50.1%; Pred. No. 7.6e-05;



OY 740 aagattgcagatttttggtttac 762  
 ||||| | | | | | | | | | |  
 Db 2149 AAGATCTGTGATTGGTCTTC 2171

Search completed: June 13, 2001, 17:39:55  
 Job time: 9374 sec

ACCESSION AF110518  
 VERSION AF110518.1 GI:4193947  
 KEYWORDS tomato.  
 SOURCE Lycopersicon esculentum  
 ORGANISM Lycopersicon esculentum  
 Eukaryota; Viridiplantae; Embryophyta; Tracheophyta; Spermatophyta;  
 Magnoliophyta; eudicotyledons; core eudicots; Asteridae; euasterids  
 I; Solanales; Solanaceae; Solanum; Lycopersicon.  
 REFERENCE 1 (bases 1 to 2836)  
 AUTHORS Kannan, P. and Giovannoni, J. J.  
 TITLE Ethylene-inducible tomato CTR1-like protein kinase  
 JOURNAL Unpublished  
 REFERENCE 2 (bases 1 to 2836)  
 AUTHORS Kannan, P. and Giovannoni, J. J.  
 TITLE Direct Submission  
 JOURNAL Submitted (02-DEC-1998) Horticultural Sciences, Texas A&M  
 University, Mail Stop 2133, College Station, TX 77843-2133, USA

FEATURES  
 source  
 1..2836  
 /organism="Lycopersicon esculentum"  
 /cultivar="Ailsa Craig"  
 /db\_xref="taxon:4081"  
 /chromosome="2"  
 /map="between TG33 and CT106A"  
 67..2556  
 /note="protein kinase homolog; ethylene and fruit ripening  
 inducible CTR1-like protein kinase; TCTR1"  
 /codon\_start=1  
 /product="ethylene-inducible CTR1-like protein kinase"  
 /protein\_id="AAD10056.1"  
 /db\_xref="GI:4193948"

CDS  
 /translation="MSGRSSYYLLNLQIPNDFQPPAFKFSAGAVLPGYESSAER  
 NRGKVFDDLMDQRMOSHNRVFRVPSGIGSOKSTEGSFRGSSLSGENVGTSTFG  
 HNEGCGSSVARNWAQTEESYQLQALAIRLSEKATCADSPFDLVLSRDSG  
 STASATMSELWINGCNSYFKVYDGYWGYWALCSVVOESGRIPSESLK  
 AVDSKAPSEVELIVRCNDLSLREKINRHSISPCITTRKAVDQLAKLYCDHMGGA  
 APAGEEELVSMKSGCNDLDRFGTIVLPIGSLVGLRHRALLFKVLADIDLPRI  
 AKGKYCNDSACLVEFDREHLYDLIGKPGVLESDPVLNGPFSISIPLRFP  
 RYRVPTTDFERSLAKOVFLDSQSLNLFLLDSSAGAAADGAGSDRSCIDRNNVSS  
 SSNRDEISOLPPLNAWKGRDKESQLSKWYRPMNPNVNMDEDVFLVKKVPPFRE  
 DAQSPFTRPDYVTRFLAGGHHVSAIAPSEELLDVEEFNIPWNDIIVLMEKIGAGSF  
 GTVHRDGHGSDVAVKILMEQDFHAERLEKELREVAIMKRLRHPNIVLPMGAVIQPPN  
 LSIYVLESRLVLLHKGAKKVLDERPCLCLAYDVANGMNYLHKRNPPVIHREDLK  
 SPNLLVDKYYTVKICDFGLSKANTFLSKTAAGTPEWMAPEVIRDEPSNEKSDVYS  
 FGVLLWELATLQOPWKNLPPQVIAAVGNFRKKLLDIPVNLPRVAIIIEACWANEPWK  
 RPSFSTINDMLRHLKSLPPLPPHTDMLLS"

BASE COUNT 745 a 567 g 672 G 852 T  
 ORIGIN

Query Match 3.7%; Score 78.2; DB 12; Length 2836;  
 Best Local Similarity 52.6%; Pred No. 0.00028;  
 Matches 170; Conservative 0; Mismatches 153; Indels 0; Gaps 0;

OY 440 aagattgttttaagagaagctgaaattttacacaaagctagatttagttacattttcca 499  
 ||||| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |  
 Db 1849 AAGAAATTTTGAGGAGGTTGCAATTAAGCGGTTGCGACATCCAAATATTGTACTT 1908

OY 500 attttggaaatttgcaactgaaatttttgggaatagtactgaaatacatgccccaaat 559  
 || | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |  
 Db 1909 TTTATGGGTGTCATTTCAGCCACCAAATTTGTCATAGTCCAGGAATATTATCGAGA 1968

OY 560 ggatcatataatgaactctacacacacaaactgaatccctgagtgtcttggccattg 619  
 || | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |  
 Db 1969 GGTACTTATATAGACTTCTTCATAAACCCTGGTGGCAAAAAGTGTGGATGAAGGCCT 2028

OY 620 agatttgcctcctcatgaataattcccttggttgtaaatccctgcacacaatgatcctc 679  
 || | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |  
 Db 2029 CCCCTGTGTGTTTACGATGGCCATGGATGAATATTCTCACAAACGCAATCCT 2088

OY 680 cctttactcatcatgacttgaagactcagaatattctttatggacaaatgaaattcattgt 739  
 || | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |  
 Db 2089 CCCATTTGTCACCGAGTTTAAAATCTCCAAATCTCTTAGTAGACAAAAAATATACAGTG 2148

**THIS PAGE BLANK (USPTO)**

---



GenCore version 4.5  
Copyright (c) 1993 - 2000 Compugen Ltd.

OM protein - protein search, using sw model

Run on: June 14, 2001, 08:04:28 ; Search time 14.27 seconds  
(without alignments)  
762.306 Million cell updates/sec

Title: US-09-445-223-1  
Perfect score: 2829  
Sequence: 1 MNGEATCSALPTIPYHKLAD.....PEILVYSRPSLNLQKSM 540

Scoring table: BLSUM62  
Gapop 10.0 , Gapext 0.5

Searched: 193259 seqs, 20144635 residues

Total number of hits satisfying chosen parameters: 193259

Minimum DB seq length: 0  
Maximum DB seq length: 2000000000  
Post-processing: Minimum Match 0%  
Maximum Match 100%  
Listing first 45 summaries

- Database : Issued\_Patents\_AA.\*
- 1: /cgn2\_6/ptodata/1/1aa/5A\_COMB.pep.\*
  - 2: /cgn2\_6/ptodata/1/1aa/5B\_COMB.pep.\*
  - 3: /cgn2\_6/ptodata/1/1aa/6A\_COMB.pep.\*
  - 4: /cgn2\_6/ptodata/1/1aa/6B\_COMB.pep.\*
  - 5: /cgn2\_6/ptodata/1/1aa/PC1US\_COMB.pep.\*
  - 6: /cgn2\_6/ptodata/1/1aa/backfiles1.pep.\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	2817	99.6	540	US-09-019-942-1	Sequence 1, Appli
2	576	20.4	787	US-09-188-930-334	Sequence 334, App
3	536	18.9	536	US-09-188-930-185	Sequence 185, App
4	394	13.9	656	US-08-444-005-15	Sequence 15, Appl
5	389	13.8	518	US-09-329-418-9	Sequence 9, Appli
6	388	13.7	518	US-09-329-418-3	Sequence 3, Appli
7	386.5	13.7	420	US-09-329-418-8	Sequence 8, Appli
8	385	13.6	518	US-09-329-418-5	Sequence 5, Appli
9	380	13.4	518	US-09-329-418-4	Sequence 4, Appli
10	376	13.3	821	US-07-928-464-2	Sequence 2, Appli
11	376	13.3	821	US-08-003-411B-2	Sequence 2, Appli
12	376	13.3	821	US-08-261-432-2	Sequence 2, Appli
13	376	13.3	821	PCT-US93-07347-2	Sequence 2, Appli
14	372	13.1	261	US-09-329-418-6	Sequence 6, Appli
15	369	13.0	263	US-09-033-706-5	Sequence 5, Appli
16	369	13.0	671	US-08-955-841-5	Sequence 5, Appli
17	369	13.0	671	US-09-132-118-2	Sequence 2, Appli
18	369.	13.0	709	US-08-444-005-17	Sequence 17, Appl
19	292.5	10.3	668	US-08-205-018-2	Sequence 2, Appli
20	292.5	10.3	859	US-08-395-580-2	Sequence 2, Appli
21	292.5	10.3	859	PCT-US95-02792-2	Sequence 2, Appli
22	291.5	10.3	455	US-09-221-235-5	Sequence 5, Appli
23	291.5	10.3	455	US-09-221-928-5	Sequence 5, Appli
24	291.5	10.3	455	US-09-221-527-5	Sequence 5, Appli
25	291.5	10.3	455	US-09-221-236-5	Sequence 5, Appli
26	291.5	10.3	455	US-09-221-416-5	Sequence 5, Appli
27	291.5	10.3	455	US-09-221-245-5	Sequence 5, Appli

28	291.5	10.3	455	4	US-09-163-115-5	Sequence 5, Appli
29	291.5	10.3	455	4	US-09-221-528-5	Sequence 5, Appli
30	291.5	10.3	455	4	US-09-593-553-5	Sequence 5, Appli
31	291.5	10.3	455	4	US-09-221-237-5	Sequence 5, Appli
32	289.5	10.2	999	2	US-08-473-553A-5	Sequence 5, Appli
33	283.5	10.0	712	1	US-08-587-889-2	Sequence 2, Appli
34	283.5	10.0	712	2	US-08-980-060-5	Sequence 5, Appli
35	283.5	10.0	712	4	US-09-307-185-5	Sequence 5, Appli
36	283.5	10.0	712	5	PCT-US96-09193-2	Sequence 2, Appli
37	274.5	9.7	527	5	PCT-US95-05008-10	Sequence 10, Appl
38	265	9.4	279	2	US-08-701-191A-37	Sequence 37, Appl
39	264.5	9.3	271	3	US-09-033-706-6	Sequence 6, Appli
40	264.5	9.3	271	3	US-08-955-841-6	Sequence 6, Appli
41	264	9.3	326	1	US-08-571-758-11	Sequence 11, Appl
42	264	9.3	326	1	US-08-909-984A-11	Sequence 11, Appl
43	264	9.3	326	1	US-08-909-983-11	Sequence 11, Appl
44	261.5	9.2	544	2	US-08-587-680A-25	Sequence 25, Appl
45	260	9.2	588	1	US-08-391-615-5	Sequence 5, Appli

ALIGNMENTS

```

RESULT 1
US-09-019-942-1
: Sequence 1, Application US/09019942
: Patent No. 6033855
: GENERAL INFORMATION:
: APPLICANT: Bertlin, John
: TITLE OF INVENTION: GENES ENCODING CASPASE RECRUITMENT
: NUMBER OF SEQUENCES: 4
: CORRESPONDENCE ADDRESS:
: ADDRESS: Fish & Richardson P.C.
: STREET: 225 Franklin Street
: CITY: Boston
: STATE: MA
: COUNTRY: USA
: ZIP: 02110-2804
: COMPUTER READABLE FORM:
: MEDIUM TYPE: Diskette
: COMPUTER: IBM Compatible
: OPERATING SYSTEM: Windows 95
: SOFTWARE: FASTSEQ for Windows Version 2.0b
: CURRENT APPLICATION DATA:
: APPLICATION NUMBER: US/09/019,942
: FILING DATE: 06-FEB-1998
: PRIORITY APPLICATION NUMBER:
: APPLICANT INFORMATION:
: FILING DATE:
: ATTORNEY/AGENT INFORMATION:
: NAME: Meiklejohn, Ph.D., Anita L.
: REGISTRATION NUMBER: 35,283
: REFERENCE/DOCKET NUMBER: 07334/0688001
: TELECOMMUNICATION INFORMATION:
: TELEPHONE: 617/542-5070
: TELEFAX: 617/542-8906
: INFORMATION FOR SEQ ID NO: 1:
: LENGTH: 540 amino acids
: TYPE: amino acid
: TOPOLOGY: linear
: MOLECULE TYPE: protein
US-09-019-942-1

Query Match          99.6%; Score 2817; DB 3; Length 540;
Best Local Similarity 99.6%; Pred. No. 1.5e-260;
Matches 538; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1 MNGEATCSALPTIPYHKLADRLYLSRGASGTVSSRHARHMVQAVKHLHIHTPLDLSR 60
|||||

```

Db 1 MNGEATCSALPTTPYHKLADRLVSRGASGTVSSARHADRWVQAVKHLHIHTPLDLSR 60  
 Qy 61 KDVLRRAEILHKARFSYIFPILGICNEPEFLGIVTEYMPNGSINELLHRKTEYPPDVAMP 120  
 Db 61 KDVLRRAEILHKARFSYIFPILGICNEPEFLGIVTEYMPNGSINELLHRKTEYPPDVAMP 120  
 Qy 121 RFRILHEIALGVNYLHMTPPLLDHDLKTONILLDNEFHVKIADFGLSKRWMSLSQSRS 180  
 Db 121 RFRILHEIALGVNYLHMTPPLLDHDLKTONILLDNEFHVKIADFGLSKRWMSLSQSRS 180  
 Qy 181 SKSAPGGTIYMPENYEPGOKSRASIKHDIYSYAVITWELSRKQPEDVTNPLQIMY 240  
 Db 181 SKSAPGGTIYMPENYEPGOKSRASIKHDIYSYAVITWELSRKQPEDVTNPLQIMY 240  
 Qy 241 SVSQGHRPVINEESLPYDIPHRARMISLESQWAQNDPERSFLKCLIELEPVLFRTFEEI 300  
 Db 241 SVSQGHRPVINEESLPYDIPHRARMISLESQWAQNDPERSFLKCLIELEPVLFRTFEEI 300  
 Qy 301 TFLAVIQLKTKLQSVSSAIHLCDKMKMELSLNIPVNHGPOEESCGSSQLHENSQSPET 360  
 Db 301 TFLAVIQLKTKLQSVSSAIHLCDKMKMELSLNIPVNHGPOEESCGSSQLHENSQSPET 360  
 Qy 361 SRSLPAPQDNDFLSRAQDCYFMKLLHCFGNHSWDSSTISGSQRAAFCDHKTTPCSSAIIN 420  
 Db 361 SRSLPAPQDNDFLSRAQDCYFMKLLHCFGNHSWDSSTISGSQRAAFCDHKTTPCSSAIIN 420  
 Qy 421 PLSTAGNSERLQPCIAQOVIOSKREDIVNOMTEACLNQSLDALLSRDLIMKEDYELVSTK 480  
 Db 421 PLSTAGNSERLQPCIAQOVIOSKREDIVNOMTEACLNQSLDALLSRDLIMKEDYELVSTK 480  
 Qy 481 PRTSKVROLDDTTDIOGEBFAKVIQKLDKNKQMGLOQPEYELLVYVSRSPSLNLLQKSM 540  
 Db 481 PRTSKVROLDDTTDIOGEBFAKVIQKLDKNKQMGLOQPEYELLVYVSRSPSLNLLQKSM 540

RESULT 2  
 US-09-188-930-334  
 ; Sequence 334, Application US/09188930A  
 ; Patent No. 6150502  
 ; GENERAL INFORMATION:  
 ; APPLICANT: Watson, James D.  
 ; APPLICANT: Strachan, Lorna  
 ; APPLICANT: Sleeman, Matthew  
 ; APPLICANT: Onrust, Rene  
 ; APPLICANT: Murison, James Greg  
 ; TITLE OF INVENTION: Compositions Isolated From Skin Cells  
 ; FILE REFERENCE: 11000.1011c1  
 ; CURRENT FILING DATE: 1998-11-09  
 ; NUMBER OF SEQ ID NOS: 348  
 ; SOFTWARE: FastSeq for Windows Version 3.0  
 ; SEQ ID NO 334  
 ; LENGTH: 787  
 ; TYPE: PRT  
 ; ORGANISM: Mouse  
 US-09-188-930-334

Query Match 20.4%; Score 576; DB 4; Length 787;  
 Best Local Similarity 33.6%; Pred. No. 2.4e-46;  
 Matches 169; Conservative 64; Mismatches 154; Indels 116; Gaps 20;  
 Qy 10 LPTPYHKLADRLVSRGASGTVSSARHADRWVQAVK---HLHIHTPLDLSRDKVLR 66  
 Db 15 LRTFDAGEFAGWEKVGSGGQYKVRHVHWKTLAICSPSLHVD---DRERMELLE 70  
 Qy 67 AEILHKARFSYIFPILGICNEPEFLGIVTEYMPNGSINELLHRKTEYPPDVAMP 126  
 Db 71 AKKEMAKFRILPVYICQEP--VGLVMEYMETGSEKLLASE---PLPDLRFRIVH 124  
 Qy 127 EIALGVNYLHMTPPLLDHDLKTONILLDNEFHVKIADFGLSKRWMSLSQSRSKSAPE 186  
 Db 127 EIALGVNYLHMTPPLLDHDLKTONILLDNEFHVKIADFGLSKRWMSLSQSRSKSAPE 186

Db 125 ETAVGMNLFHCMSPPLLDHDLKPANILLDAHYHVKISDFGLAKCMGSHSHDLSM-----D 180  
 Qy 187 G--GTYIYMPENYEPGOKSRA-SIKHDIYSYAVITWELSRKQPEDVTNPLQIMYSVS 243  
 Db 181 GULFGIAYLPPERIR--EKSRFLDTKHVDYFAIYVIGVLTQKKPFADKKNILLHMKV 238  
 Qy 244 QGHRPVINEESLPYDIPHR---ARMISLESQWAQNDPERSFLKCLIELEPVLFRTFEEI 300  
 Db 239 KGRHP---ELPPICRPRACASLIGLMQRCHWADPOVRP-----TFQBI 280  
 Qy 301 TFLAVIQLKTKLQSVSSAIHLCDKMKMELSLNIPVNHGPOEESCGSSQLHENSQSPET 360  
 Db 281 T-----SETEDLCEKPEDEVK---DLAHEPEKESLSSEKSEARPESSL 321  
 Qy 361 SRSLPAPQDNDF-----LSRKAQDCYFMKLL-----HHCPCGNH 392  
 Db 322 KRASAPPDNDGSLSELLSOLDGIGISQTLGPEELSRSSSEC---KLPSSSSGKRLSGVS 378  
 Qy 393 SWDSTIS--GSQRAAF-----CDHKTPCCSSAIINPLSTAGNSERLQPCIAQO 439  
 Db 379 SVDSAFSSRGSLSLSEFEREASTGDLGPTDIOAKKLVDAII-----SGDTSRL---MKI 428  
 Qy 440 IQSKREDIVNOMTEACLNQSLDA 462  
 Db 429 LQPQDVLVLDSSASLLLAVER 451

RESULT 3  
 US-09-188-930-185  
 ; Sequence 185, Application US/09188930A  
 ; Patent No. 6150502  
 ; GENERAL INFORMATION:  
 ; APPLICANT: Watson, James D.  
 ; APPLICANT: Strachan, Lorna  
 ; APPLICANT: Sleeman, Matthew  
 ; APPLICANT: Onrust, Rene  
 ; APPLICANT: Murison, James Greg  
 ; TITLE OF INVENTION: Compositions Isolated From Skin Cells  
 ; FILE REFERENCE: 11000.1011c1  
 ; CURRENT FILING DATE: 1998-11-09  
 ; NUMBER OF SEQ ID NOS: 348  
 ; SOFTWARE: FastSeq for Windows Version 3.0  
 ; SEQ ID NO 185  
 ; LENGTH: 536  
 ; TYPE: PRT  
 ; ORGANISM: mouse  
 US-09-188-930-185

Query Match 18.9%; Score 536; DB 4; Length 536;  
 Best Local Similarity 32.5%; Pred. No. 8.9e-43;  
 Matches 164; Conservative 64; Mismatches 159; Indels 118; Gaps 21;  
 Qy 10 LPTPYHKLADRLVSRGASGTVSSARHADRWVQAVK---HLHIHTPLDLSRDKVLR 66  
 Db 15 LRTFDAGEFAGWEKVGSGGQYKVRHVHWKTLAICSPSLHVD---DRERMELLE 70  
 Qy 67 AEILHKARFSYIFPILGICNEPEFLGIVTEYMPNGSINELLHRKTEYPPDVAMP 126  
 Db 71 AKKEMAKFRILPVYICQEP--VGLVMEYMETGSEKLLASE---PLPDLRFRIVH 124  
 Qy 127 EIALGVNYLHMTPPLLDHDLKTONILLDNEFHVKIADFGLSKRWMSLSQSRSKSAPE 185  
 Db 125 ETAVGMNLFHCMSPPLLDHDLKPANILLDAHYHVKISDFGLAKCMGSHSHDLSM--- 180  
 Qy 186 EG--GTYIYMPENYEPGOKSRA-SIKHDIYSYAVITWELSRKQPEDVTNPLQIMYSV 242  
 Db 181 DGULFGIAYLPPERIR--EKSRFLDTKHVDYFAIYVIGVLTQKKPFADKKNILLHMKV 238  
 Qy 243 SOGHRPVINEESLPYDIPHR---ARMISLESQWAQNDPERSFLKCLIELEPVLFRTFEE 299  
 Db 243 SOGHRPVINEESLPYDIPHR---ARMISLESQWAQNDPERSFLKCLIELEPVLFRTFEE 299

Db 239 YKGRP-----ELPPICRPRACASLIGLMQRCMHADPQVRP-----TFQE 280  
 Qy 300 ITFLEAVIOLKTKLQSYSSATHLGDKKMELSLNIPVNHGPOEESCGSSQLHENSQSP 359  
 Db 281 IT-----SETEDLCEKPEDEVK---DLAHEPEKSSLESSEARPESSR 321  
 Qy 360 TSSRLPAPDNDF-----LSRKAQDCYFMKL-----HHCPCG 390  
 Db 322 LKRASAPFDNDCSLSELLSOLDSGIFPRLLKGPPELSRSSEC---KLPSSSSGKRLSG 378  
 Qy 391 NHSWSTIS--GSQRAAF-----CDHKTPCSAIINPLSTAGNSRRLQPGIAQ 437  
 Db 379 VSSYDFAESRGLSLSEFEREASTGLDPTDIQKKLKYDAIIT-----SGDTSRL-----M 428  
 Qy 438 OWIOSKREDIVNQMTAEACLNQSLDA 462  
 Db 429 KILQPDVDLVDSSASLLHLAVEA 453

RESULT 4  
 US-08-444-005-15  
 ; Sequence 15, Application US/08444005  
 ; Patent No. 5674734  
 ; GENERAL INFORMATION:  
 ; APPLICANT: Leder, Philip  
 ; APPLICANT: Seed, Brian  
 ; APPLICANT: Stanger, Ben Z.  
 ; APPLICANT: Lee, Tae-Ho  
 ; APPLICANT: Kim, Emily  
 ; TITLE OF INVENTION: CELL DEATH PROTEIN  
 ; NUMBER OF SEQUENCES: 35  
 ; CORRESPONDENCE ADDRESS:  
 ; ADDRESS: Fish & Richardson P.C.  
 ; STREET: 225 Franklin Street, Suite 3100  
 ; CITY: Boston  
 ; STATE: MA  
 ; COUNTRY: USA  
 ; ZIP: 02110-2804  
 ; COMPUTER READABLE FORM:  
 ; MEDIUM TYPE: Floppy disk  
 ; COMPUTER: IBM PC compatible  
 ; OPERATING SYSTEM: PC-DOS/MS-DOS  
 ; SOFTWARE: patentin Release #1.0, Version #1.30  
 ; CURRENT APPLICATION DATA:  
 ; APPLICATION NUMBER: US/08/444,005  
 ; FILING DATE:  
 ; CLASSIFICATION: 435  
 ; ATTORNEY/AGENT INFORMATION:  
 ; NAME: Clark, Paul T.  
 ; REGISTRATION NUMBER: 30,164  
 ; REFERENCE/DOCKET NUMBER: 00383/026001.  
 ; TELECOMMUNICATION INFORMATION:  
 ; TELEPHONE: 617/542-5070  
 ; TELEFAX: 617/542-8906  
 ; TELE: 200154  
 ; INFORMATION FOR SEQ ID NO: 15:  
 ; SEQUENCE CHARACTERISTICS:  
 ; LENGTH: 656 amino acid  
 ; TYPE: amino acid  
 ; STRANDEDNESS: not relevant  
 ; TOPOLOGY: linear  
 ; MOLECULE TYPE: protein  
 US-08-444-005-15

Query Match 13.9%; Score 394; DB 1; Length 656;  
 Best Local Similarity 31.08; Pred. No. 4.4e-29;  
 Matches 131; Conservative 66; Mismatches 144; Indels 82; Gaps 19;  
 Qy 24 LSRGASGTSSARHADRWVAVKHLHHTPLLDSEKDV-LREAEILHKARFSYIFPIL 82  
 Db 23 LDSGGFGRVSLCYHRSHGFVILKK---VYTGPNRAYEVNLLLEEGKMMHRLHRSRVKLL 79

Qy 83 GICNEPEFLGIVTEYMPNGSLNELLHRKTEYDVAVMPVLRFRILHEIALGVNLYLHNTTPEL 142  
 Db 80 GIIIEEGYSLVMEYMEKGNLMHVL--KTQI--DVPLSLKGRILVIAIEGMCVLDH--KGV 134  
 Qy 143 LHHDLKTONILDNEFHVKIADFGLSKWRMMS--LSQSRSSKSAP-----EGTIIYM 193  
 Db 135 IHKDLKPENILVDRDFHIKIADLGVASFRTWSKLTKEKDNKQKEYSSTTKKNGGCTLYM 194  
 Qy 194 PPE-----NYEPGQKSRASIKHDIYSYAVITWEVLSRKPDPEDYVNPLOIMYSVQGHPR 248  
 Db 195 APEHLNDLNAKPTKS-----DVSFGIVLWAIFAKKEPYENVICTEQFVICIKSGNRP 248  
 Qy 249 VINE--ESLPYDIPHRARMISLIESGWAQNPDERESFLKCLIELEP-VLRTFEEITFLEA 305  
 Db 249 NVEEILEYCPREI-----ISLMERCWAIPAEDRPTFLGIEEERFPFYLSHPEEYV-ED 301  
 Qy 306 VIOLKK-----TKLOSVAATHLC-----DKKMELSLNPVNHGPOEESCGSSO 350  
 Db 302 VASLKKKEYPDQSPVLRMFLQHDQVPLPPSRNSNEQFGLSHSSQGLQMGVPEESWFS- 360  
 Qy 351 LHENSGSPETSRLPAPODNDFLSRKAQDCYFMKLHHCPCGNHSDSTISSGQRAAFCDHK 410  
 Db 361 -----YPODENDRSVQA-----KLOEASVYHAF-----GIFAQK 393  
 Qy 411 TTP 413  
 Db 394 TKP 396

RESULT 5  
 US-09-329-418-9  
 ; Sequence 9, Application US/09329418  
 ; Patent No. 6096539  
 ; GENERAL INFORMATION:  
 ; APPLICANT: ZENECA Limited  
 ; TITLE OF INVENTION: PROTEIN ACTIVATOR OF APOPTOSIS  
 ; FILE REFERENCE: PHM.70536  
 ; CURRENT APPLICATION NUMBER: US/09/329,418  
 ; CURRENT FILING DATE: 1999-06-11  
 ; NUMBER OF SEQ ID NOS: 39  
 ; SOFTWARE: FastSeq for Windows Version 3.0  
 ; SEQ ID NO 9  
 ; LENGTH: 518  
 ; TYPE: PRT  
 ; ORGANISM: Artificial Sequence  
 ; FEATURE:  
 ; OTHER INFORMATION: Dominant Negative Mutant Embodiment  
 US-09-329-418-9

Query Match 13.8%; Score 389; DB 3; Length 518;  
 Best Local Similarity 25.7%; Pred. No. 9.1e-29;  
 Matches 132; Conservative 84; Mismatches 183; Indels 114; Gaps 20;  
 Qy 11 PPIPHKLAADRLYRSRGASGTSSARHADRWVAVKHLHHTPLLDSEKDVLRAEIL 70  
 Db 14 PLVSTEELENOELVKGFGFTVFRQHRKRWGYDVAVKIVN-----SKAISREVKAM 64  
 Qy 71 HKARESYIFPILGICNEPEF-----LGVITYEYMPNGSLNELLHRKTEYDVAVMPVLRFRIL 125  
 Db 65 ASLDNEFVLRLEGVIEKVNWDQDPKALVTKFMENGLSGLLOSCQPRP---WPLDCLRLL 121  
 Qy 126 HEIALGVNLYLHNTTPELHDLKTONILDNEFHVKIADFGLSKWRMMSLSQSRSSKSAP 185  
 Db 122 KEVLLGMFVLDQNPVLLHRLDKPSNVLDPVLLPELHVKLADFGLSFTQ--GGSGSGTSGEP 179  
 Qy 186 EGGTIIYMPENYEPGQKSRASIKHDIYSYAVITWEVLSRKPDPEDYVNPLOIMYSV-SQ 244  
 Db 180 -GGTLGLAPELFL-VNVARKASTADSVYSGILMNAVLAGE-VELPTEPSLVEAVCNR 236  
 Qy 245 GHRPVINEESLPY---DIPHRARMISLIESGWAQNPDERPSFLKCLIELEPVLRTFEE-- 299  
 Db 237 QNRPSLAE--LPOAGPETPGLGELKELMQLCWSSEPKORPSFQECPLPKTDEYFQMVENNM 294

QY 300 -----ITFEAVIOLKK-----TKLQSVSSAIH-----LCKDKKMWELSL 333  
 Db 295 NAAVSTVKDFLSQLRSSNRFRSIPESGGGTGEMDFRRTIENOHRSNRDVMVSEWLKML 354  
 QY 334 NIPVNHGP-----QEE-----SCGSSQLHENSOSPETS----- 361  
 Db 355 EEPSPVPKCPKSLTKRRAQEOVPOAWTAGTSSDSMAOQQTPPTSTFRNQMPST 414  
 QY 362 -RSLPAPQDNDFLSRKAOCY-----FMKLHHCPCGNHSDSTIGSORAAFC 407  
 Db 415 GTPSPGRNGOAGRAEOMNASCRTPEPNVGTGRPLVNIYNCSGVQGDNNYLTMQ----- 469

RESULT 6  
 US-09-329-418-3  
 ; Sequence 3, Application US/09329418  
 ; Patent No. 6096539  
 ; GENERAL INFORMATION:  
 ; APPLICANT: ZENECA Limited  
 ; TITLE OF INVENTION: PROTEIN ACTIVATOR OF APOPTOSIS  
 ; FILE REFERENCE: PHM.70536  
 ; CURRENT APPLICATION NUMBER: US/09/329,418  
 ; CURRENT FILING DATE: 1999-06-11  
 ; NUMBER OF SEQ ID NOS: 39  
 ; SOFTWARE: FastSeq for Windows Version 3.0  
 ; SEQ ID NO 3  
 ; TYPE: PRT  
 ; ORGANISM: Homo Sapiens  
 US-09-329-418-3

Query Match 13.7%; Score 388; DB 3; Length 518;  
 Best Local Similarity 32.0%; Pred. No. 1.1e-28;  
 Matches 102; Conservative 62; Mismatches 125; Indels 30; Gaps 11;  
 QY 11 PPIPYHKLADLRYLRSRGASGTSSARHADRWQVAVKHLHIHTPLLDSEKRVLRRAEIL 70  
 Db 14 PLVSIIELENOELVGGGGFTVFRHQHRKWGYDVAVKIVN-----SKAISREVKAM 64  
 QY 71 HKARFSYFPIILGICNEPEF-----LGIVTEYMPNGSLNELHHRKTEYPDVAMPLRFRIL 125  
 Db 65 ASLDNEFVLRLEGVIEKVNDDQPKPALVTKEFNENGSLGSLQSQCPPR---WPLLCRLL 121  
 QY 126 HEIALGVNYLHNMTPTLLHDLKTONILLDNEFHVKIADFGLSKWRMMSLSQSRSSKSAP 185  
 Db 122 KEVVLGMYFLHDQNPVLLHRDLKPSNVLLDPELHVKLDLDFLSTFQ--GGSQGTGSGEP 179  
 QY 186 EGGTIIYMPENVEPQGKSRASIKHDIYSYAVITWVLSRKQPFEDVTNPLQIMYSV-SQ 244  
 Db 180 -GGTGLYLAPELF-VVNVNRRKASTADSVYSGILMVAWLAGRE-VELPTEPSLYEAVCNR 236  
 QY 245 GHRVINEESLIPY---DIPHRARMISLIESGWAQNPDEPERSFLKCLIELEPVLRTFEEIT 301  
 Db 237 QNRPSLAE--LPQAGPETPGLGKELMQLCWSSEPKDRFQECLEPKTDEVFQMVN--N 292  
 QY 302 FLEAVIOLKTKLQSVSSA 320  
 Db 293 NMNAAVSTVKDFLSQLRSS 311  
 RESULT 7  
 US-09-329-418-8  
 ; Sequence 8, Application US/09329418  
 ; Patent No. 6096539  
 ; GENERAL INFORMATION:  
 ; APPLICANT: ZENECA Limited  
 ; TITLE OF INVENTION: PROTEIN ACTIVATOR OF APOPTOSIS

; FILE REFERENCE: PHM.70536  
 ; CURRENT APPLICATION NUMBER: US/09/329,418  
 ; CURRENT FILING DATE: 1999-06-11  
 ; NUMBER OF SEQ ID NOS: 39  
 ; SOFTWARE: FastSeq for Windows Version 3.0  
 ; SEQ ID NO 8  
 ; LENGTH: 420  
 ; TYPE: PRT  
 ; ORGANISM: Artificial Sequence  
 ; FEATURE:  
 ; OTHER INFORMATION: Delta Death Domain  
 US-09-329-418-8

Query Match 13.7%; Score 386.5; DB 3; Length 420;  
 Best Local Similarity 32.1%; Pred. No. 1.1e-28;  
 Matches 103; Conservative 62; Mismatches 123; Indels 33; Gaps 12;  
 QY 11 PPIPYHKLADLRYLRSRGASGTSSARHADRWQVAVKHLHIHTPLLDSEKRVLRRAEIL 70  
 Db 14 PLVSIIELENOELVGGGGFTVFRHQHRKWGYDVAVKIVN-----SKAISREVKAM 64  
 QY 71 HKARFSYFPIILGI-----CNEPEFLGIVTEYMPNGSLNELHHRKTEYPDVAMPLRFR 123  
 Db 65 ASLDNEFVLRLEGVIEKVGSSQDPK-PALVTKEFNENGSLGSLQSQCPPR---WPLLCR 120  
 QY 124 ILHEIALGVNYLHNMTPTLLHDLKTONILLDNEFHVKIADFGLSKWRMMSLSQSRSSKS 183  
 Db 121 LLKEVVLGMYFLHDQNPVLLHRDLKPSNVLLDPELHVKLDLDFLSTFQ--GGSQGTGSG 178  
 QY 184 APEGGTIIYMPENVEPQGKSRASIKHDIYSYAVITWVLSRKQPFEDVTNPLQIMYSV- 242  
 Db 179 EP-GGTGLYLAPELF-VVNVNRRKASTADSVYSGILMVAWLAGRE-VELPTEPSLYEAVC 235  
 QY 243 SOGHRVINEESLIPY---DIPHRARMISLIESGWAQNPDEPERSFLKCLIELEPVLRTFEE 299  
 Db 236 NQRNPRLAE--LPQAGPETPGLGKELMQLCWSSEPKDRFQECLEPKTDEVFQMVN- 292  
 QY 300 ITFLEAVIOLKTKLQSVSSA 320  
 Db 293 -NMNAAVSTVKDFLSQLRSS 312

RESULT 8  
 US-09-329-418-5  
 ; Sequence 5, Application US/09329418  
 ; Patent No. 6096539  
 ; GENERAL INFORMATION:  
 ; APPLICANT: ZENECA Limited  
 ; TITLE OF INVENTION: PROTEIN ACTIVATOR OF APOPTOSIS  
 ; FILE REFERENCE: PHM.70536  
 ; CURRENT APPLICATION NUMBER: US/09/329,418  
 ; CURRENT FILING DATE: 1999-06-11  
 ; NUMBER OF SEQ ID NOS: 39  
 ; SOFTWARE: FastSeq for Windows Version 3.0  
 ; SEQ ID NO 5  
 ; LENGTH: 518  
 ; TYPE: PRT  
 ; ORGANISM: Dartificial Sequence  
 ; FEATURE:  
 ; OTHER INFORMATION: Dominant Negative Mutant Embodiment  
 US-09-329-418-5

Query Match 13.6%; Score 385; DB 3; Length 518;  
 Best Local Similarity 31.7%; Pred. No. 2.2e-28;  
 Matches 101; Conservative 63; Mismatches 125; Indels 30; Gaps 11;  
 QY 11 PPIPYHKLADLRYLRSRGASGTSSARHADRWQVAVKHLHIHTPLLDSEKRVLRRAEIL 70  
 Db 14 PLVSIIELENOELVGGGGFTVFRHQHRKWGYDVAVKIVN-----SKAISREVKAM 64  
 QY 71 HKARFSYFPIILGICNEPEF-----LGIVTEYMPNGSLNELHHRKTEYPDVAMPLRFRIL 125

```

; : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
Db 65 ASLDNEFVLRLEGVIEKVNWDDPKPALVTKEWENGLSGLLQSQCPRP--WPLICRLL 121
QY 126 HEIALGVNVLHNTWTPPLHLDLKTQNIILLDNFHKIADFGLSKWRMSLSQSRSSKSAP 185
Db 122 KEVVLGFMFLHDQNPVLLHRLDKPNSVLDPELHKLADFLGLSTFQ--GGSQSGTGSGEP 179
QY 186 EGGTIYMPPEYFPGQKSRASIKHDIYSYAVITWEVLSRKQPFEDVNTPLQIMYSV-SQ 244
Db 180 -GCTLGLAPELF-VNVRKASTASDVYSFGILMVAVLAGE-VLPTPEPSLVYEAVCNR 236
QY 245 GHRPVINEESLEY---DIPHRARMSLIESGWAQNDPDRPSPFLKCLIELEPVLRTFEEIT 301
Db 237 QNRPSLAE--LFOAGPETPGLGKELMQLCWSSEPKRPSFQECPLKTDVEVFMVE--N 292
QY 302 FLEAVIQLKTKLQSVSSA 320
Db 293 NNNAAVSTVKDFLSQLRSS 311

```

```

RESULT 9
; Sequence 4, Application US/09329418
; Patent No. 6096639
; GENERAL INFORMATION:
; APPLICANT: ZENECA Limited
; TITLE OF INVENTION: PROTEIN ACTIVATOR OF APOPTOSIS
; FILE REFERENCE: PHM.70536
; CURRENT APPLICATION NUMBER: US/09/329,418
; CURRENT FILING DATE: 1999-06-11
; NUMBER OF SEQ ID NOS: 39
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 4
; LENGTH: 518
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Dominant Negative Mutant Embodiment
US-09-329-418-4

```

```

Query Match 13.4%; Score 380; DB 3; Length 518;
Best Local Similarity 31.7%; Pred. No. 6.6e-28;
Matches 101; Conservative 62; Mismatches 126; Indels 30; Gaps 11;

QY 11 FTRPYHKLADRLYLRGASGYSSARHADWRVQVAVKHLHIHTPLDLSERKQVLRREALL 70
Db 14 PLVSTEELENOELVKGGGGTVFRAQRKRWYDVAVKIYN-----SKAISREVKAM 64
QY 71 HKARFYPPIILGICNEPEF-----LGVITVYMPNGSLNELLHRKTEYPDVAVPLRFRLL 125
Db 65 ASLDNEFVLRLEGVIEKVNWDDPKPALVTKEWENGLSGLLQSQCPRP--WPLICRLL 121
QY 126 HEIALGVNVLHNTWTPPLHLDLKTQNIILLDNFHKIADFGLSKWRMSLSQSRSSKSAP 185
Db 122 KEVVLGFMFLHDQNPVLLHRLDKPNSVLDPELHKLADFLGLSTFQ--GGSQSGTGSGEP 179
QY 186 EGGTIYMPPEYFPGQKSRASIKHDIYSYAVITWEVLSRKQPFEDVNTPLQIMYSV-SQ 244
Db 180 -GCTLGLAPELF-VNVRKASTASDVYSFGILMVAVLAGE-VLPTPEPSLVYEAVCNR 236
QY 245 GHRPVINEESLEY---DIPHRARMSLIESGWAQNDPDRPSPFLKCLIELEPVLRTFEEIT 301
Db 237 QNRPSLAE--LFOAGPETPGLGKELMQLCWSSEPKRPSFQECPLKTDVEVFMVE--N 292
QY 302 FLEAVIQLKTKLQSVSSA 320
Db 293 NNNAAVSTVKDFLSQLRSS 311

RESULT 10
; Sequence 2, Application US/07928464

```

```

; Patent No. 5367065
; GENERAL INFORMATION:
; APPLICANT: Ecker, Joseph R.
; APPLICANT: Kieber, Joseph J.
; TITLE OF INVENTION: Constitutive Triple Response Gene and
; TITLE OF INVENTION: Mutations
; NUMBER OF SEQUENCES: 6
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Woodcock, Washburn, Kurtz, Mackiewicz and
; ADDRESS: No. 5367065ris
; STREET: One Liberty Place - 46th Floor
; CITY: Philadelphia
; STATE: PA
; COUNTRY: U.S.A.
; ZIP: 19103
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/07/928,464
; FILING DATE: 19920810
; CLASSIFICATION: 800
; ATTORNEY/AGENT INFORMATION:
; NAME: Miller, Suzanne E.
; REGISTRATION NUMBER: 32,279
; REFERENCE/DOCKET NUMBER: UPN-1086
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 215-568-3100
; INFORMATION FOR SEQ ID NO: 2:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 821 amino acids
; TYPE: AMINO ACID
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; US-07-928-464-2

```

```

Query Match 13.3%; Score 376; DB 1; Length 821;
Best Local Similarity 30.7%; Pred. No. 3.2e-27;
Matches 98; Conservative 60; Mismatches 111; Indels 50; Gaps 12;

QY 1 MNGEAFCSALPT-----IPYHKLADRLYLRGASGYSSARHADWR-VQVA 45
Db 520 MNAAPTQPVPNRRANRELGLDGDMDIPW---CDLNIKEKIGAGSFGTVHRAEHWGSDVA 576
QY 46 VKHL---HIHTPDLDSER-KDVLREAEIHLKARFSYIFPILGICNEPEFLGIVTEYMPNG 101
Db 577 VKILMEQDFH-----AERVNEFLREVAIMKRLRHPNIVLFMGAVTQPPNLSIVTEYLSRG 631
QY 102 SENELLRKTEYPDVAVPLRFRLLHEIALGVNVLHNTWTPPLHLDLKTQNIILLDNFHKV 161
Db 632 SLYRLLHKSQAREQDLEDRRLRSMAYDAVKAMNYLHNRNPPIVHRDLKSPNLLVDRKRYTK 691
QY 162 IADFGLSKWRMSLSQSRSSKSAPEGGTIYMPPE--NYEPQKSRASIKHDIYSYAVIT 219
Db 692 VCDGFLSRLKASTFLSSKSAAGTPE-----WMAPEVLRDEPSNE-----KSDYVSEGVLL 741
QY 220 WEVLSRKQPFEDVNTPLQIMYSVQSHRVPVINEESLPYDIPH--RARMISLIESGWAQNP 277
Db 742 WELATLQQPWGNL-NPAQVVAAGVGFCKRL-----EIPRNLNPOVAAIIEGCTWNEP 792
QY 278 DERPSFLKCLIELEPVLRT 296
Db 793 WKRRPSFATIMDLRLPLIKS 811

RESULT 11
US-08-003-311B-2
; Sequence 2, Application US/08003311B
; Patent No. 5444166
; GENERAL INFORMATION:

```

```

; APPLICANT: Ecker, Joseph R.
; APPLICANT: Kieber, Joseph J.
; TITLE OF INVENTION: Constitutive Triple Response Gene
; TITLE OF INVENTION: and Mutations
; NUMBER OF SEQUENCES: 13
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Woodcock Washburn Kurtz Mackiewicz and
; STREET: One Liberty Place - 46th Floor
; CITY: Philadelphia
; STATE: PA
; COUNTRY: U.S.A.
; ZIP: 19103
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: WordPerfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/003,311B
; FILING DATE: January 12, 1993
; CLASSIFICATION: 800
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 07/928,464
; FILING DATE: August 10, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Lori Y. Beardell
; REGISTRATION NUMBER: 34,293
; REFERENCE/DOCKET NUMBER: UPN-1108
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 215-568-3100
; TELEFAX: 215-568-3439
; INFORMATION FOR SEQ ID NO: 2:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 821 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; US-08-003-311B-2

```

```

Query Match 13.3%; Score 376; DB 1; Length 821;
Best Local Similarity 30.7%; Pred. No. 3.2e-27;
Matches 98; Conservative 60; Mismatches 111; Indels 50; Gaps 12;

QY 1 MNGEATCSALPT-----IPYKHLADLRLYLRGASGTYSRHHADWR-VQVA 45
   ||||| :|| : ||| : | : | : | : ||||| :|
Db 520 MNAPPISQPVNRRANRELGLDGDMDIPW---CDLNKEKIGAGSFTVHRAEWHGSDVA 576
   ||| | | | : | : | : | : | : | : | | | | | | |
QY 46 VKHL---HIHTPLDSEK-DKVLREAEILHKARFSYIFFILGTCNEPEFELGIVTYEYMPNG 101
   ||| | | | | : | : | : | : | : | : | : | : | : |
Db 577 VKTLMEDQDFH----AERVNEFLREVAIMKRLRHPNIVLFMGAVTQPPNLSIVTYEYLSRG 631
QY 102 SMLNELLHRKTEYPDVAVPLRFRILHEIALGVNLHNMTPPLHLLDHTKTONILLDNEFHKV 161
   ||| : | : | : | : | : | : | : | : | : | : |
Db 632 SLYRLLHKSGARQLEDRRRLLSMAYDVAKGMVYLNHRNPPIVHRDLKSPNLLVDKYYTKV 691
QY 162 IADFGLSKWRMWSLSRSKSAPEGGTIIYMPPE--NVEPGOKSRASIKHDIYSYAVIT 219
   ||||| : |||| : |||| : |||| : ||| : | : | : | : |
Db 692 VCDGGLSRLKASTFLSKSAAGTPE----WMAPEVLRDEPSNE-----KSDVYSGVIL 741
QY 220 WEVLSRKQPVEDYTNPLQIMYSYQSHRPVINEESLPYDIPH--RARMISLIESGWAQNP 277
   ||| : | : | : | : | : | : | : | : | : | : |
Db 742 WELATLQQPMGNL-NPAQVVAAGVGFCKRLL-----EIPRNINPQVAAIIEGCWTNEP 792
QY 278 DERPSFLKCLIELEPVLR 296
   ||||| : | | : | : |
Db 793 WKRPFATIMDLLRPLIKS 811

```

RESULT 12

US-08-261-432-2

; Sequence 2, Application US/08261432

```

; Patent No. 5602322
; GENERAL INFORMATION:
; APPLICANT: Ecker, Joseph R.
; APPLICANT: Kieber, Joseph J.
; TITLE OF INVENTION: Constitutive Triple Response Gene
; TITLE OF INVENTION: and Mutations
; NUMBER OF SEQUENCES: 13
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Woodcock Washburn Kurtz Mackiewicz and
; STREET: One Liberty Place - 46th Floor
; CITY: Philadelphia
; STATE: PA
; COUNTRY: U.S.A.
; ZIP: 19103
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: WordPerfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/261,432
; FILING DATE: June 17, 1994
; CLASSIFICATION: 800
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/003,311
; FILING DATE: January 12, 1993
; ATTORNEY/AGENT INFORMATION:
; NAME: Lori Y. Beardell
; REGISTRATION NUMBER: 34,293
; REFERENCE/DOCKET NUMBER: UPN-1864
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 215-568-3100
; TELEFAX: 215-568-3439
; INFORMATION FOR SEQ ID NO: 2:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 821 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; US-08-261-432-2

```

```

Query Match 13.3%; Score 376; DB 1; Length 821;
Best Local Similarity 30.7%; Pred. No. 3.2e-27;
Matches 98; Conservative 60; Mismatches 111; Indels 50; Gaps 12;

QY 1 MNGEATCSALPT-----IPYKHLADLRLYLRGASGTYSRHHADWR-VQVA 45
   ||||| :|| : ||| : | : | : | : ||||| :|
Db 520 MNAPPISQPVNRRANRELGLDGDMDIPW---CDLNKEKIGAGSFTVHRAEWHGSDVA 576
   ||| | | | : | : | : | : | : | : | | | | | | |
QY 46 VKHL---HIHTPLDSEK-DKVLREAEILHKARFSYIFFILGTCNEPEFELGIVTYEYMPNG 101
   ||| | | | | : | : | : | : | : | : | : | : | : |
Db 577 VKTLMEDQDFH----AERVNEFLREVAIMKRLRHPNIVLFMGAVTQPPNLSIVTYEYLSRG 631
QY 102 SMLNELLHRKTEYPDVAVPLRFRILHEIALGVNLHNMTPPLHLLDHTKTONILLDNEFHKV 161
   ||| : | : | : | : | : | : | : | : | : | : |
Db 632 SLYRLLHKSGARQLEDRRRLLSMAYDVAKGMVYLNHRNPPIVHRDLKSPNLLVDKYYTKV 691
QY 162 IADFGLSKWRMWSLSRSKSAPEGGTIIYMPPE--NVEPGOKSRASIKHDIYSYAVIT 219
   ||||| : |||| : |||| : |||| : ||| : | : | : | : |
Db 692 VCDGGLSRLKASTFLSKSAAGTPE----WMAPEVLRDEPSNE-----KSDVYSGVIL 741
QY 220 WEVLSRKQPVEDYTNPLQIMYSYQSHRPVINEESLPYDIPH--RARMISLIESGWAQNP 277
   ||| : | : | : | : | : | : | : | : | : | : |
Db 742 WELATLQQPMGNL-NPAQVVAAGVGFCKRLL-----EIPRNINPQVAAIIEGCWTNEP 792
QY 278 DERPSFLKCLIELEPVLR 296
   ||||| : | | : | : |
Db 793 WKRPFATIMDLLRPLIKS 811

```

RESULT 13

PCT-US93-07347-2  
; Sequence 2, Application PC/TUS9307347  
; GENERAL INFORMATION:  
; APPLICANT: ZENECA Limited  
; TITLE OF INVENTION: PROTEIN ACTIVATOR OF APOPTOSIS  
; FILE REFERENCE: PHM.70536  
; CURRENT APPLICATION NUMBER: US/09/329,418  
; TITLE OF INVENTION: Constitutive Triple Response Gene and Mutations  
; TITLE OF INVENTION: Mutations  
; NUMBER OF SEQUENCES: 6  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Woodcock, Washburn, Kurtz, Mackiewicz and  
; STREET: One Liberty Place - 46th Floor  
; CITY: Philadelphia  
; STATE: PA  
; COUNTRY: U.S.A.  
; ZIP: 19103  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.25  
; CURRENT APPLICATION NUMBER: PCT/US93/07347  
; FILING DATE: 19930805  
; CLASSIFICATION:  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Miller, Suzanne E.  
; REGISTRATION NUMBER: 32,279  
; REFERENCE/DOCKET NUMBER: UFN-1086  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: 215-568-3100  
; INFORMATION FOR SEQ ID NO: 2:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 821 amino acids  
; TYPE: amino acid  
; TOPOLOGY: linear  
; MOLECULE TYPE: Protein  
PCT-US93-07347-2

```

Query Match      13.3%; Score 376; DB 5; Length 821;
Best Local Similarity 30.7%; Pred No. 3.2e-27;
Matches 98; Conservative 60; Mismatches 11; Indels 50; Gaps 12;

Qy 1  MNGEAIKALPT-----IPYKLDLRLYLRSGASGTVSSARHADWR-VQVA 45
  ||  | :|  :|  :|  :|  :|  :|  :|  :|  :|  :|  :|  :|  :|
Db 520 MNAPPISQVPVPRANRELGLDGDMDIPW---CDLNIREKIGAGSFGIVHRAEWHGSDVA 576

Qy 46 VKHL---HHPTLLDSEKDVLRRAEILHKARFYSIPIPLGICWNEPEFLGIVTYEMNG 101
  ||  | :|  :|  :|  :|  :|  :|  :|  :|  :|  :|  :|  :|
Db 577 VKILMEODFH-----AERVNREFLEVAITMKRLRHPNIVLFMGAVTQPPNLSIVTYEYLSRG 631

Qy 102 SLNELLRKTEYVDVWPLRFRILRHEIALGVNVLHNMTPPLLHDLKTONILLDNEFHVK 161
  ||  | :|  :|  :|  :|  :|  :|  :|  :|  :|  :|  :|  :|
Db 632 SLYRLLHSGAREQEDLRRRRLSMAYDVAKGMNLYLHNRPPIVHRLDLSVLEVYKKYTKV 691

Qy 162 IADFLGKRWKMSLSQSRSKSAPEGGTIIYMPPE--NVEPKQKSRASIKHDIYSYAVIT 219
  ||  | :|  :|  :|  :|  :|  :|  :|  :|  :|  :|  :|  :|
Db 692 VCDGLSLRKAASFVLSKSACTPE-----WMAPEVLRDEFSNE-----KSDVYVSGVIL 741

Qy 220 WEVLSRKQPFEDVTNPLOITMYSVSGOGRHPVINEESLPYDIPH--RARMISLIESGWAQNP 277
  ||  | :|  :|  :|  :|  :|  :|  :|  :|  :|  :|  :|  :|
Db 742 WELATFLOQPNL--NPAQVVAAGVKCKRL-----EIPRNLNPVAAIIEGCWTNEP 792

Qy 278 DERPSFKLIELEPVLT 296
  :|||  | :|  :|  :|  :|
Db 793 WKRPSFATIMDLRLLIKS 811

RESULT 14
US-09-329-418-6
; Sequence 6, Application US/09329418
; Patent No. 6096539

```

```

; GENERAL INFORMATION:
; APPLICANT: ZENECA Limited
; TITLE OF INVENTION: PROTEIN ACTIVATOR OF APOPTOSIS
; FILE REFERENCE: PHM.70536
; CURRENT APPLICATION NUMBER: US/09/329,418
; CURRENT FILING DATE: 1999-06-11
; NUMBER OF SEQ ID NOS: 39
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 6
; LENGTH: 261
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Kinase Domain
US-09-329-418-6

Query Match      13.1%; Score 372; DB 3; Length 261;
Best Local Similarity 34.1%; Pred. NO. 1.3e-27;
Matches 95; Conservative 53; Mismatches 103; Indels 28; Gaps 10;

Qy 18 LADLRLSRGASGTVSSARHADWRVQVAVKKHLIHTPLLDSEKDKVLREAEILHKARFYSY 77
  ||  | :|  :|  :|  :|  :|  :|  :|  :|  :|  :|  :|  :|  :|
Db 1  LENOELVKGSGFTVRAQHRKKGVDVAVKIVN-----SKAISREVKAWASLDNEF 51

Qy 78 IPIPLGICNEPEF-----LGIIVTEYMPNGSLNELLHKRTEYPDVAVPLRFRILRHEIALGV 132
  ||  | :|  :|  :|  :|  :|  :|  :|  :|  :|  :|  :|  :|  :|
Db 52 VLRLSGVIEKVNMDQDPKALVTKFMENGLSGLLSQCSQPRP---WPLLCLRLKKEVWLG 108

Qy 133 NYLHNWTPPLHHDLKTONILLDNEFHVKIADFGLSKRWMSLSQSRSKSAPEGGTIIY 192
  ||  | :|  :|  :|  :|  :|  :|  :|  :|  :|  :|  :|  :|  :|
Db 109 FYLHDQNPVLLHRDLKPSNVLLDPELHVKLADFLSFTFO--GGSQSGTSGSGEP--GGT 165

Qy 193 MPENVEPKQKSRASIKHDIYSYAVITWEVLSRKQPFEDVTNPLOITMYSV--SQGHRPV 251
  ||  | :|  :|  :|  :|  :|  :|  :|  :|  :|  :|  :|  :|  :|
Db 166 LAPELF--VNVNRKASTASDVYFGLMVAVLAGE--VELPTPEPSLVYEAVCRNQRPSLA 223

Qy 252 EESLEY---DIPHARMISLIESGWAQNPDERPSFKL 287
  ||  | :|  :|  :|  :|  :|  :|  :|  :|  :|  :|  :|  :|
Db 224 E--LPAQGPETPGLEGLKELMQLCWSSEPKDRPSFOECL 260

RESULT 15
US-09-035-706-5
; Sequence 5, Application US/09035706
; Patent No. 6001622
; GENERAL INFORMATION:
; APPLICANT: Dedhar, Shoukat
; APPLICANT: Hannigan, Greg
; TITLE OF INVENTION: Integrin-Linked Kinase and
; TITLE OF INVENTION: its Uses
; NUMBER OF SEQUENCES: 11
; CORRESPONDENCE ADDRESS:
; ADDRESS: Bozicevic & Reed, LLP
; STREET: 285 Hamilton Avenue, Suite 200
; CITY: Palo Alto
; STATE: CA
; COUNTRY: USA
; ZIP: 94301
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: DOS
; SOFTWARE: FastSeq for Windows Version 2.0
; CURRENT APPLICATION NUMBER: US/09/035,706
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER:
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Sherwood, Pamela J

```

REGISTRATION NUMBER: 36,677  
 REFERENCE/DOCKET NUMBER: KIN-2C1P1  
 TELECOMMUNICATION INFORMATION:  
 TELEPHONE: 650-327-3400  
 TELEFAX: 650 327-3231  
 TELEX:

INFORMATION FOR SEQ ID NO: 5:  
 SEQUENCE CHARACTERISTICS:  
 LENGTH: 263 amino acids  
 TYPE: amino acid  
 STRANDEDNESS: single  
 TOPOLOGY: linear  
 MOLECULE TYPE: protein  
 US-09-035-706-5

Query Match 13.0%; Score 369; DB 3; Length 263;  
 Best Local Similarity 32.4%; Pred. No. 2.6e-27;  
 Matches 94; Conservative 56; Mismatches 104; Indels 36; Gaps 11;

QY 13 IPYHKLADLRYLSRGASGTVSSARHADWR-VQVAVKHL--HIHTPLDSEK-KDYLREA 67  
 Db 1 IPW---CDLNIKEKIGAGSFGTVHRAEWHGSDVAVKILMEQDFH-----AERVNEFLREV 52

QY 68 EILHKARFSYIFPILGICNEPEFLGIVTEYMPNGSLNELLHRKTEYPDVAWPLRFRILHE 127  
 Db 53 AIMKRLRHPNIVLFMGAVTOPPNLSIVTEYLSRGLYRLLHKSGAREQLDERRRLSMAYD 112

QY 128 IALGVNVLHNMTPPLLHDKTONILLDNEFHVKIADFGLSKWRMMSLSQSRSSKSAPEG 187  
 Db 113 VAKGMNVLHNRNPPVHRDLKSPNLLVDRKTYKVCDFGLSLRLKASTFLSSKSAAGTPE- 171

QY 188 GTIYMPPE--NYEPGQKSRASIKHDIYSYAVITWVLSRKOPFEDVTNPLQIMYSVSOG 245  
 Db 172 ----WMAPEVLRDEPSNE-----KSDVYSEGVILWELATLQOPWGNL-NPAQVVAAVGEK 221

QY 246 HRPVINEESLPYDIPH--RARMISLIESGWAQNPDERPSEFLKCLIELEPY 293  
 Db 222 CKRL-----ETPRNLNPQVAAIIEGCWTNEPKRPSFATIMDLRLPL 263

Search completed: June 14, 2001, 08:06:04  
 Job time: 96 sec



GenCore version 4.5
Copyright (c) 1993 - 2000 Compugen Ltd.

OM protein - protein search, using sw model

Run on: June 14, 2001, 08:04:28 ; Search time 13.68 Seconds
(without alignments)
1352.190 Million cell updates/sec

Title: US-09-445-223-1

Perfect score: 2829

Sequence: 1 MNGEAIKSAIPYHKLAD.....PEILVYVRSPLNLLQKSM 540

Scoring table: BLOSOM62

Gapop 10.0 , Gapext 0.5

Searched: 93435 seqs, 34255486 residues

Total number of hits satisfying chosen parameters: 93435

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database : SwissProt\_39:\*

Pred. No. is the number of results predicted by chance to have a
score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Table with columns: Result No., Score, Query Match, Length, DB ID, Description. Lists various protein entries like ANR3\_HUMAN, RIP\_MOUSE, etc.

Table with columns: ID, ANR3\_HUMAN, STANDARD, PRT, 832 AA. Lists various protein entries like APKB\_ARATH, CRIA\_MAIZE, etc.

ALIGNMENTS

RESULT 1
ANR3\_HUMAN
AC P57078;
DT 01-OCT-2000 (Rel. 40, Created)
DT 01-OCT-2000 (Rel. 40, Last sequence update)
DE SERINE/THREONINE-PROTEIN KINASE ANKRD3 (EC 2.7.1.-) (ANKRYRIN REPEAT
DE DOMAIN PROTEIN 3).
GN ANKRD3.
OS Homo sapiens (Human)
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
ON NCBI\_TaxID=9606;
RX MEDLINE=20289799; PubMed=10830953;
RA Hattori M., Fujiyama A., Taylor T.D., Watanabe H., Yada T.,
RA Park H.-S., Toyoda A., Ishii K., Totoki Y., Choi D.-K., Soeda E.,
RA Ohki M., Takagi T., Sakaki Y., Taudien S., Blechschmidt K., Polley A.,
RA Menzel U., Delabar J., Kumpf K., Lehmann R., Patterson D.,
RA Reichwald K., Rump A., Schillhabel M., Schudy A., Zimmermann W.,
RA Rosenthal A., Kudoh J., Shibuya K., Kawasaki K., Asakawa S.,
RA Shintani A., Sasaki T., Nagamine K., Mitsuyama S., Antonarakis S.E.,
RA Minoshima S., Shimizu N., Nordstieck G., Hornischer K., Brandt P.,
RA Scharfe M., Schoen O., Desario A., Reichelt J., Kauer G., Bloecker H.,
RA Ramsar J., Beck A., Klages S., Hennig S., Riesselmann L., Dagand E.,
RA Wehrmeyer S., Borzlym K., Gardiner K., Yaspo M.-L.;
RA Lehmach H., Reinhardt R., Yaspo M.-L.;
RT "The DNA sequence of human chromosome 21.";
RL Nature 405:311-319(2000).
CC -1- SIMILARITY: BELONGS TO THE SER/THR FAMILY OF PROTEIN KINASES.
CC -1- SIMILARITY: CONTAINS 10 ANK REPEATS.
CC -----
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC or send an email to license@isb-sib.ch).
CC -----
CC EMBL; AP001743; BAA95526.1;
DR PROSITE; PS00107; PROTEIN\_KINASE\_ATP; 1.
DR PROSITE; PS00108; PROTEIN\_KINASE\_ST; 1.
DR PROSITE; PS50011; PROTEIN\_KINASE\_DOM; 1.
DR PROSITE; PS50297; ANK\_REPEAT\_REGION; 1.
DR PROSITE; PS50088; ANK\_REPEAT; 9.
KW Transferase; Serine/threonine-protein kinase; ATP-binding; Repeat;
KW ANK repeat.
FT DOMAIN 22 286
FT REPEAT 485 514
FT REPEAT 518 547
FT REPEAT 551 580
FT REPEAT 584 613
FT REPEAT 617 647

Cell 81:513-523(1995).  
 -!- FUNCTION: INTERACTS WITH THE DEATH DOMAIN OF FAS AND TRADD AND INITIATES APOPTOSIS. IT IS RECRUITED BY TRADD TO TNFR1 IN A TNF-DEPENDENT PROCESS. REQUIRED FOR TNFR1 ACTIVATION OF NF-KAPPA B.  
 -!- TISSUE SPECIFICITY: FOUND AT LOW LEVELS IN ALL TISSUES.  
 -!- SIMILARITY: BELONGS TO THE SRR/THR FAMILY OF PROTEIN KINASES.  
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration between the Swiss Institute of Bioinformatics and the EMBL outstation at the European Bioinformatics Institute. There are no restrictions on its use by non-profit institutions as long as its content is in no way modified and this statement is not removed. Usage by and for commercial entities requires a license agreement (See http://www.isb-sib.ch/announce/ or send an email to license@isb-sib.ch).  
 -----

RL Cell 81:513-523(1995).  
 CC -!- FUNCTION: INTERACTS WITH THE DEATH DOMAIN OF FAS AND TRADD AND  
 CC INITIATES APOPTOSIS. IT IS RECRUITED BY TRADD TO TNFR1 IN A TNF-  
 CC DEPENDENT PROCESS. REQUIRED FOR TNFR1 ACTIVATION OF NF-KAPPA B.  
 CC -!- TISSUE SPECIFICITY: FOUND AT LOW LEVELS IN ALL TISSUES.  
 CC -!- SIMILARITY: BELONGS TO THE SRR/THR FAMILY OF PROTEIN KINASES.  
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration  
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation  
 CC at the European Bioinformatics Institute. There are no restrictions on its  
 CC use by non-profit institutions as long as its content is in no way  
 CC modified and this statement is not removed. Usage by and for commercial  
 CC entities requires a license agreement (See http://www.isb-sib.ch/announce/  
 CC or send an email to license@isb-sib.ch).  
 -----

EMBL: U25995; AAB60487.1; .  
 HSP; P11362; IFCI.  
 DR MGD; MGI:108212; RipK1.  
 DR InterPro; IPR000488; .  
 DR InterPro; IPR000719; .  
 DR Pfam; PF00531; death; 1.  
 DR Pfam; PF00069; pkinase; 1.  
 DR PROSITE; PS00108; PROTEIN\_KINASE\_ST; 1.  
 DR PROSITE; PS00017; DEATH\_DOMAIN; 1.  
 DR Transferase; Serine/threonine-protein kinase; ATP-binding;  
 KW Apoptosis.  
 FT DOMAIN 17 290 PROTEIN KINASE.  
 FT NP\_BIND 23 31 ATP (BY SIMILARITY).  
 FT BINDING 49 49 ATP (BY SIMILARITY).  
 FT ACT\_SITE 138 138 BY SIMILARITY.  
 FT DOMAIN 568 654 DEATH DOMAIN.  
 FT VARIANT 473 473 T -> I.  
 SQ SEQUENCE 656 AA; 74854 MW; ABB350B523879933 CRC64;

DR EMBL: U25995; AAB60487.1; .  
 DR HSP; P11362; IFCI.  
 DR MGD; MGI:108212; RipK1.  
 DR InterPro; IPR000488; .  
 DR InterPro; IPR000719; .  
 DR Pfam; PF00531; death; 1.  
 DR Pfam; PF00069; pkinase; 1.  
 DR PROSITE; PS00108; PROTEIN\_KINASE\_ST; 1.  
 DR PROSITE; PS00017; DEATH\_DOMAIN; 1.  
 DR Transferase; Serine/threonine-protein kinase; ATP-binding;  
 KW Apoptosis.  
 FT DOMAIN 17 290 PROTEIN KINASE.  
 FT NP\_BIND 23 31 ATP (BY SIMILARITY).  
 FT BINDING 49 49 ATP (BY SIMILARITY).  
 FT ACT\_SITE 138 138 BY SIMILARITY.  
 FT DOMAIN 568 654 DEATH DOMAIN.  
 FT VARIANT 473 473 T -> I.  
 SQ SEQUENCE 656 AA; 74854 MW; ABB350B523879933 CRC64;

Query Match 13.9%; Score 394; DB 1; Length 656;  
 Best Local Similarity 31.0%; Pred. No. 4e-20;  
 Matches 131; Conservative 66; Mismatches 144; Indels 82; Gaps 19;

Query Match 13.9%; Score 394; DB 1; Length 656;  
 Best Local Similarity 31.0%; Pred. No. 4e-20;  
 Matches 131; Conservative 66; Mismatches 144; Indels 82; Gaps 19;

QY 24 LSRGASGYSSARHADRWVQAVKHLHHTPLDSDRQDV-LREAELHKARFSYIFPL 82  
 DB 23 LQSGGKVSVCYHRSHGVILKK---VITGNRAEYNEVLEEGKMHRLHRSRVKLL 79  
 QY 83 GICNEPEFLGIYVTEYMPNGSLNELHHRKTEYPDVAMPRLRFRILHEIALGVNVLHNTTPLL 142  
 DB 80 GIIEEGNSLYMEYMEKGNLHVL--KTQI-DVPLSLKGRIVEAIEGMCYLHD--KGV 134  
 QY 143 LHDLKTQILLNDFEYVIADEGLSKWRMS--LSQSRSSKSNP-----EGGTIIM 193  
 DB 135 IHKDLKPENILVDRDFHIKIDLGVAISFKTWSKLTKEKDNKQKEVSSYTKKNGGFLIYM 194  
 QY 194 PPE----NVEPGOKSRASIKHDIYSYAVITWELSRKQPFEDVTNPLQIMTYSVSGQHRP 248  
 DB 195 APHLNDINAKPTEKS-----DVYSGIVLWAIFAKPEYENVICTEQFVICIKSGNRP 248  
 QY 249 VINE--ESLPYDIPHRARMISLFEAGNAQNPDRPFLKCLELEP-VLTFEEITFLEA 305  
 DB 249 NVBEILEYCPREI-----ISLMERCWAQIPEDRPTFLGIEEERFPYLSHFEEYV-EED 301  
 QY 306 VIQLKK-----TKLQSVSSAIHLK-----DKKMWLSLNIPVNHGPOEESGSSQ 350  
 DB 302 VASLKKEYPDQSPVQLQRMFSLQHDVPLPPSRNSNSQPSLSSQSLQMGVPEESWFS- 360  
 QY 351 LHENSGSPPTSRSLPAPQNDFLSRKAQCYFMKHLHCPGNHNSWDSTISGSORAAFCDHK 410  
 DB 361 -----SPE-----YPQDENRSVQA-----KLQEAASYHAF-----GIFAEKQ 393

QY 27 GASGYSSARHADRWVQAVK---HLHHTPLDSDRQDV-LREAELHKARFSYIFPL 83  
 DB 31 GGFQGVYKVRHWKWTALKCSPLRVD---DRERMELLEAKMEMAKERYILPVYV 86  
 QY 84 ICNPEFLGIVTEYMPNGSLNELHHRKTEYPDVAMPRLRFRILHEIALGVNVLHNTTPLL 143  
 DB 87 ICREP--VGLYMEYMETGSEKLLASE---PLPWLDRFRILHEITAVGNLHCHMAPPLL 140  
 QY 144 HLDLKTQILLNDFEYVIADEGLSKWRMSLSQSRSSKSNP---GTTIYMPPEYEG 201  
 DB 141 HLDLKPANILLDAHRYHKISDFGLKACNGLSHSHDLSM---DGLFTIAYLPPERIR-- 194  
 QY 202 QKSR--SIKHDIYSYAVITWELSRKQPFEDVTNPLQIMVSYVSGHRPVINEBSLPYDIP 260  
 DB 195 EKRFLRKHDIYSYAVITWELSRKQPFEDVTNPLQIMVSYVSGHRPVINEBSLPYDIP 249  
 QY 261 HRAR---MISLIESGWAQNPDRPSPF-----LKLIELEPLVRFTEITFL 303  
 DB 250 ARPACSHLIRLMQRGQGGPRVPTFOGNGLNGELIRQVLAALLPVTGRWRSPPGEGFRL 309  
 QY 304 EAVIQLKKT---KLSVSSAIIH-LCKD---KMWLSLNIPVNHGPOEESGSSQLHENS 355  
 DB 310 ESEVIRIVTCLSSPQITSETEDLCEKPDDEVKETAHLDLVKSPPEPRS-----E 360  
 QY 356 GSPETSRLPAPQ-DNDF-LSRRAQDCYFMKHLHCPGNHNSWDSTISGSORAAFCDHK 413  
 DB 361 VVPAKLKASAPTFDNDLSLSELL-----SQLDGVSQAVGPEPELSR 403  
 QY 414 CSSAINPLSTAGNSERLQPIAQOIQSKREDIVNAQMTAEALQSLDALLSRDLIMKED 473  
 DB 404 SSSS--SKLPSSGSKRLS-GVS-----SVDSAFSSRGSLSLS 438  
 QY 474 YELVSTPRTFTSKVRLQDLDITDQGEFAKVIYOKLKNQKMGLOPYPELLVYSRPSL 532  
 DB 439 FE-----REPSTSD-----LGTVDYOKKLVDAIVSGDTSKLMKILQPDQVDLALD 489

RESULT 2  
 RIP\_MOUSE .STANDARD; PRT; 656 AA.  
 AC Q60855;  
 DT 01-NOV-1997 (Rel. 35, Created)  
 DT 01-NOV-1997 (Rel. 35, Last sequence update)  
 DT 01-OCT-2000 (Rel. 40, Last annotation update)  
 DE SERINE/THREONINE PROTEIN KINASE RIP (EC 2.7.1.-) (CELL DEATH PROTEIN  
 DE RIP) (RECEPTOR INTERACTING PROTEIN).  
 GN RIP1 OR RIP OR RINP.  
 OS Mus musculus (Mouse).  
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.  
 OX NCBI\_TaxID=10090;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RC STRAIN=C57BL/6 X CHA; TISSUE=Thymus;  
 RX MEDLINE=95277838; PubMed=7538908;  
 RA Stanger B.Z., Leder P., Lee T.-H., Kim E., Seed B.;  
 FT \*RIP: a novel protein containing a death domain that interacts with  
 FT Fas/APO-1 (CD95) in yeast and causes cell death.\*;

Query Match 13.9%; Score 394; DB 1; Length 656;  
 Best Local Similarity 31.0%; Pred. No. 4e-20;  
 Matches 131; Conservative 66; Mismatches 144; Indels 82; Gaps 19;

```

RESULT 3
CTRL_ARATH STANDARD; PRT; 821 AA.
AC Q05609;
DT 01-NOV-1995 (Rel. 32, Created)
DT 01-NOV-1995 (Rel. 32, Last sequence update)
DT 01-OCT-2000 (Rel. 40, Last annotation update)
DE SERINE/THREONINE-PROTEIN KINASE CTRL1 (EC 2.7.1.37).
GN CTRL1 OR FI7C15_150.
OS Arabidopsis thaliana (Mouse-ear cress).
OC Eukaryota; Viridiplantae; Embryophyta; Tracheophyta; Spermatophyta;
OC Magnoliophyta; eudicotyledons; core eudicots; Rosidae; eurosids II;
OC Brassicales; Brassicaceae; Arabidopsids.
OX NCBI_TaxID=3702;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=CV_COLUMBIA; TISSUE=Seedling;
RX MEDLINE=93161417; Pubmed=8431946;
RA Kieber J.J., Rothenberg M., Roman G., Feldmann K.A., Ecker J.R.;
RT "CTRL1, a negative regulator of the ethylene response pathway in
FT Arabidopsis, encodes a member of the raf family of protein kinases.";
RL Cell 72:427-441(1993).
RN [2]
RP SEQUENCE FROM N.A.
RC STRAIN=CV_COLUMBIA;
RA Bevan M., Pohl T., Weizenegger T., Bancroft I., Mewes H.-W., Rudd S.,
RA Lemcke K., Mayer K.F.X.;
RL Submitted (MAR-2000) to the EMBL/GenBank/DBJ databases.
CC -1- FUNCTION: ACTS AS A NEGATIVE REGULATOR IN THE ETHYLENE RESPONSE
CC PATHWAY.
CC -1- TISSUE SPECIFICITY: EXPRESSED IN BOTH SEEDLINGS AND ADULT PLANTS.
CC -1- MISCELLANEOUS: CTRL1 MUTANTS DISPLAY ETHYLENE-TREATED PHENOTYPES,
CC RESULTING IN PLANTS WITH SMALL, UNEXPANDED LEAVES AND WHOSE SEED
CC COTYLEDON GROWTH IS IMPAIRED.
CC -1- SIMILARITY: BELONGS TO THE SER/THR FAMILY OF PROTEIN KINASES.
CC MIL/RAF SUBFAMILY.
CC
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL Outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC or send an email to license@isb-sib.ch).
CC
DR EMBL; L08789; AAA32779.1;
DR EMBL; L08790; AAA32780.1;
DR EMBL; AL162506; CAB82938.1;
DR HSP; P11362; IFGI.
DR InterPro; IPR000719;
DR InterPro; IPR002290;
DR Pfam; PF00069; pkinase.1.
DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
KW Transferrase; Serine/threonine-protein kinase; ATP-binding.
FT DOMAIN 65 69
FT POLY-GLY.
FT DOMAIN 135 141
FT POLY-GLY.
FT DOMAIN 551 809
FT PROTEIN KINASE.
FT NP_BIND 557 565
FT ATP (BY SIMILARITY).
FT BINDING 578 578
FT ATP (BY SIMILARITY).
FT ACT_SITE 676 676
FT BY SIMILARITY.
FT MUTAGEN 596 596
FT TREATED PHENOTYPE.
FT D->E: IN CTRL1-4; EXHIBITS ETHYLENE-
FT TREATED PHENOTYPE.
FT MUTAGEN 694 694
SQ SEQUENCE 821 AA; 90306 MW; 2922D3DCD0CC15BC CRC64;
Query Match 13.3%; Score 376; DB 1; Length 821;
Best Local Similarity 30.7%; Pred. No. 9.6e-19;
Matches 98; Conservative 60; Mismatches 111; Indels 50; Gaps 12;

```

```

QY 1 MNGEAICSALPT-----IPYHKLADLRYLSRGASGTVSSARHADWR-VOYA 45
Db 520 MNAPPISQVPMRANRELGLDGDMDIPW---CDLNKEIKIGAGSFGTVHRAEWGSDVA 576
QY 46 VKHL---HIHTELDSEK-KOYLREAEILHKARFSYIPIELGICNEPEFLGIVTEYMPNG 101
Db 577 VKILMEQDFH-----AERVNFEFLREVAIMKRLRHPNIVLFMGAVTQPPNLSIVTEVLSRG 631
QY 102 SLNELLHRKTEYPDVAWPLRFRILHAIAGVNYLHNMTPPLLHDLKTONILLDNEFHVK 161
Db 632 SYLRLLHSGAREQLDERRRLSMAYDVAKGMNLYHNRNPPVIVHRDLKSPNLLVDRKRYTK 691
QY 162 IADFGLSKWRMMSLSQSRSSKSAPEGTTIYMPPE--NYEPQOKSRASIKHDIYSAVIT 219
Db 692 VCDFGLSRLKASTFLSSKSAAGTPE-----WVAPEVLRDEPSNE-----KSDVYSEGVLL 741
QY 220 WEVLSRKOPFDVTPNPLQIMYSVSOGRHPVINEESLPYDIPH--RARMISLLESQAQNP 277
Db 742 WELATLQOPWGNL-NPAQVVAAVGFKCKRL-----EIPRNLNPOVAAIIEGCWTEP 792
QY 278 DERPSFLKLIIELEPLVLT 296
Db 793 WKRPSPFATIMDLRLPLIKS 811

RESULT 4
RIP_HUMAN
ID RIP_HUMAN STANDARD; PRT; 671 AA.
AC Q13546; Q13180;
DT 01-NOV-1997 (Rel. 35, Created)
DT 30-NOV-2000 (Rel. 39, Last sequence update)
DT 01-OCT-2000 (Rel. 40, Last annotation update)
DE SERINE/THREONINE PROTEIN KINASE RIP (EC 2.7.1.-) (CELL DEATH PROTEIN
DE RIP) (RECEPTOR INTERACTING PROTEIN).
GN RIPK1 OR RIP.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX NCBI_TaxID=9606;
RN [1]
RP SEQUENCE FROM N.A.
RC TISSUE=umbilical vein endothelial cells;
RX MEDLINE=96200892; Pubmed=8612133;
RA Hsu H., Huang J., Shu H.-B., Baichwal V.R., Goeddel D.V.;
RT "TNF-dependent recruitment of the protein kinase RIP to the TNF
RL receptor-1 signaling complex.";
RN [2]
RP IMMUNITY 4:387-396(1996).
RP REVISION TO 120.
RA Huang J., Hsu H., Baichwal V.R., Goeddel D.V.;
RL Submitted (AUG-1998) to the EMBL/GenBank/DBJ databases.
RN [3]
RP SEQUENCE OF 300-671 FROM N.A.
RX MEDLINE=95277838; Pubmed=7538908;
RA Stanger B.Z., Leder P., Lee T.-H., Kim E., Seed B.;
RT "Rip: a novel protein containing a death domain that interacts with
RL Fas/APO-1 (CD95) in yeast and causes cell death.";
RN [4]
RP CELL 81:513-523(1995).
CC -1- FUNCTION: INTERACTS WITH THE DEATH DOMAIN OF FAS AND TRADD AND
CC INITIATES APOPTOSIS. IT IS RECRUITED BY TRADD TO TNFR1 IN A TNF-
CC DEPENDENT PROCESS. REQUIRED FOR TNFR1 ACTIVATION OF NF-KAPPA B.
CC -1- SIMILARITY: BELONGS TO THE SER/THR FAMILY OF PROTEIN KINASES.
CC
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL Outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC or send an email to license@isb-sib.ch).
CC
DR EMBL; U50062; AAC32232.1;

```

```

RA EMBL; U25994; AAC50137.1; -.
DR HSSP; P11362; 1FGI.
DR MIM; 603453; -.
DR InterPro; IPR000488; -.
DR InterPro; IPR000719; -.
DR InterPro; IPR002290; -.
DR Pfam; PF00531; death; 1.
DR Pfam; PF00069; pkinase; 1.
DR PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR PROSITE; PS50017; DEATH_DOMAIN; 1.
KW Transferase; Serine/threonine-protein kinase; ATP-binding;
APoptosis.
FT DOMAIN 17 289 PROTEIN KINASE.
FT NP_BIND 23 31 ATP (BY SIMILARITY).
FT BINDING 49 49 ATP (BY SIMILARITY).
FT ACT_SITE 138 138 BY SIMILARITY.
FT DOMAIN 583 669 DEATH DOMAIN.
FT DOMAIN 411 414 POLY-ARG.
FT CONFLICT 514 514 T -> S (IN REF. 3).
SQ SEQUENCE 671 AA; 75958 MW; BADCAE7E704566ABE CRC64;

```

Query Match 13.0%; Score 369; DB 1; Length 671; Best Local Similarity 28.8%; Pred. No. 2.2e-18; Matches 112; Conservative 67; Mismatches 146; Indels 64; Gaps 12;

```

QY 24 LSRGASVTSARHADRWQ-VAVKHLHIHTPLDSEKDVLDREAELLHKARFYIFPIL 82
DB 23 LSDGGFGKSLCFH---RTQGLMIMKTVYKGNPCIEHNEALLEEAKMNNLRHSRVKLL 79
QY 83 GICNEPEFLGVTVEYMPGNSLNLNLLHRTKTEYDPVAVWPRFRILRHLRHEIAGLGVNLYLHNMTPPL 142
DB 80 GVITTEGYSLVMEYMEKGNLHVLRKEMSTP---LSVKGRIILIEEGMCLYHG--KGV 134
QY 143 LHDLKTONLLNDFHVKADFGLSKRWMSLSQRSKSAPE-----GGTIYMP 194
DB 135 IHKDLKPENILVNDHFHFKIADGLASFKMSKLNNEEHRELREVDGTAKKNGGTLIYMA 194
QY 195 PE-----NYSPGKSRASIKRDIYSYAVITWELVRKQPEDVTNPLQIMYSVQGRPV 249
DB 195 PEHLNDVNAKPTKNS-----DVTSFVLVVAIFANKEPYENAEIQEQLLWCKISGNRPD 248
QY 250 INE--ESLPYDIPRHARMISLIEGWAQNDEPSPFLKCLIELEPVLRTFEEITFLEAVI 307
DB 249 VDDITTEYCPREI-----ISLMKLEWANEPEARPTFPIEIKRFPFVLSQLESVEEDVK 302
QY 308 QLKK-----TKLQS-----SSAIHLCDKKMELSLNIPVNHGPOEESCGSSQ 350
DB 303 SLKKEYSNENAVAKRMQSLQDCVAVPSSRSNSATEQPGSLHSSQGLGMLGVPVEEWFAPS 362
QY 351 LHENSGSPSTRSLPAPQDNDFLSRKAOD 379
DB 363 LEH-----PQENEPSLQSLQD 380

RESULT 5
ID KYKL_DICDI STANDARD; PRT; 1584 AA.
AC P18160;
DT 01-NOV-1990 (Rel. 16, Created)
DT 01-OCT-1996 (Rel. 34, Last sequence update)
DT 30-MAY-2000 (Rel. 39, Last annotation update)
DE NON-RECEPTOR TYROSINE KINASE SPORE LYSIS A (EC 2.7.1.112) (TYROSINE-
DE . PROTEIN KINASE 1).
GN PYKA OR SPLA OR DPVK1
OS Dictyostelium discoideum (Slime mold).
OC Eukaryota; Mycetozoa; Dictyostellida; Dictyostellium.
OX NCBI_TaxID=44689;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=JH10.
RA MEDLINE=97053827; PubMed=8898241;

```

Query Match 11.1%; Score 313.5; DB 1; Length 1584; Best Local Similarity 28.1%; Pred. No. 5.3e-14; Matches 91; Conservative 59; Mismatches 119; Indels 55; Gaps 10;

```

RA Nuckolls G.H., Osheroov N., Loomis W.F., Spudich J.A.;
RT "The Dictyostelium dual-specificity kinase spla is essential for
RL spore differentiation.";
RL Development 122:3295-3305(1996).
RN [2]
RP SEQUENCE OF 1248-1584 FROM N.A.
RX MEDLINE=90287147; PubMed=1972546;
RA Tan J.L., Spudich J.A.;
RT "Developmentally regulated protein-tyrosine kinase genes in
RL Dictyostelium discoideum.";
RL Mol. Cell. Biol. 10:3578-3583(1990).
CC -!- FUNCTION: ESSENTIAL FOR SPORE DIFFERENTIATION.
CC -!- CATALYTIC ACTIVITY: ATP + A PROTEIN TYROSINE = ADP +
CC PROTEIN TYROSINE PHOSPHATE.
CC -!- DEVELOPMENTAL STAGE: EXPRESSED THROUGHOUT DEVELOPMENT WITH A PEAK
CC DURING THE MOUND STAGE OF MORPHOGENESIS
CC -!- SIMILARITY: TO OTHER PROTEIN-TYROSINE KINASES BUT ALSO TO
CC SERINE/THREONINE PROTEIN KINASES.
CC -----
CC THIS SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC or send an email to license@isb-sib.ch).
CC -----
DR EMBL; U32174; AAB41125.1; -.
DR EMBL; M33785; AAB33202.1; -.
DR PIR; A35670; A35670.
DR HSSP; P11362; 1FGI.
DR DictyDB; DD03010; PYKA.
DR InterPro; IPR000107; -.
DR InterPro; IPR000719; -.
DR InterPro; IPR001245; -.
DR InterPro; IPR001660; -.
DR Pfam; PF00536; SAM; 1.
DR Pfam; PF00622; SPRY; 3.
DR Pfam; PF00069; pkinase; 1.
DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR PROSITE; PS00109; PROTEIN_KINASE_TYR; 1.
DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR Transferase; Tyrosine-protein kinase; ATP-binding; Phosphorylation.
KW DOMAIN 403 420 POLY-ASN.
FT DOMAIN 428 435 POLY-THR.
FT DOMAIN 449 480 POLY-ASN.
FT DOMAIN 483 491 POLY-ASN.
FT DOMAIN 494 508 POLY-ASN.
FT DOMAIN 512 532 POLY-ASN.
FT DOMAIN 596 600 POLY-ASN.
FT DOMAIN 808 811 POLY-PHE.
FT DOMAIN 1026 1029 POLY-SER.
FT DOMAIN 1195 1210 POLY-ASN.
FT DOMAIN 1215 1220 POLY-GLN.
FT DOMAIN 1224 1233 POLY-GLN.
FT DOMAIN 1266 1274 POLY-PRO.
FT DOMAIN 1289 1561 . PROTEIN KINASE.
FT NP_BIND 1295 1303 ATP (BY SIMILARITY).
FT BINDING 1316 1316 ATP (BY SIMILARITY).
FT ACT_SITE 1417 1417 BY SIMILARITY.
FT CONFLICT 1248 1248 D -> R (IN REF. 2).
FT CONFLICT 1435 1435 V -> L (IN REF. 2).
SQ SEQUENCE 1584 AA; 174304 MW; 5D1589458D8E01E3 CRC64;

```

QY 72 KARFSYIFPILGICNE--PEFLGIVTEYMPNGSLNELLHRKTEYDVAWPLRFRILHEIA 129  
 Db 1341 KLRHPNVVQFLGACTAGGEDHHCIVTEWMMGGSLRQFLTDHFNLLNQNPIRLKALDIA 1400  
 QY 130 LGVNYLHNWTPPLLHDLKTONILLDN-----EFHVKIADFGLSKWRMMSLS 176  
 Db 1401 KGMNYLHGWTPTPLHRDLSSRNILLDHNIDPKNPVYSSRQDIKCKISDFGLSR-----LK 1455  
 QY 177 QRSRKSAPEGGTIYMPENYEPGOKSRASIKHDIYSYAVITWEVLSRKOPEDVNTPL 236  
 Db 1456 KEQASQMTQSVGICPYMAEYFVKGSNSE---KSDVYSYGMVLFELLTSDPEQDDM-KPM 1511  
 QY 237 QIMY-SVSGHRPVIINESLPYDIPHRARMISLIEGWAQNDPDERPFLKCLIELEPVL 295  
 Db 1512 KMAHLAAYESYRP-----PIPLTSSKWKKEILTQCWDSNPDSRP----- 1550  
 QY 296 TFEETFLAVIOLKTKLQVSS 319  
 Db 1551 -----FFKQIIVHLKEMEDQGVSS 1569

RESULT 6  
 M3K7\_MOUSE STANDARD; PRT; 579 AA.  
 AC Q62073;  
 DT 01-OCT-2000 (Rel. 40, Created)  
 DT 01-OCT-2000 (Rel. 40, Last sequence update)  
 DT 01-OCT-2000 (Rel. 40, Last annotation update)  
 DE MITOGEN-ACTIVATED PROTEIN KINASE KINASE 7 (EC 2.7.1.-)  
 DE (TRANSFORMING GROWTH FACTOR-BETA-ACTIVATED KINASE 1) (TGF-BETA-ACTIVATED KINASE 1).  
 GN MAP3K7 OR TAK1.  
 OS Mus musculus (Mouse).  
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.  
 OX NCBI\_TaxID=10090;  
 RN [1]  
 RP SEQUENCE FROM N.A.; PubMed=8533096;  
 RX MEDLINE=96123277; PubMed=8533096;  
 RA Yamaguchi K., Shirakabe K., Shibuya H., Irie K., Ohishi I., Ueno N.,  
 RA Taniguchi T., Nishida E., Matsumoto K.;  
 RT "Identification of a member of the MAPKK family as a potential  
 mediator of TGF-beta signal transduction.";  
 RL Science 270:2008-2011(1995).  
 CC !- FUNCTION: CAN PHOSPHORYLATE AND ACTIVATE YET UNDEFINED MAPKKS.  
 CC MEDIATOR OF TGF-BETA SIGNAL TRANSDUCTION. STIMULATES NF-KAPPA B  
 CC ACTIVATION.  
 CC !- SIMILARITY: BELONGS TO THE SER/THR FAMILY OF PROTEIN KINASES.  
 CC MAP KINASE KINASE SUBFAMILY.  
 CC !- SIMILARITY: IN THE C-TERMINAL SECTION; STRONG, TO C21ORF7.

CC This SWISS-PROT entry is copyright. It is produced through a collaboration  
 between the Swiss Institute of Bioinformatics and the EMBL outstation  
 at the European Bioinformatics Institute. There are no restrictions on its  
 use by non-profit institutions as long as its content is in no way  
 modified and this statement is not removed. Usage by and for commercial  
 entities requires a license agreement (See <http://www.isb-sib.ch/announce/>)  
 or send an email to [license@isb-sib.ch](mailto:license@isb-sib.ch).  
 DR EMBL; D76446; BAAL1184.1;  
 DR MGI; MGI:1346877; Map3k7.  
 DR InterPro; IPR000719;  
 DR InterPro; IPR002290;  
 DR Pfam; PF00069; pkinase; 1.  
 DR PROSITE; PS00107; PROTEIN\_KINASE\_ATP; 1.  
 DR PROSITE; PS00108; PROTEIN\_KINASE\_ST; 1.  
 DR PROSITE; PS50011; PROTEIN\_KINASE\_DOM; 1.  
 KW Transferase; Serine/threonine-protein kinase; ATP-binding.  
 FT DOMAIN 8 16 POLY-SER.  
 FT DOMAIN 36 291 PROTEIN KINASE.  
 FT NP\_BIND 42 50 ATP (BY SIMILARITY).  
 FT BINDING 63 63 ATP (BY SIMILARITY).  
 FT ACT\_SITE 156 156 BY SIMILARITY.

SQ SEQUENCE 579 AA; 64227 MW; 97C8F6F3C8E283EE CRC64;  
 Query Match 11.0%; Score 311; DB 1; Length 579;  
 Best Local Similarity 23.5%; Pred. No. 2e-14;  
 Matches 136; Conservative 97; Mismatches 246; Indels 100; Gaps 22;  
 QY 13 IPYHKLADLRLYLSRGASGTVSSARHARWYO-VAVKHLHTHTLLDSEKDKVLRAEILH 71  
 Db 31 IDYKEVEVEVGRGAFVGVCKAK--WRAKVAIKQIE-----SESERKAFIVELRQLS 82  
 QY 72 KARFSYIFPILGICNEPEFLGIVTEYMPNGSLNELLHRKTEYDVAWPLRFRIL 125  
 Db 83 RVNHPNIVKLYGACLNP--VCLVMYEAEGSLVNLHGAEPLPYTAAHAMSACL----- 135  
 QY 126 HETALGVNVLHNWTP-PLLHDLKTONILL-DNEFHVKIADFGLSKWRMMSLSQRSKSS 183  
 Db 136 -QCSQGVAYLHSMOPKALIHRLDKLPPNLLVAGVTGKICDFGTAGDIQTHMTNNK---- 190  
 QY 184 APEGGTIYMPENYEPGOKSRASIKHDIYSYAVITWEVLSRKOPEDVNTP-LQIMYSV 242  
 Db 191 ----GSAANWAPVFE---GSNVSEKCDVFSWGIILWEVITRRKPFDEIGGPAFRIMWAV 243  
 QY 243 SQGHRPVIINESLPYDIPHRARMISLIEGWAQNDPDERPFLKCLIELEPVLRTF---E 298  
 Db 244 HNGTRPPL-IKNLPKPIE-----SLMTRCWSKDPORSMSIEIVKIMTHLMRYFPGADE 296  
 QY 299 EI-----TFLEAVIOLKTKLQVSSAIHLCDKMKMELSLNIPVNH 339  
 Db 297 PLOYPCOYDSEGQSNATSTGSMFDIASNTSNKSDTNMEQVPAINTDKRLESKLLKNQ 356  
 QY 340 GPOEESCGSQLHENSQSPETSRSRSLPAPQNDPFLSRKAODCYPMKLRHCPGNHS----- 393  
 Db 357 AKQSESGRLSLGASRGS--SVESLPTSEGKMSADMSEIE-ARIVATAGNQPRRSI 413  
 QY 394 WDSITSGSORAAFCDHKHTPCCSAIINPLSTAGNSERLQPGIAQOVIQSKRREDIVNOMTE 453  
 Db 414 QDLTVTGTGEPGVSSRSRSPSVRMITGTSPTSEKPARSHPTWPTDDSTDTNGSDNSIPMAY 473  
 QY 454 ACLNQSLD-----ALLSRDLINKEDYELVSTKTRTSKVRQLLDTTDIOGEEF 501  
 Db 474 LTLHDLOQLAPCPNKSMAVFEQHCCKMAQYKMQVT-----EIALLLQ-----RQEL 523  
 QY 502 AKVIVQKLD--NKOMGLQPIPELIVVRSRPSLNLQNK 538  
 Db 524 VAELDQDERDQNTSRLVQEHKLLDENKLSLYYQOCK 562

RESULT 7  
 KYK2\_DICDI STANDARD; PRT; 410 AA.  
 AC P18161;  
 DT 01-NOV-1990 (Rel. 16, Created)  
 DT 01-NOV-1990 (Rel. 16, Last sequence update)  
 DE TYROSINE-PROTEIN KINASE 2 (EC 2.7.1.112) (FRAGMENT).  
 GN PYKB OR DPYK2.  
 OS Dictyostelium discoideum (Slime mold).  
 OC Eukaryota; Mycetozoa; Dictyostelida; Dictyostelium.  
 OX NCBI\_TaxID=44689;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RX MEDLINE=90287147; PubMed=1972546;  
 RA Tan J.L., Spudich J.A.;  
 RT "Developmentally regulated protein-tyrosine kinase genes in  
 Dictyostelium discoideum.";  
 RL Mol. Cell. Biol. 10:3578-3583(1990).  
 CC !- CATALYTIC ACTIVITY: ATP + A PROTEIN TYROSINE - ADP +  
 CC PROTEIN TYROSINE PHOSPHATE.  
 CC !- SIMILARITY: TO OTHER PROTEIN-TYROSINE KINASES BUT ALSO TO  
 CC SERINE/THREONINE PROTEIN KINASES.  
 CC -----  
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration



QY 380 -CYFMKLLHCP-----GNHS-----WDSFISGSRQAAFCDDHKTTPCCSAILNPLSTAGN 427  
 Db 415 TASFNGILDVPEIVISGNGPARRRSIQDLTVTCTEGQVSSRSRSPSVRMITTSQPTSEK 474  
 QY 428 SRRLPGIAQWQTSKREDIVNOMTEACLNQSLD-----ALLSRDLIMKEDYE 475  
 Db 475 PFRSHPTDDSDTNGSDNSIPMAYLTLDHQLOPLAPCPNSKESMAVFEQHCCKMAQEYM 534  
 QY 476 LVSTKPTRTSKVQLLDDTDIOGEEFAKIVQKLD--NKQMGLOPYPELVVSRPSLNL 533  
 Db 535 KYQT-----EIALLLQ-----RKQELVAELDQDEKQOQNTSRVQEHKLLDENKLSIY 584  
 QY 534 LLQNK 538  
 Db 585 YQCK 589

RESULT 9  
 ANPB\_ANGLE STANDARD; PRT: 1050 AA.  
 AC P55202;  
 DT 01-OCT-1996 (Rel. 34, Created)  
 DT 01-OCT-1996 (Rel. 34, Last sequence update)  
 DT 01-OCT-2000 (Rel. 40, Last annotation update)  
 DE ATRIAL NATRIURETIC PEPTIDE RECEPTOR B PRECURSOR (ANP-B) (ANPRB) (GC-B)  
 DE ATRIAL NATRIURETIC PEPTIDE RECEPTOR B PRECURSOR (ANP-B) (ANPRB) (GC-B)  
 DE B-TYPE RECEPTOR.  
 OS Anguilla japonica (Japanese eel).  
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 OC Actinopterygii; Neopterygii; Teleostei; Anguilliformes; Anguillioidei;  
 OC Anguillidae; Anguilla.  
 OX NCBI\_TaxID=7937;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RC TISSUE=Gill;  
 RX MEDLINE=94298823; PubMed=7913035;  
 RA Katafuchi T., Takashima A., Kashiwagi M., Hagiwara H., Takei Y.,  
 RA Hirose S.;  
 RT "Cloning and expression of eel natriuretic-peptide receptor B and  
 RT comparison with its mammalian counterparts.";  
 RL Eur. J. Biochem. 222:835-842(1994).  
 CC -!- FUNCTION: RECEPTOR FOR NATRIURETIC PEPTIDES. HAS GUANYLATE  
 CC CYCLASE ACTIVITY ON BINDING TO LIGAND. THE ORDER OF POTENCY OF  
 CC LIGANDS IN STIMULATING GC ACTIVITY IS CNP > VNP > ANP.  
 CC -!- CATALYTIC ACTIVITY: GTP = 3',5'-CYCLIC GMP + PYROPHOSPHATE.  
 CC -!- SUBCELLULAR LOCATION: TYPE I MEMBRANE PROTEIN.  
 CC -!- TISSUE SPECIFICITY: HIGH LEVELS FOUND IN LIVER, ATRIUM AND GILL.  
 CC MODERATE LEVELS FOUND IN BRAIN AND VENTRICLE, AND LOW LEVELS IN  
 CC OESOPHAGEAL SPHINCTER, STOMACH, POSTERIOR INTESTINE AND KIDNEY.  
 CC -!- INDUCTION: BY OSMOSIS. LEVELS DECREASE UNDER SALINE CONDITIONS.  
 CC -!- MISCELLANEOUS: THERE SEEM TO BE AT LEAST THREE ANP RECEPTORS. TWO  
 CC WITH GUANYLATE CYCLASE ACTIVITY (ANP-A AND ANP-B) AND ONE (ANP-C)  
 CC WHICH IS PROBABLY RESPONSIBLE FOR THE CLEARANCE OF ANP FROM THE  
 CC CIRCULATION WITHOUT A ROLE IN SIGNAL TRANSDUCTION.  
 CC -!- SIMILARITY: SOME SIMILARITY WITH CONSERVED REGION OF CATALYTIC  
 CC DOMAIN OF PROTEIN KINASES.  
 CC -!- SIMILARITY: BELONGS TO ADENYLYL CYCLASE CLASS-4/GUANYLYL CYCLASE  
 CC FAMILY.  
 CC -!- SIMILARITY: TO ANP-A ON THE COMPLETE SEQUENCE, AND TO ANP-C IN  
 CC THE EXTRACELLULAR AND TRANSMEMBRANE DOMAINS.

CC This SWISS-PROT entry is copyright. It is produced through a collaboration  
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation  
 CC the European Bioinformatics Institute. There are no restrictions on its  
 CC use by non-profit institutions as long as its content is in no way  
 CC modified and this statement is not removed. Usage by and for commercial  
 CC entities requires a license agreement (See [http://www.isb-sib.ch/](http://www.isb-sib.ch/announce/)  
 CC or send an email to [license@isb-sib.ch](mailto:license@isb-sib.ch)).  
 CC -----  
 CC EMBL: D25417; BAA05007.1;  
 CC HSSP: Q02846; IAWL.  
 CC InterPro: IPR000719;  
 CC InterPro: IPR001054;  
 DR  
 DR  
 DR

DR InterPro: IPR001170; -.  
 DR InterPro: IPR001828; -.  
 DR Pfam: PF01094; ANF\_receptor; 1.  
 DR Pfam: PF00069; pkinase; 1.  
 DR PRINTS: PRO0255; NATPEPTIDER.  
 DR PROSITE: PS00452; GUANYLATE\_CYCLASES\_1; 1.  
 DR PROSITE: PS50125; GUANYLATE\_CYCLASES\_2; 1.  
 DR PROSITE: PS50011; PROTEIN\_KINASE\_DOM; 1.  
 KW Receptor; Transmembrane; Glycoprotein; Phosphorylation; Lyase;  
 KW GMP synthesis; Signal.  
 FT SIGNAL 1 19 POTENTIAL.  
 FT CHAIN 20 1050 ATRIAL NATRIURETIC PEPTIDE RECEPTOR B.  
 FT DOMAIN 20 460 EXTRACELLULAR (POTENTIAL).  
 FT TRANSMEM 461 481 POTENTIAL.  
 FT DOMAIN 482 1050 CYTOPLASMIC (POTENTIAL).  
 FT DOMAIN 517 790 PROTEIN KINASE LIKE.  
 FT DISULFID 84 110 BY SIMILARITY.  
 FT DISULFID 236 339 BY SIMILARITY.  
 FT DISULFID 443 443 INTERCHAIN (PROBABLE).  
 FT DISULFID 452 452 INTERCHAIN (PROBABLE).  
 FT CARBOHYD 26 26 N-LINKED (GLCNAC. .) (POTENTIAL).  
 FT CARBOHYD 74 74 N-LINKED (GLCNAC. .) (POTENTIAL).  
 FT CARBOHYD 169 169 N-LINKED (GLCNAC. .) (POTENTIAL).  
 FT CARBOHYD 203 203 N-LINKED (GLCNAC. .) (POTENTIAL).  
 FT CARBOHYD 285 285 N-LINKED (GLCNAC. .) (POTENTIAL).  
 FT CARBOHYD 352 352 N-LINKED (GLCNAC. .) (POTENTIAL).  
 FT CARBOHYD 366 366 N-LINKED (GLCNAC. .) (POTENTIAL).  
 FT CARBOHYD 415 415 N-LINKED (GLCNAC. .) (POTENTIAL).  
 SQ SEQUENCE 1050 AA; 119857 MW; F3AC6DDDL17BD3832 CRC64;

Query Match 10.4%; Score 295; DB 1; Length 1050;  
 Best Local Similarity 29.0%; Pred. No. 5.9e-13;  
 Matches 87; Conservative 65; Mismatches 90; Indels 58; Gaps 16;  
 QY 15 YHKLADRLYL--SRGAS-GTVSSARADWRV-----QVAVKHLHHTPLLSERK 61  
 Db 511 YHKCAGSRLTISQSGSYGLTA-HGKYQFAKTYGFKGNLVAIK--HVNKRIELTRQ 567  
 QY 62 DVLRREAILHKAQFVIFPILGICNEPEFLGIVTEKMPNGSLNELLHRKTEYDVAWPLR 121  
 Db 568 -VLFELKHMVDVQFNHLTRFAGACIDPPNICIVTEYCPGSLQDIL--ENESINLDMWFR 624  
 QY 122 FRLLHETALGVNLYLHNMTPELLHDLKTONILLDNFFHVADFGLSKWRMMSLSQ---- 177  
 Db 625 YSLINDIVKGMNLFHNSYIG-SHGNLKSNCVVDVSRFLKIDYGLASFSSCENEDSHA 683  
 QY 178 --SRSSKSAPEGGTIIY--MPPENYEPGQKSRASIKHDIYSYAVITWVLSRKPFF---- 229  
 Db 684 LYAKKLWTAPE--LLIYDRHPPOQTQK-----DVYSFGIILQEIARNGPFYVDG 732  
 QY 230 EDVNTNQLQIMYSVQSHRPVINEESLPYDIP-----HARMISLIESGWAQNPDRPSF 283  
 Db 733 MDL-SPKEIVQKVRNGOK-----PYFRPTDTSCHSEELSILMGCWAEADPADRPF 783

RESULT 10  
 ANPB\_ANGLE STANDARD; PRT: 1047 AA.  
 AC P16067;  
 DT 01-APR-1990 (Rel. 14, Created)  
 DT 01-APR-1990 (Rel. 14, Last sequence update)  
 DT 01-OCT-2000 (Rel. 40, Last annotation update)  
 DE ATRIAL NATRIURETIC PEPTIDE RECEPTOR B PRECURSOR (ANP-B) (ANPRB) (GC-B)  
 DE ATRIAL NATRIURETIC PEPTIDE RECEPTOR B PRECURSOR (ANP-B) (ANPRB) (GC-B)  
 DE (GUANYLATE CYCLASE) (EC 4.6.1.2) (NPR-B) (ATRIAL NATRIURETIC PEPTIDE  
 DE B-TYPE RECEPTOR).  
 GN NPR2.  
 OS Rattus norvegicus (Rat).  
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Rattus.  
 OX NCBI\_TaxID=10116;  
 RN [1]  
 RP SEQUENCE FROM N.A.

RX MEDLINE=89376566; PubMed=2570641;  
 RA Schulz S., Singh S., Bellet R.A., Singh G., Tubb D.J., Chin H.,  
 RA Garbers D.L.;  
 RT "The primary structure of a plasma membrane guanylate cyclase  
 RT demonstrates diversity within this new receptor family.";  
 RL Cell 58:1155-1162(1989).  
 CC -1- FUNCTION: RECEPTOR FOR ATRIAL NATRIURETIC PEPTIDE. HAS GUANYLATE  
 CC CYCLASE ACTIVITY ON BINDING OF ANF. SEEMS TO BE STIMULATED MORE  
 CC EFFECTIVELY BY BRAIN NATRIURETIC PEPTIDE (BNP) THAN BY ANP.  
 CC -1- CATALYTIC ACTIVITY: GTP -> 3',5'-CYCLIC GMP + PYROPHOSPHATE.  
 CC -1- SUBCELLULAR LOCATION: TYPE I MEMBRANE PROTEIN.  
 CC -1- MISCELLANEOUS: THERE SEEM TO BE AT LEAST THREE ANP RECEPTORS: TWO  
 CC WITH GUANYLATE CYCLASE ACTIVITY (ANP-A AND ANP-B) AND ONE (ANP-C)  
 CC WHICH IS PROBABLY RESPONSIBLE FOR THE CLEARANCE OF ANP FROM THE  
 CC CIRCULATION WITHOUT A ROLE IN SIGNAL TRANSDUCTION.  
 CC -1- SIMILARITY: SOME SIMILARITY WITH CONSERVED REGION OF CATALYTIC  
 CC DOMAIN OF PROTEIN KINASES.  
 CC -1- SIMILARITY: BELONGS TO ADENYL CYCLASE CLASS-4/GUANYLYL CYCLASE  
 CC FAMILY.  
 CC -1- SIMILARITY: TO ANP-A ON THE COMPLETE SEQUENCE, AND TO ANP-C IN TH  
 CC EXTRACELLULAR AND TRANSMEMBRANE DOMAINS.  
 CC -----  
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration  
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation  
 CC the European Bioinformatics Institute. There are no restrictions on its  
 CC use by non-profit institutions as long as its content is in no way  
 CC modified and this statement is not removed. Usage by and for commercial  
 CC entities requires a license agreement (See http://www.isb-sib.ch/announce/  
 CC or send an email to license@isb-sib.ch).  
 CC -----  
 DR EMBL; M26896; AAA41205.1; .  
 DR PIR; A33300; OYRTR.  
 DR HSSP; Q02846; IAWL.  
 DR InterPro; IPR000719; .  
 DR InterPro; IPR01054; .  
 DR InterPro; IPR001170; .  
 DR InterPro; IPR001828; .  
 DR Pfam; PF01094; ANF\_receptor; 1.  
 DR Pfam; PF00069; pkinase; 1.  
 DR PRINTS; PR00255; NATPEPTIDER.  
 DR PROSITE; PS00458; ANF\_RECEPTORS; 1.  
 DR PROSITE; PS00452; GUANYLATE\_CYCLASES\_1; 1.  
 DR PROSITE; PS00125; GUANYLATE\_CYCLASES\_2; 1.  
 DR PROSITE; PS50011; PROTEIN\_KINASE\_DOM; 1.  
 KW Receptor; Transmembrane; Glycoprotein; Phosphorylation; Lyase;  
 KW GMP synthesis; Signal.  
 FT SIGNAL 1 22  
 FT CHAIN 23 1047 POTENTIAL.  
 FT DOMAIN 23 458 ATRIAL NATRIURETIC PEPTIDE RECEPTOR B.  
 FT TRANSMEM 459 478 EXTRACELLULAR (POTENTIAL).  
 FT DOMAIN 479 1047 POTENTIAL.  
 FT DOMAIN 513 786 CYTOPLASMIC (POTENTIAL).  
 FT DISULFID 75 101 PROTEIN KINASE LIKE.  
 FT DISULFID 439 439 BY SIMILARITY.  
 FT DISULFID 448 448 INTERCHAIN (PROBABLE).  
 FT CARBOHYD 24 24 INTERCHAIN (PROBABLE).  
 FT CARBOHYD 35 35 N-LINKED (GLCNAC. . .) (POTENTIAL).  
 FT CARBOHYD 161 161 N-LINKED (GLCNAC. . .) (POTENTIAL).  
 FT CARBOHYD 195 195 N-LINKED (GLCNAC. . .) (POTENTIAL).  
 FT CARBOHYD 244 244 N-LINKED (GLCNAC. . .) (POTENTIAL).  
 FT CARBOHYD 277 277 N-LINKED (GLCNAC. . .) (POTENTIAL).  
 FT CARBOHYD 349 349 N-LINKED (GLCNAC. . .) (POTENTIAL).  
 SQ SEQUENCE 1047 AA; 117126 MW; 5062C49228CC14A3 CRC64;

Query Match 10.38; Score 292.5; DB 1; Length 1047;  
 Best Local Similarity 27.38; Pred. No. 8, 8e-13;  
 Matches 102; Conservative 80; Mismatches 114; Indels 77; Gaps 21;

QY 62 DVLREAEILHKARFSEYIFPILGICNEPEFFLGIYVEYMPNGSLNELLHRKTEYDVAWPLR 121  
 Db 564 -VLFELKHMEDVQFNHLTRIGACIDPPNICIVTEYCPGSLQDIL--ENDSINLDMW 620  
 QY 122 FRILHETALGVNVLHNMTPPELHDLKQTLNLDNEPHVKIADPGLSKWRMMSLSQSRSS 181  
 Db 621 YSLINDLVKGMALHNSIIS-SHGSLKSSNCVVDREVLRKIDYGLASFR-----S 670  
 QY 182 KSAPEGGTIY-----MPPF-----NYEPGOKSRASIKHDIYVAVITWEVLSRKQPF--E 230  
 Db 671 TAPEDDSDHALYAKLWAPPELLSGNPLP---TTGCMQADVYSFAIILOETALRSQPFYLE 727  
 QY 231 DV-TNPLQIMYSVQSHRPV-----INEESLPYDIPHRARMISLISGWAQNPDR 280  
 Db 728 GLDLSPEIKVQKVRNGQRPYFRPSIDRTQLNEE-----LVLLMERCWAQDPTR 776  
 QY 281 PSELKCLIELEPVLRTFEE---ITFLE-AVTLKK-----TKLQSVSSATHLCKDKKMWEL 331  
 Db 777 PDF-----GQIKGFIIRREKGGTSILDNLLRMEQYANNLEKLVERTQAYLEEKRAEA 832  
 QY 332 SLNIPVNHGPOEE 344  
 Db 833 LLYQILPHSVAREQ 845  
 RESULT 11  
 M3KA\_HUMAN STANDARD; PRT; 954 AA.  
 ID M3KA\_HUMAN Q12761; Q14871;  
 DC Q02779; Q12761; Q14871;  
 DT 01-FEB-1994 (Rel. 28, Created)  
 DT 30-MAY-2000 (Rel. 39, Last sequence update)  
 DT 01-OCT-2000 (Rel. 40, Last annotation update)  
 DE DE MITOGEN-ACTIVATED PROTEIN KINASE KINASE 10 (EC 2.7.1.-)  
 DE (MIXED LINEAGE KINASE 2) (PROTEIN KINASE MST).  
 GN MAP3K10 OR MLK2 OR MST.  
 OS Homo sapiens (Human)  
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 OC Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.  
 OX NCBI\_TaxID=9606;  
 RX [1]  
 RN SEQUENCE FROM N.A.  
 RP TISSUE=Brain;  
 RC MEDLINE=96128179; PubMed=8536694;  
 RA Dorow D.S., Devereux L., Tu G.F., Price G., Nicholl J.K.,  
 RA Sutherland G.R., Simpson R.J.;  
 RA "Complete nucleotide sequence, expression, and chromosomal  
 RA localisation of human mixed-lineage kinase 2.";  
 RL Eur. J. Biochem. 234:492-500(1995).  
 RL [2]  
 RN SEQUENCE FROM N.A.  
 RP TISSUE=Brain;  
 RC MEDLINE=95249256; PubMed=7731697;  
 RA Katoh M., Hirai M., Sugimura T., Terada M.;  
 RA "Cloning and characterization of MST, a novel (putative)  
 RA serine/threonine kinase with SH3 domain.";  
 RL Oncogene 10:1447-1451(1995).  
 RN [3]  
 RP SEQUENCE OF 244-480 FROM N.A.  
 RC TISSUE=Colon epithelium;  
 RC MEDLINE=93238756; PubMed=8477742;  
 RA Dorow D.S., Devereux L., Dietzsch E., de Kretsch T.;  
 RA "Identification of a new family of human epithelial  
 RA containing two leucine/isoleucine-zipper domains.";  
 RL Eur. J. Biochem. 213:701-710(1993).  
 CC -1- TISSUE SPECIFICITY: EXPRESSED IN BRAIN AND SKELETAL MUSCLE.  
 CC -1- SIMILARITY: BELONGS TO THE SER/THR FAMILY OF PROTEIN KINASES.  
 CC MAP KINASE KINASE SUBFAMILY.  
 CC -1- SIMILARITY: CONTAINS 1 SH3 DOMAIN.  
 CC -----  
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration  
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -  
 CC the European Bioinformatics Institute. There are no restrictions on its  
 CC use by non-profit institutions as long as its content is in no way

QY 15 YHKLADURY-LUS-RGAS-GTVSSARHADRWV-----QVAVKHLHHHTPLDSEK 61  
 Db 507 YHKGAGSRLTLRSLRSGSSYGLMATA-HGKYQIFANTGHFKGNVAIK--HVNKKRIELTRQ 563



modified and this statement is not removed. Usage by and for commercial entities requires a license agreement (See http://www.isb-sib.ch/announce/ or send an email to license@isb-sib.ch).

EMBL; X90846; CAA62351.1; ...
EMBL; Z48615; CAA88531.1; ...
PIR; S32468; S32468.
HSSP; P00523; 2PTK.
MIM; 600137;
InterPro; IPR000719;
InterPro; IPR001245;
InterPro; IPR001452;
InterPro; IPR002965;
Pfam; PF00018; SH3; 1.
Pfam; PF00069; pkinase; 1.
PRINTS; PR00109; TYRKINASE.
PRINTS; PR00452; SH3DOMAIN.
PRINTS; PR01217; PRICHEXTENS.
PROSITE; PS00107; PROTEIN\_KINASE\_ATP; 1.
PROSITE; PS00108; PROTEIN\_KINASE\_ST; 1.
PROSITE; PS50011; PROTEIN\_KINASE\_DOM; 1.
PROSITE; PS50002; SH3; 1.
Transferase; Serine/threonine-protein kinase; Tyrosine-protein kinase;
ATP-binding; SH3 domain.
DOMAIN 2 5 POLY-GLU.
DOMAIN 16 81 SH3.
DOMAIN 98 360 PROTEIN KINASE.
NP\_BIND 104 112 ATP (BY SIMILARITY).
BLIND 125 125 ATP (BY SIMILARITY).
ACT\_SITE 222 222 BY SIMILARITY.
DOMAIN 384 405 LEUCINE-ZIPPER (BY SIMILARITY).
DOMAIN 419 440 LEUCINE-ZIPPER (BY SIMILARITY).
DOMAIN 449 463 ARG/LYS-RICH (BASIC).
CONFLICT 462 464 SRL -> AV (IN REF. 2).
CONFLICT 471 471 G -> S (IN REF. 2).
CONFLICT 807 807 G -> R (IN REF. 2).
CONFLICT 818 818 V -> A (IN REF. 2).
CONFLICT 465 480 LKLRGGSHSLSPSGF -> AQAAAGRRQHPQALWL (IN REF. 3).

SEQUENCE 954 AA; 538F4AAA59B0ABA CRC64;
Query Match 10.38; Score 290; DB 1; Length 954;
Best Local Similarity 23.7%; Pred. No. 1.2e-12;
Matches 123; Conservative 78; Mismatches 174; Indels 144; Gaps 23;
QY 13 IPYHKLADRLVSRGASVSSARHADWR-VQVAVKHLHIHTPLDSEK-----KDVLR 65
DB 93 IPFHELOEEITIGVGGKVTYRAL---WRGEEVAVK-----AARLDPEKDPAVTAEOVCO 144
QY 66 EAELLHKARFSYIPILGICNEPEFLGIVTEYMPNGSLNELLHRKTEYDVA--WPLRFR 123
DB 145 EARLFGALQHPNIIALRGACLNPHLCVMEYARGGALSRLVAGRRVPPHVLVWAV--- 201
QY 124 ILHEIALGVNLYHNWTP-PLLHLDKTONILLDN--EFH-----VKIADPGLSK-WRMM 173
DB 202 --QVARGMYLHNDAPVPIIHRDLKSNILILEAIEHNHLADTVLTKITDPLAREWH-- 256
QY 174 SLSQSRSSKAPEGTIYMPPEYNEFCQKRSRASKHDIYSYAVITWEVLSRKPFFEDVT 233
DB 257 -----KTKMS-AGATVAMAPEVIRLSLFSKSS---DVWSFGVLLWELLTGEVYREI- 306
QY 234 NPLQIMYSVSGHRPVINEESLPYDIPHRARMISLIESGWAQNPDERPSFLKLIETLEPV 293
DB 307 DALAVAGVA-----MNKLTLPISCPPEFARLLEECWDPDPHGRDFGSIKRLLEVI 360
QY 294 -----LRFTEITFELEAVI- 307
DB 361 EQSALFOMPLESFHSLQEDKWLKLEIQHMFDLRTKELRSREELLRAAQQRQEQELR 420
QY 308 ----QLAKTKLQVSSAIHLCKDKKMLSLNIPVNHGPOEESCSGLHNSGSPETSRS 363
DB 421 RREQLEAEREMDIYVERLHLL---MCLSQSEK-----RVRKRGKFKRSR 464

364 LPAPQDNDFLKRKAQDCYFMYLHLHCPGNHNSWDSTISGS---QRAAFCDHKTTPCSSLII- 419
465 LKLRGGSHS-----LPSFGEHKITVQASPTLDKRRKSGDCGSPASPSPSIIP 511
QY 420 -----NPLSTAGNSERLQFCIAQOVIQS---KREDIV 448
DB 512 RLRAIRLTPVDVCGGSSGSSGSSGSGTWSRGGPPKKELV 550
RESULT 12
ID RLK5\_ARATH STANDARD; PRT; 999 AA.
AC P47735;
DT 01-FEB-1996 (Rel. 33, Created)
DT 01-FEB-1996 (Rel. 33, Last sequence update)
DE 01-OCT-2000 (Rel. 40, Last annotation update)
DE RECEPTOR-LIKE PROTEIN KINASE 5 PRECURSOR (EC 2.7.1.-).
GN RLK5 OR AT4G28490 OR F2109.180.
OS Arabidopsis thaliana (Mouse-ear cress).
OC Eukaryota; Viridiplantae; Embryophyta; Tracheophyta; Spermatophyta;
OC Magnoliophyta; eudicotyledons; core eudicots; Rosidae; eurosids II;
OC Brassicales; Brassicaceae; Arabidopsids.
OX NCBI\_TaxID=3702;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=CV\_COLUMBIA;
RX MEDLINE=94035150; PubMed=8220453;
RA Walker J.C.;
RT "receptor-like protein kinase genes of Arabidopsis thaliana.";
RL Plant J. 3:451-456(1993).
[2]
RC SEQUENCE FROM N.A.
RC STRAIN=CV\_COLUMBIA;
RX MEDLINE=20083488; PubMed=10617198;
RA Mayer K.F.X., Schueller C., Wambutt R., Murphy G., Volckaert G.,
Pohl T., Duesterhoeft A., Stiekema W., Entian K.-D., Terryn N.,
Harris B., Ansoorge W., Brandt P., Grivell L., Rieger M.,
Weichselgartner M., de Simone V., Obermaier B., Mache R., Mueller M.,
Kreis M., Delsen M., Puigdomenech P., Watson M., Schmidheini T.,
Reichert B., Portetelle D., Perez-Alonso M., Boutry M., Bancroft I.,
Vos P., Hoheisel J., Zimmermann W., Wedler H., Ridley P.,
Langham S.-A., McCullagh B., Bilham L., Robben J.,
Van der Schueren J., Grynoprez B., Chuang Y.-J., Vandenbussche F.,
Braeken M., Welljens I., Voet M., Bastiaens I., Aert R., Defoor E.,
Weitzenecker T., Bothe G., Ransperger U., Hilbert H., Braun M.,
Holzer E., Brandt A., Peters S., van Staveren M., Dirkse W.,
Mooijman P., Klein Lankhorst R., Rose M., Hauf J., Koetter P.,
Bernelser S., Hempel S., Feldpausch M., Lambert S., Van den Daele H.,
De Keyser A., Buysshaert C., Gielen J., Villarroel R., De Clercq R.,
Van Montagu M., Rogers J., Cronin A., Quail M., Bray-Allen S.,
Clark L., Doggett J., Hall S., Kay M., Lennard N., McLay K., Mayes R.,
Pettett A., Rajandream H.-A., Lyne M., Benes V., Reclmann S.,
Borkova D., Bloeker H., Scharfe M., Grimm M., Loehner T.-H.,
Dose C., de Haan M., Maarse A., Schaefer M., Mueller-Auer S.,
Gabel C., Fuchs M., Fartmann B., Granderath K., Dauner D., Herzl A.,
Neumann S., Argirou A., Vitale D., Liquori R., Piravandi E.,
Massenet O., Ougley F., Clabaud G., Mueandlein A., Felber R.,
Schnabl S., Hiller R., Schmidt W., Lechany A., Aubourg S.,
Zaccaria P., Bevan M., Wilson R.K., de la Bastide M., Habermann K.,
Parnell L., Dedhia N., Gnoj L., Schutz K., Huang E., Spiegel L.,
RA Sekhon M., Murray J., Sheet P., Cordes M., Abu-Threideh J.,
Perez-Perez A., Purnelle B., Bent E., Johnson S., Tacon D., Jesse T.,
RA Heijnen L., Schwarz S., Scholler P., Heber S., Francis P., Bieleke C.,
RA Frishman D., Haase D., Lemcke K., Mewes H.-W., Stocker S.,
RA Zaccaria P., Bevan M., Wilson R.K., de la Bastide M., Habermann K.,
RA Parnell L., Dedhia N., Gnoj L., Schutz K., Huang E., Spiegel L.,
RA Sekhon M., Murray J., Sheet P., Cordes M., Abu-Threideh J.,
RA Stoneking T., Kalicki J., Graves T., Harmon G., Edwards J.,
RA Latreille P., Courtney L., Cloud J., Abbott A., Scott K., Johnson D.,
RA Minx P., Bentley D., Fulton B., Miller N., Greco T., Kemp K.,
RA Kramer J., Fulton L., Mardis E., Dante M., Pepin K., Hillier L.,
RA Nelson J., Spieth J., Ryan E., Andrews S., Geisel C., Layman D.,
RA Du H., Ali J., Berghoff A., Jones K., Drone K., Cotton M., Joshu C.,

RA Antonoiu B., Zidanic M., Strong C., Sun H., Lamar B., Jordan C.,  
 RA Ma P., Zhong J., Preston R., Vil D., Shekher M., Matero A., Shah R.,  
 RA Swaby I.K., O'Shaughnessy A., Rodriguez M., Hoffman J., Till S.,  
 RA Granat S., Shondy N., Hasegawa A., Hameed A., Lodhi M., Johnson A.,  
 RA Chen E., Marra M., Martienssen R., McCormbie W.R.;  
 RT "Sequence and analysis of chromosome 4 of the plant Arabidopsis  
 RT thaliana.";  
 RL Nature 402:769-777(1999).  
 RP [3]  
 RP CHARACTERIZATION.  
 RX MEDLINE=94368830; PubMed=8086440;  
 RA Horn M.A., Walker J.C.;  
 RT "Biochemical properties of the autophosphorylation of RLK5, a  
 RT receptor-like protein kinase from Arabidopsis thaliana.";  
 RL Biochim. Biophys. Acta 1208:65-74(1994).  
 CC -!- COFACTOR: HAVE SIGNIFICANTLY GREATER ACTIVITY IN THE PRESENCE OF  
 CC MN2+ THAN MG2+.  
 CC -!- TISSUE SPECIFICITY: EXPRESSED IN ROOTS AND ROSETTES.  
 CC -!- PTM: AUTOPHOSPHORYLATED ON SERINE AND THREONINE RESIDUES.  
 CC -!- SIMILARITY: TO PROTEIN KINASES IN THE C-TERMINUS. BUT DOES NOT  
 CC SEEM TO HAVE CONSERVED A KINASE ACTIVITY.  
 CC -!- SIMILARITY: CONTAINS 18 LEUCINE-RICH REPEATS (LRR).  
 CC  
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration  
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -  
 CC the European Bioinformatics Institute. There are no restrictions on its  
 CC use by non-profit institutions as long as its content is in no way  
 CC modified and this statement is not removed. Usage by and for commercial  
 CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>  
 CC or send an email to [license@isb-sib.ch](mailto:license@isb-sib.ch)).  
 CC  
 CC EMBL; M84660; AAA32859.1;  
 DR EMBL; AL021749; CAA16889.1;  
 DR EMBL; AL161572; CAB79651.1;  
 DR HSP; P00523; 2ptk  
 DR InterPro; IPR000719;  
 DR InterPro; IPR001611;  
 DR InterPro; IPR002290;  
 DR Pfam; PF00560; LRR; 14.  
 DR Pfam; PF00069; pkInase; 1.  
 DR PRINTS; PR00019; LEURICHRPT.  
 DR PROSITE; PS00107; PROTEIN\_KINASE\_ATP; 1.  
 DR PROSITE; PS00108; PROTEIN\_KINASE\_SF; 1.  
 DR PROSITE; PS00111; PROTEIN\_KINASE\_DOM; 1.  
 DR Transferrase; Serine/threonine-protein kinase; ATP-binding;  
 KW Transmembrane; Glycoprotein; Phosphorylation; Leucine-rich repeat;  
 KW Repeat; Signal.  
 FT SIGNAL 1 14 POTENTIAL.  
 FT CHAIN 15 999 RECEPTOR-LIKE PROTEIN KINASE 5.  
 FT DOMAIN 15 621 EXTRACELLULAR (POTENTIAL).  
 FT TRANSMEM 622 641 POTENTIAL.  
 FT DOMAIN 642 999 CYTOPLASMIC (POTENTIAL).  
 FT REPEAT 88 112 LRR 1.  
 FT REPEAT 114 138 LRR 2.  
 FT REPEAT 138 161 LRR 3.  
 FT REPEAT 163 186 LRR 4.  
 FT REPEAT 188 211 LRR 5.  
 FT REPEAT 235 261 LRR 6.  
 FT REPEAT 263 283 LRR 7.  
 FT REPEAT 283 306 LRR 8.  
 FT REPEAT 306 330 LRR 9.  
 FT REPEAT 332 353 LRR 10.  
 FT REPEAT 354 378 LRR 11.  
 FT REPEAT 402 426 LRR 12.  
 FT REPEAT 426 450 LRR 13.  
 FT REPEAT 452 474 LRR 14.  
 FT REPEAT 498 522 LRR 15.  
 FT REPEAT 524 547 LRR 16.  
 FT REPEAT 549 567 LRR 17.  
 FT REPEAT 567 592 LRR 18.  
 FT DOMAIN 683 968 PROTEIN KINASE.  
 FT CARBOHYD 98 98 N-LINKED (GLCNAC. . .) (POTENTIAL).  
 FT CARBOHYD 102 102 N-LINKED (GLCNAC. . .) (POTENTIAL).

FT CARBOHYD 150 150 N-LINKED (GLCNAC. . .) (POTENTIAL).  
 FT CARBOHYD 185 185 N-LINKED (GLCNAC. . .) (POTENTIAL).  
 FT CARBOHYD 210 210 N-LINKED (GLCNAC. . .) (POTENTIAL).  
 FT CARBOHYD 269 269 N-LINKED (GLCNAC. . .) (POTENTIAL).  
 FT CARBOHYD 282 282 N-LINKED (GLCNAC. . .) (POTENTIAL).  
 FT CARBOHYD 452 452 N-LINKED (GLCNAC. . .) (POTENTIAL).  
 FT CARBOHYD 576 576 N-LINKED (GLCNAC. . .) (POTENTIAL).  
 FT NP\_BIND 689 697 ATP (BY SIMILARITY).  
 FT BINDING 711 711 ATP (BY SIMILARITY).  
 FT ACT\_SITE 819 819 ATP (BY SIMILARITY).  
 FT MUTAGEN 711 711 K->E; LOSS OF CATALYTIC ACTIVITY.  
 SQ SEQUENCE 999 AA; 109095 MW; F5793D899EA0C6A7 CRC64;  
 Query Match 10.2%; Score 289.5; DB 1; Length 999;  
 Best Local Similarity 32.3%; Pred. No. 1.3e-12;  
 Matches 97; Conservative 49; Mismatches 12; Indels 31; Gaps 12;  
 QY 16 HKLADL----RYLSRGASGTYSSARHADRWVQVAVKHLHIHTP-----LLDSEKRDVL- 64  
 DB 677 HEIADCLDEKNVIGFGSSGKVKYKVELRGEV-VAVKLNKNSVKGGDDEYSSDLSLRDVF 735  
 QY 65 REAEILHKARFSYIFPILGICNEPEFLGIVTEYMPNGSLNELLH--RKTEYPDVAWPLRF 122  
 DB 736 ABEVLTGTRHKSIVRLWCCSSGCKLLVYEMPNGSLADVLHGDRKGGVV-LGWPERL 794  
 QY 123 RLHETALGVNYL-HNMTPLLHDLKTONILLDNEFHVKIADFGLSKWRMMSLSQSRSS 181  
 DB 795 RIALDAAEGLSYLHDCVPPVHRDVKSSNILLSDYGAKVADFGIAKVGOMSGSKTPEA 854  
 QY 182 KSAPEGGIIYPPENYEPGQKSRASIKHDIYSYAVITWEVLSRKPPEDEVTPNLIQIMS 241  
 DB 855 MSG- IAGSCGYTAPEV---YTLRVNEKSDIYSFGVLELVTKGPTDSELGDKDMAKW 910  
 \*QY 242 VSO-----GHRPVINEESLPYDIPHRARMISLIESG---WAQNPDPERPFLKLEIEPV 293  
 DB 911 VCTALDKCGLEVPIDPK---LDLKFKEISKVIHIGLLCTSPLELNRPMSRKRVMVQLQEV 967  
 RESULT 13  
 KRAF\_CAEEL  
 ID KRAF\_CAEEL STANDARD; PRT: 813 AA.  
 AC Q07292;  
 DT 01-OCT-1994 (Rel. 30, Created)  
 DT 01-OCT-1994 (Rel. 30, Last sequence update)  
 DT 01-OCT-2000 (Rel. 40, Last annotation update)  
 DE RAF HOMOLOG SERINE/THREONINE-PROTEIN KINASE (EC 2.7.1.-).  
 GN LIN-45 OR RAF-1.  
 OS Caenorhabditis elegans.  
 OC Eukaryota; Metazoa; Nematoda; Chromadorea; Rhabditida; Rhabditoidea;  
 OC Rhabditidae; Peloderinae; Caenorhabditis.  
 OX NCBI\_TaxID=6239;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RX MEDLINE=93247635; PubMed=8483497;  
 RA Han M., Golden A., Han Y., Sternberg P.W.;  
 RT "C. elegans lin-45 raf gene participates in let-60 ras-stimulated  
 RT vulval differentiation.";  
 RL Nature 363:133-140(1993).  
 CC -!- FUNCTION: PROTEIN KINASE THAT PARTICIPATES IN THE INDUCTION OF  
 CC C-ELEGANS VULVA. ACTS DOWNSTREAM OF THE RAS PROTEIN LET-60.  
 CC -!- SIMILARITY: BELONGS TO THE SER/THR FAMILY OF PROTEIN KINASES.  
 CC MIL/RAF SUBFAMILY.  
 CC -!- SIMILARITY: CONTAINS 1 ZINC-DEPENDENT PHORBOL-ESTER AND DAG  
 CC BINDING DOMAIN.  
 CC  
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration  
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -  
 CC the European Bioinformatics Institute. There are no restrictions on its  
 CC use by non-profit institutions as long as its content is in no way  
 CC modified and this statement is not removed. Usage by and for commercial  
 CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>  
 CC or send an email to [license@isb-sib.ch](mailto:license@isb-sib.ch)).

RT EMBL; LI5347; AAA28142.1; .  
 RT PIR; S33261; S33261.  
 RL HSSP; P11362; 1AGW.  
 DR InterPro; IPR000719; .  
 DR InterPro; IPR002219; .  
 DR InterPro; IPR002290; .  
 DR Pfam; PF00130; DAG\_PE-bind; 1.  
 DR Pfam; PF00069; pkinase; 1.  
 DR PROSITE; PS00479; DAG\_PE\_BIND\_DOM\_1; 1.  
 DR PROSITE; PS50081; DAG\_PE\_BIND\_DOM\_2; 1.  
 DR PROSITE; PS00107; PROTEIN\_KINASE\_ATP; 1.  
 DR PROSITE; PS50011; PROTEIN\_KINASE\_ATP; 1.  
 DR PROSITE; PS00108; PROTEIN\_KINASE\_DOM; 1.  
 DR PROSITE; PS00108; PROTEIN\_KINASE\_ST; 1.  
 KW Phorbol-ester binding.  
 FT DOMAIN 171 217 PHORBOL-ESTER AND DAG BINDING.  
 FT DOMAIN 481 748 PROTEIN KINASE.  
 FT NP\_BIND 487 495 ATP (BY SIMILARITY).  
 FT BINDING 507 507 ATP (BY SIMILARITY).  
 FT ACT\_SITE 602 602 BY SIMILARITY.  
 SQ SEQUENCE 813 AA; 90491 MW; 63776968C6859E49 CRC64;

Query Match 10.2%; Score 287.5; DB 1; Length 813;  
 Best Local Similarity 27.7%; Pred. No. 1.4e-12;  
 Matches 91; Conservative 65; Mismatches 127; Indels 45; Gaps 14;

QY 11 PTPYKHLADLRYS-----RGASGTVSSARHADRWVQAVKHLHITPLLSDERKDV 63  
 DQ 466 PPKPHE--DWELLNERTIYKVGSGSFGTVYREFFGTVAIKLNVVDP--TPSQMAAF 522  
 QY 64 LREAELHKARFSYIFPILIGINEPEFLGIVTEYMPNGSINELLHRKTEYDPVAMPLR-- 121  
 DQ 523 KNEVAVLKTRHNLNLLFMGWVREPE-TAIIQWCEGSSLYRHH--YQEPRVRFEMGAI 579  
 QY 122 FRILHEIALGVNLLNMPPLHLHDKTQNI--LLDNEFHVKTADFGL-----SKRWMSLS 176  
 DQ 580 IDILKQVSLGMYLHSHKN--IHRDLKNNIFLMDMTVTKIGDFLAVTKVTKVNGSQ 637  
 QY 177 QSRSSKAPEGGTIIYMPENYEPGOKSRASIKHDIYVAVITWEVLSRKQPFEDVSNPL 236  
 DQ 638 QOQQPT-----GSIWLMAPEVIRMQDDNPYTPQSDYVFGICMYELLSHLPSINNRD 692  
 QY 237 QIIYSVGSQGH-RPVINEESLPYDIPRHARMISLIESGWAQNPDERSFLKCLILEPVLVR 295  
 DQ 693 QILFVWVGRYLRP--DRSKIRHDTN--KSMKLYDNCIMFDRNERPVF----- 736  
 QY 296 TFEETFLFVAVIQKTKLQSVSSAIHL 323  
 DQ 737 -GEVLERLRDIILPKLTRSQSAPNVLHL 763

RESULT 14  
 ANPB\_HUMAN STANDARD; PRT; 1047 AA.  
 ID ANPB\_HUMAN  
 AC P20594; Q9UQ50; O60871;  
 DT 01-FEB-1991 (Rel. 17, Created)  
 DT 01-FEB-1991 (Rel. 17, Last sequence update)  
 DT 01-OCT-2000 (Rel. 40, Last annotation update)  
 DE ATRIAL NATRIURETIC PEPTIDE RECEPTOR B PRECURSOR (ANP-B) (ANPRB) (GC-B)  
 DE (GUANYLATE CYCLASE) (EC 4.6.1.2) (NPR-B) (ATRIAL NATRIURETIC PEPTIDE  
 DE B-TYPE RECEPTOR).  
 GN NPR2 OR ANPRB.  
 OS Homo sapiens (Human).  
 OC Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;  
 OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
 OX NCBI\_TaxID=9606;  
 RN [1]  
 RP SEQUENCE FROM N.A. (LONG ISOFORM).  
 RC TISSUE=Brain.  
 RX MEDLINE=89365195; PubMed=2570358;  
 RA Chang M.S., Lowe D.G., Lewis M., Hellmiss R., Chen E., Goettel D.V.;

"Differential activation by atrial and brain natriuretic peptides of two different receptor guanylate cyclases.;" Nature 341:68-72(1989). [2]  
 SEQUENCE FROM N.A. (LONG ISOFORM).  
 TISSUE=Blood;  
 PubMed=10082481;  
 Rehemudula D., Nakayama T., Soma M., Takahashi Y., Uwabo J., Sato M., Izumi Y., Kamatsuse K., Ozawa Y.;  
 "Structure of the type B human natriuretic peptide receptor gene and association of a novel microsatellite polymorphism with essential hypertension.;" Circ. Res. 84:605-610(1999). [3]  
 SEQUENCE FROM N.A. (SHORT ISOFORM).  
 TISSUE=Kidney;  
 Hirsch J.R., Meyer M., Magert H.J., Forssmann W.G., Mollerup S., Herter P., Weber G., Cermak R., Ankorina-Stark I., Schlatter E., Krühoffer M.;  
 "cGMP-dependent and independent inhibition of a K<sup>+</sup> conductance by natriuretic peptides. Molecular and functional studies in human proximal tubule cells.;" Submitted (APR-1998) to the EMBL/GenBank/DBJ databases.  
 FUNCTION: RECEPTOR FOR ATRIAL NATRIURETIC PEPTIDE. HAS GUANYLATE CYCLASE ACTIVITY ON BINDING OF ANP. SEEMS TO BE STIMULATED MORE EFFECTIVELY BY BRAIN NATRIURETIC PEPTIDE (BNP) THAN BY ANP.  
 CATALYTIC ACTIVITY: GTP -> 3',5'-CYCLIC GMP + PYROPHOSPHATE.  
 SUBCELLULAR LOCATION: TYPE I MEMBRANE PROTEIN.  
 ALTERNATIVE PRODUCTS: 2 ISOFORMS; A LONG FORM (SHOWN HERE) AND A SHORT FORM/NPR-BI; ARE PRODUCED BY ALTERNATIVE SPLICING.  
 MISCELLANEOUS: THERE SEEM TO BE AT LEAST THREE ANP RECEPTORS: TWO WITH GUANYLATE CYCLASE ACTIVITY (ANP-A AND ANP-B) AND ONE (ANP-C) WHICH IS PROBABLY RESPONSIBLE FOR THE CLEARANCE OF ANP FROM THE CIRCULATION WITHOUT A ROLE IN SIGNAL TRANSDUCTION.  
 SIMILARITY: SOME SIMILARITY WITH CONSERVED REGION OF CATALYTIC DOMAIN OF PROTEIN KINASES.  
 SIMILARITY: BELONGS TO ADENYLATE CYCLASE CLASS-4/GUANYLATE CYCLASE FAMILY.  
 SIMILARITY: TO ANP-A ON THE COMPLETE SEQUENCE, AND TO ANP-C IN THE EXTRACELLULAR AND TRANSMEMBRANE DOMAINS.  
 This SWISS-PROT entry is copyright. It is produced through a collaboration between the Swiss Institute of Bioinformatics and the EMBL outstation at the European Bioinformatics Institute. There are no restrictions on its use by non-profit institutions as long as its content is in no way modified and this statement is not removed. Usage by and for commercial entities requires a license agreement (See http://www.isb-sib.ch/announce/ or send an email to license@isb-sib.ch).  
 EMBL; AB005647; BAA81737.1; .  
 EMBL; AB005626; BAA81737.1; JOINED.  
 EMBL; AB005627; BAA81737.1; JOINED.  
 EMBL; AB005628; BAA81737.1; JOINED.  
 EMBL; AB005629; BAA81737.1; JOINED.  
 EMBL; AB005630; BAA81737.1; JOINED.  
 EMBL; AB005631; BAA81737.1; JOINED.  
 EMBL; AB005632; BAA81737.1; JOINED.  
 EMBL; AB005633; BAA81737.1; JOINED.  
 EMBL; AB005634; BAA81737.1; JOINED.  
 EMBL; AB005635; BAA81737.1; JOINED.  
 EMBL; AB005636; BAA81737.1; JOINED.  
 EMBL; AB005637; BAA81737.1; JOINED.  
 EMBL; AB005638; BAA81737.1; JOINED.  
 EMBL; AB005639; BAA81737.1; JOINED.  
 EMBL; AB005640; BAA81737.1; JOINED.  
 EMBL; AB005641; BAA81737.1; JOINED.  
 EMBL; AB005642; BAA81737.1; JOINED.  
 EMBL; AB005643; BAA81737.1; JOINED.  
 EMBL; AB005644; BAA81737.1; JOINED.  
 EMBL; AB005645; BAA81737.1; JOINED.  
 EMBL; AB005646; BAA81737.1; JOINED.  
 EMBL; AJ005282; CAU06466.1; .  
 PIR; S05514; S05514.



```

Db 300 EKELRTWEE-----ELTRAAALQOKNOE-ELLRRREOELAEREIDILERELELNIIHQ 350
Oy 341 POEESCGSSOLHENSOGSPETSR---SLPAPQDNDFLSRKAQDCYFMKHLHCPG--NHSW 394
Db 351 COEK----PRYKRRKRFRKSRLAQPVLPPFHGS-----RCPGGTSSW 391

```

Search completed: June 14, 2001, 08:04:51  
Job time: 23 sec

**THIS PAGE BLANK (USPTO)**

GenCore version 4.5  
Copyright (c) 1993 - 2000 Compugen Ltd.

OM protein - protein search, using sw model

Run on: June 14, 2001, 08:04:28 ; Search time 53.04 Seconds  
(without alignments)  
699.668 Million cell updates/sec

Title: US-09-445-223-1  
Perfect score: 2829  
Sequence: 1 MNGEAICSAALPTIPYHKLAD.....PEILVSRSPSLNLLONKSM 540  
Scoring table: BLOSUM62  
Gapop 10.0 , Gapext 0.5

Searched: 198801 seqs, 68722935 residues  
Total number of hits satisfying chosen parameters: 198801

Minimum DB seq length: 0  
Maximum DB seq length: 2000000000  
Post-processing: Minimum Match 0%  
Maximum Match 100%  
Listing first 45 summaries

Database : PIR\_67: \*  
1: pir1: \*  
2: pir2: \*  
3: pir3: \*  
4: pir4: \*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Match	Length	DB	ID	Description
1	394	13.9	656	2	I49299	receptor interacti
2	385.5	13.6	829	2	T07406	probable protein k
3	376	13.3	821	2	T48400	serine/threonine-p
4	369	13.0	671	2	T09479	serine/threonine p
5	359.5	12.7	963	2	T09911	probable serine/th
6	359	12.7	1015	2	T00726	probable serine/th
7	348.5	12.3	370	2	T46150	protein kinase AVN
8	340	12.0	982	2	T06576	probable protein k
9	335.5	11.9	736	2	T05137	protein kinase hom
10	327.5	11.6	406	2	T52626	probable mitogen-a
11	317.5	11.2	462	2	T29851	protein kinase 6 (
12	316.5	11.2	776	2	T02584	hypothetical prote
13	313.5	11.1	1584	2	T16276	protein-tyrosine k
14	312	11.0	579	2	JCS595	transforming growt
15	307	10.9	553	2	T04683	hypothetical prote
16	306.5	10.8	475	2	T12955	probable protein k
17	306.5	10.8	567	2	JCS957	transforming growt
18	306.5	10.8	888	2	A55318	serine/threonine p
19	306.5	10.8	888	2	JCS399	dual leucine zippe
20	305	10.8	784	2	T45697	hypothetical prote
21	303.5	10.7	410	2	B35670	protein-tyrosine k
22	302.5	10.7	390	2	T01451	protein kinase hom
23	301.5	10.7	886	2	T48544	MAP3K delta-1 prot
24	300.5	10.6	606	2	JCS596	transforming growt
25	300	10.6	443	2	T01182	hypothetical prote
26	297.5	10.5	545	2	T05675	hypothetical prote
27	295	10.4	1050	2	S45636	natriuretic-peptid
28	292.5	10.3	668	2	JC2363	protein kinase (EC
29	292.5	10.3	1047	1	OYRTBR	atrial natriuretic

30	292	10.3	1338	2	T18287	protein-tyrosine k
31	290.5	10.3	816	2	T45684	hypothetical prote
32	290	10.3	954	1	S68178	mixed-lineage prot
33	289.5	10.2	999	1	S27756	receptor-like prot
34	289.5	10.2	1192	2	T48499	receptor-like prot
35	289	10.2	855	2	T10665	hypothetical prote
36	288.5	10.2	871	2	T45692	serine/threonine-s
37	288	10.2	884	2	T02731	serine/threonine-s
38	287.5	10.2	813	1	S33261	protein kinase lin
39	287.5	10.2	1047	1	OYHUBR	natriuretic peptid
40	287	10.1	656	2	T10664	serine/threonine-s
41	286	10.1	819	2	T45690	receptor-like prot
42	285.5	10.1	694	2	T01134	hypothetical prote
43	284	10.0	394	2	JU0229	mixed-lineage prot
44	283	10.0	356	2	T50811	ser/thr specific p
45	283	10.0	402	2	T51791	ser/thr specific p

ALIGNMENTS

RESULT

I49299  
receptor interacting protein RIP - mouse  
C:Species: Mus musculus (house mouse)  
C:Date: 09-Mar-1996 #sequence\_revision 09-Mar-1996 #text\_change 05-Nov-1999  
C:Accession: I49299  
R:Stanger, B.Z.; Leder, P.; Lee, T.H.; Kim, E.; Seed, B.  
Cell 81, 513-523, 1995  
A:Title: RIP: a novel protein containing a death domain that interacts with Fas/APO-1  
A:Reference number: A56913; MUID:95277838  
A:Accession: I49299  
A>Status: preliminary  
A:Molecule type: mRNA  
A:Residues: 1-656 <RES>  
A:Cross-references: EMBL:U25995; NID:g829618; PIDN:AA60487.1; PID:g829619  
C:Genetics:  
A:Gene: RIP  
C:Superfamily: protein kinase homology  
F:15-293/Domain: protein kinase homology <KIN>

Query Match 13.9%; Score 394; DB 2; Length 656;  
Best Local Similarity 31.0%; Pred. No. 1.1e-15;  
Matches 131; Conservative 66; Mismatches 144; Indels 82; Gaps 19;

QY	24	LSRCASGTVSSARRADRWVQVAVKHHLHPTLDDSERKDV-LREAELLKARFYFPIL 82
DB	23	LDSGGFGKVSCLYHRGHGFVILAK--VVTGPNRAEYNEVLLDEGKMMHLRHSRVYKLL 79
QY	83	GICNEPEFLGIVTEYPMGNSLLELHHRKTEYPDVWPLRFRILHEIATGALGVNYLHNMTPPL 142
DB	80	GIIIEGNSLVMEYKGNLHVLL--KTQI-DVPLSLKGRRIIVEAIEGMCYLHD--KGV 134
QY	143	LHDLTKQIILLDNEFHVIADFLSKWRMS-LSOSRSKSNAP-----EGGTIIY 193
DB	135	IHKDLKPNILVDRFHKIDGLVAFKTSWKLKTEKDNKQEVSTTKKNGGTLIYM 194
QY	194	PPE-----NVEPQCKSRASIKHDIYSYAVITWVLSRQPFEDVTPVPLQIMYSVSGHRP 248
DB	195	APEHLNDINAKPTKES-----DVYSGFIVLWAFKAKEPYENVICTEQFVICIKSGRNP 248
QY	249	VINE--ESLPSYDIPHRARMISLIESGWAQNPDRPFLKCLILEP-VLRTFEEIFLEA 305
DB	249	NVEIIEYCPREI-----ISLMERCWAQIPEDRPFPLGIEEERFPYLSHFEEYV-EED 301
QY	306	VIQLKK-----TKLQSVSAIHLCL-----DKKMKELSLNIPVNHGPEECGSSQ 350
DB	302	VASLKKREYDDQSPVLQRMFSLQHCYVLPFPRSNSSEPGSLHSSQGLQMGVPEESFSS- 360
QY	351	LHENSQSPETSRSLPAPQDNDFLSRKAQDCYFMKLHHCPCGNHSDWSTISGSRRAACDHK 410
DB	361	-----SPE-----YPODENDRSVQA-----KLOFEASVYHAF-----GIFAEK 393

QY 411 TTP 413
| |
Db 394 TKP 396

RESULT 2

T07406

Probable protein kinase - tomato

C:Species: Lycopersicon esculentum (tomato)

C:Date: 14-May-1999 #sequence\_revision 14-May-1999 #text\_change 08-Oct-1999

C:Accession: T07406

R;Wang, Y.

submitted to the EMBL Data Library, May 1997

A:Reference number: Z16016

A:Accession: T07406

A:Status: preliminary; translated from GB/EMBL/DBJ

A:Molecule type: mRNA

A:Residues: 1-829 <WAN>

A:Cross-references: EMBL:Y13273; NID:e1050452; PIDN:CAA73722.1; PID:e334294

A:Experimental source: strain UC82B; sub\_species Mill

C:Superfamily: unassigned Ser/Thr or Tyr-specific protein kinases; protein kinase homolo

Query Match 13.6%; Score 385.5; DB 2; Length 829;

Best Local Similarity 33.2%; Pred. No. 4.7e-15;

Matches 104; Conservative 56; Mismatches 108; Indels 45; Gaps 12;

QY 3 GEATCSALPT-----IPYHKLADLRLYLSRGASGVSSARHADMR-VQVAVKHL- 49

Db 529 GGHVVAIPSEELDVEEFNIPWNLITLMEKIGAGSFGTV---HRDWHGSDVAVKILM 585

QY 50 --HIHTPLDSEKDVLRREARILHKARFSYIFPILGICNEPEFELGIVTEYMPNGSLNELL 107

Db 586 EODFAERL---KEFLREVAIMKRLRHPNIVLPMGAVIQPPNLSIVTEYLSRGLYRLL 641

QY 108 HRKTEYDVAMPRLFRILHETALGVNLYLHNTPLLLHDLKTONILLDNEFHVKIADFGL 167

Db 642 HKPGAREVLDERRLRCLMAYDVANGMNYLHKRNPPVIVHRDLKSPNLLVDKYYTKICDFGL 701

QY 168 SKWRMSSLQSRSSKSAPEGGTIIYMPPE--NYEPGOKSRASIKHDIYSVAVITWEVLSR 225

Db 702 SRFKANTFLSKTAAGTPE-----WMAPEVIRDEPSNE----KSDVYSEGVILWELATL 751

QY 226 KOPFEDVTPNLOIMYSVQGRHPVINEESLPYDIPH--RARMISLIESGWAQNPDRPSF 283

Db 752 QOPWNKL-NPPOVIAAVG-----FNRKRL--DIPSDLNPOVAIIIEACWANEPWKRPSF 802

QY 284 LKCLIELEPVLT 296

Db 803 STIMDLRPHLKS 815

RESULT 3

T48400

serine/threonine-protein kinase ctrl - Arabidopsis thaliana

N:Alternate names: protein F17C15.150

C:Species: Arabidopsis thaliana (mouse-ear cress)

C:Date: 20-Apr-2000 #sequence\_revision 20-Apr-2000 #text\_change 17-Nov-2000

C:Accession: T48400; A45178

R;Beyan, M.; Pohl, T.; Weizenegger, T.; Bancroft, I.; Mewes, H.W.; Rudd, S.; Lemcke, K.

submitted to the Protein Sequence Database, March 2000

A:Reference number: Z24492

A:Accession: T48400

A:Status: preliminary

A:Molecule type: DNA

A:Residues: 1-821 <BEV>

A:Cross-references: EMBL:AL162506

A:Experimental source: cultivar Columbia; BAC clone F17C15

R;Kieber, J.J.; Rothenberg, M.; Roman, G.; Feldmann, K.A.; Ecker, J.R.

Cell 72, 427-441, 1993

A:Title: CTRL, a negative regulator of the ethylene response pathway in Arabidopsis, end

A:Reference number: A45178; MUID:93161417

A:Contents: Columbia
A:Accession: A45178
A:Status: preliminary; not compared with conceptual translation
A:Molecule type: DNA
A:Residues: 1-468,470-821 <KIE>
A>Note: sequence extracted from NCBI backbone (NCBIP:124878)
C:Genetics:

A:Map position: 5
A:Introns: 216/3; 317/2; 364/3; 399/2; 468/1; 560/1; 573/3; 596/3; 630/2; 658/3; 691/
A:Notes: F17C15.150
C:Superfamily: unassigned Ser/Thr or Tyr-specific protein kinases; protein kinase hom
C:Keywords: ATP
F:549-812/Domain: protein kinase homology <KIN>
F:557-565/Region: protein kinase ATP-binding motif

Query Match 13.3%; Score 376; DB 2; Length 821;

Best Local Similarity 30.7%; Pred. No. 1.6e-14;

Matches 98; Conservative 60; Mismatches 111; Indels 50; Gaps 12;

QY 1 MNGEAICSALPT-----IPYHKLADLRLYLSRGASGVSSARHADMR-VQVA 45

Db 520 MNAPPISQPPVNRANRELGLGDGDDMDIPW---CDLNIKEKIGAGSFGTVHRAEWHGSDVA 576

QY 46 VKHL---HIHTPLDSEKDVLRREARILHKARFSYIFPILGICNEPEFELGIVTEYMPNG 101

Db 577 VKILMEQDFH-----AERVNFEFLREVAIMKRLRHPNIVLPMGAVTQPPNLSIVTEYLSRG 631

QY 102 SLNELLHRKTEYDVAMPRLFRILHETALGVNLYLHNTPLLLHDLKTONILLDNEFHVK 161

Db 632 SLYRLLHKSARGQLDERRLRCLMAYDVANGMNYLHNRNPPVIVHRDLKSPNLLVDKYYTK 691

QY 162 IADFGLSKWRMSSLQSRSSKSAPEGGTIIYMPPE--NYEPGOKSRASIKHDIYSVAVIT 219

Db 692 VCDGFLSRLKASTFLSKSAAGTPE-----WMAPEVLRDEPSNE----KSDVYSEGVIL 741

QY 220 WEVLSRKPQFEDVTPNLOIMYSVQGRHPVINEESLPYDIPH--RARMISLIESGWAQNP 277

Db 742 WEIATLQPPWGNL-NPAQVVAAVGFKCKRL-----EIPRNLPQVAALIEGCTWNEP 792

QY 278 DERPSFLKCLIELEPVLT 296

Db 793 WKRPSPFATIMDLRPHLKS 811

RESULT 4

T09479

serine/threonine protein kinase (EC 2.7.1.1-) RIP - human

C:Species: Homo sapiens (man)

C:Date: 16-Jul-1999 #sequence\_revision 16-Jul-1999 #text\_change 17-Nov-2000

C:Accession: T09479; I38992

R;Huang, J.; Hsu, H.; Baichwal, V.R.; Goeddel, D.V.

submitted to the EMBL Data Library, August 1998

A:Reference number: Z16685

A:Accession: T09479

A:Status: preliminary; translated from GB/EMBL/DBJ

A:Molecule type: mRNA

A:Residues: 1-671 <HUA>

A:Cross-references: EMBL:U50062; NID:g3426026; PID:g3426027

R;Stanger, B.Z.; Leder, P.; Lee, T.H.; Kim, E.; Seed, B.

Cell 81, 513-523, 1995

A:Title: RIP: a novel protein containing a death domain that interacts with Fas/APO-1

A:Reference number: A56913; MUID:95277838

A:Accession: I38992

A:Status: preliminary

A:Molecule type: mRNA

A:Residues: 300-513, S, 515-671 <RES>

A:Cross-references: EMBL:U25994; NID:g829616; PIDN:AAC50137.1; PID:g829617

C:Genetics:

A:Gene: RIP

C:Keywords: ATP binding; phosphotransferase



Query Match 13.0%; Score 369; DB 2; Length 671;  
 Best Local Similarity 28.8%; Pred. No. 3.3e-14;  
 Matches 112; Conservative 67; Mismatches 146; Indels 64; Gaps 12;

Qy 24 LSRGASGVSSARHADRWQ-VAVKHLHIHPPLDSEKDKVLRREAEIHLKARFSYIFPIL 82  
 Db 23 LDSGGFGKVSICFH---RTOGLMIMKTVYKGNPCIEHNEALLEAKMMNRLRHSRVVKLL 79  
 Qy 83 GICNEPEFLGIVTEYMPNGSLNELLHRKTEYDVAWPLFRLLHLEIALGVLVYLNHNTPL 142  
 Db 80 GVIEEGKYSILVMEYKGNLMLHKAEMSTP---LSVKGRILIEIIEGMCYLHG--RGV 134  
 Qy 143 LHHDLKTONILLDFHVKIADFGLSKWRMMSLSRSKSAPE-----GGTIIYMP 194  
 Db 135 IHKDLKPNILVNDHFHIAKDLGLASPKMWSKLNNEHEHNEHREVDGTAKNKGGLIYMA 194  
 Qy 195 PE-----NYEPGQKSRASIKHDIYSYAVITWEVLSRKQPFEDVNTPLQIMYSVSGHRPV 249  
 Db 195 PEHLMDVNAKPTKS-----DVYSFAVVLWAIFAFAKPEPYNAICEQQLIMCIGKGNRPD 248  
 Qy 250 INE--ESLPYDIPHRARMISLIESGWAQNPPDRPSPFLKCLIELELVRTFEITLEAVI 307  
 Db 249 VDDITEYCPREI-----ISLMLKWEANPEARFPFGIEKFRFYLSQLEESVEEDVK 302  
 Qy 308 QLKK-----TKLQSV-----SSAIHLCDKMKMELSNIPVNHGPOEESCGSSQ 350  
 Db 303 SLKKEYSNENAVKRMQSLQDCVAVPSSRSNSATEQPGSLHSSOGLGMGPVEESWFAPS 362  
 Qy 351 LHENSGSPETSRLPAPDNDFLSRAQD 379  
 Db 363 LEH-----PQENEPFSLQSLQD 380

RESULT 5  
 T09911  
 Probable serine/threonine-specific protein kinase (EC 2.7.1.-) T22A6.310 - Arabidopsis  
 C:Species: Arabidopsis thaliana (mouse-ear cress)  
 C:Date: 16-Jul-1999 #sequence\_revision 16-Jul-1999 #text\_change 15-Oct-1999  
 C:Accession: T09911  
 R:Bevan, M.; Zimmermann, W.; Gruenisen, A.; Wambutt, R.; Bancroft, I.; Mewes, H.W.; May  
 submitted to the Protein Sequence Database, June 1999  
 A:Reference number: Z16896  
 A:Accession: T09911  
 A:Molecule type: DNA  
 A:Residues: 1-963 <BEV>  
 A:Cross-references: EMBL:AL078637; GSPDB:GN00062; ATSP:T22A6.310  
 A:Experimental source: cultivar Columbia; BAC clone T22A6  
 C:Genetics:  
 A:Gene: ATSP:T22A6.310  
 A:Map position: 4  
 A:Introns: 286/3; 386/2; 434/3; 473/2; 543/1; 678/1; 691/3; 719/3; 753/2; 788/3; 821/3;  
 C:Keywords: phosphotransferase; protein kinase

Query Match 12.7%; Score 359.5; DB 2; Length 963;  
 Best Local Similarity 31.7%; Pred. No. 1.8e-13;  
 Matches 93; Conservative 60; Mismatches 105; Indels 35; Gaps 11;

Qy 20 DLRYLSRGASGVSSARHADRW-VQVAVKHLHIHPPLDSEKDKVLR-----AEILHKA 73  
 Db 668 ELHIERKYGAGSGFGVHRAEHWGSDVAVKILSIQ-DFHDDQDFREFLEVEYCKQAVAIMKRV 726  
 Qy 74 RFSYFFPILGICNEPEFLGIVTEYMPNGSLNELLHRKT--EYPDVAWPLFRRI----LH 126  
 Db 727 RHPNVVLFMGAVTERPRLSIIEYLPGRSLFRLIHRPAGSELDDQRRRLMALDVCVCAIP 786  
 Qy 127 ETALGVNLYLNHTPPLLHDLKTONILLDNEHFKIADFGLSKWRMMSLSRSKSAPE 186  
 Db 787 HYAKGLNVLHCLNPPVHWDLKSPLLVDKNTVVKVCFDGLSFRKANTFIPSKSVAGTPE 846  
 Qy 187 GGTIIYMPPE--NYEPGQKSRASIKHDIYSYAVITWEVLSRKQPFEDVNTPLQIMYSV- 243  
 Db 847 -----WMAPEFLRGEPTNE-----KSDVYFSGVWLWELITLQPPWNL-SPAQVYGVAVAF 895

Qy 244 QGHRPVINEESLPYDIPHRARMISLIESGWAQNPPDRPSPFLKCLIELELVRT 296  
 Db 896 QNRRLIIPNTPSPV-----LVSLMEACWADEPSPORPAFGSIVDTLTKLLKLS 941

RESULT 6  
 T00726  
 Probable serine/threonine-specific protein kinase (EC 2.7.1.-) F22O13.21 - Arabidopsi  
 C:Species: Arabidopsis thaliana (mouse-ear cress)  
 C:Date: 12-Feb-1999 #sequence\_revision 12-Feb-1999 #text\_change 22-Oct-1999  
 C:Accession: T00726  
 R:Shinn, P.; Buehler, E.; Dewar, K.; Peng, J.; Kim, C.; Li, Y.; Sun, H.; Conway, A.;  
 eologis, A.; Ecker, J.R.  
 submitted to the EMBL Data Library, April 1998  
 A:Description: Genomic sequence for Arabidopsis thaliana BAC F22O13.  
 A:Reference number: Z14200  
 A:Accession: T00726  
 A:Status: translated from GB/EMBL/DBJ  
 A:Molecule type: DNA  
 A:Residues: 1-1015 <SHI>  
 A:Cross-references: EMBL:AC003981; NID:g3063438; PID:g3063459; GSPDB:GN00059; ATSP:F2  
 A:Experimental source: cultivar Columbia  
 C:Genetics:  
 A:Gene: ATSP:F22O13.21  
 A:Map position: 1  
 A:Introns: 71/3; 219/3; 360/3; 395/2; 760/1; 773/3; 796/3; 830/2; 856/3; 889/3; 912/3  
 C:Keywords: phosphotransferase; protein kinase

Query Match 12.7%; Score 359; DB 2; Length 1015;  
 Best Local Similarity 32.9%; Pred. No. 2.1e-13;  
 Matches 96; Conservative 53; Mismatches 105; Indels 38; Gaps 11;

Qy 13 IPYHKLADRYLSRGASGVSSARHADRW-VQVAVKHLHIHPPLDSE-----RKDVLRE 66  
 Db 746 IPWDLVIAERIGLGSYGVV---YHADWHGTEVAVK-----KFLDQDFSGAALAEFRSE 796  
 Qy 67 AEILHKA RFSYFFPILGICNEPEFLGIVTEYMPNGSLNELLHRKTEYDVAWPLFRRI 126  
 Db 797 VRIMRRHRPNVFFELGAVTRPPNLSIVTEFLPGRSLYRILHRPKSHIDER--RRIKMAL 854  
 Qy 127 ETALGVNLYLNHTPPLLHDLKTONILLDNEHFKIADFGLSKWRMMSLSRSKSAPE 186  
 Db 855 DVAMGMNCLHTSTPIYVHRDLKTNLLVDNNVNVKGVDFGLSKLHNTFLSSKSTACTPE 914  
 Qy 187 GGTIIYMPPE--NYEPGQKSRASIKHDIYSYAVITWEVLSRKQPFEDVNTPLQIMYSV- 243  
 Db 915 -----WMAPEVLRNPSNE-----KCDVYFSGVILWELATLRLPWRGM-NPMQVYGVAVGF 963  
 Qy 244 QGHRPVINEESLPYDIPHRARMISLIESGWAQNPPDRPSPFLKCLIELELVRT 295  
 Db 964 QNRRLIIPKELDPV-----VGRILECQWTDPNLRPSFAQUTEVYLKPLNR 1008

RESULT 7  
 T46150  
 Protein kinase ATN1-like protein - Arabidopsis thaliana  
 N:Alternate names: protein T3A5.i10  
 C:Species: Arabidopsis thaliana (mouse-ear cress)  
 C:Date: 04-Feb-2000 #sequence\_revision 04-Feb-2000 #text\_change 17-Mar-2000  
 C:Accession: T46150; T08394  
 R:Blöcker, H.; Mewes, H.W.; Mayer, K.F.X.; Lemcke, K.; Schueller, C.; Quettier, F.; S  
 submitted to the Protein Sequence Database, December 1999  
 A:Reference number: Z23024  
 A:Accession: T46150  
 A:Status: preliminary  
 A:Molecule type: DNA  
 A:Residues: 1-370 <BL0>  
 A:Cross-references: EMBL:AL132979  
 A:Experimental source: cultivar Columbia; BAC clone T3A5  
 R:Quettier, F.; Rieger, M.; Gabel, C.; Mueller-Auer, S.; Schaefer, M.; Zipp, M.; Salan  
 submitted to the Protein Sequence Database, May 1999





C:Genetics:

A:Gene: splA
A:Introns: 47/3; 72/2
C:Superfamily: unassigned Ser/Thr or Tyr-specific protein kinases; protein kinase homolog
C:Keywords: ATP; phosphotransferase; tyrosine-specific protein kinase
F:1287-1566/domain: protein kinase homology <KIN>
F:1295-1303/Region: protein kinase ATP-binding motif

Query Match 11.1%; Score 313.5; DB 2; Length 1584;
Best Local Similarity 28.1%; Pred. No. 1.5e-10;
Matches 91; Conservative 59; Mismatches 119; Indels 55; Gaps 10;

QY 13 IPYHKLADRLYLSRGASGVSSARHADRWVQVAVKHLHHTPLDSEKRDVLRAREIILH 71
Db 1284 IDNELEFGTIGKGFGEV---KRGVWRETVAIKIYRDQFKTKSLVWFQNEVGILS 1340
QY 72 KARFSYIFPILGICNE--PEFLGIVTEYMPNGSLNELLHRKTEYDVPVAMPFRFRILHEIA 129
Db 1341 KLRHPNVVQFLGACTAGGEDHHCIVTEWMMGGSLRQPLTDHFNLLLEQNPRIKALALDIA 1400
QY 130 LGVNYLHNMTPLLLHDLKTONILLD-----EFHVKTADFGLSKWRMMSLS 176
Db 1401 KGMNLYHGWTPIIHRDLSRNLDDHNDPKNPVSSRQDIKCKISDFGLSR-----LK 1455
QY 177 QSRSSKAPEGGTTIYMPPEYGGOKSRASIKHDIYSYAVITWELVSRKQPEEDVTNPL 236
Db 1456 KEQASQMTQSVGCIPIYMAPEVFKGDSNSE---KSDVYSYGMVLFELLTSDPEQDDM-KPM 1511
QY 237 QIMY-SVSGQHRPVINEESLPYDIPHRARMISLESWAQNDPDRPFSFLKCLIELEPVL 295
Db 1512 KMAHLAAEYRFP-----PIPLTSSKWKKEILTQCWDSNPDSPR-----L550
QY 296 TFEETIFLEAVIQKTKKQSVSS 319
Db 1551 ----TFKQIIVHKEMEDQGVSS 1569

RESULT 14

JC5955
transforming growth factor-beta activated kinase (EC 2.7.-.-) 1a - human
C:Species: Homo sapiens (man)
C:Date: 16-Jul-1999 #sequence\_revision 16-Jul-1999 #text\_change 21-Jul-2000
C:Accession: JCS955
R:Sakurai, H.; Shigemori, N.; Hasegawa, K.; Sugita, T.
Biochem. Biophys. Res. Commun. 243, 545-549, 1998
A:Title: TGF-beta-activated kinase 1 stimulates NF-kappaB activation by an NF-kappaB-ind
A:Reference number: JCS955; MUID:98153801
A:Accession: JCS955
A:Status: preliminary
A:Molecule type: DNA
A:Residues: 1-579 <SAK>
A:Cross-references: DDBJ:AB009356; NID:g2924623; PIDN:BAA25025.1; PID:g2924624
C:Superfamily: unassigned Ser/Thr or Tyr-specific protein kinases; protein kinase homolog
C:Keywords: phosphotransferase

Query Match 11.0%; Score 312; DB 2; Length 579;
Best Local Similarity 23.5%; Pred. No. 5.5e-11;
Matches 136; Conservative 97; Mismatches 246; Indels 100; Gaps 22;

QY 13 IPYHKLADRLYLSRGASGVSSARHADRWVQVAVKHLHHTPLDSEKRDVLRAREIILH 71
Db 31 IDYKEVEEVGRGAFVGVCKRAK---WRAKDVAIKQIE-----SESERKAFIVELRQLS 82
QY 72 KARFSYIFPILGICNEPEFLGIVTEYMPNGSLNELLHRKTEYDVPVAMPFRFRIL 125
Db 83 RYNHPNIVLYGACLANP---VCLVMVEYEGGSLYLVNLRGAEPLPYTAAMNSWCL----- 135
QY 126 HEIALGVNLYLHNMTPLLLHDLKTONILL-DNEFHVKIADFGLSKWRMMSLSQSRSSKS 183
Db 136 -QCSQGVAYLHSMQKALIHRLDKPPNILLVAGGTVLKICDFGTACDIQTHMTNNK---- 190

QY 184 APEGTTIYMPPEYGGOKSRASIKHDIYSYAVITWELVSRKQPEEDVTNP-LQIMYSV 242
Db 191 ----GSAWMAPEYFE---GSNYSEKCDVFSWGIILWELITRRKPFDEIGGPAFRIMWAY 243
QY 243 SQGRPVINEESLPYDIPHRARMISLESWAQNDPDRPFSFLKCLIELEPVLRTF---E 298
Db 244 HNGTRPPL-IKNLPKPIE-----SLMTRCWSKDPSPRSMEEIVKIMTHLMRYFPGADE 296
QY 299 EI-----TFLEAVIQKTKKQSVSSAIHLCDKMKMELSLNIPVNH 339
Db 297 PLOYPCOYSDGOSNATSITGSEFMEDIASTNTSNKSDTMEQVPATNDTIKRLESKLLKNO 356
QY 340 GPOEESGSSQLHENSGETSRLPAPQDNDFLSRAQDCYPMKLLHHCNHS----- 393
Db 357 AKQOESGRULSASRGS--SVESLPPTSEGRKMSADMSETE-ARIAATGTNGQPRRSI 413
QY 394 WDSTIIGSORAAFCRDKHTPCSSAINPLTAGNSERLQPCIAQOQWIOSKREDIVNQWTE 453
Db 414 QDLTVGTETPCQVSSRSSSPSRMITTSPTSEKPTRSHPTWDDSDTNGSDNSIPMAY 473
QY 454 ACLNQLSD-----ALLSRDLIMKEDYELVSTKPTRSKVQRLDITDIOGEEF 501
Db 474 LTLDHQLOPLAPCNSKESMAVFEHQCKMAQYMKVQT-----EIALLLQ----RKOEL 523
QY 502 AKVIVQKLD--NKQMGLOPYPELLVYVSRPSLNLLQNK 538
Db 524 VAELODQDKQQWTSRLVQEHKLLDENKLSLYYQOCK 562

RESULT 15

T04683
hypothenical protein F8D20.290 - Arabidopsis thaliana
C:Species: Arabidopsis thaliana (mouse-ear cress)
C:Date: 23-Apr-1999 #sequence\_revision 23-Apr-1999 #text\_change 21-May-1999
C:Accession: T04683
R:Bevan, M.; Rose, M.; Hempel, S.; Entian, K.D.; Jesse, T.; Heijnen, L.; Vos, P.; Mew
submitted to the Protein Sequence Database, July 1998
A:Reference number: Z15381
A:Accession: T04683
A:Molecule type: DNA
A:Residues: 1-553 <BEV>
A:Cross-references: EMBL:AL031135
A:Experimental source: cultivar Columbia; BAC clone F8D20
C:Genetics:

A:Map position: 4
A:Introns: 69/2; 107/3; 176/2; 194/3; 231/3; 289/2; 325/2; 350/1; 408/3; 440/3; 467/3
A:Note: F8D20.290
Query Match 10.9%; Score 307; DB 2; Length 553;
Best Local Similarity 29.0%; Pred. No. 1e-10;
Matches 88; Conservative 59; Mismatches 112; Indels 44; Gaps 11;

QY 7 CSALPT-----IPYHKLADRLYLSRGASGVSSARHADRWVQVAVKHLHHTPLDSE 59
Db 257 CVEIPTDGTDEWIDMKQKIEKKVACGSGYELFRGTYCS--QEVAIK-----ILKPE 307
QY 60 R-----KDVLRAREIILHRKARFSYIFPILGICNEPEFLGIVTEYMPNGSLNELLHRKTEY 113
Db 308 RYNAEMLRFEQSVYIMRVRHKNVYVQVFGACTRSNLCIVTEFTRGSIYDLFHHKGV 367
QY 114 PDVAMPDLRFRILHEIALGVNLYLHNMTPLLLHDLKTONILLDNEFHVKIADFGLSKWRMM 173
Db 368 FKIQSLLKVAL--DVSKGMNLYHQNN--IIHRDLKTNALLMDEBHVYKAVDFGVAR---- 419
QY 174 SLSQSRSSKASAPEGGTTIYMPPEYGGOKSRASIKHDIYSYAVITWELVSRKQPEEDVT 233
Db 420 --VQFESGVMTAETGYRWMVAPEYEHKPYDH---RADVFSYAVILWELLTGLPYSYLT 474
QY 234 NPLQIMYSVQ-GHRPVINEESLPYDIPHRARMISLESWAQNDPDRPFSFLKCLIELEP 292
Db 475 -PLQAAVGVVQKLRPKIPKETHP-----KLTLELEKCKWQDDPALRPNFAEIIEMLNQ 526

QY 293 VLR 295  
:::  
Db 527 LIR 529

Search completed: June 14, 2001, 08:05:48  
Job time: 80 sec

**THIS PAGE BLANK (USPTO)**

OM of: US-09-445-223-1 to: GenEmbl.\* out\_format: pfs
Date: Jun 13, 2001 6:34 PM
About: Results were produced by the GenCore software, version 4.5,
Copyright (c) 1993-2000 CompuGen Ltd.

Command line parameters:
-MODEL=frame-p2n.model -DEV=xlp
-Q/cgml\_1/USPTO\_spool/US09445223/runat\_13062001\_092033\_29644/app\_query.fasta\_1.604
-DB=GenEmbl -OFMT=fastp -SURFIX=p2n.rge -GAPOP=12.000
-GAPEXT=4.000 -MINMATCH=0.100 -LOOPEXT=0.000
-QGAPOP=4.500 -QGAPEXT=0.050 -XGAPOP=10.000 -XGAPEXT=0.500
-FGAPOP=6.000 -FGAPEXT=7.000 -YGAPOP=10.000 -YGAPEXT=0.500
-DELOP=6.000 -DELEXT=7.000 -START=1 -MATRIX=blotsum62
-TRANS=human40.cgi -LIST=45 -DOCALIGN=200 -THR\_SCORE=pct
-THR\_MAX=100 -THR\_MIN=0 -ALIGN=15 -MODE=LOCAL -OUTFMT=pfs
-NORM=ext -MINLEN=0 -MAXLEN=200000000
-USER=US09445223\_cgml\_1\_6920 -NCPU=6 -ICPU=3 -LONGLOG -NO\_XLPXY
-WAIT -THREADS=1

Search information block:

Query: US-09-445-223-1
Query length: 540
Database: GenEmbl.\*
Database sequences: 1283235
Database length: 1216004940
Search time (sec): 2258.700000

score\_list:

Table with columns: Sequence, Strd Orig, zScore, EScore, Len, Documentation. Lists sequence identifiers and their corresponding scores and lengths.

gb\_f01.RAPPK + 313.50 413.37 8.3e-15 3754 | D49785 Rattus norvegicus mf
gb\_in3.DDU32174 + 313.50 408.85 1.5e-14 5931 | U32174 Dictyostelium discoi
gb\_pr1.AB009356 + 312.00 414.29 7.3e-15 2769 | AB009356 Homo sapiens mRNA
gb\_br8.HSAJ5282 + 311.50 411.34 1.1e-14 3482 | AJ005282 Homo sapiens mRNA
gb\_br9.HUMGUANCYC + 311.50 409.77 1.3e-14 4081 | L13436 Homo sapiens guanyla
seq\_name: gb\_pat1:A82777
seq\_documentation\_block: 2098 bp DNA PAT 21-JAN-2000
LOCUS A82777
DEFINITION Sequence 2 from Patent WO9855507.
ACCESSION A82777
VERSION A82777.1 GI:6732464
KEYWORDS
SOURCE
ORGANISM
unidentified.
unidentified
unclassified
REFERENCE 1 (bases 1 to 2098)
AUTHORS Boldin,M. and Wallach,D.
TITLES MODULATORS OF INTRACELLULAR INFLAMMATION, CELL DEATH AND CELL SURVIVAL PATHWAYS
JOURNAL Patent: WO 985507-A 2 10-DEC-1998; BOLDIN MARK (IL); WALLACH DAVID (IL)
FEATURES
source
Location/Qualifiers
1..2098
/organism="unidentified"
/db\_xref="taxon:32644"
BASE COUNT 649 a 452 c 449 g 539 t 9 others
ORIGIN

alignment\_scores:
Quality: 2829.00 Length: 540
Ratio: 5.239 Gaps: 0
Percent Similarity: 100.000 Percent Identity: 100.000
alignment\_block:
US-09-445-223-1 x A82777
Align seg 1/1 to: A82777 from: 1 to: 2098
1 MetAsnGlyGluAlaAlaIleCysSerAlaLeuProThrIleProTyHisLy 17
260 ATGAACGGGGAGCCACTCTGCAGCGCCCTGCCACCACATTTCCCTACCACAA 309
17 sleuAlaAspLeuArgTyLeuSerArgGlyAlaSerGlyThrValSerS 34
310 ACTCGCCGACCTGGCTACTGAGCGCGCCCTGGCCTGGCCTGGCTGCT 359
34 erAlaArghHisAlaAspTrpArgValGlnValAlaValLysHisLeuHis 50
360 CGCCCGCCAGCAGACTGGCCGCTCCAGGTGGCCGCGAAGCACCCTGCAC 409
51 IleHisThrProLeuLeuAspSerGluArgLysAspValLeuArgGluAl 67
410 ATCCACACTCCCTGCTCGACAGTGAAGAAAGAGATGTTTAAAGAGAAGC 459
67 aGluIleLeuHisLysAlaArgPheSerTyIlePheProIleLeuGlyI 84
460 TGAATTTTACAAAGCTAGATTTAGTTTACATTTTCCCAATTTTGGGAA 509
84 leCysAsnGluProGluPheLeuGlyIleValThrGluTyrrMetProAsn 100
510 TTTTGAATGAGCCTGAATTTTGGGAATAGTACTGAAATACATGACCAAT 559
101 GlySerLeuAsnGluLeuLeuHisArgLysThrGluTyrrProAspVal 117
560 GGATCATTAATGACTCTCATAGAAAGAACTGAATATCTCTGATGCTGC 609
117 arPrpProLeuArgPheArgIleLeuHisGluIleAlaLeuGlyValAsn 134
610 TTGGCCATTTGAGATTTTCGATCCTGCATGAAATTTGCCCTTGGTAAAT 659

134 YrLeuHisAsnMetThrProLeuLeuHisHisAspLeuLysThrGln 150  
 151 AsnIleLeuLeuAspAsnGluPheHisValLysIleAlaAspPheGlyLe 167  
 660 ACCTGCACAATATGACTCCCTCCCTTACTTTCATCATGACTGACACTCAG 709  
 710 AATATCTTATTGGCAATGAATTTATGTTAAGATTGACAGATTTGGTTT 759  
 167 uSerLysTrpArgMetSerLeuSerGlnSerArgSerLysSera 184  
 760 ATCAAAGTGGCGATGATGTCCTCTCACAGTCCAGAAAGTAGCAAACTG 809  
 184 laProGluGlyThrIleIleLysMetProGluAsnTyrGluPro 200  
 810 CACGAAAGGAGGACAAATTTATATGACCCTGAAAACCTATGARACCT 859  
 201 GlyGlnLysSerArgAlaSerIleLysHisAspIleTyrSerTyrAlaVa 217  
 860 GGCAAAAATCAAGGGCCAGTATCAAGCAGCATATATATAGCTATGCACT 909  
 217 lIleThrTrpGluValLeuSerArgLysGlnProPheGluAspValThra 234  
 910 TATCACATGGGAAGTGTATCCAGAAACAGCCCTTTTGAAGATGTCACCA 959  
 234 snProLeuGlnIleMetTyrSerValSerGlnGlyHisArgProValIle 250  
 960 ATCCTTTGCAGATTAATGTATAGTGTGTCCACAGGACATCGACCTGTTAT 1009  
 251 AsnGluSerLeuProTyrAspIleProHisArgAlaArgMetIleSe 267  
 1010 AATGAAGAAAGTTGGCATATGATATACCTCAGCGAGCAGGTATGATCTC 1059  
 267 rLeuIleGluSerGlyTrpAlaGlnAsnProAspGluArgProSerPheL 284  
 1060 TCTAATAGAAGTGGATGGGCACAAAATCCAGATGAAGACCAATCTTCT 1109  
 284 euLysCysLeuIleGluLeuGluProValLeuArgThrPheGluGluIle 300  
 1110 TAAATGTTAATAGACTTGAACCAGCTTTTGAAGCAATTTGAAGAGATA 1159  
 301 ThrPheLeuGluAlaValIleGlnLeuLysLysThrLysLeuGlnSerVa 317  
 1160 ACTTTTCTGAACTGTTATTCAGCTAAAGAAAACAAGTTTACAGAGTGT 1209  
 317 lSerSerAlaIleHisLeuCysAspLysLysMetGluLeuSerLeuA 334  
 1210 TTCAGTCCCAATCCATGATGTGACAGAAAGAAATGGAATATATCTCTGA 1259  
 334 snIleProValAsnHisGlyProGlnGluSerCysGlySerSerGln 350  
 1260 ACATACCTGTAATCATGGTCCACAGAGGAATCATGTGGATCCCTCAG 1309  
 351 LeuHisGluAsnSerGlySerProGluThrSerArgSerLeuProAlaPr 367  
 1310 CTCCATGAAAATAGTGGTCTCCGAACTTCAAGGTCCTCCCTGCGAGCTCC 1359  
 367 oGlnAsnAspPheLeuSerArgLysAlaGlnAspCysTyrPheMetL 384  
 1360 TCAAGACAAATGATTTTATCTAGAAAAGCTCAAGACTGTTATTTATGA 1409  
 384 ysLeuHisHisCysProGlyAsnHisSerTrpAspSerThrIleSerGly 400  
 1410 AGCTGCATCACTGTCCTGGAATACACAGTTGGGATAGCACCATTTCGGA 1459  
 401 SerGlnArgAlaAlaPheCysAspHisLysThrThrProCysSerSerAl 417  
 1460 TCTCAAAGGGTGCATCTGTGTGATCAAGAACCACTCCATGCTCTTCCAGC 1509  
 417 aIleIleAsnProLeuSerThrAlaGlyAsnSerGluArgLeuGlnProG 434  
 1510 AATAAATCCACTCACTCACTGAGGAAACTCAGAACCTGCGAGCCTG 1559  
 434 lyIleAlaGlnGlnTrpIleGlnSerLysArgGluAspIleValAsnGln 450

1560 GTATAGCCAGCAGTGGATCCAGAGCAAAAAGGGAAGACATTTGTGAACCAA 1609  
 451 MetThrGluAlaCysLysLeuAsnGlnSerLeuAspAlaLeuLeuSerArgAs 467  
 1610 ATGACAGAAGCCCTGCTTAAACCAGTCGTAGATGCGCTTCTGTCCAGGGA 1659  
 467 pLeuIleMetLysGluAspTyrGluLeuValSerThrLysProThrArgT 484  
 1660 CTTGATCATGAAAGAGCAGTATGAACTTGTAGTACCAAGCCTACAAGGA 1709  
 484 hrSerLysValArgGlnLeuLeuAspThrThrAspIleGlnGlyGluGlu 500  
 1710 CCTCAAAAGTCAGACAATTTACTAGACACTACTGACATCCAAGGAGAAGAA 1759  
 501 PheAlaLysValIleValGlnLysLeuLysAspAsnLysGlnMetGlyLe 517  
 1760 TTTGCCAAAAGTTATAGTACAAAATTTGAAAGATTAACAAAATAATGGTCT 1809  
 517 uGlnProTyrProGluIleLeuValSerArgSerProSerLeuAsnL 534  
 1810 TCAGCCTTACCCGAAATACTTGTGTCTTCTAGATCACCATCTTTAAAT 1859  
 534 euLeuGlnAsnLysSerMet 540  
 1860 TACTTCAAAAATAAAAGCATG 1879  
 seq\_name: gb\_pr4:AF078530  
 seq\_documentation\_block:  
 LOCUS AF078530 1623 bp mRNA PRI 28-JUL-1998  
 DEFINITION Homo sapiens receptor interacting protein 2 (RIP2) mRNA, complete cds.  
 ACCESSION AF078530  
 VERSION AF078530.1 GI:3342909  
 KEYWORDS  
 SOURCE human.  
 ORGANISM Homo sapiens  
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
 REFERENCE  
 AUTHORS McCarthy, J.V., Ni, J. and Dixit, V.M.  
 TITLE RIP2 is a novel NF-kappaB-activating and cell death-inducing kinase  
 JOURNAL J. Biol. Chem. 273 (27), 16968-16975 (1998)  
 MEDLINE 98307936  
 REFERENCE 2 (bases 1 to 1623)  
 AUTHORS McCarthy, J.V., Ni, J. and Dixit, V.M.  
 TITLE Direct Submission  
 JOURNAL Submitted (15-JUL-1998) Molecular Oncology, Genentech Inc, 1 DNA  
 Way, South San Francisco, CA 94080, USA  
 FEATURES  
 Location/Qualifiers  
 1..1623  
 /organism="Homo sapiens"  
 /db\_xref="taxon:9606"  
 /gene="RIP2"  
 /gene="RIP2"  
 /function="activates NF-kappaB"  
 /function="induces cell death"  
 /note="RIP2; serine/threonine kinase homolog; contains CARD motif"  
 /codon\_start=1  
 /product="receptor interacting protein 2"  
 /protein\_id="AAC2722.1"  
 /db\_xref="GI:3342910"  
 /translation="MNGEAIQCSALPTIPVHKLADLYLRSAGSCTVSSARHADRWVOV  
 AVKLUHHTPLDSEKDDVLRREAEILHKARESYIILPILGICNPEPELGIIVTYEMNGS  
 LNELHRRKTEYPDVAVMPLRFRLLHEALGVNLYLHNKTPPLLHHDUKTQNLIDNDFHV  
 KIADFLSKWRMMSLSQSRSSKSAEGETIYMPENPEPGQKSRASIKHDIYSYAVI  
 TWEVLSRKPQFEDVFNLIQIMYSVQGHPRVINEESLPYDIPHRARMLSLISGWAQN  
 PDERPSFLKLELPELVTFEITFLEAVIQLKKTQLQSVSSAHLCDKMKMELSLN  
 ITPVNHGPEQESGSQLHENSQSPETSRLSRLPAPQNDFLSRKAQDCYFMKLHLCFNGH



SWDSTISGSORAAFCDDHKHTPPCSSAIINPLSTAGNSERLQPGIAOQNIQSKREDIVNO  
 MTEACLNQSDALSRDLIMKEDYELVSTKPTRTSKVRLQLLDFDDIQEDEFKVIYQK  
 LKNKQMGLOPYPEILVVSRSPLNLIKQNSM\*  
 BASE COUNT 519 a 362 c 320 g 422 t  
 ORIGIN

alignment\_scores:  
 Quality: 2823.00 Length: 540  
 Ratio: 5.228 Gaps: 0  
 Percent Similarity: 100.000 Percent Identity: 99.815

alignment\_block:  
 US-09-445-223-1 x AF078530

Align seg 1/1 to: AF078530 from: 1 to: 1623

1 MetAsnGlyGluAlaIleCysSerAlaLeuProThrIleProTyrHisly 17  
 1 ATGAAAGGGGGAGCCACTGTCAGCGCCCTGCCACCACCATTCCTACCACAA 50  
 17 sLeuAlaAspLeuArgTyrLeuSerArgGlyAlaSerGlyThrValSerS 34  
 51 ACTCGCCGACCTGCGCTACTGAGCGCGCGCCCTCTGGCAGCTGTGCTGT 100  
 34 erAlaArgHisAlaAspTrpArgValGlnValAlaValLysHisLeuHis 50  
 101 CGCCCGCCAGCAGACTGCGCGCTCCAGTGGCCGTGAAGCAGCTGCAC 150  
 51 IleHisThrProLeuLeuAspSerGluArgLysAspValLeuArgGluAl 67  
 151 ATCCACACTCCCGCTGCTGACAGTGAAGAAAGGATGCTTAAGAAGAGC 200  
 67 agluIleLeuHisLysAlaArgPheSerTyrIlePheProIleLeuGlyT 84  
 201 TGRAAATTTACAAAGCTGATGATTTAGTTTACATCTTCCAAATTTGGGAA 250  
 84 leCysAsnGluProGluPheLeuGlyIleValThrGluTyrMetProAsn 100  
 251 TTTGCAATGAGCCTGAAATTTGGGAATAGTTACTGAATACATGCCAAAT 300  
 101 GlySerLeuAsnGluLeuHisArgLysThrGluTyrProAspValAl 117  
 301 GGATCATTAATGAATCTCTACATAGGAAACTGAAATTCCTGATGTGC 350  
 117 atrpProLeuArgPheArgIleLeuHisGluIleAlaLeuGlyValAsnT 134  
 351 TTGGCCATTCAGATTCGATCTCCGATCGAATAATGGCCCTGGTGTAAAT 400  
 134 yrLeuHisAsnMetThrProProLeuLeuHisHisAspLeuLysThrGln 150  
 401 ACCTGCACAATATGACTCCTCTTACTTCAATCATGACTTGAAGACTCAG 450  
 151 AsnIleLeuLeuAspAsnGluPheHisValLysIleAlaAspPheGlyLe 167  
 451 AAATATCTTATGGACAATGAAATTCATGTTAAGATTCGACATTTGGTTT 500  
 167 uSerLysTrpArgMetMetSerLeuSerGlnSerArgSerSerLysSerA 184  
 501 ATCAAGTGGCCGATGATGCTCCTCTCACAGTCACGAAAGTACGAAATCTG 550  
 184 laProGluGlyGlyThrIleIleTyrMetProProGluAsnTyrGluPro 200  
 551 CACCAGAGGGGACAATATCTATATGCCACCTGAAACTATGAACCT 600  
 201 GlyGlnLysSerArgAlaSerIleLysHisAspIleTyrSerTyrAlaVa 217  
 601 GGACAAAATCAAGGGCCAGTATACAGCAGATATATATAGTATGTCAGT 650  
 217 lIleThrTrpGluValLeuSerArgLysGlnProPheGluAspValThrA 234  
 651 TATCAGTGGGAGTGTATCCAGAAAACAGCCCTTTTGAAGATGTCACCA 700

234 snProLeuGlnIleMetTyrSerValSerGlnGlyHisArgProValIle 250  
 701 ATCTTTTGCAGATAAATGATAGTGTGTCAACAAGGACATCGACCTGTATT 750  
 251 AsnGluGluSerLeuProTyrAspIleProHisArgAlaArgMetIleSe 267  
 751 AATGAAGRAAGTTTGCATATGATATACCTCACCGAGCACGATATGATCTC 800  
 267 rLeuIleGluSerGlyTrpAlaGlnAsnProAspGluArgProSerPheL 284  
 801 TCTAATAGAAAAGTGGATGGCCACAAAATCCAGATGAAGACCATCTTTCT 850  
 284 euLysCysLeuIleGluLeuGluProValLeuArgThrPheGluGluIle 300  
 851 TAAAATGTTTAAATAGAACTTGAACCAAGTTTGAACAATTTGAAGAGATA 900  
 301 ThrPheLeuGluAlaValIleGlnLeuLysLysThrLysLeuGlnSerVa 317  
 901 ACTTTTCTTGAAGCTGTTATTCAGCTAAAAGAAAACAAGTTACAGAGTGT 950  
 317 lSerSerAlaIleHisLeuCysAspLysLysMetGluLeuSerLeuA 334  
 951 TTCAGTGCCATTCACATATGTGACAAAGAAAATGGAATTAATCTCTGA 1000  
 334 snIleProValAsnHisGlyProGlnGluSerCysGlySerSerGln 350  
 1001 ACATACCTGTAATCATGTTCCACAAAGAAATCATGTGGATCTCTCAG 1050  
 351 LeuHisGluAsnSerGlySerProGluThrSerArgSerLeuProAlaPr 367  
 1051 CTCCATGAAATAGTGGTTCTCCTGAAACTTCAAGGTCCCTGCCAGCTCC 1100  
 367 oGlnAspAsnAspPheLeuSerArgLysAlaGlnAspCysTyrPheMetL 384  
 1101 TCNAGACAATGATTTTATCTAGAAAAGCTCAAGACTGTTATTTATGA 1150  
 384 ysLeuHisCysProGlyAsnHisSerTrpAspSerThrIleSerGly 400  
 1151 AGCTGCATCCTCTCTGGAAATCACAGTTGGACAGCACCATTTCTGGA 1200  
 401 SerGlnArgAlaAlaPheCysAspHisLysThrThrProCysSerSerAl 417  
 1201 TCTCAAAGGGCTGCATTCGTGATCAACAAGACCACCTCCATGCTTTCAGC 1250  
 417 alIleLeuAsnProLeuSerThrAlaGlyAsnSerGluArgLeuGlnPro 434  
 1251 AATAATTAATTCACCTCAACTCAAGTCAAGAACTCAGAACTGCTGCACCTG 1300  
 434 lylIleAlaGlnGlnTrpIleGlnSerLysArgGluAspIleValAsnGln 450  
 1301 GTATAGCCAGCAGTGGATCCAGAGCAAAAAGGGAAGACATTTGGAACCAA 1350  
 451 MetThrGluAlaCysLeuAsnGlnSerLeuAspAlaLeuLeuSerArgAs 467  
 1351 ATGACAGAAGCCCTGCCTTAACCCAGTCCAGTATGACCTTCCCTTCTGTC 1400  
 467 pLeuIleMetLysGluAspTyrGluValSerThrLysProThrArgT 484  
 1401 CTTGATCATGAAAGAGACTATGAACCTTGTAGTACCAAGCCCTACAAGGA 1450  
 484 hrSerLysValArgGlnLeuLeuAspThrThrAspIleGlnGlyGluGlu 500  
 1451 CCTCAAAAGTCAGACAATTAAGTACTAGACACTACTGACATCCAAGGAGAAGA 1500  
 501 PheAlaLysValIleValGlnLysLeuLysAspAsnLysGlnMetGlyLe 517  
 1501 TTTGCCAAAAGTATAGTACAAAATTTGAAGATAAACAACAATGGGTCT 1550  
 517 uGlnProTyrProGluIleLeuValSerArgSerProSerLeuAsnL 534  
 1551 TCAGCCTTACCCGGAATACTTGTGGTTTCTAGATCACCATCTTTAAAT 1600  
 534 euLeuGlnAsnLysSerMet 540

```

|||||
1601 TACTTCAAAATAAAGCATG 1620
seq_name: gb_pr4:AF064824
seq_documentation_block:
LOCUS AF064824 1902 bp mRNA PRI 07-JUL-1998
DEFINITION Homo sapiens CARD-containing ICE associated kinase mRNA, complete cds.
ACCESSION AF064824
VERSION AF064824.1 GI:3290171
SOURCE human.
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominoidea; Homo.
REFERENCE 1 (bases 1 to 1902)
AUTHORS Thome, M., Hofmann, K., Burns, K., Martinon, F., Bodmer, J.-L.,
Mattmann, C. and Tschopp, J.
TITLE Identification of CARDIAK, a RIP-like kinase that associates with
caspase-1
JOURNAL Curr. Biol. 8 (1998) In press
REFERENCE 2 (bases 1 to 1902)
AUTHORS Thome, M., Hofmann, K., Burns, K., Martinon, F., Bodmer, J.-L.,
Mattmann, C. and Tschopp, J.
TITLE Direct Submission
JOURNAL Submitted (12-MAY-1998) Institute of Biochemistry, University of
Lausanne, Chemin des Boveresses, 155, Epalinges, CH 1066,
Switzerland
FEATURES
source
1..1902
/organism="Homo sapiens"
/db_xref="taxon:9606"
/db_xref="dbEST:AA16113"
/clone_lib="Stratagene library, catalog number 937208"
/cell_type="pancreatic adenocarcinoma"
243..1865
/notes="CARDIAK; RIP-like kinase"
/codon_start=1
/products="CARD-containing ICE associated kinase"
/protein_id="AAC25668.1"
/db_xref="GI:3290172"
/translacion="MNGEAICSAALPTIPYHKLADLYLRSRGASGVSSRSHADRWVQV
AVKHLHPDLSEKRDVREAILHKARFSYILPILGICNEPEFLGLVTEYMPNGS
LNELHHRKTEYDVAWLPFRILHETALGVNYLHRMTPELLHDLKTLQNLIDNEFHV
KIADFLSKWRMMSLSQRSKSAPEGGTIIYMPENEPGQKSRASIKHDIYSYAVI
TWEVLSRKQPFEDVTNPLQIMVSVSQHRPVINEESLPYDIPHRARMSLIESGWAQN
PQEPSFKLIELEPVLTFEETFEAVIOIKTKLQSVSSAHLCDKMKMELSLN
IPVNHGQSESGSSDLHENSQSPETSRSLPAPQNDFLSRKQDCYFMKLLHPCGNH
SWDSTLSSORAFCDHKITPCSSALINFLPSTAGNSERLQPGIAQQWIOSKREDIVNQ
MTEACLNQSLDALLSRDLIMKEDYELVSTKPTRTSKVRQLDITDIIQGEFAKVIQVK
LKDNKMGQLQPYEILLVRSFSLNLLQKSN"
misc_feature
294..1124
/notes="encodes kinase domain"
misc_feature
1125..1544
/notes="encodes intermediate domain"
misc_feature
1545..1811
/notes="encodes CARD motif"
BASE COUNT 582 a 432 c 419 g 468 t 1 others
ORIGIN
alignment_scores:
Quality: 2823.00 Length: 540
Ratio: 5.228 Gaps: 0
Percent Similarity: 100.000 Percent Identity: 99.815
alignment_block:
US-09-445-223-1 x AF064824
Align seg 1/1 to: AF064824 from: 1 to: 1902
1 MetAsnGlyGluAlaIleCysSerAlaLeuProThrIleProTyHisLys 17
|||||
243 ATGACGGGGAGGCCATCTGCAGCGCCCTGCCACCATTCCCTACCACAA 292
17 sLeuAlaAspLeuArgTyLeuSerArgGlyAlaSerGlyThrValSerS 34
|||||
293 ACTCGCGGACCTCGCTACCTAGCGCGCGCCCTCTGCACCTGTGTCT 342
34 eRAlaArgHisAlaAspTpArgValGlnValAlaValLysHisLeuHis 50
|||||
343 CCGCCCGCCAGGACTGGCGCTCCAGGTGCCCGTGAAGCACCTGCAC 392
51 IleHisThrProLeuLeuAspSerGluArgLysAspValLeuArgGluAl 67
|||||
393 ATCCACACTCCGCTGCTGCACAGTGAAGAAGAGATGCTCTTAAGAGAAG 442
67 aGluIleLeuHisLysAlaArgPheSerTyIlePheProIleLeuGlyI 84
|||||
443 TGAATTTTACACAAAGCTAGATTTAGTTACATCTCTCCANNTTTGGGA 492
84 leCysAsnGluProGluPheLeuGlyIleValThrGluTyMetProAsn 100
|||||
493 TTTGCAATGAGCCTGAATTTTGGGAATAGTTACTGAATACATGCCAAAT 542
101 GlySerLeuAsnGluLeuLeuHisArgLysThrGluTyProAspValAl 117
|||||
543 GGATCATTAATGAATCCCTACATAGAACTGAATATCCTGATGTTC 592
543 GATATCAATTAATGAATCCCTACATAGAACTGAATATCCTGATGTTC 592
117 aTpProLeuArgPheArgIleLeuHisGluIleAlaLeuGlyValAsn 134
|||||
593 TTGGCCATTCAGATTCGCATCCTGGATGAATTTGCCCTTGGTGAAT 642
134 YrLeuHisAsnMetThrProLeuLeuHisHisaspLeuLysThrGln 150
|||||
643 ACCTGCACAATATGACTCCCTCTTACTTCATCATGACTTTGAAGACTCAG 692
151 AsnIleLeuLeuAspAsnGluPheHisValLysIleAlaAspPheGlyLe 167
|||||
693 AATATCTTATTGGCAATGAATTTCAATGTTAAGATTCAGATTTGGTTT 742
167 userLysTrpArgMetMetSerLeuSerGlnSerArgSerSerLysSerA 184
|||||
743 ATCAAGTGGCGCATGATGTCCTCTCACAGTCACGAAGTAGCAAAATCTG 792
184 laProGluGlyGlyThrIleIleTyMetProProGluAsnTyGluPro 200
|||||
793 CACCAGAAGGAGGACAAATATCTATATGCCCCTGAAACTATGAACCT 842
201 GlyGlnLysSerArgAlaSerIleLysHisAspIleTySerTyAlaVa 217
|||||
843 GCACAAAATCAAGGGCCAGTATCAAGCAGGATATATAGCTATGCAGT 892
217 IleThrTrpGluValLeuSerArgLysGlnPropheGluAspValThra 234
|||||
893 TATCAGATGGAGTGTATCCAGAAAACAGCCTTTTGAAGATGTCACCA 942
234 snProLeuGlnIleMetTySerValSerGlnGlyHisArgProValIle 250
|||||
943 ATCTTTGCAGATANTGTATAGTGTGTCACAGGACATCGACCTGTATT 992
251 AsnGluGluSerLeuProTyAspIleProHisArgAlaArgMetIleSe 267
|||||
993 AATGAAGAAGTTGGCCATATGATATACCTCACCAGCAGCAGTATGATCTC 1042
267 rLeuIleGluSerGlyTrpAlaGlnAsnProAspGluArgProSerPheL 284
|||||
1043 TCTAATAGAAAAGTGGATGGGCACAAAATCCAGATCAAAGACCACTTTCT 1092
284 euLysCysLeuIleGluLeuGluProValLeuArgThrPheGluGluIle 300
|||||
1093 TAAATGTTTAAATAGACTTGACACAGTTTTCAGAACATTTGAAGAGATA 1142
301 ThrPheLeuGluAlaValIleGlnLeuLysLysThrLysLeuGlnSerVa 317
|||||

```

```

|||||
1601 TACTTCAAAATAAAGCATG 1620
seq_name: gb_pr4:AF064824
seq_documentation_block:
LOCUS AF064824 1902 bp mRNA PRI 07-JUL-1998
DEFINITION Homo sapiens CARD-containing ICE associated kinase mRNA, complete cds.
ACCESSION AF064824
VERSION AF064824.1 GI:3290171
SOURCE human.
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominoidea; Homo.
REFERENCE 1 (bases 1 to 1902)
AUTHORS Thome, M., Hofmann, K., Burns, K., Martinon, F., Bodmer, J.-L.,
Mattmann, C. and Tschopp, J.
TITLE Identification of CARDIAK, a RIP-like kinase that associates with
caspase-1
JOURNAL Curr. Biol. 8 (1998) In press
REFERENCE 2 (bases 1 to 1902)
AUTHORS Thome, M., Hofmann, K., Burns, K., Martinon, F., Bodmer, J.-L.,
Mattmann, C. and Tschopp, J.
TITLE Direct Submission
JOURNAL Submitted (12-MAY-1998) Institute of Biochemistry, University of
Lausanne, Chemin des Boveresses, 155, Epalinges, CH 1066,
Switzerland
FEATURES
source
1..1902
/organism="Homo sapiens"
/db_xref="taxon:9606"
/db_xref="dbEST:AA16113"
/clone_lib="Stratagene library, catalog number 937208"
/cell_type="pancreatic adenocarcinoma"
243..1865
/notes="CARDIAK; RIP-like kinase"
/codon_start=1
/products="CARD-containing ICE associated kinase"
/protein_id="AAC25668.1"
/db_xref="GI:3290172"
/translacion="MNGEAICSAALPTIPYHKLADLYLRSRGASGVSSRSHADRWVQV
AVKHLHPDLSEKRDVREAILHKARFSYILPILGICNEPEFLGLVTEYMPNGS
LNELHHRKTEYDVAWLPFRILHETALGVNYLHRMTPELLHDLKTLQNLIDNEFHV
KIADFLSKWRMMSLSQRSKSAPEGGTIIYMPENEPGQKSRASIKHDIYSYAVI
TWEVLSRKQPFEDVTNPLQIMVSVSQHRPVINEESLPYDIPHRARMSLIESGWAQN
PQEPSFKLIELEPVLTFEETFEAVIOIKTKLQSVSSAHLCDKMKMELSLN
IPVNHGQSESGSSDLHENSQSPETSRSLPAPQNDFLSRKQDCYFMKLLHPCGNH
SWDSTLSSORAFCDHKITPCSSALINFLPSTAGNSERLQPGIAQQWIOSKREDIVNQ
MTEACLNQSLDALLSRDLIMKEDYELVSTKPTRTSKVRQLDITDIIQGEFAKVIQVK
LKDNKMGQLQPYEILLVRSFSLNLLQKSN"
misc_feature
294..1124
/notes="encodes kinase domain"
misc_feature
1125..1544
/notes="encodes intermediate domain"
misc_feature
1545..1811
/notes="encodes CARD motif"
BASE COUNT 582 a 432 c 419 g 468 t 1 others
ORIGIN
alignment_scores:
Quality: 2823.00 Length: 540
Ratio: 5.228 Gaps: 0
Percent Similarity: 100.000 Percent Identity: 99.815
alignment_block:
US-09-445-223-1 x AF064824
Align seg 1/1 to: AF064824 from: 1 to: 1902
1 MetAsnGlyGluAlaIleCysSerAlaLeuProThrIleProTyHisLys 17
|||||
243 ATGACGGGGAGGCCATCTGCAGCGCCCTGCCACCATTCCCTACCACAA 292
17 sLeuAlaAspLeuArgTyLeuSerArgGlyAlaSerGlyThrValSerS 34
|||||
293 ACTCGCGGACCTCGCTACCTAGCGCGCGCCCTCTGCACCTGTGTCT 342
34 eRAlaArgHisAlaAspTpArgValGlnValAlaValLysHisLeuHis 50
|||||
343 CCGCCCGCCAGGACTGGCGCTCCAGGTGCCCGTGAAGCACCTGCAC 392
51 IleHisThrProLeuLeuAspSerGluArgLysAspValLeuArgGluAl 67
|||||
393 ATCCACACTCCGCTGCTGCACAGTGAAGAAGAGATGCTCTTAAGAGAAG 442
67 aGluIleLeuHisLysAlaArgPheSerTyIlePheProIleLeuGlyI 84
|||||
443 TGAATTTTACACAAAGCTAGATTTAGTTACATCTCTCCANNTTTGGGA 492
84 leCysAsnGluProGluPheLeuGlyIleValThrGluTyMetProAsn 100
|||||
493 TTTGCAATGAGCCTGAATTTTGGGAATAGTTACTGAATACATGCCAAAT 542
101 GlySerLeuAsnGluLeuLeuHisArgLysThrGluTyProAspValAl 117
|||||
543 GGATCATTAATGAATCCCTACATAGAACTGAATATCCTGATGTTC 592
543 GATATCAATTAATGAATCCCTACATAGAACTGAATATCCTGATGTTC 592
117 aTpProLeuArgPheArgIleLeuHisGluIleAlaLeuGlyValAsn 134
|||||
593 TTGGCCATTCAGATTCGCATCCTGGATGAATTTGCCCTTGGTGAAT 642
134 YrLeuHisAsnMetThrProLeuLeuHisHisaspLeuLysThrGln 150
|||||
643 ACCTGCACAATATGACTCCCTCTTACTTCATCATGACTTTGAAGACTCAG 692
151 AsnIleLeuLeuAspAsnGluPheHisValLysIleAlaAspPheGlyLe 167
|||||
693 AATATCTTATTGGCAATGAATTTCAATGTTAAGATTCAGATTTGGTTT 742
167 userLysTrpArgMetMetSerLeuSerGlnSerArgSerSerLysSerA 184
|||||
743 ATCAAGTGGCGCATGATGTCCTCTCACAGTCACGAAGTAGCAAAATCTG 792
184 laProGluGlyGlyThrIleIleTyMetProProGluAsnTyGluPro 200
|||||
793 CACCAGAAGGAGGACAAATATCTATATGCCCCTGAAACTATGAACCT 842
201 GlyGlnLysSerArgAlaSerIleLysHisAspIleTySerTyAlaVa 217
|||||
843 GCACAAAATCAAGGGCCAGTATCAAGCAGGATATATAGCTATGCAGT 892
217 IleThrTrpGluValLeuSerArgLysGlnPropheGluAspValThra 234
|||||
893 TATCAGATGGAGTGTATCCAGAAAACAGCCTTTTGAAGATGTCACCA 942
234 snProLeuGlnIleMetTySerValSerGlnGlyHisArgProValIle 250
|||||
943 ATCTTTGCAGATANTGTATAGTGTGTCACAGGACATCGACCTGTATT 992
251 AsnGluGluSerLeuProTyAspIleProHisArgAlaArgMetIleSe 267
|||||
993 AATGAAGAAGTTGGCCATATGATATACCTCACCAGCAGCAGTATGATCTC 1042
267 rLeuIleGluSerGlyTrpAlaGlnAsnProAspGluArgProSerPheL 284
|||||
1043 TCTAATAGAAAAGTGGATGGGCACAAAATCCAGATCAAAGACCACTTTCT 1092
284 euLysCysLeuIleGluLeuGluProValLeuArgThrPheGluGluIle 300
|||||
1093 TAAATGTTTAAATAGACTTGACACAGTTTTCAGAACATTTGAAGAGATA 1142
301 ThrPheLeuGluAlaValIleGlnLeuLysLysThrLysLeuGlnSerVa 317
|||||

```

1143 ACTTTTCTTGAAGCTGTTATTCAGCTAAAGAAAAACAAAGTTACAGAGTGT 1192  
 317 lSerSerAlaIleHisLeuCysAspLysLysMetGluLeuSerLeuA 334  
 1193 TTCAGTGCATTCACCTATGTCACAAAGAAAGAAATGGAATATATCTCTGA 1242  
 334 snIleProValAsnHisGlyProGlnGluSerCysGlySerSerGln 350  
 1243 ACATACCTGTAAATCATGTTCCACAGAGGAATCATGTGGATCTCTCAG 1292  
 351 LeuHisGluAsnSerGlySerProGluThrSerArgSerLeuProAlaPr 367  
 1293 CTCCTATGAAATAGTGTCTCTCTCAACTTCAAGTCCCTGCCAGCTCC 1342  
 367 oGlnAspAsnAspPheLeuSerArgLysAlaGlnAspCysTyrPheMetL 384  
 1343 TCAAGACATGATTTTATCTAGAAAAAGCTCAAGACTGTATTTATGA 1392  
 384 ysLeuHisCysProGlyAsnHisSerTrpAspSerThrIleSerGly 400  
 1393 AGCTGATCCTCTCTGGAAATCACAGTTGGATAGCACCAATTTCTGGA 1442  
 401 SerGlnArgAlaAlaPheCysAspHisLysThrThrProCysSerSerAl 417  
 1443 TCTCAAGGGCTGCATTTCTGTATCAAGAACCCACTCCATGCTTTCAGC 1492  
 417 alleleAsnProLeuSerThrAlaGlyAsnSerGluArgLeuGlnProG 434  
 1493 APTAATAATCCACTCTCAACTCCAGGAAACTCAGAACCTCTCCAGCCTG 1542  
 434 lyIleAlaGlnInTrpIleGlnSerLysArgGluAspIleValAsnGln 450  
 1543 GTATAGCCAGCAGTGGATCCAGCAAAAGGAAAGACATTTGTAACCAA 1592  
 451 MetThrGluAlaCysLeuAsnGlnSerLeuAspAlaLeuLeuSerArgAs 467  
 1593 ATCAGAGAAGCCCTGCTTAAACCACTGCTAGATGCTTCTGTCACAGGA 1642  
 467 pLeuIleMetLysGluAspTyrGluLeuValSerThrLysProThrArgT 484  
 1643 CTTGATCATGAAGAGACTATCAACTTGTAGTACCAAGCCTACAAAGGA 1692  
 484 hrSerLysValArgGlnLeuLeuAspThrThrAspIleGlnGlyGluGlu 500  
 1693 CCTCAAAAGTCCAGCAATTAAGTACTAGACACTACTGACATCCAAAGGAA 1742  
 501 PheAlaLysValIleValGlnLysLeuLysAspAsnLysGlnMetGlyLe 517  
 1743 TTGTCARAGTTATAGTACAAAATTTGAAAGATAACAAAATGGTCT 1792  
 517 uGlnProTyrProGluIleLeuValSerArgSerProSerLeuAsnL 534  
 1793 TCAGCCTTACCCGAAATACTTGTGTTCTAGATCACCATCTTAAAT 1842  
 534 euLeuGlnAsnLysSerMet 540  
 1843 TACTTCAAAATAAAGCATG 1862

seq\_name: gb\_pr4:AF027706

seq\_documentation\_block: 2501 bp mRNA PRI 10-SEP-1998  
 LOCUS AF027706  
 DEFINITION Homo sapiens serine/threonine kinase RICK (RICK) mRNA, complete cds.

ACCESSION AF027706  
 VERSION AF027706.1 GI:3123886

KEYWORDS  
 SOURCE human.

ORGANISM Homo sapiens  
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 Mammalia; Eutheria; Primates; Catarrhini; Hominiidae; Homo.  
 REFERENCE  
 1 (bases 1 to 2501)  
 AUTHORS Inohara,N., del Peso,L., Koseki,T., Chen,S. and Nunez,G.

TITLE RICK, a novel protein kinase containing a caspase recruitment domain, interacts with CLARP and regulates CD95-mediated apoptosis  
 J. Biol. Chem. 273 (20), 12296-12300 (1998)  
 JOURNAL 98241596  
 MEDLINE 2 (bases 1 to 2501)  
 AUTHORS Inohara,N., Koseki,T., Chen,S., del Peso,L. and Nunez,G.  
 DIRECT SUBMISSION  
 TITLE Submitted (01-OCT-1997) Dept. Pathology, Comprehensive Cancer & Geriatrics Center, 4-131 CGCG 1500 E. Medical Center Dr, Ann Arbor, MI 48109, USA

FEATURES  
 Location/Qualifiers  
 1..2501

source  
 /organism="Homo sapiens"  
 /db\_xref="taxon:9606"  
 /chromosome="8"  
 /map="8q21"  
 1..2501  
 /gene="RICK"  
 225..1847  
 /gene="RICK"  
 /function="regulates apoptosis"  
 /note="CARD domain protein; phosphorylated protein"  
 /codon\_start=1  
 /product="serine/threonine kinase RICK"  
 /protein\_id="AAC34970.1"  
 /db\_xref="GI:3123887"

translation="MNGEAIQSALPTIPVHKLADLRYLSRGSAGTVSSARHADRVQV  
 AVKHUHTPLLDSEKDVLEAEILHRARFVILPILGICNEPEFLGIVTRYMPNGS  
 LNEHLRKYEPDYAWPLRFRILHEILALGVNLYLNKMTPELHLDLKTQNILLDNEFV  
 KIAEFLSKRMMSLQSRSSKSAPEGGTIYMPPEPEGQKSRASRKHDIYSYAVI  
 TWEVLSRKPFDVTPNLIQIVYVSQHRPVINEESLPYDIPHRARMISLIESGWAQN  
 PDERPFLKLIETLEPVRTFEITFLEAVLQIKTKLQSVSSAHLCDKMKMELSLN  
 IPVNHGPOESCGSOLHENSQSPETSRSLPAPONDFLSRKAOCYFMKHLHCPCGNH  
 SWDPTISGSOAAFCDDHTTCCSSAIINPLSTAGNSERLPGIAOQWIOSKRFEDIVN  
 MTEACLNQSLDALLSRDLIMKEDYELVSTKPTRTSKVQLLDTTIOESEFAKVIYQK  
 LKDNKQMGQPYPEILLVVSRSFSLNLLQKNS"

polya\_signal  
 polyA\_site  
 polyA\_signal  
 polyA\_site  
 /gene="RICK"  
 1869  
 /gene="RICK"  
 2479..2484  
 /gene="RICK"  
 2501  
 /gene="RICK"

BASE COUNT 768 a 535 c 499 g 699 t  
 ORIGIN

alignment\_scores:

Quality: 2823.00 Length: 540  
 Ratio: 5.228 Gaps: 0  
 Percent Similarity: 100.000 Percent Identity: 99.815

alignment\_block:  
 US-09-445-223-1 x AF027706 ..

Align seg 1/1 to: AF027706 from: 1 to: 2501

1 MetAsnGlyGluAlaIleCysSerAlaLeuProThrIleProTyrHisLy 17  
 225 ATGAACGGGAGGCCAFTCTGCAGCGCCCTCCACCATTCCCTACCACAA 274  
 17 sLeuAlaAspLeuArgTyrLeuSerArgGlyAlaSerGlyThrValSerS 34  
 275 ACTCGCCGACCTCGCTACCTGAGCCGCGCCCTCTGGCAGCTGTGTCGT 324  
 34 erAlaArgHisAlaAspTrpArgValGlnValAlaValLysHisLeuHis 50  
 325 CCGCCGCCAGCAGACTGGCGGTCCAGGTGGCCGGAAGACCCTGCAC 374  
 51 IleHisThrProLeuLeuAspSerGluArgLysAspValLeuArgGluAl 67  
 375 ATCCACACTCCGCTGCTCGACAGTGAAGAAGAGGATGCTTAAAGAGAAGC 424

```

67  aGluIleuHisLysAlaArgPheSerTyrIlePheProIleLeuGlyI 84
425  TGAATTTTACAAAGCTAGATTTAGTTACATTCCTTCCAATTTGGGAA 474
84  leCysAsnGluProGluPheLeuGlyIleValThrGluTyrMetProAsn 100
475  TTTGCAATGAGCCGCAATTTTGGGAATAGTACTGAAATACATGCCAAT 524
101  GlySerLeuAsnGluLeuLeuHisArgLysThrGluTyrProAspValAl 117
525  GGATCATTAATAAGAACCTTACATAGAAAACCTGAATATCCTGATGTGC 574
117  aTrpProLeuArgPheArgIleLeuHisGluIleAlaLeuGlyValAsnT 134
575  TTGGCCATTTGAGATTTCCGATCCCTGCATGAAATTTGCCCTTGGTAAAT 624
134  yrLeuHisAsnMetThrProProLeuLeuHisAspLeuLysThrGln 150
625  ACCTGCAAAATATGACTCCCTTACTTACTTCAATCATGACTTGAAGACTCAG 674
151  AsnIleLeuLeuAspAsnGluPheHisValLysIleAlaAspPheGlyLe 167
675  AATATCTTATTGGCAATGAAATTTTCATGTTAAGATTCAGATTTTGGT 724
167  uSerLysTrpArgMetSerLeuSerGlnSerArgSerSerLysSerA 184
725  ATCAAAAGTGGCCGATGATGTCCCTCCACAGTCCAGGAAGTAGCAAAATCTG 774
184  laProGluGlyGlyThrIleIleTyrMetProGluAsnTyrGluPro 200
775  CACCAGAAGGAGGACAAATTTATCTATATGCCACCCTGAAAACATATGAACCT 824
201  GlyGlnLysSerArgAlaSerIleLysHisAspLysTyrSerTyrAlaVa 217
825  GGACAAAATCAAGGGCCAGTATCAAGCAGCATATATATAGCTATGCGAGT 874
217  lIleThrTrpGluValLeuSerArgLysGlnProPheGluAspValThrA 234
875  TATCATATGGGAAGTCTTCCAGAAAACACCCCTTTTGAAGATGTCACCA 924
234  snProLeuGlnIleMetTyrSerValSerGlnGlyHisArgProValIle 250
925  ATCCCTTGCAGATATGATATAGTGTGTCCACCAAGGACATCGACCTGTATT 974
251  AsnGluGluSerLeuTyrAspIleProHisArgAlaArgMetIleSe 267
975  AATGAAGAAGTGTCCCATATGATATACCTCACCAGGACCGTATGATCTC 1024
267  rLeuIleGluSerGlyTyrAlaGlnAsnProAspGluArgProSerPheL 284
1025  TCTAATAGAAAGTGGATGGCCACAAAATCCAGATGAAAGACCATCTTTCT 1074
284  euLysCysLeuIleGluLeuGluProValLeuArgThrPheGluIle 300
1075  TAAAATGTTTAAATAGAACTTGAACCAAGTGTGAGAACATTTGAAGAGATA 1124
301  ThrPheLeuGluAlaValIleGlnLeuLysThrLysLeuGlnSerVa 317
1125  ACTTTTCTGAACCTGTATTATCCAGTAAAGAAAACAAAGTTACAGAGTGT 1174
317  lSerSerAlaIleHisLeuCysAspLysLysLysMetGluLeuSerLeuA 334
1175  TTTCAAGTGCATTCACCTATGTGACAAGAAGAAAATGGAATATATCTCTGA 1224
334  snIleProValAsnHisGlyProGlnGluGluCysLysSerGln 350
1225  ACATACCTGTAATCATGTCCCAAGAGGAAATCATGTGGATCCCTCTCAG 1274
351  LeuHisGluAsnSerGlySerProGluThrSerArgSerLeuProAlaPr 367
1275  CTCCATGAAAATAGTGTCTCCTGAAACTTCAAGTCCCTGCCAGCTCC 1324

```

seq\_name: gb\_pri:AC004003

```

seq documentation_block:
LOCUS AC004003 116650 bp DNA PRI 21-DEC-1999
DEFINITION Homo sapiens BAC clone CTA-437L15 from 8q21, complete sequence.
ACCESSION AC004003
VERSION AC004003.1 GI:2772557
KEYWORDS HTG.
SOURCE human.
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Cranialta; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
AUTHORS Ozersky,P., Holmes,A. and Brody,M.
TITLE The sequence of Homo sapiens BAC clone CTA-437L15
JOURNAL Unpublished
REFERENCE 2 (bases 1 to 116650)
AUTHORS Waterston,R.
TITLE Direct Submission
JOURNAL Submitted (15-JAN-1998) Department of Genetics, Washington
University, 4444 Forest Park Avenue, St. Louis, Missouri 63108, USA
REFERENCE 3 (bases 1 to 116650)
AUTHORS Waterston,R.
TITLE Direct Submission
JOURNAL Submitted (27-JUN-1998) Department of Genetics, Washington
University, 4444 Forest Park Avenue, St. Louis, Missouri 63108, USA
REFERENCE 4 (bases 1 to 116650)
AUTHORS Waterston,R.
TITLE Direct Submission

```



```

/rpt_family="MIR"
repeat_region 3380..33437
/rpt_family="MIR"
repeat_region 3433..34514
/rpt_family="MER2_type"
repeat_region 34525..34939
/rpt_family="MaLR"
repeat_region 34999..35256
/rpt_family="Alu"
repeat_region 35388..35477
/rpt_family="MER2_type"
repeat_region 35994..36286
/rpt_family="Alu"
repeat_region 36686..36985
/rpt_family="Alu"
repeat_region 37488..37673
/rpt_family="L2"
repeat_region 37862..38161
/rpt_family="Alu"
repeat_region 38297..38599
/rpt_family="Alu"
repeat_region 41954..42006
/rpt_family="L2"
repeat_region 42596..42777
/rpt_family="MER1_type"
repeat_region 43357..43658
/rpt_family="Alu"
repeat_region 44088..44386

```

```

alignment_scores:
  Quality: 726.00      Length: 364
  Ratio: 4.400        Gaps: 2
  Percent Similarity: 45.330  Percent Identity: 45.055

```

```

alignment_block:
US-09-445-223-1 x AC004003
Align seg 1/1 to: AC004003 from: 1 to: 116650

```

```

376 LysAlaGlnAspCysTyrPheMetLysLeuHisCysProGlyAsnHi 392
|||||
39125 AAAGCTCAAGACTGTTATTTATGAAGTGCATCCTGCTGGAAATCA 39174
392 sSerTrpAspSerThrIleSerGlySerGlnArgAlaAlaPheCysAspH 409
|||||
39175 CAGITGGATAGCACCATTCTGGATCTCAAAGGCTGCATTCGTGATC 39224
409 IsLysThrProCysSerSerAlaIleIleAsnProLeuSerThrAla 425
|||||
39225 ACAAGACCCTCCATGCTCTTCCAGCAATAAATAATCCACTCTCAACTGCA 39274
426 GlyAsnSer..... 428
39275 GGAACTCAGGTAAATATTTACTGTGAACACCCTTGTAAAGTATGCCATT 39324
428 ..... 428
39325 GACCTTACATATCTGTGTTTCAAGTGGATTACCAYACAATGAGTTTGTCT 39374
428 ..... 428
39375 TTATTTCTCAATATGATAAATAATACATACCTTCTTAAGTAGGAACAATA 39424
428 ..... 428
39425 CCCAGAGATGGATGATGATGATGCCCAAAATGGTATTCTATGAAATC 39474
428 ..... 428
39475 TAAATAGGAGGAGCTGCTAAAGAGGAGGTATTAACATATTACTAATGTA 39524
428 ..... 428

```

```

39525 AGTTATTTTGGTTTATTAAACAAATTTGCAGGTATCTTTTATATTTGAA 39574
428 ..... 428
39575 ATAAATGGACATCAAAACAAACTGAACAAATCCCAAGATGGGAATGA 39624
428 ..... 428
39625 TGACATAAAGTGGTTTGGCCCGGTGATTATACATATAGGAAAAGCAGT 39674
428 ..... 428
39675 GCCTTTTCGGGGAGTGAGGGGGAGATAACCCAAATCTCTGAATGTTTCC 39724
428 ..... 428
39725 TGAAAATGACACCATTCCCAAGTGTGGTGTTCATATTTGGCACAAT 39774
428 ..... 428
39775 CATAGGAAATATGTTTATGCTTATTTATTTTTCATGGAATTTTACT 39824
428 ..... 428
39825 TATTGCTATGCTCTCTCACCTTTTAAATATTATTCATTCCTTGTTCCT 39874
429 ...Glu..ArgLeuGlnProGlyTleAlaGlnGlnTrpIleGlnSerLys 443
::: |||||
39875 TTCAGAACCTTCGCAGCTGGTATAGCCCGCAGTGGATCCAGAGCAAA 39924
444 ArgGluAspIleValAsnGlnMetThrGluAlaCysLeuAsnGlnSerLe 460
|||||
39925 AGGGAAGACATTTGAAACCAATGACAGAAGCCTGCCTTAACCCAGTCGT 39974
460 uAspAlaLeuLeuSerArgAspLeuIleMetLysGluAspTyrGluLeuV 477
|||||
39975 AGATGCCCTTCTGTCAGGACTTGATCATGAAAGAGACTATGAACTTG 40024
477 alSerThrLysProThrArgThrSerLysValArgGlnLeuLeuAspThr 493
|||||
40025 TTAGTACCAAGCCTACAAGGACCTCAAAGTCAAGCAATTTACTAGACAT 40074
494 ThrAspIleGlnGlyGluIuPreAlaAlaValIleValGlnLysLeuLy 510
|||||
40075 ACTGACATCCAAGGAGAAATTTGCCAAAGTTATAGTACAAAATTTGAA 40124
510 sAspAsnLysGlnMetGlyLeuGlnProTyrProGluIleLeuValVal 527
|||||
40125 AGATAACAACAATGGTCTTCAGCCTTACCCGGAATACTTGTGGTTT 40174
527 erArgSerProSerLeuAsnLeuLeuGlnAsnLysSerMet 540
|||||
40175 CTAGATCACCATCTTTAAATTTACTTCAAAATAAAGCATG 40215

```

seq\_name: gb\_pr4:AF117829

```

seq_documentation_block:
LOCUS AF117829 320250 bp DNA PRI 13-JAN-1999
DEFINITION Homo sapiens Bq21.3: RICK gene, complete sequence.
ACCESSION AF117829
VERSION AF117829.1 GI:4151947
KEYWORDS HTG
SOURCE human.

```

```

ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1 (bases 1 to 320250)
AUTHORS Platzer, M. and Varon, R.
TITLE Direct Submission
JOURNAL Submitted (30-DEC-1998) Genome Analysis, Institute of Molecular
Biotechnology, Beutenbergstrasse 11, Jena 07745, Germany
COMMENT This sequence is part of a larger genomic contig. The start of this
sequence is directed towards the centromere. The end of this

```

sequence (320001..320250) overlaps with the start of the neighbourhooding Acc\_number AF049895 (1..250).

FEATURES

source

1..320250
/organism="Homo sapiens"
/db\_xref="taxon:9606"
/map="8q21.3"
1..137184
/organism="Homo sapiens"
/db\_xref="taxon:9606"
/clon="P64M4"
complement(572..704)
/rpt\_family="MIR"
705..870
/rpt\_family="MIR"
complement(930..985)
/rpt\_family="MIR"
222..2456
/rpt\_family="L2"
2538..2661
/rpt\_family="L2"
complement(2695..2845)
/rpt\_family="FAM"
2913..3485
/rpt\_family="L2"
3559..3679
/rpt\_family="L2"
3776..3930
/rpt\_family="MIR"
complement(4035..4247)
/rpt\_family="MIR"
complement(5211..5655)
/rpt\_family="L2"
5997..6100
/rpt\_family="L2"
6800..6850
/rpt\_family="(TAGA)n"
8389..8709
/rpt\_family="L2"
complement(9413..9761)
/rpt\_family="MLT1A1"
10399..10473
/rpt\_family="L2"
11341..11507
/rpt\_family="MIR"
complement(11525..11570)
/rpt\_family="(YRA)n"
11931..11985
/rpt\_family="(CATG)n"
complement(12051..12149)
/rpt\_family="MERS3"
complement(12351..12760)
/rpt\_family="MSTA"
14544..14734
/rpt\_family="MIR"
complement(15740..15847)
/rpt\_family="MIR"
16491..16558
/rpt\_family="MIR"
18103..18162
/rpt\_family="MIR"
18343..18639
/rpt\_family="AluSx"
19005..19075
/rpt\_family="MERS7-internal"
complement(19478..19560)
/rpt\_family="MIR"
complement(23416..23710)
/rpt\_family="AluSg"
complement(24833..25025)
/rpt\_family="MIR"
complement(25333..25392)

repeat\_region /rpt\_family="MER81"
25969..26053
/rpt\_family="L1MB8"
26167..26302
/rpt\_family="L1M4"
complement(26512..26684)
/rpt\_family="AluJo"
26685..26712
/rpt\_family="(TA)n"
complement(26713..26841)
/rpt\_family="AluJo"
complement(27456..27620)
/rpt\_family="MERSA"
complement(27724..28020)
/rpt\_family="AluY"
28147..28283
/rpt\_family="AluY"
28284..28311
/rpt\_family="(TA)n"
28312..28476
/rpt\_family="AluY"
29222..29518
/rpt\_family="L1M2"
29454..32583
/rpt\_family="L1M6"
32636..33403
/rpt\_family="L1M6"
33404..33705
/rpt\_family="AluSc"
33706..33960
/rpt\_family="L1M6"
complement(34346..34614)
/rpt\_family="MER8"
34786..34873
/rpt\_family="MIR"
34839..35057
/rpt\_family="L2"
complement(35173..35382)
/rpt\_family="AluYa5"
35577..35746
/rpt\_family="MLT1D"
complement(35747..36046)
/rpt\_family="AluY"
36047..36323
/rpt\_family="MLT1D"
complement(36593..36761)
/rpt\_family="MIR"
complement(37858..37899)
/rpt\_family="L2"
38652..38895
/rpt\_family="L1M2"
38959..39811
/rpt\_family="L1M3e"
39885..39989
/rpt\_family="L1M2"
40242..43133
/rpt\_family="L1M2"
43134..43499
/rpt\_family="MLT1A1"
43500..44075
/rpt\_family="L1M2"
44076..44391
/rpt\_family="AluJo"
44392..45758
/rpt\_family="L1MA4A"
complement(45759..46216)
/rpt\_family="L1PA7"
46217..47676
/rpt\_family="L1MA4A"
47693..47955
/rpt\_family="L1MA5A"
48227..48421
/rpt\_family="L2"

```

repeat_region complement(49170..49277)
repeat_region /rpt_family="MIR"
repeat_region complement(49409..50232)
repeat_region /rpt_family="L1PA2"
repeat_region 50233..50476
repeat_region /rpt_family="L1PA4"
repeat_region complement(50588..50644)
repeat_region /rpt_family="MIR"
repeat_region complement(51729..52082)
repeat_region /rpt_family="THEIC"
repeat_region complement(52083..53629)
repeat_region /rpt_family="THEIC-internal"
repeat_region complement(53632..53992)
repeat_region /rpt_family="THEIC"
repeat_region 54101..54351
repeat_region /rpt_family="L2"
repeat_region 54433..54822
repeat_region /rpt_family="L2"
repeat_region 54823..55177
repeat_region /rpt_family="MLT1A2"
repeat_region 55178..55291
repeat_region /rpt_family="L2"
repeat_region complement(55316..55371)
repeat_region /rpt_family="L2"
repeat_region 55545..55878
repeat_region /rpt_family="L2"
repeat_region 57436..57481
repeat_region /rpt_family="(TAAA)n"
repeat_region 60524..60721
repeat_region /rpt_family="LIME"
repeat_region complement(61481..61865)
repeat_region /rpt_family="MSTA"
repeat_region 62004..62295
repeat_region /rpt_family="MLT1E"
repeat_region 62427..67614
repeat_region /rpt_family="L1PA2"
repeat_region 62833..145579
source /organism="Homo sapiens"

alignment_scores:
Quality: 726.00 Length: 364
Ratio: 4.400 Gaps: 2
Percent Similarity: 45.330 Percent Identity: 45.055

alignment_block:
US-09-445-223-1 x AF117829 ..
Align seg 1/1 to: AF117829 from: 1 to: 320250
376 LysAlaGlnAspCysTyrPheMetLysLeuHisCysProGlyAsnHi 392
178694 AAAGTCAAGACTGTTATTTATGAAGCTGCATCACTGCTGGAAATCA 178743
392 sSerTrpAspSerThrIleSerGlySerGlnArgAlaAlaPheCysAspH 409
178744 CAGTTGGATAGACCACATTTCTGGATCTCAAAGGGTGCATCTGTGATC 178793
409 IsLysThrThrProCysSerSerAlaIleLeuAsnProLeuSerThrAla 425
178794 ACAGACCACCTCCATGCTTTCAGCAATTAATCCACTCTCAACTGCA 178843
426 GlyAsnSer..... 428
178844 GGAAACTCAGGTAATAATTTACTGTGAAACACCTTGTAAAGTATGCCCAT 178893
428 ..... 428
178894 GACCTTACATAFTCTGTTCAGTGGATTTACCATACAAATGAGGTTTGTCT 178943
428 ..... 428
178944 TTATTTCTCAATATGATAAATACATACCTTCTTAAAGTAGAAACAAAT 178993

```

```

428 ..... 428
178994 CCCAGAGATGGGAATGATGACATGCGCCCAAAATGGTATTCATGACATC 179043
428 ..... 428
179044 TAAATAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG 179093
428 ..... 428
179094 AAGTTATTTTGTATTTAAATAAATTTGCAGGATATCTTTTATATTTGAA 179143
428 ..... 428
179144 ATAAATGGACATCAACAACAACTGAACAATCCCAGAAAGATGAAATGA 179193
428 ..... 428
179194 TGACATAAAGTGGTTTTTGGCCCCGATTTATACCATAGGAAAGCAAT 179243
428 ..... 428
179244 GCCTTTTCTGGGAGTGAGGGGAGATTAACCCAAATCTCTGATGTTTCC 179293
428 ..... 428
179294 TGAAAAATGACACCAATTTCCCAAAAGTGTGGTGTCCATATTTGGCACAAT 179343
428 ..... 428
179344 CATAGAAAAATATGTTTTTATGCTTTTATTTTATTTTTCATGGAATTTACT 179393
428 ..... 428
179394 TATTTGCTATGATCTGCTCACCTTTTAAATTTATTTCAATCTCTGTTCTT 179443
429 ...Glu..ArgLeuGlnProGlyIleAlaGlnGlnTrpIleGlnSerLys 443
179444 TTTTCAGAACGCTGCACAGCTGGTATAGCCCGAGCGAGTGGATCCAGACAAA 179493
444 ArgGluAspIleValAsnGlnMetThrGluAlaCysLeuAsnGlnSerLe 460
179494 AGGGAAGACATTTGAAACCAAAATGACAGAAAGCCTGCTTAAACCAGTCGCT 179543
460 uAspAlaLeuLeuSerArgAspLeuIleMetLysGluAspTyrGluLeuV 477
179544 AGATGCCCTTCTGCCAGGACTTGATCATGAAAGAGGACTATGAACTTG 179593
477 aISerThrLysProThrArgThrSerLysValArgGlnLeuLeuAspThr 493
179594 TTAGTACCAAGCCTACCAAGGACCTCAAAAGTCAGACAAATTTACTAGACACT 179643
494 ThrAspIleGlnGlyGluGluPheAlaLysValIleValGlnLysLeuLy 510
179644 ACATACATCCCAAGGAGAAAGAAATTTGCCAAAAGTTATAGTACAAAAATTTGAA 179693
510 sAspAsnLysGlnMetGlyLeuGlnProTyrProGluIleLeuValIls 527
179694 AGATAACAAAATAAATGGTCTTCAGCCCTTACCCGGAAAAATACTTGTGTTTT 179743
527 erArgSerProSerLeuAsnLeuLeuGlnAsnLysSerMet 540
179744 CTAGTACCACTCTTTAAATTTACTTCAAAATTAAGCAATG 179784

```

```

seq_name: gb_rol:AF302127
seq_documentation_block:
LOCUS AF302127 3559 bp mRNA ROD 08-NOV-2000
DEFINITION Mus musculus PKC-regulated kinase PKK mRNA, complete cds.
ACCESSION AF302127
VERSION AF302127.1 GI:11120430
KEYWORDS house mouse.
SOURCE

```



ORGANISM Mus musculus  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.  
REFERENCE 1 (bases 1 to 3559)  
AUTHORS Chen, L., Haider, K., Cariappa, A., Rowitch, D. and Pillai, S.  
TITLE PKK, a novel ankyrin repeat-containing protein kinase regulated by protein kinase C-beta  
JOURNAL Unpublished  
REFERENCE 2 (bases 1 to 3559)  
AUTHORS Chen, L., Haider, K., Cariappa, A. and Pillai, S.  
TITLE Direct Submission  
JOURNAL Submitted (01-SEP-2000) Cancer Center, Massachusetts General Hospital, 149 13th Street, Charlestown, MA 02129-2060, USA  
FEATURES  
source 1..3559  
/organism="Mus musculus"  
/db\_xref="taxon:10090"  
50..2410  
/codon\_start=1  
/product="PKC-regulated kinase PKK"  
/protein\_id="AAG30871.1"  
/db\_xref="GI:11120431"  
/translation="MEGEGRWALGRLTRFDAGEFAGWKEKVGSGGQVYKVRHVHW  
KTLAIKCSPLVHDDREMLLEAKMEMAKFRYLPVYRICOEPEVGLVMEYMETG  
SLEKLAEPDLPDRIRIVHETAVGNFLHRCMSPPLHLLDLKPANILLDAHVKVTS  
DFGLAKNGSHSQDLSDGLFGTIAYLPPERIREKSLRFDTKHDVYSEATVWGVLT  
QKPFADENKILHIMKVKVGHPELPICEPRACASLIGLQRCWHADPPVRFIP  
QETISEDEDICERDFDEVDKLAHPGKESLESSEARPESSRUKRASAPFDNDCSL  
SELLSDISGISOLEPELESPLSGSKLPSSSKRLSSVSDSAFSSRSLSLS  
FERAFTGLPTDIQKKLVDAIISGDTLRMLKIQPOVDVLDLSDSSALLHLAVEA  
GOEECVKLLNANPNLNRKGSPLHMAVERKGIIVELLARKTSVNAKDEDMWT  
ALHFAONGDEASTRLLLEKNAVNEVDFEGRTPMVACOGQENIVRTLLRRGVVYG  
LOGKDAWLPDYAAWOGHLPVLLAKOPGVSVNAOPLDGTPLHLAARQGHVEARI  
LIDLCSYVNICLQAQPLHVAETGHTSTARLLLRGAKKEALTSERYTALHLAQN  
LHLAAVRLLEERADYWARPNQTLHAAARSHSEVEELVSAIDLILSDDEQGLSA  
LHLAAQRHSQTVETLLKHAHINLQSLKFTGGQSSAATLLRRSKT"  
BASE COUNT 826 a 901 c 1000 g 832 t  
ORIGIN

alignment\_scores:  
Quality: 577.00 Length: 553  
Ratio: 1.930 Gaps: 27  
Percent Similarity: 54.069 Percent Identity: 33.816  
alignment\_block:  
US-09-445-223-1 x AF302127 ..  
Align seg 1/1 to: AF302127 from: 1 to: 3559  
1 MetAsnGlyGluAla.....IleCysSerAlaLeuProThrI1 13  
|||||  
50 ATGGAGGGGAGGGCCGGGGCTGGGGCTGGGGCTGGCCACCTT 99  
|||  
13 eProFyrHisLysLeuAlaAspLeuAryFyrLeuSerArgGlyAlaSerG 30  
|||||  
100 CGACCGCGGCAATTCGACGCTGGGAAAGGTGGGCTCGGGGGCTTCG 149  
|||  
30 lYThrValSerSerAlaArgHisAlaAspTriaArgValGlnValAlaVal 46  
|||||  
150 GGCAGGTGTACAAAGTGGCCATGTGCACCTGGGAAGACGTGGGTCCGATC 199  
|||  
47 Lys.....HisLeuHisIleHisThrProLeuLeuAspSerGluAr 60  
|||||  
200 AAGTCTGCCACGTCTGCACGCTGCAC.....GACAGGGAACG 237  
|||  
60 gLysAspValLeuArgGluAlaGluIleLeuHisLysAlaArgPheSerT 77  
|||||  
238 AATGGAGCTCTGGGAAAGCTAAGAAGATGGAGATGGCCAAAGTCCGAT 287  
|||  
77 YIlePheProIleLeuGlyIleCysAsnGluProGluPheLeuGlyIle 93  
|||||  
|||||

288 ACATTCTACCTGTGTACCGCATATGCCAGGAACCT.....GTCCGGCTTG 331  
94 ValThrGluTyrMetProAsnGlySerLeuAsnGluLeuLeuHisArgLys 110  
|||||  
332 GCATGGAGTACATGAGACGCTCCCTGGAAAGACTGCTGGCCCTCAGA 391  
|||  
110 sThrGluTyrProAspValAlaThrProLeuAryPheArgIleLeuHisG 127  
|||  
382 G.....CCATTGCCITGGGACCTGGCTTTCGCATCGTGCACG 419  
|||  
127 luleAlaLeuGlyValAsnTyrLeuHisAsnMetThrProProLeuLeu 143  
|||||  
420 AGACAGCCCTGGCATTGAACTTCTGATGATGCTCGCCACCTGCTC 469  
|||  
144 HisHisAspLeuLysThrGlnAsnIleLeuLeuAspAsnGluPheHisVa 160  
|||||  
470 CACCTAGACCTGAAGCCAGGAAACATCCCTGGTGGTACCAATACCATGT 519  
|||  
160 llyIleAlaAspPheGlyLeuSerLysTyrArgMetMetSerLeuSerG 177  
|||||  
520 CAAGATTTCTGACTTGGCTGGCCAAAGTCCAAATGGCATGCTCCCACTTC 569  
|||  
177 InSerArgSerLysSerAlaProGluGly.....GlyThrIleLeu 191  
|||||  
570 AGGACCTCAGCATG.....GATGGCCTGTTGGTACAAATCGCT 607  
|||  
192 TyrMetProProGluAsnTyrGluProGlyGlnLysSerArgAla...Se 207  
|||||  
608 TACCTCCCTCCAGAGGAAATTCG.....GAGAAGAGCCGCTGTTGTGA 651  
|||  
207 rIleYHisAspIleTyrSerTyrAlaValIleThrTrpGluValLeu 224  
|||||  
652 CACCAAAACATGATGATACAGCTTCCCAATGATGATGGGGTGTCTTA 701  
|||  
224 eArgLysGlnProPheGluAspValThrAsnProLeuGlnIleMetTyr 240  
|||||  
702 CACAGAAGAAGCCATTGGCAGATGAAAGAACAATCCATACATCATGATG 751  
|||  
241 SerValSerGlnGlyHisArgProValIleAsnGluLysLeuProTyr 257  
|||||  
752 AAGTGGTAAAGGCCACCACCCCA.....GAGCTGCCACCCAT 789  
|||  
257 rAspIleProHisArg.....AlaArgMetIleSerLeuIleGlu 271  
|||||  
790 CTGCAGACCCCGCGCGCTGTGCCAGCCTGATAGGGCTCATGCACAAC 839  
|||  
271 eGlyTrpAlaGlnAsnProAspGluArgProSerPheLeuLysCysLeu 287  
|||||  
840 GGTGTGGCATGCAGACCACAGTGGCCGCC..... 871  
|||  
288 IleGluLeuGluProValLeuArgThrPheGluGluIleThrPheLeuG 304  
|||||  
872 .....ACCTTCCAAGAAATTAAC..... 889  
|||  
304 uAlaValIleGlnLeuLysLysThrLysLeuGlnSerValSerSerAlaI 321  
|||||  
890 .....TCTGAACACAG 899  
|||  
321 leHisLeuCysAspLysLysMetGluLeuSerLeuAsnIleProVal 337  
|||||  
900 AAGACCTTGTGAGAAGCCTGATGAGAGGTTGAAA.....GACCTG 940  
|||  
338 AsnHisGlyProGlnGluSerCysGlySerSerGlnLeuHisGluAs 354  
|||||  
941 GCTCATGACCCAGCCAGGAAAGACTCTTAGACTCCAAGAGTGGAGGCC 990  
|||  
354 nSerGlySerProGluThrSerArgSerLeuProAlaProGlnAspAsn 371  
|||||  
991 GCCCGAGCTCTCACGGCTCAAGCGGCCCTCTGCTCCCCCCTCGATAACG 1040  
|||  
371 sp.PheLeuSerArgLysAlaGlnAspCysTyrPheMetLysLeuHisI 387  
|||||  
1041 ACTGCAGTCTCT.....CCGAGTTC..... 1061



```

174 SerLeuSerGlnSerArgSerSerLysSerAlaProGluGly.....GI 188
    ||| |||:|:|:| ||| :||| ||| :|||:|:|:|
559 TCCCACTCCACTCACCACAGCAGTC.....GATGGCCTGTTGG 596
    ||| |||:|:|:| ||| :||| ||| :|||:|:|:|
188 yThrIleIleTyrMetProGluAsnTyrGluProGlyGlnLysSerA 205
    ||| |||:|:|:| ||| :||| ||| :|||:|:|:|
597 CACAACTCCACTCACCACAGCAGCAGTCAGG.....GAGAAGAGCC 640
    ||| |||:|:|:| ||| :||| ||| :|||:|:|:|
205 IqAla...SerIleLysHisAspIleTyrSerTyrAlaValIleThrTp 220
    ||| |||:|:|:| ||| :||| ||| :|||:|:|:|
641 GGCCTCTCCACACCACAGCAGCAGTCATACAGCTTCGCGATGFCATCTGG 690
    ||| |||:|:|:| ||| :||| ||| :|||:|:|:|
221 GluValLeuSerArgLysGlnProPheGluAspValThrAsnProLeuGI 237
    ||| |||:|:|:| ||| :||| ||| :|||:|:|:|
691 GCGCTGTCCACACAGAGAAGCGTTTCAGATGAGAAGACATCCTGCCA 740
    ||| |||:|:|:| ||| :||| ||| :|||:|:|:|
237 nIleMetTyrSerValSerGlnGlyHisArgProValIleAsnGluGlu 254
    ||| |||:|:|:| ||| :||| ||| :|||:|:|:|
741 CATCATGGTGAAGGTGGTGAAGGCCACCGCC...G 775
    ||| |||:|:|:| ||| :||| ||| :|||:|:|:|
254 erLeuProTyrAspIleProHisArgAlaArg.....MetIle 266
    ||| |||:|:|:| ||| :||| ||| :|||:|:|:|
776 AGCTGGCCCGCCGTGCAGAGCCCGCCGCGCTGCAGCCACCTGATA 825
    ||| |||:|:|:| ||| :||| ||| :|||:|:|:|
267 SerLeuIleGluSerGlyTrpAlaGlnAsnProAspGluArgProSerPh 283
    ||| |||:|:|:| ||| :||| ||| :|||:|:|:|
826 CGCCTCATCAGCGGTGGCAGGGGATCCCGAGTTAGGCC..... 870
    ||| |||:|:|:| ||| :||| ||| :|||:|:|:|
283 eLeuLysCysLeuIleGluLeuGluProValLeuArgThrPheGluGluI 300
    ||| |||:|:|:| ||| :||| ||| :|||:|:|:|
871 .....ACCTTCCAAGAAA 883
    ||| |||:|:|:| ||| :||| ||| :|||:|:|:|
300 IeThrPheLeuGluAlaValIleGlnLeuLysLysThrLysLeuGlnSer 316
    ||| |||:|:|:| ||| :||| ||| :|||:|:|:|
884 TTRACT..... 888
    ||| |||:|:|:| ||| :||| ||| :|||:|:|:|
317 ValSerSerAlaIleHisLeuCysAspLys.....Lysly 328
    ||| |||:|:|:| ||| :||| ||| :|||:|:|:|
889 ...TCTGAAACCGGACGACCTGTGTGAAAAGCCCTGATGAGGAAGTGAAGA 935
    ||| |||:|:|:| ||| :||| ||| :|||:|:|:|
328 sMetGluLeuSerLeuAsnIleProValAsnHisGlyProGlnGluClus 345
    ||| |||:|:|:| ||| :||| ||| :|||:|:|:|
936 AACTGCTCATGATCTGGACGTGAAAGCCCGCCGAGCCAGGAGCGAGG 985
    ||| |||:|:|:| ||| :||| ||| :|||:|:|:|
345 er_CysGlySerSerGlnLeuHisGluAsnSerGlySerProGluThrSe 361
    ||| |||:|:|:| ||| :||| ||| :|||:|:|:|
986 TGGTGC.....CTGGCAGGCTCAAGCGGG..... 1009
    ||| |||:|:|:| ||| :||| ||| :|||:|:|:|
361 rArgSerLeuProAlaProGlnAspAsnAspPheLeuSerArgLysAlag 378
    ||| |||:|:|:| ||| :||| ||| :|||:|:|:|
1010 ...CCTCTGCCCCACCCTCG.....ATAACGACTACAGCCT 1043
    ||| |||:|:|:| ||| :||| ||| :|||:|:|:|
378 InAspCysTyrPheMetLysLeuHisHisCysProGlyAsnHisSerTtp 394
    ||| |||:|:|:| ||| :||| ||| :|||:|:|:|
1044 CTCGCGAGCTTC.....TCTCAGACTGG 1066
    ||| |||:|:|:| ||| :||| ||| :|||:|:|:|
395 AspSerThrIleSerGlySerGlnArgAlaAlaPheCysAspHisLysTh 411
    ||| |||:|:|:| ||| :||| ||| :|||:|:|:|
1067 ACTCTGGAGTTTCCCAGGCTCGAGGCC..... 1096
    ||| |||:|:|:| ||| :||| ||| :|||:|:|:|
411 rThrProCysSerSerAlaIle.....IleAsnPro...LeuSerThrAl 425
    ||| |||:|:|:| ||| :||| ||| :|||:|:|:|
1097 ...CGGAGGAGCTACGCCGACCTCTCTGAGTCCAAGCTGCCATCGTC 1142
    ||| |||:|:|:| ||| :||| ||| :|||:|:|:|
425 aGlyAsnSerGluArgLeuLysProGlyIleAlaGlnGlnThrIleGlnS 442
    ||| |||:|:|:| ||| :||| ||| :|||:|:|:|
1143 CGGCAGTGGGAAGAGCTCG...GGGTGTCC..... 1173
    ||| |||:|:|:| ||| :||| ||| :|||:|:|:|
442 erLysArgGluAspIleValAsnGlnMetThrGluAlaCysLeuAsnGln 458
    ||| |||:|:|:| ||| :||| ||| :|||:|:|:|
1173 ..... 1173

```

```

459 SerLeuAspAlaLeuLeuSerArgAspLeuIleMetLysGluAspTyrGI 475
    ||| |||:|:|:| ||| :||| ||| :|||:|:|:|
1174 TCGGTGGACTCCGCTCTCTCCAGAGATCACTGTCCGCTCTCTTGA 1223
    ||| |||:|:|:| ||| :||| ||| :|||:|:|:|
475 LeuValSerThrLysProThrArgThrSerLysValArgGlnLeuLeuA 492
    ||| |||:|:|:| ||| :||| ||| :|||:|:|:|
1224 G.....CGGAACCTTCAACCAGCGAT.....CTGG 1249
    ||| |||:|:|:| ||| :||| ||| :|||:|:|:|
492 spThrThrAspIleGlnGluGluPheAlaLysValIleValGlnLys 508
    ||| |||:|:|:| ||| :||| ||| :|||:|:|:|
1250 GTRACCAGACGTCAGAGAAGACCTGTGGATCCATCTGTCCGGG 1299
    ||| |||:|:|:| ||| :||| ||| :|||:|:|:|
509 LeuLysAspAsnLysGlnMetGlyLeuGlnProTyrProGluIleLeuVa 525
    ||| |||:|:|:| ||| :||| ||| :|||:|:|:|
1300 GACACCAAGCAACTGATGAAGATCTGCAGCCCGCAGACCTGGCCTGGC 1349
    ||| |||:|:|:| ||| :||| ||| :|||:|:|:|
525 lValSerArgSerProSerLeu 532
    ||| |||:|:|:| ||| :||| ||| :|||:|:|:|
1350 ACTGGACAGCGGTGCCAGCCTG 1371
    ||| |||:|:|:| ||| :||| ||| :|||:|:|:|
seq_name: gb_rol:AF178953
seq_documentation_block: 1833 bp mRNA ROD 19-OCT-1999
LOCUS AF178953
DEFINITION Mus musculus receptor interacting protein 3 (Rip3) mRNA, complete
cds.
ACCESSION AF178953
VERSION AF178953.1 GI:6063100
KEYWORDS house mouse.
SOURCE Mus musculus
ORGANISM Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
REFERENCE
AUTHORS Padernik,N.J., Donner,D.B., Goebel,M.G. and Harrington,M.A.
TITLE Mouse Interacting Protein 3 Does Not Contain a Caspase-Recruiting
or a Death Domain but Induces Apoptosis and Activates NF-kappaB
MOL. CELL. BIOL. 19 (1999) In press
REFERENCE
AUTHORS Padernik,N.J., Donner,D.B., Goebel,M.G. and Harrington,M.A.
TITLE Direct Submision
JOURNAL Submitted (19-AUG-1999) Walther Oncology Center, Indiana University
School of Medicine, 1044 West Walnut Street, Indianapolis, IN
46202, USA
FEATURES
Location/Qualifiers
source 1. 1833
/organism="Mus musculus"
/db_xref="taxon:10090"
gene 1. 1833
/misc_feature /gene="Rip3"
151..894
/misc_feature /gene="Rip3"
/Note="Region: N-terminal protein kinase domain"
151..1611
/Note="Region: N-terminal protein kinase domain"
151..1611
/misc_feature /gene="Rip3"
/product="receptor interacting protein 3"
/protein_id="AAF03133.1"
/db_xref="GI:6063101"
/translation="MSSVVKLWPTGASAVLVSRELKLEFVGKGGFVGFRAHRTW
NHDVAKIVNSKKISWEVKAMNLRNENLVLLGVTEDLQWDFVSGQALVTRFMENGS
LAGLQPECPRPWPLLCRLQVVLGMCYLHSLDPLLRDLKFSNILLDELAKLA
DFGLSTFOGSGSOGSGGSDGTLAYLDPELLFVNLKASKASDVYFGILVWA
VLGAEALVDKTSIIRETVCDROSRLPTLPPGSPPTGKLEKLEIMHWCQSOSE
NRPFDCEPKTNEYVNLVKDYDAANVSEVKHLYLSHRSSRNLSAREPFGTEMD
PRETVSKMLDRHLHEEPGVPKCRDQDTSVGPATPARKYSSDVPVAGTQPPIPT
LPFRGVTGVPVFTTGGHPQRNODGRHGTWYPYPTPPMTPPPALVFNCCSEVQI
GNYSLVAPPRTTASSSKAYDAQFGRGHWQPFHK"
BASE COUNT 466 a 497 c 477 g 393 t
ORIGIN
alignment_scores:

```



ACCESSION I68122  
 VERSION I68122.1 GI:2830244  
 KEYWORDS  
 SOURCE Unknown.  
 ORGANISM Unclassified.  
 REFERENCE 1 (bases 1 to 2268)  
 AUTHORS Leder, P., Seed, B., Stanger, B. Z., Lee, T. and Kim, E.  
 TITLE Cell death protein  
 JOURNAL Patent: US 5674734-A 14 07-OCT-1997;  
 FEATURES Location/Qualifiers  
   source  
     i. 2268  
     /organism="unknown"  
 BASE COUNT 719 a 491 c 576 g 482 t  
 ORIGIN

alignment\_scores:  
   Quality: 397.00 Length: 609  
   Ratio: 1.272 Caps: 25  
   Percent Similarity: 51.232 Percent Identity: 25.452

alignment\_block:  
 US-09-445-223-1 x I68122 ..  
 Align seg 1/1 to: I68122 from: 1 to: 2268

24 LeuSerArgGlyAlaSerGlyThrValSerSerAlaArgHisAlaAspTr 40  
 118 CTAGACGGGAGGCTCGGGAAGGTGCTTGGTGTACCACAGARAGCCA 167  
 40 pArgValGlnValAlaValLysHisLeuHisIleHisThrProLeuLeuA 57  
 168 TGGATTGTTCATCCGTGMAAAA.....GTATACACAGGGCCCAACC 208  
 57 spSerGluArgLysAspVal...LeuArgGluAlaGluIleLeuHisLys 72  
 209 GCGCTGAGTACAAATGAGGTCTCTGGAGAGGGGAAGATGATGCACAGA 258  
 73 AlaArgPheSerTyrIlePheProIleLeuGlyIleCysAsnGluProGl 89  
 259 CTGACACACAGTCGAGTGTGTGAGTACTGGCCATCATCATAGAGAAG 308  
 89 uPheLeuGlyIleValThrGluTyrMetProAsnGlySerLeuAsnGluL 106  
 309 GAACATTCGCTGGTGTGATGATGATGATGATGATGATGATGATGATG 358  
 106 euLeuHisArgLysThrGluTyrProAspValAlaTrpProLeuArgPhe 122  
 359 TGCTA.....AAGACCCAGATA...GATGCCACTTTCATTTGAAAGA 399  
 123 ArgIleLeuHisGluIleAlaLeuGlyValAlaAsnTyrLeuHisAsnMet 139  
 400 AGGATAATCGTGGAGCCATAGAAAGCCATGCTACTTACATGAC..... 444  
 139 rProProLeuLeuHisHisAspLeuLysThrGlnAsnIleLeuLeuAspA 156  
 445 AAAGGTGTGATACACAGGACCTGAAGCCTGAGAATATCCCTGTTGATC 493  
 156 snGluPheHisValLysIleAlaAspPheGlyLeuSerLysTrpArgMet 172  
 494 GTGACTTTCACATTAAGATPAGCCGATCTGGTGTGGCTTCCCTTAAAGA 543  
 173 MetSer...LeuSerGlnSerArgSerSerAlaPro..... 185  
 544 TGGACCAAACTGACTTAGGAGAAACACACAAAGCAGAAAGAGTGAAGCAG 593  
 186 .....GlucGlyThrIleIleTyrMetProProGlu. 196  
 594 CACCCTAAGAAGAACAAATGGTGGTACCCTTTACTACTACATGGCCCGAAC 643  
 197 .....AsnTyrGluProGlyGlnLysSerArgAlaSerIle 208

644 ACCTGAATGACATCAATGCAAAAGCCACCGAGAAGTCG..... 681  
 209 LysHisAspIleTyrSerTyrAlaValIleThrTrpGluValLeuSerAr 225  
 682 .....GACGTGTACAGCTTGGCAATTTGGCAATATTTGCCAAA 725  
 225 gLysGlnProPheGluAspValThrAsnProLeuGlnIleMetTyrSerV 242  
 726 AAAGGAGCCCTATGAGAATGTCTATCTGTACTGAGCAGTTCGTCATCTGCA 775  
 242 aIserGlnGlyHisArgProValIleAsnGlu.....GluSerLeuPro 256  
 776 TAAATCTGGAAACAGGCCAAATGTAGAGGAAATCCTTGAGTACTGTCCA 825  
 257 TyrAspIleProHisArgAlaArgMetIleSerLeuIleGluSerGlyTr 273  
 826 AGGGAGATC.....ATCAGCCTCATGGAGCGGTGCTG 857  
 273 pAlaGlnAsnProAspGluArgProSerPheLeuLysCysLeuIleGluL 290  
 858 GCAGGCGATCCACAGACAGCCACATTTCTTGGCATTGAGAGAGAAAT 907  
 290 euGluPro...ValLeuArgThrPheGluGluIleThrPheLeuGluAla 305  
 908 TTAGGCTTTTACTTAAGTCAATTTTGAAGAATATGTA...GAAGAGGAT 954  
 306 ValIleGlnLeuLysLys.....ThrLysLeuGlnSe 316  
 955 GTGGCAGTTTAAAGAAAGAGATCCAGATCAAAGCCCAAGTCTGCAGAG 1004  
 316 rValSerSerAlaIleHisLeuCys..... 324  
 1005 AATGTTTTTCATCGCAGCATGCTGTACCTTACCTCCAGCAGGTCAA 1054  
 325 ..AspLysLysLysMetGluLeuSerLeuAsnIleProValAsnHisGly 340  
 1055 ARTCAGAACAACTGGATCGTGCAGATCCAGATCCAGGGGTCCAGATGGT 1104  
 341 ProGlnGluGlySerCysGlySerGln.....LeuHisGl 353  
 1105 CCTGTGGAGGAGTCTGGTTCCTCCACAGATCCACAGCAGCAGCA 1154  
 353 uAsnSerGlySerProGluThr..... 360  
 1155 GAATGATCGAGTGTGAGCTGAAGCTGCAAGAGGAGGAGCAGTATCATG 1204  
 361 .....SerArgSerLeuProAlaProGlnAspAsn 370  
 1205 CTTTTGGAATATTTGCAGAGAAACAGACAAAACCCGACCAAGCCAGAAT 1254  
 371 AspPheLeuSerArgLysAlaGlnAspCysTyrPheMetLysLeuHisH 387  
 1255 GAGGCTTACACAGAGAGGAGGNA.....AGGAACAGAGGGTCTCTCA 1298  
 387 sCysPro..... 389  
 1299 TGACCCCTTTGCACAGCAGAGAGCTGCTGAGAATATTAAGAGTGCAGGAG 1348  
 390 ..GlyAsnHisSerTrpAspSerThrIleSerGlySerGlnArgAlaAla 405  
 1349 CAAGAGGTTCATTTGATCCACACACAGAT.....CGTGAAT 1389  
 406 PheCysAspHisLysThrThrProCysSerSerAlaIleLeuAsn.... 420  
 1390 GCAGTCCACAGCTGTATGCGCAGCCACCCCAACAGTTTGGAAACAATGG 1439  
 421 .....ProLeuSerThrAlaGlyAsnSerGluArgLeuG 432  
 1440 ATGTATATAATCAGCATGGATTTGGAACTACAGTACAGGAGTTGGTATC 1489  
 432 InProGlyIleAlaGlnInTrpIleGlnSerLys..... 443  
 1490 CGCCAAATCTAAGCCAAATGTATAGTACTTATAAAAACCTCCAGTGCAGAG 1539

PTFLIGTEERPEVLSHFEEVVEVSLAKKEYPDQSPVQLQRMFSLQHDCVPLPPSPRS
NSFQPSLSHSSQGLMGQVPESSPEYDNDNDRSVQAKLQEASVHAFGIFAEK
QTRPQPRNRYANREERKRRVSHDPAQORARENKLSAGARGHSDPSTSRGLAVQO
LSWPATQVWNNGLYNOHGEGTGTGVWVYFPNLSOMYSTKYTPPETNIGSPPTMPY
FSGPVADDLIKYTFINSSGIQGNHNHMDVGLNSPPNNTCKEESTRHOAIEDNTIS
LTDEHLNPIRENGLRWKNCARKLFTTESQIDIEDIHDYERDLKELKRYVQMLQKWLMLRE
GTKGATVGLKLAALHOCRRIDLLHLHLRASQS"
1469
/variation
/gene="RIP"
/annotation="apparent polymorphism resulting in a Thr vs Ile
variation"
/replace="r"
1623
/variation
/gene="RIP"
/annotation="silent polymorphism"
/replace="c"
577 g 482 t

BASE COUNT 719 a 490 c 577 g 482 t
ORIGIN
alignment\_scores:
Quality: 397.00 Length: 609
Ratio: 1.272 Gaps: 25
Percent Similarity: 51.232 Percent Identity: 25.452

alignment\_block:
US-09-445-223-1 x MMU25995 ..
Align seg 1/1 to: MMU25995 from: 1 to: 2268
24 LeuSerArgGlyAlaSerGlyThrValSerSerAlaArgHisAlaAspTr 40
118 CTAGACAGGGAGGCTCGGAAAGGTCTCTTGGAAAGGGGAAAGTGTGACAGCA 167
40 pArgValGlnValAlaValLysHisLeuHisIleHisThrProLeuLeu 57
168 TGGATTGTGATCTCTGAAAAA.....GTATACACAGGGCCCAACC 208
57 spSerGluArgLysAspVal....LeuArgGluAlaGluLeuLeuHisLys 72
209 CGCGTGAAGTACAAGTCTCTTGGAAAGGGGAAAGTGTGACAGCA 258
73 AlaArgPheSerThrIlePheProIleLeuGlyIleCysAsnGluProGI 89
259 CTGAGACACAGTCCAGTGCTGCACTACTGGCATCATCATAGAGAAGG 308
89 upheLeuGlyIleValThrGluTyrMetProAsnGlySerLeuAsnGluL 106
309 GAACTATTCCTGCTGGTGTAGTACATGAGTGAAGAAGGGCAACCTGATG 358
106 euLeuHisArgLysThrGluTyrProAspValAlaTrpProLeuArgPhe 122
359 TGCTA.....AAGACCCAGATA....GATGTCCACTTTCATTGAAAGGA 399
123 ArgTLeuHisGluLeuAlaLeuGlyValAsnTyrLeuHisAsnMetTh 139
400 AGGATAATCTGGAGCCATAGAGGCTGTGCTACTTACATGAC..... 444
139 rProProLeuLeuHisAspLeuLysThrGlnAsnIleLeuLeuAsp 156
445 AAAGGTGTGATACACAAGGACCTGAAGCCTGAGAATATCCTCGTTGATC 493
156 snGluPheHisValLysIleAlaAspPheGlyLeuSerLysTrpArgMet 172
494 GTGATTTTCACATTATGATGATGCTGCTGTTGGCTTCCTTAAAGACA 543
173 MetSer...LeuSerGlnSerArgSerLysSerAlaPro..... 185
544 TGGACCAACTGACTAGGAAAGACACAACAAGCAAGAAAGAGTGCAG 593
186 .....GluGlyGlyThrIleIleTyrMetProFroGlu. 196
594 CACCACACTAAGAAGAACAATGTGTGCTGCTTACTTACTACATGCACCCG 643

variation
variation
BASE COUNT
ORIGIN
alignment\_scores:
Quality:
Ratio:
Percent Similarity:
alignment\_block:
Align seg 1/1 to:
24
118
40
168
57
209
73
259
89
309
106
359
123
400
139
445
156
494
173
544
186
594

seg documentation\_block:
LOCUS MMU25995 2268 bp mRNA ROD 24-MAY-1995
DEFINITION Mus musculus cell death protein (RIP) mRNA, complete cds.
ACCESSION U25995
VERSION U25995.1 Gi:829618
KEYWORDS Fas; TNF receptor.
SOURCE house mouse.
ORGANISM Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.

REFERENCE 1 (bases 1 to 2268)
AUTHORS Stanger,B.Z., Leder,P., Lee,T.H., Kim,E. and Seed,B.
TITLE RIP: a novel protein containing a death domain that interacts with
Fas/APO-1 (CD95) in yeast and causes cell death
JOURNAL Cell 81 (4), 513-523 (1995)
MEDLINE 95277838
REFERENCE 2 (bases 1 to 2268)
AUTHORS Stanger,B.Z.
TITLE Direct Submission
JOURNAL Submitted (01-MAY-1995) Ben Z. Stanger, Genetics, Harvard Medical
School, 200 Longwood Avenue, Boston, MA 02115, USA

FEATURES
source
1. .2268.
/organism="Mus musculus"
/strain="(C57BL/6 X CBA)F1"
/db\_xref="taxon:10090"
/tissue\_type="thymus"
/clone="III2"
52. .2022
/gene="RIP"
52. .2022
/gene="RIP"
/function="Fas interacting protein; cell death"
/product="RIP"
/protein\_id="AA860487.1"
/db\_xref="gi:829619"

translation="MQPDMSLDNKMASSDLLLEKTDLDSGGKVSCLYHRSHGFFVIL
KVYVTGNRAEYNEVLLEEKMMRLRHSRVKLLGIIEEKNYSLVMEYMEKGNLMH
VKLQTDVPLSLKGVIIIVEALGEMGVLHDKGVIHKDLPENILVDRDFHIKTDLGVA
SFKTWSKLNKEDKNKQYSSFTFKNNGGTLYMAPHLNDINAKPTEKSDVYSFVIG
LMAIFAKKPEYENVICTEQFVICKSNGRPNEIIEYCPREIISLMERCWQAIPEDR

443 ..... 443
1540 ACCAACATACCGGAAGACACACCACCACCACCACCACCATTCTCTGGGCCAGT 1589
444 ArgGluAspIleVal.AsnGlnMet..... 451
1590 AGCAGATGACCTATAAAATATACTATATCAATAGTTCTTGGTATTCA 1639
452 ThrGluAlaCysLeuAsnGlnSerLeuLeuAlaLeuSerArgAspLe 468
1640 TTGAAACCAACATATATAGTGATTGGACTGAATTCACAACCCACAAC 1689
468 uIleMetLysGluAspTyrGluLeuValSerThrLysProThrArgThrS 485
1690 AATACTTGCAAAGAGAGTCTGACCTCCAGACCAACCAACCCATTGTATA 1739
485 erLysValArgGlnLeuLeuAspThrThrAspIleGlnGlyGlu..... 499
1740 CACACTAGTCTGACTGATGAGAACACCTGACCCCTATCAGGGAACCTGG 1789
500 .....GluPheAlaLysValIleValGI 507
1790 GAAGGCACTGAAAAAAGCTGCTCGCCGCAAGCTGGCTTCACTAGACTCTCAG 1839

507 nLysLeuLysAspAsnLysGlnMet 515
1840 ATCGATGAAATCGACCATGACTATG 1864

```

197 .....AsnTyrGluProGlyGlnLysSerArgAlaSerIle 208
    ||| :||| :| :|||
644 ACCTGAATGACATCAATGTCAAGCCACCAGGAGGAGTCG..... 681
209 LysHisAspIleTyrSerTyrAlaValIleThrTrpGluValLeuSerAr 225
    ||| :||| :||| :||| :||| :||| :||| :||| :||| :||| :|||
682 .....GACGTGTACACCTTTGTCATTTGCTTTGGCAATATTTGCCAAA 725
225 gLysGlnPropheGluAspValThrAsnProLeuGInIleMetTyrSerV 242
    ||| :||| :||| :||| :||| :||| :||| :||| :||| :||| :|||
726 AAGAGCCCTATGAGAAATGTCATCTGACTGACCAGTTCGTGATCTGCCA 775
242 alSerGlnGlyHisArgProValIleAsnGlu.....GluSerLeuPro 256
    ||| :||| :||| :||| :||| :||| :||| :||| :||| :||| :|||
776 TAAATCTGGAAACAGCCCAAAATGTAGAGGAATCCCTTGAGTACTGTCCA 825
257 TyrAspIleProHisArgAlaArgMetIleSerLeuIleGluSerGlyTr 273
    ||| :||| :||| :||| :||| :||| :||| :||| :||| :||| :|||
826 AGGAGATC.....ATCAGCCTCATGAGGGTGTGCTG 857
273 pAlaGlnAsnProAspGluArgProSerPheLeuLysCysLeuIleGluL 290
    ||| :||| :||| :||| :||| :||| :||| :||| :||| :||| :|||
858 GCAGCCGATCCCAGAGACAGCCACAACTTTCTTGCCATTGAAGAAGAA 907
290 euGluPro...ValLeuArgThrPheGluGluIleThrPheLeuGluAla 305
    ||| :||| :||| :||| :||| :||| :||| :||| :||| :||| :|||
908 TTAGGCCTTTTACTTAAGTCAATTTGAAGAATATGTA...GAAGAGGAT 954
306 ValIleGlnLeuLysLys.....ThrLysLeuGlnInse 316
    ||| :||| :||| :||| :||| :||| :||| :||| :||| :||| :|||
955 GTGGCAGTTTAAAGAAAGAGTATCCAGATCAAAGCCAGTGTGTCAGAG 1004
316 rValSerSerAlaIleHisLeuLys..... 324
    ||| :||| :||| :||| :||| :||| :||| :||| :||| :||| :|||
1005 AATGTTTCTACTCAGCATGCTGTACTCCCTTACCTCCGAGGAGTCAA 1054
325 ..AspLysLysLysMetGluLeuSerLeuAsnIleProValAsnHisGly 340
    ||| :||| :||| :||| :||| :||| :||| :||| :||| :||| :|||
1055 ATTCAAGAACACCTGGATCTGCACAGTCCAGGGGCTCCAGATGGGT 1104
341 ProGlnGluLysSerCysGlySerSerGln.....LeuHisGI 353
    ||| :||| :||| :||| :||| :||| :||| :||| :||| :||| :|||
1105 CBTGTGGAGGACTCTGGTCTTCTCTCCACAGATPACCCACAGGACGA 1154
353 uAsnSerGlySerProGluThr..... 360
    ||| :||| :||| :||| :||| :||| :||| :||| :||| :||| :|||
1155 GAATGATCGCAGTGTGAGCTAAGCTGCAAGAGGAAAGCCAGCTATCATG 1204
361 .....SerArgSerLeuProAlaProGlnAspAsn 370
    ||| :||| :||| :||| :||| :||| :||| :||| :||| :||| :|||
1205 CTTTTGGAAATTTGCAGAGAAACAGACAAACCCGAGCCAGCCAGCAGAA 1254
371 AspPheLeuSerArgLysAlaGlnAspCysTyrPheMetLysLeuHisH1 387
    ||| :||| :||| :||| :||| :||| :||| :||| :||| :||| :|||
1255 GAGGCTTACAACAGAGAGGAGAA.....AGGAAACGAAGGCTCTCTCA 1298
387 sCysPro..... 389
    ||| :||| :||| :||| :||| :||| :||| :||| :||| :||| :|||
1299 TGACCCCTTTCACACAGAGAGCTCGTAGAAATATTAAAGAGTGCAGGAG 1348
390 ..GlyAsnHisSerTrpAspSerThrIleSerGlySerGlnArgAlaAla 405
    ||| :||| :||| :||| :||| :||| :||| :||| :||| :||| :|||
1349 CAAGAGGTCATTCTGATCCAGCACAACAGAGT.....CGTGGAAAT 1389
406 PheCysAspHisLysThrThrProCysSerSerAlaIleIleAsn..... 420
    ||| :||| :||| :||| :||| :||| :||| :||| :||| :||| :|||
1390 GCAGTGCACACAGCTGTCATGGCCAGCCACCACAAACAGATTTGGAAACAATGG 1439
421 .....ProLeuSerThrAlaGlyAsnSerGluArgLeuG 432
    ||| :||| :||| :||| :||| :||| :||| :||| :||| :||| :|||
1440 ATTGTATATFACAGCATGGATTTGGAACTACAGGTACAGGAGTTGGTATC 1489

```

```

432 InProGlyIleAlaGlnInLtrIleGlnSerLys..... 443
    ||| :||| :||| :||| :||| :||| :||| :||| :||| :||| :|||
1490 CGCAAATCTAAGCAAAATGTATAGTACTTATAAAAACCTCCAGTCCAGAG 1539
443 ..... 443
1540 ACCAAATACCGGGAAGCAGCACCCACCATGCCATCTTCTTGGGCCAGT 1589
444 .ArgGluAspIleVal.AsnGlnMet..... 451
    ||| :||| :||| :||| :||| :||| :||| :||| :||| :||| :|||
1590 ACCAGATGACCTCATATAAATATACTATATTAATTAATGTTCTGTGATTTCAGA 1639
1640 TTGAAACCACTAATATATGATGGTGTGACTGAATTCACAACCCACCAAC 1689
468 uIleMetLysGluAspTyrGluLeuValSerThrLysProThrArgThrS 485
    ||| :||| :||| :||| :||| :||| :||| :||| :||| :||| :|||
1690 AATACTTGCAAAGAGAGTCCGACTTCCAGACACCAAGCCATCTTTGTATAA 1739
485 erLysValArgGlnLeuAspThrThrAspIleGlnGlyGlu..... 499
    ||| :||| :||| :||| :||| :||| :||| :||| :||| :||| :|||
1740 CACCACTAGTCTGACTGATGAACACTGAACCTATCAGGGAAACCTGG 1789
500 .....GluPheAlaLysValIleValGI 507
    ||| :||| :||| :||| :||| :||| :||| :||| :||| :||| :|||
1790 GAAGGCAGTGTGAAAAACTGTCCCGCAAGCTTCACTGAGTCTCAG 1839
507 nLysLeuLysAspAsnLysGlnMet 515
    ||| :||| :||| :||| :||| :||| :||| :||| :||| :||| :|||
1840 ATCGATGAAATCGACCATGACTATG 1864

```

```

seq_name: gb_pat1:AR105328
seq documentation block:
LOCUS AR105328 1557 bp DNA PAT 14-FEB-2001
DEFINITION Sequence 2 from patent US 6096539.
ACCESSION AR105328
VERSION AR105328.1 GI:12818925
KEYWORDS
SOURCE
  ORGANISM
    Unclassified.
  REFERENCE
    1 (bases 1 to 1557)
  AUTHORS
    Gomes, B.Charles, Kasof, G.M. and Prosser, J.Caroline.
  TITLE
    Protein activator of apoptosis
  JOURNAL
    Patent: US 6096539-A 2 01-AUG-2000;
  FEATURES
    source
      1..1557
    /organism="unknown"
  BASE COUNT
    395 a 422 c 448 g 291 t 1 others
  ORIGIN
    alignment_scores:
      Quality: 395.00 Length: 499
      Ratio: 1.452 Gaps: 21
    Percent Similarity: 54.509 Percent Identity: 28.056
  alignment_block:
    us-09-445-223-1 x AR105328
  Align seg 1/1 to: AR105328 from: 1 to: 1557
    11 ProThrIleProTyrHisLysLeuAlaAspLeuArgTyrLeuSerArgGI 27
        ||| :||| :||| :||| :||| :||| :||| :||| :||| :||| :|||
    40 CCCTTGGTCTCCATCGAGAACTGGAGAACCCAGGAGCTCGCGCAAAGG 89
        ||| :||| :||| :||| :||| :||| :||| :||| :||| :||| :|||
    27 YAlaSerGlyThrValSerSerAlaArgHisAlaAspTrpArgValGlnV 44
        ||| :||| :||| :||| :||| :||| :||| :||| :||| :||| :|||
    90 CCGGTCCGACAGTGTTCGGCGCAACATPAGGAGTGGGGCTACAGT 139
        ||| :||| :||| :||| :||| :||| :||| :||| :||| :||| :|||
    44 alAlaValLysHisLeuHisIleHisThrProLeuLeuAspSerGluArg 60

```

140 TGGCGTCAAGATCGTAAAC.....TCG 162  
 61 LysAspValLeuArgGluAlaGluLeuHisLysAlaArgPheSerTy 77  
 163 AAGCGGATATCCAGGAGGTCAGGCCATGCAAGTCTGGATACGAATT 212  
 77 rIlePheProIleLeuGlyIleCysAsnGluProGluPhe..... 90  
 213 CGTGTGGCCCTAGAAAGGGTTATCGAGAAGGTAAGTGGGACCAAGATC 262  
 91 .....LeuGlyIleValThrGluThrMetProAsnGlySerLeuAsnGlu 105  
 263 CCAAGCCGGCTCTGGTACTAAATTCATGGAGAACGGCTCTTGTCCGGG 312  
 106 LeuLeuHisArgLysThrGluThrProAspValAlaTrpProLeuArgPh 122  
 313 CTGCTGCAGTCCAGTGGCCCTGGCC.....TGGCCGCTCCTTTG 353  
 122 eArgIleLeuHisGluIleAlaLeuGlyValAsnTyrLeuHisAsnMetT 139  
 354 CGCCTGTGAAAGAAAGTGGTGTGGATTTTGGCTGTCCACATTTTCAG... 501  
 139 hrProProLeuLeuHisAspLeuLysThrGlnAsnIleLeuLeuAsp 155  
 404 ACCCGGTGCTCTGCACCGGACCTCAAGCCATCCAACTCTGTGTGGAC 453  
 156 AsnGluPheHisValLysIleAlaAspPheGlyLeuSerLysTrpArgMe 172  
 454 CCAGAGCTGCAGTCAAGCTGAGATTTGGCTGTCCACATTTTCAG... 501  
 172 tMetSerLeuSerGlnSerArgSerLysSerAlaProGluGlyGlyT 189  
 502 ....GGAGCTCACACTCAGGACAGGTCGGGGAGCCA...GGGGCA 544  
 189 hrIleIleTyrMetProGluAsnTyrGluProGlyGlnLysSerArg 205  
 545 CCCTGGCTACTTGGCCCGACAACTGTTT...GTTAACGTTAAACCGGAAG 591  
 206 AlaSerIleLysHisAspIleTyrSerTyrAlaValIleThrTrpGluVa 222  
 592 GCCTCCACAGCCAGTACGCTACAGCTTCGGATCCCTAACTGGGCGAGT 641  
 222 lLeuSerArgLysGlnProPheGluAspValThrAsnProLeuGlnIleM 239  
 642 GCTTGTGGAGAGAA...GTTGAGTTGCCAACCAAGCAATCACCTCGTGT 688  
 239 etYrSerVal...SerGlnGlyHisArgProValIleAsnGluGluSer 254  
 689 ACAAGCAGTGTGCACAGGACAGACCGGCCCTTCAITGGCTGAG..... 732  
 255 LeuProTyr.....AspIleProHisArgAlaArgMetIleSerIle 268  
 733 CTGCCCCAGCCGGGCTGAGACTCCCGCTTAGAAGGACTGAAGGAGCT 782  
 268 uIleGluSerGlyTrpAlaGlnAsnProAspGluArgProSerPheLeuL 285  
 783 AATGACGCTCTGTGGAGGAGTGGAGCCCAAGGACAGACCCCTCTCCAG 832  
 285 yScysLeuIleGluLeuProValLeuArgThrPheGluGluIleThr 301  
 833 AATGCTTACCAAAATGATGAAAGTCTCCAGATGGTGGAG.....AAC 876  
 302 PheLeuGluAlaValIleGlnLeuLysLysThrLysLeuGlnSerValSe 318  
 877 AATATGATGCTCTCTCCAGGGTAAGGATTTCTCTCTCAGCTCAG 926  
 318 rSerAlaIle.....HisLeuCysAspLysLysMetGlu..... 330  
 927 GAGCAATAGGAGATTTTCTATCCAGAGTCAGGCCAAGGAGGAGAC 976  
 331 .....LeuSerLeuAsnIlePro.....ValAs 338

977 AAATGGATGGCTTTAGGAGAACCATAGAAAAACCCAGCAGCTCTCGTAATGAT 1026  
 338 n.HisGly.....ProGlnGluSerCysGlySerSerGln 350  
 1027 GTCATGGTTTCTGAGTGGTAAACAACAACTGAATCTAGAGGAGCTCCAG 1076  
 351 LeuHisGluAsnSerGlySerProGluThrSerArgSerLeuProAlaPr 367  
 1077 CTC.....TGTTCCTAAAAAATGCCCGAGCC 1102  
 367 oGlnAspAsnAspPheLeuSerArgLysAla..... 377  
 1103 TTACCAAGAGGAGGAGGACCAAGAGAGGAGGTTCCACAAGCTGGACA 1152  
 378 .....GlnAsp 379  
 1153 GCAGGCACATCTTCAGATTCATGATGGCCCAACCTCCCGAGACTCCAGAGAC 1202  
 380 CysTyrPheMetLysLeuHisHisCysPro.....GlyAsnH1 392  
 1203 CTCAACTTTCAGAAAACAGATGCCAGCCCTACCTCAACTGGAACACCAA 1252  
 392 sSerTrpAspSerThrIleSerGlySerGlnArgAlaAlaPheCysAspH 409  
 1253 GTCCTGGACCCCGAGGAAATCAGGGGCTGAGAG..... 1286  
 409 isLysThrThrProCysSerSerAlaIleIleAsnProLeuSerThrAla 425  
 1287 .....ACAAGCATGAAGTGGTCTGCAGGACCCCGGAGCCAAATCC 1328  
 426 GlyAsnSerGluArgLeuGlnProGlyIleAlaGlnGlnTrpIleGlnSe 442  
 1329 AGTAACAGGGCGACCGCTGTTAAATACATACTGCTGGGGTGGCAAG 1378  
 442 rLysArgGluAspIleValAsnGlnMetThrGluAlaCysLeu 456  
 1379 TTGAGACAGCAACTACTGTGACTATGCCAAGACAGCAACTGCCTT 1421

seq\_name: gb\_pat2:AX067677  
 seq\_documentation\_block: 1557 bp DNA PAT 19-JAN-2001  
 LOGUS AX067677 Sequence 2 from Patent WO0077200.  
 DEFINITION AX067677  
 ACCESSION AX067677  
 VERSION AX067677.1 GI:12329571  
 KEYWORDS human.  
 SOURCE  
 ORGANISM Homo sapiens  
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.  
 REFERENCE 1 (bases 1 to 1557)  
 AUTHORS Gomes,B.C., Kasof,G.M. and Prosser,J.C.  
 TITLE Receptor interacting protein rip3  
 JOURNAL Patent: WO 0077200-A 2 21-DEC-2000;  
 AstraZeneca AB (SE)  
 FEATURES  
 source Location/Qualifiers  
 1..1557 /organism="Homo sapiens"  
 /db\_xref="taxon:9606"  
 BASE COUNT 395 a 422 c 448 g 291 t 1 others  
 ORIGIN  
 alignment\_scores:  
 Quality: 395.00 Length: 499  
 Ratio: 1.452 Gaps: 21  
 Percent Similarity: 54.509 Percent Identity: 28.056  
 alignment\_block:  
 US-09-445-223-1 x AX067677 ..  
 Align seg 1/1 to: AX067677 from: 1 to: 1557



11 ProThrIleProTyrHisLysLeuAlaAspLeuArgTyrLeuSerArgG1 27  
 ||| : : : : : ||| : : : : : ||| : : : : : ||| : : : : : ||| : : : : :  
 40 CCCTGGTTCATCAGGAACTGGAGAACCCAGAGGCTCGTCGGCAAAAG 89  
 27 yAlaSerGlyThrValSerSerAlaArgHisAlaAspTrpArgValGlnV 44  
 | : : : : | | | | | | | : : : : | | | | | | | : : : : | | | | | | | : : : :  
 90 CGGGTTCGGCACAGTGTCCGGGGCCACATAGGAAGTGGGGCTACGATG 139  
 44 alAlaValLysHisLeuHisIleHisIleThrProLeuLeuAspSerGluArg 60  
 | | | | | | | | : : : : | | | | | | | | : : : : | | | | | | | | : : : :  
 140 TGGCGGTCAAGATCGTAAC . . . . . TCC 162  
 61 LysaspValLeuArgGluAlaGluLeuHisLysAlaArgPheSerTy 77  
 | | | | | | | | : : : : | | | | | | | | : : : : | | | | | | | | : : : :  
 163 AAGCGATATCCAGGAGGTCGAAGCCATGGAAGTGGCAAGTAACGAATT 212  
 77 rIlePheProIleLeuGlyIleCysAsnGluProGluPhe . . . . . 90  
 : : : : : : : : : : | | | | | | | | : : : : : : : : : : : : : : : : : : : :  
 213 CGTGTCCCTAGAGGGGTTATCGAAGAGTGAACCTGGGACCAAGATC 262  
 91 . . . . .LeuGlyIleValThrGluTyrMetProAsnGlnSerLeuAsnGlu 105  
 : : : : : | | | | | | | | : : : : : | | | | | | | | : : : : : | | | | | | | | : : : :  
 263 CCAAGCCGCTCTGTGACTAAATCATGGACAGCGCTCTGTGCGGG 312  
 106 LeuLeuHisArgLysThrGluTyrProAspValAlaIleTrpProLeuArgPh 122  
 | | | | | | | | : : : : | | | | | | | | : : : : | | | | | | | | : : : :  
 313 CTGCTGCAGTCCAGTGCCTTGGCC . . . . . TGGCCGCTCTTTG 353  
 122 eArgIleLeuHisGluIleAlaLeuGlyValAsnTyrLeuHisAsnMetF 139  
 | | | | | | | | : : : : | | | | | | | | : : : : | | | | | | | | : : : :  
 354 CGCCTGTGAAGAAGTGGTGTGGATGTTTACCTGCACGACCAGA 403  
 139 hrProProLeuLeuHisLysLeuHisLysThrGlnAsnIleLeuLeuAsp 155  
 : : : : : | | | | | | | | : : : : : | | | | | | | | : : : : : | | | | | | | | : : : :  
 404 ACCCGGTCTCTGCACGGGACCTCAAGCCATCCACAGCTCTGTGTGAC 453  
 156 AsnGluPheHisValLysIleAlaAspPheGlyLeuSerLysTrpArgMe 172  
 | | | | | | | | : : : : | | | | | | | | : : : : | | | | | | | | : : : :  
 454 CCAGAGCTGCAGTCAAGCTGAGATTTGGCCCTGCCACATTCAG . . . 501  
 172 tMetSerLeuSerGlnSerArgSerSerLysSerAlaProGluGlyGlyT 189  
 : : : : : | | | | | | | | : : : : : | | | | | | | | : : : : : | | | | | | | | : : : :  
 502 . . . . .GGAGCTCACAGTCAAGGACAGGTCGGGGAGCCA . . . . .GGGGGCA 544  
 189 hrIleIleTyrMetProGluAsnTyrGluProGlyGlnLysSerArg 205  
 | | | | | | | | : : : : | | | | | | | | : : : : | | | | | | | | : : : :  
 545 CCCTGGGTACTTGCCTCCAGAACGTTT . . . . .GTTAACGTAACCCGGAAG 591  
 206 AlaSerIleLysHisAspIleLysSerTyrAlaValIleThrTrpGluVa 222  
 | | | | | | | | : : : : | | | | | | | | : : : : | | | | | | | | : : : :  
 592 GCCTCCACAGCCAGTGCAGTCTACAGTTCGGGATCCCTAATGTGGCAGT 641  
 222 lIleSerArgLysGlnProPheGluAspValPheAsnProLeuGlnIleM 239  
 | | | | | | | | : : : : | | | | | | | | : : : : | | | | | | | | : : : :  
 642 GCTTCTGGAAGAAA . . . . .GTTAGTTCACCAACCCAGCACTCCTCGTGT 688  
 239 etTyrSerVal . . . . .SerGlnGlyHisArgProValIleAsnGluLuser 254  
 | : : : : | | | | | | | | : : : : | | | | | | | | : : : : | | | | | | | | : : : :  
 689 ACGAAGCAGTGTGCAACAGGCAACCCGCTTTCATTTGGCTGAG . . . . . 732  
 255 LeuProTyr . . . . .AspIleProHisArgAlaArgMetIleSerLe 268  
 | | | | | | | | : : : : | | | | | | | | : : : : | | | | | | | | : : : :  
 733 CTGCCCCAAGCCGCTCAGACCTCCCGCTTAGAAGGACTGAAGGAGCT 782  
 268 uIleGluSerGlyTyrAlaGlnAsnProAspGluArgProSerPheLeuL 285  
 | : : : : | | | | | | | | : : : : | | | | | | | | : : : : | | | | | | | | : : : :  
 793 AATGCAGCTCTGTGGACAGTGGACCAAGGACAGACCCCTCTCTCCAGG 832  
 285 ysCysLeuIleGluLeuGluProValLeuArgThrPheGluGluIleThr 301  
 : : | | | | | | : : : : | | | | | | | | : : : : | | | | | | | | : : : :  
 833 AATGCCTACCAAAACTGATGAAGTCTCCAGATGTTGGAG . . . . .AAC 876  
 302 PheLeuGluAlaValIleGlnLeuLysLysThrLysLeuGlnSerValSe 318

877 AATATGAATGCTGCTCTCCAGGTAAGGATTCCTGCTCAGCTCAG 926  
 | : : : : | | | | | | | | : : : : | | | | | | | | : : : : | | | | | | | | : : : :  
 318 rSerAlaIle . . . . .HisLeuCysAspLysLysLysMetGlu . . . . . 330  
 | | | | | | | | : : : : | | | | | | | | : : : : | | | | | | | | : : : :  
 927 GAGCAGCAATAGGAGATTTCTATCCAGAGTCAGGCCAAGGAGGACAG 976  
 | : : : : | | | | | | | | : : : : | | | | | | | | : : : : | | | | | | | | : : : :  
 331 . . . . .LeuSerLeuAsnIlePro . . . . .ValAs 338  
 : : : : : | | | | | | | | : : : : | | | | | | | | : : : : | | | | | | | | : : : :  
 977 AATGATGGCTTAGGAGAACCATAGAAAACCCAGCACTCTCGTAATGAT 1026  
 338 n.HisGly . . . . .ProGlnGluLuserCysGlySerSerGln 350  
 | | | | | | | | : : : : | | | | | | | | : : : : | | | | | | | | : : : :  
 1027 GTCATGGTTTCAGTGGCTAAACAACAACTGAATCTAGAGGAGCTCCAG 1076  
 | : : : : | | | | | | | | : : : : | | | | | | | | : : : : | | | | | | | | : : : :  
 351 LeuHisGluAsnSerGlySerProGluThrSerArgSerLeuProAlaPr 367  
 | | | | | | | | : : : : | | | | | | | | : : : : | | | | | | | | : : : :  
 1077 CTC . . . . .TGTCTTAAAAAATGCCGAGCC 1102  
 367 oGlnAspAsnAspPheLeuSerArgLysAla . . . . . 377  
 | : : : : | | | | | | | | : : : : | | | | | | | | : : : : | | | | | | | | : : : :  
 1103 TTACCAAGAGGACGAGCCACAAAGAGGACGAGTCCACAAAGCCCTGGACA 1152  
 378 . . . . .GlnAsp 379  
 : : : : : | | | | | | | | : : : : | | | | | | | | : : : : | | | | | | | | : : : :  
 1153 GCAGGCACATCTCAGATTCGATGGCCCAACCTCCAGACTCCAGAGAC 1202  
 380 CysTyrPheMetLysLeuHisCysPro . . . . .GlyAsnH 392  
 | : : : : | | | | | | | | : : : : | | | | | | | | : : : : | | | | | | | | : : : :  
 1203 CTCAACTTTCAGAAACACAGATCCCGAGCCCTACCTCACTGGAACACCAA 1252  
 392 sSerTrpAspSerThrIleSerGlySerGlnArgAlaAlaPheCysAspH 409  
 | | | | | | | | : : : : | | | | | | | | : : : : | | | | | | | | : : : :  
 1253 GTCCTGGACCCCGAGGAAATCAGGGGCTGAGAG . . . . . 1286  
 409 lLysThrThrProCysSerSerAlaIleIleAsnProLeuSerThrAla 425  
 | | | | | | | | : : : : | | | | | | | | : : : : | | | | | | | | : : : :  
 1287 . . . . .ACAAGGATGAACCTGCTCGAGGACCCCGGAGCAAAATCC 1328  
 426 GlyAsnSerGluArgLeuGlnProGlyIleAlaGlnTrpIleGlnSe 442  
 : : : : : | | | | | | | | : : : : | | | | | | | | : : : : | | | | | | | | : : : :  
 1329 AGTACAGGGGACCCGCTGTTAACATATACAACTGCTCTGGGTGCAAG 1378  
 442 rLysArgGluAspIleValAsnGlnMetThrGluAlaCysLeu 456  
 | | | | | | | | : : : : | | | | | | | | : : : : | | | | | | | | : : : :  
 1379 TTGGAGACAACAACACTTGACTATGCAACAGACAACTGCCCTT 1421  
 seq\_name: gb\_pat1:AR105327

seq\_documentation\_block:  
 LOCUS AR105327 1873 bp DNA PAT 14-FEB-2001  
 DEFINITION Sequence 1 from patent US 6096539.  
 ACCESSION AR105327  
 VERSION AR105327.1 GI:12818924  
 KEYWORDS  
 SOURCE Unknown.  
 ORGANISM Unclassified.  
 REFERENCE 1 (bases 1 to 1873)  
 AUTHORS Gomes,B.Charles, Kasof,G.M. and Prosser,J.Caroline.  
 TITLE Protein activator of apoptosis  
 JOURNAL Patent: US 6096539-A 1 01-AUG-2000;  
 FEATURES Location/Qualifiers  
 source 1..1873  
 /organism="unknown"  
 BASE COUNT 471 a 531 c 518 g 353 t  
 ORIGIN

alignment\_scores:  
 Quality: 392.50 Length: 501  
 Ratio: 1.443 Gaps: 22  
 Percent Similarity: 54.291 Percent Identity: 28.144

alignment\_block:

US-09-445-223-1 x ARI05327

Align seg 1/1 to: ARI05327 from: 1 to: 1873

11 ProThrIleProTyrHisLysLeuAlaAspLeuArgTyrLeuSerArgL 27  
 204 CCCTTGGTTCATCCAGGAATGGAGAACCCAGGAGCTCTCGGCAANAGG 253  
 27 yAlaSerGlyThrValSerSerAlaArgHisAlaAspTrpArgValGlnV 44  
 254 CCGGTTCCGCACAGTTCCTCGGCGCACATAGGAAGTGGGCTACGATG 303  
 44 aAlaValLysHisLeuHisIleHisThrProLeuLeuAspSerGluArg 60  
 304 TGGCGTCAAGATCGTAAAC.....TCG 326  
 61 LysAspValLeuArgGluAlaGluIleLeuHisLysAlaArgPheSerTy 77  
 327 AAGCGGATATCCAGGAGGTCAGAGCCATGGCCATGGCAAGTCTGGATNACGAAAT 376  
 77 rIlePheProIleLeuGlyIle.....CysAsnG 87  
 377 CTTGCTCCGCTAGAGGGTTATCGAGAGGTCGGCGGCTCGAGCCAAG 426  
 87 luProGluPheLeuGlyIleValThrGluTyrMetProAsnGlySerLeu 103  
 427 ATCCCAAG...CGGGCTCTGGTACTAAATTCATGGAGAACGGCTCCTTG 473  
 104 AsnGluLeuLeuHisArgLysThrGluTyrProAspValAlaTrpProLe 120  
 474 TCGGGGCTGCTGACGCTCCAGTCCCTCCGCCCC.....TGGCGGCT 514  
 120 uArgPheArgIleLeuHisGluIleAlaLeuGlyValAsnTyrLeuHisA 137  
 515 CTTTGGCGCTCTCTGAAGAAGTGTGTGGTGGATTTTTTACCTGCACG 564  
 137 snMetThrProProLeuHisHisAspLeuLysThrGlnAsnIleLeu 153  
 565 ACCAGAACCCTGCTCTCCGCGGGACCTCAAGCCATCCACAGCTCCTG 614  
 154 LeuAspAsnGluPheHisValLysIleAlaAspPheGlyLeuSerTyr 170  
 615 CTGACCCAGAGCTGCACGTCAGCTGCACATTTTGGCCCTGCCACATT 664  
 170 pArgMetSerLeuSerGlnSerArgSerSerLysSerAlaProGluG 187  
 665 TCAG...GGAGCTCACAGTCCAGGACAGGGTCCGGGGAGCCA...G 705  
 187 lYGlyThrIleIleTyrMetProGluAsnTyrGluProGlyGlnLys 203  
 706 GGGCCACCCCTGGCTACTTGGCCCCAGAACTGTTT...GTTAAGGTAAAC 752  
 204 SerArgAlaSerIleLysHisAspIleTyrSerTyrAlaValIleThr 220  
 753 CGGAAGGCTCCACAGGACGTCAGCTACAGCTTCGGGATCTTAATGTG 802  
 220 pGluValLeuSerArgLysGlnProPheGluAspValThrAsnProLeuG 237  
 803 GCCAGTGTCTCGGAAGAAA...GTTGAGTTGCCAACCCGAACCATCAC 849  
 237 lnIleMetTyrSerVal...SerGlnGlyHisArgProValIleAsnGlu 252  
 850 TCGGTAGCAAGCAGTGTGCAACAGGACAGAACCCCGCTTCATTCGGCTGAG 899  
 253 GluSerLeuProTyr.....AspIleProHisArgAlaArgMetI 266  
 900 .....CTGCCCAAGCGGGCCCTGAGACTCCCGCTTAGAAGGACTGAA 943  
 266 eSerLeuIleGluSerGlyTyrAlaGlnAsnProAspGluArgProSerP 283  
 944 GGAGCTAATGAGCTCTCTGGAGCAGTGGAGCCCAAGGACAGACCCCTCT 993

283 heLeuLysCysLeuIleGluLeuGluProValLeuArgThrPheGluGlu 299  
 994 TCCAGGAATGCCCTACAAAACACTGATGAAGTCTTCCAGATGGTGAG... 1040  
 300 IleThrPheLeuGluAlaValIleGlnLeuLysLysThrLysLeuGlnSe 316  
 1041 ...AACAAATATGAATGCTGCTGTCTCCACGGTAAAGGATTTCTCTCTCA 1087  
 316 rValSerSerAlaIle.....HisLeuCysAspLysLysLysMetGlu 330  
 1088 GCTCAGGAGACCAATAGAGATTTCTATCCAGAGTCAGCCCAAGAGG 1137  
 331 .....LeuSerLeuAsnIlePro..... 336  
 1138 GCACAGAAATGGATGGCTTAGAGAACCATAGAAAACCAGCACACTCTCT 1187  
 337 ValAsnHisGly.....ProGlnGluGluSerCysGlySer 348  
 1188 AATGATGTCATGGTTCTGAGTGGCTAAACAACAACTGAATCTAGAGGAGCC 1237  
 349 SerGlnLeuHisGluAsnSerGlySerProGluThrSerArgSerLeuPr 365  
 1238 TCCAGCTC.....TGTTCTATAAAAATGCC 1263  
 365 oAlaProGlnAspAsnAspPheLeuSerArgLysAla..... 377  
 1264 CGAGCTTACCAAGAGGACGAGGCAAGAGAGGAGGTTCCACAAGCC 1313  
 377 ..... 377  
 1314 TGGACAGCAGGCACACTTTCAGATTCGATGGCCCAACCTCCCCAGACTCC 1363  
 378 GlnAspCysTyrPheMetLysLeuHisLysCysPro.....G1 390  
 1364 AGAGACTCAACTTCAGAAACCAGATGCCCGCCCTACTCAACTCACTGAA 1413  
 390 yAsnHisSerTrpAspSerThrIleSerGlySerGlnArgAlaAlaPheC 407  
 1414 CACCAAGTCTGGACCCCGGGAATCAGGGGCTGAGAG..... 1453  
 407 ysAspHisLysThrThrProCysSerSerAlaIleIleAsnProLeuSer 423  
 1454 .....ACAGGCATGAAGTCTGCAGGACCCCGGAGCC 1489  
 424 ThrAlaGlyAsnSerGluArgLeuGlnProGlyIleAlaGlnGlnTrpI 440  
 1490 AAATCCAGTAAACAGGGCGGCTCGTAAACATATACAACACTGCTCTGGG 1539  
 440 eGlnSerLysArgGluAspIleValAsnGlnMetThrGluAlaCysLeu 456  
 1540 TGCAAGTTGGAGACAACTACTTACTATGCAACAGACAGACACTGCCT 1588

seq\_name: gb\_pat2:AX067676

seq\_documentation\_block: 1873 bp DNA PAT 19-JAN-2001  
 LOCUS AX067676  
 DEFINITION Sequence 1 from Patent WO0077200.  
 ACCESSION AX067676  
 VERSION AX067676.1 GI:12329570

SOURCE human.  
 ORGANISM Homo sapiens  
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.

REFERENCE 1 (bases 1 to 1873)  
 AUTHORS Gomes, B.-C., Kasof, G.M. and Prosser, J.C.  
 TITLE Receptor Interacting protein rip3  
 JOURNAL Patent: WO 0077200-A 1 21-DEC-2000;  
 Astrazeneca AB (SE)

FEATURES  
 Location/Qualifiers  
 1..1873 /organism="Homo sapiens"

BASE COUNT 471 a 531 c 518 g 353 t

/db\_xref="taxon:9606"

ORIGIN

alignment\_scores:

Quality: 392.50 Length: 501
Ratio: 1.443 Gaps: 22
Percent Similarity: 54.291 Percent Identity: 28.144

alignment\_block:

US-09-445-223-1 x AX067676 ..
Align seg 1/1 to: AX067676 from: 1 to: 1873
11 ProThrIleProTyrHisLysLeuAlaAspLeuArgTyrLeuSerArgG1 27
204 CCCTTGGTCCATCCAGGAACTGGAGAACCCAGGAGCTCCGGCAAAGG 253
27 yAlaSerGlyThrValSerSerAlaArgHisAlaAspTTPArGVaIGlnV 44
254 CGGTTCCGGCACAGTGTCCGGCGCAACATAGAAAGTGGGGCTACGATG 303
44 aAlaValLysHisLeuHisIleHisThrProLeuLeuAspSerGluArg 60
304 TGGCGTCAAGATCGTAAC.....TCG 326
61 LysAspValLeuArgGluAlaGluIleLeuHisLysAlaArgPheSerTy 77
327 AAGCGATATCCAGGAGGTTCAGGCCATGGCAAGTCTGGTAACGAAYT 376
77 rIlePheProIleLeuGlyIle.....CysAsnG 87
377 CGTCTGGCGCTCAAGAGGGTTATCAGAAAGTTCGGGGCTCCAGCCAAG 426
87 luProGluPheLeuGlyIleValThrGluTyrMetProAsnGlySerLeu 103
427 ATCCCAAG...CGGGTCTGGTACTAATAATTCATGGAGAACGGCTCTTG 473
104 AsnGluLeuHisArgLysThrGluTyrProAspValAlaIleProLe 120
474 TCGGGGCTCTGCGAGTCCAGTCCCTCGGCC.....TGGCGCT 514
120 uArgPheArgIleLeuHisGluIleAlaLeuGlyValAsnTyrLeuHis 137
515 CCYTTGGCGCTCTGAAAGAACTGGTGTGGATGTTTACCTGCACG 564
137 snMetThrProProLeuLeuHisAspLeuLysThrGlnAsnIleLeu 153
565 ACCAGAACCCGGTCTTCCTGCACCGGGACCTCAAGCCATCCAAAGTCTTG 614
154 LeuAspAsnGluPheHisValLysIleAlaAspPheGlyLeuSerLysTr 170
615 CTGGACCCAGAGTGCACGTCAGCTGAGGATTTGGCGTGTCCACAYT 664
170 pArgMetMetSerLeuSerGlnSerArgSerSerLysSerAlaProGlu 187
665 TCAG.....GGAGGTTCACAGTTCAGGACAGGGTCCGGGGAGCCA...G 705
187 lYclyThrIleIleTyrMetProGluAsnTyrGluProGlyGlnLys 203
706 GGGCACCCCTGGCTACTTGGCCCCAGAACTGTTT...GTTAACGGTAAC 752
204 SerArgAlaSerIleLysHisAspIleTyrSerTyrAlaValIleThrTr 220
753 CGGAAGCCCTCCACACCCAGTACGCTACAGCTTCGGGATCCTAATG 802
220 pGluValLeuSerArgLysGlnProPheGluAspValThrAsnProLeu 237
803 GCGAGTGTCTGTGGAAGAA...GTTGAGTTGCCAACCGAACCATCAC 849
237 InIleMetTyrSerVal...SerGlnGlyHisArgProValIleAsnGlu 252

850 TCCTGTACGAAGCAGTGTCAACAGAGGCGAGAACCGCGCTTCATTGGCTGAG 899
253 GluSerLeuProTyr.....AspIleProHisArgAlaArgMetII 266
900 .....CTGCCCAAGCCGGCTGAGACTCCCGGCTTAGAAGGACTGAA 943
266 eSerLeuIleGluSerGlyTrpAlaGlnAsnProAspGluArgProSerP 283
944 GGACTAATGCACGCTCTGCTGGAGCAGTACCCCAAGGACAGACCTCTCT 993
283 heLeuLysCysLeuIleGluLeuGluProValLeuArgThrPheGluGlu 299
994 TCCAGGAATGCTTACCACCAAACTGATGAAGTCTTCCAGATGTGGAG... 1040
300 IleThrPheLeuGluAlaValIleGlnLeuLysLysThrLysLeuGlnSe 316
1041 ...AACAAATGATGCTGTCTCCACGGTAAGGATTTCTCTGTCTCA 1087
316 rValSerSerAlaIle.....HisLeuCysAspLysLysLysMetGlu 330
1088 GCTCAGGAGCAATAGGAGATTTTCTATCCAGAGTCCAGGCCAAGGAG 1137
331 .....LeuSerLeuAsnIlePro..... 336
1138 GGACAGAAATGGATGGCTTTAGGAGAACCATAGAAAACCCAGCACTCTCGT 1187
337 .ValAsnHisGly.....ProGlnGluGluSerCysGlySer 348
1188 AATGATGTCATGGTTCTGAGTGGCTAAACAACTGNAITCTAGAGGAGCC 1237
349 SerGlnLeuHisGluAsnSerGlySerProGluThrSerArgSerLeuPr 365
1238 TCCAGGCTC.....TGTTCTTAAAAAATGCC 1263
365 oAlaProGlnAspAsnAspPheLeuSerArgLysAla..... 377
1264 CGAGCCTTACCAAGAGGAGCGGACAAAGAGGAGCAGGTTCCACAAGCC 1313
377 ..... 377
1314 TGGACACAGGCACTTCAGATTCGATGGCCCAACCTCCCCAGACTCC 1363
378 GlnAspCysTyrPheMetLysLeuHisHisCysPro.....G1 390
1364 AGAGACCTCAACTTTCAGAAACCAGATGCCCGCCCTACCTCAACTGAA 1413
390 yAsnHisSerTrpAspSerThrIleSerGlySerGlnArgAlaAlaPheC 407
1414 CACCAAGTCTGGACCCCGAGGAAATCAGGGGCTGAGAG..... 1453
407 ysAspHisLysThrThrProCysSerSerAlaIleIleAsnProLeuSer 423
1454 .....ACAAGCATGAATGGTCTCCAGGACCCCGGAGCC 1489
424 ThrAlaGlyAsnSerGluArgLeuGlnProGlyIleAlaGlnGlnTrpII 440
1490 AAATCCAGTAACAGCGCCGCTTAACTATATATACTCAACTGCTCTGGG 1539
440 eGlnSerLysArgGluAspIleValAsnGlnMetThrGluAlaCysLeu 456
1540 TGCARGTGGAGAACAACTACTTGTACTATGCAACAGCAACTGCCTT 1588



OM of: US-09-445-223-1 to: N\_Geneseq\_0401.\* out\_format : pfs  
 Date: Jun 13, 2001 6:38 PM  
 About: Results were produced by the GenCore software, version 4.5,  
 Copyright (C) 1993-2000 CompuGen Ltd.

Command line parameters:  
 -MODEL=frame+p2n.model -DEV=xlp  
 -O=/cgnl\_1/USPTO\_spool/US09445223/runat\_13062001\_092033\_29676/app\_query.fasta\_1.604  
 -DB=N\_Geneseq\_0401 -OPMT=fastap -SUFFIX=p2n.rng -GAPOP=12.000  
 -GAPEXT=4.000 -MINWATCH=0.100 -LOOPEXT=0.000 -LOOPEXT=0.000  
 -GAPOP=4.500 -GAPEXT=0.050 -XGAPOP=10.000 -XGAPEXT=0.500  
 -FGAPOP=6.000 -FGAPEXT=7.000 -YGAPOP=10.000 -YGAPEXT=0.500  
 -DELOP=6.000 -DELEXT=7.000 -START=1 -MATRIX=blousum62  
 -TRANS=human40.cdi -LIST=45 -DOCALIGN=200 -THR\_SCORE=pct  
 -THR\_MAX=100 -THR\_MIN=0 -ALIGN=15 -MODE=LOCAL -OUTFMT=pfs  
 -NORM-ext -MINLEN=0 -MAXLEN=2000000000  
 -USER=US09445223@cgnl\_1\_0 -NCPU=6 -ICPU=3 -LONGLOG -NO\_XLPXY  
 -WAIT -THREADS=1

Search information block:  
 Query: US-09-445-223-1  
 Query length: 540  
 Database: N\_Geneseq\_0401.\*  
 Database sequences: 678276  
 Database length: 291890651  
 Search time (sec): 125.040000

score\_list:

Sequence	Strd Orig	zScore	EScore	Len	Documentation
/cgnl_8/gcgdata/geneseq/NA1999.DAT:X02558		2829.00	4448.48	2098	7.6e-240
/cgnl_8/gcgdata/geneseq/NA2000.DAT:Z46143		2823.00	4439.38	2024	2.4e-239
/cgnl_8/gcgdata/geneseq/NA2000.DAT:C77779		2823.00	4436.20	2709	3.7e-239
/cgnl_8/gcgdata/geneseq/NA1999.DAT:Z09246		2817.00	4430.40	1931	7.7e-239
/cgnl_8/gcgdata/geneseq/NA2000.DAT:Z48762		2808.00	4413.34	2502	6.9e-238
/cgnl_8/gcgdata/geneseq/NA2000.DAT:F21841		787.00	1251.03	463	9.6e-62
/cgnl_8/gcgdata/geneseq/NA2000.DAT:Z61161		579.00	888.41	2370	1.5e-41
/cgnl_8/gcgdata/geneseq/NA2000.DAT:Z611784		579.00	884.11	3516	2.6e-41
/cgnl_8/gcgdata/geneseq/NA2001.DAT:C99717		579.00	884.11	3516	2.6e-41
/cgnl_8/gcgdata/geneseq/NA2000.DAT:Z61830		577.00	888.41	1774	1.5e-41
/cgnl_8/gcgdata/geneseq/NA2001.DAT:C99763		577.00	888.41	1774	1.5e-41
/cgnl_8/gcgdata/geneseq/NA2000.DAT:Z58584		577.00	885.60	2294	2.2e-41
/cgnl_8/gcgdata/geneseq/NA2000.DAT:Z61671		548.00	841.86	1888	5.9e-39
/cgnl_8/gcgdata/geneseq/NA2001.DAT:C99604		548.00	841.86	1888	5.9e-39
/cgnl_8/gcgdata/geneseq/NA1997.DAT:T43752		397.00	601.03	2268	1.5e-25
/cgnl_8/gcgdata/geneseq/NA1999.DAT:V99827		397.00	601.03	2268	1.5e-25
/cgnl_8/gcgdata/geneseq/NA2000.DAT:AA7702		395.00	601.97	1873	1.4e-25
/cgnl_8/gcgdata/geneseq/NA2000.DAT:AA7701		392.50	596.00	1573	2.9e-25
/cgnl_8/gcgdata/geneseq/NA1999.DAT:V99818		391.00	586.05	1750	1.0e-24
/cgnl_8/gcgdata/geneseq/NA2000.DAT:AY5675		388.00	587.43	2140	8.8e-25
/cgnl_8/gcgdata/geneseq/NA2000.DAT:Z50788		381.00	579.83	1557	2.3e-24
/cgnl_8/gcgdata/geneseq/NA1994.DAT:Q57911		376.00	565.17	2890	1.5e-23
/cgnl_8/gcgdata/geneseq/NA1995.DAT:Q98816		376.00	564.64	3033	1.6e-23
/cgnl_8/gcgdata/geneseq/NA1997.DAT:T67126		376.00	564.64	3033	1.6e-23
/cgnl_8/gcgdata/geneseq/NA1997.DAT:T43753		371.50	561.35	2137	2.5e-23
/cgnl_8/gcgdata/geneseq/NA1997.DAT:T66408		370.00	559.61	2016	3.1e-23
/cgnl_8/gcgdata/geneseq/NA2000.DAT:Z99748		369.00	555.18	2617	5.5e-23
/cgnl_8/gcgdata/geneseq/NA1998.DAT:V33547		367.00	579.54	210	4.2e-24
/cgnl_8/gcgdata/geneseq/NA2001.DAT:C90484		359.00	537.58	3081	5.3e-22
/cgnl_8/gcgdata/geneseq/NA2001.DAT:C90486		341.50	509.10	3116	2.0e-20
/cgnl_8/gcgdata/geneseq/NA2000.DAT:AA7606		337.50	503.78	3025	4.0e-20
/cgnl_8/gcgdata/geneseq/NA2000.DAT:AA7607		334.50	501.09	2505	5.7e-20
/cgnl_8/gcgdata/geneseq/NA2001.DAT:F44702		334.50	501.08	2508	5.7e-20
/cgnl_8/gcgdata/geneseq/NA2001.DAT:C90485		330.50	492.23	3160	1.8e-19
/cgnl_8/gcgdata/geneseq/NA2000.DAT:C48526		320.50	479.96	2283	3.5e-19
/cgnl_8/gcgdata/geneseq/NA2000.DAT:AA79714		316.00	469.64	3062	4.2e-18
/cgnl_8/gcgdata/geneseq/NA2000.DAT:AA7609		313.50	467.88	2505	4.0e-18
/cgnl_8/gcgdata/geneseq/NA2000.DAT:AA7608		313.50	465.82	3026	5.2e-18
/cgnl_8/gcgdata/geneseq/NA1999.DAT:V99698		313.00	471.29	1704	2.6e-18
/cgnl_8/gcgdata/geneseq/NA1999.DAT:V99698		312.00	469.18	1788	3.4e-18

/cgnl\_8/gcgdata/geneseq/NA1997.DAT:T85095 + 312.00 468.19 3.9e-18  
 /cgnl\_8/gcgdata/geneseq/NA1999.DAT:X56279 + 312.00 464.87 5.9e-18  
 /cgnl\_8/gcgdata/geneseq/NA2000.DAT:A39105 + 312.00 464.87 5.9e-18  
 /cgnl\_8/gcgdata/geneseq/NA1999.DAT:X99696 + 312.00 464.35 6.3e-18  
 /cgnl\_8/gcgdata/geneseq/NA1991.DAT:Q10324 + 311.50 460.47 1.0e-17  
 /cgnl\_8/gcgdata/geneseq/NA1999.DAT:X02558

seq\_name: /cgnl\_8/gcgdata/geneseq/NA1999.DAT:X02558  
 seq\_documentation\_block:  
 ID X02558 standard; cDNA; 2098 BP.  
 XX  
 AC X02558;

XX  
 DT 07-MAY-1999 (first entry)  
 XX  
 DE Human B1 CDNA.  
 XX

XX B1 protein; intracellular mediator; modulator; inflammation; cell death;  
 KW cell survival pathway; intracellular signalling; AIDS; cancer; human; ss.  
 XX  
 OS Homo sapiens.  
 XX  
 PN W09855507-A2.  
 XX  
 PD 10-DEC-1998.  
 XX  
 PF 01-JUN-1998; 98WO-IL00255.  
 XX  
 PR 11-SEP-1997; 97IL-0121746.  
 PR 05-JUN-1997; 97IL-0121011.  
 PR 30-JUN-1997; 97IL-0121199.  
 XX

XX (YEDA ) YEDA RES & DEV CO LTD.  
 XX  
 XX Boldin M, Mollin N, Wallach D;  
 XX  
 DR WPI; 1999-070258/06.  
 XX  
 DR P-PSDB; W92795.  
 XX

XX New B1 protein regulates cell death and cell survival pathways -  
 PT derivatives, DNA and antibodies, also regulate intracellular  
 PT inflammation; for treating AIDS, cancer  
 XX  
 PS Claim 4; Fig 3B; 90pp; English.  
 XX

XX This invention describes the isolation of a novel human B1 protein which  
 CC can interact with intracellular mediators or modulators of inflammation,  
 CC cell death and/or cell survival pathways, directly or indirectly. Cells  
 CC can be modulated or mediated in inflammation, cell death or cell survival  
 CC pathways or another intracellular signalling activity using B1.  
 CC Conditions such as AIDS and cancer can be treated using B1. Antibodies,  
 CC oligonucleotides and ribozymes can also be used to regulate the above  
 XX pathways.  
 XX  
 SQ Sequence 2098 BP; 649 A; 452 C; 449 G; 539 T; 9 other;

alignment\_scores:  
 Quality: 2829.00 Length: 540  
 Ratio: 5.239 Gaps: 0  
 Percent Similarity: 100.000 Percent Identity: 100.000

alignment\_block:  
 US-09-445-223-1 x X02558  
 Align seg 1/1 to: X02558 from: 1 to: 2098

1 MetAsnGlyGluAlaIleCysSerAlaLeuProThrIleProTyrHisLy 17  
 ||||||||||||||||||||||||||||||||||||||||||||||||  
 260 ATGARCCGGGAGGCCATCTCGAGCGCCCTGCCACCATTCCCTACCACAA 309  
 ||||||||||||||||||||||||||||||||||||||||||||||||

17 sLeuAlaAspLeuArgTyrLeuSerArgGlyAlaSerGlyThrValSerS 34  
 ||||||||||||||||||||||||||||||||||||||||||||||||

310 ACTCCCGCACCTGCCTACCTGAGCCCGCGCCCTCTGGCACTGTGTCTGT 359  
34 erAlaAArgHisAlaAspTrpArgValGlnValAlaValLysHisLeuHis 50  
360 CGCCCGCCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAG 409  
51 lleHisThrProLeuLeuAspSerGluArgLysAspValLeuArgGluAl 67  
410 ATCCACACTCCGCTCTCGACAGTGAAGAAGGATGTTTTAAGAGAAGC 459  
67 agLuIleLeuHisLysAlaArgPheSerTyrIlePheProIleLeuGlyI 84  
460 TGAATTTTACCAAGCTAGATTAGTTACATTTTCCAAATTTGGGAA 509  
84 leCysAsnGluProGluPheLeuGlyIleValThrGluTyrMetProAsn 100  
510 TTTGCAATGAGCCTGAAATTTGGGAATAGTTACTGAATACATGCCAAAT 559  
101 GlySerLeuAsnGluLeuLeuHisArgLysThrGluTyrProAspValAl 117  
560 GGATCATTAAATGAATCCTACATAGGAAACTGAATATCCTGATGTTGC 609  
117 atrpProLeuArgPheArgIleLeuHisGluIleAlaLeuGlyValAsnT 134  
610 TTGGCCATTTGAGATTTCCATCCTCATGAAATTTGCCCTTGGTGTAAAT 659  
134 yLeuHisAsnMetThrProProLeuLeuLeuHisHisAspLeuLysThrGln 150  
660 ACCTGCACAATATGACTCCTCTTACCTTACATCCTGACTGTAAGACTCAG 709  
151 AsnIleLeuLeuAspAsnGluPheHisValLysIleAlaAspPheGlyLe 167  
710 AATATCTTATTGGACAAATGAAATTTTCATGTTAGATTGCAGATTTGGTT 759  
167 uSerLysTrpArgMetMetSerLeuSerGlnSerArgSerSerLysSerA 184  
760 ATCAAAGTGGCGCATGATGCCCTCTCACAGTTCACGAAAGTAGCAAAATCTG 809  
184 laProGluGlyGlyThrIleIleTyrMetProProGluAsnTyrGluPro 200  
810 CACCAGAAGGGAGCAATTTATTTATGCCCACCTTGAAMAACHTGAACTT 859  
201 GlyGlnLysSerArgAlaSerIleLysHisAspIleTyrSerTyrAlaVa 217  
860 GGACAAAATCAAGGCCAGTATCAAGCACGATATATATAGTATGCACT 909  
217 lleThrTrpGluValLeuSerArgLysGlnProPheGluAspValThra 234  
910 TATCACATGGGAAGTGTATTCAGAAAACAGCCCTTTTGAAGATGTCACCA 959  
234 snProLeuGlnIleMetTyrSerValSerGlnGlyHisArgProValIle 250  
960 ATCCITTCAGATAATGATATAGTGTGTACAGGACATCGACCTGTTATT 1009  
251 AsnGluLeuSerLeuProTyrAspIleProHisArgAlaArgMetIleSe 267  
1010 AATGAAAAGATTTGGCATATGATATACCTACCAGCAGCAGTATGATCTC 1059  
267 rIleLeuGluSerGlyTrpAlaGlnAsnProAspGluArgProSerPheL 284  
1060 TCTAAATAGAAAAGTGGATGGCACAANATCCAGATGAAGACCTCTTCT 1109  
284 euLysCysLeuIleGluLeuGluProValLeuArgThrPheGluGluIle 300  
1110 TAAATGTTTAAATAGAACTTGAACCTTTTGAAGACATTTGAAGAGATA 1159  
301 ThrPheLeuGluAlaValIleGlnLeuLysLysThrLysLeuGlnSerVa 317  
1160 ACTTTTCTTGAAGCTGTTATTCAGCTTAAAGAAAACAAAGTTACAGAGTGT 1209  
317 lSerSerAlaIleHisLeuCysAspLysLysLysMetGluLeuSerLeuA 334  
1210 TTCAAGTGCATTCACCTATGTGACRAGAAAATGGAAATATATCTCTGA 1259

334 snIleProValAsnHisGlyProGlnGluSerCysGlySerSerSerGln 350  
1260 ACATPACCTGTAATTCATGGTCCACAGAGAAATCATGTGGATCTCTCAG 1309  
351 LeuHisGluAsnSerGlySerProGluThrSerArgSerLeuProAlaPr 367  
1310 CTCCTGAAAATAGTGGTTCTCCTCAAACTTCAAGGTCCTCCAGCAGTCC 1359  
367 oGlnAspAsnAspPheLeuSerArgLysAlaGlnAspCysTyrPheMetL 384  
1360 TCAAGACAAATGATTTTTATCTAGAAAAGCTCAAGACTGTTATTTATGA 1409  
384 ysLeuHisHisCysProGlyAsnHisSerTrpAspSerThrIleSerGly 400  
1410 AGCTGCATCCTGCTGGAAATCACAGTTGGGATAGCACCANTTCTGGA 1459  
401 SerGlnArgAlaAlaPheCysAspHisLysThrThrProCysSerSerAl 417  
1460 TCTCAAAGGGCTGCATTTCTGTGATCAACAAGACCACCTCATCTCTCAGC 1509  
417 alleleAsnProLeuSerThrAlaGlyAsnSerGluArgLeuGlnProG 434  
1510 AATAATAATCCACTCACTCACTGAGGAAACTCAGAAGCTGTGCAGCCTG 1559  
434 ylIleAlaGlnGlnTrpIleGlnSerLysArgGluAspIleValAsnGln 450  
1560 GTATAGCCACAGCTGGATCCAGACAAAAGGAAGACATTTGTGAACCAA 1609  
451 MetThrGluAlaCysLeuAsnGlnSerLeuAspAlaLeuLeuSerArgAs 467  
1610 ATGACAGAAGCTGCCTTAACCCAGTCCGTAGATGCCCTTCTGTCCAGGGA 1659  
467 pLeuIleMetLysGluAspTyrGluLeuValSerThrLysProThrArgT 484  
1660 CTTGATCATGAAGAGGACTATGAACCTTGTAGTACCAGGCTACAGGA 1709  
484 hrSerLysValArgGlnLeuLeuAspThrThrAspIleGlnGlyGluGlu 500  
1710 CCTCAAAAAGTCAGACAAATTTACTAGACACTACTGACATCCAAGGAGAAGA 1759  
501 PheAlaLysValIleValGlnLysLeuLysAspAsnLysGlnMetGlyLe 517  
1760 TTTGCCAAAAGTTATAGTACAAAATTTGAAGATACAAAACAAATGGGTCT 1809  
517 uGlnProTyrProGluIleLeuValValSerArgSerProSerLeuAsnL 534  
1810 TCAGCCTTACCAGAAATACCTGTGGTTCTAGATCACCATCTTTAAATT 1859  
534 euLeuGlnAsnLysSerMet 540  
1860 TACTTCAAAAATAAAGCATG 1879

seq\_name: /cgnl\_8/gcgdata/geneseq/geneseq/NA2000.DAT:Z46143

seq\_documentation\_block:

ID Z46143 standard; cDNA; 2024 BP.

XX

AC Z46143;

XX

DT 16-MAY-2000 (first entry)

XX

DE cDNA sequence encoding a human phosphorylation effector PHSP-6.

XX Human; phosphorylation effector; PHSP; proliferative disorder;

KW immune disorder; neuronal disorder; ss.

XX

OS Homo sapiens.

XX

PH Location/Qualifiers

FT CDS

FT /tag= a

FT /product= "phosphorylation effector"

XX WO200006728-A2.  
 XX 10-FEB-2000.  
 XX 28-JUL-1999; 99WO-US171132.  
 XX 28-JUL-1998; 98US-0123494.  
 PR 14-SEP-1998; 98US-0152814.  
 PR 14-OCT-1998; 98US-0173482.  
 PR 03-NOV-1998; 98US-0106889.  
 PR 19-NOV-1998; 98US-0109093.  
 PR 22-DEC-1998; 98US-0113796.  
 PR 12-JAN-1999; 99US-0173482.  
 PR 12-JAN-1999; 99US-0229005.  
 XX (INCY-) INCYTE PHARM INC.  
 XX Hillman JL, Lal P, Tang YT, Corley NC, Guegler KJ, Baughn MR;  
 PI Patterson C, Bandman O, Au-Young J, Gorgone GA, Yue H, Azimzai Y;  
 PI Reddy R, Lu DAM, Shih LL;  
 XX WPI: 2000-183125/16.  
 DR P-PSDB; Y68774.  
 XX

New human phosphorylation effectors useful for the diagnosis, treatment and prevention of proliferative, immune and neuronal disorders  
 PS Claim 9; Page 121-122; 142pp; English.

XX 246138-246168 encode human phosphorylation effectors (PHSP), designated PHSP1-PHSP31 (the protein sequence for PHSP28 is not given in the specification). The sequences were isolated from cDNA libraries prepared from various human tissues. The PHSP proteins are useful for the diagnosis, treatment and prevention of proliferative disorders, immune disorders and neuronal disorders. The PHSP proteins form pharmaceutical compositions which useful for treating or preventing disorders associated with decreased PHSP expression/activity. PHSP antagonists are useful for treating or preventing disorders associated with increased PHSP expression/activity.  
 XX Sequence 2024 BP; 612 A; 445 C; 434 G; 533 T; 0 other;

alignment\_scores:  
 Quality: 2823.00 Length: 540  
 Ratio: 5.228 Gaps: 0  
 Percent Similarity: 100.000 Percent Identity: 99.815

alignment\_block:  
 US-09-445-223-1 x Z46143 ..  
 Align seg 1/1 to: Z46143 from: 1 to: 2024

1 MetAsnGlyGluAlaIleCysSerAlaLeuProThrIleProFyrHisLy 17  
 203 ATCAACGGGGAGGCCATCTGCAGCCCTGCCACCATTCCCTACACCAA 252  
 17 sLeuAlaAspLeuArgTyrLeuSerArgGlyAlaSerGlyThrValSer 34  
 253 ACTCCGGCCAGCTCGCTTACCTGAGCCGGCGCCCTCTGGCCACTGTGCT 302  
 34 exAlaArgHisAlaAspTppArgValGlnValAlaValLysHisLeuHis 50  
 303 CGCCCGCCACCGGACTGGCGGCTCCAGGTGGCCGTGAGACACCTGCAC 352  
 51 IleHisThrProLeuLeuAspSerGluArgLysAspValLeuArgGluAl 67  
 353 ATCCACACTCCGCTGCTGCACAGTGAAGAAGGATGCTTTAAGAGAAGC 402  
 67 aGluIleLeuHisLysAlaArgPheSerTyrIlePheProIleLeuGlyI 84  
 403 TGAATTTTACACAAAGCTAGATTTAGTTACATTTCTCCAAATTTGGGAA 452

84 leCysAsnGluProGluPheLeuGlyIleValThrGluTyrMetProAsn 100  
 453 TTTGCARTGAGCCTGAATTTTGGGAATAGTACTGAATACATGCCCAAT 502  
 101 GlySerLeuAsnGluLeuHisArgLysThrGluTyrProAspValAl 117  
 503 GGATCATTAATGAATCCTACATAGAAAACCTGAATATCCTGATGTGC 552  
 117 aTrpProLeuArgPheArgIleLeuHisGluIleAlaLeuGlyValAsn 134  
 553 TTGGCCATTTGAGATTTCCGATCCTCGATGAATTTGCCCTTGGTGAAT 602  
 134 yrLeuHisAsnMetThrProProLeuLeuHisAspLeuLysThrGln 150  
 603 ACCTGCACAATATGACTCCTCCTTACTTTCATCATGACTTGAAGACTCAG 652  
 151 AsnIleLeuLeuAspAsnGluPheHisValLysIleAlaAspPheGlyLe 167  
 653 AATATCTTATTTGGACAATGAATTTTCATGTTAAGATTTGCAGATTTGGTT 702  
 167 uSerLysTppArgMetSerLeuSerGlnSerArgSerLysSerA 184  
 703 ATCAAAGTGGCCGCTGATGTCCTCTCACAGTCCGAAAGTAGCAAAATCTG 752  
 184 laProGluGlyThrIleIleIleIleIleIleIleIleIleIleIleIle 200  
 753 CACCAGAGGAGGACAAATTTATCTATATGCCACCTGAAAACACTATGAACCT 802  
 201 GlyGlnLysSerArgAlaSerIleLysHisAspIleIleIleIleIleIle 217  
 803 GGACAAAATCAAGGGCCAGTATCAAGCAGATATATATAGCTATGCGAGT 852  
 217 lIleThrTrpGluValLeuSerArgLysGlnProPheGluAspValThr 234  
 853 TATCACATGGGAAGTGTATCCAGAAAACAGCCCTTTTGAAGATGTCCACCA 902  
 234 snProLeuGlnIleMetTyrSerValSerGlnGlyHisArgProValIle 250  
 903 ATCCTTTGCAGATAATGATAGTGTGTCCACAAGGACATCGACCTGTTATT 952  
 251 AsnGluLeuSerLeuProTyrAspIleProHisArgAlaArgMetIleSe 267  
 953 AATGAAGAAAAGTTTGGCCATATGATATACCTCACCCGAGCAGCTATGATCTC 1002  
 267 rLeuIleGluSerGlyTrpAlaGlnAsnProAspGluArgProSerPheL 284  
 1003 TCTAATAGAAAAGTGGATGGCCACAAAATCCAGATGAAGACCAATCTTCT 1052  
 284 eulysCysLeuIleGluLeuGluProValLeuArgThrPheGluGluIle 300  
 1053 TAAATGTTTTAATAGAACCTTGACCACTTTTGAGACATTTGAAGAGATA 1102  
 301 ThrPheLeuGluAlaValIleGlnLeuLysLysThrLysLeuGlnSerVa 317  
 1103 ACTTTTCTTGAAGCTGTTATTCAGCTAAAGAAAACAAAAGTTACAGAGTGT 1152  
 317 lSerSerAlaIleHisLeuCysAspLysLysLysMetGluLeuSerLeuA 334  
 1153 TTCAGTGCCATTCACCTATGTGACAAGAAAATGGAATTTATCTCTGA 1202  
 334 snIleProValAsnHisGlyProGlnGluSerCysGlySerSerGln 350  
 1203 ACATACCTGTAATATGTTCCACAGAGGAAATCATGTGGATCTCTCTCAG 1252  
 351 LeuHisGluAsnSerGlySerProGluThrSerArgSerLeuProAlaPr 367  
 1253 CTCATGAAAATAGTGGTCTCTCTGAAAACCTCAAGGTCCTCCCTGCCACTCC 1302  
 367 oGlnAspAsnAspPheLeuSerArgLysAlaGlnAspCysTyrPheMetL 384  
 1303 TCAAGACAATGATTTTTTATCTAGAAAAGCTCAAGACTGTTATTTATGTA 1352

384 ysLeuHisHsCysProGlyAsnHisSerTrpAspSerThrIleSerGly 400  
 |||  
 1353 AGCTGCATCACTGCTCCGGAAATCACAGTTGGATAGACACCATTTCTGGA 1402  
 |||  
 401 serGlnArgAlaAlaPheCysAspHisLysThrProCysSerSerAl 417  
 |||  
 1403 TCTCAAAGGGCTGCTATTCTGTGATCACAAGACCACCTCATGCTTCTCAGC 1452  
 |||  
 417 alleIleAsnProLeuSerThrAlaGlyAsnSerGluArgLeuGlnProG 434  
 |||  
 1453 AATAATAATCCACTCTCAACTGCAGGAAACTCAGAACGCTGCAGGCTG 1502  
 |||  
 434 lyIleAlaGlnGlnTrpIleGlnSerLysArgGluAspIleValAsnGln 450  
 |||  
 1503 GTATAGCCACGACTGATCCAGAGCAAAAGGGNAGACATTTGCAACCA 1552  
 |||  
 451 MetThrGluAlaCysLeuAsnGlnSerLeuAspAlaLeuLeuSerArgAs 467  
 |||  
 1553 ATGACAGAAGCTGCCTTAACCCAGTCGTAGATGCCCTTCTGCCAGGGA 1602  
 |||  
 467 pLeuIleMetLysGluAspTyrGluLeuValSerThrLysProThrArgT 484  
 |||  
 1603 CTTGATCATGAAAGAGGACTATGAACTTTGTTAGTACCACCAAGCCTACAAGGA 1652  
 |||  
 484 hrSerLysValArgGlnLeuLeuAspThrAspIleGlnGlyGluGlu 500  
 |||  
 1653 CCTCAAAGTCCAGCAATTAAGTACTAGACTACTGACATCCAAAGGAGAA 1702  
 |||  
 501 PheAlaLysValIleValGlnLysLeuLysAspAsnLysGlnMetGlyLe 517  
 |||  
 1703 TTTGCCAAAGTATAGTACAAAATTGAAAGATAACAAACAAATGGGTCT 1752  
 |||  
 517 uGlnProTyrProGluIleLeuValValSerArgSerProSerLeuAsnL 534  
 |||  
 1753 TCAGCCTTACCCGGAAATACATTTGGTTCTTAGATCACCATCTTTAAATT 1802  
 |||

534 euLeuGlnAsnLysSerMet 540  
 |||  
 1803 TACTTCAAATTAAGCATG 1822

seq\_name: /cgn1\_8/gcgdata/geneseq/geneseq/NA2000.DAT:C77779

seq\_documentation\_block:  
 ID C77779 standard; cDNA; 2709 BP.

AC C77779;  
 XX  
 XX  
 DT 08-FEB-2001 (first entry)  
 XX  
 XX Human cancer associated gene sequence SEQ ID NO:173.  
 DE  
 XX Human; cancer associated gene; cancer antigen; detection; cancer;  
 KW diagnosis; cytostatic; proliferative; vulnery; immunomodulator;  
 KW antidiabetic; antiasthmatic; antirheumatic; antiarthritic; antiviral;  
 KW antiinflammatory; antithyroid; antiallergic; antibacterial; cardiac;  
 KW dermatological; neuroprotective; thrombolytic; coagulant; neutropic;  
 KW vasotropic; antipsoriatic; antiangiogenic; gene therapy; inflammation;  
 KW immune disorder; haematopoietic cell disorder; autoimmune disorder;  
 KW allergic reaction; graft versus host disease; organ rejection;  
 KW haemostatic; thrombolytic; cardiovascular disorder; infection;  
 KW neurological disease; drug screening; ss.  
 XX  
 OS Homo sapiens.  
 XX  
 XX WO200055350-A1.  
 PN  
 XX  
 PD 21-SEP-2000.  
 XX  
 XX 08-MAR-2000; 2000WO-US05882.  
 XX  
 XX 12-MAR-1999; 99US-0124270.  
 XX  
 XX (HUMA-) HUMAN GENOME SCI INC.  
 PA

XX Rosen CA, Ruben SM;  
 XX WPI; 2000-587533/55.  
 DR P-PSDB; B43570.  
 XX  
 XX Novel isolated nucleic acids comprising sequences encoding peptides  
 XX useful for treating or diagnosing e.g. cancer -  
 XX  
 XX Claim 1; Page 751-752; 2352pp; English.  
 XX  
 CC C77607 to C78448 encode the human cancer associated proteins given in  
 CC B43398 to B44239. The proteins can have activities based on the tissues  
 CC and cells the genes are expressed in. Example of activities include:  
 CC cytostatic; proliferative; vulnery; immunomodulator; antidiabetic;  
 CC antiasthmatic; antirheumatic; antiarthritic; antiinflammatory;  
 CC antithyroid; antiallergic; antibacterial; antiviral; dermatological;  
 CC neuroprotective; cardiac; thrombolytic; coagulant; neutropic;  
 CC vasotropic; antipsoriatic and antiangiogenic. The polynucleotides and  
 CC polypeptides can be used for preventing, treating or ameliorating medical  
 CC conditions and diagnosing pathological conditions. Polynucleotides,  
 CC polypeptides, antibodies, agonists and antagonists from the present  
 CC invention may be used to treat immune disorders by activating or  
 CC inhibiting the proliferation, differentiation or mobilisation of immune  
 CC cells, to treat disorders of haematopoietic cells, autoimmune disorders,  
 CC allergic reactions, graft versus host disease and organ rejection,  
 CC modulate haemostatic or thrombolytic activity, modulate inflammation,  
 CC cancers, cardiovascular disorders, neurological disease and bacterial or  
 CC viral infections. The peptides, nucleotides, antibodies, agonists and  
 CC antagonists may be also be used in drug screens. C78449 to C78457 and  
 CC B44240 represent sequences used in the exemplification of the present  
 CC invention.  
 XX  
 SQ Sequence 2709 BP; 810 A; 580 C; 540 G; 769 T; 10 other;

alignment\_scores:  
 Quality: 2823.00 Length: 540  
 Ratio: 5.228 Gaps: 0  
 Percent similarity: 100.000 Percent Identity: 99.815

alignment\_block:  
 US-09-445-223-1 x C77779

Align seg 1/1 to: C77779 from: 1 to: 2709

1 MetAsnGlyGluAlaIleCysSerAlaLeuProThrIleProFyrHisLys 17  
 |||  
 267 ATGAACGGGGAGGCCATCTGCAGCGCCCTGCCACCATTCCCTACCACAA 316  
 |||  
 17 sLeuAlaAspLeuArgTyrLeuSerArgGlyAlaSerGlyThrValSerS 34  
 |||  
 317 ACTCGCCGACCTGGCTACCTAGACCGCCGGCGCTCTGGCACCCTGTGCTG 366  
 |||  
 34 erAlaArgHisAlaAspTyrArgValGlnValAlaValLysHisLeuHis 50  
 |||  
 367 CCGCCCGCCACGACACTGGCCGCTCCAGGTGGCCGTGAAGCACCCTGCAC 416  
 |||  
 51 IleHisThrProLeuLeuAspSerGluArgLysAspValLeuArgGluAl 67  
 |||  
 417 ATCCACACTCCGCTGCTCGACAGTGAAGAAAGGATGCTTAAGAGAAGC 466  
 |||  
 67 aGluIleLeuHisLysAlaArgPheSerTyrIlePheProIleLeuGlyI 84  
 |||  
 467 TGAATTTTACACAAAGCTAGATTTAGTTACATTTCTTCCAAATTTGGGAA 516  
 |||  
 84 LeCysAsnGluProGluPheLeuGlyIleValThrGluTyrMetProAsn 100  
 |||  
 517 TTTGCATGACCCCTGAATTTTGGGAATAGTTACTGAATACATGCCAAAT 566  
 |||  
 101 GlySerLeuAsnGluLeuLeuHisArgLysThrGluTyrProAspValAl 117  
 |||  
 567 GGATCAATTAATGAATCCTACATAGGAAAACACTGAATATCCTGATGTTC 616  
 |||



117 atrpProLeuAArgPheArgIleLeuHISGluIleAlaLeuGlyValAsnT 134  
|||||  
617 TTGGCCATTGAGATTCCGATCCGATCGATAAATGGCCCTTGGTGAAT 666  
|||||  
134 yLeuHISasnMetThrProProLeuLeuHISAspLeuLysThrGln 150  
|||||  
667 ACCTGCACAATATGACTCCCTCTTACTTCAATGACTGATGAAGACT 716  
|||||  
151 AsnIleLeuLeuAspAsnGluPheHISValLysIleAlaAspPheGly 167  
|||||  
717 AATATCTTATTGACAAATGAAATTCATGTTAAGATTGCAGATTGGTT 766  
|||||  
167 uSerLysTrpArgMetMetSerLeuSerGlnSerArgSerLysSerA 184  
|||||  
767 ATCAAAGTGGCCGATGATGCTCTCCCTCACAGTCAAGTACGAATCT 816  
|||||  
184 laProGluGlyThrIleIleTyMetProGluAsnTyrGluPro 200  
|||||  
817 CACCAAGAGGAGCAATATATATATATATATATATATATATATAT 866  
|||||  
201 GlyGlnLysSerArgAlaSerIleLysHISAspIleTyrSerTyrAla 217  
|||||  
867 GGACAAAATCAAGGCCAGTATACAGCAGATATATATATATATATAT 916  
|||||  
217 IileThrTrpGluValLeuSerArgLysGlnProPheGluAspValThr 234  
|||||  
917 TATCATGGAAGTGTATCCAGAAAACAGCCCTTTTGAAGTGTCAACA 966  
|||||  
234 snProLeuGlnIleMetTyrSerValSerGlnGlyHisArgProVal 250  
|||||  
967 ATCCTTTCGAGATAATGATAGTGTGTCAAGAGCATCGACCTGTATT 1016  
|||||  
251 AsnGluGluSerLeuProTyrAspIleProHISArgAlaArgMetIle 267  
|||||  
1017 AATGAAAGATGTTGCCATATGATATACCTCACCGAGCAGTATGAT 1066  
|||||  
267 rLeuLeuGluSerGlyTTPAlaGlnAsnProAspGluArgProSerPhe 284  
|||||  
1067 TCTAATAGAAAGTGGATGGCCAAAATCCAGATGAAGACCCTTTCTCT 1116  
|||||  
284 euLysCysLeuIleGluLeuGluProValLeuArgThrPheGluGlu 300  
|||||  
1117 TAAATGTTTAAATAGAACATGAACCACTTTTGGAAATTTGAAGAGA 1166  
|||||  
301 ThrPheLeuGluAlaValIleGlnLeuLysTyrThrLysLeuGlnSer 317  
|||||  
1167 ACTTTCTTGAAGCTGTATTCAGCTAAACAACAAAGTTACAGAGTGT 1216  
|||||  
317 lSerSerAlaIleHISLeuCysAspLysLysMetGluLeuSerLeuA 334  
|||||  
1217 TACAAGTGCCATTCACCTATGTGACAAGAAAGAAATGGAATATCTCT 1266  
|||||  
334 snIleProValAsnHISGlyProGlnGluSerCysGlySerSerGln 350  
|||||  
1267 ACTACTCTTAATCATGTTCCACRAGAGGAATCATGTGGATCCCTCT 1316  
|||||  
351 LeuHISGluAsnSerGlySerProGluThrSerArgSerLeuProAla 367  
|||||  
1317 CTCCATGAAAATAGTGGTCTCCCTGAAACTTCAAGTCCCTGCCAGCT 1366  
|||||  
367 oGlnAspAsnAspPheLeuSerArgLysAlaGlnAspCysTyrPheMet 384  
|||||  
1367 TCAAGACAATGATTTTTATCTAGAAAAGCTCAAGACTGTTATTTATGA 1416  
|||||  
384 yLeuHISHisCysProGlyAsnHISerTrpAspSerThrIleSerGly 400  
|||||  
1417 AGCTCATCACCTGCTGGAAATCAGATGGGAYAGCACCATTCTGGA 1466  
|||||  
401 SerGlnArgAlaAlaPheCysAspHISLysThrThrProCysSerSer 417  
|||||  
1467 TCTCAAAGGGCTTCATCTCTGATCACAAAGACCCTCAATGCTCTTCAG 1516  
|||||

417 alleleAsnProLeuSerThrAlaGlyAsnSerGluArgLeuGlnProG 434  
|||||  
1517 AATAATAAATCCACTCTCAACTGCAGAAACTCAGAACGCTGCAGCCT 1566  
|||||  
434 yIleAlaGlnGlnTrpIleGlnSerLysArgGluAspIleValAsnGln 450  
|||||  
1567 GTATAGCCAGCAGTGGATCCAGACAAAAGGAGAGACATTTGTAAAC 1616  
|||||  
451 MetThrGluAlaCysLeuAsnGlnSerLeuSerLeuAspAlaLeuSer 467  
|||||  
1617 ATGACAGAAGCCCTGCCTTAACCAAGTCGTAGATGCCCCTTGTGCCAG 1666  
|||||  
467 pLeuIleMetLysGluAspTyrGluLeuValSerThrLysProThrArg 484  
|||||  
1667 CTTGATCATGAAAGAGACTATGACTTTGTAGTACCACCAAGCCTACA 1716  
|||||  
484 hrSerLysValArgGlnLeuLeuAspThrThrAspIleGlnGlyGlu 500  
|||||  
1717 CCTCAAAAGTCAGACAATTTACTAGACACTACTGACATCCAAAGGAGA 1766  
|||||  
501 PheAlaLysValIleValGlnLysLeuLysAspAsnLysGlnMetGly 517  
|||||  
1767 TTGCCCAGAGTTATAGTACAAAATTTGAAGATAACAAAATAATGGGTCT 1816  
|||||  
517 uGlnProTyrProGluIleLeuValSerArgSerProSerLeuAsnL 534  
|||||  
1817 TCAGCCTTACCAGAAATACTTGTGGTTCTAGATCACCACCTTTAAAT 1866  
|||||  
534 euLeuGlnAsnLysSerMet 540  
|||||  
1867 TACTTCAAAAATAAAGCATG 1886  
|||||

seq\_name: /cgnl\_8/gcgdata/geneseq/geneseq/NA1999.DAT:Z09246

seq\_documentation\_block:

ID Z09246 standard; cDNA; 1931 BP.

XX Z09246;

XX AC

XX DT 25-Oct-1999 (first entry)

XX Human CARD-3 cDNA.

XX CARD-3; caspase recruitment domain; CARD-4; regulation; detection;

KW caspase activation; detection; screening; therapy; diagnosis; disease;

KW apoptotic cell death; Fas/APO-1 receptor complex; TNF receptor complex;

KW cancer; follicular lymphoma; carcinoma; p53 mutation; viral infection;

KW hormone-dependent tumour; autoimmune disorder; Alzheimer's disease;

KW systemic lupus erythematosus; immune-mediated glomerulonephritis; stroke;

KW Parkinson's disease; amyotrophic lateral sclerosis; retinitis pigmentosa;

KW spinal muscular dystrophy; cerebellar degeneration; anaemia; drug;

KW myelodysplastic syndrome; myocardial infarction; cell proliferation;

KW cell differentiation; cell survival; CARD-4L; CARD-4S; CARD-4Y;

KW CARD-4Z; human; ds.

XX Homo sapiens.

XX Key Location/Qualifiers

FT CDS 214..1836

FT /\*\*tag= a

FT /product= "CARD-3"

XX W09940102-A1.

XX 12-AUG-1999.

XX 05-FEB-1999; 99WO-US02544.

XX 08-DEC-1998; 98US-0207359.

XX 06-FEB-1998; 98US-0019942.

XX 17-JUN-1998; 98US-0099041.

XX (MILL-) MILLENNIUM PHARM INC.

XX PA

101 GlySerLeuAsnGluLeuLeuHisArgLysThrGluTyrProAspValAl 117  
 514 GGATCATTAAGTGAACCTCTACATAGGAAACTGAATATCCCTGATGTTC 563  
 117 atpProLeuArgPheArgLysLeuHisGluLeuAlaLeuGlyValAsnT 134  
 564 TTGGCCATTGAGATTCCTGATCCCTGCATGAATTGCCCTTGCTGTAAT 613  
 134 yrLeuHisAsnMetThrProLeuLeuHisHisAspLeuLysThrGln 150  
 614 ACCTGCACAAATATGACTCCCTTTACTTCATCATCATGACTTGAAGACTCAG 663  
 151 AspIleLeuLeuAspAsnGluPheHisValLysIleAlaAspPheGlyLe 167  
 664 AATATCTTATGGCAACTGAAATTTCATGTTAAGATTGCAGATTTGGT 713  
 167 userLysTyrArgMetMetSerLeuSerGlnSerArgSerLysSerA 184  
 714 ATCAAAAGTGGCCAGTATGTCCCTCTCACAGTCCAGAACTAGCAAAATCTG 763  
 184 lAprGluGlyGlyThrIleIleTyrMetProProGluAsnTyrGluPro 200  
 764 CACGAAAGGAGGACAAATTCCTATATGGCCCTGAAAACCTATGAACT 813  
 201 GlyGlnLysSerArgAlaSerIleLysHisAspIleTyrSerTyrAlaVa 217  
 814 GGACAAAATCAAGGCCAGTATCAAGCAGGATATATATAGCTATGCGAGT 863  
 217 lIleThrTrpGluValLeuSerArgLysGlnProPheGluAspValThra 234  
 864 TATCACATGGGAAGTGTATTCAGAAAACAGCCCTTTGAAAGATGTCACCA 913  
 234 snProLeuGlnIleMetTyrSerValSerGlnGlyHisArgProValIle 250  
 914 ATCCTTTGCAGATAAGTATAGTGTGTCCAGCAGGACATCCAGCCTGTATT 963  
 251 AsnGluGluSerLeuProTyrAspIleProHisArgAlaArgMetIleSe 267  
 964 AATGAAGAAAAGTTGCCATATGATATACCTCACCAGCAGCATGATGATCT 1013  
 267 rLeuIleGluSerGlyTrpAlaGlnAsnProAspGluArgProSerPheL 284  
 1014 TCATAATAGAAAAGTGGATGGGCACAAAATCCAGATGAAAAGACCAATCT 1063  
 284 euLysCysLeuIleGluLeuProValLeuArgThrPheGluGluIle 300  
 1064 TAAATGTTTTAGAAACTTGACCCAGTTTGAGAACATTTGAAGAGATA 1113  
 301 ThrPheLeuGluAlaValIleGlnLeuLysLysThrLysLeuGlnSerVa 317  
 1114 ACTTTTCTTGAAGCTGTATTTCAGTAAAGAAAACAATAAGTTACAGAGTGT 1163  
 317 lserSerAlaIleHisLeuCysAspLysLysMetGluLeuSerLeuA 334  
 1164 TTCAGTGGCCATCACCTATGTGACAAAGAAAATAAGTATATCTCTGA 1213  
 334 snIleProValAsnHisGlyProGlnGluSerCysGlySerSerGln 350  
 1214 ACATACCTGTAAATCATGGTCCACAGAGAAATCATGTTGGATCCTCTCAG 1263  
 351 LeuHisGluAsnSerGlySerProGluThrSerArgSerLeuProAlaPr 367  
 1264 CTCATGAAAATAGTGGTTCTCTGAAAACCTCAAGGTCCTGCCAGCTCC 1313  
 367 oGlnAspAsnAspPheLeuSerArgLysAlaGlnAspCystTyrPheMetL 384  
 1314 TCAAGACAAATGATTTTCTATAGAAAGCTCAAGACTGTTATTTATGA 1363  
 384 ysLeuHisHisCysProGlyAsnHisSerTrpAspSerThrIleSerGly 400

Bertin J;  
 WPI: 1999-494269/41.  
 P-PSDB; Y31140.  
 Novel CARD-3 and CARD-4 genes and polypeptides used or treating  
 regulation of cellular proliferation and differentiation and cell  
 survival  
 Example 2; Fig 1; 18ipp; English.  
 This invention describes the isolation of novel human caspase  
 recruitment domain, CARD-3 and CARD-4 polynucleotides and proteins and a  
 partial murine CARD-4i protein and genes. The genes and proteins of  
 the invention are involved in the regulation of caspase activation.  
 The caspase recruitment domain (CARD) polynucleotides, polypeptides,  
 homologues and antibodies can be used in screening assays, detection  
 assays, predictive medicine and therapeutic and prophylactic methods of  
 treatment. The methods may be used to diagnose and treat patients which  
 are suffering from a disorder associated with abnormal level or rate of  
 apoptotic cell death, abnormal activity of the Fas/Apo-1 receptor  
 complex, abnormal activity of the TNF receptor complex, or abnormal  
 activity of a caspase. Diseases that may be treated include cancer  
 (particularly follicular lymphoma, carcinomas associated with mutations  
 in p53 and hormone-dependent tumours), autoimmune disorders (e.g.  
 systemic lupus erythematosus, immune-mediated glomerulonephritis), viral  
 infections, Alzheimer's disease, Parkinson's disease, amyotrophic lateral  
 sclerosis, retinitis pigmentosa, spinal muscular dystrophy, cerebellar  
 degeneration, anaemia, myelodysplastic syndrome, myocardial infarction,  
 and stroke. CARD-3 protein interacts with other cellular proteins, and so  
 can be used for regulation of cellular proliferation and differentiation  
 and cell survival. The CARD proteins may also be used to for screen drugs  
 or compounds which modulate their activity. The CARD-4 gene can express a  
 long transcript that encodes CARD-4L, a short transcript that encodes  
 CARD-4S or two CARD-4 splice variants, CARD-4y and CARD-4z. This sequence  
 encodes the human CARD-3 protein described in the method of the  
 invention.

Sequence 1931 BP; 613 A; 429 C; 416 G; 473 T; 0 other;  
 alignment\_scores:  
 Quality: 2817.00 Length: 540  
 Ratio: 5.226 Gaps: 0  
 Percent Similarity: 99.815 Percent Identity: 99.630

alignment\_block:  
 US-09-445-223-1 x 209246 ..  
 Align seg 1/1 to: 209246 from: 1 to: 1931

1 MetAsnGlyGluAlaIleCysSerAlaLeuProThrIleProTyrHisLy 17  
 |||||  
 214 AFGAAGGGAGGAGCCTACTGAGGCGCCCTGCCACCATTCCCTACCACAA 263

17 sLeuAlaAspLeuArgTyrLeuSerArgGlyAlaSerGlyThrValSerS 34  
 |||||  
 264 ACTGCCGACCTGGCCTACTTGAGCGGGCCCTCTGCCACTGTGTCGT 313

34 erAlaArgHisAlaAspTrpArgValGlnValAlaValLysHisLeuHis 50  
 |||||  
 314 CCGCCCGCCACGACACTGGCCGCTCCAGTGGCCGTTGAAGACCTGCAC 363

51 lleHisLThrProLeuLeuAspSerGluArgLysAspValLeuArgGluAl 67  
 |||||  
 364 ATCCACACTCCGCTGCTGCACAGTGAAGGATGCTTAAGAGRAGC 413

67 agLulleLeuHisLysAlaArgPheSerTyrIlePheProIleLeuGlyI 84  
 |||||  
 414 TGAATTTTACACAAAAGCTAGATTTAGTACATTTCTCCAATTTGGGAA 463

84 leCysAsnGluProGluPheLeuGlyIleValThrGluTyrMetProAsn 100

1364 AGCTGCATCACTCTCTCGAAATACACAGTTGGATAGCACCACCTTTCTGGA 1413  
 401 SerGlnArgAlaAlaPheCysAspHisLysThrProCysSerSerAl 417  
 1414 TCTCAAGGGCTGCAATCTGTGATCAAGACCAATTCATGCTCTTCAGC 1463  
 417 alleLeAsnProLeuSerThrAlaGlyAsnSerGluArgLeuGlnProG 434  
 1464 AATAATAAATCCACTCTCAACTGCAGGAAACTCAGAACCTCTGCAGCCG 1513  
 434 lylleAlaGlnTrpIleGlnSerLysArgGluAspIleValAsnGln 450  
 1514 GTATAGCCAGAGTGGATCCAGAGCAAAAGGAGACATTTGTGAACCAA 1563  
 451 MetThrGluAlaCysLeuAsnGlnSerLeuAspAlaLeuSerArgAs 467  
 1564 ARGACAGAAGCTGCTTAAACCAAGTCGCTTAGATGCCCTTCTGTCCAGGGA 1613  
 467 pleuIleMetLysGluAspTyrGluLeuValSerThrLysProThrArg 484  
 1614 CTTGATCATGAAAGAGGACTATGAATCTTAGTACCAGCCTTACAAGGA 1663  
 484 hrSerLysValArgGlnLeuLeuAspThrThrAspIleGlnGlyGlu 500  
 1664 CTTCAAAAGTCAGCAATTTACTAGACACTACTGACATCCCAAGGAGAAGA 1713  
 501 PheAlaLysValIleValGlnLysLeuLysAspAsnLysGlnMetGlyLe 517  
 1714 TTTGCCAAAGTTATAGTACAAAATTTGAAAGATACAAACAATGGGCTCT 1763  
 517 uGlnProTyrProGluIleLeuValValSerArgSerProSerLeuAsnL 534  
 1764 TCAGCCTTACCAGGAAATCTTGTGGTTCTAGATCACCATCTTTAAAT 1813  
 534 euLeuGlnAsnLysSerMet 540  
 1814 TACTTCAAAATAAAGCAATG 1833

seq\_name: /cgnl\_8/gcgdata/geneseq/geneseq/NA2000.DAT:248762

seq\_documentation\_block:

ID 248762 standard; CDNA; 2502 BP.

AC 248762;

DT 21-MAR-2000 (first entry)

XX Human RICK coding sequence.

DE RICK; human; RIP-like interacting CLARP kinase; apoptosis regulator; ARC;  
 KW caspase-8; caspase-10; CD95 signalling; apoptosis signalling pathway;  
 KW CIDE-A; CIDE-B; DREP-1; diagnosis; cell growth; apoptosis dysregulation;  
 KW gene therapy; cardiac disorder; cancer; neurodegenerative disorder; AIDS;  
 KW aplastic anaemia; ischaemic injury; toxin-induced liver disease; ss.

OS Homo sapiens.

XX WO9955134-A2.

XX 04-NOV-1999.

XX 27-APR-1999; 99WO-US09183.

XX 27-APR-1998; 98US-0069023.

XX (UNWI ) UNIV MICHIGAN.

XX Nunez G, Inohara N, Koseki T;

XX WPI; 2000-072163/06.

XX P-PSDB; Y59404.

XX Compositions for identifying apoptosis signalling pathway inhibitors

PT useful for treating diseases -

XX Claim 8; Fig 7b; 93pp; English.

CC This sequence encodes the human RICK (RIP-like interacting CLARP kinase)  
 CC protein of the invention. The RICK protein acts as a positive regulator  
 CC of apoptosis, potentiating apoptosis induced by caspase-8 and caspase-10  
 CC during CD95 signalling. The invention provides methods for identifying  
 CC apoptosis signalling pathway inhibitors and activators, and methods and  
 CC compositions for screening compounds which will modulate the interactions  
 CC of the various compositions identified: ARC, RICK, and the CIDE family of  
 CC activators (CIDE-A, CIDE-B and DREP-1). RICK is useful in screening  
 CC assays for agents, useful in the diagnosis, prognosis or treatment of  
 CC disease associated with excess cell growth and dysregulation of  
 CC apoptosis. Complexes containing RICK and CLARP can be used in drug  
 CC screening assays to identify inhibitor molecules blocking CD95-mediated  
 CC apoptosis. Overexpression of ARC in an in vitro cell system can be used  
 CC to identify inhibitors of the enzymatic activity of caspase-8.  
 CC Identification of ARC-like inhibitory compounds may be useful for gene  
 CC therapy treatment of disease with increased cell death in muscle tissue  
 CC and cardiac disorders. Therapeutic compositions of CIDEs can be used to  
 CC treat e.g. cancer, AIDS, neurodegenerative disorders, aplastic anaemia,  
 CC ischaemic injury, and toxin-induced liver disease. Antirick antibodies  
 CC can be used as reagents for the preparation or affinity chromatography  
 CC media, and for diagnostically measuring RICK levels. A specific inhibitor  
 CC of an essential step in the biochemistry of apoptosis is needed. RICK  
 CC interaction with intracellular factors such as CLARP and FADD appears to  
 CC be essential for apoptosis, inhibitors of RICK binding to intracellular  
 CC apoptosis factors are potential drug candidates.

XX SQ Sequence 2502 BP; 769 A; 535 C; 499 G; 699 T; 0 other;

alignment\_scores:

Quality: 2808.00 Length: 541

Ratio: 5.200 Gaps: 1

Percent Similarity: 99.815 Percent Identity: 99.445

alignment\_block:

US-09-445-223-1 x 248762

Align seg 1/1 to: 248762 from: 1 to: 2502

1 MetAsnGlyGluAlaIleCysSerAla.LeuProThrIleProTyrHisL 17  
 |||||  
 225 ATGAACGGGGAGGCCATCTGCAGCGCCCATGCCACCATTCCCTACCACA 274  
 17 ysLeuAlaAspLeuArgTyrLeuSerArgGlyAlaSerGlyThrValSer 33  
 |||||  
 275 AACTCCCGCAGCTGCCTACCTGAGCGCGCGCTCTGGCAGCTGTGCG 324  
 34 SerAlaArgHisAlaAspTrpArgValGlnValAlaValLysHisLeuH 50  
 |||||  
 325 TCCGCCCGCCACGACGACGCGCGCGCTCCAGGTCGCGCGGCAAGCCCTGCA 374  
 50 sIleHisThrProLeuLeuAspSerGluArgLysAspValLeuArgGluA 67  
 |||||  
 375 CATCCACACTCCGCTCGACAGTGAAGAAGAGGATGCTTAAGAGAAG 424  
 67 laGluIleLeuHisLysAlaArgPheSerTyrIlePheProIleLeuGly 83  
 |||||  
 425 CTGAAATTTTACAAAAGCTAGATTTAGTTACATCTCCAAATTTTGGGA 474  
 84 IleCysAsnGluProGluPheLeuGlyIleValThrGluTyrMetProAs 100  
 |||||  
 475 APTTGCANTGAGCCCTGAATTTTGGGAATAGTTACTGAATACATGCCAAA 524  
 100 nGlySerLeuAsnGluLeuHisArgLysThrGluTyrProAspValA 117  
 |||||  
 525 TGGATCATTAATGAAGACTCCTACATAGGAAACTGAATATCCTCGATGTTG 574  
 117 laTrpProLeuArgPheArgIleLeuHisGluIleAlaLeuGlyValAsn 133  
 |||||

575 CTTGGCCATTGAGATTTCCGCATCCTGCATGAAATGGCCCTGGCTGATAAT 624  
 134 TyrLeuHisAsnMetThrProProLeuLeuHisHisAspLeuLysThrGI 150  
 625 TACCTGCACAATATGACTCTCTCTTACTTCAATCATGACTTGAAGACTCA 674  
 150 nAsnIleLeuLeuAspAsnGluPheHisValLysIleAlaAspPheGlyL 167  
 675 GAATATCTTATGGACAATGAATTCATGTTAAGATGGCAGATTTGGTT 724  
 167 euSerLysTrpArgMetSerLeuSerGlnSerArgSerSerLysSer 183  
 725 TATCAAAAGTGGCGCATGATCGCTCTCACAGTCCAGCAAGTAGCAATCT 774  
 184 AlaProGluGlyThrIleIleTyrMetProProGluAsnTyrGluPr. 200  
 775 GCACCAAGAGGGGCAATATCTATATGCCACCTGAAAACATAAGACC 824  
 200 OGLyGlnLysSerArgAlaSerIleLysHisAspIleTyrSerTyrAlay. 217  
 825 TGGACAAAATCAAGGCCAGTATCAAGCAGCATATATATAGCTATGCAG 874  
 217 alIleThrTrpGluValLeuSerArgLysGlnProPheGluAspValThr 233  
 875 TTATFCATGGAAAGTGTATCCAGAAAACAGCCCTTTTGAAGATGTCACC 924  
 234 AsnProLeuGlnIleMetTyrSerValSerGlnGlyHisArgProValII 250  
 925 AATCCTTTGCAGATTAATGTATGTAGTGTGTCAAGGACATCGACTGTAT 974  
 250 eAsnGluGluSerLeuProTyrAspIleProHisArgAlaArgMetIles 267  
 975 TAATGAAGAAGTTGCCATATGATATACCTCACCAGCAGCATGATGATCT 1024  
 267 erLeuIleGluSerGlyTrpAlaGlnAsnProAspGluArgProSerPhe 283  
 1025 CTCATAGAAAGTGGATGGCCACAAAATCCAGATGAAGACCATCTTTC 1074  
 284 LeuLysCysLeuIleGluLeuGluProValLeuArgThrPheGluGluII 300  
 1075 TTAANAATTTAATGAACTTGAACCACTTTTGAACAATTTGAAGAGAT 1124  
 300 eThrPheLeuGluAlaValIleGlnLeuLysLysThrLysLeuGlnSerV 317  
 1125 AACTTTCTTGAAGCTGTATTCAGCTAAAGAAAACAAGTTACAGAGTG 1174  
 317 alSerSerAlaIleHisLeuCysAspLysLysLysMetGluLeuSerLeu 333  
 1175 TTTCAAGTGCATTCACCTATGTGACRANGAAGAAAATGGAATATCTCTG 1224  
 334 AsnIleProValAsnHisGlyProGlnGluSerCysGlySerSerGI 350  
 1225 AACATACCTGTAATCATGTGTCACAAAGAGAAATCATGTGATCCTCTCA 1274  
 350 nLeuHisGlnAsnSerGlySerProGluThrSerArgSerLeuProAlap 367  
 1275 GCTCCATGAAAATAGTGGTCTCTGAAACTTCAAGGTCCCTGCCAGCTC 1324  
 367 roGlnAspAsnAspPheLeuSerArgLysAlaGlnAspCysTyrPheMet 383  
 1325 CTCRAGACAATGATTTTTATCTAGAAAAGCTCAAGACTGTTATTTATG 1374  
 384 LysLeuHisHisCysProGlyAsnHisSerTrpAspSerThrIleSerGI 400  
 1375 AAGCTGCATCACTCTCTGGAATCACAGTTGGGATAGCACCATTCTGG 1424  
 400 ySerGlnArgAlaAlaPheCysAspHisLysThrThrProCysSerSerA 417  
 1425 TTCAAAAGGGGTGCATTTCTGTGATCAAGACCACCTCCATGCTCTTCAG 1474  
 417 laIleIleAsnProLeuSerThrAlaGlyAsnSerGluArgLeuGlnPro 433  
 1475 CAATAAATAAATCCACTCTCACTGCAGGAAACTCAGAAGCTCTGCAGCCT 1524

434 GlyIleAlaGlnGlnTrpIleGlnSerLysArgGluAspIleValAsnGI 450  
 1525 GGTATACCCACAGCTGGATCCAGACAAAAGGAAAGACATTTGTGAACCA 1574  
 450 nMetThrGluAlaCysLeuAsnGlnSerLeuAspAlaLeuLeuSerArgA 467  
 1575 AATGACAGAAGCCCTGCTTAAACCAGTCCGCTAGATGCCCTTCTGTCACGG 1624  
 467 spLeuIleMetLysGluAspTyrGluLeuValSerThrLysProThrArg 483  
 1625 ACTGTGATCATGAAAGAGGACTATGAACTTGTAGTACCAGCCCTACAAG 1674  
 484 ThrSerLysValArgGlnLeuLeuAspThrThrAspIleGlnGlyGluI 500  
 1675 ACCTCAAAAGTCCAGACAATTACTAGACACTACTGACATCCAAGGAGAAGA 1724  
 500 uPheAlaLysValIleValGlnLysLeuLysAspAsnLysGlnMetGlyL 517  
 1725 ATTTGGCAAAGTTATAGTACAAAAAATTTGAAAGATAACAACAATAATGGTTC 1774  
 517 euGlnProTyrProGluIleLeuValValSerArgSerProSerLeuAsn 533  
 1775 TTCAGCCTTACCCTGGAATACTTGTGTTCTAGATCACCATCTTTAAT 1824  
 534 LeuLeuGlnAsnLysSerMet 540  
 1825 TTACTTCARAAATAAAAGCATG 1845

seq\_name: /cgnl\_8/gcgdata/geneseq/geneseq/Na2000.DAT:F21841

seq\_documentation\_block:

ID F21841 standard; DNA; 463 bp.

XX AC F21841;

XX DT 27-MAR-2001 (first entry)

XX DE Human breast and ovarian cancer associated antigen gene SEQ ID 228.

XX KW Human; breast cancer; ovarian cancer; cytostatic; immunosuppressive;  
 KW neotropic; neuroprotective; antiviral; antiangiogenic; hepatotropic;  
 KW antiabietic; antiinflammatory; antiulcer; vulnery; anticonvulsant;  
 KW antibacterial; antifungal; antiparasitic; cardiant; immune disorder;  
 KW Addison's disease; allergy; autoimmune haemolytic anaemia;  
 KW autoimmune thyroiditis; diabetes mellitus; Crohn's disease;  
 KW multiple sclerosis; rheumatoid arthritis; ulcerative colitis;  
 KW cardiovascular disorder; wound healing; neurological disease; ds.

XX OS Homo sapiens.

XX PN WO200055173-A1.

XX PD 21-SEP-2000.

XX PF 08-MAR-2000; 2000WO-US05881.

XX PR 12-MAR-1999; 99US-0124270.

XX PA (HUMA-) HUMAN GENOME SCI INC.

XX PI Rosen CA, Ruben SM;

XX DR WPI; 2000-611515/58.

XX DR P-PSDB; B58938.

XX PT New human breast and ovarian cancer associated gene sequences and the

XX PT polypeptides encoded by these genes, useful in the prevention,

XX PT treatment and diagnosis of cancer, immune disorders, cardiovascular

XX PT disorders and neurological diseases -

XX PS Claim 1; Page 653; 1299pp; English.

CC Sequences F21614 - F22031 represent DNA sequences encoding human proteins  
 CC B58711 - B59128. The DNA and protein sequences are associated with  
 CC breast and ovarian cancer. Included in the invention are sequences  
 CC F2032 - F22040 and B59129 which are used in the isolation and  
 CC characterisation of the DNA and protein sequences of the invention. The  
 CC breast and ovarian cancer associated DNA, protein, agonist or antagonist  
 CC sequences exhibit cytostatic; immunosuppressive; neurotropic;  
 CC neuroprotective; antiviral; anti-allergic; hepatotropic; antidiabetic;  
 CC anti-inflammatory; anti-ulcer; vulnery; anticonvulsant; antibacterial;  
 CC antifungal; antiparasitic and cardiant activity. The polynucleotide and  
 CC protein sequences are used in the diagnosis of cancer, particularly  
 CC breast and ovarian cancer. The nucleic acid sequences, proteins, agonists  
 CC and agonists may also be used in the diagnosis, prevention and treatment  
 CC of immune disorders e.g. Addison's disease, allergies, autoimmune  
 CC haemolytic anaemia, autoimmune thyroiditis, diabetes mellitus, Crohn's  
 CC disease, multiple sclerosis, rheumatoid arthritis and ulcerative colitis;  
 CC cardiovascular disorders such as myocardial ischaemias; wound healing;  
 CC neurological diseases such as cerebral anoxia and epilepsy; and  
 CC infectious diseases.  
 XX  
 SQ Sequence 463 BP; 150 A; 92 C; 89 G; 131 T; 1 other;

alignment\_scores:  
 Quality: 797.00 Length: 150  
 Ratio: 5.349 Gaps: 0  
 Percent Similarity: 99.333 Percent Identity: 99.333

alignment\_block:

US-09-445-223-1 x F21841

Align seg 1/1 to: F21841 from: 1 to: 463

97 TYRMetProAsnGlySerLeuAsnGluLeuLeuHisArgLysThrGluTy 113  
 |||||  
 3 TACATGCCRAATGGATCAATTAATGAACCTCTACATAGGAAACTGNATA 52  
 |||||  
 113 rProAspValAlaTrpProLeuArgPheArgIleLeuHisGluIleAlaL 130  
 |||||  
 53 TCCTGATGTTGCTGGCCATFGATGATTCGCATCCTGCATGAATTCGCC 102  
 |||||  
 130 euGlyValAsnTyrLeuHisAsnMetThrProProLeuLeuHisHisAsp 146  
 |||||  
 103 TTGGTGTAAATTAACCTGCACAAATATGACTCCTCTTTTACATCATGAC 152  
 |||||  
 147 LeuLysThrGlnAsnIleLeuLeuAspAsnGluPheHisValLysIleAl 163  
 |||||  
 153 TTGAGACTCAGATATCTATTATGGACAATGAATTCATGTTAGATTGC 202  
 |||||  
 163 aAspPheGlyLeuSerLysTrpArgMetMetSerLeuSerGlnSerArgS 180  
 |||||  
 203 AGATTTTGGTTTATCAAGTGGCCGATGATGTCCTCTCACAGTCACGAA 252  
 |||||  
 180 erSerLysSerAlaProGluGlyThrIleIleIleIleIleIleIleIle 196  
 |||||  
 253 GTAGCAAAATTCGACCAAGAGGAGGACAAATTAATCTATATGCCACCTGAA 302  
 |||||  
 197 AsnTyrGluProGlyGlnLysSerArgAlaSerIleLysHisAspIleTy 213  
 |||||  
 303 AACTATGACCTGGACAAAATCAAGGGCCAGTATCAGCACCATATATA 352  
 |||||  
 213 rSerTyrAlaValIleThrTrpGluValLeuSerArgLysGlnProPheG 230  
 |||||  
 353 TAGCTATGCAAGTTATCAGATGGGAAGTGTATCCAGAAAACAGCCITTTG 402  
 |||||  
 230 luAspValThrAsnProLeuGlnIleMetTyrSerValSerGlnGlyHis 246  
 |||||  
 403 AAGATGTCACCAATCTTTTCAGATAATGTATAGTGTGTACCAAGGACAT 452  
 |||||

seq\_name: /cgnl\_8/gcgdata/geneseq/geneseq/Nr2000.DAT:261161

seq\_documentation\_block:

ID Z61161 standard; DNA; 2370 BP.

XX Z61161;  
 AC  
 XX  
 XX  
 DT 30-MAY-2000 (first entry)  
 XX  
 DE DNA encoding a death associated kinase with ankyrin repeats.  
 XX  
 KW Death associated kinase protein containing ankyrin repeats; DAKAR;  
 KW kinase; quality assurance agent; shelf life; marker; ss.  
 XX  
 OS Mus sp.  
 XX  
 FH  
 FT 10..2370 Location/Qualifiers  
 FT /\*tag= a  
 FT /transl\_except= (pos:10..12, aa: Met)  
 XX  
 PN W0200008177-A2.

XX  
 PD 17-FEB-2000.  
 XX  
 PF 04-AUG-1999; 99WO-US17576.  
 XX  
 PR 04-AUG-1998; 98US-0095269.  
 PR 11-SEP-1998; 98US-0099973.  
 PR 09-FEB-1989; 99US-0119353.  
 XX  
 PA (IMV ) IMMUNEX CORP.  
 XX  
 PI Bird TA, Virca GD;  
 XX  
 DR WPI; 2000-195582/17.  
 DR P-PSDB; Y69163.

XX Novel death associated kinase containing ankyrin repeats (DAKAR) used as molecular weight marker and as controls for peptide fragmentation

XX Claim 1; Page 9-10; 71pp; English.

XX The present sequence encodes a murine death associated kinase protein, containing ankyrin repeats, designated DAKAR. The DAKAR polynucleotides can be used to express the polypeptides, and as probes to identify nucleic acids encoding proteins having kinase activity. DAKAR polypeptides and fragmented polypeptides are used for purifying proteins, e.g. to measure protein activity; as quality assurance agents to monitor shelf life and stability of binding partner proteins; as research agents, e.g. in assays to determine protein kinase activity, to identify novel molecules involved in signal transduction pathways, and to identify therapeutic compounds which may interfere with apoptosis; as molecular weight and isoelectric focusing markers; as controls for peptide fragmentation; identification of unknown proteins, e.g. by comparison with proteins in databases; and for preparation of antibodies. The antibodies can be used in assays to detect the presence of the protein, and to purify the protein by immunoaffinity chromatography. The antibodies can also be used to block binding of the DAKAR polypeptides to their binding partners. Compounds that inhibit or enhance the kinase activity of DAKAR can be used to treat diseases characterized by overproduction or unregulated production or underproduction or downregulated production of DAKAR.

XX Sequence 2370 BP; 536 A; 660 C; 700 G; 474 T; 0 other;

alignment\_scores:  
 Quality: 579.00 Length: 540  
 Ratio: 1.969 Gaps: 26  
 Percent Similarity: 54.444 Percent Identity: 34.074

alignment\_block:

US-09-445-223-1 x Z61161

Align seg 1/1 to: Z61161 from: 1 to: 2370



angiogenesis; tumour vascularisation; growth disorder; developmental disorder; skin wound; hair follicle disorder; anti-inflammatory; cytostatic; neuroprotective; vulnery; ss.

Mus sp.
W09955865-A1.
04-NOV-1999.
29-APR-1999; 99WO-NZ00051.
29-APR-1998; 98US-0069726.
09-NOV-1998; 98US-0188930.
(GENE-) GENESIS RES & DEV CORP LTD.

Strachan L, Sleeman M, Watson JD, Onrust R, Kumble A, Murison JG;
P-PSDB; Y76079.

Novel polynucleotides useful for the treatment of various conditions including wounds and cancer

Claim 1; Page 158-159; 235pp; English.

The invention relates to novel nucleic acid sequences derived from rat dermal papilla, human keratinocytes and neonatal foreskin fibroblasts and mouse embryonic skin, keratinocyte stem cells and transit amplifying cells. Polypeptides of the invention may be used to treat inflammation, cancer and neurological diseases. The proteins may be used to stimulate the growth and motility of keratinocytes, to inhibit the growth of cancer cells, to modulate angiogenesis and tumour vascularisation, to modulate skin inflammation, to modulate epithelial cell growth and to inhibit binding of HIV-1 to leukocytes. The invention may also be used to treat growth and developmental defects, skin wounds and hair follicle disorders. Sequences Z61606-Z61832 represent cDNA sequences derived from several mouse, rat or human skin cell types. Sequences Z61606-Z61649, CC Z61725-Z61765, Z61802-Z61811 and Z61826 encode proteins with an N-terminal signal sequence, indicating that the proteins are secreted. CC Sequences Z61650-Z61668, Z61766-Z61780, Z61812-Z61817 and Z61827-Z61829 CC encode proteins with one or more putative transmembrane domains.

Sequence 3516 BP; 810 A; 886 C; 988 G; 832 T; 0 other.

alignment\_scores:
Quality: 579.00 Length: 540
Ratio: 1.969 Gaps: 26
Percent Similarity: 54.444 Percent Identity: 34.074

alignment\_block:
US-09-445-223-1 x Z61784

Align seg 1/1 to: Z61784 from: 1 to: 3516

10 LeuProThrIleProTyrHisLysLeuAlaAspLeuArgTyrLeuSerAr 26
43 CTGCGCACCTTCACCCCGGGGAAATTCGGAGGCTGGGAAAGTGGGCTC 92
26 gGlyAlaSerGlyThrValSerSerAlaArgHisAlaAspTrpArgValG 43
93 GGCGCGCTTCGGCGAGGTGTACAAAGTGGCCCATGTGCACCTGGAGACGT 142
43 InValAlaValLys.....HisLeuHisIleHisThrProLeuLeu 56
143 GGCTCGCGATCAAGTCTGCCCGCAGTCTGCACGTCGAC..... 180
57 AspSerGluArgLysAspValLeuArgGluAlaGluLeuHisLysAl 73
181 GACAGGAAAGAAATGAGTCTCTGGAGGAAAGCTTAAGAAATGGATGGC 230

73 aArgPheSerTyrIlePheProIleLeuGlyIleCysAsnGluProGluP 90
231 CAAATTCAGTACATCTTACCTGTGTACGCATATCCAGGAACCT.... 276
90 heuLeuIleValThrGluTyrMetProAsnGlySerLeuAsnGluLeu 106
277 ..GTCGGCTGGTGCATGGAGTACATGGAGACAGGCTCCCTGGAGAAGCTG 324
107 LeuHisArgLysThrGluTyrProAspValAlaIleTyrProLeuArgPheAr 123
325 CTGGCCTCAGAG.....CCATTCCCTGGGACCTGCCTTCG 362
123 gIleLeuHisGluIleAlaLeuGlyValAsnTyrLeuHisAsnMetThrP 140
363 CATGTGCACGAGACAGCGGTGGCATGAATTCCTGCATTCATGCTC 412
140 rOpProLeuHisHisAspLeuLysThrGlnAsnIleLeuLeuAspAsn 156
413 CGCCACTGCTGCACCTAGACCTGAAGCCAGCCAGCAATCTCTGGATGCC 462
157 GluPheHisValLysIleAlaAspPheGlyLeuSerLysTrpArgMetMe 173
463 CACTACCATGTCAAAGATTCTGACTTGGCTGGCCCAAGTGCATGGCAT 512
173 tSerLeuSerGlnSerArgSerLysSerAlaProGluGly.....G 188
513 GTCCCACTCTCATGACTCAGCATG.....GATGGCCTGTTT 550
188 lYThrIleIleTyrMetProGluAsnTyrGluProGlyGlnLysSer 204
551 GTACAATGCTTACCTCCCTCCAGAGCAATTCGT.....GAGAAGAGC 594
205 ArgAla....SerIleLysHisAspIleTyrSerTyrAlaValIleThrT 220
595 CGTGTGTTGCACCAACATGATGATACAGCTTGCCTTCATTCGATCTG 644
220 pGluValLeuSerArgLysGlnProPheGluAspValThrAsnProLeuG 237
645 GGGTGTGCTTACACAGAAGAAGCAATTTGCAGATGAAGAAGCAATCTCA 694
237 lnIleMetTyrSerValSerGlnGlyHisArgProValIleAsnGluGlu 253
695 ACATCATGATGAAAGTGGTAAAGGGCCAGCCGCCA.....GAG 732
254 SerLeuProTyrAspIleProHisArg.....AlaArgMetIleSe 267
733 CTGCCACCCACTGTCAGACCCCGCGCTGCTGTGCCAGCCTGATAGG 782
267 rLeuIleGluSerGlyTrpAlaGlnAsnProAspGluArgProSerPheL 284
783 GCTCATGCAACGGTGTGGCATGCAGACCCACAGGTGGGCCCC..... 825
284 euLysCysLeuIleGluLeuGluProValLeuArgThrPheGluGluIle 300
826 .....ACCTTCCAAGAAATT 840
301 ThrPheLeuGluAlaValIleGlnLeuLysLysThrLysLeuGlnSerVa 317
841 ACC..... 843
317 lSerSerAlaIleHisLeuCysAspLysLysLysMetGluLeuSerLeuA 334
844 .TCTGAACACAGAAGACCTTTGTGAGAAGCCTGTAGAGGAGGTGAAA.... 888
334 snIleProValAsnHisGlyProGlnGluSerCysGlySerGln 350
889 .....GACCTGGCTCATGAGCCAGCGGAGAAAAGCTCTTAGAGTCCAAG 933
351 LeuHisGluAsnSerGlySerProGluThrSerArgSerLeuProAlaPr 367
934 AGTGAAGCCAGGCCCGGAGTCTCAGCCCTCAGCGGCTCTGCTCCCCC 983
367 oGlnAspAsnAsp.PheLeuSerArgLysAlaGlnAspCysTyrPheMet 383

```

984 CTTTCGATAACGACTCGAGTCTCT.....CCGAGTTGC..... 1015
384 LysLeuHisHisCysProGlyAsnHisSerTrpAspSerThrIleSerG1 400
1016 .....TGT.....CACAGTTGG.....ACTCTGGG 1035
400 ySerGlnArgAlaAlaPheCysAspHisLysThrProCysSerSerA 417
1036 ATCTCCAGACTCTTG.....AAGGCCCGAAGAGCTCAG 1070
417 lalleleAsnProLeuSerThrAlaGlyAsnSerGluArgLeuGlnPro 433
1071 CCGAAGTT...CCTCTG.....AATGCAAGCTCCCATCTCCA 1105
434 GlyIleAlaGln.....GlnTrpIleGlnSerLysAr 444
1106 GCAGTGGCAGAGGCTCTCGGGGTGTCTCTCAGTGGACTCAGCCTTTTCC 1155
444 gGluAspIleValAsnGlnMetThrGluAlaCysLeuAsnGlnSerLeuA 461
1156 TCCAGAG.....GATCGCTCT.....C 1172
461 sPalaLeuLeuSerArgAspLeuIleMetLysGluAspTyrGluLeuVal 477
1173 ACTGCTTTTGAGC..... 1186
478 SerThrLysProThrArgThrSerLysValArgGlnLeu...LeuAspThr 493
1187 .....GGGAAGCTTCAACAGCGCGCTGGGCCCC 1215
494 ThrAspIleGlnGluGluPheAlaLysValIleValGlnLysLeuLy 510
1216 ACAGACATCCAGAAAGAGACTAGTGGTCCATCATATCAGGGGACAC 1265
510 sAspAsnLysGlnMetGlyLeuGlnProTyrProGluIleLeuValValS 527
1266 CAGCAGGCTGATGAAGATCTACAGCCCCAAGATGTGGACTTGGTTCTAG 1315
527 erArgSerProSer 532
1316 ACACAGTGGCCAGCCTG 1332

```

seq\_name: /cgni\_8/gcgdata/geneseq/geneseq/NA2001.DAT.C99717

```

seq_documentation_block:
ID C99717 standard; cDNA; 3516 BP.
XX
AC C99717;
XX
DT 08-MAR-2001 (first entry)
XX
DE Skin cell cDNA, SEQ ID NO: 257.
XX
KW Mouse; skin cell; cytostatic; antiinflammatory; anti-HIV;
KW nootropic; neuroprotective; vulnerary; immunomodulatory; vaccine;
KW keratinocyte growth stimulation; cancer; angiogenesis inhibition;
KW inflammation; neurological disease; ss.
XX
OS Mus sp.
XX
PN WO200069884-A2.
XX
PD 23-NOV-2000.
XX
PF 15-MAY-2000; 2000WO-NZ00075.
XX
PR 14-MAY-1999; 99US-0312283.
XX
PA (GENE-) GENESIS RES & DEV CORP LTD.
XX
PI Watson JD, Strachan L, Onrust R, Sleeman M, Kumble KD, Murison JG;
XX

```

```

DR WPT: 2001-007495/01.
DR P-PSDB; B55958.
XX
PT New isolated polynucleotide used in the identification of genetic
PT disorders and encoding polypeptides used for treating inflammatory
PT disease, cancer and neurological diseases -
XX
XX Claim 1; Page 216-218; 352pp; English.
XX
CC The present polynucleotide encodes a polypeptide which is expressed in
CC mammalian skin cells. The polypeptide is useful for stimulating
CC keratinocyte growth and motility, inhibiting the growth of cancer cells,
CC modulating angiogenesis, inhibiting angiogenesis and vascularisation of
CC tumours, modulating skin inflammation, stimulating the growth of
CC epithelial cells, inhibiting the binding of human immunodeficiency virus
CC (HIV)-1 to leukocytes, and treating inflammatory disease, cancer and
CC neurological diseases. The polynucleotide can be used as a marker, in
CC the identification of genetic disorders, and for the design of
CC oligonucleotides for examining expression patterns.
XX
SQ Sequence 3516 BP; 810 A; 886 C; 988 G; 832 T; 0 other;

```

```

alignment_scores:
Quality: 579.00 Length: 540
Ratio: 1.969 Caps: 26
Percent Similarity: 54.444 Percent Identity: 34.074
alignment_block:
US-09-445-223-1 x C99717
Align seg 1/1 to: c99717 from: 1 to: 3516
10 LeuProThrIleProTyrHisLysLeuAlaAspLeuArgTyrLeuSerAr 26
43 CTGCGCACCTTCGACCGCCGGCGAATTCGCGAGGCTGGGAGAAGTGGGCTC 92
26 gGlyAlaSerGlyThrValSerSerAlaArgHisAlaAspTrpArgValG 43
93 GGGCGGCTTCGGCGAGGTGTACAAGGTGGCCCATGTGCACATGGGAAGACGT 142
43 lnValAlaValLys.....HisLeuHisIleHisThrProLeuLeu 56
143 GGCCTCGGATCAAGTCTCGCCCGAGCTGCACGTCGCAC..... 180
57 AspSerGluArgLysAspValLeuArgGluAlaGluLeuHisLysAl 73
181 GACAGGGAGCGAATGGAGCTCTCGGAGGAAGCTAAGAAAGATGGAGATGGC 230
73 aArgPheSerTyrIlePheProIleLeuGlyIleCysAsnGluProGluP 90
231 CAAGTTCGGATACATTCTACTGTGTACGGCATATGCCAGGAACCT.... 276
90 heLeuGlyIleValThrGluTyrMetProAsnGlySerLeuAsnGluLeu 106
277 ..GTCGGCTGGTTCATGGACTACATGGAGACAGGCTCCCTGGAGAAGCTG 324
107 LeuHisArgLysThrGluTyrProAspValAlaIleTrpProLeuArgPheAr 123
325 CTGGCCTCAGAG.....CCATTGCTGGGACCTGGCGCTTTCG 362
123 gIleLeuHisGluIleAlaLeuGlyValAsnTyrLeuHisAsnMetThrP 140
363 CATCGTGCAGAGACAGCCGTGGGCATGAACCTTCTCCTGCATTCATGCTCTC 412
140 roProLeuLeuHisHisAspLeuLysThrGlnAsnIleLeuLeuAspAsn 156
413 CGCCACTGCTGCACCTAGACTGAAGCCAGCGAACAATCTCTGCTGGATGCC 462
157 GluPheHisValLysIleAlaAspPheGlyLeuSerLysTrpArgMetMe 173
463 CACTACCATGTCAAGATTTCTGACTTTGGGCTGGCCCAAGTGCATGCAT 512

```



```

173 tSerLeuSerGlnSerArgSerLysSerAlaProGluGly.....G 188
||||| ||||| ||||| |||||
513 GTCCCACCTCATGACCTCAGCATG.....GATGGCCTGTTG 550
188 lYThrIleIleYrMetProGluAsnTyrgluProGlyGlnLysSer 204
||||| ||||| ||||| ||||| |||||
551 GFACAATCCCTACCTCCCTCCAGAGCGGAATTCGT.....GAGAAGAGC 594
205 ArgAla...SerIleIleHisAspIleTySerTyrrAlaValIleThrTr 220
||||| ||||| ||||| ||||| ||||| ||||| |||||
595 CGCTTTTTCACACCAACATGATGATACAGCTTCGCCATTTGTGATCG 644
220 pGluValLeuSerArgLysGlnProPheGluAspValThrAsnProLeuG 237
||||| ||||| ||||| ||||| ||||| |||||
645 GGSTGTGCTTACACAGAAGAAGCAATTTGCAGATGAAGAACAATCTCTAC 694
237 lnIleMetYrSerValSerGlnGlyHisArgProValIleAsnGluGlu 253
||| ||||| ||||| ||||| ||||| ||||| |||||
695 ACATCATGATGAMAGTGTAAGGGCCACCGCCCA.....GAG 732
254 SerLeuProTyraSPIleProHisArg.....AlaArgMetIleLe 267
||||| ||||| ||||| |||||
733 CTGCCACCCATCTGCAGACCCCGCGCTGCTGTGCCAGCCTGATAGG 782
267 rLeuIleGluSerGlyTrpAlaGlnAsnProAspGluArGProSerPheL 284
||||| ||||| ||||| ||||| ||||| |||||
783 GCTCATGCAACGGTGCTGGCATGCAGACCCACAGGTGCGGCC..... 825
284 euLysCysLeuIleGluLeuGluProValLeuArgThrPheGluGluIle 300
||||| ||||| ||||| |||||
826 ||||| ||||| ||||| ||||| ||||| ||||| ACCTTCCAGAAGATT 840
301 ThrPheLeuGluAlaValIleGlnLeuLysLysThrLysLeuGlnSerVa 317
||| ||||| ||||| ||||| ||||| |||||
841 ACC..... 843
317 lSerSerAlaIleHisLeuCysAspLysLysMetGluLeuSerLeuA 334
||||| ||||| ||||| ||||| ||||| ||||| |||||
844 .TCTGAACAGAAGACTTTGTGAGAAGCCTGATGAGGAGGTGAAA.... 888
334 snIleProValAsnHisGlyProGlnGluLysCysGlySerGln 350
||| ||||| ||||| ||||| ||||| ||||| |||||
889 .....GACCTGGCTCATGACCGAGCGGAGAAAAGCTCTCTAGAGTCCAAG 933
351 LeuHisGluAsnSerGlySerProGluThrSerArgSerLeuProAlaPr 367
||| ||||| ||||| ||||| ||||| ||||| |||||
934 AGTGAGCCAGGCCGAGCTCTCAGCCCTCAAGCGGCCCTGCTGCCCCC 983
367 oGlnAspAsnAsp.PheLeuSerArgLysAlaGlnAspCysTyrrPheMet 383
||| ||||| ||||| ||||| ||||| ||||| |||||
984 CTTCGATAACGACTGCAGTCTCT.....CCGAGTTGC..... 1015
384 LysLeuHisCysProGlyAsnHisSerTrpAspSerThrIleSerGI 400
||| ||||| ||||| ||||| ||||| ||||| |||||
1016 .....TGT.....CACAGTTGG.....ACTCTGGG 1035
400 ySerGlnArgAlaAlaPheCysAspHisLysThrProCysSerSera 417
||||| ||||| ||||| ||||| ||||| |||||
1036 ATCTCCACGACTCTG.....AAGGCCCCGAAGAGCTCAG 1070
417 laIleIleAsnProLeuSerThrAlaGlyAsnSerGluArgLeuGlnPro 433
||||| ||||| ||||| ||||| ||||| ||||| |||||
1071 CCGAAGT...CCTCTG.....ANTGCAAGCTCCCATCCGCA 1105
434 GlyIleAlaGln.....GlnTrpIleGlnSerLysAr 444
||||| ||||| ||||| ||||| ||||| ||||| |||||
1106 GCAGTGGCAGAGGCTCTCGGGGTCTCTCAGTGAGCTCAGCCCTTTTCC 1155
444 gGluAspIleValAsnGlnMetThrGluAlaCysLeuAsnGlnSerLeuA 461
||| ||||| ||||| ||||| ||||| ||||| |||||
1156 TCCAGAG.....GATCGCTGT.....C 1172
461 spAlaLeuSerArgAspLeuIleMetLysGluAspTyrrGluLeuVal 477

```

```

1173 ACTGTCTTTTGGC..... 1186
478 SerThrlYsProThrArgThrSerLysValArgGlnLeu..LeuAspThr 493
||||| ||||| ||||| |||||
1187 .....GGGAAGCTTCAACAGCGGCACCTGGGCC 1215
494 ThrAspIleGlnGlyGluGluPheAlaLysValIleValGlnLysLeu 510
||||| ||||| ||||| ||||| ||||| ||||| |||||
1216 ACAGACATCCAGAAGAAGCTAGTGGATGCCATCATATCAGGGGACAC 1265
510 sAspAsnLysGlnMetGlyLeuGlnProTyrrProGluIleLeuVal 527
||||| ||||| ||||| ||||| ||||| |||||
1266 CAGCAGCGTGAAGATCTACAGCCCAAGATGTGGACTGTGGTTCTAG 1315
527 erArgSerProSerLeu 532
||| ||||| ||||| |||||
1316 ACAGCAGTCCAGCGCTG 1332

```

seq\_name: /cgnl\_8/gcgdata/geneseq/geneseq/NA2000.DAT:Z61830  
seq\_documentation\_block:  
ID Z61830 standard; cDNA; 1774 BP.  
XX AC Z61830;  
XX DT 27-MAR-2000 (first entry)  
XX DE cDNA encoding murine RIP protein kinase homologue, SEQ ID NO:403.  
KW Skin; dermal papilla; keratinocyte; neonatal foreskin fibroblast;  
KW embryonic skin cell; keratinocyte stem cell; transit amplifying cell;  
KW secreted; transmembrane; inflammation; cancer; neurological disease;  
KW angiogenesis; tumour vascularisation; growth disorder;  
KW developmental disorder; skin wound; hair follicle disorder;  
KW anti-inflammatory; cytostatic; neuroprotective; vulnery; ss.  
XX Mus sp.  
XX PN WO9955865-A1.  
XX XX 04-NOV-1999.  
XX PD 29-APR-1999; 99WO-NZ00051.  
XX PF 29-APR-1998; 98US-0069726.  
XX PR 09-NOV-1998; 98US-0188930.  
XX XX (GENE-) GENESIS RES & DEV CORP LTD.  
XX PA Strachan L, Sleeman M, Watson JD, Onrust R, Kumble A, Murison JG;  
XX PI WPI: 2000-072177/06.  
XX DR P-PSDB; Y76123.  
XX XX Novel polynucleotides useful for the treatment of various conditions  
PT including wounds and cancer -  
PT Claim 1; Page 228-229; 235pp; English.  
XX CC The invention relates to novel nucleic acid sequences derived from rat  
CC dermal papilla, human keratinocytes and neonatal foreskin fibroblasts,  
CC and mouse embryonic skin, keratinocyte stem cells and transit amplifying  
CC cells. Polypeptides of the invention may be used to treat inflammation,  
CC cancer and neurological diseases. The proteins may be used to stimulate  
CC the growth and motility of keratinocytes, to inhibit the growth of  
CC cancer cells, to modulate angiogenesis and tumour vascularisation, to  
CC modulate skin inflammation, to modulate epithelial cell growth and to  
CC inhibit binding of HIV-1 to leukocytes. The invention may also be used to  
CC treat growth and developmental defects, skin wounds and hair follicle  
CC disorders. Sequences Z61806-Z61832 represent cDNA sequences derived from  
CC several mouse, rat or human skin cell types. Sequences Z61806-Z61849,  
CC Z61725-Z61765, Z61802-Z61811 and Z61826 encode proteins with an



```

:: ||| |||||
1318 ACAGCAGTGCAGCCTG 1334
seq_name: /cgnl_8/ycydata/geneseq/geneseq/NA2001.DAT:C99763
seq_documentation_block:
ID C99763 standard; cDNA; 1774 BP.
AC C99763;
XX
DT 08-MAR-2001 (first entry)
XX
DE Skin cell cDNA, SEQ ID NO: 403.
XX
KW Mouse; skin cell; cytostatic; antiinflammatory; anti-HTV;
KW neutropic; neuroprotective; vulnery; immunomodulatory; vaccine;
KW keratinocyte growth stimulation; cancer; angiogenesis inhibition;
KW inflammation; neurological disease; ss.
OS
XX Mus sp.
XX
XX WO200069884-A2.
XX
XX 23-NOV-2000.
XX
XX 15-MAY-2000; 2000WO-NZ00075.
XX
XX 14-MAY-1999; 99US-0312283.
XX
XX (GENE-) GENESIS RES & DEV CORP LTD.
XX
XX Watson JD, Strachan L, Onrust R, Sleeman M, Kumble KD, Murison JG;
XX
XX WPI: 2001-007495/01.
XX
XX P-PSDB; B56062.
XX
XX New isolated polynucleotide used in the identification of genetic
XX disorders and encoding polypeptides used for treating inflammatory
XX disease, cancer and neurological diseases -
XX
XX Claim 1; Page 305-306; 352pp; English.
XX
XX The present polynucleotide encodes a polypeptide which is expressed in
XX mammalian skin cells. The polypeptide is useful for stimulating
XX keratinocyte growth and motility, inhibiting the growth of cancer
XX cells, modulating angiogenesis, inhibiting angiogenesis and vascularisation of
XX tumours, modulating skin inflammation, stimulating the growth of
XX epithelial cells, inhibiting the binding of human immunodeficiency virus
XX (HIV)-1 to leukocytes, and treating inflammatory disease, cancer and
XX neurological diseases. The polynucleotide can be used as a marker, in
XX the identification of genetic disorders, and for the design of
XX oligonucleotides for examining expression patterns.
XX
XX Sequence 1774 BP; 406 A; 490 C; 526 G; 352 T; 0 other;

```

```

alignment_scores:
Quality: 577.00 Length: 540
Ratio: 1.963 Gaps: 26
Percent Similarity: 54.444 Percent Identity: 33.889

```

```

alignment_block:
US-09-445-223-1 x C99763 ..
Align seg 1/1 to: C99763 from: 1 to: 1774
10 LeuProThrIleProTyrHisLysLeuAlaAspLeuArgTyrLeuSerAr 26
||| |||::: |||::: |||::: |||::: |||::: |||:::
45 CTGCGCACCTTCGACCGCGGGAATTCGAGCTGGGGAAGAGTGGGCTC 94
26 gGlyAlaSerGlyThrValSerSerAlaArgHisAlaAspTyrArgVal 43
||||::: ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
95 GGGCGGCTTCGGGCGAGGTGTACAAGGTGCGCCCAATGTCACACTGGAAGACGT 144

```

```

43 InValAlaValLys.....HisLeuHisIleHisThrProLeuLeu 56
:::|||||:::||||| |||||:::
145 GGCTCGGATCAAGTGTCTGCCAGTCTGCACGTCGAC..... 182
57 AspSerGluArgLysAspValLeuArgGluAlaGluIleLeuHisLysAl 73
||| ||||| :::::|||||::: |||||::: |||||::: |||||:::
183 GACAGGGAAGAAATGGAGCTCTGAGAGAAAGTAAAGATGGAGATGGC 232
73 aArgPheSerTyrIlePheProIleLeuGlyIleCysAsnGluProGlu 90
:::|||||:::|||||::: |||||::: |||||::: |||||::: |||||:::
233 CAAGTTCGATACATTCTACCTGTGTACGGCATATGCCAGAACCT... 278
90 heLeuGlyIleValThrGluTyrMetProAsnGlySerLeuAsnGluLe 106
||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
279 .GTCGGCTGGTCAATGGAGTACATGGAGACAGGCTCCCTGGGAAAGCT 326
||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
107 LeuHisArgLysThrGluTyrProAspValAlaIleTrpProLeuArgPhe 123
||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
327 CTGGCCTCAGAG.....CCATTGCTTGGGACCTCGCCTTTCG 364
123 gIleLeuHisGluIleAlaLeuGlyValAsnTyrLeuHisAsnMetThr 140
||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
365 CAYCGTCAGCAGACAGCGGTGGCATGAACCTCTCGATTCATGTCATC 414
140 roProLeuLeuHisAspLeuLysThrGlnAsnIleLeuLeuAspAsn 156
||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
415 CGCCACTGCTGCACCTAGACCTGAAGCCAGGAAACATCTCTGCTGGATGC 464
157 GluPheHisValLysIleAlaAspPheGlyLeuSerLysTyrArgMetMe 173
||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
465 CACTACCATGTCAAAGATTTCTGACTTTGGGCTGGCCAAAGTCAATGG 514
173 tSerLeuSerGlnSerArgSerLysSerAlaProGluGly.....G 188
||| |||||::: ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
515 GTCCACCTCTCATGACCTCAGCATG.....GATGGCCTGTTG 552
188 lyThrIleIleTyrMetProGluAsnTyrGluProGlyGlnLysSer 204
||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
553 GTACAATCGCTTACTCCTCCAGAGGCAATTCGT.....GAGAAGAGC 596
205 ArgAla...SerIleLysHisAspIleTyrSerTyrAlaValIleThrTr 220
||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
597 CGCTGTTTGCACCAACATGATGATACAGCTTCGCCATTTGTGATCG 646
220 pGluValLeuSerArgLysGlnProPheGluAspValThrAsnProLeu 237
||| |||||::: ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
647 GGGTGTCTTACACAGAGAGCCATTTGCAGATGAAAAGAACATCTCTAC 696
237 InIleMetTyrSerValSerGlnGlyHisArgProValIleAsnGluGlu 253
||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
697 ACATCATGATGAAAGTGTAAAGGGCCACCGCCCA.....GAG 734
254 SerLeuProTyrAspIleProHisArg.....AlaArgMetIleSe 267
||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
735 CTGCCACCCATCTGCAGACCCCGCGCTGCTGTGCCAGCTGATAGG 784
267 rLeuIleGluSerGlyTyrAlaGlnAsnProAspGluArgProSerPhe 284
||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
785 GATANTCAACGGTGTGGCATGACAGACCCACAGGTGCGGCC..... 827
284 euLysCysLeuIleGluLeuGluProValLeuArgThrPheGluGluIle 300
||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
828 .....ACCTTCCAAGAAATT 842
301 ThrPheLeuGluAlaValIleGlnLeuLysLysThrLysLeuGlnSerVa 317
|||
843 ACC..... 845
317 lSerSerAlaIleHisLeuCysAspLysLysLysMetGluLeuSerLeu 334
||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
846 .TCTGAACAGAGACCTTTGTGAGAAGCTGTGATGAGGAGGTGAAA.... 890

```



124 ILeuHisGluLeuAlaLeuGlyValAsnTyrLeuHisAsnMetThrPr 140  
 |||:||||| |||:|||||:|||||:||||| |||:|||||  
 294 ATCGTCACGAGACACCGTGGGCATCTCCGATGCTCC 343  
 140 oProLeuLeuHisAspLeuLysThrGlnAsnIleLeuLeuAspAsnG 157  
 |||:||||| |||:||||| |||:||||| |||:||||| |||:|||||  
 344 GCCACTGCTGACCTAGACTGAGCCAGGAAACATCCTGCTGGATGCC 393  
 157 luPheHisValLysIleAlaAspPheGlyLeuSerLysTyrArgMetMet 173  
 :||:||||| |||:|||||:|||||:||||| |||:|||||  
 394 ACTACCATGCAAGATTCTGACTTTGGCTGGCCCAAGTCCAATGGCATG 443  
 174 SerLeuSerGlnSerArgSerLysSerAlaProGluGly.....G1 188  
 |||:||||| |||:||||| |||:||||| |||:||||| |||:|||||  
 444 TCCCACTCATGACCTCAGCATG.....GATGGCCTGTTGG 481  
 188 yThrIleIleTyrMetProGluAsnTyrGluProGlyGlnLysSera 205  
 |||:||||| |||:|||||:|||||:||||| |||:|||||  
 482 TACAACTGCTTACCTCCAGAGGAAATTCGT.....GAGAAGAGCC 525  
 205 rgAla...SerIleLysHisAspIleTyrSerTyrAlaValIleThrTrp 220  
 |||:||||| |||:|||||:|||||:||||| |||:|||||  
 526 GCTTGTTCACACCAACATGATGTATACAGCTTCGCCATTGTGATCTG 575  
 221 GluValLeuSerArgLysGlnProPheGluAspValThrAsnProLeuG1 237  
 |||:||||| |||:|||||:|||||:||||| |||:|||||  
 576 GGTGTCTTACACAGAAAGCCATTTGCAGATGAAAGAACAATCCTACA 625  
 237 nIleMetTyrSerValSerGlnGlyHisArgProValIleAsnGluLus 254  
 :||:||||| |||:|||||:|||||:||||| |||:|||||  
 626 CATCATGATCAAGTGTAAAGGGCCACCAGCCCA.....GAGC 663  
 254 erLeuProTyrAspIleProHisArg.....AlaArgMetIleSer 267  
 |||:||||| |||:|||||:|||||:||||| |||:|||||  
 664 TGCCACCCATCTGCAGACCCGCCCGCTGCTGCCAGCTGATAGGG 713  
 268 LeuIleGluSerGlyTrpAlaGlnAsnProAspGluArgProSerPheLe 284  
 |||:||||| |||:|||||:|||||:||||| |||:|||||  
 714 CTCATCAACAGGTGCTGGCATCGAGACCACAGCGGCCCC.....755  
 284 uLysCysLeuIleGluLeuGluProValLeuArgThrPheGluGluIleT 301  
 |||:||||| |||:|||||:|||||:||||| |||:|||||  
 756 .....ACCTTCCAAAGAATTA 771  
 301 hrPheLeuGluAlaValIleGlnLeuLysLysThrLysLeuGlnSerVal 317  
 |||:||||| |||:|||||:|||||:||||| |||:|||||  
 772 CC..... 773  
 318 SerSerAlaIleHisLeuCysAspLysLysLysMetGluLeuSerLeuAs 334  
 |||:||||| |||:|||||:|||||:||||| |||:|||||  
 774 TCTGAACAAGAGACCTTTGTGAGAAGCCCTGATGAGGAGGTGAAA.... 818  
 334 nIleProValAsnHisGlyProGlnGluSerCysGlySerSerGlnL 351  
 :||:||||| |||:|||||:|||||:||||| |||:|||||  
 819 ....GACCTGGCTCATCAGCCAGCCGAGAAAGCTCTTAGAGTCCCAAGA 864  
 351 euHisGluAsnSerGlySerProGluThrSerArgSerLeuProAlaPro 367  
 :||:||||| |||:|||||:|||||:||||| |||:|||||  
 865 GTGAGCCAGCCCGGAGTCTCAGCCCTCAAGCGCCCTGCTCCGCCCC 914  
 368 GlnAspAsnAsp\_PheLeuSerArgLysAlaGlnAspCysTyrPheMetL 384  
 |||:||||| |||:|||||:|||||:||||| |||:|||||  
 915 TTCGATAAGACTGCAGTCTCT.....CCGAGTTGC..... 945  
 384 ysLeuHisHisCysProGlyAsnHisSerTrpAspSerThrIleSerGly 400  
 |||:||||| |||:|||||:|||||:||||| |||:|||||  
 946 .....TGT.....CACAGTGG.....ACTCTGGGA 966  
 401 SerGlnArgAlaAlaPheCysAspHisLysThrProCysSerSerAl 417  
 |||:||||| |||:|||||:|||||:||||| |||:|||||  
 967 TCTCCAGACTCTG.....AAGGCCCCGAAAGCTCAGC 1001  
 417 aileIleAsnProLeuSerThrAlaGlyAsnSerGluArgLeuGlnProG 434

1002 CGAAGT...CCTCTG.....AATGCAAGTCCCATCGTCCAG 1036  
 |||:||||| |||:|||||:|||||:||||| |||:|||||  
 434 lyIleAlaGln.....GlnTrpIleGlnSerLysArg 444  
 :||:||||| |||:|||||:|||||:||||| |||:|||||  
 1037 CAGTGCAGAGAGGCTCTCGGGGTFGCTCAGTGGACTCAGCCTTTTCC 1086  
 445 GluAspIleValAsnGlnMetThrGluAlaCysLeuAsnGlnSerLeuAs 461  
 :||:||||| |||:|||||:|||||:||||| |||:|||||  
 1087 CCAGAG.....GATCGCTGT.....CA 1103  
 461 pAlaLeuLeuSerArgAspLeuIleMetLysGluAspTyrGluLeuValS 478  
 :||:||||| |||:|||||:|||||:||||| |||:|||||  
 1104 CTGCTTTTGGAGC..... 1116  
 478 erThrLysProThrArgThrSerLysValArgGlnLeu...LeuAspThrT 494  
 :||:||||| |||:|||||:|||||:||||| |||:|||||  
 1117 .....GGGAAGCTTCAACAGCGGACCTGGGCCCA 1146  
 494 hrAspIleGlnGlyGluGluPheAlaLysValIleValGlnLysLeuLys 510  
 |||:||||| |||:|||||:|||||:||||| |||:|||||  
 1147 CAGACATCCAGAAAGAGACTAGTGGATGCCATCATATCAGGGGACACC 1196  
 511 AspAsnLysGlnMetGlyLeuGlnProTyrProGluIleLeuValValSe 527  
 :||:||||| |||:|||||:|||||:||||| |||:|||||  
 1197 AGCAGGCTGATGAAGATCTACAGCCCAAGATGTGGACTTGTCTTAGA 1246  
 527 rArgSerProSerLeu 532  
 :||:||||| |||:|||||:|||||:||||| |||:|||||  
 1247 CAGCAGTCCAGCCTG 1262

seq\_name: /cgn1\_8/gcgdata/geneseqr/NA2000.DAT:261671  
 seq\_documentation\_block:  
 ID Z61671 standard; CDNA; 1888 BP.  
 XX  
 AC Z61671;  
 XX  
 DT 27-MAR-2000 (first entry)  
 XX  
 DE CDNA encoding murine RIP protein kinase homologue, SEQ ID NO:66.  
 XX  
 KW skin; dermal papilla; keratinocyte; neonatal foreskin fibroblast;  
 KW embryonic skin cell; keratinocyte stem cell; transit amplifying cell;  
 KW secreted; transmembrane; inflammation; cancer; neurological disease;  
 KW angiogenesis; tumour vascularisation; growth disorder;  
 KW developmental disorder; skin wound; hair follicle disorder;  
 KW anti-inflammatory; cytostatic; neuroprotective; vulnery; ss.  
 XX  
 OS Mus sp.  
 XX  
 PN W09955865-A1.  
 XX  
 PD 04-NOV-1999.  
 XX  
 PF 29-APR-1999; 99WO-NZ00051.  
 XX  
 PR 29-APR-1998; 98US-0069726.  
 PR 09-NOV-1998; 98US-0188930.  
 XX  
 PA (GENE-) GENESIS RES & DEV CORP LTD.  
 XX  
 PI Strachan L, Sleeman M, Watson JD, Onrust R, Kumble A, Murison JG;  
 XX  
 DR WPI; 2000-072177/06.  
 DR P-PSDB; Y76007.  
 XX  
 PT Novel polynucleotides useful for the treatment of various conditions  
 PT including wounds and cancer -  
 XX  
 PS Claim 1; Page 85-86; 235pp; English.  
 XX  
 CC The invention relates to novel nucleic acid sequences derived from rat

CC dermal papilla, human keratinocytes and neonatal foreskin fibroblasts,  
 CC and mouse embryonic skin, keratinocyte stem cells and transit amplifying  
 CC cells. Polypeptides of the invention may be used to treat inflammation,  
 CC cancer and neurological diseases. The proteins may be used to stimulate  
 CC the growth and motility of keratinocytes, to inhibit the growth of  
 CC cancer cells, to modulate angiogenesis and tumour vascularisation, to  
 CC modulate skin inflammation, to modulate epithelial cell growth and to  
 CC inhibit binding of HIV-1 to leukocytes. The invention may also be used to  
 CC treat growth and developmental defects, skin wounds and hair follicle  
 CC disorders. Sequences 261606-261832 represent cDNA sequences derived from  
 CC several mouse, rat or human skin cell types. Sequences 261606-261649,  
 CC 261725-261765, 261802-261811 and 261826 encode proteins with an  
 CC N-terminal signal sequence, indicating that the proteins are secreted.  
 CC Sequences 261650-261668, 261766-261780, 261812-261817 and 261827-261829  
 CC encode proteins with one or more putative transmembrane domains.  
 XX

Sequence 1888 BP: 433 A; 518 C; 554 G; 380 T; 3 other;

alignment\_scores:  
 Quality: 548.00 Length: 541  
 Ratio: 1.845 Gaps: 27  
 Percent Similarity: 54.898 Percent Identity: 33.272

alignment\_block:  
 US-09-445-223-1 x 261671 ..

Align seg 1/1 to: 261671 from: 1 to: 1888

- 10 LeuProThrIleProTyrHisLysLeuAlaAspLeuArgTyrLeuSerAr 26
- 43 CTCCGACCTTCAGCCGGCGGCGGAGCGTGGGAAAGTGGGCTC 92
- 26 gGlyAlaSerGlyThrValSerSerAlaArgHisAlaAspTIPArgValG 43
- 93 GGGCGGCTCGGCGAGGTGTACAAAGGTGGCCCAITGTGACTGGAAGACGT 142
- 43 InValAlaValLys.....HisLeuHisIleHisThrProLeuLeu 56
- 143 GGCTCGGATCAAGTGTCTGCCCGCAGTCTGCACCTCGAC..... 180
- 57 AspSerGluArgLysAspValLeuArgGluAlaAlaLeuLeuHisLysAl 73
- 181 GACAGGGAAGCAATGAGCTCCGAGGAAAGCTAAGAAGATGAGATGGC 230
- 73 aArgPheSerTyrIlePheProIleLeuGlyIleCysAsnGluProGluP 90
- 231 CAAGTCCGATACATCTACTGTTACGGCATATGCCAGAACCT.... 276
- 90 heLeuGlyIleValThrGluTyrMetProAsnGlySerLeuAsnGluLeu 106
- 277 ..GTCGGCTGGTTCATGGATACATGAGACAGGCTCCCTGGAGAAGCTG 324
- 107 LeuHisArgLysThrGluTyrProAspValAlaTrpProLeuArgPheAr 123
- 325 CTGGCTCAGAG.....CCATTCCTTGGACCTGGCCTTCG 362
- 123 gIleLeuHisGluIleAlaLeuGlyValAsnTyrLeuHisAsnMetThrP 140
- 363 CATCGTGACGACAGCCGCTGGGCATGAACCTTCCTGCATTGCATGTCTC 412
- 140 roProLeuLeuHisAspLeuLysThrGlnAsnIleLeuLeuLeuAspAsn 156
- 413 CGCCACTGTGCACCTAGACCTGAAGCCAGCAACATCTTGCTGGATGCC 462
- 157 GluPheHisVal...LysIleAlaAspPheGlyLeuSerLysTrpArgMe 172
- 463 CACTACCAATATGCAGAAATTTCTACTTTGGCTGGCCCAAGTGCRAATGG 512
- 172 tMetSerLeuSerGlnSerArgSerLysSerAlaProGluGly.... 187
- 513 CATGCTCCACTCTCATGACCTCAGCATG.....GATGGCCTGT 550

- 188 ..GlyThrIleLeuTyrMetProGluAsnTyrGluProGlyGlnLys 203
- 551 TTGGTACATCGCTACCCTCCACAGCGCAATTCGT.....GAGAAG 594
- 204 SerArgAla...SerIleLysHisAspIleTyrSerTyrAlaValIleTh 219
- 595 AGCCGCTGTTTGCACACCAACATGATGTATACAGCTTCGCCATTTGTGAT 644
- 219 rTrpGluValLeuSerArgLysGlnProPheGluAspValThrAsnProL 236
- 645 CTGGGTGTGTACACAGAAATAATCCATTTGCAGATGAAAGAACATCC 694
- 236 euGlnIleMetTyrSerValSerGlnGlyHisArgProValIleAsnGlu 252
- 695 TACACATCATGATCAAGAGTGTAAAGGGCCACCGCCCA..... 732
- 253 GluSerLeuProTyrAspIleProHisArg.....AlaArgMetI 266
- 733 GAGCTGCCACCATCTGCAGACCCGCGCGTGCCTGTGCCACGCCTGAT 782
- 266 eSerLeuIleGluSerGlyTrpAlaGlnAsnProAspGluArgProSerP 283
- 783 AGGCTCATGCAACGGTGTGTCATGCAGACCCACAGGTCGGGCC.... 828
- 283 heLeuLysCysLeuIleGluLeuGluProValLeuArgThrPheGluGlu 299
- 829 .....GACCTGGTTCATGAGCCAGCGGAGAAAGCTCTAGAGTCC 840
- 300 IleThrPheLeuGluAlaValIleGlnLeuLysLysThrLysLeuGlnSe 316
- 841 ATTACC..... 846
- 316 rValSerSerAlaIleHisLeuCysAspLysLysMetGluLeuSerL 333
- 847 ....TCTGAACACAGACACCTTGTGAGAACCTGTAGGAGGTGAAA. 891
- 333 euAsnIleProValAsnHisGlyProGlnGluLysCysGlySerSer 349
- 892 .....GACCTGGTTCATGAGCCAGCGGAGAAAGCTCTAGAGTCC 933
- 350 GlnLeuHisGluAsnSerGlySerProGluThrSerArgSerLeuProAl 366
- 934 AAGAGTGGCCAGGCGGAGTCTCAGCGCTCAAGCCGCGCCCTCTGTCTCC 983
- 366 aProGlnAspAsnAsp..PheLeuSerArgLysAlaGlnAspCysTyrPhe 382
- 984 CCCCTTCGATACGACTGCAGTCTCT.....CGAGTTC.... 1018
- 383 MetLysLeuHisCysProGlyAsnHisSerTrpAspSerThrIleSe 399
- 1019 .....TGT.....CACAGTTGG.....ACTCTGGG 1038
- 399 rGlySerGlnArgAlaAlaPheCysAspHisLysLysThrProCysSerS 416
- 1039 ATCTTCCCAA.....GACTCTGAAGCCCGCCAGAGACT 1073
- 416 erAlaIleIleAsnProLeuSerThrAlaGlyAsnSerGluArgLeuGln 432
- 1074 CAGCCGAAGTT...CCTCTG.....AATGCAAGCTCCCATCTCGT 1108
- 433 proGlyIleAlaGln.....GlnTrpIleGlnSerLy 443
- 1109 CCAGCAGTGGCAAGAGGCTCTCGGGGTGTCTCAGCTGGAGACTCAGCCTTT 1158
- 443 sArgGluAspIleValAsnGlnMetThrGluAlaCysLeuAsnGlnSerL 460
- 1159 TCCTCCAGAG.....GATCGCTGT..... 1177
- 460 euAspAlaLeuLeuSerArgAspLeuIleMetLysGluAspTyrGluLeu 476
- 1178 ..CACTGCTCTTTGAGC..... 1192
- 477 ValSerThrLysProThrArgThrSerLysValArgGlnLeu...LeuAsp 492



283 heLeuLysCysLeuIleGluLeuGluProValLeuArgThrPheGluGlu 299  
 829 .....ACCTTCCAGAA 840  
 300 IleThrPheLeuGluAlaValIleGlnLeuLysLysThrLysLeuGlnSe 316  
 841 AVTACC..... 846  
 316 rValSerSerAlaIleHisLeuLysLysLysMetGluLeuSerL 333  
 847 ...TCTGAACAAGAGACCTTGTGAGAAGCCTGATGAGGAGGTGAAA. 891  
 333 euAsnIleProValAsnHisGlyProGlnGluSerCysGlySerSer 349  
 892 .....GACCTGGCTCATGAGCCAGGAGGAGAAAGCTCTAGAGTCC 933  
 350 GlnLeuHisGluAsnSerGlySerProGluThrSerArgSerLeuProAl 366  
 934 AAGAGTGAGCCAGCCGAGGCTCCTCAGCCTCAAGCGGCTCTGCTCC 983  
 366 aProGlnAspAsnAsp.PheLeuSerArgLysAlaGlnAspCysTyrPhe 382  
 984 CCCCTTCGATACGACTGCAGTCTC.....CCGAGTGC..... 1018  
 383 MetLysLeuHisCysProGlyAsnHisSerTyrPaspSerThrIleSe 399  
 1019 .....TGT.....CACAGTTG.....ACTCTGGG 1038  
 399 rGlySerGlnArgAlaAlaPheCysAspHisLysThrThrProCysSerS 416  
 1039 ATCTTCCCAA.....GACTCTTGAAGGCCCCGAGAGCT 1073  
 416 erAlaIleIleAsnProLeuSerThrAlaGlyAsnSerGluArgLeuGln 432  
 1074 CAGCCGAGTT...CCTCTG.....AATCCAGCTCCCATCGT 1108  
 433 ProGlyIleAlaGln.....GlnTrpIleGlnSerLy 443  
 1109 CCAGCAGTGGCAGAGAGGCTCTCGGGGTGTCTCAGTGGACTCAGCCTTT 1158  
 443 sArgGluAspIleValAsnGlnMetThrGluAlaCysLeuAsnGlnSerL 460  
 1159 TCCTCCAGAG.....GATCCCTGT..... 1177  
 460 euAspAlaLeuLeuSerArgAspLeuIleMetLysGluAspTyrGluLeu 476  
 1178 ..CACTGCTTTTGAGC..... 1192  
 477 valSerThrLysProThrArgThrSerLysValArgGlnLeu...LeuAsp 492  
 1193 .....GGGAAGCTTCAACAGCGGACCTGGGC 1218  
 493 ThrThrAspIleGlnGlyGluPheAlaLysValIleValGlnLysLe 509  
 1219 CCACAGACATCCAGAGAAGAGAGCTAGTGGATGCCATCATATCAGGGGA 1268  
 509 uLysAspAsnLysGlnMetGlyLeuGlnProTyrProGluIleLeuValy 526  
 1269 CACCAGCAGCTGATGAAGATCTACAGCCCAAGATGTGACTGGTTC 1318  
 526 alSerArgSerProSerLeu 532  
 1319 TAGACAGCAGTCCAGCCTG 1338

seq\_name: /cgnl\_8/gcgdata/geneseq/geneseq/NA1997.DAT:43752

seq\_documentation\_block:

ID T43752 standard; cDNA; 2268 BP.

AC T43752;

DT 13-FEB-1997 (first entry)

XX

DE Mouse receptor interacting protein gene.  
 XX Receptor interacting protein; RIP; cell death; apoptosis;  
 KW Fas; APO-1; signal transduction; cancer; gene therapy; ss.  
 XX Mus sp.  
 FH Key Location/Qualifiers  
 FT CDS 52..2022  
 XX /\*tag= a  
 PN W09636730-A1.  
 XX 21-NOV-1996.  
 XX 18-APR-1996; 96WO-US05386.  
 XX 18-MAY-1995; 95US-0444005.  
 XX (GEHO ) GEN HOSPITAL CORP.  
 XX (HARD ) HARVARD COLLEGE.  
 PI Kim E, Leder P, Lee T, Seed B, Stranger BZ;  
 XX WPI; 1997-012100/01.  
 DR P-PSDB; W04627.  
 XX Receptor interacting protein having death and kinase domain - useful  
 PT to control diseases that involve abnormal apoptosis, and for  
 PF diagnosis and drug screening  
 XX Disclosure: Page 38-39; 64pp; English.  
 XX A cDNA clone (T43752) codes for mouse receptor interacting protein  
 CC (RIP) (W04627), a protein which contains a C-terminal death domain  
 CC through which RIP interacts with the Fas/APO-1 intracellular domain  
 CC (ICD). RIP overexpression leads to cell death. The RIP cDNA was  
 CC identified from a mouse thymus cDNA library by screening with the  
 CC human RIP coding sequence (see also T43753) and sequence analysis  
 CC of overlapping clones. It can be used as a probe and to produce  
 CC recombinant RIP in host cells.  
 XX Sequence 2268 BP; 719 A; 491 C; 576 G; 482 T; 0 Other;  
 SQ

alignment\_scores:

Quality: 397.00 Length: 609

Ratio: 1.272 Gaps: 25

Percent Similarity: 51.232 Percent Identity: 25.452

alignment\_block:

US-09-445-223-1 x T43752

Align seg 1/1 to: T43752 from: 1 to: 2268

24 LeuSerArgGlyAlaSerGlyThrValSerSerAlaArgHisAlaaspTr 40

118 CTAGACAGCGGAGGCTCGGAAAGGTCTCTGTGTATCCACAGAACGCA 167

40 pArgValGlnValAlaValLysHisLeuHisIleHisThrProLeuLeuA 57

168 TGGATTGTTCATCTGAAAAA.....GTATACACAGGCCCCAACCC 208

57 spSerGluArgLysAspVal...LeuArgGluAlaGluIleLeuHisLys 72

209 GCCTGAGTACATAGGTTCTCTGGAAGGGGAGAGATGATCCACAGA 258

73 AlaArgPheSerTyrIlePheProIleLeuGlyIleCysAsnGluProG1 89

259 CTGACACACAGCTCCGAGTGTGAAGCTACTGGCATCATATAGAAGAAGG 308

89 uPheLeuGlyIleValThrGluTyrMetProAsnGlySerLeuAsnGluL 106



361 .....,SerArgSerLeuProAlaProGlnAspAsn 370  
1205 CTTTTGGATATTTGCAGAAAACACAAAACCCGCGACCGCAGCAGCAGAT 1254  
371 AspPheLeuSerArgLysAlaGlnAspCysTyrPheMetLysLeuHisH1 387  
1255 GAGGCTTACAACAGAGAGAGGAA.....AGGAAACGAAAGSGTCTCTCA 1298  
387 SCYSPRO..... 389  
1299 TGACCCCTTTGCCACAGAGAGCTCGTGAGAATATTAAAGAGTCAGGAG 1348  
390 ..GlyAsnHisSerTrpAspSerTrpIleSerGlySerGlnArgAlaA1a 405  
1349 CAAGAGGTCTATCTGTATCCAGCCACCAACGAGT.....CGTGGAAAT 1389  
406 PheCysAspHisLysThrProCysSerSerAlaIleIleAsn..... 420  
1390 GCAGTGCAACAGCTGTATGGCCGCCCCCAACAGTTTTGGAAACAATGG 1439  
421 .....,ProLeuSerThrAlaGlyAsnSerGluArgLeuG 432  
1440 AFTGTATAATCAGCATGGATTGGAACTACAGGTACAGGAGTTTGTATC 1489  
432 InProGlyIleAlaGlnTrpIleGlnSerLys..... 443  
1490 CGCCAAATCTAAGCCAATGTATAGTACTTATATAAACTCCAGTCGCCAG 1539  
443 .....,ArgGluAspIleVal,AsnGlnMet..... 451  
1540 ACCAACATACCGGGAAGCACACCACCAGTCATCTCTCTGGCCAGT 1589  
444 ArgGluAspIleVal,AsnGlnMet..... 451  
1590 AGCAGATGACCTCAATAAAATATAFATATTCATAGTTTGGTTCATTTCAG 1639  
452 ThrGluAlaCysLeuAsnGlnSerLeuAspAlaLeuLeuSerArgAspLe 468  
1640 TTGGAAACCAACAAATATATGGATGGGAGTTTGCAGTGAATTCACACCACCAAC 1689  
468 uIleMetLysGluAspTyrGluLeuValSerThrLysProThrArgThrs 485  
1690 AATACCTTCAAAAGAGAGAGTCCAGACTCCAGACACCAAGCCATCTTTGATAA 1739  
485 eLysValArgGlnLeuAspThrAspIleGlnGlyGlu..... 499  
1740 CACCACCTAGTCTGACCTGACACCTGAACCTTATCAGGGAAAACCTGG 1789  
500 .....,GluPheAlaLysValIleValG1 507  
1790 GAAGGCAGTGGAAAACACTGTGCCCGCAAGCTGGCTTCACTGAGTCTCAG 1839  
507 nLysLeuLysAspAsnLysGlnMet 515  
1840 ATCGATGAATCGACCATGACTATG 1864

309 GAACCTATTCCTGGTGGATGGAGTACATGGAGAGAGGCAACCTGATGCACG 358  
106 euLeuHisArgLysThrGluTyrProAspValAlaIleTrpProLeuArgPhe 122  
359 TGCTA.....AAGACCCAGATA...GATGTCACCTTCATTTGAAGGA 399  
123 ArgIleLeuHisGluIleAlaLeuGlyIleValAsnTyrLeuHisAsnMetTh 139  
400 AGGATAAATCGTGGAGCCATAGAAGCAATGTGCTACTTACATGAC..... 444  
139 rProProLeuLeuHisHisAspLeuLysThrGlnAsnIleLeuLeuAspa 156  
445 AAAGTGTGATACACAGAGCCCTGAAGCCTGAGAATATCCTCGTTGATC 493  
156 snGluPheHisValLysIleAlaAspPheGlyLeuSerLysTrpArgMet 172  
494 GTGACTTTCACATTAAGATAGCGATCTGGTGGCTTCCTTTAAGACA 543  
173 MetSer...LeuSerGlnSerArgSerLysSerAlaPro..... 185  
544 TGGAGCAAACTGACTAAGGAGAGAACACAAAGCAGAGAAAAGTAGGAGCAG 593  
186 .....,GluGlyClyThrIleIleTyrMetProGlu, 196  
594 CACCACCTAAGAAGAACATGGTGGTACCTTTACTATACATGGCACCCGAA 643  
197 .....,AsnTyrGluProGlyGlnLysSerArgAlaSerIle 208  
644 ACCTGAATGACATCAATGCAAGCCCAAGCGAGAACTG..... 681  
209 LysHisAspIleTyrSerTyrAlaValIleThrTrpGluValLeuSerAr 225  
682 .....,GAGCTTACAGCTTGTGCAATTCCTTGGCAATATTTGCCAAA 725  
225 gLysGlnProPheGluAspValThrAsnProLeuGlnIleMetTyrSerV 242  
726 AAAGAGCCCTATGAGAATGTACTGTACTGAGCAGTTCGGTACTGCCA 775  
242 aIserGlnGlyHisArgProValIleAsnGlu.....GluSerLeuPro 256  
776 TAAATCTGGGAACAGGCCAAATGTAGAGAAATCCTTCAGTACTGTCCA 825  
257 TyrAspIleProHisArgAlaIleMetIleSerLeuIleGluSerGlyTr 273  
826 AGGAGATC.....ATCAGCCTCATGGAGCGGTGCTG 857  
273 pAlaGlnAsnProAspGluArgProSerPheLeuLysCysLeuIleGluL 290  
858 GCAGGCGATCCCAGAGAGAGCCCAACATTTCTTGGCATTGGAAGAAT 907  
290 euGluPro...ValLeuArgThrPheGluIleThrPheLeuGluAla 305  
908 TTAGGCTTTTACTTAAGTCAATTTTGAAGAATATGTA...GAAGAGAT 954  
306 ValIleGlnLeuLysLys.....ThrLysLeuGlnSe 316  
955 GTGGCAAGTTTAAAGAAGAGATCCAGATCAAAGCCCAAGCTGTGCAGAG 1004  
316 rValSerSerAlaIleHisLeuLys..... 324  
1005 AATGTCTTACCTGACCATGACTGTGTACCTTACCCTCCGAGCAGTCAA 1054  
325 ..AspLysLysMetGluLeuSerLeuAsnIleProValAsnHisGly 340  
1055 ATTCAGAACAACTGGATGCGTGCAGATTCCAGGGGCTCCAGATGGGT 1104  
341 ProGlnGluLysCysGlySerGln.....LeuHisG1 353  
1105 CCTGTGGAGAGTCTCGTTTCTCCCTCCAGAGTACCCAGACGACCA 1154  
353 uAsnSerGlySerProGluThr..... 360  
1155 GAATGATCCAGTGTGCAAGGCTGAAGGAGGAAAGCCAGCTATATCATG 1204



OM of: US-09-445-223-1 to: EST.\* out\_format : pfs
Date: Jun 13, 2001 5:56 PM
About: Results were produced by the GenCore software, version 4.5, Copyright (c) 1993-2000 Compugen Ltd.

Command line parameters:
-MODEL=frame-p2n.model -DEV=xlp
-O=/cgm1\_1/USPTO.spool/US09445223/runat\_13062001\_092032\_29632/app\_query.fasta\_1.604
-DB=EST -OFP=fastap -SUFFIX=p2n.rst -GAPOP=12.000 -GAPEXT=4.000
-MINARCH=0.100 -LOOPCL=0.000 -LOOPEXT=0.000 -QGAPOP=4.500
-QGAPEXT=0.050 -XGAPOP=10.000 -XGAPEXT=0.500 -FGAPOP=6.000
-FGAPEXT=7.000 -YGAPOP=10.000 -YGAPEXT=0.500 -DELOP=6.000
-DELEXT=7.000 -START=1 -MATRIX=blotsum62 -TRANS=human40.cgi
-LIST=15 -DOCALLIGN=200 -THR\_SCORE=pct -THR\_MAX=100 -THR\_MIN=0
-ALIGN=15 -MODE=LOCAL -OUTFMT=pfs -NORM=ext -MINLEN=0
-MAXLEN=2000000000 -USER=US09445223\_SCGN1\_1\_3541 -NCPU=6
-ICPU=3 -LONGLOG -NO\_XLPXY -WAIT -THREADS=1

Search information block:

Query: US-09-445-223-1
Query length: 540
Database: EST.\*
Database sequences: 9623517
Database length: 73081774
Search time (sec): 1225.860000

score\_list:

Table with columns: Sequence, Strd Orig, ZScore, EScore, Len, Documentation. Lists sequence identifiers and their corresponding scores and documentation references.

gb\_est5:AA301765 + 572.00 1034.81 1.5e-48 337 | AA301765 EST14819 Aorta endo
gb\_est68:BE002713 - 578.00 1031.20 2.4e-48 446 | BE002713 QV4-BN0090-210300-1
gb\_est12:AA826052 - 568.00 1025.27 5.1e-48 400 | AA826052 QG60B09\_s1 NCI\_CGAP
gb\_est92:BF825562 - 565.00 1021.64 8.2e-48 346 | BF825562 CMI-HN0016-161100-5

seq\_name: gb\_est97:BG170405

seq\_documentation\_block:
LOCUS BG170405 811 bp mRNA EST 06-FEB-2001
DEFINITION G02322736F1 NIH\_MGC\_89 Homo sapiens cDNA clone IMAGE:4426016 5',
mRNA sequence.

ACCESSION BG170405
VERSION BG170405.1 GI:12677108
KEYWORDS EST.
SOURCE human.

ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1 (bases 1 to 811)
AUTHORS NIH-MGC http://mgc.nci.nih.gov/.
TITLE National Institutes of Health, Mammalian Gene Collection (MGC)
JOURNAL Unpublished (1999)
COMMENT Contact: Robert Strausberg, Ph.D.
Tel: (301) 496-1550
Email: Robert\_Strausberg@nih.gov

Tissue Procurement: ATCC
CDNA Library Preparation: Life Technologies, Inc.
CDNA Library Arrayed by: The I.M.A.G.E. Consortium (LLNL)
DNA Sequencing by: Incyte Genomics, Inc.
Clone distribution: MGC clone distribution information can be
found through the I.M.A.G.E. Consortium/LLNL at:
http://image.llnl.gov
Plate: LLAM10172 row: 9 column: 09
High quality sequence stop: 721.

FEATURES
Location/Qualifiers
1..811
/organism="Homo sapiens"
/db\_xref="taxon:9606"
/clone="IMAGE:4426016"
/clone\_lib="NIH\_MGC\_89"
/tissue\_type="hyperneoplasia, cell\_line"
/lab\_host="DH10B (phage-resistant)"
/note="Organ: kidney; Vector: pCMV-SPORT6; Site\_1: NotI;
Site\_2: SalI; Cloned unidirectionally; Oligo-dT primed.
Average insert size 1.3 kb. Library enriched for
full length clones and constructed by Life Technologies.
Note: this is a NIH\_MGC Library."
BASE COUNT 272 a 177 c 156 g 206 t
ORIGIN

alignment\_scores:
Quality: 1282.50 Length: 270
Ratio: 4.933 Gaps: 3
Percent Similarity: 96.296 Percent Identity: 94.074
alignment\_block:
Align seg 1/1 to: BG170405 from: 1 to: 811
259 ILeProHisArgAlaArgMetIleSerLeuIleGluSerGlyTrpAlaGI 275
|||||
3 ATACCTCCAGCAGCAGGTATGATCTCTCTAATAAGAAAGTGGATGGCACA 52
|||||
275 nAsnProAspGluArgProSerPheLeuLysCysLeuIleGluLeuGluP 292
|||||
53 AAATCCAGATGAAGACCACCTCTCTTAAATGTTTAAATAGAACCITGAAC 102
|||||
292 roValLeuArgThrPheGluGluIleThrPheLeuGluAlaValIleGln 308
|||||
103 CAGTGTGAGAACATTTGAAGAGATTAACATTTCTTGAAGCTGTTATTCAG 152
|||||

309 LeuLysLysThrLysLeuGlnSerValSerSerAlaIleHisLeuCysAs 325  
 |||  
 153 CTAAGAAAACAAAGTTACAGAGTGTTCAGTGCATTCACCTATGTGA 202  
 |||  
 325 pLysLysMetGluLeuSerLeuAsnIleProValAsnHisGlyProG 342  
 |||  
 203 CAAGAAGAAAATGGAATATCTGAAACATCTGTAATCATGTGCCAC 252  
 |||  
 342 lnGluGluSerCysGlySerGlnLeuHisGluAsnSerGlySerPro 358  
 |||  
 253 AAGAGGAATCATGTGCATCTCTCAGCTCCATGAAATAGTGGTCTCCT 302  
 |||  
 359 GluThrSerArgSerLeuProAlaProGlnAspAsnAspPheLeuSerAr 375  
 |||  
 303 GAAACTTCAAGTCCCTGCCGCTCCTCAAGACAAATGATTTTATCTAG 352  
 |||  
 375 gLysAlaGlnAspCysTyrPheMetLysLeuHisLysCysProGlyAsnH 392  
 |||  
 353 AAAAGCTCAAGACTGTTATTTATGAACTGCATCCTGCTCCGGAATC 402  
 |||  
 392 IserTrpAspSerThrIleSerGlySerGlnArgAlaAlaPheCysAsp 408  
 |||  
 403 ACAGTTGGGATAGCACCATTTCTGGATCTCAAAGGGCTGCATCTGTGAT 452  
 |||  
 409 HisLysThrProCysSerAlaIleIleAsnProLeuSerThrAl 425  
 |||  
 453 CACAAGNCACTCCATGCTCTCCAGCAATAATAATCCACTCTCAACTGC 502  
 |||  
 425 aGlyAsnSerGluArgLeuGlnProGlyIleAlaGlnGlnTrpIleGlnS 442  
 |||  
 503 AGGAAACTCAGAAGCTGTGCAGCTGTGTATAGCCACAGTGGATCCAGA 552  
 |||  
 442 erLysArgGluAspIleValAsnGlnMetThrGluAlaCysLeuAsnGln 458  
 |||  
 553 GAAAAGGGAGACATTTGTGAACCAATGACAGAGCCCTGCTTAACCAG 602  
 |||  
 459 SerLeuAspAlaLeuLeuSerArgAspLeuIleMetLysGluAspTyrG1 475  
 |||  
 603 TCGTAGACTCCCTTCTGTCCAGGACTTGCATCATGAAAGAGGACTATGA 652  
 |||  
 475 uLeuValSerThrLysProThrArgThrSerLysValArg. GlnLeuLeu 491  
 |||  
 653 ACTTGTGTAGTACCAGGCTCAAGGACTCAAAAGTCAGACCAATACTA 702  
 |||  
 492 AspThrThrAspIleGlnGlyGluGluPheAlaLysValIleValGlnLy 508  
 |||  
 703 GACTACTGACATCCAAAGGAGAGATTTGCCAAAGTTATACGTACAAA 752  
 |||  
 508 sLeu.LysAspAsnLysGlnMetGlyLeuGlnProTyrProGluIleLeu 524  
 |||  
 753 ATTGACGA...TTACCAACAATGGTCTTAAGCCTTACCAGGAAAATACTG 799  
 |||  
 525 ValVal 526  
 |||  
 800 TGGGTT 805  
 |||

seq\_name: gb\_est79:BE877822  
 seq\_documentation\_block:  
 LOCUS BE877822 870 bp mRNA EST 20-OCT-2000  
 DEFINITION G0148632F1 NIH\_MGC\_69 Homo sapiens cDNA clone IMAGE:3888815 5',  
 mRNA sequence.  
 ACCESSION BE877822  
 VERSION BE877822.1 GI:10326598  
 KEYWORDS EST.  
 SOURCE human.  
 ORGANISM Homo sapiens  
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
 REFERENCE 1 (bases 1 to 870)  
 AUTHORS NIH-MGC <http://mgi.nci.nih.gov/>.  
 TITLE National Institutes of Health, Mammalian Gene Collection (MGC)  
 JOURNAL Unpublished (1999)

COMMENT Contact: Robert Strausberg, Ph.D.  
 Tel: (301) 496-1550  
 Email: Robert\_Strausberg@nih.gov  
 Tissue Procurement: DCFD/DFP/Gazdar  
 cDNA Library Preparation: Life Technologies, Inc.  
 cDNA Library Arrayed by: The I.M.A.G.E. Consortium (LNL)  
 DNA Sequencing by: Incyte Genomics, Inc.  
 DNA distribution: MGC clone distribution information can be  
 found through the I.M.A.G.E. Consortium/LNL at:  
<http://image.llnl.gov>  
 Plate: LLAM9669 row: g column: 24  
 High quality sequence stop: 739.

FEATURES  
 source  
 1..870  
 /organism="Homo sapiens"  
 /db\_xref="taxon:9606"  
 /clone\_lib="NIH\_MGC\_69"  
 /tissue\_type="large cell carcinoma, undifferentiated"  
 /lab\_host="DH10B (phage-resistant)"  
 /note="Organ: lung; Vector: pCMV-SPORT6; Site\_1: NotI;  
 Site\_2: SalI; Cloned unidirectionally. primer: Oligo dt.  
 Average insert size 1.1 kb. Library constructed by Life  
 Technologies."  
 BASE COUNT 288 a 200 c 170 g 212 t  
 ORIGIN

alignment\_scores:  
 Quality: 1168.00 Length: 244  
 Ratio: 4.846 Gaps: 3  
 Percent Similarity: 98.770 Percent Identity: 98.361  
 alignment\_block:  
 US-09-445-223-1 x BE877822

Align seg 1/1 to: BE877822 from: 1 to: 870  
 299 GluIleThrPheLeuGluAlaValIleGlnLeuLysLysThrLysLeuG1 315  
 |||  
 2 GAGATAACTTTTCTTGAAGCTGTATTTCAGCTAAAGAAAACAAAGTTACA 51  
 |||  
 315 nSerValSerSerAlaIleHisLeuCysAspLysLysMetGluLeuS 332  
 |||  
 52 GAGTGTTCAGTGCATTCACCTATGTGCACAAAGAAAATGGAATAT 101  
 |||  
 332 erLeuAsnIleProValAsnHisGlyProGlnGluSerCysGlySer 348  
 |||  
 102 CTTCTGAACTACCTGTAATCATGTCACCAAGAGAAATCATGTGCATCC 151  
 |||  
 349 SerGlnLeuHisGluAsnSerGlySerProGluThrSerArgSerLeuPr 365  
 |||  
 152 TCTCAGCTCCATGAAAATAGTGTCTCTGAAAACCTCAAGGTCCTCGCC 201  
 |||  
 365 oAlaProGlnAspAsnAspPheLeuSerArgLysAlaGlnAspCysTyrP 382  
 |||  
 202 AGCTCTCAAGACATGATTTTTTATCTAGAAAAGCTCAAGACTGTTATT 251  
 |||  
 382 heMetLysLeuHisLysCysProGlyAsnHisSerTrpAspSerThrIle 398  
 |||  
 252 TTATGAAAGTGCATCAGTCTGGAATACACAGTTGGGATAGCACCATT 301  
 |||  
 399 SerGlySerGlnArgAlaAlaPheCysAspHisLysThrProCysSe 415  
 |||  
 302 TCTGGATCTCAAAGGGCTGCATCTGTGATCACAAGACCACTCAATGCTC 351  
 |||  
 415 rSerAlaIleIleAsnProLeuSerThrAlaGlyAsnSerGluArgLeuG 432  
 |||  
 352 TTCAGCAATTAATCACTCTCAACTGCAGGAAACTCAGAACCTCTGC 401  
 |||  
 432 lnProGlyIleAlaGlnGlnTrpIleGlnSerLysArgGluAspIleVal 448  
 |||  
 402 AGCCTGTATAGCCAGCTGGATCCAGAGCAAAAGGGAAGACATTTGTG 451  
 |||

Percent Similarity: 99.512 Percent Identity: 99.512  
 alignment\_block:  
 US-09-445-223-1 x BE875947

Align seg 1/1 to: BE875947 from: 1 to: 828

```

337 ValAsnHisGlyProGlnGluSerCysGlySerSerGlnLeuHisG1 353
5  G T A A A T C A T G G T C C A C A A G A G G A A T C A T G T G G A T C C T C C A G C T C C A T G A 54
353 uAsnSerGlySerProGluThrSerArgSerLeuProAlaProGlnAspA 370
55  A A A T A G T G G T T C C T G A A A C T T C A A G G T C C C T G C C A G C T C C T C A A G A C A 104
370 snAspPheLeuSerArgLysAlaGlnAspCysTyrPheMetLysLeuHis 386
105 A T G A T T T T T A T C T A G A A A G C T C A A G A C T G T T A T T T A T A G A A G C T G C A T 154
387 HisCysProGlyAsnHisSerTrpAspSerThrIleSerGlySerGlnAr 403
155 C A C T G T C C T G G A A T C A C A G T T G G G A T A G C A C C A T T T C T G G A T C T C A A G 204
403 gAlaAlaPheCysAspHisLysThrThrProCysSerSerAlaIleIlea 420
205 G G C T G C A T T C T G T G A T C A C A A G A C C A C T C C A T G C T C T T C A G C A A T A A T A A 254
420 snProLeuSerThrAlaGlyAsnSerGluArgLeuGlnProGlyIleAla 436
255 A T C C A C T C T C A A C T G C A G G A A A C T C A G A A C G T C T G C A G C T G G T A T A G C C 304
437 GlnGlnTrpIleGlnSerLysArgGluAspIleValAsnGlnMetThrG1 453
305 C A G C A G T G G A T C C A G A C A A A A G G G A A G A C A T T G T C A A C C A A A T G A C A G A 354
453 uAlaCysLeuAsnGlnSerLeuAspAlaLeuLeuSerArgAspLeuIleM 470
355 A G C C T G C C T T A A C C A G T C G T A G A T G C C C T T C T G T G C C A G . G A C T T G A T C A 403
470 etLysGluAspTyrGluLeuValSerThrLysProThrArgThrSerLys 486
404 T G A A G A G G A C T A T A G A C T T G T T A G T A C C A A G C T A C A A G G C C T C A A A A 453
487 ValArgGlnLeuLeuAspThrThrAspIleGlnGlyGluGluPheAlaLys 503
454 G T C A G A C A A T T A C T A G A C A C A C T A C T G A C A T C C A A G A G A G A A G A A T T G C C A A 503
503 sValIleValGlnLysLeuLysAspAsnLysGlnMetGlyLeuGlnProf 520
504 A G T T A T A T A C A A A A A T T G A A G A T A A C A A A C A A A T G G G T C T T C A G C G C T T 553
520 yrProGluIleLeuValSerArgSerProSerLeuAsnLeuG1 536
554 A C C C G G A A A T A C T G T G G T T T C T A G A T C A C C A T C T T T A A A T T T A C T T C A 603
536 nAsnLysSerMet 540
604 A A A T A A A A G C A T G 616
seq_name: gb_est75:BE536247
seq_documentation_block:
LOCUS BE536247 654 bp mRNA EST 09-AUG-2000
DEFINITION 601062632F1 NIH_MGC_10 Homo sapiens cDNA clone IMAGE:3449311 5',
mRNA sequence.
ACCESSION BE536247
VERSION BE536247.1 GI:9764892
KEYWORDS EST.
SOURCE human.
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominiidae; Homo.
REFERENCE 1 (bases 1 to 654)

```

```

449 AsnGlnMetThrGluAlaCysLeuAsnGlnSerLeuAspAlaLeuLeuSe 465
|||||
452 AACCAAAATGACAGAGCCTGCCTTACCAGTCGCTAGATGCCCTTCTGTC 501
|
465 rArgAspLeuIleMetLysGluAspTyrGluLeuValSerThrLysProf 482
|
502 CAG.GACTTGATCATGAAAGAGGACTATGAACCTGTTAGTACCAGCCTA 550
|
482 hrArgThrSerLysValArgGlnLeuLeuAspThrThrAspIleGln.G1 498
|||||
551 CAAGGACCTCAAAAGTCAGACAAATTAAGACACTACTGACATCCAAAGG 600
|
498 yGluGluPheAlaLysValIleValGlnLysLeuLysAspAsnLysGlnM 515
|||||
601 AGAAGAATTTGCCAAAGTTATAGTACAAAATTTGAAAGATAACAAACAAA 650
515 etGlyLeu..GlnProTyrProGluIleLeuValSerArgSerProS 531
|||||
651 TGGGTCTTTTCAGGCCCTTACCCGGAATACTTGTGGTTTCTAGATCACCAT 700
|
531 etLeuAsnLeuLeuGlnAsnLysSer 539
701 CTTTAAATTTTACTTCAGAAATAAAGC 727
seq_name: gb_est79:BE875947
seq_documentation_block:
LOCUS BE875947 828 bp mRNA EST 20-OCT-2000
DEFINITION 601486423F1 NIH_MGC_69 Homo sapiens cDNA clone IMAGE:3888965 5',
mRNA sequence.
ACCESSION BE875947
VERSION BE875947.1 GI:10324723
KEYWORDS EST.
SOURCE human.
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominiidae; Homo.
REFERENCE 1 (bases 1 to 828)
AUTHORS NIH-MGC http://mgc.nci.nih.gov/.
TITLE National Institutes of Health, Mammalian Gene Collection (MGC)
JOURNAL Unpublished (1999)
COMMENT Contact: Robert Strausberg, Ph.D.
Tel: (301) 496-1550
Email: Robert.Strausberg@nih.gov
Tissue Procurement: DCTD/btp/Gazdar
cDNA Library Preparation: Life Technologies, Inc.
cDNA Library Arrayed by: The I.M.A.G.E. Consortium (LLNL)
DNA Sequencing by: Incyte Genomics, Inc.
Clone distribution: MGC clone distribution information can be
found through the I.M.A.G.E. Consortium/LLNL at:
http://image.llnl.gov
Plate: LLAM9669 row: n column: 06
High quality sequence stop: 795.
FEATURES
Location/Qualifiers
1..828
/organism="Homo sapiens"
/db_xref="taxon:9606"
/clone="IMAGE:3888965"
/tissue_lib="NIH_MGC_69"
/tissue_type="large cell carcinoma, undifferentiated"
/lab_host="DH10B (phage-resistant)"
/note="Organ: lung; Vector: pCMV-Sport6; Site:1: NotI;
Site:2: SalI; Cloned unidirectionally. Primer: Oligo dt.
Average insert size 1.1 kb. Library constructed by Life
Technologies."
BASE COUNT 287 a 163 c 165 g 213 t
ORIGIN
alignment_scores:
Quality: 1026.00 Length: 205
Ratio: 5.029 Gaps: 1

```

AUTHORS NIH-MGC http://mgc.nci.nih.gov/
TITLE National Institutes of Health, Mammalian Gene Collection (MGC)
JOURNAL Unpublished (1999)
COMMENT Contact: Robert Strausberg, Ph.D.
Tel: (301) 496-1550
Email: Robert\_Strausberg@nih.gov
Tissue Procurement: ATCC

CDNA Library Preparation: Life Technologies, Inc.
CDNA Library Arrayed by: Incyte Genomics, Inc.
DNA Sequencing by: Incyte Genomics, Inc.
Clone distribution: MGC clone distribution information can be found through the I.M.A.G.E. Consortium/LLNL at:
http://image.llnl.gov
Plate: LLM8425 row: 0 column: 08
High quality sequence stop: 650.

FEATURES
source
1..654
Location/Qualifiers
/organism="Homo sapiens"
/db\_xref="taxon:9606"
/clone="IMAGE:3449311"
/clone\_lib="NIH\_MGC\_10"
/cell\_line="MGC36"
/lab\_host="DH10B"
/Note="Organ: cervix; Vector: pCMV-SPORT6; Site\_1: NotI; Site\_2: SalI; Cloned unidirectionally. Primer: Oligo dt. Average insert size 1.5 kb. Library prepared by Life Technologies."

BASE COUNT 214 a 149 c 131 g 158 t 2 others
ORIGIN

alignment\_scores:
Quality: 1019.00 Length: 219
Ratio: 4.807 Gaps: 4
Percent Similarity: 96.804 Percent Identity: 95.890

alignment\_block:
US-09-445-223-1 x BE536247
Align seg 1/1 to: BE536247 from: 1 to: 654

311 LysThrLysLeuGlnSerValAlaIleHisLeuCysAspLysLy 327
3 AAAACAAGTTTACAGAGTGTTCCTCAAGTGCCATTCACCTATGTGACAAGAA 52
327 sLysMetGluLeuSerLeuAsnIleProValAsnHisGlyProGlnGluG 344
53 GAAATGGAAATTTCTGTACATACCTGTAATCATGGTCCACAGAGG 102
344 luSerCysGlySerSer.GlnLeuHisGluAsnSerGlySerProGluTh 360
103 AATCATGTGGATCCTCTCANGCTCCATGAAATAGTGGTTCTCCTGAAC 152
360 rSerArgSerLeuProAlaProGlnAspAspPheLeuSerArgLysA 377
153 TTCAGGTTCCTGCGAGCTCTCAAGACAAATGATTTTTATCTAGAAAG 202
377 laGlnAspCysTyrPheMetLysLeuHisLysCysProGlyAsnHisSer 393
203 CTCRAGACTGTTATTTATGAAGCTGCATCCTCTCTGGAAATCACAGT 252
394 TrpAspSerThrIleSerGlySerGlnArgAlaAlaIleHisCysAspHisLy 410
253 TGGGATAGCACCATTCTGGATCTCAAAAGGCTGCAATCTCTGTATCACA 302
410 sThrThrProCysSerSerAlaIleIleAsnProLeuSerThrAlaGlyA 427
303 GACCACTCATGCTCTTCAGCAATAAATAATCCACTCTCAACTGCAGAA 352
427 snSerGluArgLeuGlnProGlyIleAlaGlnGlnTrpIleGlnSerLys 443
353 ACTCAGAACGCTCTGAGGCTGTATAGCCAGAGAGAGAGGATCCAGAGCAA 402

444 ArgGluAspIleValAsnGlnMetThrGluAlaCysLeuAsnGlnSerLe 460
403 AGGGAAGACATTTGTGAACCAATGACAGAAGCCCTCTT.ACCACGTCGCT 451
460 uAspAlaLeuLeuSerArgAspLeuIleMetLysGluAspTyrGluLeuV 477
452 AGATGCCCTTCTGTCCAGGGACTTGCATCATGAAAGAGGACTATGAAC 501
477 alSerThrLysProThrArgThrSerLysValArgGlnLeuLeuAspThr 493
502 TTATGACCAAGCCTCAAGGACTCAAAAGTCCAGCAATTTGCTAGACACT 551
494 ThrAspIleGlnGly.GluGluPheAlaLysValIleValGlnLys.Leu 509
552.ACTGACATCCAGGCAGAGAAATTTGGCANAGCTTATAGTACAAAATTTG 601
510 LysAspAsn.LysGlnMetGlyLeuGlnProTyrProGluIleLeuVal 525
602 CAAGATAACCAACAATGGGTTTCAGCCTTACCCCGGAATACTTTGTG 650

seq\_name: gb\_est3:AA160647
seq\_documentation\_block:
LOCUS AA160647 645 bp mRNA EST 16-DEC-1996
DEFINITION Zg49C11.r1 Stragatene hNT neuron (#937233) Homo sapiens CDNA clone
IMAGE:633044 5', mRNA sequence.

ACCESSION AA160647
VERSION AA160647.1 GI:1736024
KEYWORDS EST.
SOURCE human.
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE 1 (bases 1 to 645)
AUTHORS Hillier,L., Lennon,G., DuBueque,T., Favello,A., Gish,W., Hawkins Chissoe,S., Dietrich,N., Lacy,M., Le,M., Le,N., Mardis,E., Moore ,M., Hultman,M., Kucaba,T., Lacey,M., Le,M., Le,N., Mardis,E., Moore Schellenberg,K., Soares,M.B., Tan,F., Thierry-Mieg,J., Treveskis,E., Underwood,K., Wohlmann,P., Waterston,R., Wilson,R. and Marra,M. Generation and analysis of 280,000 human expressed sequence tags Genome Res. 6 (9), 807-828 (1996)

TITLE JOURNAL
MEDLINE 97044478
COMMENT Contact: Wilson RK
Washington University School of Medicine
4444 Forest Park Parkway, Box 8501, St. Louis, MO 63108
Tel: 314 286 1800
Fax: 314 286 1810
Email: est@watson.wustl.edu

This clone is available royalty-free through LLNL; contact the IMAGE Consortium (info@image.llnl.gov) for further information.
Seq primer: -28M13 rev2 from Amersham
High quality sequence stop: 373.

FEATURES
Location/Qualifiers
1..645
/organism="Homo sapiens"
/db\_xref="GDB:5183128"
/db\_xref="taxon:9606"
/clone="IMAGE:633044"
/dev\_stage="hNT neurons"
/lab\_host="SOLR (kanamycin resistant)"
/Note="Vector: pBluescript SK-; Site\_1: EcoRI; Site\_2: XhoI; Cloned unidirectionally. Primer: Oligo dt. size: 1.5 kb; Uni-ZAP XR Vector; -5' adaptor sequence: 5' GAATTCGGCAGAG 3' -3' adaptor sequence: 5' CTCGAGTATTTTTTTTTTTT 3' "

BASE COUNT 205 a 138 c 123 g 178 t 1 others
ORIGIN
alignment\_scores:

Quality: 995.00 Length: 211
Ratio: 4.901 Gaps: 2
Percent Similarity: 96.209 Percent Identity: 92.891

alignment\_block:
US-09-445-223-1 x AA160647

Align seg 1/1 to: AA160647 from: 1 to: 645

232 ValThrAsnProLeuGlnIleMetTyrSerValSerGlnGlyHisArgPr 248
2 GTCCACCAATCCTTTCAGATAAATGATAGTGTCTCACAAGGACATCGACC 51
248 OValIleAsnGluLeuSerLeuProTyrAspIleProHisArgAlaArgM 265
52 TGTATATATGAAGAAGTTCATATGATATACCTCCAGGACAGCTA 101
265 etIleSerLeuIleGluSerGlyTyrPAlaGlnAsnProAspGluArgPro 281
102 TGTATCTCTAATPAGAAGTGGATGGCCACAAAATCCAGATGAAGACCA 151
282 SerPheLeuLysCysLeuIleGluLeuGluProValIleuArgThrPheG1 298
152 TCTTCTTAATGTTTAAATAGAACCTTGAACCCAGTCTTGAACAATTTGA 201
298 uGluIleThrPheLeuGluAlaValIleGlnLeuLysLysThrLysLeuG 315
202 AGAGATAACTTTCCTGAGCTCTTATTCAGCTAAGAAACAAAGTTAC 251
315 lnSerValSerSerAlaIleHisLeuLysCysAspLysLysMetGluLeu 331
252 AGAGTGTTCACAGTGCATTCACCTATGTGACAAAGAAGAAATGGAATTA 301
332 SerLeuAsnIleProValAsnHisGlyProGlnGluSerCysGlySe 348
302 TCTCTGAACATACCTGTAATCATGCTGTCACAAAGAGAAATCATGTGGATC 351
348 rSerGlnLeuHisGluAsnSerGlySerProGluThrSerArgSerLeuP 365
352 CTCTCAGCTCCATGAAATAGTGGTCTCTCTGAAACTTCAAGTCCCTGC 401
365 roAlaProGlnAspAsnAspPheLeuSerArgLysAlaGlnAspCysTyr 381
402 CAGCTCCTCAAGACAATGATTTTTTATCTAGAAAAGCTCAAGACTGTTAT 451
382 PheMetLysLeuHisCysProGlyAsnHisSerTyrAspSerThrI1 398
452 TTTATGAGCTGCATCCTCTGGAATCACAGTTGGATGACACCAT 501
398 eSerGlySerGlnArgAlaAlaPheCysAspHisLysThrThrProCys 415
502 TTCTGGATCTCAAAGGCTGCAATCTGTGATTCACAGACCACCTCCATGCT 551
415 erSerAlaIleIleAsnProLeuSerThrAlaGlyAsnSerGluArgLeu 431
552 CTTTCAGC.ATAATAAATCCACTCTACTCTGAG...GAATCCGAACGTTG 597
432 GlnProGlyIleAlaGlnInTrpIleGlnSer 442
598 CAGCCT...GTATGCCCGCAGTGGATCCGACCA 627

seq\_name: gb\_est24:AI745575
seq\_documentation\_block:
LOCUS AI745575 592 bp mRNA EST 17-DEC-1999
DEFINITION wc34f12.x1 NCI\_CGAP\_Pr28 Homo sapiens cDNA clone IMAGE:2317103 3'
similar to TR:O43353 O43353 SERINE/THREONINE KINASE RICK. ; mRNA
sequence.
ACCESSION AI745575
VERSION AI745575.1 GI:5113863
KEYWORDS EST.
SOURCE human.
ORGANISM Homo sapiens

Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
1 (bases 1 to 592)
NCI-CGAP http://www.ncbi.nlm.nih.gov/ncicgap.
National Cancer Institute, Cancer Genome Anatomy Project (CGAP),
Tumor Gene Index
Unpublished (1997)
Contact: Robert Strausberg, Ph.D.
Tel: (301) 496-1550
Email: Robert\_Strausberg@nih.gov
Tissue Procurement: Michael J. Brownstein, M.D., Ph.D., Michael R.
Emmert-Buck, M.D., Ph.D.
cDNA Library Preparation: M. Bento Soares, Ph.D.
DNA Library Arrayed by: Greg Lennon, Ph.D.
DNA Sequencing by: Washington University Genome Sequencing Center
Clone distribution: NCI-CGAP clone distribution information can be
found through the I.M.A.G.E. Consortium/LLNL at:
www-bio.llnl.gov/bbrp/image/image.html
Insert Length: 673 Std Error: 0.00
Seq primer: -40UP from Gibco
High quality sequence stop: 459.
Location/Qualifiers

source
I. .592
/organism="Homo sapiens"
/db\_xref="taxon:9606"
/clone="IMAGE:2317103"
/clone\_lib="NCI\_CGAP\_Pr28"
/sex="male"
/dev\_stage="adult"
/lab\_host="DHI0B"
/note="Organ: prostate; Vector: pT7T3D-Pac (Pharmacia)
with a modified polylinker; Plasmid DNA from the
normalized library NCI\_CGAP\_Pr22 was prepared, and ss
circles were made in vitro. Following HAP purification,
this DNA was used as tracer in a subtractive hybridization
reaction. The driver was PCR-amplified cDNAs from a pool
of 5,000 clones made from the same library (clonoids
985608-986759, 1101192-1101959, and 1217928-1220615)."
Subtraction by Bento Soares and M. Fatima Bonaldo.
BASE COUNT 153 a 111 c 128 g 200 t
ORIGIN

alignment\_scores:
Quality: 940.00 Length: 181
Ratio: 5.193 Gaps: 0
Percent Similarity: 100.000 Percent Identity: 100.000
alignment\_block:
US-09-445-223-1 x AI745575/rev ..

Align seg 1/1 to reverse of: AI745575 from: 1 to: 592
360 ThrSerArgSerLeuProAlaProGlnAspAsnAspPheLeuSerArgLy 376
592 ACTCAAGGTCCTCCAGCTCCTCAAGACAATGATTTTTTATCTAGAAA 543
376 sAlaGlnAspCysTyrPheMetLysLeuHisLysCysProGlyAsnHis 393
542 AGCTCAAGACTGTTATTTATGAACTGTCATCCTCTGCGAAATCACA 493
393 erTrpAspSerThrIleSerGlySerGlnArgAlaAlaPheCysAspHis 409
492 GTTGGATAGCACCAATTCGGATCTCAAGGGCTGCATCTCTGATCAC 443
410 LysThrThrProCysSerSerAlaIleIleAsnProLeuSerThrAlaG1 426
442 AAGACCACCTCATGCTCTTTCAGCAATAATAAATCCACTCTCAACTGCAGG 393
426 yAsnSerGluArgLeuGlnProGlyIleAlaGlnGlnTrpIleGlnSerL 443
392 AACTCAGAACGCTCTGACCCCTGGTATPAGCCCGCAGCAGTGGATCCAGACA 343

443 ysArgGluAspIleValAsnGlnMetThrGluAlaCysLeuAsnGlnSer 459  
 342 AAGAGGAGACATTTGACCAAAATGCACAGAGCTTGAAGCCTTAAACCAAGTGG 293  
 460 LeuAspAlaLeuLeuSerArgAspLeuIleMetLysGluAspFyrGluLe 476  
 292 CTAGATGCCCTTCTCCAGGACTTGAATCATGAAAAGAGGACTATGAAC 243  
 476 uValSerThrLysProThrArgThrSerLysValArgGlnLeuAsp 493  
 242 TGTAGTACCAAGCTTCAAGAGCTTCAAAAGTCAACAAATATTACTAGACA 193  
 493 hrThrAspIleGlnGlyGluGluPheAlaLysValIleValGlnLysLeu 509  
 192 CTACTGACATCCRAAGAGAAATTTGCCAAAGTATTAGTACAAAAATTG 143  
 510 LysAspAsnLysGlnMetGlyLeuGlnProFyrProGluIleLeuValVa 526  
 142 AAAGATAACAAACAATGGTCTTCAGCTTACCCGGAATAATATTGTTGGT 93  
 526 lSerArgSerProSerLeuAsnLeuLeuGlnAsnLysSerMet 540  
 92 TTCAGATCACCATCTTTAAATTTACTTTCAAAAATATAAAGCATG 50

seq\_name: gb\_est53:AW960501  
 seq\_documentation\_block:  
 LOCUS AW960501 647 bp mRNA EST 01-JUN-2000  
 DEFINITION EST372572 MAGE resequences, MAGF Homo sapiens cdna, mRNA sequence.  
 ACCESSION AW960501  
 VERSION AW960501.1 GI:8150185  
 KEYWORDS EST.  
 SOURCE human.  
 ORGANISM Homo sapiens  
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 Mammalia; Eutheraia; Primates; Catarrhini; Homiidae; Homo.  
 REFERENCE 1 (bases 1 to 647)  
 AUTHORS Hegde,P., Qi,R., Abernathy,K., Dharap,S., Gaspard,R., Gay,C., Holt  
 I.E., Saeed,A.I., Sharov,V., Lee,N.H., Yeatman,T.J. and  
 Quackenbush,J.  
 TITLE Assessment of gene expression patterns in a model of colon tumor  
 metastasis using a 19,200 element cdna microarray  
 JOURNAL Unpublished (2000)  
 CONTACT: John Quackenbush  
 COMMENT The Institute for Genomic Research  
 9712 Medical Center Dr., Rockville, MD 20850, USA  
 Tel: 301 838 3528  
 Fax: 301 838 0208  
 Email: johndqu@igf.org  
 Plate: 147  
 Seq primer: Forward.  
 Location/Qualifiers  
 source  
 1..647  
 /organism="Homo sapiens"  
 /db\_xref="taxon:9606"  
 /clone\_lib="MAGE resequences, MAGF"  
 /note="Vector: pBluescriptSKm"  
 BASE COUNT 165 a 128 c 141 g 213 t  
 ORIGIN

634 TGCCAGAAATTCGGCACGAGGAAAAAATAGTGTTCCTTTAAAAATTCACAG 585  
 362 g\_serLeuProAlaProGlnAspAsnAspPheLeuSerArgLysAlaGln 378  
 584 GFTCCCTGCCACCTCCCAAGCAATGATTTTTTATCTAGAAAAGCTCAA 535  
 379 AspCysTyrPheMetLysLeuHisCysProGlyAsnHisSerTrpAs 395  
 534 GCCTGTTATTTATGAAGCTGCATCCTCTCGGAAATCAGAGTTGGGA 485  
 395 pSerThrIleSerGlySerGlnArgAlaAlaPheCysAspHisLysThr 412  
 484 TAGCACCAATTTGGGATCTCAAGGGCTCATTTCTGTGATCAAGACCA 435  
 412 hrProCysSerSerAlaIleIleAsnProLeuSerThrAlaGlyAsnSer 428  
 434 CTCATGCTCTTCAGCAATAATAATCCACTCTCAACTCAGGAAACTCA 385  
 429 GluArgLeuGlnProGlyIleAlaGlnGlnTrpIleGlnSerLysArg 445  
 384 GAACGTCCTGACGCTGGTATAGCCACGACAGTGGATCCAGAGCAAAA 335  
 445 uAspIleValAsnGlnMetThrGluAlaCysLeuAsnGlnSerLeuAsp 462  
 334 AGACATTTGTAAACCAATGACAGAAACCTTCCTTAAACAGCTGCTAGATG 285  
 462 lAlaLeuSerArgAspLeuIleMetLysLysGluAspFyrGluLeuValSer 478  
 284 CCCTTCTCCAGGACTTGATCATGAAAAGAGACTATGAACCTGTTAGT 235  
 479 ThrLysProThrArgThrSerLysValArgGlnLeuLeuAspThrTrp 495  
 234 ACCAAGCCTACAAGGACCTCAAAAAGTCAGACAATTTACTAGACACTACTGA 185  
 495 pIleGlnGlyGluGluPheAlaLysValIleValGlnLysLeuLysAsp 512  
 184 CATTCCAAAGGAGAGAAATTTGCCAAAGTATTAGTACAAAATTTGAAA 135  
 512 snLysGlnMetGlyLeuGlnProFyrProGluIleLeuValSerArg 528  
 134 ACAACAATTTGGTCTTCAGCTTACCCGGAATAACTTTGGTTTCTAGA 85  
 529 SerProSerLeuLeuLeuGlnAsnLysSerMet 540  
 84 TCACCATCTTTAAATTTACTTTCAAAAATATAAAGCATG 49

seq\_name: gb\_est75:BE551615  
 seq\_documentation\_block:  
 LOCUS BE551615 636 bp mRNA EST 10-AUG-2000  
 DEFINITION 7a4zg06.x1 NCI\_CGAP\_GC6 Homo sapiens cdna clone IMAGE:3221434 3,  
 similar to TR:043353 OX3353 SERINE/THREONINE KINASE RICK. ;, mRNA  
 sequence.  
 ACCESSION BE551615  
 VERSION BE551615.1 GI:9793227  
 KEYWORDS EST.  
 SOURCE human.  
 ORGANISM Homo sapiens  
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 Mammalia; Eutheraia; Primates; Catarrhini; Homiidae; Homo.  
 REFERENCE 1 (bases 1 to 636)  
 AUTHORS NCI-CGAP <http://www.ncbi.nlm.nih.gov/ncicgap>.  
 TITLE National Cancer Institute, Cancer Genome Anatomy Project (CGAP),  
 Tumor Gene Index  
 JOURNAL Unpublished (1997)  
 COMMENT Contact: Robert Strausberg, Ph.D.  
 Tel: (301) 496-1550  
 Email: Robert.Strausberg@nih.gov  
 Tissue Procurement: Christopher A. Moskaluk, M.D., Ph.D., Michael  
 R. Emmert-Buck, M.D., Ph.D.  
 cdna Library Preparation: M. Bento Soares, Ph.D., M. Fatima  
 Bonaldo, Ph.D.  
 cdna Library Arrayed by: Greg Lennon, Ph.D.

FEATURES  
 source  
 1..647  
 /organism="Homo sapiens"  
 /db\_xref="taxon:9606"  
 /clone\_lib="MAGE resequences, MAGF"  
 /note="Vector: pBluescriptSKm"  
 BASE COUNT 165 a 128 c 141 g 213 t  
 ORIGIN  
 alignment\_scores:  
 Quality: 917.00 Length: 196  
 Ratio: 4.930 Gaps: 1  
 Percent Similarity: 94.898 Percent Identity: 92.857  
 alignment\_block:  
 US-09-445-223-1 x AW960501/rev ..  
 Align seg 1/1 to reverse of: AW960501 from: 1 to: 647  
 346 CysGlySerSerGlnLeuHisGlnAsnSerGlySerProGluThrSerAr 362  
 ||| ::: : :::::||||| ||| ::::: |||



DNA Sequencing by: Washington University Genome Sequencing Center  
Clone distribution: NCI-CGAP clone distribution information can be  
found through the I.M.A.G.E. Consortium/LLNL, send email to:  
info@image.llnl.gov

Seq primer: -40UP from Gibco  
High quality sequence stop: 455.  
Location/Qualifiers  
1. .636

FEATURES

source  
/organism="Homo sapiens"  
/db\_xref="taxon:9606"  
/clone\_lib="IMAGE:3221434"  
/tissue\_type="pooled germ cell tumors"  
/lab\_host="DH10B"  
/note="Vector: p77T3D-Pac (Pharmacia) with a modified  
polylinker; Plasmid DNA from the normalized library  
NCI-CGAP\_G64 was prepared, and ss circles were made in  
vitro. Following HAP purification, this DNA was used as  
tracer in a subtractive hybridization reaction. The driver  
was PCR-amplified cDNAs from a pool of 5,000 clones made  
from the same library (cloneIDs 1257096-1258631,  
1469064-1470983, and 1475592-1476743). Subtraction by  
Bento Soares and M. Fatima Bonaldo."  
BASE COUNT 175 a 118 c 135 g 208 t  
ORIGIN

alignment\_scores:  
Quality: 894.00 Length: 181  
Ratio: 5.022 Gaps: 0  
Percent Similarity: 98.343 Percent Identity: 98.343

alignment\_block:  
US-09-445-223-1 x BE551615/rev ..

Align seg 1/1 to reverse of: BE551615 from: 1 to: 636

360 ThrSerArgSerLeuProLaProGlnAspAsnAspPheLeuSerArgly 376  
|||||  
636 ACTTCAGGGTCCCTGCCAGCTCCTCAAGACAATGT.TTTTTATCTAGAAA 588  
  
376 sAlaGlnAspCysTyrPheMetLysLeuHisCysProGlyAsnHis 393  
|||||  
587 AGCTCAAGACTGTATTTATGAAGTGCATCCTCCTGGAAAATCACA 538  
  
393 erTrpAspSerThrIleSerGlySerGlnArgAlaAlaPheCysAspHis 409  
|||||  
537 GTTGGATAGCACCAATTCGTGATCTCAAAGGGCTGCATTCGTGATCAC 488  
  
410 LysThrThrProCysSerSerAlaIleIleAsnProLeuSerThrAlaGl 426  
|||||  
487 AAGACCACCTCCATGCTTTCAGCAATAATAAATCCACTCTCAACTGCAGG 438  
  
426 yAsnSerGluArgLeuGlnProGlyIleAlaGlnGlnTrpIleGlnSerL 443  
|||||  
437 AACTCAGAACGCTCCAGCCCTGGTATAGCCCAAGAGTGGATCCAGAGCA 388  
  
443 ysArgGluAspIleValAsnGlnMetThrGluAlaCysLeuAsnGlnSer 459  
|||||  
387 AAAGGAAGACATTTGAAACCAATACAGAAAGCCTGCTTACACAGTCG 338  
  
460 LeuAspAlaLeuLeuSerArgAspLeuIleMetLysGluAspTyrGluLe 476  
|||||  
337 CTAGATGCCCTTCTGTCCAGGGACTTGTATCATGAAAAGGACTATGAAC 288  
  
476 uValSerThrLysProThrArgThrSerLysValArgGlnLeuLeuAspT 493  
|||||  
287 TGTATTACCAAGCCCTACAAAGACCTCAAAGGTCAGACAAATTTACTAGA 238  
  
493 hrThrAspIleGlnGlyGluAlaAlaLysValIleValGlnLysLeu 509  
|||||  
237 CTACTGACATCCAAAGGAGAAATTTGCCAAAGTTATAGTACAAAAATTC 188

510 LysAspAsnLysGlnMetGlyLeuGlnProTyrProGluIleLeuValVa 526  
|||||  
187 AAGATAACAAACAATGGTCTTCAGCCTTACCCGAAATACTTGTGGT 138  
  
526 lSerArgSerProSerLeuAsnLeuLeuGlnAsnLysSerMet 540  
|||||  
137 TTCTAGATCACCATCTTAAATTTACTTCAAAAATAAAGCATG 95

seq\_name: gb\_est3:AA161113

seq\_documentation\_block:  
LOCUS AA161113 568 bp mRNA EST 09-MAR-1998  
DEFINITION z058d05.s1 Stratagene pancreas (#937208) Homo sapiens cDNA clone  
IMAGE:591081.3, mRNA sequence.

ACCESSION AA161113  
VERSION AA161113.1 GI:1735349  
KEYWORDS EST.

SOURCE human.

ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE 1 (bases 1 to 568)  
AUTHORS Hillier,L.; Allen,M., Bowles,L., Dubuque,T., Geisel,G., Jost,S.,  
Krizman,D., Kucaba,T., Lacy,M., Le,N., Lennon,G., Marra,M., Martin  
,J., Moore,B., Schellenberg,K., Steptoe,M., Tan,F., Theising,B.,  
White,Y., Wylie,T., Waterston,R. and Wilson,R.  
WashU-NCI human EST Project  
Unpublished (1997)  
Contact: Wilson RK

TITLE  
JOURNAL  
COMMENT  
Washington University School of Medicine  
4444 Forest Park Parkway, Box 8501, St. Louis, MO 63108  
Tel: 314 286 1800  
Fax: 314 286 1810

Email: est@watson.wustl.edu  
This clone is available royalty-free through LLNL; contact the  
IMAGE Consortium (info@image.llnl.gov) for further information.

Insert Length: 1942 Std Error: 0.00  
Seq primer: -40M13 fwd. from Amersham  
High quality sequence stop: 256.  
FEATURES  
Location/Qualifiers  
1..568  
/organism="Homo sapiens"  
/db\_xref="GDB:4622467"  
/db\_xref="taxon:9606"  
/clone="IMAGE:591081"  
/lab\_host="SOLR cells (kanamycin resistant)"  
/note="Organ: pancreas; Vector: pBluescript SK-; Site\_1:  
EcoRI; Site\_2: XhoI; Cloned unidirectionally. Primer:  
Oligo dt. Pancreatic adenocarcinoma cell line. Average  
insert size: 1.0 kb; Uni-ZAP XR Vector; -5' adaptor  
sequence: 5' GAATTCGGCAGGAG 3' -3' adaptor sequence: 5'  
CTCGAGTTTTTTTTTTTTTTT 3'.

BASE COUNT 140 a 111 c 127 g 185 t 5 others  
ORIGIN

alignment\_scores:  
Quality: 877.00 Length: 183  
Ratio: 4.983 Gaps: 2  
Percent Similarity: 96.175 Percent Identity: 95.628

alignment\_block:  
US-09-445-223-1 x AA161113/rev ..

Align seg 1/1 to reverse of: AA161113 from: 1 to: 568

360 ThrSerArgSerLeuProLaProGlnAspAsnAspPheLeuSerArgly 376  
|||||  
568 ACTTCAGGGTCCCTGCCAGCTCCTCAAGACAATGATTTTTATCTAGAAA 519  
  
376 sAlaGlnAspCysTyrPheMetLysLeuHisCysProGlyAsnHis. 392  
|||||

518 GGCTCAAGACTGTTATTTTANGAAGTCATCACTGTCTCGGAATCACC 469  
 393 SerTnpAspSerThrIleSerGlySerGlnArgAlaAlaPheCysAspHi 409  
 |||||  
 468 AGTTGGATAGCACCATTCTCGATCTCAANGCCGTCNCAITCTGTGATCA 419  
 409 slystThrProCysSerAlaIleLeuAsnProLeuSerThrAlaG 426  
 |||||  
 418 CAAGACCCTCCATCTTTCAGCAATAATAAATCCACTCTCAACTGCAG 369  
 426 lyAsnSerGluArgLeuGlnProGlyIleAlaGlnGlnThrPileGlnSer 442  
 |||||  
 368 GAAGNCTCAGAACGCTGCGACCGGGTATAGCCCGAGCGAGTGCAGAGC 319  
 443 LysArgGluAspIleValAsnGlnMetThrGluAlaCysLeuAsnGln\_S 459  
 |||||  
 318 AAAGGGAGAGNCATTTGTARACCCARATGACAGAAGCGCTCTTAACCCAGGT 269  
 459 erLeuAspAlaLeuLeuSerArgAspLeuIleMetLysGluAspTyrGlu 475  
 |||||  
 268 CGCTAGATGCCCTCTGCTCCAGGACTTGATCATGAAAGAGGACTATGAA 219  
 476 LeuValSerThrLysProThrArgThrSerLysValArgGlnLeuLeuAs 492  
 |||||  
 218 CTGTGTAGTACCAAGCCCTCAAGGACTCAAAAGTCCAGACAATTACTAGA 169  
 492 pThrThrAspIleGlnGlyGluIlePheAlaLysValIleValGlnLysL 509  
 |||||  
 168 CACTACTGACATCCAGGAGAGAATTTGCCAAGTTATAGTACAAAAAT 119  
 509 eulyAspAsnLysGlnMetGlyLeuGlnProTyrProGluIleLeuVal 525  
 |||||  
 118 TGAAGATAACAACAATAATGGTCTTCAGCCCTTACCCTCCGGAATPACTTGTG 69  
 526 ValSerArgSerProSerLeuAsnLeuGlnAsnLysSerMet 540  
 |||||  
 68 GTTCTAGATCACCATCTTTAAATTTACTTCAAAAATAAAGCAATG 24

seq\_name: gb\_est26:AI904799  
 seq\_documentation\_block: 762 bp mRNA EST 30-MAR-2000  
 LOCUS AI904799  
 DEFINITION IL-BT067-190199-023 BT067 Homo sapiens cdna, mRNA sequence.  
 ACCESSION AI904799  
 VERSION AI904799.1 GI:6495186  
 KEYWORDS EST.  
 SOURCE human.  
 ORGANISM Homo sapiens  
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.  
 1 (bases 1 to 762)  
 Dias Neto, E., Garcia Correa, R., Verjovski-Almeida, S., Briones, M.R.,  
 Nagai, M.A., da Silva, W. Jr., Zagó, M.A., Bordin, S., Costa, F.P.,  
 Goldman, G.H., Carvalho, A.F., Matsukuma, A., Bala, G.S., Simpson, D.H.,  
 Brunstein, A., deOliveira, P.S., Bucher, P., Jongeneel, C.V., O'Hare  
 , M.J., Soares, F., Brentani, R.R., Reis, L.F., de Souza, S.J. and  
 Simpson, A.J.J.  
 TITLE Shotgun sequencing of the human transcriptome with ORF expressed  
 sequence tags  
 JOURNAL Proc. Natl. Acad. Sci. U.S.A. 97 (7), 3491-3496 (2000)  
 MEDLINE 20202663  
 COMMENT Contact: Simpson A.J.G.  
 Laboratory of Cancer Genetics  
 Ludwig Institute for Cancer Research  
 Rua Prof. Antonio Prudente 109, 4 andar, 01509-010, Sao Paulo-SP,  
 Brazil  
 Tel: +55-11-2704922  
 Fax: +55-11-2707001  
 Email: asimpson@ludwig.org.br  
 This sequence was derived from the FAPESP/LICR Human Cancer Genome  
 Project. This entry can be seen in the following URL  
 (http://www.ludwig.org.br/seq/gethtml.pl?tl=IL&t2=IL-BT067-023.html  
 &t3=190199&t4=1)

FEATURES  
 source  
 Seq primer: puc 18 forward.  
 Location/Qualifiers  
 1..762  
 /organism="Homo sapiens"  
 /db\_xref="taxon:9606"  
 /clone\_lib="BT067"  
 /sex="female"  
 /dev\_stage="Adult"  
 /note="Organ: breast; Vector: puc18; Site\_1: SmaI; Site\_2:  
 SmaI; A mini-library was made by cloning products derived  
 from ORESTES PCR (U.S. Letters Patent application No. 196  
 716 - Ludwig Institute for Cancer Research) profiles  
 into the pUC 18 vector. Reverse transcription of tissue  
 mRNA and cDNA amplification were performed under low  
 stringency conditions."  
 BASE COUNT 232 a 157 c 137 g 208 t 28 others  
 ORIGIN  
 alignment\_scores:  
 Quality: 876.00 Length: 226  
 Ratio: 4.424 Gaps: 0  
 Percent Similarity: 87.611 Percent Identity: 80.088  
 alignment\_block:  
 US-09-445-223-1 x AI904799 ..  
 Align seg 1/1 to: AI904799 from: 1 to: 762  
 225 ArgGlyGlnProPheGluAspValThrAsnProLeuGlnIleMetYrSe 241  
 |||||  
 2 AGAAAACAGCCTTTTGAAGATGTCCACCAATCCTTTGCAGATAATGTATAG 51  
 241 rValSerGlnGlyHisArgProValIleAsnGluSerLeuProTyrA 258  
 |||||  
 52 TGNCTCACANGGNCATCGNCCCTGNTATTAATGAAGAAAAGTTGGCCATG 101  
 258 spileProHisArgAlaArgMetIleSerLeuIleGluSerGlyTyrPala 274  
 |||||  
 102 ATACACCTCCAGCAGCAGTATGATCTCTCTAATAAGAAAGTGGATGGCA 151  
 275 GlnAsnProAspGluArgProSerPheLeuLysCysLeuIleGluLeuG 291  
 |||||  
 152 CAAAATCCAGATGAAAAGACCCTCTTTCTTAAATGTTTAAATAGAAC 201  
 291 uProValLeuArgThrPheGluGluIleThrPheLeuGluAlaValIleG 308  
 |||||  
 202 ACCAGTTTGGAGAACATTTGAAGAGATAACTTTCTTGAAGCTGTATT 251  
 308 lnLeuLysLysThrLysLeuGlnSerValSerSerAlaIleHisLeuCys 324  
 |||||  
 252 AGCTAAAGAAAACAAAAGTTACAGAGTGTTCAAAGTGGCAATTCACCTAT 301  
 325 AspLysLysMetGluLeuSerLeuAsnIleProValAsnHisGlyPr 341  
 |||||  
 302 GACAGAAGAAAATGGAATTTATCTGAAACATACCTGTAATCATGTTCC 351  
 341 oGlnGluSerCysGlySerSerGlnLeuHisGluAsnSerGlySerP 358  
 |||||  
 352 ACAAGGAAATCATGTGGATCCTCTCAGCTCCATGAAATAGTGGGCTT 401  
 358 roGluThrSerArgSerLeuProAlaProGlnAspAsnAspPheLeuSer 374  
 |||||  
 402 CTGAAATCTCAAGTCCCTGCCAGCTCCCTCAAGACAATGATTTTTTATN 451  
 375 ArgLysAlaGlnAspCysTyrPheMetLysLeuHisCysProGlyAs 391  
 |||||  
 452 TANAAAGCTCAAGACTGTTNTTTTGAACCTGCATCC.TGTCTGGNAA 500  
 391 nHisSerTnpAspSerThrIleSerGlySerGlnArgAlaAlaPheCysA 408  
 |||||  
 501 TCCGACTGGGATAC.ACCATTTTGGATTTNNAAGGGTTNATTTTGGG 549



```

AW085560.1 GI:6040712
EST.
human.
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
1 (bases 1 to 606)
NCI-CGAP http://www.ncbi.nlm.nih.gov/ncicgap.
National Cancer Institute, Cancer Genome Anatomy Project (CGAP),
Tumor Gene Index
Unpublished (1997)
Contact: Robert Strausberg, Ph.D.
Tel: (301) 496-1550
Email: Robert.Strausberg@nih.gov
This clone is available royalty-free through LLNL; contact the
IMAGE Consortium (infoimage.llnl.gov) for further information.
Insert Length: 885 Std Error: 0.00
Seq primer: -400P from Gibco
High quality sequence stop: 470.
Location/Qualifiers
1 .606
/organism="Homo sapiens"
/db_xref="taxon:9606"
/clone_image="IMAGE:2553606"
/clone_lib="Soares_NSF_F8_9W_OT_PA_P_S1"
/lab_host="DH10B"
/note="organ: pooled; Vector: pT7T3D-pac (Pharmacia) with
a modified polylinker; Site_1: Not I; Site_2: Eco RI;
Equal amounts of plasmid DNA from five normalized
libraries were mixed, and ss circles were made in vitro.
Following HAP purification, this DNA was used as tracer in
a subtractive hybridization reaction. The driver was
PCR-amplified cDNAs from pools of 5,000 clones made from
the same 5 libraries. The pools consisted of the following
libraries and clones: Soares NBHSF pool 1:
309384-310919, 323208-325895 Soares NDZHP pool 1:
145032-147335, 147720-148103, 148872-149255, 15002 -
150407, 151176-152327 Soares NBHF8-9W pool 1:
758280-760583, 772104-774407 Soares NBHPA pool 1:
304776-306311, 320136-322823, 326280-326663 Soares NBHOT
pool 1: 723370-726407, 739080-740999 Subtraction by Bento
Soares and M. Fatima Bonaldo."
166 a 114 c 122 g 203 t 1 others
BASE COUNT
ORIGIN

```

```

alignment_scores:
Quality: 838.00 Length: 166
Ratio: 5.110 Gaps: 1
Percent Similarity: 98.795 Percent Identity: 98.795
alignment_block:
US-09-445-223-1 x AW085560/rev ..
Align seg 1/1 to reverse of: AW085560 from: 1 to: 606
376 LysAlaGlnAspCysTyrPheMetLysLeuHisCysProGlyAsnHi 392
|||||
606 AAAGCTCAAGACTTATNTATGAAGCTGCATCAGTCTCGTGGAAATCA 557
|||||
392 sSerTrpAspSerThrIleSerGlySerGlnArgAlaAlaPheCysAspH 409
|||||
556 CAGTTGGGATAGCACCATTCTGGACTCAAAGGGCTGCATTCGTGTGATC 507
|||||
409 isLysThrProCysSerAlaIleLeuAsnProLeuSerThrAla 425
|||||
506 ACAAGACCACCTTCATGCTTCACCAATATAATCCACCTCAACTGCA 457
|||||
426 GlyAsnSerGluArgLeuGlnProGlyIleAlaGlnInTrpIleGlnSe 442
|||||
456 GAAACTCAGAACCTGTCAGCCCTGGTATAGCCAGCAGTGGATCCAGAG 407
|||||
442 tLysArgGluAspIleValAsnGlnMetThrGluAlaCysLeuAsnGlnS 459
|||||

```

```

seq_name: gb_est5:AA315575
seq_documentation_block:
LOCUS AA315575 484 bp mRNA EST 19-APR-1997
DEFINITION EST187344 Colon carcinoma (HCC) cell line II Homo sapiens cDNA 5',
end, mRNA sequence.
ACCESSION AA315575
VERSION AA315575.1 GI:1967904
KEYWORDS EST.
SOURCE human.
ORGANISM Homo sapiens
Eukaryota; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
1 (bases 1 to 484)
AUTHORS Adams,M.D., Kerlavage,A.R., Fleischmann,R.D., Feldner,R.A., Bult
,C.J., Lee,N.H., Kirkness,E.F., Weinstock,K.G., Gocayne,J.D., White
,O., Sutton,G., Blake,J.A., Brandon,R.C., Man-Wai,C., Clayton,R.A.,
Claine,T.R., Cotton,M.D., Earle-Hughes,J., Fine,L.D., Fitzgerald
,L.M., Fitzhugh,W.M.C., Fritchman,J.L., Geoghagen,N.S., Glodek,A.,
Gnehm,C.L., Hanna,M.C., Heblom,E., Hinkley,P.S., Jr., Kelley,J.M.,
Kelley,J.C., Liu,L.-I., Marmaros,S.M., Merrick,J.M.,
Moreno-Palauques,R.F., McDonald,L.A., Nguyen,D.T., Palligrino,S.M.,
Phillips,C.A., Ryder,S.E., Scott,J.L., Saudek,D.M., Shirley,R.,
Small,K.V., Spriggs,T.A., Utterback,T.R., Weidman,J.F., Li,F.,
Bednarek,D.P., Cao,L., Cepeda,M.A., Coleman,T.A., Collins,E.J.,
Dimke,D., Feng,D.-F., Ferris,A., Fischer,C., Hastings,G.A., He,W.W.,
Hu,J.S., Greene,J.M., Gruber,J., Hudson,P., Kim,A.K., Kozak,D.L.,
Kunsch,C., HungJun,J., Li,H., Meissner,P.S., Olsen,H., Raymond,L.,
Wei,Y.F., Wing,J., Xu,C., Yu,G.L., Ruben,S.M., Dillion,P.J., Fannon
,M.R., Rosen,C.A., Haseltine,W.A., Fields,C., Fraser,C.M. and
Venter,J.C.
Initial assessment of human gene diversity and expression patterns
based upon 83 million nucleotides of cDNA sequence
Nature 377 (6547 Suppl), 3-174 (1995)
JOURNAL
MEDLINE 96026280
COMMENT Other_ESTs: THC188294
Contact: Kerlavage, AR
Bioinformatics
The Institute for Genomic Research
9712 Medical Center Drive, Rockville, MD 20850 USA
Tel: 3018699056
Fax: 3018699423
Email: arkerlavet@igf.org
For clone availability, additional sequence and expression
information related to this EST, please check the TIGR Human Gene
Index (http://www.tigr.org/tdb/hgi/hgi.html)
Seq primer: M13 Reverse.
Location/Qualifiers
1 .484
/organism="Homo sapiens"

```

```

FEATURES
source

```

```

seq_name: gb_est5:AA315575
seq_documentation_block:
LOCUS AA315575 484 bp mRNA EST 19-APR-1997
DEFINITION EST187344 Colon carcinoma (HCC) cell line II Homo sapiens cDNA 5',
end, mRNA sequence.
ACCESSION AA315575
VERSION AA315575.1 GI:1967904
KEYWORDS EST.
SOURCE human.
ORGANISM Homo sapiens
Eukaryota; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
1 (bases 1 to 484)
AUTHORS Adams,M.D., Kerlavage,A.R., Fleischmann,R.D., Feldner,R.A., Bult
,C.J., Lee,N.H., Kirkness,E.F., Weinstock,K.G., Gocayne,J.D., White
,O., Sutton,G., Blake,J.A., Brandon,R.C., Man-Wai,C., Clayton,R.A.,
Claine,T.R., Cotton,M.D., Earle-Hughes,J., Fine,L.D., Fitzgerald
,L.M., Fitzhugh,W.M.C., Fritchman,J.L., Geoghagen,N.S., Glodek,A.,
Gnehm,C.L., Hanna,M.C., Heblom,E., Hinkley,P.S., Jr., Kelley,J.M.,
Kelley,J.C., Liu,L.-I., Marmaros,S.M., Merrick,J.M.,
Moreno-Palauques,R.F., McDonald,L.A., Nguyen,D.T., Palligrino,S.M.,
Phillips,C.A., Ryder,S.E., Scott,J.L., Saudek,D.M., Shirley,R.,
Small,K.V., Spriggs,T.A., Utterback,T.R., Weidman,J.F., Li,F.,
Bednarek,D.P., Cao,L., Cepeda,M.A., Coleman,T.A., Collins,E.J.,
Dimke,D., Feng,D.-F., Ferris,A., Fischer,C., Hastings,G.A., He,W.W.,
Hu,J.S., Greene,J.M., Gruber,J., Hudson,P., Kim,A.K., Kozak,D.L.,
Kunsch,C., HungJun,J., Li,H., Meissner,P.S., Olsen,H., Raymond,L.,
Wei,Y.F., Wing,J., Xu,C., Yu,G.L., Ruben,S.M., Dillion,P.J., Fannon
,M.R., Rosen,C.A., Haseltine,W.A., Fields,C., Fraser,C.M. and
Venter,J.C.
Initial assessment of human gene diversity and expression patterns
based upon 83 million nucleotides of cDNA sequence
Nature 377 (6547 Suppl), 3-174 (1995)
JOURNAL
MEDLINE 96026280
COMMENT Other_ESTs: THC188294
Contact: Kerlavage, AR
Bioinformatics
The Institute for Genomic Research
9712 Medical Center Drive, Rockville, MD 20850 USA
Tel: 3018699056
Fax: 3018699423
Email: arkerlavet@igf.org
For clone availability, additional sequence and expression
information related to this EST, please check the TIGR Human Gene
Index (http://www.tigr.org/tdb/hgi/hgi.html)
Seq primer: M13 Reverse.
Location/Qualifiers
1 .484
/organism="Homo sapiens"

```

```

FEATURES
source

```

```

seq_name: gb_est5:AA315575
seq_documentation_block:
LOCUS AA315575 484 bp mRNA EST 19-APR-1997
DEFINITION EST187344 Colon carcinoma (HCC) cell line II Homo sapiens cDNA 5',
end, mRNA sequence.
ACCESSION AA315575
VERSION AA315575.1 GI:1967904
KEYWORDS EST.
SOURCE human.
ORGANISM Homo sapiens
Eukaryota; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
1 (bases 1 to 484)
AUTHORS Adams,M.D., Kerlavage,A.R., Fleischmann,R.D., Feldner,R.A., Bult
,C.J., Lee,N.H., Kirkness,E.F., Weinstock,K.G., Gocayne,J.D., White
,O., Sutton,G., Blake,J.A., Brandon,R.C., Man-Wai,C., Clayton,R.A.,
Claine,T.R., Cotton,M.D., Earle-Hughes,J., Fine,L.D., Fitzgerald
,L.M., Fitzhugh,W.M.C., Fritchman,J.L., Geoghagen,N.S., Glodek,A.,
Gnehm,C.L., Hanna,M.C., Heblom,E., Hinkley,P.S., Jr., Kelley,J.M.,
Kelley,J.C., Liu,L.-I., Marmaros,S.M., Merrick,J.M.,
Moreno-Palauques,R.F., McDonald,L.A., Nguyen,D.T., Palligrino,S.M.,
Phillips,C.A., Ryder,S.E., Scott,J.L., Saudek,D.M., Shirley,R.,
Small,K.V., Spriggs,T.A., Utterback,T.R., Weidman,J.F., Li,F.,
Bednarek,D.P., Cao,L., Cepeda,M.A., Coleman,T.A., Collins,E.J.,
Dimke,D., Feng,D.-F., Ferris,A., Fischer,C., Hastings,G.A., He,W.W.,
Hu,J.S., Greene,J.M., Gruber,J., Hudson,P., Kim,A.K., Kozak,D.L.,
Kunsch,C., HungJun,J., Li,H., Meissner,P.S., Olsen,H., Raymond,L.,
Wei,Y.F., Wing,J., Xu,C., Yu,G.L., Ruben,S.M., Dillion,P.J., Fannon
,M.R., Rosen,C.A., Haseltine,W.A., Fields,C., Fraser,C.M. and
Venter,J.C.
Initial assessment of human gene diversity and expression patterns
based upon 83 million nucleotides of cDNA sequence
Nature 377 (6547 Suppl), 3-174 (1995)
JOURNAL
MEDLINE 96026280
COMMENT Other_ESTs: THC188294
Contact: Kerlavage, AR
Bioinformatics
The Institute for Genomic Research
9712 Medical Center Drive, Rockville, MD 20850 USA
Tel: 3018699056
Fax: 3018699423
Email: arkerlavet@igf.org
For clone availability, additional sequence and expression
information related to this EST, please check the TIGR Human Gene
Index (http://www.tigr.org/tdb/hgi/hgi.html)
Seq primer: M13 Reverse.
Location/Qualifiers
1 .484
/organism="Homo sapiens"

```

/db\_xref="ATCC (inhost):110668"  
/db\_xref="taxon:9606"  
/clone\_lib="Colon carcinoma (HCC) cell line II"  
/tissue\_type="colon"  
/cell\_type="KM12c"  
/cell\_line="KM12c(HCC)-parental human colon carcinoma  
;Dukes B2"  
/note="Organ: colon; Vector: pBluescript SK-; Site\_1:  
ECORI; Site\_2: XhoI"  
BASE COUNT 136 a 109 c 101 g 136 t 2 others  
ORIGIN

alignment\_scores:  
Quality: 820.00 Length: 161  
Ratio: 5.157 Gaps: 1  
Percent Similarity: 98.758 Percent Identity: 98.137

alignment\_block:  
US-09-445-223-1 x AA315575 ..  
Align seg 1/1 to: AA315575 from: 1 to: 484

27 GlyAlaSerGlyThrValSerAlaArgHisAlaAspTrpArgValGI 43  
|||||  
2 GGCGCCCTGGGCACCTGTGGTCCGCCGCCACGCGCAGCTGGCGCTCCA 51  
|||||

43 nValAlaValLysHisLeuHisIleHisThrProLeuLeuAspSerGluA 60  
|||||  
52 GGTGGCCGAGAACCTCCACATCCACATCCGCTGCTGGCAGAGNAA 101  
|||||

60 rGlyAspValLeuArgGluAlaGluLeuLeuHisLysAlaArgPheSer 76  
|||||  
102 GAAAGGATCTTAAAGAGAGCTGAAATTTACACAAAGCTAGATTAGT 151  
|||||

77 TyrIlePheProIleLeuGlyIleCysAsnGluProGluPheLeuGlyI 93  
|||||  
152 TACATTCTCCAAATTTGGGAATTTGCAATGAGCCCTGAATTTTGGGA 201  
|||||

93 eValThrGluTyrMetProAsnGlySerLeuAsnGluLeuLeuHisArgL 110  
|||||  
202 AGTTACTGAATACATGCCAARTGGNTCAATTAATGAATCCCTACATAGA 251  
|||||

110 ySthrGluTyrProAspValAlaIrrProLeuArgPheArgIleLeuHis 126  
|||||  
252 AAATGAATATCTGTATGTTGGCCATTTGAGATTTCCGATCCCTGCAT 301  
|||||

127 GluIleAlaLeuGlyValAsnTyrLeuHisAsnMetThrProProLeuLe 143  
|||||  
302 GAAATGGCCCTTGGTGTAAATACCTGCACAAATATGACTCCCTCTTACT 351  
|||||

143 uHisHisAspLeuLysThrGlnAsnIleLeuLeuAspAsnGluPheHis 160  
|||||  
352 TCATCATGACTGAAGACCTCAGAAATATCTATTGGACAAATGATTCATG 401  
|||||

160 aLysIleAlaAspPheGlyLeuSerLysTrpArgMetMetSerLeuSer 176  
|||||  
402 TTAAGATTGCAGATTTGGTTTATCAAAAGTGGGCGCATGATGTCCCTCTCA 451  
|||||

177 GlnSerArgSerSerLysSerAlaProGlu 186  
|||||  
452 CAGTCACGAAGTAGCAAAATCTGCACCAGAA 482  
|||||

seq\_name: gb\_est10:AA655189  
seq\_documentation\_block:  
LOCUS AA655189 503 bp mRNA EST 04-NOV-1997  
DEFINITION vj13a12.1 Stratagene mouse heart (#937316) Mus musculus cDNA clone  
IMAGE:1211518 5', similar to TR:G1236943 G1236943 RIP PROTEIN  
KINASE, ; mRNA sequence.

ACCESSION AA655189  
VERSION AA655189.1 GI:2591343  
KEYWORDS EST.

SOURCE house mouse.  
ORGANISM Mus musculus  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.  
REFERENCE 1 (bases 1 to 503)  
AUTHORS Marra,M., Hillier,L., Allen,M., Bowles,M., Dietrich,N., Dubuque,T.,  
Geisel,S., Kucaba,T., Lacy,M., Le,M., Martin,J., Morris,M.,  
Schellenberg,K., Steptoe,M., Tan,F., Underwood,K., Moore,B.,  
Theising,B., Wylie,T., Lennon,G., Soares,B., Wilson,R. and  
Waterston,R.  
TITLE The WashU-HMI Mouse EST Project  
JOURNAL Unpublished (1996)  
COMMENT Contact: Marra M/Mouse EST Project  
WashU-HMI Mouse EST Project  
Washington University School of MedicineP  
4444 Forest Park Parkway, Box 8501, St. Louis, MO 63108  
Tel: 314 286 1800  
Fax: 314 286 1810

Email: mouseest@watson.wustl.edu  
This clone is available royalty-free through LLNL ; contact the  
IMAGE Consortium (info@image.llnl.gov) for further information.  
MGI:647862  
Seq primer: -28ml3 rev1 ET from Amersham  
High quality sequence stop: 436.

FEATURES  
source  
1..503  
Location/Qualifiers  
/organism="Mus musculus"  
/strain="NIH/Swiss"  
/db\_xref="taxon:10090"  
/clone="IMAGE:1211518"  
/clone\_lib="Stratagene mouse heart (#937316)"  
/sex="pooled"  
/tissue\_type="heart"  
/dev\_stage="13 day embryos"  
/lab\_host="SOLR (kanamycin resistant)"  
/note="Organ: heart; Vector: pBluescript SK-; Site\_1:  
ECORI; Site\_2: XhoI; Cloned unidirectionally. Primer:  
Oligo dT. 93 pooled NIH/Swiss 13 day embryo hearts.  
Average insert size: 1.0 kb; Uni-ZAP XR Vector: -5'  
adaptor sequence: 5' GAATTCGGCAGAG 3' -3' adaptor  
sequence: 5' CTCGAGTTTTTTTTTTTTTTTTTT 3'

BASE COUNT 158 a 102 c 105 g 138 t  
ORIGIN  
alignment\_scores:  
Quality: 811.00 Length: 167  
Ratio: 5.006 Gaps: 0  
Percent Similarity: 97.006 Percent Identity: 91.617

alignment\_block:  
US-09-445-223-1 x AA655189 ..  
Align seg 1/1 to: AA655189 from: 1 to: 503

142 LeuLeuHisHisAspLeuLysThrGlnAsnIleLeuLeuAspAsnGluPh 158  
|||||  
2 CTCGTTTCATCATGCACTAAAGACTCAGAAATATCTTTGGATTAATGAAAT 51  
|||||


158 eHisValLysIleAlaAspPheGlyLeuSerLysTrpArgMetMetSerL 175  
|||||  
52 TCATGTTAAAGATTGCAGATTTGGTTTATCAAAATGGCGCATGATGTCAC 101  
|||||

175 eUerGlnSerArgSerSerLysSerAlaProGluGlyGlyThrIleIle 191  
|||||  
102 TCCTCAATCAGCAAGTTACAAATCTGCACCCGAGGAGGAAACAATCATC 151  
|||||

192 TyrMetProGluAsnTyrGluProGlyGlnLysSerArgAlaSerI 208  
|||||  
152 TATATCCACCCTGAGAACTATGAGCCAGGACAGAAATCAAGGGCCAGTGT 201  
|||||

208 eLysHisAspIleTyrSerTyrAlaValIleThrTrpGluValLeuSerA 225  
|||||





**THIS PAGE BLANK (USPTO)**



OM of: US-09-445-223-1 to: Issued\_Patents\_NA.\* out\_format : pfs  
 Date: Jun 13, 2001 6:36 PM  
 About: Results were produced by the GenCore software, version 4.5,  
 Copyright (c) 1993-2000 Compugen Ltd.

Command line parameters:  
 -MODEL=frame.p2n.model -DEV=xlp  
 -O=/cgnl\_1/USPTO.spool/US09445223/runat\_13062001\_092033\_29663/app\_query.fasta\_1.604  
 -DB=Issued\_Patents\_NA\_QFMT=fastap -SUFFIX=p2n.rni  
 -GAPOP=12.000 -GAPEXT=4.000 -MINMATCH=0.100 -LOOPCL=0.000  
 -LOPEXT=0.000 -XGAPOP=4.500 -XGAPEXT=0.050 -XGAPOP=10.000  
 -YGAPEXT=0.500 -YGAPOP=6.000 -YGAPEXT=7.000 -YGAPOP=10.000  
 -MATRIX=blotsum62 -TRANS=human40.cdi -LIST=45 -DOCALIGN=200  
 -THR\_SCORE=pcr -THR\_MAX=100 -THR\_MIN=0 -ALIGN=15 -MODE=LOCAL  
 -OUTFMT=pfs -NORM=ext -MINLEN=0 -MAXLEN=200000000  
 -USER=US09445223\_@CGN1\_1\_88 -NCPU=6 -ICPU=3 -LONGLOG -NO\_XLPXY  
 -WAIT -THREADS=1

Search information block:  
 Query: US-09-445-223-1  
 Query length: 540  
 Database: Issued\_Patents\_NA.\*  
 Database sequences: 302621  
 Database length: 87301344  
 Search time (sec): 68.920000

Sequence	Strd Orig	ZScore	Escore	Len	Documentation
/cgnl_7/ptodata/1/ina/6A_COMB.seq:US-09-019-942-2	+	2817.00	5441.25	1.7e-295	1931
/cgnl_7/ptodata/1/ina/5A_COMB.seq:US-09-019-942-2	+	579.00	1078.43	1.7e-52	3516
/cgnl_7/ptodata/1/ina/6B_COMB.seq:US-09-188-930-257	+	548.00	1026.11	1.4e-49	1888
/cgnl_7/ptodata/1/ina/6B_COMB.seq:US-09-188-930-257	+	548.00	1026.11	1.4e-49	1888
/cgnl_7/ptodata/1/ina/5A_COMB.seq:US-08-444-005-14	+	397.00	729.91	4.5e-33	2268
/cgnl_7/ptodata/1/ina/6A_COMB.seq:US-09-329-418-2	+	395.00	730.86	4.0e-33	1557
/cgnl_7/ptodata/1/ina/6A_COMB.seq:US-09-329-418-1	+	392.50	723.62	1.0e-32	1873
/cgnl_7/ptodata/1/ina/5A_COMB.seq:US-07-928-464-1	+	376.00	685.92	1.3e-30	2890
/cgnl_7/ptodata/1/ina/PCTUS_COMB.seq:PCT-US93-07347-1	+	376.00	685.92	1.3e-30	2890
/cgnl_7/ptodata/1/ina/5A_COMB.seq:US-08-003-3118-1	+	376.00	685.30	1.4e-30	3033
/cgnl_7/ptodata/1/ina/5A_COMB.seq:US-08-261-432-1	+	376.00	685.30	1.4e-30	3033
/cgnl_7/ptodata/1/ina/6B_COMB.seq:US-09-132-111-1	+	369.00	676.94	4.0e-30	2016
/cgnl_7/ptodata/1/ina/5A_COMB.seq:US-08-444-005-16	+	369.00	676.19	4.4e-30	2137
/cgnl_7/ptodata/1/ina/6A_COMB.seq:US-09-161-443-1	+	369.00	673.58	6.2e-30	2617
/cgnl_7/ptodata/1/ina/5A_COMB.seq:US-08-700-575-31	+	367.00	702.19	1.6e-31	210
/cgnl_7/ptodata/1/ina/5B_COMB.seq:US-08-685-625A-1	+	315.50	570.35	3.5e-24	2443
/cgnl_7/ptodata/1/ina/5B_COMB.seq:US-08-685-625A-5	+	312.00	562.46	9.6e-24	2656
/cgnl_7/ptodata/1/ina/5A_COMB.seq:US-08-395-580-1	+	302.00	539.86	1.7e-22	3389
/cgnl_7/ptodata/1/ina/5A_COMB.seq:US-08-205-018-1	+	302.00	539.73	1.8e-22	3426
/cgnl_7/ptodata/1/ina/6A_COMB.seq:US-09-221-235-6	+	291.50	531.15	5.3e-22	1365
/cgnl_7/ptodata/1/ina/6B_COMB.seq:US-09-221-235-6	+	291.50	531.15	5.3e-22	1365
/cgnl_7/ptodata/1/ina/6B_COMB.seq:US-09-221-527-6	+	291.50	531.15	5.3e-22	1365
/cgnl_7/ptodata/1/ina/6B_COMB.seq:US-09-221-236-4	+	291.50	531.15	5.3e-22	1365
/cgnl_7/ptodata/1/ina/6B_COMB.seq:US-09-221-416-4	+	291.50	531.15	5.3e-22	1365
/cgnl_7/ptodata/1/ina/6B_COMB.seq:US-09-221-236-6	+	291.50	531.15	5.3e-22	1365
/cgnl_7/ptodata/1/ina/6B_COMB.seq:US-09-221-236-4	+	291.50	531.15	5.3e-22	1365
/cgnl_7/ptodata/1/ina/6B_COMB.seq:US-09-221-235-4	+	291.50	525.48	1.1e-21	2120
/cgnl_7/ptodata/1/ina/6B_COMB.seq:US-09-221-928-4	+	291.50	525.48	1.1e-21	2120
/cgnl_7/ptodata/1/ina/6B_COMB.seq:US-09-221-527-4	+	291.50	525.48	1.1e-21	2120
/cgnl_7/ptodata/1/ina/6B_COMB.seq:US-09-221-236-4	+	291.50	525.48	1.1e-21	2120
/cgnl_7/ptodata/1/ina/6B_COMB.seq:US-09-221-416-4	+	291.50	525.48	1.1e-21	2120
/cgnl_7/ptodata/1/ina/6B_COMB.seq:US-09-221-245-4	+	291.50	525.48	1.1e-21	2120
/cgnl_7/ptodata/1/ina/6B_COMB.seq:US-09-163-115-4	+	291.50	525.48	1.1e-21	2120
/cgnl_7/ptodata/1/ina/6B_COMB.seq:US-09-221-528-4	+	291.50	525.48	1.1e-21	2120
/cgnl_7/ptodata/1/ina/6B_COMB.seq:US-09-593-553-4	+	291.50	525.48	1.1e-21	2120
/cgnl_7/ptodata/1/ina/5A_COMB.seq:US-08-587-889-1	+	283.50	503.12	1.9e-20	3590
/cgnl_7/ptodata/1/ina/PCTUS_COMB.seq:PCT-US96-09193-1	+	283.50	503.12	1.9e-20	3590
/cgnl_7/ptodata/1/ina/5B_COMB.seq:US-08-888-982A-42	+	280.50	501.90	2.3e-20	2510
/cgnl_7/ptodata/1/ina/5B_COMB.seq:US-08-276-151-1	+	271.50	482.18	2.8e-19	2977

/cgnl\_7/ptodata/1/ina/5A\_COMB.seq:US-08-306-691B-17 + 271.50 482.18 2.8e-19 2977  
 /cgnl\_7/ptodata/1/ina/5B\_COMB.seq:US-08-756-806A-64 + 271.50 482.18 2.8e-19 2977  
 /cgnl\_7/ptodata/1/ina/6A\_COMB.seq:US-08-328-239A-4 + 271.50 482.18 2.8e-19 2977  
 /cgnl\_7/ptodata/1/ina/6A\_COMB.seq:US-09-143-214-64 + 271.50 482.18 2.8e-19 2977  
 /cgnl\_7/ptodata/1/ina/6B\_COMB.seq:US-09-209-668-12 + 271.50 482.18 2.8e-19 2977

seq\_name: /cgnl\_7/ptodata/1/ina/6A\_COMB.seq:US-09-019-942-2

```

seq_documentation_block:
; Sequence 2, Application US/09019942
; Patent No. 6033855
; GENERAL INFORMATION:
; APPLICANT: Bertin, John
; TITLE OF INVENTION: GENES ENCODING CASPASE RECRUITMENT
; TITLE OF INVENTION: DOMAIN POLYPEPTIDES
; NUMBER OF SEQUENCES: 4
; CORRESPONDENCE ADDRESS:
; ADDRESSSEE: Fish & Richardson P.C.
; STREET: 225 Franklin Street
; CITY: Boston
; STATE: MA
; COUNTRY: USA
; ZIP: 02110-2804
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: Windows 95
; SOFTWARE: FastSeq for Windows Version 2.0b
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/019,942
; FILING DATE: 06-FEB-1998
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER:
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Meikie John, Ph.D., Anita L.
; REGISTRATION NUMBER: 35,283
; REFERENCE/DOCKET NUMBER: 07334/068001
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 617/542-8070
; TELEFAX: 617/542-8906
; TELEX: 200154
; INFORMATION FOR SEQ ID NO: 2:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 1931 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: cDNA
; US-09-019-942-2

```

alignment\_scores:  
 Quality: 2817.00 Length: 540  
 Ratio: 5.226 Gaps: 0  
 Percent Similarity: 99.815 Percent Identity: 99.630

alignment\_block:  
 US-09-445-223-1 x US-09-019-942-2

Align seg 1/1 to: US-09-019-942-2 from: 1 to: 1931

1 MetAsnGlyGLuAlaIleCysSerAlaLeuProThrIleProTyrHisly 17  
 |||||  
 214 ATGAACGGGGAGCCATCTGCAGCGCCCTCCACCATCCCTACCACAA 263

17 sLeuAlaAspLeuArgTyrLeuSerArgGlyAlaSerGlyThrValSer 34  
 |||||  
 264 ACTCGCCGACCTCGCTACCTAGCCGCGCCCTCTGGCACTGTGTCGT 313

34 eAlaArgHisAlaAspTrrArgValGlnValAlaVallyHisLeuHis 50  
 |||||  
 314 CCGCCGCGCCAGCAGACTCGCGCGCTCCAGGTGCGCGTGAAGCACCTGCAC 363

351 LeuHisGluAsnSerGlySerProGluThrSerArgSerLeuProAlaPr 367  
 1264 CTCATGAATAAGTGGTCTCTGAACTTCAAGTCCCTCCAGCTCC 1313  
 367 oGlnAspAsnAspPheLeuSerArgLysAlaGlnAspCysTyrPheMetL 384  
 1314 TCAAGACAATGATTTTATCTAGAAAAGCTCAAGACTGTTATTTATGA 1363  
 384 yLeuHisHisCysProGlyAsnHisSerTyrAspSerThrIleSerGly 400  
 1364 AGCTGATCAGTCTGCTGGAAATACAGTTGGATAGCACCATTTCTGGA 1413  
 401 SerGlnArgAlaAlaPheCysAspHisLysThrProCysSerAl 417  
 1414 TCTCAAAGGCTGCTTCTGATCACAAGACCATTTCCATGCTCTTCAGC 1463  
 417 alerIleAsnProLeuSerThrAlaGlyAsnSerGluArgLeuGlnProG 434  
 1464 AATAATAAATCCACTCTCAACTGCAGGAAACTCAGAACTGTCAGCCTG 1513  
 434 yIleAlaGlnGlnTrpIleGlnSerLysArgGluAspIleValAsnGln 450  
 1514 GTATGCCAGCAGTGGATCCAGAGCAAAAGGGAAGACATTTGGAACCAA 1563  
 451 MetThrGluAlaCysLeuAsnGlnSerLeuAspAlaLeuLeuSerArgAs 467  
 1564 ATGACAGAAGCCTGCTTAACAGTCCGTAGATGCCCTTCTGTCCAGGGA 1613  
 467 pLeuIleMetLysGluAspTyrGluLeuValSerThrLysProThrArgT 484  
 1614 CTTGATCATGAAAGAGGACTTGAAGCTTGTAGTACCAAGCCTTACAAGGA 1663  
 484 hrSerLysValArgGlnLeuLeuAspThrThrAspIleGlnGlyGluGlu 500  
 1664 CCICAAAGTCCAGCAATTTACTAGACACTACTGCATCCCAAGGAGAAGAA 1713  
 501 PheAlaLysValIleValGlnLysLeuLysAspAsnLysGlnMetGlyLe 517  
 1714 TTTGCCAAAGTTATAGTACAAAATTTCAAAGATAACAACAATAATGGTCT 1763  
 517 uGlnProTyrProGluIleLeuValSerArgSerProSerLeuAsnL 534  
 1764 TCAGCCTTACCCGGAAATCTGTGGTTCTAGATCACCATCTTTAAAT 1813  
 534 euLeuGlnAsnLysSerMet 540  
 1814 TACTTCAAATAAAAAGCATG 1833

seq\_name: /cgnl\_7/ptodata/1/ina/6B\_COMB.seq:US-09-188-930-257  
 seq\_documentation\_block:  
 ; Sequence 257, Application US/09188930A  
 ; Patent No. 6150502  
 ; GENERAL INFORMATION:  
 ; APPLICANT: Watson, James D.  
 ; APPLICANT: Strachan, Lorna  
 ; APPLICANT: Sleeman, Matthew  
 ; APPLICANT: Onrust, Rene  
 ; TITLE OF INVENTION: Compositions Isolated From Skin Cells  
 ; TITLE OF INVENTION: and Methods For Their Use  
 ; FILE REFERENCE: 11000.1011c1  
 ; CURRENT APPLICATION NUMBER: US/09/188,930A  
 ; CURRENT FILING DATE: 1998-11-09  
 ; NUMBER OF SEQ ID NOS: 348  
 ; SOFTWARE: FASTSEQ for Windows Version 3.0  
 ; SEQ ID NO 257  
 ; LENGTH: 3516  
 ; TYPE: DNA  
 ; ORGANISM: Mouse  
 US-09-188-930-257

51 IleHisThrProLeuLeuAspSerGluArgLysAspValLeuArgGluAl 67  
 364 ATCCACACTCCGCTGTCGACAGTGAAGAAGGATGCTTAAAGAGAAGC 413  
 67 aGluIleLeuHisAlaArgPheSerTyrIlePheProIleLeuGlyI 84  
 414 TGAATTTTACAAAGCTAGATTTAGTTACATTTCTCCAATTTGGGAA 463  
 84 leCysAsnGluProGluPheLeuGlyIleValThrGluTyrMetProAsn 100  
 464 TTTGCAATGAGCCTGAATTTTGGGAATAGTTACTGAATACATGCCAAAT 513  
 101 GlySerLeuAsnGlnLeuLeuHisArgLysThrGluTyrProAspValAl 117  
 514 GGATCAFTAATAAATGAATCTTACATGAAACTGAAATATCTCTGATGTC 563  
 117 atPpProLeuArgPheArgIleLeuHisGluIleAlaLeuGlyValAsnT 134  
 564 TTGCCAATTCAGATTTCCGATCTCTGATGAAATTTGCCITGGTGTAAAT 613  
 134 yrLeuHisAsnMetThrProProLeuLeuHisHisAspLeuLysThrGln 150  
 614 ACCTGCACAATATGACTCTCTCTTACTTCCATGACTTGAAGACTCAG 663  
 151 AsnIleLeuLeuAspAsnGluPheHisValLysIleAlaAspPheGlyLe 167  
 664 AATATCTTATGGCAATGAATTTCAFTGTTAAGATTCAGATTTGGT 713  
 167 uSerLysTrpArgMetSerLeuSerGlnSerArgSerSerLysSerA 184  
 714 ATCAAAGTGGCCATGATGTCCTCTCACAGTCCAGCAAGTAGCAAAATCTG 763  
 184 laProGluGlyThrIleIleTyrMetProProGluAsnTyrGluPro 200  
 764 CACCAGAAGGGGACAAATTTACTATATGCCCTGAAACTATGAACCT 813  
 201 GlyGlnLysSerArgAlaSerIleLysHisAspIleTyrSerTyrAlaVa 217  
 814 GGACAAAANTCAAGGGCCAGTCAACAGCAGATATATAGCTATGCAGT 863  
 217 lIleThrTrpGluValLeuSerArgLysGlnProPheGluAspValThrA 234  
 864 TATCATGTTGGAGTGTATCCAGAAAACAGCCTTTTGAAGATGTCACCA 913  
 234 snProLeuGlnIleMetTyrSerValSerGlnGlyHisArgProValIle 250  
 914 ATCCTTTGCAGATATGTTAGTGTGTCCAGAGACATCCAGCCTGTTATT 963  
 251 AsnGluLeuSerLeuProTyrAspIleProHisArgAlaArgMetIleSe 267  
 964 AATGAAGAAAGTTTGCATATGATATACCTCACCAGCAGCATGATGATCTC 1013  
 267 rLeuIleGluSerGlyTrpAlaGlnAsnProAspGluArgProSerPheL 284  
 1014 TCTAATGAAAAGTGGATGGGCACAAAATCCAGATGAAAGACCATCTTCT 1063  
 284 euLysCysLeuIleGluLeuGluProValLeuArgThrPheGluGluIle 300  
 1064 TAAATGTTTAAAGACTTGAACAGCTTTTGAACACTTTGAAGAGATA 1113  
 301 ThrPheLeuGluAlaValIleGlnLeuLysLysThrLysLeuGlnSerVa 317  
 1114 ACTTTTCTTGAAGCTGTTATTTCAGTAAAGAAAACAAAGTTTACAGAGTGT 1163  
 317 lSerSerAlaIleHisLeuCysAspLysLysLysMetGluLeuSerLeuA 334  
 1164 TTCAAGTCCCAATTCACCTATGTTGACAAAGAAAATGGAATTTACTCTG 1213  
 334 snIleProValAsnHisGlyProGlnGluSerCysGlySerSerGln 350  
 1214 ACATACCTGTTAAATCATGTTCCACAAGGAATCATGTGGATCCTCTCAG 1263

alignment\_scores:  
 Quality: 579.00 Length: 540  
 Ratio: 1.969 Gaps: 26  
 Percent Similarity: 54.444 Percent Identity: 34.074

alignment\_block:  
 US-09-445-223-1 x US-09-188-930-257

Align seg 1/1 to: US-09-188-930-257 from: 1 to: 3516

```

10 LeuProThrIleProTyrHisLysLeuAlaAspLeuArgTyrLeuSerAr 26
   ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
   ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
43 CTGCGCACCTTCGACGGCGGGCAATTCGCGCTGGGAGAGTGGGCTC 92
   ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
26 gGlyAlaSerGlyThrValSerSerAlaArgHisAlaAspTyrArgValG 43
   ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
93 GGGCGGCTTCGGCAGGTGTACAAAGTGGCCCATGTGCRACCTGGAAGCCT 142
   ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
43 InValAlaValLys .....HisLeuHisIleHisThrProLeuLeu 56
   ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
143 GGCTCCGATCAAGTGTCTGCCAGTCTGCACCTGCAC ..... 180
   ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
57 AspSerGluArgLysAspValLeuArgGluAlaGluIleLeuHisLysAl 73
   ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
181 GACGGGACGAAATGGAGTCTCTGGAGGAAGCTAAGAAGATGGAGATGGC 230
   ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
73 aArgPheSerTyrIlePheProIleLeuGlyIleCysAsnGluProGluP 90
   ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
231 CAAGTTCGGATACATCTACCTGTGTACGGCATATGCCAGGAACTT ..... 276
   ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
90 heLeuGlyIleValThrGluTyrMetProAsnGlySerLeuAsnGluLeu 106
   ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
277 ..GTGGGTTGGTATGGAGTACATGGAGACAGGCTCCCTGGGAAAGCTG 324
   ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
107 LeuHisArgLysThrGluTyrProaspValAlaTyrProLeuArgPhear 123
   ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
325 CTGGGCTCAGAG .....CAATTCTGGGACCTGGCTTTTCG 362
   ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
123 gIleLeuHisGluIleAlaLeuGlyValAsnTyrLeuHisAsnMetThrP 140
   ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
363 CATCTGGCAGAGACAGCGGTGGCATGAACCTTCCTGCATTCATGTCCTC 412
   ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
140 roProLeuLeuHisHisAspLeuLysThrGlnAsnIleLeuLeuAspAsn 156
   ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
413 CGCCACTGTGCACCTAGACCTGAAGCCAGCCAGCAACATCTCTGTGGATCC 462
   ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
157 GluPheHisValLysIleAlaAspPheGlyLeuSerLysTyrArgMetMe 173
   ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
463 CACTACCATGTCAAGATTCTCAGTTTGGCTGGCCCAAGTGCATGGCAT 512
   ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
173 tSerLeuSerGlnSerArgSerSerLysSerAlaProGluGly .....G 188
   ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
513 GTCCACATCTCATGACCTCAGCATG .....GATGGCTGTTTG 550
   ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
188 lYThrIleIleTyrMetProGluAsnTyrGluProGlyGlnLysSer 204
   ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
551 GTACAATCGCTTACCTCCCTCCAGAGCAATTCGT .....GAGAAGAC 594
   ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
205 ArgAla...SerIleLysHisAspIleTyrSerTyrAlaValIleThrTr 220
   ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
595 CGCTTGTTCACACCAAGATGTATACAGTTCGGCTGGCCCAATGTGATCTG 644
   ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
220 pGluValLeuSerArgLysGlnProPheGluAspValThrAsnProLeuG 237
   ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
645 GGGTGTGTACACAGAGAACCCATTTCAGATGNAAGACATCCCTAC 594
   ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
237 InIleMetTyrSerValSerGlnGlyHisArgProValIleAsnGluGlu 253
   ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
695 ACATCATGATGAAGTGGTAAAGGGCCACCGCCCA .....GAG 732
   ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
254 SerLeuProTyrAspIleProHisArg .....AlaArgMetIleSe 267
   ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
733 CTGCCACCCATCTGCAGACCCCGCGGCTGTGCTGTGCCAGCCTGATAGG 782
  
```

```

267 rLeuIleGluSerGlyTyrAlaGlnAsnProAspGluArgProSerPheL 284
   ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
783 GCTCATGCAACCGTCTGGCATGCAGACCCACAGGTGGCGGCC ..... 825
   ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
284 euLysCysLeuIleGluLeuGluProValLeuArgThrPheGluGluIle 300
   ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
826 .....ACCTTCCAGAAAT 840
   ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
301 ThrPheLeuGluAlaValIleGlnLeuLysLysThrLysLeuGlnSerVa 317
   ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
841 ACC ..... 843
   ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
317 lSerSerAlaIleHisLeuCysAspLysLysMetGluLeuSerLeuA 334
   ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
844 .TCTNAACAGAGACCTTTGTGAGAACCTGATGAGGAGGTGAAA ..... 888
   ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
334 snIleProValAsnHisGlyProGlnGluSerCysGlySerSerGln 350
   ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
889 .....GACCTGGCTCATGAGCCAGCGGAGAAAAGCTCTCTAGAGTCCAAG 933
   ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
351 LeuHisGluAsnSerGlySerProGluThrSerArgSerLeuProAlaPr 367
   ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
934 AGTGGCCAGCGCCGAGTCTCAGCCCTCAAGCGGCTCTGTCTCCCC 983
   ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
367 oGlnAspAsnAsp.PheLeuSerArgLysAlaGlnAspCystyrPheMet 383
   ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
984 CTTGCATACAGCTGCAGTCTCT .....CCGAGTTGC ..... 1015
   ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
384 LysLeuHisHisCysProGlyAsnHisSerTyrPaspSerThrIleSerG 400
   ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
1016 .....TGT .....CACAGTTGG .....ACTCTGG 1035
   ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
400 ySerGlnArgAlaAlaPheCysAspHisLysThrThrProCysSerSerA 417
   ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
1036 ATCTCCAGACTCTTG .....AAGCCCGCAAGAGCTCAG 1070
   ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
417 laIleIleAsnProLeuSerThrAlaGlyAsnSerGluArgLeuGlnPro 433
   ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
1071 CGGAAGTT...CTCTG .....AATCGAAGCTCCCATCGTCCA 1105
   ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
434 GlyIleAlaGln .....GlnTrpIleGlnSerLysAr 444
   ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
1106 GCAGTGGCAAGAGGCTCTCGGGGTCTCCTCAGTGGACTCAGCCTTTTCC 1155
   ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
444 gGluAspIleValAsnGlnMetThrGluAlaCysLeuAsnGlnSerLeuA 461
   ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
1156 TCCAGAG .....GATCGCTGT .....C 1172
   ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
461 spAlaLeuLeuSerArgAspLeuIleMetLysGluAspTyrGluLeuVal 477
   ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
1173 ACTGTCTTTTGGC ..... 1186
   ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
478 SerThrLysProThrArgThrSerLysValArgGlnLeu...LeuaspThr 493
   ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
1187 .....GGGAAGCTTCAACAGCGGACCTGGGCC 1215
   ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
494 ThrAspIleGlnGlyGluPheAlaLysValIleValGlnLysLeuL 510
   ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
1216 ACAGACTCCAGAAAGAGCTAGTGGATGCCATCATATCAGGGGACAC 1265
   ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
510 sAspAsnLysGlnMetGlyLeuGlnProTyrProGluIleLeuValVal 527
   ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
1266 CAGCAGCTGATCAAGATCTCTACAGCCCAAGATGTGGACTTGGTCTAG 1315
   ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
527 erArgSerProSerLeu 532
   ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
1316 ACAGCAGTCCAGCCTG 1332
  
```

seq\_name: /cgnl\_7/ptodato/1/ina/6B\_COMB.seq:US-09-188-930-66  
 seq\_documentation\_block:  
 ; Sequence 66, Application us/09188930A

```

; Patent No. 6150502
; GENERAL INFORMATION:
; APPLICANT: Watson, James D.
; APPLICANT: Strachan, Lorna
; APPLICANT: Sleeman, Matthew
; APPLICANT: Onrust, Rene
; APPLICANT: Murison, James Greg
; TITLE OF INVENTION: Compositions Isolated From Skin Cells
; FILE REFERENCE: 11000.101lic
; CURRENT APPLICATION NUMBER: US/09/188.930A
; CURRENT FILING DATE: 1998-11-09
; NUMBER OF SEQ ID NOS: 348
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 66
; LENGTH: 1888
; TYPE: DNA
; ORGANISM: mouse
; FEATURE:
; NAME/KEY: unsure
; LOCATION: (1690)...(1690)
; NAME/KEY: unsure
; LOCATION: (1755)...(1755)
; NAME/KEY: unsure
; LOCATION: (1864)...(1864)
; US-09-188-930-66

```

```

alignment_scores:
  Quality: 548.00      Length: 541
  Ratio: 1.845        Gaps: 27
  Percent Similarity: 54.898  Percent Identity: 33.272

```

```

alignment_block:
US-09-445-223-1 x US-09-188-930-66

```

```

Align seg 1/1 to: US-09-188-930-66 from: 1 to: 1888
10 LeuProthrlleProTyrHisLysLeuAlaAspLeuArgTyrLeuSerAr 26
||| ||||| : : : : : ||||| : : : : :
43 CTGGCCACTTCGACCGCCGGAATTCGCAGGCTGGGAGAAGTGGGCTC 92
26 gGlyAlaSerGlyThrValSerSerAlaArgHisAlaAspTyrArgVal 43
||||: ||| ||| : : : : : ||||| : : : : :
93 GGGCGGCTTCGGGAGGTGTACAAGTGCACATGTCACCTGGAAGACGT 142
43 lnValAlaValLys.....HisLeuHisIleHisThrProLeuLeu 56
: : : : : ||| : : : : : ||||| : : : : :
143 GGTCTGGGATCAAGTGTCTGCCCGAGTCTGCACCGTCGAC..... 180
57 AspSerGluArgLysAspValLeuArgGluAlaGluIleLeuHisLysAl 73
||| ||||| : : : : : ||||| : : : : :
181 GACAGGAACGAATGGAGCTCCTGGGAGCACTAAGAAGATGGAGATGGC 230
73 aArgPheSerTyrIlePheProIleLeuGlyIleCysAsnGluProGluP 90
: : : : : ||||| : : : : : ||||| : : : : :
231 CAAGTTCGATACATTCCTACCTGTGTACGGCATATGCCAGGAACCT... 276
90 heLeuGlyIleValThrGluTyrMetProAsnGlySerLeuAsnGluLeu 106
: : : : : ||||| : : : : : ||||| : : : : :
277 .GTCCGCTGGTCTAGGTATACATGAGACAGGCTCCCTGGGAGAGCTG 324
107 LeuHisArgLysThrGluTyrProAspValAlaIleThrProLeuArgPheAr 123
: : : : : ||||| : : : : : ||||| : : : : :
325 CTGGCCCTCAGAG.....CCATTGCCCTGGGACCTGCCCTTTCG 362
123 gIleLeuHisGluIleAlaLeuGlyValAsnTyrLeuHisAsnMetThrP 140
||||: ||||| : : : : : ||||| : : : : :
363 CATCGTCACGAGACACCGCTGGGCATGAATTCCTGATTCATGCTGTC 412
140 roProLeuHisHisAspLeuLysThrGlnAsnIleLeuLeuAspAsn 156
||||: ||||| : : : : : ||||| : : : : :
413 CCACCATGCTGCACCTAGACCTGAGCCGACCGCAACATCTGCTGGATGC 462

```

```

157 GluPheHisVal...LysIleAlaAspPheGlyLeuSerLysTyrArgMe 172
: : : : : ||||| : : : : : ||||| : : : : :
463 CACTACCAANTCTCAAGATTTCTTACITTTGGCTGGCCAAAGTGCANLYG 512
172 tMetSerLeuSerGlnSerArgSerSerLysSerAlaProGluGly.... 187
||||| ||||| : : : : : ||||| : : : : :
513 CATGTCACCACTCTCATGACCTCAGCATG.....GATGGCCTGT 550
188 ..GlyThrIleIleIleTyrMetProGluAsnTyrGluProGlyGlnLys 203
||||| ||||| : : : : : ||||| : : : : :
551 TTGGTACAATCGCTACCTCCCTCCAGACGGAATTCGT.....GAGAAG 594
204 SerArgAla...SerIleLysHisAspIleTyrSerTyrAlaValIleTh 219
||||| ||||| : : : : : ||||| : : : : :
595 AGCCGCTGTTTGACACCAACATGATGATACAGCTTCGCCATTTGTGAT 644
219 rTrpGluValLeuSerArgLysGlnProPheGluAspValThrAsnProL 236
||| ||||| : : : : : ||||| : : : : :
645 CTGGGCTGTGCTTACACAGAATAATCCATTTGCAGATGAAAAGAATCC 694
236 euGlnIleMetTyrSerValSerGlnGlyHisArgProValIleAsnGlu 252
||: ||||| : : : : : ||||| : : : : :
695 TACACATCATGATGAAAGTGGTAAAGGGCCACCGCCCA..... 732
253 GluSerLeuProTyrAspIleProHisArg.....AlaArgMetI 266
||| ||||| : : : : : ||||| : : : : :
733 GAGCTGCCACCCATCTGCAGACCCCGCCGCTGCTGTGCCACGCTGAT 782
266 eserLeuIleGluSerGlyTrpAlaGlnAsnProAspGluArgProSerP 283
||||: ||||| : : : : : ||||| : : : : :
783 AGGGCTCATGCAACGGTGTGGCATGCAGACCCACAGGTGGGCCCC... 828
283 heLeuLysCysLeuIleGluLeuGluProValLeuArgThrPheGluGlu 299
||||: ||||| : : : : : ||||| : : : : :
829 .....ACCITCCAAGAA 840
300 IleThrPheLeuGluAlaValIleGlnLeuLysLysThrLysLeuGlnse 316
|||||
841 ATTACC..... 846
316 rValSerSerAlaIleHisLeuCysAspLysLysMetGluLeuSerL 333
||||: ||||| : : : : : ||||| : : : : :
847 ....TCTGAACACAGACACCTTTGTGAGAAGCTGTAGGAGGTGAAA.. 891
333 euAsnIleProValAsnHisGlyProGlnGluSerCysGlySerSer 349
: : : : : ||||| : : : : : ||||| : : : : :
892 .....GACCTGGCTCATGAGCCAGCGGAGAAAGCTCTCTAGAGTCC 933
350 GlnLeuHisGluAsnSerGlySerProGluThrSerArgSerLeuProAl 366
: : : : : ||||| : : : : : ||||| : : : : :
934 AAGAGTGGAGCCAGCCGAGTCTCAGCCCTCAAGCGCCCTCTGCTCC 983
366 aProGlnAspAsnAsp.PheLeuSerArgLysAlaGlnAspCysTyrPhe 382
||| ||||| : : : : : ||||| : : : : :
984 CCCCTTCGATPACAGCTGACGTCT.....CCAGTTGC..... 1018
383 MetLysLeuHisCysProGlyAsnHisSerTrpAspSerThrIleSe 399
||| ||||| : : : : : ||||| : : : : :
1019 .....TGT.....CACAGTTGG.....ACTCTGGG 1038
399 rGlySerGlnArgAlaPheCysAspHisLysThrThrProCysSerS 416
: : : : : ||||| : : : : : ||||| : : : : :
1039 ATCTTCCCAA.....GACTCTTGAAGGCCCCCGAAGAGCT 1073
416 erAlaIleAsnProLeuSerThrAlaGlyAsnSerGluArgLeuGln 432
||| ||||| : : : : : ||||| : : : : :
1074 CAGCCGAGTT...CCTCTG.....AATGCAAGCTCCCATCGT 1108
433 ProGlyIleAlaGln.....GlnTrpIleGlnSerLy 443
||: ||||| : : : : : ||||| : : : : :
1109 CCAGCAGTGGCAAGAGGCTCTCGGGGGTGTCTCAGTGGACTCAGCCTT 1158

```



```

858 GCAGGGCATCCCAAGACAGACAGCCCAACATTTCTGGCATTGAAGAAGAT 907
      |||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
290 euGluPro...ValLeuArgThrPheGluGluIleThrPheLeuGluAla 305
      |||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
908 TTAGGCCCTTTTAAAGTCAATTTGAAGAAATATGTA...GAAGAGGAT 954
      |||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
306 ValIleGluLeuLysLys.....ThrLysLeuGlnSe 316
      |||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
955 GTGGCAAGTTTAAAGAAAGAGTATCCAGATCAAGCCAGTGTGCAGAG 1004
      |||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
316 rValSerAlaIleHisLeuCys..... 324
      |||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
1005 AATGTTTCTACTCCAGCATGCTGTGTACCTTACCTCCGAGCAGTCAA 1054
      |||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
325 ..AspLysLysMetGluLeuSerLeuAsnIleProValAsnHisGly 340
      |||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
1055 ATTCAGAAACACCTGGATGGCTCACAGTTCACAGGGGCTCCAGATGGGT 1104
      |||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
341 ProGlnGluSerCysGlySerSerGln.....LeuHisG1 353
      |||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
1105 CCTGTGAGAGGTCCTGGTTTCTTCTCCCGAGATACCACAGGACCA 1154
      |||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
353 uAsnSerGlySerProGluThr..... 360
      |||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
1155 GAATGATCGCACTGTGCGAGGCTAAGCTGCAAGAGGAAGCCAGCTATCATG 1204
      |||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
361 .....SerArgSerLeuProAlaProGlnAspAsn 370
      |||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
1205 CTTTGGAAATATTGGAGAAACAGACAAAACCCGACCCAGCCAGAGAAAT 1254
      |||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
371 AspPheLeuSerArgLysAlaGlnAspCysTyrPheMetLysLeuHisH1 387
      |||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
1255 GAGCCTTACAACAGAGAGGAGAA.....AGGAAACGAAGGGCTCTCA 1298
      |||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
387 SCysPro..... 389
      |||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
1299 TGACCCCTTTGCACAGCAGAGAGCTCGTGAATATTAAGAGTGCAGGAG 1348
      |||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
390 ..GlyAsnHisSerTyrAspSerThrIleSerGlySerGlnArgAlaAla 405
      |||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
1349 CAGAGGTCATTCATGCCAGCACACACAGT.....CGTGGAAAT 1389
      |||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
406 PheCysAspHisLysThrProCysSerSerAlaIleIleAsn..... 420
      |||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
1390 GCAGTGCACAGAGCTGTATGCCAGCCACCCAAACAGTTTGGAAACAAATGG 1439
      |||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
421 .....ProLeuSerThrAlaGlyAsnSerGluArgLeuG 432
      |||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
1440 ATTGATATAATCAGCATGGATTTGGAACTACAGGTACAGGATTTGGTATC 1489
      |||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
432 lnProGlyIleAlaClnGlnTrpIleGlnSerLys..... 443
      |||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
1490 CGCCAAATCTAAGCCAAATGTATAGTACTTATAAACTCCAGTCCAGAG 1539
      |||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
443 ..... 443
      |||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
1540 ACCAACATACCGGAGACACACCCACCACCTATCTCTCTGGGCCAGT 1589
      |||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
444 ArgGluAspIleVal_AsnGlnMet..... 451
      |||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
1590 AGCAGATGACCTATAAAATATAATATCAATAGTTCTGGTATTTCAGA 1639
      |||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
452 ThrGluAlaCysLeuAsnGlnSerLeuAspAlaLeuLeuSerArgAspLe 468
      |||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
1640 TTGGAAACCACCAATATATGATGTGGACTGTAATTCACAACCACCACCAAC 1689
      |||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
468 uIleMetLysGluAspTyrGluLeuValSerThrLysProThrArgThrS 485
      |||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
1690 AATACTTCAAAAGAGAGTCCGACTCCAGACACCCAAAGCCATCTTTGATAA 1739
      |||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
485 rLysValArgClnLeuLeuAspThrThrAspIleGlnGlyGlu..... 499
      |||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:

```

```

1740 CACCACCTAGTCTGACTGATGAACACCTGAACCCCTATCAGGGAAAAACCTGG 1789
500 .....GluPheAlaLysValIleValG1 507
1790 GAAGGCAGTGGAAAAAAGTGTGCCCCCAAGCTGGCTTCACTGAGTCTCAG 1839
507 nLysLeuLysAspAsnLysGlnMet 515
1840 ATCGATGAAATCGACCATGATG 1864
seq_name: /cgn1_7/ptodata/1/ina/6A_COMB.seq:US-09-329-418-2
seq_documentation_block:
; Sequence 2, Application US/09329418
; Patent No. 6096539
; GENERAL INFORMATION:
; TITLE OF INVENTION: PROTEIN ACTIVATOR OF APOPTOSIS
; FILE REFERENCE: PHM.70536
; CURRENT APPLICATION NUMBER: US/09/329.418
; CURRENT FILING DATE: 1999-06-11
; NUMBER OF SEQ ID NOS: 39
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 2
; LENGTH: 1557
; TYPE: DNA
; ORGANISM: Homo Sapiens
; US-09-329-418-2
alignment_scores:
Quality: 395.00 Length: 499
Ratio: 1.452 Gaps: 21
Percent Similarity: 54.509 Percent Identity: 28.056
alignment_block:
US-09-445-223-1 x US-09-329-418-2
Align seg 1/1 to: US-09-329-418-2 from: 1 to: 1557
11 ProThrIleProTyrHisLysLeuAlaAspLeuArgTyrLeuSerArgG1 27
|||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
40 CCTTGGTGTCCATCGAGGAAGTGGAGAACCCAGGAGCTCGTCGGCAAAGG 89
27 yAlaSerGlyThrValSerSerAlaArgHisAlaAspTyrArgValGlnV 44
|||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
90 CGGGTTCGGCACAGTGTCTCCGGCCCAACATAGGAAGTGGGGCTACGATG 139
44 aIAlaValLysHisLeuHisIleHisThrProLeuLeuAspSerGluArg 60
|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
140 TGGCGGTCAAGATCGTAAC.....TCG 162
61 LysAspValLeuArgGluAlaGluIleLeuHisLysAlaArgPheSerTy 77
|||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
163 AAGCGCATATCCAGGGAGTCAAGGCCATCGCAAGTCTGGATAACGAATT 212
77 rIlePheProIleLeuGlyIleCysAsnGluProGluPhe..... 90
|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
213 CGTGTCCGCTAGAAGGGGTTATCGAGAAGGTGAAGTGGGACCAAGATC 262
91 .....LeuGlyIleValThrGluTyrMetProAsnGlySerLeuAsnGlu 105
|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
263 CCAAGCCGGCTCTGGTCACTAAATTCATGGAGAACGGCTCTTGTCCGGG 312
106 LeuLeuHisArgLysThrGluTyrProAspValAlaTyrProLeuArgPh 122
|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
313 CTGCTCAGTCCCGCTCCCTYGGCC.....TGGCCGCTCCTCTTGT 353
122 eArgIleLeuHisGluIleAlaLeuGlyValAsnTyrLeuHisAsnMetT 139
|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
354 CCGCTCTGAAAGAGAGTGTGTGGATGTTTACCTCAGCAGCCAGA 403
139 hrProProLeuLeuHisHisAspLeuLysThrGlnAsnIleLeuLeuAsp 155

```

```

1253 GTCTGGACCCCGAGGAAATCAAGGGGGCTGAGAG..... 1286
409 islysthrThrProCysSerSerAlaIleIleasnProLeuSerThrAla 425
1287 .....ACRAGGATGAATGCTCTGAGGACCCCGGAGCAATCC 1328
426 GlyAsnSerGluArgLeuGlnProGlyIleAlaGlnGlnTrpIleGlnSe 442
1329 AGTAACAGCGGACCCGCTGTTAAACATATAACAACCTGCTCTGGGGTCAAG 1378
442 rlyserGluAspIleValasnGlnMetThrGluAlaCysLeu 456
1379 TTGGAGACAACAACACTACTTGGACTATGCAACAGACAACACTGCCTT 1421
seq_name: /cgnl_7/ptodata/1/ina/6A_COMB.seq:US-09-329-418-1
seq_documentation_block:
; Sequence 1, Application US/09329418
; Patent No. 6096539
; GENERAL INFORMATION:
; APPLICANT: ZENECA Limited
; TITLE OF INVENTION: PROTEIN ACTIVATOR OF APOPTOSIS
; FILE REFERENCE: PHM.70536
; CURRENT APPLICATION NUMBER: US/09/329,418
; CURRENT FILING DATE: 1999-06-11
; NUMBER OF SEQ ID NOS: 39
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 1
; LENGTH: 1873
; TYPE: DNA
; ORGANISM: Homo Sapiens
; US-09-329-418-1

```

```

alignment_scores:
Quality: 392.50 Length: 501
Ratio: 1.443 Gaps: 22
Percent Similarity: 54.291 Percent Identity: 28.144

```

```

alignment_block:
US-09-445-223-1 x US-09-329-418-1 ..
Align seg 1/1 to: US-09-329-418-1 from: 1 to: 1873
11 ProThrIleProTyrHisLysLeuAlaAspLeuArgTyrLeuSerArgG1 27
204 CCCTGGTGTCCATCGAGGAACCTGGAGAACCGAGGCTCGTCGGCAAGG 253
27 yAlaSerGlyThrValSerSerAlaArgHisAlaAspTrpArgValGlnV 44
254 CGGGTTCGGCACAGTGTTCGGGGCCCAACATAGGAAAGTGGGGCTACGATG 303
44 aAlaValLysHisLeuHisIleHisThrProLeuLeuAspSerGluArg 60
304 TGGCGCTCAAGATCGTAAC.....TCG 326
61 LysAspValLeuArgGluAlaGluIleLeuHisLysAlaArgPheSerTy 77
327 AAGCGCATATCCAGGGAGGTCAAGGCCATGGCAAGTCTGGATAACGAATY 376
77 rIlePheProIleLeuGlyIle.....CysAsnG 87
377 CGTGTGCGCCTAGAAGGGTTCATCAGAAAGTTCGGGGCTCGAGCAAG 426
87 luProGluPheLeuGlyIleValThrGluTyrMetProAsnGlySerLeu 103
427 ATCCCAAG...CCGGCTCTGGTACTAAATTCATGGAGAAGCGCTCTCTTG 473
104 AsnGluLeuLeuHisArgLysThrGluTyrProAspValAlaTrpProLe 120
474 TCGGGGCTCTGCAGTCCAGTCCCGCCCTCGGCC.....TGGCCGCT 514
120 uArgPheArgIleLeuHisGluIleAlaLeuGlyValAsnTyrLeuHisA 137

```

```

404 ACCCGGTGCTCTGACCGGGACCTCAAGCCATCAACCTGCTGCTGGAC 453
156 AsnGluPheHisValIleAlaAspPheGlyLeuSerLysTrpArgMe 172
454 CCAGAGTGCACGCTCAGTGGCAGATTTGGCCCTGCCACATTCAG... 501
172 tMetSerLeuSerGlnSerArgSerSerLysSerAlaProGluGlyGlyT 189
502 ...GGAGCTCACAGTCAAGGACAGGGTCCGGGGGCA...GGGGGCA 544
189 hrIleIleTyrMetProGluAsnTyrGluProGlyGlnLysSerArg 205
545 CCCTGGCTACTTGGCCCGAGAACTGTTT...GTTAACGTAAACCGGAAG 591
206 AlaSerIleLysHisAspIleTyrAlaValIleThrTrpGluVa 222
592 GCCTCCACAGCAGTGTACAGTCTACAGTCTGGGATCTTAATGTGGCAGT 641
222 LeuSerArgLysGlnProPheGluAspValThrAsnProLeuGlnIleM 239
642 GCTTCTGGAAGAAA...GTTGAGTGTCCAAACCGAACCATCCTGCTGT 688
239 etTyrSerVal...SerGlnGlyHisArgProValIleAsnGluGluSer 254
689 ACGAAGCAGTGTGCAACAGGCAAGCCGCTTCAATGGCTGAG..... 732
255 LeuProTyr.....AspIleProHisArgAlaArgMetIleSerLe 268
733 CTGCCCCCAAGCGGCTGAGACTCCCGCTTAGAAGGACTGAAGGAGCT 782
268 uIleGluSerGlyTrpAlaGlnAsnProAspGluArgProSerPheLeuL 285
783 AATGCAGCTCTGAGGAGGAGCCCAAGGACAGACCCCTCTCCAGG 832
285 ysCysLeuIleGluLeuGluProValLeuArgThrPheGluGluIleThr 301
833 AATGCCTACCAAAAATGTAGTAAGTCTCCAGATGGTGGAG.....AAC 876
302 PheLeuGluAlaValIleGlnLysLysThrLysLeuGlnSerValSe 318
877 AATATGATGCTGCTGCTCCAGGTAAGGATTCCTGTCTCAGCTCAG 926
318 rSerAlaIle.....HisLeuCysAspLysLysMetGlu..... 330
927 GAGCAGCAATAGGATTTCTATCCAGAGTCAAGGCAAGGAGGACAG 976
331 .....LeuSerLeuAsnIlePro.....ValAs 338
977 AATGGATGGCTTAGGAGAACCAATAGAAAACAGCAGCTCTCGTATGAT 1026
338 n.HisGly.....ProGlnGluLysSerCysGlySerGln 350
1027 GTCATGGTTCAGTGGCTAAACAACATCAATCTAGAGAGCCCTCCAG 1076
351 LeuHisGluAsnSerGlySerProGluThrSerArgSerLeuProAlaPr 367
1077 CTC.....TGTCTTAAATAAATCCCGAGCC 1102
367 cGlnAspAsnAspPheLeuSerArgLysAla..... 377
1103 TTACCAGAGGAGGAGGCAAGAGGAGGAGGATCCACAAAGCCTGGACA 1152
378 .....GlnAsp 379
1153 GCAGGCACATCTCAGATTCAGTGGTCCCAACCTCCAGACTCCAGAGAC 1202
380 CysTyrPheMetLysLeuHisCysPro.....GlyAsnHi 392
1203 CTCAACTTCAGAAACAGATCCCGAGCCCTACCTCAACTGGAACACCAA 1252
392 sSerTrpAspSerThrIleSerGlySerGlnArgAlaAlaPheCysAspH 409

```





Align seg 1/1 to: US-07-928-464-1 from: 1 to: 2890

1 MetAsnGlyGluAlaIleCysSerAlaLeuProThr..... 12  
 1675 ATGAATGCCCAATCAGTCAGCCAGTCCCAACAGCGGCAAAATAGGA 1724

13 .....IleProTyrHisLysLeuAla 20  
 1725 ACTTGGACTTGATGGTATGATGACATCCCGTGG.....TG 1765

20 sPLeuArgTyrLeuSerArgGlyAlaSerGlyThrValSerSerAlaArg 36  
 1766 AFTCTAATAAAGAAAAGATGGAGCAGGTCCTTTGGCAGTCTCCAC 1815

37 HisAlaAspTIPArg...ValGlnValAlaValLysHisLeu..... 49  
 1816 CGTGTGAGTGGCTCGGATGCTGTGAAAATCTCATGGAGCA 1865

50 HisLeHisThrProLeuLeuAspSerGluArg...LysAspValLeu 65  
 1866 AGACTTCCAT.....GCTGAGCGTGTAAATGAGTCTTAA 1900

65 tGluAlaGluIleLeuHisLysAlaAaGpPheSerTyrIlePheProIle 81  
 1901 GAGAGTTCGATATGAAACCCCTTCGCCACCCCTAACATTTCTCTTC 1950

82 LeuGlyIleCysAsnGluProGluPheLeuGlyIleValThrGluTyrMe 98  
 1951 ATGGGTGGCTCACCACTCAAAATTTGTCATAGTCACAGATATTT 2000

98 tProAsnGlySerLeuAsnGluLeuHisArgLysThrGluTyrProA 115  
 2001 GTCAAGAGGTAGTTATACAGACTTTGCATAAAAGTGGAGGAGGAC 2050

115 sPValAlaTrpProLeuArgPheArgIleLeuHisGluIleAlaLeuGly 131  
 2051 AATAGATGAGAGAGCTGCCCTGAGTATGCTGATGATGGCTAAGGA 2100

132 ValAsnTyrLeuHisAsnMetThrProProLeuLeuHisHisAspLeu 148  
 2101 ATGAATATCTTCAACATCGCAATCTCCAAATGTCATAGATCTAAA 2150

148 sThrGlnAsnIleLeuLeuAspAsnGluPheHisValLysIleAlaAsp 165  
 2151 AFTCTCAAACATTTATGGTTGACAAAAATATACAGTCAAGGTTGTGAT 2200

165 heGlyLeuSerLysTyrArgMetMetSerLeuSerGlnSerArgSer 181  
 2201 TTGGTCTCTCCGATGAAAGCCAGCAGCTTCTTCTCCGAAAGTCAGCA 2250

182 LysSerAlaProGluGlyThrIleIleTyrMetProProGlu..... 196  
 2251 GCTGGAACCCCGAG.....TGGATGGCACCAGAAAGTCTCT 2285

197 AsnTyrGluProGlyGlnLysSerArgAlaSerIleLysHisAspIle 213  
 2286 GCGAGATGACCGCTAATGAA.....AAGTCAGATGTGT 2320

213 YrSerTyrAlaValIleThrTTPGluValLeuSerArgLysGlnProphe 229  
 2321 ACAGCTTCGGGTCACTTCTGGGAGCTGCTACATTCGAACAACCATGG 2370

230 GluAspValThrAsnProLeuGlnIleMetTyrSerValSerGlnGlyH 246  
 2371 GGTAACCTTA...AATCCGCTCAGGTGTGAGCTGGGTTGGTTCAAGTG 2417

246 sArgProValIleAsnGluSerLeuProTyrAspIleProHis.... 261  
 2418 TAAACGGGTG.....GAGATCCCGGTAATC 2443

262 ..ArgAlaArgMetIleSerLeuIleGluSerGlyTrpAlaGlnAsnPro 277  
 2444 TGAATCTCAGGTGACCCATAATCGAGGGTGTGAGCAATGAGCCA 2493

278 AspGluArgProSerPheLeuLysCysLeuIleGluLeuGluProValle 294  
 2494 TGAAGCGTCCATCAITTCACACTAATAATGAGACTTCTAAGACCAATTGAT 2543

294 uArgThr 296  
 2544 CAAATCA 2550

seq\_name: /cgnl\_7/ptodata/1/ina/PCTUS\_COMB.seq: PCT-US93-07347-1

seq\_documentation\_block:  
 ; Sequence 1, Application PC/TUS9307347  
 ; GENERAL INFORMATION:  
 ; APPLICANT: Ecker, Joseph R.  
 ; APPLICANT: Kieber, Joseph J.  
 ; TITLE OF INVENTION: Constitutive Triple Response Gene and  
 ; NUMBER OF SEQUENCES: 6  
 ; CORRESPONDENCE ADDRESS:  
 ; ADDRESSEE: Woodcock, Washburn, Kurtz, Mackiewicz and  
 ; STREET: One Liberty Place - 46th Floor  
 ; CITY: Philadelphia  
 ; STATE: PA  
 ; COUNTRY: U.S.A.  
 ; ZIP: 19103  
 ; COMPUTER READABLE FORM:  
 ; MEDIUM TYPE: Floppy disk  
 ; COMPUTER: IBM PC compatible  
 ; OPERATING SYSTEM: PC-DOS/MS-DOS  
 ; SOFTWARE: Patent In Release #1.0, Version #1.25  
 ; CURRENT APPLICATION DATA:  
 ; APPLICATION NUMBER: PCT/US93/07347  
 ; FILING DATE: 19930805  
 ; CLASSIFICATION:  
 ; ATTORNEY/AGENT INFORMATION:  
 ; NAME: Miller, Suzanne E.  
 ; REGISTRATION NUMBER: 32,279  
 ; REFERENCE/DOCKET NUMBER: UPN-1086  
 ; TELECOMMUNICATION INFORMATION:  
 ; TELEPHONE: 215-568-3100  
 ; INFORMATION FOR SEQ ID NO: 1:  
 ; SEQUENCE CHARACTERISTICS:  
 ; LENGTH: 2890 base pairs  
 ; TYPE: nucleic acid  
 ; STRANDEDNESS: single  
 ; TOPOLOGY: linear  
 ; MOLECULE TYPE: cDNA  
 ; FEATURE:  
 ; NAME/KEY: CDS  
 ; LOCATION: 118..2583  
 ; PCT-US93-07347-1

alignment\_scores:  
 Quality: 376.00 Length: 319  
 Ratio: 1.861 Gaps: 12  
 Percent Similarity: 63.323 Percent Identity: 30.721

alignment\_block:  
 US-09-445-223-1 x PCT-US93-07347-1 ..  
 Align seg 1/1 to: PCT-US93-07347-1 from: 1 to: 2890

1 MetAsnGlyGluAlaIleCysSerAlaLeuProThr..... 12  
 1675 ATGAATGCCCAATCAGTCAGCCAGTCCCAACAGCGGCAAAATAGGA 1724

13 .....IleProTyrHisLysLeuAla 20  
 1725 ACTTGGACTTGATGGTATGATGACATCCCGTGG.....TG 1765

```

20- spLeuArgTyrLeuSerArgGlyAlaSerGlyThrValSerSerAlaArg 36
|||||:.....:|||||:.....:|||||:.....:
1766 ATCTTAATAATAAAGAAAGATTGGAGCAGGTTCTTTGGCACTGTCCAC 1815

37 HisAlaAspTrpArg...ValGlnValAlaValLysHisLeu..... 49
:|||||:.....:|||||:.....:|||||:.....:
1816 CGTGTCTGAGTGGATGGCTCGGATGTTGCTGAAATTTCTCATGGAGCA 1865

50 HisIleHisThrProLeuLeuAspSerGluArg...LysAspValLeuA 65
:|||||:.....:|||||:.....:|||||:.....:
1866 AGACTTCCAT.....:GCTGAGCGTGTAAATGAGTCTTAA 1900

65 rgLualAlaGluIleLeuHisLysAlaArgPheSerTyrIlePheProIle 81
|||||:.....:|||||:.....:|||||:.....:
1901 GAGAGGTGGATTAATAAAGAAAGCTTTCGCCACCCTAACATTTGTTCTTTC 1950

82 LeuGlyIleCysAsnGluProGluPheLeuGlyIleValThrGluTyrMe 98
|||||:.....:|||||:.....:|||||:.....:
1951 ATGGTCCGGTCACTCACTCACTCACTCACTCACTCACTCACTCACTCACT 2000

98 tProAsnGlySerLeuAsnGluLeuHisArgLysThrGluTyrProA 115
:|||||:.....:|||||:.....:|||||:.....:
2001 GTCAGAGGTAGTATACAGCTTTCAGCTTTCAGCTTTCAGCTTTCAGCT 2050

115 spValAlaTrpProLeuArgPheArgTleLeuHisGluIleAlaLeuGly 131
:|||||:.....:|||||:.....:|||||:.....:
2051 AATTAGATGAGACGTCGCTGAGTAGTATGCTTATGATGCTGAGGTAAGGA 2100

132 ValAsnTyrLeuHisAsnMetThrProProLeuLeuHisHisAspLeu 148
|||||:.....:|||||:.....:|||||:.....:
2101 ATGAATATCTTACAAATCGCAATCTCCAAATGTCATAGATAGATAA 2150

148 sThrGlnAsnIleLeuLeuAspAsnGluPheHisValLysIleAlaAsp 165
:|||||:.....:|||||:.....:|||||:.....:
2151 ATCTCCAAACTTATGTTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTTG 2200

165 heGlyLeuSerLysTrpArgMetSerLeuSerGlnSerArgSer 181
|||||:.....:|||||:.....:|||||:.....:
2201 TTGCTCTCGCGATTCAGGCCAGCACGTTTCTTCTCCTCAAGTCAGCA 2250

182 LysSerAlaProGluGlyThrIleIleTyrMetProGlu..... 196
:|||||:.....:|||||:.....:|||||:.....:
2251 GCTGGAAACCCCGAG.....:TGGATGGCACCCAGAAGTCT 2285

197 AsnTyrGluProGlyGlnLysSerArgAlaSerIleLysHisAspIle 213
|||||:.....:|||||:.....:|||||:.....:
2286 CGGATGAGCCGCTTAATGAA.....:AAGTCAGATGTT 2320

213 yrSerTyrAlaValIleThrTrpGluValLeuSerArgLysGlnProPhe 229
|||||:.....:|||||:.....:|||||:.....:
2321 ACAGCTTCGGGGTCACTTCTGGGAGCTTGTACATTGCCAACACCATGG 2370

230 GluAspValThrAsnProLeuGlnIleMetTyrSerValSerGlnGlyH 246
:|||||:.....:|||||:.....:|||||:.....:
2371 GGTAACTTA...AATCCGGCTCAGGTTGTAGCTCGGTTGGTTCAACTG 2417

246 sArgProValIleAsnGluSerLeuProTyrAspIleProHis.... 261
:|||||:.....:|||||:.....:|||||:.....:
2418 TAAAGGGGTG.....:GAGATCCCGGTAATC 2443

262 ArgAlaArgMetIleSerLeuIleGluSerGlyTrpAlaGlnAspPro 277
|||||:.....:|||||:.....:|||||:.....:
2444 TGAATCTCAGGTCAGCCATAATCGAGGTTTGTGGACCAATGAGCCA 2493

278 AspGluArgProSerPheLeuLysCysLeuIleGluLeuGluProVal 294
:|||||:.....:|||||:.....:|||||:.....:
2494 TGGAGCGTCCATCATTTGCCAACHATATATGACATTGCTAAGACCATTCAT 2543

294 uArgThr 296
:|||||:.....:
2544 CAAATCA 2550

seq_name: /cgnl_7/ptodata/1/ina/5A_COMB.seq:us-08-003-311B-1

```

```

seq_documentation_block:
; Sequence 1, Application US/08003311B
; Patent No. 5441166
; GENERAL INFORMATION:
; APPLICANT: Ecker, Joseph R.
; APPLICANT: Kieber, Joseph J.
; TITLE OF INVENTION: Constitutive Triple Response Gene
; TITLE OF INVENTION: and Mutations
; NUMBER OF SEQUENCES: 13
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Woodcock Washburn Kurtz Mackiewicz and
; ADDRESS: No. 5441166ris
; STREET: One Liberty Place - 46th Floor
; CITY: Philadelphia
; STATE: PA
; COUNTRY: U.S.A.
; ZIP: 19103
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; OPERATING SYSTEM: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: wordperfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/003,311B
; FILING DATE: January 12, 1993
; CLASSIFICATION: 800
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 07/928,464
; FILING DATE: August 10, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Lori Y. Beardell
; REGISTRATION NUMBER: 34,293
; REFERENCE/DOCKET NUMBER: UPN-1108
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 215-568-3100
; TELEFAX: 215-568-3439
; INFORMATION FOR SEQ ID NO: 1:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 3033 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: cDNA
; FEATURE:
; NAME/KEY: CDS
; LOCATION: 118..2583
; US-08-003-311B-1

```

```

alignment_scores:
Quality: 376.00 Length: 319
Ratio: 1.861 Gaps: 12
Percent Similarity: 63.323 Percent Identity: 30.721

```

```

alignment_block:
US-09-445-223-1 x US-08-003-311B-1
Align seg 1/1 to: US-08-003-311B-1 from: 1 to: 3033
1 MetAsnGlyGluAlaIleCysSerAlaLeuProThr..... 12
|||||:.....:|||||:.....:
1675 ATGATGCCCCACCACCAATCAGTCAGCCAGTTCCAAACAGCGCAATAAGGGA 1724
13 .....IleProTyrHisLysLeuAlaA 20
1725 ACTTGGACTTGATGGTATGATATGGACATCCCGTGG.....TGTG 1765
20 spLeuArgTyrLeuSerArgGlyAlaSerGlyThrValSerSerAlaArg 36
|||||:.....:|||||:.....:
1766 ATCTTAATAATAAAGAAAGATTGGAGCAGGTTCTTTGGCACTGTCCAC 1815
37 HisAlaAspTrpArg...ValGlnValAlaValLysHisLeu..... 49

```



```

1866 AGACTTCCAT.....GCTGAGCGTGTAAATGAGTCTTAA 1900
65 rgGluAlaGluIleLeuHisLysAlaArgPheSerTyrIlePheProIle 81
|||||: |||: : : ||| |||
1901 GAGAGGTGGATAAATAAAGCGCTTCGCCACCTAACATGTTCTCTTC 1950
82 LeuGlyIleCysAsnGluProGluPheLeuGlyIleValThrGluTyrMe 98
|||||: |||: : : ||| ||| ||| ||| ||| ||| ||| |||
1951 ATGGGTGGGTCACTCACTCACTCACTCACTCACTCACTCACTCACT 2000
98 tProAsnGlySerLeuAsnGluLeuHisArgLysThrGluTyrProA 115
: : ||| ||| ||| ||| ||| ||| ||| ||| ||| :
2001 GTCAAGAGGTAGTTTATACAGACTTTTGCATAAAAGTGGAGCAAGGAGC 2050
115 spValAlaIrrpProLeuArgPheArgIleLeuHisGluIleAlaLeuGly 131
: : ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
2051 AATTAGATGAGACATCGCTCCCTCAGTATGGCTTATGATGGGTAAAGGA 2100
132 ValAsnTyrLeuHisAsnMetThrProProLeuLeuHisHisAspLeu 148
: : ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
2101 ATGAATTAICTTCACTCACTCACTCACTCACTCACTCACTCACTCACT 2150
148 sThrGlnAsnIleLeuLeuAspAsnGluPheHisValLysIleAlaAsp 165
-|||: |||: |||: |||: |||: |||: |||: |||: |||: |||: |||
2151 ATCTCAAACTTATGGTTGACAAAATAATACAGCAAGGTTTGTGAT 2200
165 heGlyLeuSerLysTTPArgMetMetSerLeuSerGlnSerArgSer 181
|||||: |||: : : ||| ||| ||| ||| ||| ||| ||| |||
2201 TTGCTCTCCGATGAGCCAGCCAGCCAGCTTCTTCTTCCGAACTCAGCA 2250
182 LysSerAlaProGluGlyThrIleIleIleIleIleIleIleIleIle 196
: : ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
2251 GCTGGAACCCCGAG.....TGGATGGCACCAGAGTCT 2285
197 AsnTyrGluProGlyGlnLysSerArgAlaSerIleLysHisAspIle 213
: : ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
2286 GCGAGATGAGCCCTCAATGAA.....AAGTCAGATGTGT 2320
213 yrSerTyrAlaValIleThrTrpGluValLeuSerArgLysGlnProPhe 229
|||||: |||: : : ||| ||| ||| ||| ||| ||| ||| ||| |||
2321 ACAGCTCGGGGTCATCTTGGGAGCTTCTACATGCAACCAACCATGG 2370
230 GluAspValThrAsnProLeuGlnIleMetTyrSerValSerGlnGly 246
: : ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
2371 GGTAACCTA...AATCGGCTCAGTTGATAGTCCGGTGGTTCAAGTG 2417
246 sArgProValIleAsnGluSerLeuProTyrAspIleProHis.... 261
: : ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
2418 TAAACGGCTG.....GAGATCCCGGTAATC 2443
262 ..ArgAlaArgMetIleSerLeuIleGluSerGlyTrpAlaGlnAsnPro 277
: : ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
2444 TGAATCCTCAGTTGACCCATAATGAGGTTGTTGGACCAATGAGCCA 2493
278 AspGluArgProSerPheLeuLysCysLeuIleGluLeuGluProVal 294
: : ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
2494 TGGAGGCTCCATCTTGGCACTATAATGAGCTTGTCTAAGACCAATTGAT 2543
294 uArgThr 296
: : ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
2544 CAATCA 2550

```

```

seq_name: /cgn_7/ptodata/1/ina/6B_COMB.seq:US-09-132-118-1,
seq_documentation_block:
; Sequence 1, Application US/09132118
; Patent No, 6211337
; GENERAL INFORMATION:
; APPLICANT: BAICHWAL, VIJAY R
; APPLICANT: HUANG, JIANJING
; APPLICANT: HSU, HAILING
; APPLICANT: GOEDEL, DAVID V
; TITLE OF INVENTION: RIP: NOVEL HUMAN PROTEIN INVOLVED IN

```

```

; TITLE OF INVENTION: TUMOR NECROSIS FACTOR SIGNAL TRANSDUCTION, AND SCREENING
; TITLE OF INVENTION: ASSAYS
; NUMBER OF SEQUENCES: 2
; CORRESPONDENCE ADDRESS:
; ADDRESS: SCIENCE & TECHNOLOGY LAW GROUP
; STREET: 75 DENISE DRIVE
; CITY: HILLSBOROUGH
; STATE: CALIFORNIA
; COUNTRY: USA
; ZIP: 94010
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/132,118
; FILING DATE:
; CLASSIFICATION:
; ATTORNEY/AGENT INFORMATION:
; NAME: OSMAN, RICHARD A.
; REGISTRATION NUMBER: 36,627
; REFERENCE/DOCKET NUMBER: T95-006-1
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (650) 343-4341
; TELEFAX: (650) 343-4342
; INFORMATION FOR SEQ ID NO: 1:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 2016 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: double
; TOPOLOGY: linear
; MOLECULE TYPE: cDNA
; FEATURE:
; NAME/KEY: CDS
; LOCATION: 1..2013
; US-09-132-118-1

```

```

alignment_scores:
Quality: 369.00 Length: 389
Ratio: 1.716 Gaps: 12
Percent Similarity: 55.270 Percent Identity: 28.792
alignment_block:
US-09-445-223-1 x US-09-132-118-1 ..
Align seq 1/1 to: US-09-132-118-1 from: 1 to: 2016
24 LeuSerArgGlyAlaSerGlyThrValSerSerAlaArgHisAlaAspTr 40
|||||: |||: ||| ||| ||| ||| ||| ||| ||| ||| |||
67 CTGGACAGCGGAGGCTTTGGGAAGGTCTCTGTGTTCCAC..... 108
40 pArgValGln...ValAlaValLysHisLeuHisIleHisThrProLeu 56
|||||: |||: : : ||| ||| ||| ||| ||| ||| ||| |||
109 .AGAACCAGGAGCTCATGATCATGATAAAGACAGTACAGGGCCCAACT 157
56 euAspSerGluArgLysAspValLeuArgGluAlaGluIleLeuHisLys 72
: : ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
158 GCATTGAGCACAAAGCCCTCTTGGAGGAGGGGAGAGATGATGACAGA 207
73 AlaArgPheSerTyrIlePheProIleLeuGlyIleCysAsnGluProG 89
||| ||| : : ||| ||| ||| ||| ||| ||| ||| ||| |||
208 CTGAGACACAGCCGGTGGTGAAGCTCTCTGGCGCTCATATAGAGGAAG 257
89 uPheLeuGlyIleValThrGluTyrMetProAsnGlySerLeuAsnGlu 106
: : ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
258 GAAGTACTCCCTGGTGGATGAGTACATGGAGAGGGCAACCTGATGCAC 307
106 euLeuHisArgLysThrGluTyrProAspValAlaIrrpProLeuArgP 122
: ||| : : ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
308 TGCTGAAAGCCGAGATGAGTACTCCG.....CTTCTGTAAGAAGGA 348

```

```

123 ArgIleLeuHisGluIleAlaLeuGlyValAsnTyrLeuHisAsnMetTh 139
|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
349 AGGATAAATTTGGAAATCATTTGAAGAATGTCTACTTACATGGA..... 393
139 rProLeuLeuHisHisAspLeuLysThrGlnAsnIleLeuLeuAspA 156
|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||
394 .AAAGCGTGATACACAGGACCTGANGCCTGAAATATATCCCTGTTGATA 442
156 snGluPheHisValLysIleAlaAspPheGlyLeuSerLysTrpArgMet 172
|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||
443 ATGACTCCACATTAAGATCGCAGACCTCGGCCCTCCCTCCTTAAAGATG 492
173 MetSerLeuSerGlnSerArgSerLysSerAlaProGlu..... 186
|||:|||||:|||||:|||||:|||||:|||||:|||||:|||||
493 TGGAGCAAACTGAATAATGAAGACCAATGAGCTGAGGGAAGTGACGG 542
187 .....GlyGlyThrIleIleTyrMetProGlu..... 196
|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||
543 CACCCGTAAGAAAGATGGCGGACCCCTCTACTACTATGGCCCGCAGCAC 592
197 .....AsnTyrGluProGlyGlnLysSerArgAlaSerIleLys 209
|||:|||||:|||||:|||||:|||||:|||||:|||||:|||||
593 TGAATGACGTCAACGCCAAGCCACAGAGAGTCG..... 627
210 HisAspIleTyrSerTyrAlaValIleThrTrpGluValLeuSerArgLy 226
|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||
628 ...GATGTGTACAGCTTGTCTGTACTACTCTGGCGCATATTTGCAATAA 674
226 sGlnProPheGluAspValThrAsnProLeuGlnIleMetTyrSerValS 243
|||:|||||:|||||:|||||:|||||:|||||:|||||:|||||
675 GGAGCCATATGAAATGCTATCTGTGAGCAGCAGTGTGATAATGTGCATA 724
243 exGlnGlyHisArgProValIleAsnGlu.....GluSerLeuProTyr 257
|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||
725 AATCTGGAAACAGCCAGATGGATGATCCTACTACTACTGACTGCCCAAGA 774
258 AspIleProHisArgAlaArgMetIleSerLeuIleGluSerGlyTrpAl 274
|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||
775 GAAAT.....ATCAGTCTCATGAAGCTCGCTGGGA 806
274 aGlnAsnProAspGluArgProSerPheLeuLysCysLeuIleGluLeu 291
|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||
807 AGCGAATCCGGAAGCTCGGCCGACATTTCTTGGCATTGAAGAAAATTTA 856
291 luProValLeuArgThrPheGluGluIleThrPheLeuGluAlaValIle 307
|||:|||||:|||||:|||||:|||||:|||||:|||||:|||||
857 GGCTTTTATTTAAGTCAATTAGAAGAAGTGTAGAAGAGGACGTCGAG 906
308 GlnLeuLysLys.....ThrLysLeuG1 315
|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||
907 AGTTTAAAGAAAGAGTATTCAACGAAATGCAATGTTGTAAGAGAAATGCA 956
315 nSerVal.....SerSerAlaIleHisLeuC 324
|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||
957 GTCCTTCAACTTGAATGTTGTGGCAGTACTTCAAGCCGGTCAAATTCAG 1006
324 ysAspLysLysLysMetGluLeuLeuSerLeuAsnIleProValAsnHisGly 340
|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||
1007 CCACAGAAGACCTGGTTCACTGCACAGTCCAGGACCTGGGATGGGT 1056
341 ProGlnGluSerCysGlySerSerGlnLeuHisGluAsnSerGlyse 357
|||:|||||:|||||:|||||:|||||:|||||:|||||:|||||
1057 CCTGTGGAGGAGTCTGGTTGTTGCTTCCCTCCCTGGAGCAC..... 1095
357 rProGluThrSerArgSerLeuProAlaProGlnAspAsnAspPheLeuS 374
|||:|||||:|||||:|||||:|||||:|||||:|||||:|||||
1096 .....CCACAAGAAAGAAATGAGCCCGCAGCCTGC 1123
374 exArgLysAlaGlnAsp 379
|||:|||||:|||||:|||||:|||||:|||||:|||||:|||||
1124 AGAGTAAACTCCAAAGAC 1140

```

seq\_name: /cgn1\_7/ptodata/1/ina/5A\_COMB.seq:us-08-444-005-16

```

seq_documentation_block:
: Sequence 16, Application US/08444005
: Patent No. 5674734
: GENERAL INFORMATION:
: APPLICANT: Leder, Philip
: APPLICANT: Seed, Brian
: APPLICANT: Stanger, Ben Z.
: APPLICANT: Lee, Tae-Ho
: APPLICANT: Kim, Emily
: TITLE OF INVENTION: CELL DEATH PROTEIN
: NUMBER OF SEQUENCES: 35
: CORRESPONDENCE ADDRESS:
: ADDRESS: Fish & Richardson P.C.
: STREET: 225 Franklin Street, Suite 3100
: CITY: Boston
: STATE: MA
: COUNTRY: USA
: ZIP: 02110-2804
: COMPUTER READABLE FORM:
: MEDIUM TYPE: Floppy disk
: COMPUTER: IBM PC compatible
: OPERATING SYSTEM: PC-DOS/MS-DOS
: SOFTWARE: PatentIn Release #1.0, Version #1.30
: CURRENT APPLICATION DATA:
: APPLICATION NUMBER: US/08/444,005
: FILING DATE:
: CLASSIFICATION: 435
: ATTORNEY/AGENT INFORMATION:
: NAME: Clark, Paul T.
: REGISTRATION NUMBER: 30,164
: REFERENCE/DOCKET NUMBER: 00383/026001
: TELECOMMUNICATION INFORMATION:
: TELEPHONE: 617/542-5070
: TELEFAX: 617/542-8906
: TELEX: 200154
: INFORMATION FOR SEQ ID NO: 16:
: SEQUENCE CHARACTERISTICS:
: LENGTH: 2137 base pairs
: TYPE: nucleic acid
: STRANDEDNESS: single
: TOPOLOGY: linear
: MOLECULE TYPE: DNA
: US-08-444-005-16

```

```

alignment_scores:
Quality: 369.00 Length: 390
Ratio: 1.732 Gaps: 13
Percent Similarity: 54.615 Percent Identity: 29.231

```

```

alignment_block:
US-09-445-223-1 x US-08-444-005-16 ..
Align seg 1/1 to: US-08-444-005-16 from: 1 to: 2137

```

```

24 LeuSerArgGlyAlaSerGlyThrValSerSerAlaArgHisAlaAspTr 40
|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||
67 CTGCAGACGGGAGCTCGGGAGGCTCTCTGTGTTCAC..... 108
40 pArgValGln...ValAlaValLysHisLeuHisIleHisThrProLeuL 56
|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||
109 .AGAACCCAGGACTCATGATCATGAAACACAGTGTACAAGGGGCCCAACT 157
56 euAspSerGluArgLysAspValLeuArgGluAlaGluIleLeuHisLys 72
|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||
158 GCATGAGCACACAGGAGCCCTCTTGGAGGAGGCGAAGATGATGACACAGA 207
73 AlaArgPheSerTyrIlePheProIleLeuGlyIleCysAsnGluProGl 89
|||:|||||:|||||:|||||:|||||:|||||:|||||:|||||
208 CTGAGCACACACCGGGTGGTGAAGCTCCTGGGGCTCATCATAGAGNAGG 257
89 upHeLeuGlyIleValThrGluTyrMetProAsnGlySerLeuAsnGlu 106

```

```

1096 .....CCACAAGAGAGAAATGAGCCAGCC 1120
373 euSerArgLysAlaGlnAsp 379
||:|:| | | | | | | | | | | | | | | | | |
1121 TGCAGAGTAACACTCCCAAGAC 1140

seq_name: /cgnl_7/ptodata/1/1na/6A_COMB.seq:US-09-161-443-1
seq_documentation_block:
; Sequence 1, Application US/09161443A
; Patent NO. 6020198
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Lex M. Cowser
; TITLE OF INVENTION: ANTISENSE MODULATION OF RIP-1 EXPRESSION
; FILE REFERENCE: RFS-0011
; CURRENT APPLICATION NUMBER: US/09/161,443A
; CURRENT FILING DATE: 1998-09-25
; NUMBER OF SEQ ID NOS: 47
; SEQ ID NO 1
; LENGTH: 2617
; TYPE: DNA
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: CDS
; LOCATION: (1)..(2016)
; FEATURE:
; NAME/KEY: unsure
; LOCATION: 2141
; OTHER INFORMATION: unknown
; FEATURE:
; NAME/KEY: unsure
; LOCATION: 2452
; OTHER INFORMATION: unknown
; NAME/KEY: unsure
; LOCATION: 2496
; OTHER INFORMATION: unknown
US-09-161-443-1

alignment_scores:
Quality: 369.00 Length: 389
Ratio: 1.716 Gaps: 12
Percent Similarity: 55.270 Percent Identity: 28.792

alignment_block:
US-09-445-223-1 x US-09-161-443-1 ..
Align seg 1/1 to: US-09-161-443-1 from: 1 to: 2617
24 LeuSerArgGlyAlaSerGlyThrValSerSerAlaArgHisAlaAspTr 40
|||||:|:| | | | | | | | | | | | | | | | | |
67 CTGACAGCGGAGGCTTGGGAGGCTGTCCTGTGTTCCAC..... 108

40 pArgValGln...ValAlaValLysHisLeuHisIleHisThrProLeuL 56
|||:|:| | | | | | | | | | | | | | | | | |
109 .AGAACCCAGGACTCATGATCATGAAACAGTGTACAAAGGGCCCAACT 157

56 euAspSerGluArgLysAspValLeuArgGluAlaGluIleLeuHisLys 72
|||||:|:| | | | | | | | | | | | | | | | | |
158 GCATTGACACACAGCGCCCTCTGGAGAGCGCAAGATGATGAACAGA 207

73 AlaArgPheSerTyrIlePheProIleLeuGlyIleCysAsnGluProGl 89
|||||:|:| | | | | | | | | | | | | | | | | |
208 CTGAGACACACCGGGTGTGAAGCTCTCTGGCGCTCATCATAGAGGAA 257

89 uPheLeuGlyIleValThrGluTyrMetProAsnGlySerLeuAsnGluL 106
||:|:| | | | | | | | | | | | | | | | | |

```

```

258 GAAGTACTCCTCGTGTATGAGTACATGGAGAAAGGGCAACCTGATGACCG 307
106 eutLeuHisArgLysThrGluTyProAspValAlaIrrpProLeuArgPhe 122
:||||| : : : : : |||
308 TGC TGAAGCCGAGATGAGTACCG.....CTTCTGTAAAGAAGGA 348
123 ArgIleLeuHisGluIleAlaLeuGlyValAsnTyrIleLeuHisAsnMetTh 139
||||| : : : : : ||| : : : : : |||
349 AGGATAATTTGGAAATCATTTGAAAGAAATGTGCTACTTACATGGA..... 393
139 rProProLeuLeuHisAspLeuHisArgLysThrGlnAsnIleLeuLeuAspA 156
: : : : : ||| : : : : : ||| : : : : : |||
394 .AAAGCGGTACACACAGCAAGCACTGAAGCCTGAAAATATCTTGTGTGATA 442
156 snGluPheHisValLysIleAlaAspPheGlyLeuSerTyrArgMet 172
||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||
443 ATGACTTCCACATTAAGATCGCAGACTCGCCCTTGCCTTCCTTAAGATG 492
173 MetSerLeuSerGlnSerArgSerLysSerAlaProGlu..... 186
||| : : : : : : : : : |||
493 TGGAGCAAACTGAATAATGAAGACACAAATGAGCTGAGGGAAGTGGACGG 542
187 .....GlyGlyThrIleIleTyrMetProProGlu..... 196
: : : : : : : : : ||| : : : : : |||
543 CACCCGTAAGAGAATGGCCGCACTCTACTATGATGGCCCGCAGCACC 592
197 .....AsnTyrGluProGlyGlnLysSerArgAlaSerIleLys 209
||| : : : : : : : : : |||
593 TGAATGACGTCAACGCAAGCCACAGAGAATCG..... 627
210 HisAspIleTyrSerTyrAlaValIleThrTrpGluValLeuSerArgLy 226
|||:|||||:|||||:|||||:|||||:|||||:|||||:|||||
628 ..GATGTGTACAGCTTGTGTPAGTACTCTGGCGCATATTTGCCAAATAA 674
226 sGlnProPheGluAspValThrAsnProLeuGlnIleMetTyrSerValS 243
:|||||:|||||:|||||:|||||:|||||:|||||:|||||
675 GGAGCCATATAAATGCTATCTGTGAGCAGCAGTGTATAATGTGCATAA 724
243 erGlnGlyHisArgProValIleAsnGlu.....GluSerLeuProTyr 257
|||:|||||:|||||:|||||:|||||:|||||:|||||
725 AATCTGGAAACAGCCAGATGTGGATGCATCATCTGACTGCCCAAGA 774
258 AspIleProHisArgAlaArgMetIleSerLeuIleGluSerGlyTrpAl 274
:||||| : : : : : ||| : : : : : |||
775 GAAAT.....ATCAGTCTCATGAAGCTCTGCTGGGA 806
274 aGlnAsnProAspGluArgProSerPheLeuLysCysLeuIleGluLeuG 291
|||||:|||||:|||||:|||||:|||||:|||||:|||||
807 AGCGAATCCGAAAGCTGGCCGCATCTCTGCTGATTTGAAGAAAATTTA 856
291 luProValLeuArgThrPheGluGluIleThrPheLeuGluAlaValIle 307
:||||| : : : : : ||| : : : : : |||
857 GGCCTTTTATTAAAGTCAATTAGAAAGAAAGTGTAGAAGAGGACGTTGAG 906
308 GlnLeuLysLys.....ThrLysLeuG1 315
:|||||:|||||:|||||:|||||:|||||:|||||
907 AGTTTAAAGAAAGAGTATTCAAACGAAAATGCAAGTTGCTGAAGAAATGCA 956
315 nSerVal.....SerSerAlaIleHisLeu 324
|||||:|||||:|||||:|||||:|||||:|||||
957 GTCTCTCAACTGATGTGGCAGTACCTTCAGCCGGTCAAATTCAG 1006
324 ysAspLysLysMetGluLeuSerLeuAsnIleProValAsnHisGly 340
: : : : : : : : : : : : : : : : : : : : : : : : :
1007 CCACAGAACAGCCTGGTTCACCTGCACAGTCCACAGGACTTGGATGGGT 1056
341 ProGlnGluSerCysGlySerSerGlnLeuHisGluAsnSerGlySe 357
||| ||| ||| ||| ||| ||| ||| ||| ||| |||
1057 CCGTGGAGGAGPCTGGTGTCTCCCTCCCTGGAGCAC..... 1095
357 rProGluThrSerArgSerLeuProAlaProGlnAspAsnAspPheLeuS 374
:|||||:|||||:|||||:|||||:|||||:|||||:|||||
1096 .....CCCAAGAAAGAAATGAGCCCGCAGCCGCTGC 1123

```

```

374 erArgLysAlaGlnAsp 379
: : ||| ||| ||| |||
1124 AGAGTAACTCCAAGAC 1140

seq_name: /cgml_7/ptodata/1/ina/5A_COMB.seq:US-08-700-575-31

seq_documentation_block:
; Sequence 31 Application US/08700575
; Patent No. 5817479
; GENERAL INFORMATION:
; APPLICANT: Au-Young, Janice
; APPLICANT: Bandman, Olga
; APPLICANT: Hawkins, Phillip R.
; APPLICANT: Wilde, Craig G.
; TITLE OF INVENTION: NOVEL HUMAN KINASE HOMOLOGS
; NUMBER OF SEQUENCES: 45
; CORRESPONDENCE ADDRESS:
; STREET: 3174 PORTER DRIVE
; CITY: PALO ALTO
; STATE: CA
; COUNTRY: USA
; ZIP: 94304
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/700,575
; FILING DATE:
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: BILLINGS, LUCY J
; REGISTRATION NUMBER: 36749
; REFERENCE/DOCKET NUMBER: SP-100 US
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 415-855-0555
; TELEFAX: 415-845-4166
; INFORMATION FOR SEQ ID NO: 31:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 210 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: cDNA
; IMMEDIATE SOURCE:
; LIBRARY: THP-1 Phorbol LPS
; CLONE: 156108
; US-08-700-575-31

alignment_scores:
Quality: 367.00 Length: 69
Ratio: 5.319 Gaps: 0
Percent Similarity: 100.000 Percent Identity: 100.000

alignment_block:
US-09-445-223-1 x US-08-700-575-31 ..
Align seg 1/1 to: US-08-700-575-31 from: 1 to: 210

196 GluAsnTyrGluProGlyGlnLysSerArgAlaSerIleLysHisAsp11 212
||||| ||||||||| ||||||||| ||||||||| |||||||||
2 GAATACTATGAACCTGGCAAAAATCAAGGCCCATGATCAAGCACGATAT 51

212 eTyrSerTyrAlaValIleThrTrpGluValLeuSerArgLysGlnProp 229
||||| ||||||||| ||||||||| ||||||||| |||||||||
52 ATATAGCTATGCAGTATCACATGGGAAGTGTATCCAGAAAACAGCCTT 101

229 heGluAspValThrAsnProLeuGlnIleMetTyrSerValSerGlnGly 245
||||| ||||||||| ||||||||| ||||||||| |||||||||

```

```

102 TTGAAGATGTCACCACCAATCCCTTTGGAGATAATGATAGTGTGTCAACAGGA 151
246 HisArgProValIleAsnGluSerLeuProTyrAspIleProHisAr 262
152 CATCGACTGTTAATAAGAAAGTTTGCATATGATATACCTCACCG 201
262 gAlaArg 264
202 AGCAGCT 208

```

```
seq_name: /cgnl_7/ptodata/1/ina/5B_COMB.seq:US-08-685-625A-1
```

```

seq_documentation_block:
; Sequence 1, Application US/08685625A
; Patent No. 5945301
; GENERAL INFORMATION:
; APPLICANT: UENO, Naoto
; APPLICANT: MATSUMOTO, Kunihiko
; APPLICANT: IRIE, Kenji
; TITLE OF INVENTION: NOVEL KINASE IN TGF-BETA FAMILY SIGNAL
; TITLE OF INVENTION: TRANSDUCTION SYSTEM
; NUMBER OF SEQUENCES: 5
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: BURNS, DOANE, SWECKER & MATHIS, L.L.P.
; STREET: P.O. Box 1404
; CITY: Alexandria
; STATE: Virginia
; COUNTRY: United States
; ZIP: 22313-1404
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/685, 625A
; FILING DATE: 24-JUL-1996
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: JP 7-253549
; FILING DATE: 29-SEP-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Meuth, Donna M.
; REGISTRATION NUMBER: 36,607
; REFERENCE/DOCKET NUMBER: 001560-267
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (703) 836-6620
; TELEFAX: (703) 836-2021
; INFORMATION FOR SEQ ID NO: 1:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 2443 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: double
; TOPOLOGY: linear
; MOLECULE TYPE: cDNA
; FEATURE:
; NAME/KEY: CDS
; LOCATION: 157..1893
US-08-685-625A-1

```

```

alignment_scores:
Quality: 315.50      Length: 589
Ratio: 1.119        Gaps: 29
Percent Similarity: 47.878      Percent Identity: 25.127

```

```

alignment_block:
US-09-445-223-1 x US-08-685-625A-1 ..
Align seg 1/1 to: US-08-685-625A-1 from: 1 to: 2443

```

```

13 IleProTyrHisLysLeuAlaAspLeuArgTyrLeuSerArgGlyAlaSe 29
||| ||| :|:::|

```

```

247 ATCGACTACAAAGAGAGATCGAGGTGGAAGAGGTTTGTCCGGAAGAGGAGCTTT 296
29 rGlyThrValSerSerAlaArgHisAlaAspTyrArgValGln...ValA 45
|||::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|
297 TGGAGTAGTTTGCACAAAGCTAAG.....TGGAGAGCAAAAAGATGTCG 337
45 laValLysHisLeuHisIleHisThrProLeuLeuAspSerGluArgLys 61
|||::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|
338 CTATTAAACAGATAGAA.....AGTGAGCTCTGAGAGGAAG 372
62 AspValLeuArgGluAlaGluIleLeuHisLysAlaArgPheSerTyrI1 78
|||::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|
373 GCTTTCATTTGGAGCTCCGGCAGTTGTCGCTGTGAACCATCTCAACAT 422
78 ePheProIleLeuGlyIleCysAsnGluProGluPheLeuGlyIleValT 95
|||::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|
423 TGTCAAGTTGTACGGAGCCTGCCTGAATCCA.....GTATGCTTGTGA 466
95 hrGluTyrMetProAsnGlySerLeuAsnGluLeuLeuHisArgLysThr 111
|||::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|
467 TGGAAATATGCAGAGGGGGCTCATTGTATAATGTGCTCATGGTCTGAA 516
112 GluTyrPro.....AspValAlaTyrProLeuArgph 122
|||::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|
517 CCATTGCCTTACTACTACGTGCTCATGCCAATGAGCTGGTGTFTA.... 561
122 eArgIleLeuHisGluIleAlaLeuGlyValAsnTyrLeuHisAsnMetT 139
|||::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|
562 .....CAGTGTTCACCAAGAGTGGCTTACCTGCACAGCATGC 598
139 hrPro...ProLeuLeuHisAspLeuLysThrGlnAsnIleLeuLeu 154
|||::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|
599 AGCCCAAAGCGCTGATTACAGAGGACCTCAAGCCTCCAAAACCTTGCCTG 648
155 ...AspAsnGluPheHisValLysIleAlaAspPheGlyLeuSerLysTr 170
|||::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|
649 GTTCAGAGGGACAGTTCTAAAATCTGCCATTTTGGTACAGCTGTGA. 698
170 pArgMetSerLeuSerGlnSerArgSerSerLysSerAlaProGluG 187
|||::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|
699 CATCCAAACACACATGACCAATAATAAA..... 726
187 LyGlyThrIleIleTyrMetProGluAsnTyrGluProGlyGlnLys 203
|||::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|
727 ..GGGAGTGTGCTGGATGGCGCTGAAGTGTGAA.....GGT 765
204 SerArgAlaSerIleLysHisAspIleTyrSerTyrAlaValIleThr 220
|||::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|
766 AGCAATTACAGTGAAGAAGTGTATGCTTTCAGCTGGGGTATATCCTCTG 815
220 pGluValLeuSerArgLysGlnProPheGluAspValThrAsnPro...L 236
|||::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|
816 GGAAGTATAACACGCCGGAACCCCTTCGATGAGATCGTGCCCGCCAGCTT 865
236 euGlnIleMetTyrSerValSerGlnGlyHisArgProValIleAsnGlu 252
|||::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|
866 TCAGAATCATGTGGCTGTTCAATAATGCACTCGACCCACCACCTG...ATC 912
253 GluSerLeuProTyrAspIleProHisArgAlaArgMetIleSerLeuI1 269
|||::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|
913 AAAATTTTACTTAAGCCCAATTGAG.....AGCTTGTAT 944
269 eGluSerGlyTyrAlaGlnAsnProAspGluArgProSer.....P 283
|||::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|
945 GACACGCTGTTGGTCTAAGGACCATCTCAGCGCCCTTCAATGGAGGAAA 994
283 heLeuLysCysLeuIleGluLeu..... 290
|||::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|
995 TTGTGAAAATAATGACTCACTTGTATGCGGTACTTCCCAGGAGCGGATGAG 1044
290 ..... 290
1045 CCATTACAGTATCCTTGTACTACTACTCTGTGATGAAGGGCAGACCACTCAGC 1094

```



290 ..... 290  
1095 CACCAGCACAGGCTCGTTCATGGACATTGCTTCACAAATACCAGTAATA 1144  
291 ..... GluProValLeuArgThrPheGluGluIleThr 301  
1145 AAAGTGACACAATAATGGAAACAGGTTCCGCCACAAACGACACTATAAA 1194  
302 PheLeuGluAlaValIleGlnLeuLysThrLysLeuGlnSerValSe 318  
1195 CGCTGGAGTCAAACTGTTGAAAACCCAGGCAACACACAGAGTGAATC 1244  
318 rSerAlaIleHisLeuCysAspIlyLysMetGluLeuSerLeuAsnI 335  
1245 TGGACCCCTGAGCTGGGAGCCCTCGTGGGAGCAGTGTGGAGAGCTGC 1294  
335 leProValAsnHisGlyProGlnGluLysSerCysGlySerSerGlnLeu 351  
1295 CCCCCACTCCGAGGCG...AAGAGGATGAGTGTGACATGCTGAAATA 1341  
352 His.....GluAsnSerGlySerProGluThrSerAr 362  
1342 GAAGCCAGGATCGTGGCGACTCGAGTACGGGCAACCAAGG...CTAG 1388  
362 gSerLeuProAlaProGlnAspAsnAspPheLeuSerArgLysAlaGlnA 379  
1389 ATCCATC.....CAAGACTT.....G 1404  
379 sCysTyrPheMetLysLeuHisCysProGlyAsnHisSerTrpAsp 395  
1405 ACTGTTAC.....TGGGAC 1418  
396 SerThrIleSerGlySerGln..... 402  
1419 AGAACCTGGTCAGTGAGCAGCGGTCATCCAGCCCTAGTGTGAGAAATGA 1468  
403 .....ArgAlaAlaPheCysAsp.HisLysThr 411  
1469 TCACTACCTCAGGACCAACCTCAGAGAAGCCAGCTCGGAGTACCCTATGG 1518  
412 ThrProCysSerSerAlaIleIleAsn.....ProLe 422  
1519 ACCCTGATGATCCACAGACACCAATGGCTCAGATAACTCCATCCCAAT 1568  
422 uSerThrAlaGlyAsnSerGluArgLeuGlnPro..... 433  
1569 GCGGTATCTTACACTGGATCACCAGTACAGCCTTAGCCCGTGCACAA 1618  
434 .....GlyIleAlaGlnGlnTrpIleGlnSerLysArg 444  
1619 ACTCCAAGAATCCATGGCAGTGTTCGAACAGCAGCTGTAATAATGGCACAG 1668  
445 GluAspIleValAsnGlnMetThrGluAlaCysLeu.....AsnGI 458  
1669 GAGTATGAAAGTTCAAAACCCAAATCCGATTTACTACAGAGAANGCA 1718  
458 nSerLeuAspAlaLeuLeuSerArgAspLeuIleMetLysGluAspTyrG 475  
1719 AGAACTAGTGCAGAAATGGACCAGGAT.....GAAAAGGACCAGC 1759  
475 luLeuValSerThrLysProThrArgThrSerLysVal..... 487  
1760 AA.....AATACATCTCGTCTGGTACAGGAACAT 1788  
488 ArgGlnLeuLeuAsp 492  
1789 AAAAAGCTTTTAGAT 1803

**THIS PAGE BLANK (USPTO)**

# SEARCH REQUEST FORM

Scientific and Technical Information Center

Requester's Full Name: \_\_\_\_\_ Examiner #: \_\_\_\_\_ Date: \_\_\_\_\_

Art Unit: \_\_\_\_\_ Phone Number 30 \_\_\_\_\_ Serial Number: \_\_\_\_\_

Mail Box and Bldg/Room Location: \_\_\_\_\_ Results Format Preferred (circle): PAPER DISK E-MAIL

**If more than one search is submitted, please prioritize searches in order of need.**

\*\*\*\*\*

Please provide a detailed statement of the search topic, and describe as specifically as possible the subject matter to be searched. Include the elected species or structures, keywords, synonyms, acronyms, and registry numbers, and combine with the concept or utility of the invention. Define any terms that may have a special meaning. Give examples or relevant citations, authors, etc, if known. Please attach a copy of the cover sheet, pertinent claims, and abstract.

Title of Invention: \_\_\_\_\_

Inventors (please provide full names): \_\_\_\_\_

Earliest Priority Filing Date: \_\_\_\_\_

*\*For Sequence Searches Only\* Please include all pertinent information (parent, child, divisional, or issued patent numbers) along with the appropriate serial number.*

\*\*\*\*\*  
**STAFF USE ONLY**

Searcher: Tony Post

Searcher Phone #: 201-3534

Searcher Location: \_\_\_\_\_

Date Searcher Picked Up: 4/13

Date Completed: 4/14

Searcher Prep & Review Time: 10

Clerical Prep Time: \_\_\_\_\_

Online Time: 10

**Type of Search**

NA Sequence (#) 2

AA Sequence (#) 1

Structure (#) \_\_\_\_\_

Bibliographic \_\_\_\_\_

Litigation \_\_\_\_\_

Fulltext \_\_\_\_\_

Patent Family \_\_\_\_\_

Other \_\_\_\_\_

**Vendors and cost where applicable**

STN \_\_\_\_\_

Dialog \_\_\_\_\_

Questel/Orbit \_\_\_\_\_

Dr.Link \_\_\_\_\_

Lexis/Nexis \_\_\_\_\_

Sequence Systems g

WWW/Internet \_\_\_\_\_

Other (specify) \_\_\_\_\_

**THIS PAGE BLANK (USPTO)**